


CİLT 2



KALP ve DAMAR CERRAHİSİ

EDİTÖRLER

Prof. Dr. Mustafa PAÇ
Prof. Dr. Atıf AKÇEVİN
Prof. Dr. Serap AYKUT AKA
Prof. Dr. Suat BÜKET
Prof. Dr. Tayyar SARIOĞLU
Prof. Dr. Ersin EREK
Prof. Dr. Mustafa ÖZBARAN

3. BASKI



© Copyright 2026

Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş.'ne aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kayıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

ISBN

978-625-375-842-4 (Tk)
978-625-375-844-8 (2.c)

Yayın Koordinatörü
Yasin DİLMEN

Kitap Adı

Kalp ve Damar Cerrahisi

Sayfa ve Kapak Tasarımı

Akademisyen Dizgi Ünitesi

Editörler

Mustafa PAÇ
ORCID iD: 0000-0002-3126-3319
Atıf AKÇEVİN
ORCID iD: 0000-0002-0799-4875
Serap AYKUT AKA
ORCID iD: 0000-0001-8642-5277
Suat BÜKET
ORCID iD: 0000-0001-5230-2842
Tayyar SARIOĞLU
ORCID iD: 0000-0001-9857-8975
Ersin EREK
ORCID iD: 0000-0003-1433-3538
Mustafa ÖZBARAN
ORCID iD: 0000-0003-0259-0799

Yayıncı Sertifika No

47518

Baskı ve Cilt

Vadi Matbaacılık

Bisac Code

MED010000

DOI

10.37609/akya.3889

Kütüphane Kimlik Kartı

Kalp ve Damar Cerrahisi / ed. Mustafa Paç, Atıf Akçevin, Serap Aykut Aka ...[ve başkaları]. 3. bsk.

Ankara : Akademisyen Yayınevi Kitabevi, 2026.

c. <2> (906) : şekil, tablo, resim. ; 195x275 mm.

Kaynakça var.

ISBN 9786253758448 (2.c)

9786253758424 (Tk.)

UYARI

Bu üründe yer alan bilgiler sadece lisanslı tıbbi çalışanlar için kaynak olarak sunulmuştur. Herhangi bir konuda profesyonel tıbbi danışmanlık veya tıbbi tanı amacıyla kullanılmamalıdır. Akademisyen Kitabevi ve alıcı arasında herhangi bir şekilde doktor-hasta, terapist-hasta ve/veya başka bir sağlık sunum hizmeti ilişkisi oluşturmaz. Bu ürün profesyonel tıbbi kararların eşleniği veya yedeği değildir. Akademisyen Kitabevi ve bağlı şirketleri, yazarları, katılımcıları, partnerleri ve sponsorları ürün bilgilerine dayalı olarak yapılan bütün uygulamalardan doğan, insanlarda ve ihazlarda yaralanma ve/veya hasarlardan sorumlu değildir.

İlaçların veya başka kimyasalların reçete edildiği durumlarda, tavsiye edilen dozunu, ilacın uygulanacak süresi, yöntemi ve kontraendikasyonlarını belirlemek için, okuyucuya üretici tarafından her ilaca dair sunulan güncel ürün bilgisini kontrol etmesi tavsiye edilmektedir. Dozun ve hasta için en uygun tedavinin belirlenmesi, tedavi eden hekimin hastaya dair bilgi ve tecrübelerine dayanak oluşturmaları, hekimin kendi sorumluluğundadır.

Akademisyen Kitabevi, üçüncü bir taraf tarafından yapılan ürüne dair değişiklikler, tekrar paketlemeler ve özelleştirmelerden sorumlu değildir.

GENEL DAĞITIM

Akademisyen Kitabevi A.Ş.

Halk Sokak 5 / A Yenışehir / Ankara

Tel: 0312 431 16 33

siparis@akademisyen.com

www.akademisyen.com

ÖNSÖZ

Kalp damar cerrahisi, sağlık bilimlerinde insan yaşamının en kritik anlarında devreye giren, hem bilimin hem de insanlığın en ince çizgide bulunduğu bir disiplindir. Ölümün hala en sık nedeninin, kardiyovasküler hastalıklar olması önemini daha da artırmaktadır. Yorucu ve meşakkatli bir uzmanlık alanı olan kalp damar cerrahisini tercih edenler çalışkan, özverili ve yüce gönüllü hekimlerdir.

Bir asıra yaklaşan ulusal kalp damar cerrahisi eğitimimizle tanı ve tedavide çağdaş, evrensel ve çok iyi sonuçlara ulaştık. Bir ülkenin gelişmesi ancak bilim ve fenle mümkündür ve bu bağlamda ana dilde öğretimin rolü yadsınamaz. Bilim alanımızda özgün, ana dilimizde deneyimlerimizi de katarak bir kalp damar ve cerrahisi kitabı yazma görevimize 2000 lerin başında karar verdik. 3. Basımını çıkardığımız bu özgün eseri Türk bilim hayatına sunmanın onurunu yaşıyoruz.

Her ameliyat, yalnızca teknik becerinin değil; sezginin, deneyimin, sorumluluğun ve en önemlisi irfanın bir bileşkesidir. Çünkü "bilimde irfan olmazsa olmaz" – bilgi, ancak yüksek değerlerle birleştiğinde gerçek anlamını bulur ve insan hayatına dokunan bir değere dönüşür. Kalbin gönülle eş anlamlılığı bu eserin verilmesinde bizlere ayrıca bir motivasyon sağlamıştır.

Eserimizin tüm kalp damar ve kardiyoloji camiası, öğrenci, asistan, uzman ve öğretim görevlileri için iyi rehber olacağına inanıyoruz. Amacımız yalnızca güncel bilgi sunmak değil; aynı zamanda bu bilginin ardındaki düşünceleri, vizyonu ve mesleğin ruhunu aktarmaktır.

Kalp damar cerrahisi, teknolojiyle iç içe gelişen, her gün yeni tekniklerle ve inovasyonlarla zenginleşen bir alandır. Robotik cerrahiden yapay zekânın yönlendirdiği karar destek sistemlerine, minimal invaziv yaklaşımlardan biyomühendislik ürünlerine kadar genişleyen bu dünyada, yalnızca bilmek yetmez yenilikleri sorgulamak, anlamlandırmak ve geleceğe uyarlamak gerekir. Bu kitap, bu yolculukta sizlere hem güvenilir bir bilgi kaynağı, hem de vizyon kazandıran bir rehber olmayı amaçlamaktadır.

Bu kitabın gerçekleşmesinde büyük katkıları olan akademisyen kitabevine, değerli editörlerimize, sayın yazarlarımıza teşekkürlerimizi sunuyoruz. Bölüm yazarları, hem klinik bilgi birikimlerini hem de mesleki deneyimlerini cömertçe paylaşarak bu eseri ortaya koymuşlardır. Her biri, kalp damar cerrahisinin yalnızca bir uzmanlık alanı değil; bir duruş, bir adanmışlık ve insanlığa hizmet sorumluluğu olduğunun bilinciyle katkı sunmuştur.

Bizi yetiştiren büyüklerimize, hocalarımıza, bu yüce meslekte bize fedakarca katlanan ailemize şükranlarımızı sunuyoruz. Yaşamını kaybeden meslektaşlarımızı ve önceki yazarlarımızı şükran ve rahmetle anıyoruz.

Bilim anlam, değer ve erdemlilikle taçlandırılırsa gönülden içerikler sunar. Kalp damar cerrahisinin geleceği, bilgiyle yoğrulan ellerinizde, irfanla aydınlanan yolunuzda daha da güçlenecektir.

Prof. Dr. Mustafa PAÇ

ÖNSÖZ

Konjenital kalp cerrahisi, doğuştan kalp anomalilerinin tanı ve tedavisinde multidisipliner yaklaşımı zorunlu kılan, yüksek düzeyde uzmanlık ve deneyim gerektiren bir alandır. Bu kitap, alanın güncel bilimsel birikimini sistematik bir çerçevede sunmayı, klinik uygulamaya yönelik kanıta dayalı bilgiyi derlemeyi ve konjenital kalp cerrahisinde karşılaşılan karmaşık klinik sorunlara kapsamlı bir rehber oluşturmayı amaçlamaktadır.

Kitabın hazırlanma süreci, farklı merkezlerden çok sayıda değerli yazarın bilimsel katkılarıyla zenginleşmiştir. Her bir bölüm, yazarlarının klinik deneyimleri, literatüre hâkimiyetleri ve akademik titizlikleri doğrultusunda özenle oluşturulmuş; böylece konjenital kalp cerrahisinin tüm yönlerini kapsayan bütüncül bir yapı ortaya çıkmıştır. Bu kolektif emek, kitabın hem eğitim hem de klinik karar süreçlerinde güvenilir bir başvuru kaynağı olma niteliğini güçlendirmektedir.

Bu eserin ortaya çıkmasında, bilimsel yaklaşımını ve editoryal desteğini süreç boyunca titizlikle sürdüren baş editörümüz Prof.Dr. Mustafa Paç' a teşekkür etmek isterim. Kendilerinin vizyonu, yönlendirmeleri ve yapıcı değerlendirmeleri, kitabın akademik bütünlüğünün sağlanmasında belirleyici olmuştur.

Ayrıca katkı sunan tüm bölüm yazarlarına, bilimsel doğruluğu önceleyen yaklaşımları ve yoğun çalışma tempolarına rağmen gösterdikleri özveri için teşekkür borçluyum. Son olarak üzerimde büyük emeği olan, bu projede görev almama vesile olan, konjenital kalp cerrahisinin duayeni sayın hocam Prof.Dr. Tayyar Sarioğlu' na minnettarlığımı belirtmek isterim.

Bu kitabın, klinik pratiğe anlamlı bir katkı sağlaması ve konjenital kalp cerrahisi alanındaki bilimsel gelişime destek vermesi en büyük dileğimdir. Değerli meslektaşlarımızın ve cerrahi uzmanlık yolculuğunda ilerleyen genç hekimlerimizin dikkatine sunulan bu kapsamlı eserin hazırlık sürecinde yer almaktan onur duyuyorum. Konjenital Kalp Cerrahisi alanında, güncel bilgi birikimini ve cerrahi tekniklerin inceliklerini bir araya getiren bu kitabın, alanındaki en önemli başvuru kaynaklarından biri olacağına yürekten inanıyorum.

Prof. Dr. Ersin EREK
Acıbadem Üniversitesi, Çocuk Kalp Cerrahisi BD.,
Acıbadem Atakent Hastanesi



MİYOKARD İNFARKTÜSÜNÜN MEKANİK KOMPLİKASYONLARINDA CERRAHİ TEDAVİ YAKLAŞIMLARI

DOI: 10.37609/akya.3889.c5372

BÖLÜM 50

Bülent TÜNERİR¹
Aykut ŞAHİN²

İçindekiler

- » GİRİŞ
- » MİYOKARD İNFARKTÜSÜNÜN MEKANİK KOMPLİKASYONLARINDA BULGULAR VE TANI YÖNTEMLERİ
 - » 1. Klinik Bulgular ve Fizik Muayene
 - » 2. Tanıda Kullanılan Yöntemler
 - » 3. Ayırıcı Tanı
- » VENTRİKÜLER SEPTAL RÜPTÜR (VSR) CERRAHİ TEDAVİSİ
 - » Cerrahi Tedavinin Zamanlaması
 - » Cerrahi Tedavi Seçenekleri
- » PAPİLLER KAS RÜPTÜRÜ VE AKUT MİTRAL YETMEZLİK CERRAHİ TEDAVİSİ
 - » Cerrahi Endikasyonlar
 - » Cerrahi Zamanlama
 - » Cerrahi Tedavi Seçenekleri
- » VENTRİKÜL ANEVİZMASININ CERRAHİ TEDAVİSİ
 - » Cerrahi Tedavi Seçenekleri
 - » Cerrahi Zamanlama
- » SERBEST DUVAR RÜPTÜRÜ CERRAHİ TEDAVİSİ

¹ Prof. Dr., Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., btunerir@hotmail.com.tr, ORCID iD: 0000-0001-8973-8885

² Doç. Dr., Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., draykutsahin@gmail.com, ORCID iD: 0000-0003-3731-6327

cıyla uygulanır. Cerrahi kararı, hastanın klinik durumu, anevrizmanın özellikleri ve eşlik eden komorbiditeler göz önünde bulundurularak multidisipliner bir yaklaşımla alınmalıdır.

SERBEST DUVAR RÜPTÜRÜ CERRAHİ TEDAVİSİ

Miyokard infarktüsü sonrası kalbin sol ventrikül serbest duvarında meydana gelen yırtılmanın sonuçları çok gürültülü ve genellikle mortalite ile seyreder. Genellikle akut miyokard infarktüsünden sonraki ilk 1-2 haftada görülür. İnfarktüs geçiren hastaların %1-3'ünde görülebilir. İlk geçirilen miyokard infarktüsü ve geniş transmural infarktüste risk daha fazladır(1,17).

Serbest duvar rüptürü, ani hemodinamik bozulma ve kardiyojenik şok ile karakterize bir durumdur. Ani hipotansiyon, bilinç kaybı, senkop, perikardiyal tamponad bulguları(Juguler venöz dolgunluk, pulsus paradoksus vb.)

Serbest duvar rüptürü acil cerrahi müdahale gerektiren bir durumdur. Hastalar acil olarak hemodinamik olarak stabilize edilmelidir. Perikardiyosentez, inotropik ajanlar, İABP gerektiğinde hızlıca kullanılmalıdır. Hastaya tanı konar konmaz şekilde çekilerek kardiyopulmoner bypass a girilmelidir.

Rüptür olan bölgeye yama uygulanır. Genellikle sentetik veya biyolojik yamalar kullanılır. Fibrin yapıştırıcılar veya destekleyici greftler kullanılabilir. Cerrahi müdahale yapılmazsa mortalite %100'e yakındır. Cerrahi ile mortalite %20-50 arasındadır(1,18).

Postoperatif komplikasyonları kalp yetmezliği, aritmiler, enfeksiyon, doku bütünlüğü iyi olmadıği için tekrar rüptür olarak gözlenir.

Sonuç olarak; miyokard infarktüsünün mekanik komplikasyonları, acil cerrahi müdahale gerektiren ciddi klinik durumlardır. Güncel cerrahi teknikler ve multidisipliner yaklaşımlar, bu hastaların yaşam kalitesini artırmakta ve mortaliteyi azaltmaktadır.

KAYNAKLAR

1. Al-Naabi MJ, Maddali MM, Venkatachlam R. Mechanical Complication After a Myocardial Infarction. J Cardiothorac Vasc Anesth. Şubat 2021;35(2):670-2.
2. Espinoza Alva D, Mallma Gómez MY, Muñoz Moreno JM. [Mechanical complications after myocardial infarction in a National Reference Hospital]. Arch Peru Cardiol Cirugia Cardiovasc. 2022;3(1):25-32.
3. David TE, Dale L, Sun Z. Postinfarction ventricular septal rupture: repair by endocardial patch with infarct excision. J Thorac Cardiovasc Surg. 1995;110(5):1315-22.
4. Kitamura S, Mendez A, Kay JH. Ventricular septal defect following myocardial infarction: experience with surgical repair through a left ventriculotomy and review of literature. J Thorac Cardiovasc Surg. 1971;61(2):186-99.
5. Cooley DA, Belmonte BA, Zeis LB, Schnur S. Surgical repair of ruptured interventricular septum following acute myocardial infarction. Surgery. 1957;41(6):930-7.
6. Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. Cardiogenic Shock After Acute Myocardial Infarction: A Review. JAMA. 09 Kasım 2021;326(18):1840-50.
7. Zhang RS, Ro R, Bamira D, Vainrib A, Zhang L, Nayar AC, vd. Echocardiography in the Recognition and Management of Mechanical Complications of Acute Myocardial Infarction. Curr Cardiol Rep. Mayıs 2024;26(5):393-404.
8. Anderson JL, Morrow DA. Acute Myocardial Infarction. Campion EW, editör. N Engl J Med. 25 Mayıs 2017;376(21):2053-64.
9. Jiang H, Fang T, Cheng Z. Mechanism of heart failure after myocardial infarction. J Int Med Res. Ekim 2023;51(10):3000605231202573.
10. Birnbaum Y, Fishbein MC, Blanche C, Siegel RJ. Ventricular Septal Rupture after Acute Myocardial Infarction. N Engl J Med. 31 Ekim 2002;347(18):1426-32.
11. Cubeddu RJ, Lorusso R, Ronco D, Matteucci M, Axline MS, Moreno PR. Ventricular Septal Rupture After Myocardial Infarction. J Am Coll Cardiol. Mayıs 2024;83(19):1886-901.
12. Assenza GE, McElhinney DB, Valente AM, Pearson DD, Volpe M, Martucci G, vd. Transcatheter Closure of Post-myocardial Infarction Ventricular Septal Rupture. Circ Cardiovasc Interv. Şubat 2013;6(1):59-67.
13. Díez-Villanueva P, Vera A, Ariza-Solé A, Alegre O, Formiga F, López-Palop R, vd. Mitral Regurgitation and Prognosis After Non-ST-Segment Elevation Myocardial Infarction in Very Old Patients. J Am Geriatr Soc. Ağustos 2019;67(8):1641-8.
14. Sharma H, Yuan M, Shakeel I, Hodson J, Radhakrishnan A, Brown S, vd. A Longitudinal Study of Mitral Regurgitation Detected after Acute Myocardial Infarction. J Clin Med. 13 Şubat 2022;11(4):965.
15. Massimi G, Matteucci M, Kowalewski M, Ronco D, Chiarini G, De Piero ME, vd. Operative strategies for acute mitral regurgitation as a mechanical complication of myocardial infarction. Ann Cardiothorac Surg. Mayıs 2022;11(3):328-36.
16. Patel NJ, Mundakkal A, Elrod-Gombash J, Chngal K. Ventricular aneurysm and ventricular septal defect after myocardial infarction. Postgrad Med J. 01 Şubat 2022;98(e1):e8-9.

17. Karic A, Haxhibeqiri-Karabdic I, Kabil E, Grabovica S, Straus S, Busevac E, vd. Left Ventricular Free Wall Rupture After Acute Myocardial Reinfarction Due to In-Stent Thrombosis in COVID-19 Patient. *Acta Inform Medica AIM J Soc Med Inform Bosnia Herzeg Cas Drustva Za Med Inform BiH*. Mart 2022;30(1):76-80.
18. Matteucci M, Ronco D, Massimi G, Di Mauro M, Lorusso R. [Mechanical complications of acute myocardial infarction: from diagnosis to treatment]. *G Ital Cardiol* 2006. Mart 2022;23(3):190-9.



MİYOKARD İNFARKTÜSÜ SONRASI GELİŞEN VENTRİKÜLER SEPTAL DEFEKT

DOI: 10.37609/akya.3889.c5373

BÖLÜM 51

Şeref Alp KÜÇÜKER ¹
Enis Burak GÜL ²

İçindekiler

- » GİRİŞ VE GENEL BİLGİLER
- » TARİHÇE
- » İNSİDANS VE RİSK FAKTÖRLERİ
- » PATOFİZYOLOJİ
- » TANI YÖNTEMLERİ
- » PREOPERATİF TEDAVİ
- » OPERASYON ZAMANLAMASI
- » OPERASYON TEKNİKLERİ
- » KORONER REVASKÜLARİZASYON
- » POSTOPERATİF BAKIM VE KOMPLİKASYONLAR
- » UZUN DÖNEM SONUÇLARI
- »
- » 1. GİRİŞ VE GENEL BİLGİLER
- » 2. KLİNİK BELİRTİLER VE TANI YÖNTEMLERİ
- » 3. TEDAVİ YAKLAŞIMLARI
- » 4. CERRAHİ TEKNİKLER
 - » Lineer anevrizmektomi
 - » Septoplasti
 - » Endoventriküler Sirküler Yama Plasti
 - » Transkateter yöntemler
- » 5. SONUÇLAR
- »

¹ Prof. Dr., SBÜ, Ankara Şehir Sağlık Uygulama ve Araştırma Merkezi, Kalp ve Damar Cerrahisi AD., serefalp@yahoo.com, ORCID iD: 0000-0003-2462-3168

² Prof. Dr., Yüksek İhtisas Kalp ve Damar Hastanesi Kalp ve Damar Cerrahisi Kliniği, enisburakgul@gmail.com, ORCID iD: 0009-0005-8038-145X

kaçan ya da kapatıldıktan sonra tekrar açılan defektler de olabilir. Bu defektler eğer kalp yetmezliği bulgularına neden oluyorsa ya da sol-sağ şant oranı (Qp/Qs) 2'den büyükse tekrar ameliyat edilmelidirler. Bu şekilde kronikleşmiş septal defektler için transatriyal yaklaşım uygun olabilir. Eğer rezidüel defekt küçük (Qp/Qs <2) ise ve hastanın yakınması yoksa medikal tedavi ile takip reoperasyondan daha uygun bir seçenek olabilir.

Post MI VSD'ler günümüzde nadir görülse de, hayati riski çok yüksek patolojilerdir. Cerrahi zamanlama ve uygun bir teknikle tamir, tecrübeli merkezlerde, tecrübeli cerrahlar tarafından yapılırsa mortalite ve morbidite daha az olabilir. En iyi şartlarda bile operatif mortalite %30'lar civarındadır. Genç cerrahların bu prosedürleri daha tecrübeli cerrahlardan öğrendikten sonra üstlenmeleri daha doğru bir yaklaşım olacaktır.

KAYNAKLAR

1. Tang L, Fang Z, Hu X, Tang J, Shen X, Lu X, et al. Non-surgical repair of ventricular septal rupture after acute myocardial infarction. *International Journal of Cardiology*. 2015;185:328-32.
2. Damluji AA, van Diepen S, Katz JN, Menon V, Tamis-Holland JE, Bakitas M, et al. Mechanical Complications of Acute Myocardial Infarction: A Scientific Statement From the American Heart Association. *Circulation*. 2021;144(2):e16-e35.
3. Latham PM. Lectures on subjects connected with clinical medicine comprising diseases of the heart 1845.
4. Brunn F. Diagnostik der erworbenen ruptur der kammercheidewand des herzens. *Wien Arch Intern Med* 6:533. 1923.
5. Sager R. Coronary thrombosis: Perforation of the infarcted interventricular septum. *Arch Intern Med*. 1934.
6. Cooley DA, Belmonte BA, Zeis LB, Schnur S. Surgical repair of ruptured interventricular septum following acute myocardial infarction. *Surgery*. 1957.
7. Payne WS, Hunt JC, Kirklin JW. Surgical repair of ventricular septal defect due to myocardial infarction: Report of a case. *JAMA*. 1963.
8. Daggett WM. Postinfarction ventricular septal defect repair: Retrospective thoughts and historical perspectives. *Ann Thorac Surg*. 1990.
9. Assenza GE, McElhinney DB, Valente AM, Pearson DD, Volpe M, Martucci G, et al. Transcatheter closure of post-myocardial infarction ventricular septal rupture. *Circ Cardiovasc Interv*. 2013;6(1):59-67.
10. Shahreyar M, Akinseye O, Nayyar M, Ashraf U, Ibebuogu UN. Post-Myocardial Infarction Ventricular Septal Defect: A Comprehensive Review. *Cardiovasc Revasc Med*. 2020;21(11):1444-9.
11. Khan MY, Waqar T, Qaisrani PG, Khan AZ, Khan MS, Zaman H, et al. Surgical Repair of post-infarction ventricular septal rupture: Determinants of operative mortality and survival outcome analysis. *Pak J Med Sci*. 2018;34(1):20-6.
12. Crenshaw BS, Granger CB, Birnbaum Y, Pieper KS, Morris DC, Kleiman NS, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. *Circulation*. 2000;101(1):27-32.
13. Ghosh S, Halder V, Mishra A, Haranal M, Aggarwal P, Barwad P, et al. Surgical Outcomes of Post-myocardial Infarction Ventricular Septal Defect/Rupture: A Systematic Review and Meta-Analysis. *Cureus*. 2023;15(8):e44135.
14. Tripathi A, Bisht H, Arya A, Konat A, Patel D, Patel J, et al. Ventricular Septal Rupture Management in Patients With Acute Myocardial Infarction: A Review. *Cureus*. 2023;15(6):e40390.
15. Dimagli A, Guida G, Sinha S, Dixon L, Fudulu D, Gemelli M, et al. Surgical outcomes of post-infarct ventricular septal defect repair: Insights from the UK national adult cardiac surgery audit database. *J Card Surg*. 2022;37(4):843-52.
16. Birnbaum Y, Fishbein MC, Blanche C, Siegel RJ. Ventricular septal rupture after acute myocardial infarction. *New England Journal of Medicine*. 2002;347(18):1426-32.
17. Sajja LR, Mannam GC, Gutti RS, Goli NR, Sompalli S, Penumatsa RR. Postinfarction ventricular septal defect: patch repair with infarct exclusion. *Asian Cardiovasc Thorac Ann*. 2008;16(3):215-20.
18. Glancy DL, Khuri BN, Mustapha JA, Menon PV, Hanna EB. Myocardial infarction with ventricular septal rupture and cardiogenic shock. *Proc (Bayl Univ Med Cent)*. 2015;28(4):512-3.
19. Matteucci M, Ronco D, Corazzari C, Fina D, Jiritano F, Meani P, et al. Surgical Repair of Postinfarction Ventricular Septal Rupture: Systematic Review and Meta-Analysis. *The Annals of Thoracic Surgery*. 2021;112(1):326-37.
20. LEE WY, CARDON L, SLODKI SJ. Perforation of Infarcted Interventricular Septum: Report of a Case with Prolonged Survival, Diagnosed Ante Mortem by Cardiac Catheterization, and Review of the Literature. *Archives of Internal Medicine*. 1962;109(6):731-41.
21. Wilson WM, Horlick EM. Management of post-myocardial infarction ventricular septal rupture. *EuroIntervention*. 2016;12 Suppl X:X18-x23.
22. Flynn CD, Morris P, Manuel L, Matteucci M, Ronco D, Massimi G, et al. Systematic review and meta-analysis of the mechanical complications of ischemic heart disease: papillary muscle rupture, left ventricle rupture and post-infarct ventricular septal defect. *Ann Cardiothorac Surg*. 2022;11(3):195-209.
23. Cooley DA, Belmonte BA, Zeis LB, Schnur S. Surgical repair of ruptured interventricular septum following acute myocardial infarction. *Surgery*. 1957;41(6):930-7.
24. Daggett WM, Guyton RA, Mundth ED, Buckley MJ, McEnany MT, Gold HK, et al. Surgery for post-myocardial infarct ventricular septal defect. *Ann Surg*. 1977;186(3):260-71.
25. David TE, Dale L, Sun Z. Postinfarction ventricular septal rupture: repair by endocardial patch with infarct exclusion. *J Thorac Cardiovasc Surg*. 1995;110(5):1315-22.

26. Shibata T, Suehiro S, Ishikawa T, Hattori K, Kinoshita H. Repair of postinfarction ventricular septal defect with joined endocardial patches. *Ann Thorac Surg.* 1997;63(4):1165-7.
27. Tanaka H, Hasegawa S, Sakamoto T, Sunamori M. Postinfarction ventricular septal perforation repair with endoventricular circular patch plasty using double patches and gelatin-resorcinol-formaldehyde biological glue. *Eur J Cardiothorac Surg.* 2001;19(6):945-8.
28. Yip H-K, Fang C-Y, Tsai K-T, Chang H-W, Yeh K-H, Fu M, et al. The Potential Impact of Primary Percutaneous Coronary Intervention on Ventricular Septal Rupture Complicating Acute Myocardial Infarction. *Chest.* 2004;125(5):1622-8.



SOL VENTRİKÜL ANEVRİZMASI

BÖLÜM 52

Hasan REYHANOĞLU ¹
İsa DURMAZ ²

DOI: 10.37609/akya.3889.c5374

İçindekiler

- » GİRİŞ VE GENEL BİLGİLER
- » KLİNİK BELİRTİLER VE TANI YÖNTEMLERİ
- » TEDAVİ YAKLAŞIMLARI
- » CERRAHİ TEKNİKLER
 - » Lineer anevrizmektomi
 - » Septoplasti
 - » Endoventriküler Sirküler Yama Plasti
 - » Transkateter yöntemler
- » SONUÇLAR

¹ Doç. Dr., İzmir Tınaztepe Üniversitesi Özel Buca Hastanesi, hreyhanoglu@hotmail.com, ORCID iD: 0000-0002-2872-3361,

² Prof. Dr., Medica International İzmir Hastanesi, drisadurmaz@gmail.com, ORCID iD:0000-0001-5777-614x

Endoanevrizmorafinin önemli bir avantajı da geç dönemde prognoza etki eden önemli bir faktör olarak kabul edilen LAD revaskülarizasyonuna olanak sağlamasıdır.⁽²⁵⁾ Endoventrikler yama plastisi tekniğinde perikardiyal yama, iç yüzeyi perikard, dış yüzeyi dacron ile kaplanmış bir yama kullanımı ve geometrik endoventriküler tamir gibi birçok yeni modifikasyon da bildirilmiştir.^(26,27)

Bunun yanında lineer onarım yapılan olgularda düşük mortalite ve %78.13 oranında NYHA klasında iyileşme sağlayan serilerde bildirilmiştir.⁽⁸⁾ Modifiye bir lineer onarım tekniğinin kros-klemsiz uygulandığı olgularda %2.6 mortalite ile 5 yıllık %84 yaşam oranı ve NYHA sınıfı ile EF'de olumlu artışlar gözlenmiştir.⁽²⁸⁾ Bu çalışmada anlamlı risk faktörleri, tamir öncesi mitral yetmezliği ve KKY bulgularının varlığı ve aritmiler olarak gösterilmiştir.

Özetlenecek olursa, sonuçları etkileyen faktörler içerisinde, iskemiden zarar gören miyokard dokusunun miktarı, kapak lezyonunun bulunup bulunmaması, ventrikül kavitesinin genişliği, VT ataklar ve koroner arter hastalığının yaygınlığı erken ve geç sonuçlar üzerinde önemli rol oynamaktadırlar. Literatüre bakıldığı zaman çok değişik mortalite ve morbidite oranları ile karşılaşılmaktadır. Endoventriküler sirküler yama tekniğinin uygulanmasından sonra bu oranlarda önemli ölçüde düşme olmuştur. Bu gün iyi merkezlerde mortalite %3-5, IABP kullanımı %18 civarındadır.

Geç sonuçlara bakıldığı zaman 5 yıllık yaşam süresi yaklaşık %84'dür. Geç sonuçlara etki eden diğer önemli bir faktör LAD'nin revaskülarizasyonudur. İnfarktüs alanında olsa bile, LAD revaskülarize edilmelidir. Beş yıllık yaşam, LAD'ye LIMA greftlemesi yapılanlarda %88, ven grefti kullanılanlarda %72, revaskülarizasyon yapılmayanlarda %65 olarak bildirilmiştir.

Sonuçlarda dikkati çeken diğer bir önemli nokta, diskinetik anevrizmalarda sonuçların daha iyi olmasıdır. Akinetik anevrizmalarda ameliyat sonrası dönemde inotropik ilaç ve IABP kullanımının daha fazla olduğu bilinmektedir. Ameliyat sonrası dönemde EF'deki artış diskinetik anevrizmalı ol-

gularda daha fazladır. Dor ve arkadaşları istatistiksel olarak her iki grup arasında fark olmadığını bildirmekteyse genel görüş akinetik anevrizmalı grupta sonuçların daha kötü olduğu şeklindedir.

Sonucu etkileyen önemli bir faktör olarak bilinen mitral yetmezliği olguların çoğunda önemli ölçüde düzelmektedir. Bu düzelme;

- » Ventrikülün küçültülmesine bağlı olarak anülüsun de küçülmesi,
- » Revaskülarizasyon sonrası papiller adale disfonksiyonunun düzelmesi,
- » Ventrikül geometrisinin düzelmesine paralel olarak papiller adalenin doğru konumuna gelerek daha etkili fonksiyon görmesi gibi postoperatif gelişmelere bağlanmaktadır. Ancak ikinci dereceden daha fazla mitral yetmezliklerinde tercihen anüloplasti ile mitral yetmezliğinin tamir edilmesinin prognozu olumlu yönde etkileyeceği unutulmamalıdır.

KAYNAKLAR

1. Fiore CA, Jatene AD. Surgical treatment of left ventricular aneurysm. In: Baue AE, Geha AS, Hammond GL, Laks H, Naunheim KS. Glenn's Thoracic and Cardiovascular Surgery. Stamford-Connecticut: Appleton& Lange, 1996;2131-40.
2. Dor V, Sabatier M, Di Donato M et al. Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction: Comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg. 1998;116:50-9.
3. Cooley DA. Left ventricular aneurysm: Endoaneurysmoplasty. In: Kaiser LR, Kron IL, Thomas LS, eds. Mastery of Cardiothoracic Surgery. Philadelphia-New York: Lippincott-Raven, 1998;430-7.
4. Jatene AD. Left ventricular aneurysmectomy: Resection or reconstruction. J Thorac Cardiovasc Surg. 1985;89:321-31.
5. Dor V, Saab M, Coste P, Kornaszewska M, Montiglio F. Left ventricular aneurysm. A new surgical approach. Thorac Cardiovasc Surg. 1989;37:11-19.
6. İslamoğlu F, Özbaran M, Yüksel M et al. Sol ventrikül anevrizmalarında cerrahi tekniklerin etkinliği ve risk faktörlerinin değerlendirilmesi. Türk Göğüs Kalp Damar Cer Derg. (Türkçe), 2002;10:15-22.
7. Everson CT, Hockmuth DR. Technical advances in the treatment of left ventricular aneurysm. Ann Thorac Surg. 1993;55:792-800.
8. Surakiatchanukul S. Repair of the left ventricular aneurysm: Twenty-two years of experience with long-term results. Ann Thorac Cardiovasc Surg. 1999;5:396-401.
9. Caldeira C, McCarthy PM. A simple method of left ventricular reconstruction without patch for ischemic cardiomyopathy. Ann Thorac Surg. 2001;72(6):2148-9.

- doi: 10.1016/s0003-4975(01)03242-8.
10. Ruzza A, Czer LSC, Arabia F, Vespignani R, Esmailian F, Cheng W, De Robertis MA, Trento A. Left Ventricular Reconstruction for Postinfarction Left Ventricular Aneurysm: Review of Surgical Techniques. *Tex Heart Inst J*. 2017;1;44(5):326-335. doi: 10.14503/THIJ-16-6068.
 11. Cox JL. Surgical management of left ventricular aneurysms: a clarification of the similarities and differences between the Jatene and Dor techniques. *Semin Thorac Cardiovasc Surg*. 1997;9(2):131-8.
 12. Demirkılıç U, Kuralay E, Cingöz F, Günay C, Yılma AT, Tatar H. Sol ventrikül anevrizmaları. In: Duran E (ed). *Kalp ve Damar Cerrahisi*. İstanbul: Çapa Tıp kitabevi; 2004. p.1503-24.
 13. Brinza C, Cinteza M, Popa IV, Burlacu A. Safety and efficacy of less-invasive ventricular enhancement procedure with the transcatheter Revivent TC™ system in patients with left ventricular aneurysm: a systematic review. *Rev Cardiovasc Med*. 2021;22(2):445-452. doi: 10.31083/j.rcm2202050.
 14. Klein P, Anker SD, Wechsler A, Skalsky I, Neuzil P, Annet LS, Bifi M, McDonagh T, Frerker C, Schmidt T, Sievert H, Demaria AN, Kelle S. Less invasive ventricular reconstruction for ischaemic heart failure. *Eur J Heart Fail*. 2019;21(12):1638-1650. doi: 10.1002/ehf.1669.
 15. Sakaguchi G, Young RL, Komeda M et al. Left ventricular aneurysm repair in rats: structural, functional, and molecular consequences. *J Thorac Cardiovasc Surg*. 2001;121:750-61.
 16. Akins CW. Resection of left ventricular aneurysm during hypothermic fibrillatory arrest without aortic occlusion. *J Thorac Cardiovasc Surg*. 1986;91:610-8.
 17. Barrat-Boyes BG, White HD, Agnew TM, JR, Wild CJ. The results of surgical treatment of left ventricular aneurysms. An assessment of the risk factors affecting early and late mortality. *J Thorac Cardiovasc Surg*. 1984;87:87-98.
 18. Di Donato M, Sabatier M, Montiglio F et al. Outcome of left ventricular aneurysmectomy with patch repair in patients with severely depressed pump function. *Am J Cardiol*. 1995;76:557-61.
 19. Louagie Y, Alouini T, Lesperance J, Pelletier LC. Left ventricular aneurysm complicated by congestive heart failure: an analysis of long-term results and risk factors of surgical treatment. *J Cardiovasc Surg (Torino)*. 1989;30:648-655.
 20. Vicol C, Rupp G, Fischer S et al. Linear repair versus ventricular reconstruction for treatment of ventricular aneurysm: A 10-year experience. *J Cardiovasc Surg (Torino)*. 1998;39:461-7.
 21. Pasini S, Gagliardotto P, Punta G et al. Early and late results after surgical therapy of postinfarction left ventricular aneurysm. *J Cardiovasc Surg (Torino)*. 1998;39:209-15.
 22. Vural KM, Sener E, Özatik MA, Taşdemir O, Bayazit K. Left ventricular aneurysm repair: An assessment of surgical treatment modalities. *Eur J Cardiotorac Surg*. 1998;13:49-56.
 23. Couper GS, Bunton RW, Birjiniuk V et al. Relative risks of left ventricular aneurysmectomy in patients with akinetic scars versus true dyskinetic aneurysms. *Circulation*. 1990;8(Suppl IV):248-56.
 24. Kawata T, Kitamura S, Kawachi K et al. Systolic and diastolic function after patch reconstruction of left ventricular aneurysm. *Ann Thorac Surg*. 1995;59:403-7.
 25. Jindani A, Williams BT. Survival after left ventricular aneurysmectomy with or without coronary artery bypass graft. *Coron Artery Dis*. 1992;3:739-44.
 26. Cohen AJ, Rubin O, Hauptman E et al. Ventricular aneurysm repair: A new approach. *J Card Surg*. 2000;15:209-16.
 27. Raman JS, Sakaguchi G, Buxton BF. Outcome of geometric endoventricular repair in impaired left ventricular function. *Ann Thorac Surg*. 2000;70:1127-9.
 28. Mickleborough LL, Carson S, Ivanov J. Repair of dyskinetic or akinetic left ventricular aneurysm: Results obtained with a modified linear closure. *J Thorac Cardiovasc Surg*. 2001;121:675-82.



KALP CERRAHİSİNDE HEMORAJİK VE TROMBOTİK KOMPLİKASYONLAR

DOI: 10.37609/akya.3889.c5375

BÖLÜM 53

Özer KANDEMİR¹
Hilmi TOKMAKOĞLU²
Ali Cem YORGANCIOĞLU³

İçindekiler

- » GİRİŞ VE GENEL BİLGİLER
- » HEMOSTAZIN PREOPERATİF DEĞERLENDİRİLMESİ
 - » Preoperatif Klinik Değerlendirme
 - » Preoperatif Laboratuvar Değerlendirmesi
 - » Fibrinojen Miktarı
- » KOAGÜLASYON MEKANİZMASI
 - » İntrensek Yolak
 - » Ekstrensek Yolak
 - » Ortak Yolak
 - » Trombositlerin Aktivasyonu
- » KARDİYOPULMONER BYPASS'IN HEMOSTAZ ÜZERİNE ETKİLERİ
 - » Fibrinolitik Aktivasyon
- » POSTOPERATİF KANAMA
 - » Tanı
 - » Postoperatif Kanama Nedenleri
 - » Preoperatif Nedenler
 - » Kardiyopulmoner Bypass Sonrası Kanama Tedavisi
- » AÇIK KALP CERRAHİSİNDE TROMBOTİK VE TROMBOEMBOLİK KOMPLİKASYONLAR
 - »

¹ Doç. Dr., Etlik Şehir Hastanesi, Kalp ve Damar Cerrahisi Kliniği, ozerkandemir@gmail.com, ORCID iD: 0000-0002-3655-4537

² Prof. Dr., Sancaktepe Şehit Prof. Dr. İlhan Varank Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, h.tokmakoglu@isnet.net.tr, ORCID iD: 0009-0005-6795-5201

³ Prof. Dr., Memorial Ankara Hastanesi, cem.yorgancioglu@gmail.com, ORCID iD: 0009-0008-6653-8758

Kapak hastalarında sol atriyumda, sol ventrikül anevrizmalı hastalarda sol ventrikülde yer alabilecek trombüslerin krosklemp konmadan önce kanülasyon esnasında embolizasyona yol açmamaları için gerekli özen gösterilmelidir. Kalp fazla maniple edilmemeli, sol atriyal ventilasyon için kanül kros-klemp sonrası konulmalıdır. Bu tip hastalarda ve kalsifik kapak hastalığı olanlarda kros-klemp sonrası trombüs veya kalsifikasyon tamamen temizlenmeli, kalp boşluklarında partikül kalmadığından emin olunmalıdır. Yine konjenital kalp hastalarında kanülasyon esnasında olabilecek hava embolizasyonlarına dikkat edilmesi gerekmektedir.

Kapak replasmanları sonrasında Coumadin ile yeterli antikoagülasyon sağlanana kadar (INR yaklaşık 2,5) tromboembolik olaylar azda olsa gözlenebilmektedir. Bu komplikasyondan sakınmak için replasman yapılan hastalarda, bazı klinikler gibi bizde hastanın drenajı kesildikten sonra (genellikle 1218 st sonra) ilk doz warfarin ile birlikte yeterli INR değeri sağlanana kadar fraksiyone heparin ajanları kullanılmaktadır.

KAYNAKLAR

- Service des Etudes. Indication des examens preopératoires. Paris: Agence Nationale pour le Développement de l'évaluation Médicale, 1992.
- Tamiya T, Yamasaki M, et al. Complement activation in cardiopulmonary bypass with special reference to anaphylatoxin production in membrane and bubble oxygenators. *Ann Thorac Surg*, 1988;46:47.
- Despotis GJ, Santaro SA, Spitznagel E et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. *J Thorac Cardiovasc Surg*, 1994;107:271-9.
- Kalter RD, Saul CM, Wetstein L, Soriano C, Reiss RF. Cardiopulmonary bypass. Associated hemostatic abnormalities. *J Thorac Cardiovasc Surg*, 1979;77:427-35.
- Heimark RL, Kurachi K, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. *Nature*, 1980;286:456-60.
- Boisclair MD, Lane DA, Philippou H et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. *Blood*, 1993;82:3350-7.
- De Haan J, Boonstra PW, Monnink SH, Ebels T, Van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. *Ann Thorac Surg*, 1995;59:901-7.
- Tabuchi N, De Haan J, Boonstra PW, Van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. *J Thorac Cardiovasc Surg*, 1993;106:828-33.
- Gram J, Janetzko T, Jespersen J, Bruhn HD. Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increases the risk of post-surgical bleeding. *Thromb Haemost*, 1990;63:241.
- Edmunds LH Jr, Ellison N, Colman RW et al. Platelet function during open heart surgery: Comparison of the membrane and bubble oxygenators. *J Thorac Cardiovasc Surg*, 1982;83:805.
- Zilla P, Fasol R, Groscurth P et al. Blood platelets in cardiopulmonary bypass operations. *J Thorac Cardiovasc Surg*, 1989;97:379.
- Cramer EM, Lu H, Caen JP et al. Differential redistribution of platelet glycoproteins Ib and IIb/IIIa after plasma stimulation. *Blood*, 1991;77:694-9.
- Coughlin SR, Vu T-KH, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. *J Clin Invest*, 1992;89:351.
- Khuri SF, Valeri CR, Loscalzo J et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. *Ann Thorac Surg*, 1995;60:1008.
- Rinder CS, Rinder HM, Smith BR et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. *J Clin Invest*, 1995;96:1564.
- Valeri CR, Khabbaz K, Khuri SF et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. *J Thorac Cardiovasc Surg*, 1992;104:108.
- Czer LSC, Bateman TM, Gray RJ et al. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. *J Am Coll Cardiol*, 1987;9:1139-47.
- Michelson EL, Torosian M, Morganroth J, MacVaugh H III. Early recognition of surgically correctable causes of excessive mediastinal bleeding after coronary artery bypass graft surgery. *Am J Surg*, 1980;139:313-7.
- Verska JJ, Lonser ER, Brewer LA III. Predisposing factors and management of hemorrhage following open heart surgery. *J Cardiovasc Surg*, 1972;13:361-8.
- Czer LSC. Mediastinal bleeding after cardiac surgery: Etiologies, diagnostic considerations, and blood conservation methods. *J Cardiothorac Anesth*, 1989;3:760-5.
- Hartstein G, Janssens M. Treatment of excessive mediastinal bleeding after cardiopulmonary bypass. *Ann Thorac Surg*, 1996;62:1951-4.
- Edmund LH Jr. Pulseless cardiopulmonary bypass. *J Thorac Cardiovasc Surg*, 1982;84:800.
- Boucher JK, Rudy LW, Edmunds LH Jr. Organ blood flow during cardiopulmonary bypass. *J Appl Physiol*, 1974;36:86.
- Tominaga R, Smith WA, Massiello A et al. Chronic nonpulsatile blood flow. Cerebral autoregulation in chronic nonpulsatile biventricular bypass: carotid blood flow response to hypercapnia. *J Thorac Cardiovasc Surg*, 1994;108:907.
- Rudy LW Jr, Heymann MA, Edmunds LH Jr. Distribution of systemic blood flow during cardiopulmonary bypass. *J Appl Physiol*, 1973;34:194.

26. Harker LA, Malpass TW, Branson HE et al. Mechanism of abnormal bleeding in patients undergoing car- diopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha granule release. *Blood*, 1980;56:284.
27. Kelton JG, Smith JW, Warkentin TE et al. Immunoglobulin G from patients with heparin-induced throm- bopenia binds to a complex of heparin and plate- let factor 4. *Blood*, 1994;83:3232.
28. Bell WR. Heparin-associated thrombocytopenia and thrombosis. *J Lab Clin Med*, 1988;111:600.
29. Shulman NR, Reid DM. Platelet immunology in Col- man RW, Hirsh J, Marder VJ, Salzman EW (eds): *Hemostasis and Thrombosis Basic Principles and Clinical Practice*. Philadelphia, Lippincott, 1994;p:414.
30. Luddington RJ. Thromboelastography/ Thromboelas- tometry. *Clin Lab Haematol*. 2005 Apr;27(2):81-90.
31. Redfern RE, Fleming K, March RL, et al. Thrombelas- tography-Directed Transfusion in Cardiac Surgery: Impact on Postoperative Outcomes. *Ann Thorac Surg*. 2019 May;107(5):1313-1318
32. Ak K, Atalan N, Tekeli A, İşbir S, Civelek A, Emekli N, Arsan S. Thromboelastography and its use in cardiac surgery. *Anadolu Kardiyol Derg*. 2008 Apr;8(2):154-62.
33. Akan M. Erişkin karaciğer transplantasyonunda yoğun bakım yönetimi. *J Turk Soc Intensive care*, 2017;15:1-20.
34. Kern FH, Morana NJ, Sears JJ, Hickey PR. Coagulation defects in neonates during cardiopulmo- nary bypass. *Ann Thorac Surg*, 1992;54:541-6.
35. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. *Blood*, 1987;70:165-72.
36. Guay J, Rivard GE. Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. *Ann Thorac Surg*, 1996;62:1955-60.
37. Maurer HM, McCue CM, Caul J, Still WJS. Impairment in platelet aggregation in congenital heart disease. *Blood*, 1972;40:207-16.
38. Dietrich W, Mössinger H, Spannagl M et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. *J Thorac Cardiovasc Surg*, 1993;105:712-20.
39. Lisi G, Sani G, Maccherini M, Biagioli B, Toscano M. Platelet function and hypothermic cardiopulmonary bypass. *Ann Thorac Surg*, 1993;56:1442-3.
40. Khuri SF, Wolfe JA, Josa M et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgi- cal blood loss. *J Thorac Cardiovasc Surg*, 1992;104:94- 107.
41. Ilabaca PA, Ochsner JL, Mills NL. Positive end-expira- tory pressure in the management of the patient with a postoperative bleeding heart. *Ann Thorac Surg*;1980; 30:281-4.
42. Gray RJ, Bateman TM, Czer LSC, Conklin C, Matloff JM. Use of esmolol in hypertension after cardiac surgery. *Am J Cardiol*, 1985;56:49-56.
43. Rodgers RPC, Levin J. A critical reappraisal of the ble- eding time. *Semin Throm Hemost*, 1990;16:1-20.
44. Uehlinger J, Adedort LM. Blood product usage in car- diac surgery. *J Cardiothorac Anesth*, 1989;3:776-84.
45. Mannucci PM. Desmopressin (DDAVP) for treat- ment disorders of hemostasis. *Prog Hemost Throm*, 1986;8:19-45.
46. Sloand EM, Alyono D, Klein HG et al. 1-Deamino-8-D- arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopul- monary bypass. *Am J Hematol*, 1994;46:199-207.
47. Vander Salm TJ, Ansell JE, Okike ON et al. The role of epsilon- aminocaproic acid in reducing bleeding after cardiac operation: A double-blind randomized study. *J Cardiovasc Surg*, 1988;95:538-40.
48. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocapro- ic acid on blood loss and transfusion requirements in patients undergoing first time coronary artery bypass grafting. A randomized, prospective, double-blind study. *J Thorac Cardiovasc Surg*;1994;108:99-108.
49. DelRossi AJ, Cernaianu AC, Botros AC, Lemole GM, Moore R. Prophylactic treatment of postperfusion ble- eding using EACA. *Chest*, 1989;96:27-30.
50. Janssens M, Harstein G, David JL. Reduction in requi- rements for allogeneic blood products: Pharmaco- logic methods. *Ann Thorac Surg*, 1996;62:1944-50.
51. Arom KV, Emery RW. Decreased postoperative draina- ge with addition of Î-aminocaproic acid before cardio- pulmonary bypass. *Ann Thorac Surg*, 1994;57:1108-13.
52. Karski JM, Teasdale SJ, Norman PH et al. Prevention of postbypass bleeding with tranexamic acid and epsi- lon-aminocaproic acid. *J Cardiothorac Vasc Anesth*, 1993;7:431-5.
53. Levy JH. Pharmacologic preservation of the hemosta- tic system during cardiac surgery. *Ann Thorac Surg*, 2001;72:1814-20.
54. Landis RC, Haskard DO, Taylor KM. New antiinflam- matory and platelet-preserving effects of aprotinin. *Ann Thorac Surg*, 2001;72:1808-13.
55. Vander Salm TJ, Ansell JE, Okike ON et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: A double-blind randomized study. *J Thorac Cardiovasc Surg*, 1988;95:538.
56. Royston D. High dose aprotinin therapy: A review of the first five years experience. *J Cardiothorac Vasc Anesth*, 1992;6:76.
57. Cosgrove DM III, Heric B, Lytle BW et al. Aprotinin the- rapy for reoperative myocardial revascularization: A placebo-controlled study (discussion). *Ann Thorac Surg*, 1992;54:1031.
58. Sundt TM III, Kouchoukos NT, Saffitz JE et al. Renal dysfunction and intravascular coagulation with apro- tinin and hypothermic circulatory arrest. *Ann Thorac Surg*, 1993;55:1418.
59. Laub GW, Riebman JB, Anderson WA et al. The impact of aprotinin on coronary artery bypass graft patency. *Chest*, 1994;106:1370.
60. Dennis MF. Anticoagulation monitoring during cardic surgery. *Anesthesiology*, 1999;91:1122-52
61. Blauth CI, Smith PL, Arnold JV et al. Influence of oxy- genator type on the prevalence and extend of micro- embolic retinal ischemia during cardiopulmonary by- pass. *J Thorac Cardiovasc Surg*, 1990;99:61.
62. Clark RE, Magraf HW, Beauchamp RA. Fat and solid filtration in clinical perfusion. *Surgery*, 1975;77:216.



DERİN STERNAL YARA ENFEKSİYONLARI

BÖLÜM 54

Görkem YİĞİT ¹

DOI: 10.37609/akya.3889.c5376

İçindekiler

- » TANIM
- » İNSİDANS VE ETİYOLOJİ
- » RİSK FAKTÖRLERİ
- » TANI
- » ÖNLEM
- » CERRAHİ YÖNETİM
 - » Primer Kapama ve İrrigasyon
 - » Yumuşak Doku Flepleri
 - » Omental Flepler
- » STERNUM FİKSASYONU
- » VAKUM DESTEKLİ KAPAMA YÖNTEMİ
- » ANTİBİYOTERAPİ
- » KORONER ARTER BYPASS CERRAHİSİNDE DERİN STERNAL YARA ENFEKSİYONLARI

¹ Doç. Dr., Balıkesir Atatürk Şehir Hastanesi, drgorkemyigit@gmail.com, ORCID iD: 0000-0002-9500-720X

KAYNAKLAR

1. Milton H. Mediastinal Surgery. *Lancet* 1897;1:872-5.
2. El Oakley RM, Wright JE. Postoperative mediastinitis: classification and management. *Ann Thorac Surg.* 1996;61(3):1030-1036. doi:10.1016/0003-4975(95)01035-1.
3. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. *Am J Infect Control.* 1999;27(2):97-96.
4. Eklund AM, Lyytikäinen O, Klemets P, et al. Mediastinitis after more than 10,000 cardiac surgical procedures. *Ann Thorac Surg.* 2006;82(5):1784-1789. doi:10.1016/j.athoracsurg.2006.05.097.
5. Poncelet AJ, Lengele B, Delaere B, et al. Algorithm for primary closure in sternal wound infection: a single institution 10-year experience. *Eur J Cardiothorac Surg.* 2008;33(2):232-238. doi:10.1016/j.ejcts.2007.11.016.
6. Tang GH, Maganti M, Weisel RD, et al. Prevention and management of deep sternal wound infection. *Semin Thorac Cardiovasc Surg.* 2004;16(1):62-69. doi:10.1053/j.semtcvs.2004.01.005.
7. Gårdlund B, Bitkover CY, Vaage J. Postoperative mediastinitis in cardiac surgery - microbiology and pathogenesis. *Eur J Cardiothorac Surg.* 2002;21(5):825-830. doi:10.1016/s1010-7940(02)00084-2.
8. Sjögren J, Malmjö M, Gustafsson R, et al. Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuum-assisted closure therapy and presentation of the Lund University Hospital mediastinitis algorithm. *Eur J Cardiothorac Surg.* 2006;30(6):898-905. doi:10.1016/j.ejcts.2006.09.020.
9. Muñoz P, Menasalvas A, Bernaldo de Quirós JC, et al. Postsurgical mediastinitis: a case-control study. *Clin Infect Dis.* 1997;25(5):1060-1064. doi:10.1086/516068.
10. Gur E, Stern D, Weiss J, et al. Clinical-radiological evaluation of poststernotomy wound infection. *Plast Reconstr Surg.* 1998;101(2):348-355. doi:10.1097/00006534-199802000-00012.
11. Quirce R, Carril JM, Gutiérrez-Mendiguchía C, et al. Assessment of the diagnostic capacity of planar scintigraphy and SPECT with 99mTc-HMPAO-labelled leucocytes in superficial and deep sternal infections after median sternotomy. *Nucl Med Commun.* 2002;23(5):453-459. doi:10.1097/00006231-200205000-00005.
12. Fynn-Thompson F, Vander Salm TJ. Methods for reduction of sternal wound infection. *Semin Thorac Cardiovasc Surg.* 2004;16(1):77-80. doi:10.1053/j.semtcvs.2004.01.004.
13. Cimochoowski GE, Harostock MD, Brown R, et al. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. *Ann Thorac Surg.* 2001;71(5):1572-1579. doi:10.1016/s0003-4975(01)02519-x.
14. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med.* 2001;345(19):1359-1367. doi:10.1056/NEJMoa011300.
15. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. *Ann Thorac Surg.* 1999;67(2):352-362. doi:10.1016/s0003-4975(99)00014-4.
16. Tavalacci MP, Merle V, Josset V, et al. Mediastinitis after coronary artery bypass graft surgery: influence of the mammary grafting for diabetic patients. *J Hosp Infect.* 2003;55(1):21-25. doi:10.1016/s0195-6701(03)00116-6.
17. Peterson MD, Borger MA, Rao V, et al. Skeletonization of bilateral internal thoracic artery grafts lowers the risk of sternal infection in patients with diabetes. *J Thorac Cardiovasc Surg.* 2003;126(5):1314-1319. doi:10.1016/s0022-5223(03)00808-0.
18. Sarr MG, Gott VL, Townsend TR. Mediastinal infection after cardiac surgery. *Ann Thorac Surg.* 1984;38(4):415-423. doi:10.1016/s0003-4975(10)62300-4.
19. Shumacker HB Jr, Mandelbaum I. Continuous antibiotic irrigation in the treatment of infection. *Arch Surg.* 1963;86:384-387. doi:10.1001/archsurg.1963.01310090034006.
20. Kirsch M, Mekontso-Dessap A, Houël R, et al. Closed drainage using redon catheters for poststernotomy mediastinitis: results and risk factors for adverse outcome. *Ann Thorac Surg.* 2001;71(5):1580-1586. doi:10.1016/s0003-4975(01)02452-3.
21. Molina JE, Nelson EC, Smith RR. Treatment of postoperative sternal dehiscence with mediastinitis: twenty-four-year use of a single method. *J Thorac Cardiovasc Surg.* 2006;132(4):782-787. doi:10.1016/j.jitcvs.2006.06.008.
22. Lee AB Jr, Schimert G, Shaktin S, et al. Total excision of the sternum and thoracic pedicle transposition of the greater omentum; useful strategies in managing severe mediastinal infection following open heart surgery. *Surgery.* 1976;80(4):433-436.
23. Graeber GM, McClelland WT. Current concepts in the management and reconstruction of the dehiscence median sternotomy. *Semin Thorac Cardiovasc Surg.* 2004;16(1):92-107. doi:10.1053/j.semtcvs.2004.01.008.
24. Jones G, Jurkiewicz MJ, Bostwick J, et al. Management of the infected median sternotomy wound with muscle flaps. The Emory 20-year experience. *Ann Surg.* 1997;225(6):766-778. doi:10.1097/00006558-199706000-00014.
25. Oh AK, Lechtman AN, Whetzel TP, et al. The infected median sternotomy wound: management with the rectus abdominis musculocutaneous flap. *Ann Plast Surg.* 2004;52(4):367-370. doi:10.1097/01.sap.0000099710.38299.a3.
26. Davison SP, Clemens MW, Armstrong D, et al. Sternotomy wounds: rectus flap versus modified pectoral reconstruction. *Plast Reconstr Surg.* 2007;120(4):929-934. doi:10.1097/01.prs.0000253443.09780.0f.
27. Cicilioni OJ Jr, Stieg FH 3rd, Papanicolaou G. Sternal wound reconstruction with transverse plate fixation. *Plast Reconstr Surg.* 2005;115(5):1297-1303. doi:10.1097/01.prs.0000156918.15595.85.
28. Agarwal JP, Ogilvie M, Wu LC, et al. Vacuum-assisted closure for sternal wounds: a first-line therapeutic management approach. *Plast Reconstr Surg.* 2005;116(4):1035-1043. doi:10.1097/01.prs.0000178401.52143.32.
29. Fleck TM, Koller R, Giovanoli P, et al. Primary or delayed closure for the treatment of poststernotomy wound infections?. *Ann Plast Surg.* 2004;52(3):310-314. doi:10.1097/01.sap.0000105524.75597.e0.
30. Gustafsson R, Johnsson P, Algotsson L, et al. Vacuum-assisted closure therapy guided by C-reactive

- protein level in patients with deep sternal wound infection. *J Thorac Cardiovasc Surg.* 2002;123(5):895-900. doi:10.1067/mtc.2002.121306.
31. Singh K, Anderson E, Harper JG. Overview and management of sternal wound infection. *Semin Plast Surg.* 2011;25(1):25-33. doi:10.1055/s-0031-1275168.
 32. Dubert M, Pourbaix A, Alkhoder S, et al. Sternal Wound Infection after Cardiac Surgery: Management and Outcome. *PLoS One.* 2015;10(9):e0139122. Published 2015 Sep 30. doi:10.1371/journal.pone.0139122.
 33. Yusuf E, Chan M, Renz N, et al. Current perspectives on diagnosis and management of sternal wound infections. *Infect Drug Resist.* 2018;11:961-968. Published 2018 Jul 16. doi:10.2147/IDR.S130172.
 34. Karra R, McDermott L, Connelly S, et al. Risk factors for 1-year mortality after postoperative mediastinitis. *J Thorac Cardiovasc Surg.* 2006;132(3):537-543. doi:10.1016/j.jtcvs.2006.04.037.
 35. Falagas ME, Tansarli GS, Kapaskelis A, et al. Impact of vacuum-assisted closure (VAC) therapy on clinical outcomes of patients with sternal wound infections: a meta-analysis of non-randomized studies. *PLoS One.* 2013;8(5):e64741. Published 2013 May 31. doi:10.1371/journal.pone.0064741.
 36. Matsa M, Paz Y, Gurevitch J, et al. Bilateral skeletonized internal thoracic artery grafts in patients with diabetes mellitus. *J Thorac Cardiovasc Surg.* 2001;121(4):668-674. doi:10.1067/mtc.2001.112824.
 37. Loop FD, Lytle BW, Cosgrove DM, et al. J. Maxwell Chamberlain memorial paper. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. *Ann Thorac Surg.* 1990;49(2):179-187. doi:10.1016/0003-4975(90)90136-t.
 38. Medalion B, Katz MG, Lorberboym M, et al. Decreased sternal vascularity after internal thoracic artery harvesting resolves with time: an assessment with single photon emission computed tomography. *J Thorac Cardiovasc Surg.* 2002;123(3):508-511. doi:10.1067/mtc.2002.120007.
 39. Ståhle E, Tammelin A, Bergström R, et al. Sternal wound complications--incidence, microbiology and risk factors. *Eur J Cardiothorac Surg.* 1997;11(6):1146-1153. doi:10.1016/s1010-7940(97)01210-4.
 40. Guvener M, Pasaoglu I, Demircin M, et al. Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting. *Endocr J.* 2002;49(5):531-537. doi:10.1507/endocrj.49.531.
 41. Nishida H, Endo M, Koyanagi H, et al. Coronary artery bypass grafting with the right gastroepiploic artery and evaluation of flow with transcutaneous Doppler echocardiography. *J Thorac Cardiovasc Surg.* 1994;108(3):532-539.



KRONİK TROMBOEMBOLİK PULMONER HİPERTANSİYONDA PULMONER TROMBOENDARTEREKTOMİ

DOI: 10.37609/akya.3889.c5377

BÖLÜM 55

Sevda KURTULMUŞ ¹
Selim İSBİR ²

İçindekiler

- » GİRİŞ
- » PATOLOJİ VE PATOGENEZ
- » KLİNİK
- » TANI YÖNTEMLERİ
- » AYIRICI TANI
- » ENDİKASYON
- » TEDAVİ
- » PULMONER TROMBOENDARTEREKTOMİ AMELİYATI
 - » Ameliyat Sonrası Bakım
- » BALON PULMONER ANJİYOPLASTİ
- » SONUÇ

¹ Op. Dr., Hakkari Devlet Hastanesi, kurtulmussevda@gmail.com, ORCID iD: 0000-0003-3597-3999

² Prof.Dr., Yeditepe Üniversitesi Hastaneleri, Kalp Damar Cerrahisi Kliniği, dr.selimisbir@gmail.com, ORCID iD: 0000-0001-9032-6407

tadır. Bu tablonun önüne geçmek açısından bazı gruplar ameliyat öncesi rutin olarak inferior vena kava filtresi konulmasını önermektedirler. Bu konuda bizim yaklaşımımız rutin filtre konulması yönündedir. Ayrıca ameliyat sonrası erken dönemde hastanın drenaj durumunda göz önüne alınarak heparin başlanılmalı ve sonrasında hayat boyu warfarin kullanımına geçilmelidir (58,59). Son yıllarda direkt oral antikoagulanlar (DOAK) sıklıkla kullanılmaya başlanmıştır. Öte yandan warfarin ile DOAK arasında yapılan çalışmalar da DOAK kullanılan hastalarda reküren tromboemboli riskinin daha fazla olduğunu göstermiştir (60). İnoperabl hastalarda medikal tedavi ayrı bir konu olduğu için burada detaylı olarak değinilmemiştir.

BALON PULMONER ANJİYOPLASTİ

Balon pulmoner anjiyoplasti (BPA), sıklıkla inoperabl veya pulmoner endarterektomi sonrası semptomatik kalıcı/reküren pulmoner hipertansiyonu olan hastalarda başvuru bir tedavi yöntemidir. Kronik tromboembolik pulmoner hipertansiyon hastalarının yaklaşık %40'ı distal hastalık, komorbidite veya diğer nedenlere bağlı olarak inoperabl kabul edilmektedir. Pulmoner arter içerisinde darlık oluşturan fibrotik bantları balonla açarak pulmoner arterde distale olan kan akımını artırır. Pulmoner endarterektomiye uygun olmayan hastalarda medikal tedaviye göre sonuçları daha iyidir. Bununla birlikte belirli komplikasyonları olan bir tedavi yöntemidir. Komplikasyonların başında pulmoner arter perforasyonu ve rüptürü gelmektedir. Bunlara bağlı olarak hastada hemoptizi ve hipoksemi ortaya çıkabilir. Literatürde BPA komplikasyon oranı olarak %2-4 olarak belirtilmektedir (61-63).

SONUÇ

Kronik tromboembolik pulmoner hipertansiyon tedavisinde, PTE ameliyatı, sonuçları açısından yüz güldürücü bir cerrahi prosedürdür. Bu hasta grubunda PTE ameliyatının tek alternatifinin akciğer nakli olduğu düşünüldüğünde bu ameliyatın ne kadar önemli olduğu ortaya çıkmaktadır.

Çeşitli merkezlerce yayınlanan vaka serilerinde mortalitenin % 5-15 arasında değiştiği görülmektedir (64-66). Geç dönem takiplerinde ise 5 yıllık hayatta kalım oranının %75 lerde olduğu bilinmektedir. Hastaların büyük çoğunluğunun klas 1-2 fonksiyonel kapasitede olması ve normal hayatlarına dönmesi tedavinin etkin olduğunu göstermektedir.

KAYNAKLAR

1. Kim NH, Delcroix M, Jais X, et al. Chronic Thromboembolic Pulmonary Hypertension. *Eur Respir J*. 2019 Jan 24;53(1):1801915. doi: 10.1183/13993003.01915-2018.
2. Pengo V, Lensing AW, Prins MH, et al. Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med*. 2004;350(22):2257-64.
3. Sanchez O, Helley D, Couchon S, et al. Perfusion defects after pulmonary embolism: risk factors and clinical significance. *J Thromb Haemost*. 2010 Jun;8(6):1248-55. doi: 10.1111/j.1538-7836.2010.03844.x.
4. Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. *Thromb Haemost*. 2005;93(3):512-6.
5. Nystrom G. Experiences with the Trendelenburg Operation for Pulmonary Embolism. *Ann Surg*. 1930;92(4):498-532.
6. Daily PO, Dembitsky WP, Daily RP. Dissectors for pulmonary thromboendarterectomy. *Ann Thorac Surg*. 1991;51(5):842-3.
7. Daily PO, Dembitsky WP, Iversen S, et al. Risk factors for pulmonary thromboendarterectomy. *J Thorac Cardiovasc Surg*. 1990 ;99(4):670-8.
8. Daily PO, Dembitsky WP, Jamieson SW. The evolution and the current state of the art of pulmonary thromboendarterectomy. *Semin Thorac Cardiovasc Surg*. 1999;11(2):152-63.
9. Daily PO, Auger WR. Historical perspective: surgery for chronic thromboembolic disease. *Semin Thorac Cardiovasc Surg*. 1999;11(2):143-51.
10. Sacks RS, Remillard CV, Agange N, et al. Molecular biology of chronic thromboembolic pulmonary hypertension. *Semin Thorac Cardiovasc Surg*. 2006 ;18(3):265-76.
11. Sacks RS, Firth AL, Remillard CV, et al. Thrombin-mediated increases in cytosolic [Ca²⁺] involve different mechanisms in human pulmonary artery smooth muscle and endothelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2008 ;295(6):L1048-55.
12. Dorfmueller P, Günther S, Ghigna MR, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. *Eur Respir J*. 2014 Nov;44(5):1275-88. doi: 10.1183/09031936.00169113. Epub 2014 Aug 19.
13. Lang IM, Klepetko W. Chronic thromboembolic pulmonary hypertension: an updated review. *Curr Opin Cardiol*. 2008;23(6):555-9.

14. Kerr KM, Elliott CG, Chin K, et al. Results from the United States Chronic Thromboembolic Pulmonary Hypertension Registry: enrollment characteristics and 1 year follow-up. *Chest*. 2021 Nov;160(5):1822-1831. doi: 10.1016/j.chest.2021.05.052. Epub 2021 Jun 4.
15. Le Gal G, Delahousse B, Lacut K, et al. Groupe d'Etudes sur la Thrombose des Hôpitaux Universitaires du Grand Ouest. Fibrinogen Aalpha-Thr312Ala and factor XIII-AVal34Leu polymorphisms in idiopathic venous thromboembolism. *Thromb Res*. 2007;121(3):333-8.
16. Suntharalingam J, Goldsmith K, van Marion V, et al. Fibrinogen Aalpha Thr312 Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2008;31(4):736-41.
17. Kapitan KS, Buchbinder M, Wagner PD, et al. Mechanisms of hypoxemia in chronic thromboembolic pulmonary hypertension. *Am Rev Respir Dis*. 1989;139(5):1149-54.
18. Lang I. Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension. *Br J Haematol*. 2010 May;149(4):478-83. doi: 10.1111/j.1365-2141.2010.08142.
19. Elhage Hassan M, Vinales J, Perkins S, et al. Pathogenesis, Diagnosis and Management of Chronic Thromboembolic Pulmonary Hypertension. *Interv Cardiol Clin*. 2023 Jul;12(35):e37-e49. doi: 10.1016/j.iccl.2024.04.003.
20. Teerapuncharn K, Bag R. Chronic Thromboembolic Pulmonary Hypertension. *Lung* 2022;200: 283-299.
21. Ryan KL, Fedullo PF, Davis GB, et al. Perfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension. *Chest*. 1988;93(6):1180-5.
22. Auger WR, Fedullo PF, Moser KM, et al. Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. *Radiology*. 1992;182(2):393-8.
23. Dogan H, de Roos A, Geleijns J, et al. The role of computed tomography in the diagnosis of acute and chronic pulmonary embolism. *Diagn Interv Radiol*. 2015 Jul-Aug;21(4):307-16. doi: 10.5152/dir.2015.14403.
24. Gopalan D, Riley JYJ, Leong K, Alsanjari S, et al. Computed Tomography Pulmonary Angiography Prediction of Adverse Long-Term Outcomes in Chronic Thromboembolic Pulmonary Hypertension: Correlation with Hemodynamic Measurements Pre- and Post-Pulmonary Endarterectomy. *Tomography*. 2023 Sep 26;9(5):1787-1798. doi: 10.3390/tomography9050142.
25. Gopalan D, Riley JYJ, Leong K, et al. Pulmonary Vein Sign on Computed Tomography Pulmonary Angiography in Proximal and Distal Chronic Thromboembolic Pulmonary Hypertension With Hemodynamic Correlation. *J Thorac Imaging*. 2023 May 1;38(3):159-164. doi: 10.1097/RTI.0000000000000706. Epub 2023 Mar 15.
26. Gopalan D, Delcroix M, Held M. Diagnosis of chronic thromboembolic pulmonary hypertension. *Eur Respir Rev*. 2017 Mar 15;26(143):160108. doi: 10.1183/16000617.0108-2016. Print 2017 Jan.
27. Guth S, Wiedenroth CB, Rieth A, et al. Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. *Eur Respir J*. 2018 Sep 17;52(3):1800458. doi: 10.1183/13993003.00458-2018. Print 2018 Sep.
28. Yang J, Madani MM, Mahmud E, et al. Evaluation and management of chronic thromboembolic pulmonary hypertension. *Chest*. 2023 Aug;164(2):490-502. doi: 10.1016/j.chest.2023.03.029. Epub 2023 Mar 28.
29. Ulrich S, Fischler M, Speich R, et al. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. *Chest*. 2006;130(3):841-6.
30. McNeil K, Dunning J. Chronic thromboembolic pulmonary hypertension (CTEPH). *Heart*. 2007;93(9):1152-8.
31. Darteville P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2004;23(4):637-48.
32. Madani MM, Jamieson SW. Technical advances of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. *Semin Thorac Cardiovasc Surg*. 2006;18(3):243-9.
33. Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. *Am J Respir Crit Care Med*. 1999;160(2):523-8.
34. Kuniyara T, Möller M, Langer F, et al. Angiographic predictors of hemodynamic improvement after pulmonary endarterectomy. *Ann Thorac Surg*. 2010;90(3):957-64.
35. Poli D, Miniati M. The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism. *Curr Opin Pulm Med*. 2011 Jul 7 Epub.
36. Bresser P, Pepke-Zaba J, Jais X, et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. *Proc Am Thorac Soc*. 2006;3(7):594-600.
37. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. *Eur Respir J*. 2010;36(4):792-9.
38. Becattini C, Manina G, Busti C, et al. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. *Thromb Res*. 2010;126(1):e51-6.
39. Jais X, D'Armini AM, Jansa P, et al. Bosentan Effects in iNoperable Forms of chronic Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effects in iNoperable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. *J Am Coll Cardiol*. 2008 Dec 16;52(25):2127-34.
40. Kenny M, Clarke MM, Pogue KT. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension. *J Pharm Pract*. 2022 Jun;35(3):437-444. doi: 10.1177/0897190020961291. Epub 2020 Oct 21.
41. Krug S, Hammerschmidt S, Pankau H, et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. *Respiration*. 2008;76(2):154-9.
42. Kramm T, Eberle B, Guth S, et al. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. *Eur J Cardiothorac Surg*. 2005;28(6):882-8.
43. Toshner MR, Gopalan D, Suntharalingam J, et al. Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. *J Heart Lung Transplant*. 2010;29(6):610-5.

44. Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. *Chest*. 2008;134(2):229-36.
45. Thistlethwaite PA, Mo M, Madani MM, et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. *J Thorac Cardiovasc Surg*. 2002;124(6):1203-11.
46. Suntharalingam J, Hughes RJ, Goldsmith K, et al. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). *Vascu Pharmacol*. 2007;46(6):449-55.
47. Olman MA, Auger WR, Fedullo PF, et al. Pulmonary vascular steal in chronic thromboembolic pulmonary hypertension. *Chest*. 1990;98(6):1430-4.
48. Moser KM, Metersky ML, Auger WR, et al. Resolution of vascular steal after pulmonary thromboendarterectomy. *Chest*. 1993;104(5):1441-4.
49. Adams A, Fedullo PF. Postoperative management of the patient undergoing pulmonary endarterectomy. *Semin Thorac Cardiovasc Surg*. 2006;18(3):250-6.
50. Levinson RM, Shure D, Moser KM. Reperfusion pulmonary edema after pulmonary artery thromboendarterectomy. *Am Rev Respir Dis*. 1986;134(6):1241-5.
51. Kramm T, Eberle B, Krummenauer F, et al. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. *Ann Thorac Surg*. 2003;76(3):711-8.
52. Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. *Eur J Cardiothorac Surg*. 2005;28(6):882-8.
53. Thistlethwaite PA, Madani MM, Kemp AD, et al. Venovenous extracorporeal life support after pulmonary endarterectomy: indications, techniques, and outcomes. *Ann Thorac Surg*. 2006;82(6):2139-45.
54. Dittrich HC, Chow LC, Nicod PH. Early improvement in left ventricular diastolic function after relief of chronic right ventricular pressure overload. *Circulation*. 1989;80(4):823-30.
55. Casaclang-Verzosa G, McCully RB, Oh JK, et al. Effects of pulmonary thromboendarterectomy on right-sided echocardiographic parameters in patients with chronic thromboembolic pulmonary hypertension. *Mayo Clin Proc*. 2006;81(6):777-82.
56. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. *Chest*. 1993;103(3):685-92.
57. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. *J Am Coll Cardiol*. 1998;32(2):297-304.
58. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *N Engl J Med*. 2003;349(12):1133-8.
59. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). *J Thromb Haemost*. 2005;3(5):848-53.
60. Humbert M, Simonneau G, Pittrow D, et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. *J Heart Lung Transplant*. 2022 Jun;41(6):716-721. doi: 10.1016/j.healun.2022.02.002.
61. Yang JZ, Poch DS, Ang L, et al. Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here? *Pulm Circ*. 2023 Nov 20;13(4):e12312. doi: 10.1002/pul2.12312.
62. Hirakawa K, Yamamoto E, Takashio S, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. *Cardiovasc Interv Ther*. 2022;37(1):60-65. doi: 10.1007/s12928-021-00775-6.
63. Lloji A, Hooda U, Sreenivasan J, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. *Am J Cardiovasc Dis*. 2021 Jun 15;11(3):330-347.
64. Corsico AG, D'Armini AM, Cerveri I, et al. Long-term outcome after pulmonary endarterectomy. *Am J Respir Crit Care Med*. 2008;178(4):419-24.
65. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med*. 2008;177(10):1122-7.
66. Thistlethwaite PA, Kemp A, Du L, et al. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. *J Thorac Cardiovasc Surg*. 2006;131(2):307-13.



PULMONER VASKÜLER HASTALIK

BÖLÜM 56

Kıvanç KAÇAR ¹
Kıvanç METİN ²

DOI: 10.37609/akya.3889.c5378

İçindekiler

- » GİRİŞ
 - » Pulmoner Hipertansiyon
 - » Pulmoner Vasküler Hastalık
 - » Eisenmenger Sendromu
- » EPİDEMİYOLOJİ
- » FİZYOLOGİ
- » KLİNİK
- » TANI
- » TEDAVİ
 - » Cerrahi dışı tedavi
 - » Cerrahi Tedavi

¹ Uzm. Dr., Dokuz Eylül Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., kivanc.kacar@gmail.com, ORCID iD: 0000-0002-8408-9107

² Prof. Dr., Dokuz Eylül Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., kivanc.metin@deu.edu.tr, ORCID iD: 0000-0001-9888-2141

kapatılması, kliniği kötüleştirir. Eisenmenger sendromu gelişmiş hastalarda şantın kapatılması kontrendikedir. Ancak son dönemde Eisenmenger gelişmemiş olsa da ASD gibi pre-triküspit şanti bulunan hastalarda PVR>5 WU ise şantın kapatılması kontrendike olarak kabul edilmektedir. Bu hastalarda PAH tedavisi ile PVR değeri 5WU altına gerilese bile kapatılma kararının dikkatle ve hasta bazlı alınması gerekmektedir. VSD ve PDA gibi post-triküspit şantlarda ise PVR> 5 mmHg ise şantın kapatılmasının kötü sonuçlanabileceği ve bu kararın multidisipliner olarak hasta bazlı değerlendirerek vermek gerektiği bilinmelidir. PVR 3-5 WU arasında ise şantın öneri düzeyi IIa, kanıt düzeyi C ile kapatılabileceği unutulmamalıdır. Eğer PVR<3 WU ise şant öneri düzeyi I, kanıt düzeyi C ile kapatılmalıdır (1).

Seçilmiş vakalarda kalp-akciğer nakli veya kardiyak cerrahi ile birlikte akciğer nakli düşünülebilir. Fakat bu alanda donör yetersizliği olması bu kararı zorlaştırmaktadır. Transplantasyon tedavisi sonrasında birinci yılda özellikle kalp-akciğer transplantasyon hastalarında mortalite oranları yüksektir (46). İzole Akciğer naklinin bazı PHT etiyolojilerinin tedavisinde yeri olsa da kalp hastalığına sekonder görülen PHT’de yeri yoktur. Bu hastalarda mutlaka altta yatan kardiyak patolojinin onarılması veya kalp-akciğer transplantasyonunun düşünülmesi gerekir. Grup 4 PHT hastalarında özellikle KTEPH hastalarında ise Pulmoner endarterektomi bir tedavi modalitesi olarak uygulanabilmektedir. KTEPH merkezlerinde bu operasyonun perioperatif mortalitesi %2,5’in altındadır (47). Hastaların %25’inde postoperatif PHT sebat etse de 3 yıllık sağkalım %90’lardadır (48-50).

KAYNAKLAR

1. M. Humbert *et al.*, “2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension,” *Eur Heart J*, vol. 43, no. 38, pp. 3618–3731, 2022, doi: 10.1093/EURHEARTJ/EHAC237.
2. G. Kovacs, A. Olschewski, A. Berghold, and H. Olschewski, “Pulmonary vascular resistances during exercise in normal subjects: a systematic review,” *European Respiratory Journal*, vol. 39, no. 2, pp. 319–328, Jan. 2012, doi: 10.1183/09031936.00008611.
3. B. A. Maron *et al.*, “Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study,” *Lancet Respir Med*, vol. 8, no. 9, pp. 873–884, Sep. 2020, doi: 10.1016/S2213-2600(20)30317-9.
4. P. Xanthouli *et al.*, “Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension,” *Ann Rheum Dis*, vol. 79, no. 3, pp. 370–378, Mar. 2020, doi: 10.1136/ANNRHEUMDIS-2019-216476.
5. B. Pieske *et al.*, “How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC),” *Eur Heart J*, vol. 40, no. 40, pp. 3297–3317, Oct. 2019, doi: 10.1093/EURHEARTJ/EHZ641.
6. K. Zeder *et al.*, “Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review,” *European Respiratory Journal*, vol. 60, no. 4, Oct. 2022, doi: 10.1183/13993003.03181-2021.
7. A. P. Fishman, “CLINICAL CLASSIFICATION OF PULMONARY HYPERTENSION,” *Clin Chest Med*, vol. 22, no. 3, pp. 385–391, Sep. 2001, doi: 10.1016/S0272-5231(05)70278-1.
8. G. Simonneau *et al.*, “Clinical classification of pulmonary hypertension,” *J Am Coll Cardiol*, vol. 43, no. 12 SUPPL., pp. S5–S12, Jun. 2004, doi: 10.1016/J.JACC.2004.02.037.
9. G. Simonneau *et al.*, “Updated Clinical Classification of Pulmonary Hypertension,” *J Am Coll Cardiol*, vol. 54, no. 1 SUPPL. 1, Jun. 2009, doi: 10.1016/J.JACC.2009.04.012.
10. G. Simonneau *et al.*, “Haemodynamic definitions and updated clinical classification of pulmonary hypertension,” *European Respiratory Journal*, vol. 53, no. 1, Jan. 2019, doi: 10.1183/13993003.01913-2018.
11. L. Leber, A. Beaudet, and A. Muller, “Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review,” *Pulm Circ*, vol. 11, no. 1, pp. 1–12, Jan. 2021, doi: 10.1177/2045894020977300.
12. E. M. T. Lau, E. Giannoulatou, D. S. Celermajer, and M. Humbert, “Epidemiology and treatment of pulmonary arterial hypertension,” *Nature Reviews Cardiology* 2017 14:10, vol. 14, no. 10, pp. 603–614, Jun. 2017, doi: 10.1038/nrcardio.2017.84.
13. “Textbook of Pulmonary Vascular Disease,” *Textbook of Pulmonary Vascular Disease*, 2011, doi: 10.1007/978-0-387-87429-6.
14. Y.-S. Li *et al.*, “The Ras-JNK Pathway Is Involved in Shear-Induced Gene Expression,” *Mol Cell Biol*, vol. 16, no. 11, pp. 5947–5954, Nov. 1996, doi: 10.1128/MCB.16.11.5947.
15. S. Lehoux and A. Tedgui, “Cellular mechanics and gene expression in blood vessels,” *J Biomech*, vol. 36, no. 5, pp. 631–643, May 2003, doi: 10.1016/S0021-9290(02)00441-4.
16. M. Rabinovitch *et al.*, “Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and trans-

- mission electron microscopy," *Lab Invest*, vol. 55, no. 6, pp. 632–653, Dec. 1986, Accessed: Dec. 04, 2024. [Online]. Available: <https://europepmc.org/article/med/3784535>
17. Y. S. J. Li, J. H. Haga, and S. Chien, "Molecular basis of the effects of shear stress on vascular endothelial cells," *J Biomech*, vol. 38, no. 10, pp. 1949–1971, Oct. 2005, doi: 10.1016/J.BIOMECH.2004.09.030.
 18. B. Meyrick and L. Reid, "Ultrastructural findings in lung biopsy material from children with congenital heart defects," *Am J Pathol*, vol. 101, no. 3, p. 527, 1980, Accessed: Dec. 04, 2024. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC1903649/>
 19. Eisenmenger V., "Die angeborenen Defecte der Kammer scheidewand des Herzens," *Z Klin Med.*, vol. 32, pp. 1–28, 1897.
 20. A. C. M. J. Van Riel *et al.*, "Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification," *Int J Cardiol*, vol. 174, no. 2, pp. 299–305, Jun. 2014, doi: 10.1016/J.IJCARD.2014.04.072.
 21. B. S. Lowe, J. Therrien, R. Ionescu-Ittu, L. Pilote, G. Martucci, and A. J. Marelli, "Diagnosis of Pulmonary Hypertension in the Congenital Heart Disease Adult Population: Impact on Outcomes," *J Am Coll Cardiol*, vol. 58, no. 5, pp. 538–546, Jul. 2011, doi: 10.1016/J.JACC.2011.03.033.
 22. A. J. Marelli, R. Ionescu-Ittu, A. S. Mackie, L. Guo, N. Dendukuri, and M. Kaouache, "Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010," *Circulation*, vol. 130, no. 9, pp. 749–756, 2014, doi: 10.1161/CIRCULATIONAHA.113.008396/-/DC1.
 23. J. T. Granton and M. Rabinovitch, "Pulmonary arterial hypertension in congenital heart disease," *Cardiol Clin*, vol. 20, no. 3, pp. 441–457, Aug. 2002, doi: 10.1016/S0733-8651(02)00017-6/ASSET/6A88E448-C700-4062-B479-977F6DB7F728/MAIN.ASSETS/GR6.SML.
 24. S. Chien, S. Li, and J. Y. J. Shyy, "Effects of mechanical forces on signal transduction and gene expression in endothelial cells," *Hypertension*, vol. 31, no. 1 Pt 2, pp. 162–169, 1998, doi: 10.1161/01.HYP.31.1.162.
 25. M. Rabinovitch, "Elastase and the Pathobiology of Unexplained Pulmonary Hypertension," *Chest*, vol. 114, no. 3, pp. 213S–224S, Sep. 1998, doi: 10.1378/CHEST.114.3.SUPPLEMENT.213S.
 26. N. Boudreau, E. Turley, and M. Rabinovitch, "Fibronectin, hyaluronan, and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration," *Dev Biol*, vol. 143, no. 2, pp. 235–247, Feb. 1991, doi: 10.1016/0012-1606(91)90074-D.
 27. P. L. Jones, K. N. Cowan, and M. Rabinovitch, "Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease," *Am J Pathol*, vol. 150, no. 4, p. 1349, 1997, Accessed: Dec. 04, 2024. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC1858188/>
 28. M. Yoshibayashi *et al.*, "Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation," *Circulation*, vol. 84, no. 6, pp. 2280–2285, 1991, doi: 10.1161/01.CIR.84.6.2280.
 29. S. Ishikawa *et al.*, "Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair," *J Thorac Cardiovasc Surg*, vol. 110, no. 1, pp. 271–273, Jul. 1995, doi: 10.1016/S0022-5223(05)80036-4.
 30. S. Fuse and T. Kamiya, "Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease," *Circulation*, vol. 90, no. 6, pp. 2952–2955, 1994, doi: 10.1161/01.CIR.90.6.2952.
 31. B. K. S. Sastry, C. Narasimhan, N. K. Reddy, and B. S. Raju, "Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study," *J Am Coll Cardiol*, vol. 43, no. 7, pp. 1149–1153, Apr. 2004, doi: 10.1016/J.JACC.2003.10.056.
 32. D. HEATH and J. E. EDWARDS, "The Pathology of Hypertensive Pulmonary Vascular Disease," *Circulation*, vol. 18, no. 4 Part 1, pp. 533–547, 1958, doi: 10.1161/01.CIR.18.4.533.
 33. A. P. Bolger *et al.*, "Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease," *Circulation*, vol. 106, no. 1, pp. 92–99, Jul. 2002, doi: 10.1161/01.CIR.0000020009.30736.3F/ASSET/E60E5B29-4D11-4BC4-94FA-D8F3546407BA/ASSETS/GRAPHIC/G21FF2.JPEG.
 34. V. V. McLaughlin *et al.*, "Survival with first-line bosentan in patients with primary pulmonary hypertension," *European Respiratory Journal*, vol. 25, no. 2, pp. 244–249, Feb. 2005, doi: 10.1183/09031936.05.00054804.
 35. N. Nickel *et al.*, "The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension," *European Respiratory Journal*, vol. 39, no. 3, pp. 589–596, Feb. 2012, doi: 10.1183/09031936.00092311.
 36. O. Sitbon *et al.*, "Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival," *J Am Coll Cardiol*, vol. 40, no. 4, pp. 780–788, Aug. 2002, doi: 10.1016/S0735-1097(02)02012-0.
 37. S. Alabed *et al.*, "Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis," *JACC Cardiovasc Imaging*, vol. 14, no. 5, pp. 931–942, May 2021, doi: 10.1016/J.JCMG.2020.08.013.
 38. A. J. Swift *et al.*, "Magnetic resonance imaging in the prognostic evaluation of patients with pulmonary arterial hypertension," *Am J Respir Crit Care Med*, vol. 196, no. 2, pp. 228–239, Jul. 2017, doi: 10.1164/RCCM.201611-2365OC/SUPPL_FILE/DISCLOSURES.PDF.
 39. R. A. Lewis *et al.*, "Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension," <https://doi.org/10.1164/rccm.201909-1771OC>, vol. 201, no. 4, pp. 458–466, Feb. 2020, doi: 10.1164/RCCM.201909-1771OC.
 40. E. Grünig *et al.*, "Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial," *Eur Heart J*, vol. 42, no. 23, pp. 2284–2295, Jun. 2021, doi: 10.1093/EURHEARTJ/EHAA696.

41. E. Wolsk *et al.*, "The Influence of Age on Hemodynamic Parameters During Rest and Exercise in Healthy Individuals," *JACC Heart Fail*, vol. 5, no. 5, pp. 337–346, May 2017, doi: 10.1016/J.JCHF.2016.10.012.
42. N. Galiè *et al.*, "Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study," *Circulation*, vol. 114, no. 1, pp. 48–54, Jul. 2006, doi: 10.1161/CIRCULATIONAHA.106.630715/ASSET/B3DFDF73-0FE8-475B-8C5A-6A1986C42B72/ASSETS/GRAPHIC/12FF2.JPEG.
43. W. A. Zuckerman, D. Leaderer, C. A. Rowan, J. D. Mituniewicz, and E. B. Rosenzweig, "Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease," *Am J Cardiol*, vol. 107, no. 9, pp. 1381–1385, May 2011, doi: 10.1016/J.AMJCARD.2010.12.051.
44. H. Nashat *et al.*, "A single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: A pilot study," *Int J Cardiol*, vol. 299, pp. 131–135, Jan. 2020, doi: 10.1016/J.IJCARD.2019.07.004.
45. M. D'Alto *et al.*, "The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome," *European Respiratory Journal*, vol. 54, no. 5, Nov. 2019, doi: 10.1183/13993003.01401-2019.
46. K. Dimopoulos *et al.*, "Heart or heart-lung transplantation for patients with congenital heart disease in England," *Heart*, vol. 105, no. 8, pp. 596–602, Apr. 2019, doi: 10.1136/HEARTJNL-2018-313984.
47. M. Lankeit *et al.*, "Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension," *The Journal of Heart and Lung Transplantation*, vol. 37, no. 2, pp. 250–258, Feb. 2018, doi: 10.1016/J.HEALUN.2017.06.011.
48. M. Newnham *et al.*, "CAMPOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension," *European Respiratory Journal*, vol. 56, no. 4, Oct. 2020, doi: 10.1183/13993003.02096-2019.
49. M. Delcroix *et al.*, "Long-Term Outcome of Patients with Chronic Thromboembolic Pulmonary Hypertension: Results from an International Prospective Registry," *Circulation*, vol. 133, no. 9, pp. 859–871, Mar. 2016, doi: 10.1161/CIRCULATIONAHA.115.016522/-/DC1.
50. W. C. Hsieh, P. Jansa, W. C. Huang, M. Nižnanský, M. Omara, and J. Lindner, "Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis," *J Thorac Cardiovasc Surg*, vol. 156, no. 3, pp. 1275–1287, Sep. 2018, doi: 10.1016/J.JTCVS.2018.04.110.



İNFEKTİF ENDOKARDİTLER

BÖLÜM 57

DOI: 10.37609/akya.3889.c5379

Rafet GÜNAY ¹
Mehmet YILMAZ ²
Tamer KEHLİBAR ³
Bülent KETENCİ ⁴
M.Murat DEMİRTAŞ ⁵

İçindekiler

- » TANIM
- » SINIFLAMA
- » EPİDEMİYOLOJİ
- » TANI
- » İNFEKTİF ENDOKARDİT TANISINDA DUKE KRİTERLERİ
- » İNFEKTİF ENDOKARDİTTE TANI YÖNTEMLERİ
- » MAJOR (CİDDİ) EMBOLİZASYONLAR
- » ENDOKARDİTE ZEMİN HAZIRLAYAN KARDİYAK DURUMLAR
- » İNFEKTİF ENDOKARDİTİN CERRAHİ TEDAVİSİ İÇİN İNDİKASYONLAR
- » BEKLEMESİZ-ÖNCELİKLİ CERRAHİ GİRİŞİM İNDİKASYONLARI
- » ÖNEMLİ CERRAHİ OLUŞUMLAR
- » NATİV MİTRAL KAPAK İNFEKTİF ENDOKARDİTİNDE TAMİRİN AVANTAJLARI
- » CERRAHİ YÖNTEMLER
- » İNFEKTİF ENDOKARDİT CERRAHİSİNDE YAPAY KAPAK SEÇİMİ
- » NATİV KAPAK ENDOKARDİTİ VE CERRAHİ SEÇENEKLER
- » CERRAHİ GİRİŞİM SONRASI ANTİBİYOTİK KULLANIMI VE PROFİLAKSİ

¹ Op. Dr., SBÜ Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi, rafetgunay@hotmail.com, ORCID iD: 0000-0001-7498-2025

² Op. Dr., SBÜ Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi, drmehmetyilmaz@gmail.com, ORCID iD: 0000-0002-6243-6876

³ Op. Dr., SBÜ Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi, tamerkehlibar@gmail.com, ORCID iD: 0000-0002-5274-7654

⁴ Prof. Dr., SBÜ Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi, bulendketenci@gmail.com, ORCID iD: 0000-0002-8493-0154

⁵ Prof. Dr., SBÜ Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi, Emekli Öğretim Üyesi, mmuratdem@hotmail.com, ORCID iD: 0000-0002-6596-6880

3. Enfekte doku ve yapıların her türlü cerrahisi
4. Gastrointestinal, üriner kanalların ve solunum yollarının cerrahileri

Antibiyotik profilaksisi ESC 2009 kılavuzunda sadece jiniyal dokunun, dişin periapikal alanının manipülasyonunu ve oral mukoza perforasyonunu içeren işlemlerde önerilmekte iken, 2023 versiyonunda solunum, gastrointestinal, genitoüriner sistem, cilt veya kas-iskelet sistemlerine yönelik invaziv tanı veya tedavi prosedürü uygulanan yüksek riskli hastalar için Sınıf IIb kanıt düzeyi C olarak önerilmektedir (22). Özellikle yapay kapağı olan bireylerde tüm invazif girişimlerde bakteriyemiye neden olmama yönünde tedbirler alınmalı, kateterler sondalar takılırken asepsi antisepsiye dikkat edilmeli, bunlar en kısa zamanda çekilmelidir. Bakteriyemi gelişirse yapay kapağı tutma oranı yüksektir, 6 hafta kadar etkili tedavi gerektirir.

Oral, dental girişimlerde, müdahaleden 30 dakika önce erişkinler için tek doz, oral 2 gram, çocuklarda 50 mg/kg amoksisilin yeterli görülmekte, ilave idame dozu önerilmemektedir. Amoksisiline allerjiklerde klindamisin, azitromisin, klaritromisin, sefadroksil, sefalekssin kullanılabilir. Genitoüriner, gastrointestinal girişimlerde, hafif-orta riskli olgularda yukarıdaki dozlarda amoksisilin veya ampisilin, yüksek riskli olgularda intravenöz veya intramüsküler amoksisilin veya ampisiline (2 gr veya 50 mg/kg) ilave gentamisin (120 mg'ı geçmeyecek şekilde 1.5 mg/kg, IV veya IM) verilmeli ve 6 saat sonra 1 gr (25 mg/kg) oral amoksisilin veya aynı doz IV-IM ampisilin tekrarlanmalıdır. Ampisilin veya amoksisiline allerjik yüksek riskli olgularda bunların yerine gentamisinle beraber girişimden 30 dakika önce bitecek şekilde, 1 – 2 saatlik infüzyon halinde 1g (20 mg/kg) vankomisin tatbik edilmelidir.

KAYNAKLAR

1. Arbulu A, Asfaw I. : Infective endocarditis. In: Glenn's Thoracic and Cardiovascular Surgery, eds: Baue AA, Geha AS, Hammond GL, Laks H, Naunueim KS. 5th ed. Appleton-Lange, Prentice-Hall Int Inc. 1991;1647-1665.
2. Patel R, Steckelberg JM. : Infections of the heart. In: Mayo Clinic Cardiology review, ed: Murphy JG. Sec. ed., Lippincott Williams & Wilkins, New York, 2000; 407-444.
3. David TE.: Complex operations of the aortic root. Endocarditis of the aortic valve. In: Cardiac Surgery in the Adult, ed: Edmunds LH, Jr. New York, McGraw-Hill, 1997; 944-947.
4. Bayer AS, Bolger AF, Taubert KA et al. :Diagnosis and Management of Infective Endocarditis and Its Complications. Circulation 1998;98:2936-2948
5. Fullerton DA, Grover FL.: Complications from cardiac prostheses. I. Prosthetic valve endocarditis. In: Surgery of the Chest, vol II, eds: Sabiston DC, Jr, Spencer FC. W.B. Saunders Comp, Philadelphia, 1995; 1703-1715.
6. Dajani AS, Taubert KA, Wilson W, et al. : Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1997;277:1794-801.
7. Delgado V, Marsan NA, Waha S et al. 2023 ESC Guidelines for management of endocarditis. Developed by task force on the management of endocarditis of the ESC, endorsed by the EACTS and ESNM. European Heart J 2023;44:3948-4042.
8. DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med. 1994;121:873-876.
9. Bayer AS, Scheld WM.: Endovascular and intravascular infections. In: Principles and practice of infectious diseases, eds: Mandell, Douglas, Bennett, Dolin, 5th ed. Philadelphia, Churchill Livingstone Inc., 2000;857-902.
10. Karchmer AW.: Infections of prosthetic valves and intravascular devices. In: Principles and practice of infectious diseases, eds: Mandell, Douglas, Bennett, Dolin, 5th ed. Philadelphia, Churchill Livingstone Inc., 2000;903-917.
11. Musci M, Siniawski H, Pasic M, Weng Y, Loforte A, Kosky S, Yankah C, Hetzer R. Surgical therapy in patients with active infective endocarditis: seven-year single centre experience in a subgroup of 255 patients treated with the Shelhigh® stentless bioprosthesis. Eur J Cardiothorac. Surg 2008; 34: 410-417.
12. Day MD, Gauvreau K, Shulman S, Newburger JW. Characteristics of children hospitalized with infective endocarditis. Circulation 2009; 119; 865-870.
13. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001; 345:1318-1330.
14. Keys TF. Infective endocarditis: a continuing challenge. J Crit Illness. 1987;2:19-32.
15. Kamalakannan D, Pai RM, Johnson LB, Gardin JM, Saravolatz LD. Patients epidemiology and clinical outcomes of infective endocarditis in hemodialysis. Ann Thorac Surg 2007; 83: 2081-2086.
16. Von Reyn CF, Levy BS, Arbeit RD, Friedland G, Crumacker CS.: Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med. 1981;94:505-518.
17. Durack DT, Lukes AS, Bright DK.: New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings: Duke Endocarditis Service. Am J Med. 1994;96:200-209.
18. Dodds GA, Sexton DJ, Durack DT, Bushore TM, Corey GR, Kisslo J.: Negative predictive value of the Duke criteria for infective endocarditis. Am J Cardiol. 1996;77:403-407.
19. Hoen B, Beguinot I, Rabaud C, et al. : The Duke criteria for diagnosing infective endocarditis are specific: analysis of 100 patients with acute fever or fever of

- unknown origin. *Clin Infect Dis*. 1996;23:298-302.
20. Klein I, Iung B, Labreuche J, Hess A, Wolff M, Messika-Zeitoun D, Lavallée P, Laissy JP, Lepoint C, Duval X; IMAGE Study Group. Cerebral microbleeds are frequent in infective endocarditis: a case-control study. *Stroke*. 2009; 40: 3461-5.
21. Vuille C, Nidorf M, Weyman AE, Picard MH. Natural history of vegetations during successful medical treatment of endocarditis. *Am Heart J*. 1994;128:1200-1209.
22. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. *Eur Heart J*. 2023;44:3948-4042.
23. Mills MT, Al-Mohammad A, Warriner DR. Changes and advances in the field of infective endocarditis. *Br J Hosp Med (Lond)* 2022 Mar2; 83(3): 1-11. doi: 10.12968/hmed.2021.0510.
24. Rohmann S, Erbel R, Gorge G, et al.: Clinical relevance of vegetation localization by transoesophageal echocardiography in infective endocarditis. *Eur Heart J*. 1992;13:446-452.
25. Moon MR, Stinson EB, Miller DC. Surgical treatment of endocarditis. *Prog Cardiovasc Dis*. 1997;40:239-264.
26. Mansur AJ, Grinberg M, da Luz PL, Bellotti G. The complications of infective endocarditis: a reappraisal in the 1980s. *Arch Intern Med*. 1992;152:2428-2432.
27. Prendergast BD, Tornos P. Surgery for infective endocarditis. Who and when? *Circulation* 2010; 121: 1141-1152.
28. Thuny F, Habib G. When should we operate on patients with acute infective endocarditis? *Heart* 2010; 96: 892-897.
29. Moon MR, Miller C, Moore KA, et al. Treatment of endocarditis with valve replacement: the question of tissue versus mechanical prosthesis. *Ann Thorac Surg* 2001; 71: 1164-71.
30. Gillinov AM, Faber CN, Sabik JF. Et al.: Endocarditis after mitral valve repair. *Ann Thorac Surg* 2002; 73: 1813-6.
31. Newton S, Hunter S. What type of valve replacement should be used in patients with endocarditis? *Interact Cardiovasc Thorac Surg* 2010; 11: 784-788
32. Couetil JPA, Argyriadis PG, Shafy A, et al.: Partial replacement of the tricuspid valve by mitral homografts in acute endocarditis. *Ann Thorac Surg* 2002; 73: 1808-12.
33. Endara SA, Corkeron MA, Diqer AM, Neal AJ, Kang D: Pneumococcal aortic valve endocarditis causing aortopulmonary artery fistula. *Ann Thorac Surg* 2001;72:1737-8
34. Prat AP, de Ibarra JIS, Vincentelli A, et al.: Ross operation for active culture-positive aortic valve endocarditis with extensive paravalvular involvement. *Ann Thorac Surg* 2001; 72: 1492-6.
35. Feindel C.: Invited commentary in: Prat AP, de Ibarra JIS, Vincentelli A, et al.: Ross operation for active culture-positive aortic valve endocarditis with extensive paravalvular involvement. *Ann Thorac Surg* 2001; 72: 1492 - 6.
36. Oswald JD, Dewan SJ, Mueller MC, Nelson S.: Highlights of a ten-year experience with the Ross procedure. *Ann Thorac Surg* 2001; 71: S331 - 5.
37. Schaff H, Carrel T, Steckelberg JM, Grunkemeier GL, Holubkov R.: Artificial Valve Endocarditis Reduction Trial (AVERT): protocol of a multicenter randomized trial. *J Heart Valve Dis* 1999; 8:131- 9.
38. Gordon SM, Serkey JM, Longworth DL, Lytle BW, Cosgrove III DM.: Early onset prosthetic valve endocarditis: the Cleveland Clinic Experience 1992-1997. *Ann Thorac Surg* 2000; 69: 1388-92.
39. Sabik JF, Lytle BW, Blackstone EH, et al. Aortic root replacement with cryopreserved allograft for prosthetic valve endocarditis. *Ann Thorac Surg* 2002; 74: 650-9.
40. Leontyev S, Borger MA, Modi P, Lehmann S, Seeburger J, Walther T, Mohr FW. Redo aortic valve surgery: Influence of prosthetic valve endocarditis on outcomes. *J Thorac Cardiovasc Surg* 2010;-1-7
41. Musci M, Hübner M, Amiri A, Stein J, Kosky S, Meyer R, Weng Y, Hetzer R. Surgical treatment for active infective prosthetic valve endocarditis: 22-year single-centre experience *Eur J Cardiothorac Surg* 2010; 38: 528-538
42. Lytle BW, Priest BP, Taylor PC, et al. Surgical treatment of prosthetic valve endocarditis. *J Thorac Cardiovasc Surg* 1996; 111:198-210.
43. Aagaard J, Andersen PV.: Acute endocarditis treated with radical debridement and implantation of mechanical or stented bioprosthetic devices. *Ann Thorac Surg* 2001; 71: 100 - 4.
44. Rezar R, Lichtenauer M, Haar M, Hödl G, Kern JM, Zhou Z, Wuppinger T, Kraus J, Strohmer B, Hoppe UC, Wernly B. Infective endocarditis - A review of current therapy and future challenges. *Hellenic J Cardiol*. 2021; 62(3): 190-200. doi: 10.1016/j.hjc.2020.10.007.
45. Del Val D, Panagides V, Mestres CA, Miró JM, Rodés-Cabau J. Infective Endocarditis After Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2023 Jan 31;81(4):394-412. doi: 10.1016/j.jacc.2022.11.028.
46. Kirklin JW, Barratt-Boyes BG.: Patent ductus arteriosus. In: *Cardiac Surgery*. John Wiley & Sons, New York, 1986; 688-9.
47. Jara FM, Lewis JF Jr, Magilligan DJ Jr. Operative experience with infective endocarditis and intracerebral mycotic aneurysm. *J Thorac Cardiovasc Surg*. 1980;80:28-30.
48. Chu VH, Sexton DJ, Cabell CH, Reller LB, Pappas PA, Singh RK, Fowler VG Jr, Corey GR, Aksoy O, Woods CW. Repeat infective endocarditis: differentiating relapse from reinfection. *Clin Infect Dis*. 2005;41:406-9.
49. Mansur AJ, Dal Bo CM, Fukushima JT, Issa VS, Grinberg M, Pomerantzeff PM. Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis. *Am Heart J* 2001; 141:78-86.
50. Larbalestier RI, Kinchla NM, Aranki SF, Couper GS, Collins JJ Jr, Cohn LH. Acute bacterial endocarditis. Optimizing surgical results. *Circulation*. 1992;86(5 Suppl):II68-74.
51. Renzulli A, Carozza A, Marra C, Romano GP, Ismeno G, De Feo M, DellaCorte A, Cotrufo M. Are blood and valve cultures predictive for long-term outcome following surgery for infective endocarditis? *Eur J Cardiothorac Surg*. 2000;17:228-33.
52. David TE, Regesta T, Gavra G, Armstrong S, Maganti MD. Surgical treatment of paravalvular abscess: long-term results. *Eur J Cardiothorac Surg*. 2007;31:43-8.
53. Fedoruk LM, Jamieson WR, Ling H, Macnab JS, Germain E, Karim SS, Lichtenstein SV. Predictors of recur-

- rence and reoperation for prosthetic valve endocarditis after valve replacement surgery for native valve endocarditis. *J Thorac Cardiovasc Surg.* 2009;137:326-33.
54. Moon MR, Miller DC, Moore KA, Oyer PE, Mitchell RS, Robbins RC, Stinson EB, Shumway NE, Reitz BA. Treatment of endocarditis with valve replacement: the question of tissue versus mechanical prosthesis. *Ann Thorac Surg.* 2001;71:1164-71.
 55. Lytle BW, Priest BP, Taylor PC, Loop FD, Sapp SK, Stewart RW, McCarthy PM, Muehrcke D, Cosgrove DM 3rd. Surgical treatment of prosthetic valve endocarditis. *J Thorac Cardiovasc Surg.* 1996;111:198-207.
 56. Musci M, Weng Y, Hübler M, Amiri A, Pasic M, Kosky S, Stein J, Siniawski H, Hetzer R. Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. *J Thorac Cardiovasc Surg.* 2010;139:665-73.
 57. Baddour LM, Bettmann MA, Bolger AF ve ark: Non-valvular cardiovascular device-related infections. *Circulation.* 2003;108:2015-31.
 58. Uslan DZ, Sohail MR, St Sauver JL ve ark: Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. *Arch Intern Med.* 2007; 167:669-75.
 59. Baddour LM, Wilson WR, Bayer AS ve ark: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for health-care professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. *Circulation* 2005;111:e394-e434.
 60. Roberts WC, Buchbinder NA. Right-sided valvular infective endocarditis. A clinicopathologic study of twelve necropsy patients. *Am J Med.* 1972;53:7-19.
 61. Arbulu A, Asfaw I. Tricuspid valvectomy without prosthetic replacement. Ten years of clinical experience. *J Thorac Cardiovasc Surg* 1981;82:684-9.
 62. Lange R, De Simone R, Bauernschmitt R, Tanzeem A, Schmidt C, Hagl S. Tricuspid valve reconstruction, a treatment option in acute endocarditis. *Eur J Cardiothorac Surg* 1996;10:320-6.
 63. Gottardi R, Bialy J, Devyatko E, Tschernich H, Czerny M, Wolner E, Seitelberger R. Midterm follow-up of tricuspid valve reconstruction due to active infective endocarditis. *Ann Thorac Surg.* 2007;84:1943-8.
 64. Chen X, Chen X, Gu F, Xie D. An alternative surgical approach for aortic infective endocarditis: vegetectomy. *Eur J Cardiothorac Surg.* 2009;35:1096-8.
 65. Lentini S, Zito C, Carerj S, Gaeta R. Valve repair treatment in active infective endocarditis. *Eur J Cardiothorac Surg.* 2010 ;37:245; author reply 246.
 66. Graupner C, Vilacosta I, SanRoman J, Ronderos R, Sarría C, Fernandez C, Mujica R, Sanz O, Sanmartín JV, Pinto AG. Periannular extension of infective endocarditis. *J Am Coll Cardiol* 2002;39:1204-1211.
 67. Anguera I, Miro JM, Vilacosta I ve ark: Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. *Eur Heart J* 2005;26:288-297.
 68. Kang N, Wan S, Ng CSH, Underwood MJ. Periannular extension of infective endocarditis. *Ann Thorac Cardiovasc Surg* 2009;15:74-81.
 69. David TE, Regesta T, Gavra G, Armstrong S, Maganti MD. Surgical treatment of paravalvular abscess: long-term results. *Eur J Cardiothorac Surg* 2007; 31:43-48.
 70. Bozbuğa N, Erentug V, Erdogan HB ve ark: Surgical treatment of aortic abscess and fistula. *Tex Heart Inst J* 2004;31:382-6.
 71. Turkoz R, Gulcan O, Uguz E, Cihan HB. Mitral valve replacement after application of atrial appendix flap in endocarditis with posterior annular abscess. *Eur J Cardiothorac Surg* 2004;26: 837-8.



KALP VE DAMAR CERRAHİSİNDE NÖROLOJİK KOMPLİKASYONLAR

BÖLÜM 58

Hakan Hadi KADIOĞLU¹

DOI: 10.37609/akya.3889.c5380

İçindekiler

- » GİRİŞ
- » NÖROLOJİK KOMPLİKASYONLARIN TİPLERİ VE İNSİDANSI
 - » İnme
 - » Hemorajik İnme
 - » Bilişsel Bozukluk
 - » Deliryum
 - » Perioperatif Nörolojik Eksiklik
 - » Nöbetler
- » Spinal kord ve periferik sinir yaralanmaları
- » NÖROLOJİK KOMPLİKASYONLARIN TEŞHİSİ
- » KOMPLİKASYON OLUŞUMUNA ZEMİN HAZIRLAYAN ÖĞELER
 - » Nörolojik Komplikasyonların Sağaltımı
- » KARDİYOVASKÜLER CERRAHİDE DEĞİŞEN UYGULAMALARA NÖROLOJİK KOMPLİKASYONLAR AÇISINDAN YAKLAŞIMLAR

¹ Prof. Dr., Atatürk Üniversitesi, Tıp Fakültesi, Beyin ve Sinir Cerrahisi AD., hakanhadi@gmail.com, ORCID iD: 0000-0002-7744-6241

Son birkaç yılda ise BT ve MRG tekniklerindeki gelişmelerin paralelinde EVT uygulama zaman aralığı 24 saate uzamıştır. (65, 66) Nörogörüntülemedeki ilerlemeler EVT ile ilgili uygulama çizelgelerini değiştirmiştir (10, 67-69) Hazırlanan güncel kılavuzlar, inme triyajı ve hasta seçiminde görüntülemenin önemini göstermiştir. (44, 67, 70) (Tablo 7)

Sonuç olarak, kardiyovasküler cerrahide değişim dinamik bir süreçtir; eski yöntemlerin yerini alan yenilikçi yaklaşımlar hem hasta güvenliğini artırmakta hem de klinik sonuçları önemli ölçüde iyileştirmektedir. Gelecekte sağlık hizmetlerinde kişiselleştirilmiş tedavi stratejilerini öne çıkaracak yenilikçi çözümler bekleniyor. Kardiyoloji pratiğinin devam eden evrimi ile paralel olarak, sürekli eğitim temelli araştırmalar yapmak kritik öneme sahiptir.

Hasta merkezli bir yaklaşım, bu süreçteki herhangi bir yeniliğin merkezinde yer alır ve hasta bakımında gözle görülür iyileşmeler sağlar.

KAYNAKLAR

- Kadioğlu HH, Açık kalp ameliyatlarının nörolojik komplikasyonları. In Paç M ve ark. (eds) Kalp ve Damar Cerrahisi, Ankara: Medikal & Nobel Yayın Dağıtım, 2006, 897-935
- Roberts A, Duncan EC, Hargrave P, et al. Complications of Cardiopulmonary Bypass From an Anesthesia Perspective: A Clinical Review. *HCA Healthc J Med*. 2023; 4(1):13-21. doi: 10.36518/2689-0216.1525.
- Roy P, Brahme I, Reddy RP, et al. Meta-Analysis of Perioperative Stroke and Mortality in CABG Patients With Carotid Stenosis. *Neurologist*. 2020; 25(5):113-116. doi: 10.1097/NRL.0000000000000277.
- Patel BM, Reinert NJ, Al-Robaidi K, et al. Independent Predictors of Perioperative Stroke-Related Mortality after Cardiac Surgery. *J Stroke Cerebrovasc Dis*. 2020; 29(5):104711. doi: 10.1016/j.jstrokecerebrovasdis.2020.104711. Epub 2020 Mar 14.
- Hood R, Budd A, Sorond FA, Hogue CW. Peri-operative neurological complications. *Anaesthesia*. 2018; 73 Suppl 1:67-75. doi: 10.1111/anae.14142.
- Ferrante MS, Pisano C, Van Rothen J, Ruvolo G, Abouliatim I. Cerebrovascular events after cardiovascular surgery: diagnosis, management and prevention strategies. *Kardiochir Torakochirurgia Pol*. 2023; 20(2):118-122. doi: 10.5114/kitp.2023.130020. Epub 2023 Jul 26.
- Gerster PA, Klesse A, Chang J, et al. Neurological Complications in Cardiac Surgery. *Curr Anesthesiol Rep* 2019; 9: 223-233.
- Shaw PJ, Bates D, Cartlidge NEF, et al. Early neurological complications of coronary artery bypass surgery. *BMJ* 291:1384-1387, 1985
- Hrdlicka CM, Wang J, Selim M. Neurological Complications of Cardiac Procedures. *Semin Neurol*. 2021; 41(4): 398-410. doi: 10.1055/s-0041-1728761.
- Al-Amoodi A, Debicki D, Sefin O, Bainbridge D. Ischemic Stroke in the Cardiac Surgery Intensive Care Unit: A Quality Improvement Study. *J Cardiothorac Vasc Anesth*. 2024; 38(7):1524-1530. doi: 10.1053/j.jvca.2024.03.012.
- Arribas JM, Garcia E, Jara R, et al. Incidence and etiological mechanism of stroke in cardiac surgery. *Neurologia (Engl Ed)*. 2020; 35(7):458-463. English, Spanish. doi: 10.1016/j.nrl.2017.10.004.
- Mehdi Z, Birns J, Partridge J, et al. Perioperative management of adult patients with a history of stroke or transient ischaemic attack undergoing elective non-cardiac surgery. *Clin Med (Lond)*. 2016; 16(6):535-540. doi: 10.7861/clinmedicine.16-6-535. PMID: 27927817; PMCID: PMC6297334
- Yang A, Nguyenhuy M, Seevanayagam S. Intracranial Atherosclerosis Increases the Risk of Postoperative Stroke After Cardiac Surgery: A Review and Meta-Analysis. *Heart Lung Circ*. 2023; 32(12):1417-1425. doi: 10.1016/j.hlc.2023.09.022.
- Yu MY, Caprio FZ, Bernstein RA. Cardioembolic Stroke. *Neurol Clin*. 2024; 42(3):651-661. doi: 10.1016/j.ncl.2024.03.002.
- Hendrikse J, Petersen ET, Chèze A, et al. Relation between cerebral perfusion territories and location of cerebral infarcts. *Stroke*. 2009; 40(5):1617-22. doi: 10.1161/STROKEAHA.108.539866.
- Suero OR, Ali AK, Barron LR, et al. Postoperative atrial fibrillation (POAF) after cardiac surgery: clinical practice review. *J Thorac Dis*. 2024; 29: 16(2):1503-1520. doi: 10.21037/jtd-23-1626.
- Papasilekas T, Themistoklis KM, Melanis K, et al. A Brief Review of Brain's Blood Flow-Metabolism Coupling and Pressure Autoregulation. *J Neurol Surg A Cent Eur Neurosurg*. 2021; 82(3):257-261. doi: 10.1055/s-0040-1721682.
- Soh S, Shim JK, Song JW, et al. Preoperative transcranial Doppler and cerebral oximetry as predictors of delirium following valvular heart surgery: a case-control study. *J Clin Monit Comput*. 2020; 34(4):715-723. doi: 10.1007/s10877-019-00385-x.
- Shin TH, Lee DY, Basith S, et al. Metabolome Changes in Cerebral Ischemia. *Cells*. 2020; 9 (7):1630. doi: 10.3390/cells9071630. PMID: 32645907
- Siesjö BK. Cerebral circulation and metabolism. *J Neurosurg*. 1984; 60 (5): 883-908. doi: 10.3171/jns.1984.60.5.0883.
- Bitar L, Puig B, Oertner TG, et al. Changes in Neuro-immunological Synapses During Cerebral Ischemia. *Transl Stroke Res*. 2024; 5. doi: 10.1007/s12975-024-01286-1.
- Deng J, Chen C, Xue S, et al. Microglia-mediated inflammatory destruction of neuro-cardiovascular dysfunction after stroke. *Front Cell Neurosci*. 2023; 17:1117218. doi: 10.3389/fncel.2023.1117218.
- Wang M, Pan W, Xu Y, et al. Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases. *J Inflamm Res*. 2022; 15: 3083-3094. doi: 10.2147/JIR.S350109.
- Weymann A, Sabashnikov A, Ali-Hasan-Al-Saegh S, et al. Predictive Role of Coagulation, Fibrinolytic, and

- Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review. *Med Sci Monit Basic Res.* 2017; 23: 97-140. doi: 10.12659/MS-MBR.902558.
25. Agarwal S, Abdelmotieleb M. Viscoelastic testing in cardiac surgery. *Transfusion.* 2020; 60 Suppl 6:S52-S60. doi: 10.1111/trf.16075.
26. Marcucci M, Painter TW, Conen D, et al. Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery : An International Randomized Controlled Trial. *Ann Intern Med.* 2023; 176(5): 605-614. doi: 10.7326/M22-3157.
27. Alsbrook DL, Di Napoli M, Bhatia K, et al. Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke. *Curr Neurol Neurosci Rep.* 2023; 23(8): 407-431. doi: 10.1007/s11910-023-01282-2.
28. Bersano A, Engele J, Schäfer MKE. Neuroinflammation and Brain Disease. *BMC Neurol.* 2023; 23(1):227. doi: 10.1186/s12883-023-03252-0.
29. Jurcau A, Simion A. Neuroinflammation in Cerebral Ischemia and Ischemia/Reperfusion Injuries: From Pathophysiology to Therapeutic Strategies. *Int J Mol Sci.* 2021; 23(1):14. doi: 10.3390/ijms23010014.
30. Kaesmacher J, Kaesmacher M, Maegerlein C, et al. Hemorrhagic Transformations after Thrombectomy: Risk Factors and Clinical Relevance. *Cerebrovasc Dis.* 2017;43(5-6):294-304. doi: 10.1159/000460265.
31. Menkis AH, Martin J, Cheng DC, et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. *Innovations (Phila).* 2012; 7(4):229-41. doi: 10.1097/IML.0b013e3182747699
32. Wang T, Huang X, Sun S, et al. Recent Advances in the Mechanisms of Postoperative Neurocognitive Dysfunction: A Narrative Review. *Biomedicine.* 2025; 13(1):115. <https://doi.org/10.3390/biomedicine13010115>
33. Miller D, Lewis SR, Pritchard MW, et al. Intravenous versus inhalational maintenance of anaesthesia for postoperative cognitive outcomes in elderly people undergoing non-cardiac surgery. *Cochrane Database Syst Rev.* 2018; 8(8):CD012317. doi: 10.1002/14651858.CD012317.pub2.
34. McDonagh DL, Berger M, Mathew JP, et al. Neurological complications of cardiac surgery. *Lancet Neurol.* 2014; 13(5): 490-502. doi: 10.1016/S1474-4422(14)70004-3.
35. Goldberg TE, Chen C, Wang Y, et al. Association of Delirium With Long-term Cognitive Decline: A Meta-analysis. *JAMA Neurol.* 2020; 77(11): 1373-1381. doi: 10.1001/jamaneurol.2020.2273.
36. Hsieh TT, Inouye SK, Oh ES. Delirium in the Elderly. *Clin Geriatr Med.* 2020; 36(2):183-199. doi: 10.1016/j.cger.2019.11.001.
37. Huang H, Li H, Zhang X, et al. Association of postoperative delirium with cognitive outcomes: A meta-analysis. *J Clin Anesth.* 2021; 75:110496. doi: 10.1016/j.jclinane.2021.110496.
38. Manji RA, Grocott HP, Leake J, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. *Can J Anaesth.* 2012; 59(1):6-13. doi: 10.1007/s12630-011-9618-z.
39. Preventza O, Liao JL, Olive JK, et al. Neurologic complications after the frozen elephant trunk procedure: A meta-analysis of more than 3000 patients. *J Thorac Cardiovasc Surg.* 2020; 160(1): 20-33.e4. doi: 10.1016/j.jtcvs.2019.10.031.
40. Gavazzi A, de Rino F, Boveri MC, Picozzi A, Franceschi M. Prevalence of peripheral nervous system complications after major heart surgery. *Neurol Sci.* 2016; 37(2): 205-9. doi: 10.1007/s10072-015-2390-z.
41. Nowinski WL. Taxonomy of Acute Stroke: Imaging, Processing, and Treatment. *Diagnostics (Basel).* 2024; 14(10):1057
42. Rehman S, Nadeem A, Akram U, et al. Molecular Mechanisms of Ischemic Stroke: A Review Integrating Clinical Imaging and Therapeutic Perspectives. *Biomedicine.* 2024; 12(4):812; 9
43. Tang Y, Wang MY, Wu TT, et al. The role of carotid stenosis ultrasound scale in the prediction of ischemic stroke. *Neurol Sci.* 2020; 41(5):1193-1199. doi: 10.1007/s10072-019-04204-8.
44. de Oliveira EP, Fiebach JB, Vagal A, et al. Controversies in Imaging of Patients With Acute Ischemic Stroke: AJR Expert Panel Narrative Review. *AJR Am J Roentgenol.* 2021; 217(5):1027-1037.
45. Campbell BCV, De Silva DA, Macleod, M.R. et al. Ischaemic stroke. *Nat Rev Dis Primers* 5, 70 (2019). <https://doi.org/10.1038/s41572-019-0118-8>
46. Motshabi-Chakane P, Mogane P, Moutlana J, et al. Contemporary Neuroprotection Strategies during Cardiac Surgery: State of the Art Review. *Int J Environ Res Public Health.* 2021;18(23):12747. doi: 10.3390/ijerph182312747.
47. Goto T, Maekawa K. Cerebral dysfunction after coronary artery bypass surgery. *J Anesth.* 2014; 28(2):242-8. doi: 10.1007/s00540-013-1699-0.
48. Gibbon Jr., JH. Application of a Mechanical Heart and Lung Apparatus to Cardiac Surgery. *Minnesota Medicine*, 1954; 37, 171-185
49. Fanning JP, Campbell BCV, Bulbulia R, et al. Perioperative stroke. *Nat Rev Dis Primers.* 2024; 10(1):3. doi: 10.1038/s41572-023-00487-6.
50. Riepen B, DeAndrade D, Floyd TF, Fox A. Postoperative stroke assessment inconsistencies in cardiac surgery: Contributors to higher stroke-related mortality? *J Stroke Cerebrovasc Dis.* 2023; 32(5): 107057. doi: 10.1016/j.jstrokecerebrovasdis.2023.107057.
51. Fong KY, Yeo S, Luo H, et al. Stroke prevention strategies for cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. *ANZ J Surg.* 2024; 94(4):522-535. doi: 10.1111/ans.18947.
52. Franz M, De Manna ND, Schulz S, et al. Minimally Invasive Mitral Valve Surgery in the Elderly. *Thorac Cardiovasc Surg.* 2024; 72(8): 607-613. doi: 10.1055/s-0043-1762940.
53. Doenst T, Lamelas J. Do we have enough evidence for minimally-invasive cardiac surgery? A critical review of scientific and non-scientific information. *J Cardiovasc Surg (Torino).* 2017; 58(4): 613-623. doi: 10.23736/S0021-9509.16.09446-5.
54. Halkos ME, Jonsson A, Badhwar V, et al. Developing Proficiency in Robotic Cardiac Surgery. *Ann Thorac Surg.* 2024; 28:S0003-4975(24)00691-X. doi: 10.1016/j.athoracsur.2024.07.049.

55. Alamouti-Fard E, Garg P, Yazji J, et al. Outcomes after noncardiac surgery in patients with left ventricular assist devices: a systematic review. *Front Cardiovasc Med*. 2024; 11:1414444. doi: 10.3389/fcvm.2024.1414444.
56. D'Oria M, Mastroilli D, Secemsky E, et al. Robustness of Longitudinal Safety and Efficacy After Paclitaxel-Based Endovascular Therapy for Treatment of Femoro-Popliteal Artery Occlusive Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Ann Vasc Surg*. 2024;101:164-178. doi: 10.1016/j.avsg.2023.11.024.
57. Naik H, White AJ, Chakravarty T, et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. *JACC Cardiovasc Interv*. 2009; 2(8):739-47. doi: 10.1016/j.jcin.2009.05.020.
58. Akhtar MI, Gautel L, Lomivorotov V, et al. Multicenter International Survey on Cardiopulmonary Bypass Perfusion Practices in Adult Cardiac Surgery. *J Cardiot-horac Vasc Anesth*. 2021; 35(4): 1115-1124. doi: 10.1053/j.jvca.2020.08.043.
59. Dhamija RK, Donnan GA. The role of neuroimaging in acute stroke. *Ann Indian Acad Neurol*. 2008; 11(Suppl 1):S12-S23.
60. Li J, Xiong J, Chen K, et al. Comparison of magnetic resonance imaging versus computed tomography-based thrombolysis treatment in patients with acute ischemic stroke. *J Clin Ultrasound*. 2022; 50(2):176-181. doi: 10.1002/jcu.23126.
61. Rapillo CM, Dunet V, Pistocchi S, et al. Moving From CT to MRI Paradigm in Acute Ischemic Stroke: Feasibility, Effects on Stroke Diagnosis and Long-Term Outcomes. *Stroke*. 2024; 55(5):1329-1338. doi: 10.1161/STROKEAHA.123.045154.
62. Patel NA, Lin D, Ha B, et al. Intraoperative ultrasound-guided pectoral nerve blocks for cardiac implantable device procedures. *J Interv Card Electrophysiol*. 2024; 67(6):1353-1357. doi: 10.1007/s10840-023-01724-4.
63. Li X, Ge Z, Kan J, et al. Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial. *Lancet*. 2024; 403(10439):1855-1865. doi: 10.1016/S0140-6736(24)00282-4. Epub 2024 Apr 8. Erratum in: *Lancet*. 2024 May 11;403(10439):1854. doi: 10.1016/S0140-6736(24)00928-0. PMID: 38604212
64. Nogueira RG, Schwamm LH, Hirsch JA. Endovascular approaches to acutestroke. Part 1. Drugs, devices, and data. *AJNR* 2009; 30:649-6614
65. Nogueira RG, Yoo AJ, Buonanno FS, Hirsch JA. Endovascular approaches to acute stroke. Part 2. A comprehensive review of studies and trials. *AJNR* 2009; 30:859-8755
66. Nael K, Sakai Y, Khatri P, et al. Imaging-based selection for endovascular treatment in stroke. *RadioGraphics* 2019; 39: 1696-17138
67. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2019; 50: e344-e418
68. Demeestere J, Wouters A, Christensen S, et al. Re-view of perfusion imaging in acute ischemic stroke: from time to tissue. *Stroke* 2020; 51:1017-1024, 10
69. Murphy A, Parsons MW, Bivard A, Aviv RI. Advances in intracranial perfusion imaging for thrombectomy patient selection. *Adv Clin Radiol* 2020; 2:299-318
70. Sluis WM, Hinsenveld WH, Goldhoorn RB, et al. Timing and causes of death after endovascular thrombectomy in patients with acute ischemic stroke. *Eur Stroke J*. 2023; 8(1):215-223. doi: 10.1177/23969873221143210. Epub 2022 Dec 14. PMID: 37021180; PMCID: PMC10069200



KARDİYAK ARİTMİLERİN CERRAHİ TEDAVİSİ

BÖLÜM 59

Zehra BAYRAMOĞLU ¹
Mehmet Kerem ORAL ²
Barış ÇAYNAK ³

DOI: 10.37609/akya.3889.c5381

İçindekiler

- » GİRİŞ
- » SUPRAVENTRİKÜLER ARİTMİLER
 - » Wolff-Parkinson-White (WPW) Sendromu
 - » Cerrahi için endikasyonlar:
 - » Endokardiyal yaklaşım:
 - » Atrio-Ventriküler Nodal Re-Entry Taşikardi (Avnrt)
 - » Atriyal Taşikardi
 - » Atriyal Flatter Ve Fibrilasyon
- » VENTRİKÜLER TAŞİKARDİ (VT) VE VENTRİKÜLER FİBRİLASYON (VF)
- » KARDİAK CERRAHİ PROSEDÜRLER SONRASI GÖRÜLEN ARİTMİLER
 - » Postoperatif Ritm Bozuklukları
 - » Bradi aritmiler ve iletim yolu düzensizlikleri
 - » Supraventriküler taşiaritmiler
 - » Venriküler taşiaritmiler
- » SONUÇ
- » KALP PİLLERİ (PACEMAKER)
 - » Bradiaritmiler için pace modları
- » PACEMAKER TEDAVİ ENDİKASYONLARI
 - » Geçici Pil Endikasyonları
 - » Kalıcı Pil Endikasyonları
 - » Hasta Sinüs Sendromu
 - » Edinsel Tam AV Blok
 - » Semptomatik Bifasiküler ve Trifasiküler Blok
 - » Akut Miyokard Enfaktüsünden Sonra Aralıklı Tam AV Blokla Birlikte Bifasiküler ay da Trifasiküler Blok
 - » Karotis Sinüs Sendromu
- » BİVENTRİKÜLER PACE
- » AICD (OTOMATİK İMPLANTE EDİLEBİLİR KARDİOVERTER DEFİBRİLATÖR)

¹ Prof. Dr., Haliç Üniversitesi, Özel Muayenehane, Zehrabay@Yahoo.com, ORCID iD: 0000-0001-6290-9779

² Op. Dr., Koç Üniversitesi Hastanesi, keremoral@gmail.com, ORCID iD: 0000-0003-3159-1790

³ Prof. Dr., İstanbul Yeni Yüzyıl Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., bariscaynak@gmail.com, ORCID iD: 0000-0002-0849-4944

hızı belirlenen değerleri aştığında aritminin başlangıcından 15-20 saniye sonra yaklaşık 25 jul'lık bir çıkış sağlanır. Akım kaynağı bir mıknatısla noninvaziv olarak aktive veya inaktive edilebilir. Dışarıdan bir aygıtla bataryanın doluluk derecesini ve kaç deşarj kaldığını anlamak ve görüntülemek mümkündür.

Genel olarak AICD implantasyonu, elektrofizyoloji laboratuvarında, hafif sedasyon altında transvenöz yol kullanılarak gerçekleştirilir. İşleme bağlı mortalite %1 civarındadır.(137,138) Sol torakotomi, median sternotomi, subkostal yada subk-sifoid yaklaşım teknikleri hemen hemen terkedilmiş, günümüzde pek kullanılmayan tekniklerdir.

Hızlı atriyal taşikardilerde yanlış algılamaya bağlı uygunsuz şok hasta için çok rahatsız edici olabilir. Kullanılan geliştirilmiş algılama sistemleri her ne kadar bu komplikasyonları azaltmışsa da tamamen önleyememiştir. Elektrodon yerinden oynaması ve migrasyon diğer önemli bir komplikasyon olup, enfeksiyon gelişimi en ciddi komplikasyonu oluşturmaktadır. Bu durum tüm sistemin sökülmesini gerektirebilir.

Günümüzde AICD Teknolojisi:

- » Yeni cihazlar şok dışında anti-takikardi pacing (ATP) de yapabiliyor.
- » Altına yerleştirilen subkutan AICD seçenekleriyle damar içi elektrot gerekmeylebiliyor.
- » Uzaktan takip sistemleriyle cihazlar evden izlenebiliyor.
- » Pil ömrü ve programlanabilirliği gelişmiş durumda.

KAYNAKLAR

1. Wolff L, Parkinson J, White PD. Bundle branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. *Am Heart J* 5:685, 1930.
2. Cox JL. Historic perspective in the development of cardiac arrhythmia surgery. *Sem Thorac Cardiovasc Surg* 1:3, 1989.
3. Cobb FR, Blumenschein SD, Sealy WC, et al. Successful surgical interruption of the bundle of Kent in a patient with Wolff-Parkinson-White Syndrome. *Circulation* 38:1018, 1968.
4. Sealy WC, Gallagher JJ. Surgical treatment of left free wall accessory pathways of atrioventricular connection of the Kent type. *J Thorac Cardiovasc Surg* 81:698,

1981. Cox JL, Ad N. Minimally invasive maze procedure. *Pace* 23:600, 2000.

5. Iva T, Ichihashi T, Hashizume T, et al. Successful surgical treatment of left atrial tachycardia. *Am Heart J* 109:160, 1985.
6. Guiraudon GM, Klein GJ, Gulamhusein S, et al. Surgical repair of Wolff-Parkinson-White Syndrome: A new closed-heart technique. *Ann Thorac Surg* 37(1):67, 1984.
7. Guiraudon G, Klein GJ, Sharma AD, et al. Use of old and new anatomic, electrophysiologic and technical knowledge to develop operative approaches to tachycardia. Brugada P, Wellens HJJ (eds.) *Cardiac Arrhythmias: Where to go from here*. Futura Publishing Company, Mount Kisco, New York p:639, 1987.
8. Bojar M. Adult Cardiac Surgery. *Cardiac Arrhythmias*, p:355, 1992.
9. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. Wagner GS, Macfarlane P, Wellens H, Josephson M, Gorgels A, Mirvis DM, Pahlm O, Surawicz B, Kligfield P, Childers R, Gettes LS, Bailey JJ, Deal BJ, Gorgels A, Hancock EW, Kors JA, Mason JW, Okin P, Rautaharju PM, van Herpen G; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. *J Am Coll Cardiol*. 2009 Mar 17;53(11):1003-11. Review.)
10. (AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, Rautaharju PM, van Herpen G, Wagner GS, Wellens H; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. *Circulation*. 2009 Mar 17;119(10):e235-40. Epub 2009 Feb 19. Review.
11. Cox JL. The status of surgery for cardiac arrhythmias. *Circulation* 71:413, 1985.
12. Jackman WM, Wang X, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. *N Engl J Med* 324:1605, 1991.
13. Cox JL, Ferguson TB. Surgery for the Wolff-Parkinson-White Syndrome: The endocardial approach. *Sem Thorac Cardiovasc Surg* 1:34, 1990.
14. Penn OC. The epicardial technique for left free-wall accessory pathways. *Cardiac Surgery: State of Art*

- Reviews. Philadelphia: Hanley and Belfus, Inc p:123, 1990.
15. Cheriex EC, Jansen EW, Penn OC, Smeets J, Brugada P, Wellens HJJ. Valve function and wall motion after surgery the Wolff-Parkinson-White Syndrome. *Pace* 12:685, 1989.
 16. Xie B, Heald SC, Bashir Y. Radiofrequency catheter ablation of septal accessory pathways. *Br Heart J*. 72:281-284, 1994.
 17. 2019 Guidelines on Supraventricular Tachycardia (for the management of patients with). *European Heart Journal* 2020;41
 18. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. *Circulation* 2023;148
 19. Ross DL, Johnson DC, Denniss AR, Cooper MJ, Richards DA, Uther JB. Curative treatment for atrioventricular junctional (A-V Nodal) re-entrant tachycardia. *J Am Coll Cardiol* 6:1383, 1985.
 20. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. *Circulation* 133,14 2015.
 21. Guiraudon G, Klein GJ, Sharma AD, Yee R. Use of old and new anatomic, electrophysiologic and technical knowledge to develop operative approaches to tachycardia. Brugada P, Wellens HJJ (eds). *Cardiac Arrhythmias: Where to go from here?* Futura Publishing Co. Mount Kisco p:639, 1987.
 22. Johnson DC, Nunn GR, Meldrum-Hanna W. Surgery for atrioventricular node reentry tachycardia; the surgical dissection technique. *Sem Thorac Cardiovasc Surg*. 1:53, 1989.
 23. Cox JL, Ferfusion TB. Surgery for atrioventricular node re-entry tachycardia; The discrete cryosurgical technique. *Sem Thorac Cardiovasc Surg*. 1:47, 1990.
 24. Holman WL. Paroxysmal supraventricular tachycardia due to atrioventricular nodal re-entry; electrophysiologic mechanism and surgical therapy. *Cardiac Surgery: State of the art reviews*. Philadelphia: Hanley and Belfus, Inc. p:175, 1990.
 25. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG. *Circulation*. 1996 Mar 15;93(6):1262-77. Review.
 26. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. *JAMA*. 2001 May 9;285(18):2370-5.
 27. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death. The Framingham heart study. *Circulation*. 1998;98:946-52.
 28. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. *Stroke* 1991;22:983-8
 29. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Hart RG, Benavente O, McBride R, Pearce LA. *Ann Intern Med*. 1999 Oct 5;131(7):492-501.
 30. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomström-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. *Circulation*. 2001 Oct 23;104(17):2118-50.
 31. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. Nadeem K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, Khunnawat C, Ngarmukos T. *J Am Coll Cardiol*. 2004 Jun 2;43(11):2044-53.
 32. Outcome of mitral valve repair in patients with preoperative atrial fibrillation. Should the maze procedure be combined with mitral valvuloplasty? Chua YL, Schaff HV, Orszulak TA, Morris JJ. *J Thorac Cardiovasc Surg*. 1994 Feb;107(2):408-15.
 33. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. European Heart Rhythm Association (EHRA); European Cardiac Arrhythmia Society (ECAS); American College of Cardiology (ACC); American Heart Association (AHA); Society of Thoracic Surgeons (STS), Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nadeem K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. *Heart Rhythm*. 2007 Jun;4(6):816-61.
 34. Ferguson TB, Cox JL. Surgery for atrial fibrillation. In: Zipes DP, Jalife J, editors. *Cardiac electrophysiology: from cell to bedside*, 2nd edn. 1995:1563-1576.
 35. Feinberg WM, Blackshear JL, Laupacis A. Prevalence, age distribution and gender of patients with atrial fibrillation. *Arch Intern Med* (155):469-73, 1995. Leitch JW, Klein G, Yee R, Guiraudon G: Sinus node-atrioventricular isolation ; long term results with the "Corridor" operation for atrial fibrillation. *J Am Coll Cardiol* 17:970, 1991.
 36. Wolf PA, Abbot RD, Kannel WF. AF as an independent risk factor for stroke. The Framingham Study. *Stroke*; 1991;22:983-988. Cox JL: Surgery for atrial fibrillation. *Cardiac Surgery: State of the art reviews*. Philadelphia

37. Hanley and Belfus, Inc p:207, 1990.
38. Cox JL, Schuessler RB, D'Agostino HJ Jr, et al. The surgical treatment of atrial fibrillation III. Development of a definitive surgical procedure. *JU Thorac Cardiovasc Surg.* 101:569, 1991.
39. Cox JL. The surgical treatment of atrial fibrillation IV; Surgical Technique. *J Thorac Surg.* 101:584, 1991.
40. Guiradon GM. Surgical treatment of atrial fibrillation. *Herz* 18: 5-59, 1993.
41. Lee JW, Choo SJ, Kim K, Song JM, Song H, Song MG. Atrial fibrillation surgery simplified with cryoablation to improve left atrial function. *Ann Thorac Surg* 72:1479-1483, 2001.
42. Kosaka Y. Maze procedure for atrial fibrillation: In: Franco K, Verrier E, editors. *Advanced Therapy in Cardiac Surgery*, Decker Inc; St.Louis 250-57, 1999.
43. Sueda T, Imai K, Ishii O, Orihashi K, Watari M, Okado K. Efficacy of pulmonary vein isolation for the elimination of chronic AF in cardiac valvular surgery. *Ann Thorac Surg* 71:1189-93, 2001.
44. Usui A, Inden Y, Mizutani S, Takagi Y, Akita T, Ueda Y. Repetitive atrial flutter as a complications of the left-sided simple maze procedure. *Ann Thorac Surg* 73:1457-59, 2002.
45. Yamuschi S, Ogasawara H, Saji Y, Bessho R, Miyasi Y, Fujii M. Efficacy of intraoperative mapping to optimize the surgical ablation of AF in cardiac surgery. *Ann Thorac Surg* 74:450-57, 2002.
46. Nakajima H, Kobayashi J, Bando K, et al. The effect of cryo-maze procedure on early and intermediate term outcome in mitral valve disease: case matched study. *Circulation* 2002;106(12 Suppl 1):146-150.
47. Melo J, Adrago P, Neves J, Ferrario MM, Pinto M. Surgery for atrial fibrillation using radiofrequency catheter ablation. Assessment of results at one year. *Eur J Cardiothorac Surg* 15:851-855, 1999.
48. Williams RM, Stewart RJ, Bolling FS, Freeman S, Anderson JT, Argenziano M, Smith C, Oz M. Surgical treatment of atrial fibrillation using radiofrequency energy. *Ann Thorac Surg* 71:1939-44, 2001.
49. Pasic M, Bergs P, Muller P, Hoffmann M, Grauhan O, Kuppe H, Hetzer R. Intraoperative radiofrequency maze ablation for atrial fibrillation. The Berlin Modification. *Ann Thorac Surg* 72:1484- 1491, 2001.
50. Sie HT, Beukema WP, Ramdal Misier R, Elvan A, Ennema J, Wellens HJJ. The radiofrequency modified maze procedure. A less invasive surgical approach to atrial fibrillation during open heart surgery. *Eur J Cardiothorac Surg* 19:443-447, 2001.
51. Sie H, Beukema WP, Elvan A, Misier ARR, Ennema J, Haalebos MMP, Wellens JHH. Radiofrequency modified maze in patients with atrial fibrillation undergoing concomitant cardiac surgery. *J Thorac Cardiovasc Surg* 122(2):249-56, 2001.
52. Khargi K, Deneke T, Haarret H, Lemke B, Grewe P, Müller K, Laczkovich A. Saline irrigated cooled tip radiofrequency ablation is an effective technique to perform the maze procedure. *Ann Thorac Surg* 72:1090-95, 2001.
53. Mustafa Güden, Belhhan Akpınar, İlhan Sanisoglu, Erhan Sağbas, and Osman Bayındır. Intraoperative saline-irrigated radiofrequency modified Maze procedure for atrial fibrillation *Ann. Thorac. Surg.*, Oct 2002; 74: 1301 – 1306.
54. Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB Jr, O'Brien SM, et al. Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons National Cardiac Database. *Ann Thorac Surg.* 2008;85: 914-5.
55. Gillinov AM. Ablation of atrial fibrillation with mitral valve surgery. *Curr Opin Cardiol.* 2005;20:107-14. // Gehi AK, Adams DH, Filsoufi F. The modern surgical management of atrial fibrillation. *Mt Sinai J Med.* 2006;73:751-8.
56. Forlani S, De Paulis R, Guerrieri Wolf L, Greco R, Polisca P, Moscarelli M, et al. Conversion to sinus rhythm by ablation improves quality of life in patients submitted to mitral valve surgery. *Ann Thorac Surg.* 2006;81:863-7.
57. Ngaage DL, Schaff HV, Mullany CJ, Barnes S, Dearani JA, Daly RC, et al. Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation justified? *Ann Thorac Surg.* 2007;84:434-42.
58. Fukunaga S, Hori H, Ueda T, Takagi K, Tayama E, Aoyagi S. Effect of surgery for atrial fibrillation associated with mitral valve disease. *Ann Thorac Surg.* 2008;86:1212-7.
59. Stulak JM, Schaff HV, Dearani JA, Orszulak TA, Daly RC, Sundt TM 3rd. Restoration of sinus rhythm by the Maze procedure halts progression of tricuspid regurgitation after mitral surgery. *Ann Thorac Surg.* 2008;86:40-5.
60. Louagi Y, Buche M, Eucher P, Schoevaerdt JC, Gerard M, Jamart J, et al. Improved patient survival with concomitant Cox Maze III procedure compared with heart surgery alone. *Ann Thorac Surg.* 2009;87:440-6.
61. James L. Cox. The longstanding, persistent confusion surrounding surgery for atrial fibrillation. *J Thorac Cardiovasc Surg.* June 2010; 139: 1374 - 1386.
62. Gillinov AM, Bakaeen F, McCarthy PM, Blackstone EH, Rajeswaran J, Pettersson G, et al. Surgery for paroxysmal atrial fibrillation in the setting of mitral valve disease: a role for pulmonary vein isolation? *Ann Thorac Surg.* 2006;81:19-28.
63. M Güden, B Akpınar, B Çaynak, Ç Türkoğlu, Z Özyedek, İ Sanisoğlu, E Sağbaş, S Aytekin, SD Öztekin. Left versus bi-atrial intraoperative saline irrigated radiofrequency modified maze procedure for atrial fibrillation. *Card Electrophysiol Rev* 2003;7:251-7.
64. Ad N, Cox JL. The Maze procedure for the treatment of atrial fibrillation: a minimally invasive approach. *J Card Surg.* 2004 May-Jun;19(3):196-200.
65. Mohr FW, Falk V, Diegler A, Walther T, Van Son JA, Autchbach R. Minimally invasive port-access mitral valve surgery. *J Thorac Cardiovasc Surg* 115:567-74, 1998.
66. Mohr FW, Fabricus AM, Falk V, Autchbach R, Doll N, Von Oppel U, Diegler A, Kottkamp H, Hindricks G. Curative treatment of AF with intraoperative RF ablation: Short term mid term results. *J Thorac Cardiovasc Surg* 123:919-27, 2002.
67. B Akpınar, M Güden, E Sağbaş, İ Sanisoğlu, U Özbek, B Çaynak, O Bayındır. Combined radiofrequency modified maze and mitral valve procedure through a port Access approach: early and mid-term results. *European Journal of Cardio-thoracic Surgery* 2003;24:223-30.
68. Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB Jr, et al. Video-assisted bilateral pul-

- monary vein isolation and left atrial appendage excision for atrial fibrillation. *J Thorac Cardiovasc Surg*. 2005;130:797-802.
68. E Sağbaş, B Akpınar, İ Sanisoğlu, B Çaynak, B Tamtekin, K Oral, B Onan. Video-Assisted Bilateral Epicardial Pulmonary Vein Isolation for the Treatment of Lone Atrial Fibrillation. *Ann Thorac Surg* 2007; 83: 1724-30.
 69. Gillinov AM, Petterson G, Rice TW. Esophageal injury during radiofrequency ablation for atrial fibrillation. *J Thorac Cardiovasc Surg* 122(6):1239-40, 2001.
 70. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Up-dated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2010;3:32-8.
 71. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet*. 2009;15:374534-42. Erratum in: *Lancet*. 2009;374:1596.
 72. Verma A, Haines DE, Boersma LV ve diğerleri; PULSED AF Araştırmacıları. Atrial fibrilasyonun tedavisinde darbeli alan ablasyonu: PULSED AF temel çalışması. *Circulation* 2023;147:1422-32.
 73. Reddy VY, Gerstenfeld EP, Natale A ve diğerleri; ADVENT Araştırmacıları. Paroksizmal atriyal fibrilasyon için darbeli alan veya geleneksel termal ablasyon. *N Engl J Med* 2023;389:1660-71.
 74. 2024 Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) *Eur Heart J* 2024 Sep 29;45(36):3314-3414.
 75. Cox J.L., Brady G.H., Damiano R.J., et al: Right ventricular isolation procedures for non-ischemic ventricular tachycardia. *J Thorac Cardiovasc Surg*, 90:212, 1985a
 76. Fontaine G., Guiraudon G., and Frank R.: Management of chronic ventricular tachycardia. In Narula O.S. (ed): Innovations in Diagnosis and Management of Cardiac Arrhythmias. Baltimore, Williams and Wilkins, 1979.
 77. Malliani A., Schwartz P.J., and Zanchetti A.: Neural mechanisms and life-threatening arrhythmias. *Am Heart J*, 100:705, 1980.
 78. Benson D.W., Jr., and Cox J. L.: Surgical treatment of cardiac arrhythmias. In Roberts N. K., and Gelband H. (eds): Cardiac Arrhythmias in the Neonate, Infant and Child, 2nd ed. East Norwalk, Appleton and Lange, 1982, pp. 341-366.
 79. Bhandari A. K., Scheinman M. M., Morady F., et al: Efficacy of left cardiac sympathectomy in the treatment of patients with the long QT syndrome. *Circulation*. 70:1018, 1984.
 80. Cardiac Arrhythmias: In Edmunds; Adult Cardiac Surgery, Blackwell Medical Sciences, Boston 1998. Graboyes TB, Lown B, Pedris PJ, et al: Long-term survival of patient with malignant ventricular arrhythmias treated with antiarrhythmic drugs. *Am J Cardiol* 50:437, 1982.
 81. Swedlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. *N Engl J Med* 508: 1436, 1983.
 82. Fisher JD, Kim CG, Roth JA, et al. Ventricular tachycardia/fibrillation: Therapeutic Alternatives. *PACE* 14:370, 1991.
 83. Rotman B, Eber B, Dusleag J. Coronary revascularisation influence on ventricular arrhythmias. *Clin Cardiol* 13:11, 1990.
 84. Ostermeyer J, Breithurt G, Borggreffe M, et al. Surgical treatment of ventricular tachycardia. Complete versus partial encircling endocardial ventriculotomy. *J thorac Cardiovasc Surg* 87:517, 1984.
 85. Swedlow CD, Mason JW, Stimon EB, et al. Results of operations for ventricular tachycardia in 105 patients. *J Thorac Cardiovasc Surg* 92:105, 1986
 86. Miller JM, Gottlieb CD, Marchlinski FE, et al. Does ventricular tachycardia mapping influence the success of antiarrhythmic surgery? *J Am Cardiol* 11:112, 1988.
 87. Lawrie GM, Pacifico A. Combined resection and cryoablation for ischemic ventricular tachycardia. Cardiac surgery, state of art reviews. Philadelphia: Hanley and Belfus. Inc p:255, 1990.
 88. Cox L. Surgery for cardiac arrhythmias. Current problems in cardiology: Chicago, Year Book Medical Publishers, 1983.
 89. Manolis AS, Rastegar H, Estes NAM. Automatic implantable cardioverter defibrillator. Current Status, *JAMA* 262:1362, 1989.
 90. Dor V, Sabatier M, Montiglio F, Rossi P, Toso A, Di Donato M. Results of nonguided subtotal endocardectomy associated with left ventricular reconstruction in patients with ischemic ventricular arrhythmias. *J Thorac Cardiovasc Surg* 1994;107:1301-8.
 91. Mickleborough LL, Merchant N, Ivanov J, Rao V, Carson S. Left ventricular reconstruction: early and late results. *J Thorac Cardiovasc Surg* 2004;128:27-37
 92. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;346:877-83.
 93. Steinberg JS, Fischer AVI, Wang P, et al. The clinical implications of cumulative right ventricular pacing in the Multicenter Automatic Defibrillator Trial II. *J Cardiovasc Electrophysiol* 2005;16:359-65.
 94. Dumbor L. Ngaage, MD, FRCS (C-Th), Alexander R.J. Cale, MD, FRCS (CTh), Michael E. Cowen, FRCS, Steven Griffin, FRCS (C-Th), Levant Guvendik, FRCS. Early and Late Survival After Surgical Revascularization for Ischemic Ventricular Fibrillation/Tachycardia: *Ann Thorac Surg* 2008;85:1278-1281
 95. Mirowski M. The automatic implantable cardioverter defibrillator ; an overview. *J Am Coll Cardiol* 6:641, 1985.
 96. Kelly PA, Cannom DS- Garan H, et al. The automatic implantable cardioverter defibrillator; efficacy, complications and survival in patients with malignant ventricular arrhythmias. *J Am Coll Cardiol* 11:1278, 1988.
 97. Winkle RA, Hardwin M, Ruder MA, et al. Long-term outcome with the ICD. *J Am Coll Cardiol* 13:1353, 1989
 98. Angelini P, Feldman MJ, Lutaschanowski R, et al. Cardiac arrhythmias during and after surgery: diagnosis and management . *Prog Cardiovasc Dis* 16:469, 1974.
 99. Ohnishi S, Kasanuki H, Takamizawa K, et al. Long-term management of bradyarrhythmias following open heart surgery: surgical A-V block and sick sinus syndrome after surgery for secundum atrial septal defects treated with permanent cardiac pacing. *Jpn Circ J* 50:903, 1986.

100. Kienzle MG, Martin JL, Horowitz LN, et al. Electrocardiographic changes following endocardial resection for ventricular tachycardia. *Am Heart J* 104:753, 1982.
101. Salazar C, Frishman W, Friedman S, et al: Beta-blockade therapy for supraventricular tachyarrhythmias after coronary surgery: a propranolol withdrawal syndrome? *Angiology* 30:816, 1979.
102. Garson A, Gillette PC. Junctional ectopic tachycardia in children: electrocardiography, electrophysiology, and pharmacologic response. *Am J Cardiol* 44:298, 1979.
103. Tam SK, Miller JM, Edmunds LH Jr. Unexpected, sustained ventricular tachyarrhythmia after cardiac operations. *J Thorac Cardiovasc Surg* 102:883, 1991.
104. Barold SS, Zipes DP. Cardiac pacemakers and antiarrhythmic devices. In Braunwald E (ed): *Heart Disease*, 5th edition. Philadelphia, WB Saunders Company, pp:705-74, 1997
105. Schechter D. C.: Early experience with resuscitation by means of electricity. *Surgery*, 69:360, 1971
106. Aldini G.: General View on the Application of Galvanism to Medical Purposes. London, J. Callow, 1819
107. Robinovitch, L.G.: Triple interrupter of direct currents for resuscitation: Portable model for ambulance service. *J. Ment. Path.* 8:195. 1907-1909
108. Hyman, A.S.: Resuscitation of the stopped heart by intracranial therapy. II: Experimental use of an artificial pacemaker. *Arch. Intern. Med.*, 50:283, 1932
109. Zoll, P.M.: Resuscitation of the heart in ventricular standstill by external electric stimulation. *N. Engl. J. Med.*, 247:768, 1952
110. Bernstein AD, Camm AJ, Fletcher R, et al. The NASPE/BPEG generic pacemaker code for antibradyarrhythmia and adaptive-rate pacing and antitachyarrhythmia devices. *PACE* 10:794, 1987.
111. Zipes DP. Management of cardiac arrhythmias: Pharmacological, electrical and surgical techniques. In Braunwald E (ed): *Heart Disease*, 5th edition. Philadelphia, WB Saunders Company, pp:593- 639, 1997.
112. Atlee JL. Perioperative cardiac dysrhythmias: Diagnosis and management. *Anesthesiology* 86:1397, 1997.
113. Spotnitz H Mi . Surgical Implantation of Pacemakers and Automatic Defibrillators. Cohn LH, ed. *Cardiac Surgery in the Adult*. New York: McGraw-Hill, 2008:1395-1428.
114. Kjekshus J, Swedberg K, Snapinn S: Effects of enalapril on long-term mortality in severe congestive heart failure. *CONSENSUS Trial Group*. *Am J Cardiol* 1992; 69: 103-7
115. Cohn JN, Archibald DG, Ziesche S et al: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. *N Engl J Med* 1986; 314: 1547-52
116. Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G: Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group. *Circulation* 1993; 87(6 Suppl): VI24-31
117. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) [see comments]. *Lancet* 1994; 344(8921): 493-8
118. Gras D, Mabo P, Tang T et al: Multi-site pacing as a supplemental treatment of congestive heart failure: Preliminary results of the Medtronic Inc. InSync study. *PACE* 1998;21(II): 2249-55
119. Daubert J, Linde C, Cazeau S, Sutton R, Kappenberger L, Bailleul C: Protocol design of the MUSTIC (multi-site stimulation in cardiomyopathy) study (Abstr). *Arch Maladies Coeur Vaisseaux* 1998; 91: 154
120. Auricchio A, Stellbrink C, Sack S, et al: The Pacing Therapies for Congestive Heart Failure (PATH-CHF) Study: Rationale, Design, and Endpoints of a Prospective Randomized Multicenter Study. *Am J Cardiol* 1999;83:130D-135D
121. Cazeau S, Ritter P, Bakdach S et al: Four chamber pacing in dilated cardiomyopathy [see comments]. *PACE* 1994;17(11 Pt 2): 1974-9
122. Bakker P, Meiburg H, de Jonge N et al: Beneficial effects of biventricular pacing in congestive heart failure (Abstr). *PACE* 1994;17: 820
123. Blanc JJ, Etienne Y, Gilard M, et al: Evaluation of different pacing sites in patients with severe heart failure: results of an acute hemodynamic study. *J Am Coll Cardiol* 1997;96:3273-7
124. Saxon LA, Kerwin WF, Cahalan MK, et al: Acute effects of intraoperative multisite ventricular pacing on left ventricular function and activation/contraction sequence in patients with depressed ventricular function. *J Cardiovasc Electrophysiol* 1998;9:13-21
125. Leclercq C, Cazeau S, Le Breton H et al: Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. *J Am Coll Cardiol* 1998; 32: 1825-31
126. Gras D, Ritter P, Cazeau S, et al: Long term outcome of advanced heart failure patients with cardiac resynchronization therapy (Abstr). *Europace* 2000;1:D37
127. Porciani MC, Puglisi A, Colella A, et al: Echocardiographic evaluation of the effect of biventricular pacing : the InSync Italian Registry. *Eur Heart J* 2000;21:J23-J30
128. Kerwin WF, Botvinick EH, O'Connell JW, et al: Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. *J Am Coll Cardiol* 2000;35:1221-7
129. Oto A, Yıldırım E, Sade M, Batur K, Aksöyek G, Kabakcı G: Konjestif kalp yetersizliği olan hastalarda kalıcı kalp pilinin etkisi (Abst). *Türk Kardiyol Dern Arş* 2000; 28:SB110
130. Oğuz E, Dağdeviren B, Bilsel T, et al: Dilate kardiyomiyopatili hastalarda atriyo-biventriküler stimülasyonun klinik durum ve kardiyak performansa etkisi (Abst). *Türk Kardiyol Dern Arş* 2000; 28:SB111
131. Kass DA, Chen CH, Curry C, et al: Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. *Circulation* 1999;99:1567-73
132. Auricchio A, Stellbrink C, Block M, et al: Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. *Circulation*. 1999;99:2993-3001
133. Nelson GS, Curry CW, Wyman BT, et al: Predictors of systolic augmentation from left ventricular pre-excitation in patients with dilated cardiomyopathy and intraventricular conduction delay. *Circulation*. 2000;101:2703-2709

134. Mirowski R, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmia with an implantable automatic defibrillator in human beings. *N Engl J Med* 303:322, 1980.
135. Olinger GN, Chapman PD, Troup PI, Almassi GH. Stratified application of the automatic implantable cardioverter defibrillator. *J Thorac Cardiovasc Surg*. 96:141, 1988.
136. Hammon JW. The role of the automatic implantable cardioverter defibrillator in the treatment of ventricular tachycardia. *Sem Thorac Cardiovasc Surg* 1:88, 1989.
137. The antiarrhythmic versus implantable defibrillator investigators (AVID): A comparison of antiarrhythmic therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. *N.Engl J. Med* 337:1576-84, 1997.
138. Indications for implantable cardioverter therapy. (European Society of Cardiology Working Group Report) *Eur Heart J* 22:1074-81, 2001.



KALP YARALANMALARI

BÖLÜM 60

Necmettin ÇOLAK ¹
Yunus NAZLI ²
Ömer ÇAKIR ³

DOI: 10.37609/akya.3889.c5382

İçindekiler

» KÜNT KALP YARALANMALARI

- » Giriş
- » Patofizyoloji
- » Kardiyak Kontüzyon (Cardiac contusion)
- » Kardiyak Konküzyon (Cardiac Concussion)
- » Tanı
- » Kardiyak Laserasyon ve Rüptür
- » Kapak Yaralanmaları
- » Perikardial Travma
- » Aort Yaralanmaları
- » Koroner Arter Yaralanmaları
- » Disritmi
- » Commotio Cordis (Ani Kardiyak Ölüm)
- » Tedavi
- » Sonuç

» PENETRAN KALP YARALANMALARI

- » Giriş
- » Tarihçe
- » Yaralanma Sebepleri
- » Cerrahi Anatomi
- » Hastane Öncesi Tedavi
- » Tanı
- » Acil Ünitesinde Tedavi
- » Cerrahi Tedavi
- » Prognoza Etki Eden Faktörler
- » Sonuçlar

¹ Prof. Dr., Lokman Hekim Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., necmettincolak3@gmail.com, ORCID iD: 0009-0008-6676-0674

² Prof. Dr., Lokman Hekim Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., yunusnazli@gmail.com, ORCID iD: 0000-0001-9573-1268

³ Prof. Dr., Ankara Yüzüncüyıl Hastanesi, Cakiromer34@yahoo.com

içi yabancı cisimler kolayca ayırt edilir. Bunlara ek olarak ventriküler fonksiyonla, intrakardiyak hava varlığı ve tamiri takiben kalan rezidüel defektlerle ilgili bilgi verir.(2,10,11,12,13,14)

Proгноza Etki Eden Faktörler

Penetran kalp yaralanmalarında survi yayınlanmış en geniş serilerde %3 ile %84 oranında bildirilmiştir. Sonuçlardaki bu büyük fark hastane öncesi mortalitenin seriye dahil edilip edilmediği ile ilgilidir. Genel olarak tüm literatürler yorumlandığında, yaralanma mekanizmasının ve hastaneye ulaşıldığı an daki hastanın fizyolojik durumun sonucu etkileyen en önemli prognostik faktör olduğu tespit edilir. Ateşli silahla yaralanma ve geldiğinde hastanın vital bulgularının olmaması kötü sonuca, KDAY ve geldiğinde hastanın vital bulgularının olması da iyi sonuca işaret eder. Bundan başka prognoza etki eden faktörler;(1) tek kalp boşluğu yaralanması/birden fazla kalp boşluğu yaralanması,(2) sağ ventrikül yaralanması/sol ventrikül yaralanması,(3) kardiyak tamponadın olması/olmaması,(4) izole kardiyak travma/birlikte multiorgan travması varlığıdır.

Penetran kalp yaralanmalarında mortalite eski çalışmalarla karşılaştırıldığında günümüzde de yüksek olarak devam etmektedir.Bunda günümüzde ateşli silahla yaralanmaların daha fazla olması ve daha önceden eksitus olarak bildirilen hastaların şimdi vital bulguları alınamayan hasta olarak bildirilmesinin rolü vardır.(2,10)

Sonuçlar

Penetran kalp yaralanmaları nadir ve son derece öldürücü özel klinik sonuçlar oluşturan bir travma şeklidir. Travmalı hastaya yaklaşımda, kardiyovasküler cerrahide dikkat çekici gelişmelere rağmen sonuçlar hala yüzgöldürücü değildir. Travmanın sosyal sebeplerini düzeltilmesi, sivil halkın ateşli silah sahipliğinin azaltılması alınacak önlemler arasındadır. Hızlı transport, hızlı tanı ve operasyon hayat kurtarıcıdır. Unstabil hastalarda tetkiklerle zaman kaybetmeksizin, sadece klinik şüphe ile acil cerrahi müdahale önemlidir.(10)

KAYNAKLAR

1. El-Chami MF, Nicholson W, Helmy T. Blunt cardiac trauma. J Emerg Med, 2008;35:127-33.
2. Cardiac trauma. In: Kouchoyos NT, Blackstone EH, Doty DB, Hanley FL, Karp RB. Cardiac surgery, Kirklin/Barrat-Boyes. 3rd ed. Pennsylvania, Philadelphia: Churchill Livingstone; 2003:1671-7.
3. Cook CC, Gleason TG. Great vessel and cardiac trauma. Surg Clin North Am, 2009;89:797-820.
4. Embrey R. Cardiac trauma. Thorac Surg Clin, 2007;17:87-93
5. Weyant MJ, Fullerton DA. Blunt thoracic trauma. Semin Thorac Cardiovasc Surg, 2008;20:26-30.
6. Schultz JM, Trunkey DD. Blunt cardiac injury. Crit Care Clin, 2004;20:57-70.
7. Orliaguet G, Ferjani M, Riou B. The heart in blunt trauma. Anesthesiology, 2001;95:544-8.
8. Navid F, Gleason TG. Great vessel and cardiac trauma: Diagnostic and management strategies. Semin Thorac Cardiovasc Surg, 2008;20:31-8.
9. Bansal MK, Maraj S, Chewaproug D, Amanullah A. Myocardial contusion injury: Redefining the diagnostic algorithm. Emerg Med J, 2005;22:465-9.
10. Kang N, Hsee L, Rizoli S, Alison P. Penetrating cardiac injury: Overcoming the limits set by Nature. Injury. 2009;40:919-27.
11. O'Connor J, Dittillo M, Scalea T. Penetrating cardiac injury. J R Army Med Corps, 2009;155:185-90.
12. Bastos R, Baisden CE, Harker L, Calhoun JH. Penetrating thoracic trauma. Semin Thorac Cardiovasc Surg, 2008;20:19-25.
13. Asensio JA, Soto SN, Forno W et al. Penetrating cardiac injuries: a complex challenge. Injury, 2001;32:533-43.
14. Degiannis E, Bowley DM, Westaby S. Penetrating cardiac injury. Ann R Coll Surg Engl, 2005;87:61-3.
15. Mejia JC, Stewart RM, Cohn SM. Emergency department thoracotomy. Semin Thorac Cardiovasc Surg, 2008;20:13-8.



PERİKART HASTALIKLARI VE CERRAHİSİ

DOI: 10.37609/akya.3889.c5383

BÖLÜM 61

Meliyke Hatun BAŞER ¹
Ufuk YILDIRIM ²
Semih Murat YÜCEL ³
Mahmut ŞAHİN ⁴

İçindekiler

- » PERİKARDIN ANATOMİK VE FİZYOLOJİK ÖZELLİKLERİ
- » KONJENİTAL PERİKART DEFEKTLERİ
- » PERİKART KİSTLERİ VE DİVERTİKÜLLERİ
- » PERİKART TÜMÖRLERİ
- » AKUT PERİKARDİT
 - » Tedavi
- » REKÜRREN PERİKARDİT
- » MİYOPERİKARDİT
- » PERİKARDİYAL EFÜZYON
 - » Tedavi
- » KARDİYAK TAMPONAT
 - » Tedavi
 - » Perikardiyosentez
 - » Subksifoidal Perikardiyal Tüp Drenajı
 - » Torakoskopik Perikardiyal Pencere
 - » Perkütan Balon Perikardiyotomisi
- » KONSTRÜKTİF PERİKARDİT
 - » Tedavi
 - » Perikardiyektomi
- » PERİKART HASTALIKLARINDA SPESİFİK ETİYOLOJİLER

¹ Arş. Gör. Dr., Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Kardiyoloji AD., meliykehatun@gmail.com, ORCID iD: 0009-0003-8043-1889

² Doç. Dr., Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Kardiyoloji AD., ufukyildirim2715@yahoo.com.tr, ORCID iD: 0000-0002-8848-8711

³ Doç. Dr., Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., semihmuratyucel@gmail.com, ORCID iD: 0000-0002-8077-828X

⁴ Prof. Dr., Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Kardiyoloji AD., drmahmutsahin@gmail.com, ORCID iD: 0000-0003-2117-4512

tedavisinin 8. haftasından sonra gelişen perikardit ise diyaliz perikarditi olarak tanımlanır. Tedavi yaklaşımı erken evrelerde diyaliz uygulamasını içerirken, dirençli olgularda diyaliz sıklığı ve etkinliği artırılmalıdır. Daha nadir olmakla birlikte, bu hastalarda konstrüktif perikardit de görülebilir.

Postkardiyak hasar sendromları: Miyokart enfarktüsü sonrasında gelişen perikardit, post-perikardiyotomi sendromu ve posttravmatik perikarditi kapsar. Kardiyak hasar sonrası ortaya çıkan ve başka bir nedenle açıklanamayan ateş, perikardiyal ya da plöritik göğüs ağrısı, perikardiyal ya da plevral sürtünme sesi, perikardiyal efüzyon, plevral efüzyona eşlik eden CRP yükseliği kriterlerinden en az 2 tanesinin olması ile tanı konur. Antiinflamatuvar tedavi önerilir (13).

KAYNAKLAR

1. LeWinter MM, Imazio M. Pericardial diseases. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF (eds.) *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 11th ed. Philadelphia: Elsevier; 2018. p. 1662-1680.
2. Riquet M, Le Pimpec-Barthes F, Hidden, G. Lymphatic drainage of the pericardium to the mediastinal lymph nodes. *Surgical and Radiologic Anatomy*. 2001;23: 317-319. doi: 10.1007/s00276-001-0317-2
3. Volpe JK, Makaryus AN. *Anatomy, Thorax, Heart and Pericardial Cavity*. Erişim adresi: <https://www.ncbi.nlm.nih.gov/books/NBK482452/> (Erişim 2025 Temmuz).
4. Narin C, Abud B, Kiriş İ, et al. Konjenital Parsiyel Sağ Perikardiyal Defekt. *Koşuyolu Heart Journal*. 2015;18(1): 57-59. doi: 10.5578/khj.6167
5. Payvandi MN, Kerber RE. Echocardiography in congenital and acquired absence of the pericardium. An echocardiographic mimic of right ventricular volume overload. *Circulation*. 1976;53(1): 86-92. doi: 10.1161/01.cir.53.1.86
6. Khayata M, Alkharabsheh S, Shah NP, et al. Case series, contemporary review and imaging guided diagnostic and management approach of congenital pericardial defects. *Open Heart*. 2020;7(1): e001103. doi: 10.1136/openhrt-2019-001103
7. Sheridan JA, Noga M, Mackie AS. Congenital Disorders of the Pericardium. *Canadian Journal of Cardiology*. 2023;39(8): 1140-1143. doi: 10.1016/j.cjca.2023.03.012
8. Maisch B, Seferović PM, Ristić AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European Society of Cardiology. *European Heart Journal*. 2004;25(7): 587-610. doi: 10.1016/j.ehj.2004.02.002
9. Verhaert D, Gabriel RS, Johnston D, et al. The role of multimodality imaging in the management of pericardial disease. *Circulation: Cardiovascular Imaging*. 2010;3(3): 333-343. doi: 10.1161/CIRCIMAGING.109.921791
10. Hirnle G, Kapalka M, Krawiec M, et al. Pericardial mesothelioma mimicking mediastinal lymphoma and systemic rheumatic disease: a case report. *Frontiers in Oncology*. 2025;14: 1481373. doi: 10.3389/fonc.2024.1481373
11. Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes. *Heart*. 2020;106(8): 569-574. doi: 10.1136/heartjnl-2019-315852
12. Dababneh E, Siddique MS. *Pericarditis*. Erişim adresi: <https://www.ncbi.nlm.nih.gov/books/NBK431080/> (Erişim 2025 Temmuz).
13. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC). *European Heart Journal*. 2015;36: 2921.
14. Imazio M. Contemporary management of pericardial diseases. *Current Opinion in Cardiology*. 2012;27(3): 308-317. doi: 10.1097/HCO.0b013e3283524f8e
15. Klein AL, Wang TKM, Cremer PC, et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. *JACC Cardiovascular Imaging*. 2024;17(8): 937-988. doi: 10.1016/j.jcmg.2024.04.010
16. Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. *Circulation*. 2014;130(18): 1601-1606. doi: 10.1161/CIRCULATIONAHA.114.010376
17. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the colchicine for acute pericarditis (COPE) trial. *Circulation*. 2005;112(13): 2012-2016. doi: 10.1161/CIRCULATIONAHA.105.542738
18. Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. *Circulation*. 2010;121(7): 916-928. doi: 10.1161/CIRCULATIONAHA.108.844753
19. Seidenberg PH, Haynes J. Pericarditis: diagnosis, management, and return to play. *Current Sports Medicine Reports*. 2006;5(2): 74-79. doi: 10.1007/s11932-006-0034-z
20. Pelliccia A, Corrado D, Bjørnstad HH, et al. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. *European Journal of Cardiovascular Prevention and Rehabilitation*. 2006;13(6): 876-885. doi: 10.1097/01.hjr.0000238393.96975.32
21. Imazio M, Brucato A, Trincheri R, et al. Individualized therapy for pericarditis. *Expert Review of Cardiovascular Therapy*. 2009;7(8): 965-975. doi: 10.1586/erc.09.82
22. Alabed S, Cabello JB, Irving GJ, et al. Colchicine for pericarditis. *Cochrane Database of Systematic Reviews*. 2014;2014(8): CD010652. doi: 10.1002/14651858.CD010652.pub2
23. Imazio M, Brucato A, Belli R, et al. Colchicine for the prevention of pericarditis: what we know and what we

- do not know in 2014 – systematic review and meta-analysis. *Journal of Cardiovascular Medicine*. 2014;15(12): 840-846. doi: 10.2459/JCM.0000000000000103
24. Imazio M, Mardigyan V, Andreis A, et al. New Developments in the Management of Recurrent Pericarditis. *Canadian Journal of Cardiology*. 2023;39(8): 1103-1110. doi: 10.1016/j.cjca.2023.04.008
 25. Khandaker MH, Schaff HV, Greason KL, et al. Pericardiectomy vs medical management in patients with relapsing pericarditis. *Mayo Clinic Proceedings*. 2012;87(11): 1062-1070. doi: 10.1016/j.mayocp.2012.05.024
 26. Collini V, De Martino M, Andreis A, et al. Efficacy and safety of colchicine for the treatment of myopericarditis. *Heart*. 2024;110(10): 735-739. doi: 10.1136/heartjnl-2023-323484
 27. Imazio M, Cooper LT. Management of myopericarditis. *Expert Review of Cardiovascular Therapy*. 2013;11(2): 193-201. doi: 10.1586/erc.12.184
 28. Shabetai R. Pericardial effusion: haemodynamic spectrum. *Heart*. 2004;90(3): 255-256. doi: 10.1136/hrt.2003.024810
 29. Önem G, Baltalarlı A, Özcan AV, et al. Kardiyak tamponad tedavisinde subsifoid perikardiyal pencere ve perkütan kateter ile drenaj. *Türk Göğüs Kalp Damar Cerrahisi Dergisi*. 2006;14(2): 107-110.
 30. Bary MA, Abdel-aal KM, Mohamed RG, et al. Video-assisted thoracoscopic pericardial window for massive pericardial effusion: South Egypt experience. *Journal of the Egyptian Society of Cardio-Thoracic Surgery*. 2017;25: 73-78. doi: 10.1016/j.jescts.2017.02.005
 31. Akkuş M, Seyrek Y. Does the Thoracoscopic Pericardial Fenestration Side Matter in Patients With Cardiac Tamponade? *Koşuyolu Heart Journal*. 2020;23(3): 203-207. doi: 10.51645/khj.20068
 32. Çardak ME, Külahçioğlu Ş. The safety and efficiency of pericardial window by using uniportal video-assisted thoracoscopic surgery for the treatment of pericardial effusion: A single-center experience. *Laparoscopic Endoscopic Surgical Science*. 2023;30(2): 37-41. doi: 10.14744/less.2023.05935
 33. Swanson N, Mirza I, Wijesinghe N, et al. Primary percutaneous balloon pericardiectomy for malignant pericardial effusion. *Catheter Cardiovascular Interventions*. 2008;71(4): 504-507. doi: 10.1002/ccd.21431
 34. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. *Circulation*. 2011;124(11): 1270-1275. doi: 10.1161/CIRCULATIONAHA.111.018580
 35. Faiza Z, Prakash A, Namburi N, et al. Fifteen-year experience with pericardiectomy at a tertiary referral center. *Journal of Cardiothoracic Surgery*. 2021;16(1): 180. doi: 10.1186/s13019-021-01561-4
 36. İyigün T, Timur B, Kyaruzi M, et al. Surgical Treatment of Constrictive Pericarditis: a Single-Center Experience. *Koşuyolu Heart Journal*. 2019;22(1): 37-41. doi: 10.5578/khj.67855
 37. Chowdhury UK, Subramaniam GK, Kumar AS, et al. Pericardiectomy for constrictive pericarditis: a clinical, echocardiographic, and hemodynamic evaluation of two surgical techniques. *The Annals of Thoracic Surgery*. 2006;81(2): 522-529. doi: 10.1016/j.athoracsurg.2005.08.009
 38. Tzani A, Doulamis IP, Tzoumas A, et al. Meta-Analysis of Population Characteristics and Outcomes of Patients Undergoing Pericardiectomy for Constrictive Pericarditis. *The American Journal of Cardiology*. 2021;146: 120-127. doi: 10.1016/j.amjcard.2021.01.033



KALP TÜMÖRLERİ

BÖLÜM 62

*Fehim Can SEVİL¹
Necip BECİT²
Hikmet KOÇAK³*

DOI: 10.37609/akya.3889.c5384

İçindekiler

- » KALP TÜMÖRLERİ
 - » Sınıflandırma
 - » Vazoformatif Tümörler
 - » Anjiyosarkoma (Hemanjiyosarkoma)
 - » Rabdomiyosarkoma
 - » Diğer Primer Malign Kardiyak Tümörler
 - » Metastatik Tümörler
 - » İnfradiafragmatik Tümörlerin Direkt Yayılımı

¹ Doç. Dr., Afyonkarahisar Sağlık Bilimleri Üniversitesi, Kalp ve Damar Cerrahisi AD., fhm_can@hotmail.com, ORCID iD: 0000-0003-3902-9831

² Prof. Dr., Afyonkarahisar Sağlık Bilimleri Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., necipbecit@hotmail.com, ORCID iD: 0000-0002-9086-515X

³ Prof. Dr., Üsküdar Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., hikmet.kocak@uskudar.edu.tr, ORCID iD: 0000-0003-0921-7575

kolaylıkla yapılabilir ve metastatik hastalığı olan genel durumu bozuk hastalarda oldukça etkilidir ve kalp tamponadı bulgularını düzeltir. Press ve Livingston(98) toplam 100 hastalık dört seriyi değerlendirdiklerinde, malign kalp tamponadı olup da subksifoid perikardiyotomi ile tedavi edilenlerin tümünde tamponad bulgularının kaybolduğunu yalnızca üç olguda rekürrens görüldüğünü ve hiç ölüm olmadığını bildirdiler. Sol anterior torakotomi veya VATS ile plöroperikardiyal pencere açılarak malign perikard efüzyonlarının etkin tedavisi yapılabilir; ancak bu uygulama genel anestezi gerektirir ve ilerlemiş kanser nedeniyle hemodinamisi bozulmuş hastalarda anlamlı morbidite ve mortalite ile birliktedir. Malign perikardiyal efüzyonu olan olgularda radyoterapi ve kemoterapi perikardiyal efüzyonların kontrol edilebilmesi için diğer uygulanabilecek tedavi alternatifleridir.

Infradiafragmatik Tümörlerin Direkt Yayılımı

Renal hücreli karsinomalı hastaların yaklaşık %5-10'unda vena kava inferiorun endovasküler invazyonu görülebilir ve bu olguların %40'ında sağ kalbe kadar invazyon ilerleyebilmektedir. Son zamanlarda bu tümörlerin tedavisinde radyoterapi ve kemoterapinin inefektif olduğu gösterilmiştir. Kaval ve kardiyak uzantılarının çıkarılması ile birlikte renal kitlenin radikal rezeksiyonu endikedir ve sağ atriumdaki tümör yayılımı cerrahi ile etkin biçimde düzeltilebilir.(94,99)Vena kava inferior ve sağ kalbe uzamış malign renal neoplazmlara asendan aortik, superior vena kava ve kommon femoral ven kanülasyonu ile kardiopulmoner bypass kullanılarak cerrahi yaklaşım yapılır. Tümör trombüsü vena kava ve atrium intimasına nadiren sıkıca yapışmıştır, ve genellikle tümör çıkarılması kavotomi ve atriotomi ile yapılır.(99) Çok yapışık ve kanamalı vakarda derin hipotermik total sirkülatuar arrest de tümörün çıkarılmasında uygulanabilecek alternatif bir yaklaşım yöntemidir. (94,99) Bu teknikle diğer gösterilebilen metatazları olmayan vena kaval invazyonlu olgularda 5 yıllık sağkalım %55 iken 10 yıllık sağkalım %43 olarak bildirilmektedir.(94,99)

KAYNAKLAR

1. Barnes AH, Beaver D and Snell AM. Primary sarcoma of the heart: Report of a case with electrocardiographic and pathological studies. *Am Heart J* 1934; 9:480.
2. Chitwood WR Jr. Clarence Crafoord and the first successful resection of a cardiac myxoma. *Ann Thorac Surg* 1992; 54:997-998.
3. Schattenberg TT. Echocardiographic diagnosis of left atrial myxoma. *Mayo Clin Proc* 1968; 43: 620-627.
4. Kosuga T, Fukunaga S, Kawara T, Yokose S, Akasu K, Tayama E, Oryoji A, Aoyagi S. Surgery for primary cardiac tumors. Clinical experience and surgical results in 60 patients. *J Cardiovasc Surg (Torino)* 2002;43:581-587.
5. King YL, Dickens P, Chan ACL. Tumors of the heart. *Arch Pathol Lab Med* 1993; 117:1027-1031.
6. Kamiya H, Yasuda T, Nagamine H, Sakakibara N, Nishida S, Kawasuji M, Watanabe G. Surgical treatment of primary cardiac tumors 28 years experience in Kanazawa University Hospital *Jpn Circ J* 2001; 65:315-319.
7. McAllister HA, Fenoglio JJ. Tumors of the cardiovascular system. *Atlas of Tumor Pathology, Series 2, Fascicle 15*. Washington, DC: Armed Forces Institute of Pathology, 1978:1-20.
8. Centofanti P, Rosa ED, Deorsola L, Dato GM, Patane F, Torre ML, Barbato L, Verzini A, Fortunato G, Summa M. Primary cardiac tumors: early and late results of surgical treatment in 91 patients. *Ann Thorac Surg* 1999; 68:1236-1241.
9. Blondeau P. Primary cardiac tumors: French studies of 533 cases. *Thorac Cardiovasc Surg* 1990; 38:192-195.
10. Keeling IM, Oberwalder P, Anelli-Monti M, Schuchlenz H, Demel U, Tilz GP, Rehak P, Rigler B. Cardiac myxomas: 24 years of experience in 49 patients. *Eur J Cardiothorac Surg* 2002; 22:971-977.
11. McAllister H, Hall R, Cooley D. Tumors of the heart and pericardium. *Carr Probl Cardiol* 1999; 24:57-116.
12. van Gelder HM, O'Brien DJ, Staples ED, Alexander JA. Familial cardiac myxoma. *Ann Thorac Surg* 1992; 53:419-424.
13. Farah MG. Familial cardiac myxoma: A study of relatives of patients with myxoma. *Chest* 1994; 105:65-68.
14. Carney JA. Carney complex: The complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. *Semin Dermatol* 1995; 14:90-98.
15. McCarthy PM, Piehler JM, Schaff HV, Pluth JR, Orszulak TA, Vidaillet HJ Jr, Carney JA. The significance of multiple, recurrent, and "complex" cardiac myxomas. *J Thorac Cardiovasc Surg* 1986;91:389-396.
16. Casey M, Mah C, Merliss AD, Kirschner LS, Taymans SE, Denio AE, Korf B, Irvine AD, Hughes A, Carney JA, Stratakis CA, Basson CT. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. *Circulation* 1998; 98:2560-2566.
17. Revankar SG, Clark RA. Infected cardiac myxoma: Case report and literature review. *Medicine (Baltimore)* 1998; 77:337-344.
18. Shimono T, Makino S, Kanamori Y, Kinoshita T, Yada I. Left atrial myxomas. Using gross anatomic tumor types to determine clinical features and coronary angiographic findings *Chest* 1995; 107:674-679.
19. Burke AP, Virmani R. Cardiac myxoma: A clinicopathologic study. *Am J Clin Pathol* 1993; 100:671-680.

20. Ha JW, Kang WC, Chung N, Chang BC, Rim SJ, Kwon JW, Jang Y, Shim WH, Cho SY, Kim SS, Cho SH. Echocardiographic and morphologic characteristics of left atrial myxoma and their relation to systemic embolism. *Am J Cardiol* 1999; 83:1579-1582.
21. Durgut K, Gormus N, Ozulku M, Ozergin U, Ozpinar C. Clinical features and surgical treatment of cardiac myxoma: report of 18 cases. *Asian Cardiovasc Thorac Ann* 2002;10:111-114.
22. Perchinsky MJ, Lichtenstein SV, Tyers GF. Primer cardiac tumors: forty years experience with 71 patients. *Cancer* 1997; 79: 1809-1815.
23. Gray IR, and Williams, W G. Recurring cardiac myxoma. *Br. Heart J* 1985; 53:645.
24. Attum AA, Johnson GS, Masri Z, Girardet R, Lansing AM. Malignant clinical behavior of cardiac myxomas and "myxoid imitators." *Ann Thorac Surg* 1987; 44:217-222.
25. Silverman NA, and Sabiston DC, Jr: Cardiac neoplasms. In Sabiston, DC, Jr. (ed): *Textbook of Surgery*. Philadelphia, W. B. Saunders Company, 1981.
26. Endo A, Ohtahara A, Kinugawa T, Ogino K, Hisatome I, Shigemasa C.. Characteristics of cardiac myxoma with constitutional signs: a multicenter study in Japan. *Clin Cardiol* 2002; 25:367-370.
27. Mochizuki Y, Okamura Y, Iida H, Mori H, Shimada K. Interleukin-6 and "complex" cardiac myxoma. *Ann Thorac Surg* 1998; 66:931-933.
28. Soeparwata R, Poeml P, Schmid C, Neuhoof H, Scheld H: Interleukin-6 plasma levels and tumor size in cardiac myxoma. *J Thorac Cardiovasc Surg* 1996; 112:1675-1677.
29. Misago N, Tanaka T, Hoshii T, Suda H, Itoh T. Erythematous papules in a patient with cardiac myxoma: a case report and review of the literature. *J Dermatol*, 1995;22:600-605.
30. McMullin GM, Lane R. A rare cause of acute aortic occlusion. *Aust N Z J Surg* 1993; 63:65-68.
31. Veroux P, Mignosa C, Veroux M, Bartoloni G, Bonanno MG, Tumminelli MG. Acute occlusion of abdominal aorta: unusual embolization site for a cardiac tumor mass. *Tumori* 2002; 88:417-419.
32. Goldberg HP, Glenn F, Dotter CT, and Steinberg I: Myxoma of the left atrium. Diagnosis made during life with operative and postmortem findings. *Circulation*, V1: 762, 1952.
33. Ztot S, Henry P, Fornes P, Boughalem K, Chauvaud S, Guermontprez JI. Left atrial myxoma and coronary embolism. *Arch Mal Coeur Vaiss* 1998; 91: 263-266.
34. Guhathakurta S, Riordan JP. Surgical treatment of right atrial myxoma. *Tex Heart Inst J* 2000; 27: 61-63.
35. Scrofani R, Carro C, Villa L, Botta M, Antona C. Cardiac myxoma: surgical results and 15-year clinical follow-up *Ital Heart J* 2002; 3:753-758.
36. Perez de Isla L, de Castro R, Zamorano JL, Almeria C, Moreno R, Moreno M, Lima P, Garcia Fernandez MA. Diagnosis and treatment of cardiac myxomas by transesophageal echocardiography. *Am J Cardiol* 2002; 15: 90:1419-21.
37. Tighe DA, Rousou JA, Kenia S, Kulshrestha P. Transesophageal echocardiography in the management of mitral valve myxoma. *Am Heart J* 1995; 130:627-9.
38. St John Sutton MG, Mercier LA, Giuliani ER, Lie JT. Atrial myxomas: a review of clinical experience in 40 patients *Mayo Clin Proc* 1980 Jun;55:371-6.
39. Espinola-Zavaleta N, Morales GH, Vargas-Barron J, Keirns C, Fraustro AA. Three-dimensional transesophageal echocardiography in tumors of the heart. *Am Soc Echocardiogr* 2002; 15:972-979.
40. Shin MS, Kirklin JK, Cain JB, Ho KJ. Primary angiosarcoma of the heart: CT characteristics. *AJR Am J Roentgenol* 1987;148:267-268.
41. Visrutaratna P, Sivasomboon C, Oranratanachai K. Clinics in diagnostic imaging. Cardiac rhabdomyoma in tuberous sclerosis. *Singapore Med J* 2002; 43: 541-546.
42. Araoz PA, Eklund HE, Welch TJ, Breen JF. CT and MR imaging of primary cardiac malignancies. *Radiographics* 1999; 19: 1421-1434.
43. Matsuoka H, Hamada M, Honda T, Kawakami H, Abe M, Shigematsu Y, Sumimoto T, Hiwada K. Morphologic and histologic characterization of cardiac myxomas by magnetic resonance imaging. *Angiology* 1996; 47:693-698.
44. Kamata J, Yoshioka K, Nasu M, Ueshima K, Mizunuma Y, Sato Y, Izumoto H, Yagi Y, Nakai K, Hiramori K, et al. Myxoma of the mitral valve detected by echocardiography and magnetic resonance imaging. *Eur Heart J* 1995;16:1435-38.
45. Rittoo D, Cotter L. Detection of a small left atrial myxoma: value and limitations of four imaging modalities. *J Am Soc Echocardiogr* 1997; 10:874-876.
46. Talwalkar NG, Livesay JJ, Treistman B, Lacle CE. Mobilization of the anterior mitral leaflet for excision of a left ventricular myxoma. *Ann Thorac Surg* 1999; 67:1476-8.
47. Isobe N, Kanda T, Sakamoto H, Morishita Y, Suzuki T, Kobayashi I. Myocardial infarction in myxoma patients with normal coronary arteries. Case reports. *Angiology* 1996; 47:819-823.
48. Reynen K. Cardiac myxomas. *N Engl J Med* 1995; 33:1610-1617.
49. Boussen K, Moalla M, Blondeau P, Ben Ayed H, Lie JT. Embolization of cardiac myxomas masquerading as polyarteritis nodosa. *J Rheumatol* 1991; 18:283-285.
50. P go-Fernandes PM, Costa PL, Fernandes F, Benvenuti LA, Oliveira SA. Right atrial lipoma. *Arq Bras Cardiol* 2003; 80:97-99.
51. McAllister HA Jr. Primary tumors and cysts of the heart and pericardium. *Curr Probl Cardiol* 1979: 4:1-51.
52. Sallee D, Spector ML, van Heeckeren DW, Patel CR. Primary pediatric cardiac tumors: a 17 year experience. *Cardiol Young* 1999; 9: 155-162.
53. Jimenez Casso S, Benito Bartolome F, Sanchez Fernandez-Bernal C. Cardiac rhabdomyomas in tuberous sclerosis: clinical symptoms and course in 18 cases diagnosed in childhood *An Esp Pediatr* 2000; 52: 36-40.
54. Chen X, Hoda SA, Edgar MA. Cardiac rhabdomyoma. *Arch Pathol Lab Med* 2002; 126:1559.
55. Santoro G, Pisacane C, Pacileo G, Iacono C, Calabro R. Multiple cardiac rhabdomyomas. *Ital Heart J* 2000; 1: 770.
56. Mehta AV. Rhabdomyoma and ventricular preexcitation syndrome: A report of two cases and review of literature. *Am J Dis Child* 1993; 147:669-671.

57. Bittner HB, Sharma AD, Landolfo KP. Surgical resection of an intracardiac rhabdomyoma. *Ann Thorac Surg* 2000; 70: 2156-2158.
58. Busch U, Kampmann C, Meyer R, Sandring KH, Hausdorf G, Konertz W. Removal of a giant cardiac fibroma from a 4-year-old child. *Tex Heart Inst J* 1995; 22:261-4.
59. Williams DB, Danielson GK, McGoon DC, Feldt RH, Edwards WD. Cardiac fibroma: Long-term survival after excision. *J Thorac Cardiovasc Surg* 1982; 84:230-236.
60. Mathur A, Airan B, Bhan A, Sharma R, Sampath Kumar A, Talwar KK, Chopra P, Venugopal P. Non-myxomatous cardiac tumors: twenty-year experience. *Indian Heart J* 2000; 52: 319-323.
61. Zidere V, Lubaua I, Laci A. Giant fibroma of the right ventricle. *Cardiol Young* 2002; 12: 584-586.
62. Kuroda H, Nitta K, Ashida Y, Hara Y, Ishiguro S, Mori T. Right atrial myxoma originating from the tricuspid valve. *J Thorac Cardiovasc Surg* 1995; 99:1249-1250.
63. Srinivas BK, Gopalakrishnan M, Mahadevan R, Satyaprasad V. Lipoma of the left ventricle. *Asian Cardiovasc Thorac Ann* 2002; 10: 64-65.
64. Meng Q, Lai H, Lima J, Tong W, Qian Y, Lai S. Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases. *Int J Cardiol* 2002; 84: 69-75.
65. Grande AM, Minzioni G, Pederzoli C, Rinaldi M, Pederzoli N, Arbustini E, Vigano M. Cardiac lipomas. Description of 3 cases. *J Cardiovasc Surg (Torino)* 1998; 39: 813-815.
66. Basu S, Folliquet T, Anselmo M, Greengart A, Sabado M, Cunningham JN Jr, Jacobowitz IJ. Lipomatous hypertrophy of the interatrial septum. *Cardiovasc Surg* 1994; 2:229-231.
67. Christiansen S, Stypmann J, Baba HA, Hammel D, Scheld HH. Surgical management of extensive lipomatous hypertrophy of the right atrium. *Cardiovasc Surg* 2000; 8: 88-90.
68. Morteale KJ, Mergo PJ, Williams WF. Lipomatous hypertrophy of the atrial septum: Diagnosis with fat suppressed MR imaging. *J Magn Reson Imaging* 1998; 8:1172-1174.
69. Meaney JF, Kazerooni EA, Jamadar DA, Korobkin M. CT appearance of lipomatous hypertrophy of the interatrial septum. *AJR* 1997; 168:1081-1084.
70. Balasundaram S, Halees SA, Duran C. Mesothelioma of the atrioventricular node: First successful follow-up after excision. *Eur Heart J* 1992; 13:718-719.
71. Bharati S, Bauernfeind R, Josephson M. Intermittent preexcitation and mesothelioma of the atrioventricular node: A hitherto undescribed entity. *J Cardiovasc Electrophysiol* 1995; 6:823-831.
72. Kurup AN, Tazelaar HD, Edwards WD, Burke AP, Virmani R, Klarich KW, Orszulak TA. Iatrogenic cardiac papillary fibroelastoma: a study of 12 cases (1990 to 2000). *Hum Pathol* 2002; 33: 1165-1169.
73. Gologorsky E, Gologorsky A. Aortic valve fibroelastomas as an incidental intraoperative transesophageal echocardiographic finding. *Anesth Analg* 2002; 95: 1198-1199.
74. Baba Y, Tsuboi Y, Sakiyama K, Nakajima M, Fjino Y, Meschia JF, Yamada T. Cardiac papillary fibroelastoma as a cause of recurrent ischemic strokes: the diagnostic value of serial transesophageal echocardiography. *Cerebrovasc Dis* 2002; 14: 256-259.
75. Fabricius AM, Heidrich L, Gutz U, Mohr FW. Papillary fibroelastoma of the tricuspid valve chordae with a review of the literature. *Cardiovasc J S Afr* 2002; 13: 122-124.
76. Gowda RM, Khan IA, Mehta NJ, Gowda MR, Gropen TI, Dogan OM, Vasavada BC, Sacchi TJ. Cardiac papillary fibroelastoma originating from pulmonary vein-a case report. *Angiology* 2002; 53: 745-748.
77. Pigato JB, Subramanian VA, McCaba IC. Cardiac hemangioma: A case report and discussion. *Tex Heart Inst J* 1998; 25:83-85.
78. Trout HH 3rd, McAllister HA Jr, Giordano JM, Rich NM. Vascular malformations. *Surgery* 1985; 97:36-41.
79. Dresler C, Cremer J, Logemann F, Haverich A. Intrapericardial pheochromocytoma. *Thorac Cardiovasc Surg* 1998; 46:100-102.
80. Hamilton BH, Francis IR, Gross BH, Korobkin M, Shapiro B, Shulkin BL, Deeb CM, Orringer MB. Intrapericardial paragangliomas (pheochromocytomas): Imaging features. *AJR Am J Roentgenol* 1997; 168:109-113.
81. Jeevanandam V, Oz MC, Shapiro B, Barr ML, Marboe C, Rose EA. Surgical management of cardiac pheochromocytoma. Resection versus transplantation. *Ann Surg* 1995; 221:415-419.
82. Goldstein DJ, Oz MC, Rose EA, Fisher P, Michler RE. Experience with heart transplantation for cardiac tumors. *J Heart Lung Transplant* 1995; 14:382-386.
83. Raaf HN, Raaf JH. Sarcomas related to the heart and vasculature. *Semin Surg Oncol* 1994; 10:374-382.
84. Yaymaci B, Kirali K, Akdemir R, Kotiloglu E, Basaran Y. Primary cardiac angiosarcoma. *Echocardiography* 2001; 18:609-611.
85. Frota Filho JD, Lucchese FA, Leaes P, Valente LA, Vieira MS, Blacher C. Primary cardiac angiosarcoma. A therapeutical dilemma. *Arq Bras Cardiol* 2002; 78:586-591.
86. Adem C, Aubry MC, Tazelaar HD, Myers JL. Metastatic angiosarcoma masquerading as diffuse pulmonary hemorrhage: clinicopathologic analysis of 7 patients. *Arch Pathol Lab Med* 2001; 125:1562-1565.
87. Jyotish CG, Godkar D, Gokhale YG, Pandit SP, Hase NK. Angiosarcoma of the heart presenting as recurrent cardiac tamponade. *J Assoc Physicians India* 2001; 49:662-663.
88. Uchita S, Hata T, Tsushima Y, Matsumoto M, Hina K, Moritani T. Primary cardiac angiosarcoma with superior vena caval syndrome: review of surgical resection and interventional management of venous inflow obstruction. *Can J Cardiol* 1998; 14:1283-1285.
89. Hammond ME, Fitzgibbons PL, Compton CC, Grignon DJ, Page DL, Fielding LP, Bostwick D, Pajak TF. College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. *Cancer Committee and Conference Participants. Arch Pathol Lab Med* 2000; 124: 958-965.
90. Fernandes F, Soufen HN, Ianni BM, Arteaga E, Ramires FJ, Mady C. Primary neoplasms of the heart. Clinical and histological presentation of 50 cases. *Arq Bras Cardiol* 2001; 76:231-237.
91. Aksoylar S, Kansoy S, Bakiler AR, Ozer E, Ozgenc F. Primary cardiac rhabdomyosarcoma. *Med Pediatr Oncol* 2002; 38:146.

92. Villacampa VM, Villarreal M, Ros LH, Alvarez R, Cozar M, Fuertes MI. Cardiac rhabdomyosarcoma: diagnosis by MR imaging. *Eur Radiol* 1999; 9: 634-7
93. Samal AK, Ventura HO, Berman A, Okereke C, Gilliland YE, Willis GW. Myxosarcoma: a rare primary cardiac tumor. *J La State Med Soc* 2002;154:308-12.
94. Mayayo Artal E, Balanza Roure R, Font Ferre L, Alvaro Naranjo T. Primary cardiac lymphoma: presentation of two cases in immunocompetent patients. *An Med Interna* 2002;19:629-631.
95. Cates CU, Virmani R, Vaughn WK and Robertson RM: Electrocardiographic markers of cardiac metastasis. *Am Heart J* 1986;112:1297-303.
96. Armstrong WF, Buck JD, Hoffman R, Waller BF: Cardiac involvement by lymphoma: Detection and follow-up by two-dimensional echocardiography. *Am Heart J* 1986; 112:627-631.
97. Zuo XY, Xu SY. A case of non-Hodgkin's lymphomas metastasize to the cardiac right atrium. *Hunan Yi Ke Da Xue Xue Bao* 2002; 28;27:175.
98. Press OW, Livingston R. Management of malignant pericardial effusion and tamponade. *JAMA* 1987; 27;257(8):1088-92
99. Marshall FF, Reitz B, Diamond DA: A new technique for management of renal cell carcinoma involving the right atrium: hypothermia and cardiac arrest. *J Urol* 1984; 131: 103-107.



DOI: 10.37609/akya.3889.c5385

KALP VE DAMAR CERRAHİSİNDE KALİTE YÖNETİMİ VE RİSK KADEMELENDİRMESİ

BÖLÜM 63

İsmet Onur TANIYAN ¹
Mehmet Cahit SARICAOĞLU ²
Salih Anıl BOĞA ³
Mizgin TAPKAN ⁴
Giorgi SULUKHIA ⁵
Ahmet KAYAN ⁶
Evren ÖZÇINAR ⁷
Ahmet Rüçhan AKAR ⁸

İçindekiler

- » GİRİŞ
- » TARİHÇE
- » RİSK TANIMI
- » KALP VE DAMAR CERRAHİSİNDE RİSK KADEMELENDİRME ÇALIŞMALARI
- » KALP CERRAHİSİNDE ULUSAL VERİ TABANI VE RİSK KADEMELENDİRME ÇALIŞMASI GEREKLİLİĞİ
- » MAKİNE ÖĞRENMESİ VE YAPAY ZEKÂ
- » KALP CERRAHİSİ MERKEZLERİNDE STANDARDİZASYON

¹ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., iotaniyan@ankara.edu.tr, ORCID iD: 0000-0001-6446-9623

² Doç. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., saricaoglu@ankara.edu.tr, ORCID iD: 0000-0002-0378-8855

³ Op. Dr., Kırıkkale Yüksek İhtisas Hastanesi, Kalp ve Damar Cerrahisi Kliniği, salihani.boga@saglik.gov.tr, ORCID iD: 0000-0002-6657-0810

⁴ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., mtapkan@ankara.edu.tr, ORCID iD: 0009-0002-1417-2631

⁵ Arş. Gör. Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., gsulukhia@ankara.edu.tr, ORCID iD: 0009-0002-0982-1692

⁶ Dr. Öğr. Üyesi, Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., akayan@ankara.edu.tr, ORCID iD: 0000-0002-1875-6258

⁷ Prof. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., ozcinar@ankara.edu.tr, ORCID iD: 0000-0001-6151-2147

⁸ Prof. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., akar@ankara.edu.tr, ORCID iD: 0000-0002-5191-5505

KAYNAKLAR

1. Dettori JR, Norvell DC, Chapman JR. Risks, Rates and Odds: What's the Difference and Why Does It Matter? *Global Spine J.* 2021;11(7):1156-8.
2. Cai T, Tian L, Lloyd-Jones DM. Comparing costs associated with risk stratification rules for t-year survival. *Biostatistics.* 2011.
3. Wang Y, Aivalioti E, Stamatelopoulous K, Zervas G, Mortensen MB, Zeller M, et al. Machine learning in cardiovascular risk assessment: Towards a precision medicine approach. *Eur J Clin Invest.* 2025;55 Suppl 1:e70017.
4. Moore WA. *The Knife Man: The Extraordinary Life and Times of John Hunter, Father of Modern Surgery.* New York: Broadway Books; 2005. 134 p.
5. Nightingale F. *Notes on Hospitals.* London: Longman; 1863.
6. Codman E. *A Study in Hospital Efficiency as Demonstrated by the Case Report of the First Five Years of a Private Hospital.* Boston: Thomas Todd Company; 1917.
7. Centers for Disease Control and Prevention (CDC). Reproductive health glossary Atlanta (GA): U.S. Department of Health and Human Services; 2024 [Available from: <https://www.cdc.gov/reproductive-health/glossary/index.html>].
8. Giddens A. Risk and Responsibility. *Modern Law Review.* 1999;doi:10.1111/1468-2230.00188.
9. Hansson SO. Risk. *Stanford Encyclopedia of Philosophy* 2007.
10. Pinna-Pintor P, Bobbio M, Sandrelli L, Giammaria M, Patane F, Bartolozzi S, et al. Risk stratification for open heart operations: comparison of centers regardless of the influence of the surgical team. *Ann Thorac Surg.* 1997;64(2):410-3.
11. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. *Circulation.* 1989;79(6 Pt 2):13-12.
12. Gabrielle F, Roques F, Michel P, Bernard A, de Vicentis C, Roques X, et al. Is the Parsonnet's score a good predictive score of mortality in adult cardiac surgery: assessment by a French multicentre study. *Eur J Cardiothorac Surg.* 1997;11(3):406-14.
13. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Rev Esp Cardiol (Engl Ed).* 2022;75(6):524.
14. Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Parandhi L. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. *JAMA.* 1992;267(17):2344-8.
15. O'Connor GT, Plume SK, Olmstead EM, Coffin LH, Morton JR, Maloney CT, et al. Multivariate prediction of in-hospital mortality associated with coronary artery bypass graft surgery. Northern New England Cardiovascular Disease Study Group. *Circulation.* 1992;85(6):2110-8.
16. Knaus WA, Wagner DP, Zimmerman JE, Draper EA. Variations in mortality and length of stay in intensive care units. *Ann Intern Med.* 1993;118(10):753-61.
17. Bradbury RC, Golec JH, Stearns FE, Jr., Steen PM. Inter-hospital mortality and morbidity variation in Pennsylvania. *J Soc Health Syst.* 1993;4(1):48-67.
18. Steen PM, Brewster AC, Bradbury RC, Estabrook E, Young JA. Predicted probabilities of hospital death as a measure of admission severity of illness. *Inquiry.* 1993;30(2):128-41.
19. Roques F, Gabrielle F, Michel P, De Vincentiis C, David M, Baudet E. Quality of care in adult heart surgery: proposal for a self-assessment approach based on a French multicenter study. *Eur J Cardiothorac Surg.* 1995;9(8):433-9; discussion 9-40.
20. Pons JM, Granados A, Espinas JA, Borrás JM, Martín I, Moreno V. Assessing open heart surgery mortality in Catalonia (Spain) through a predictive risk model. *Eur J Cardiothorac Surg.* 1997;11(3):415-23.
21. Saleh SS, Racz M, Hannan E. The effect of preoperative and hospital characteristics on costs for coronary artery bypass graft. *Ann Surg.* 2009;249(2):335-41.
22. DiGiorgi PL, Baumann FG, O'Leary AM, Schwartz CF, Grossi EA, Ribakove GH, et al. Differences in mitral valve disease presentation and surgical treatment outcome between Hispanic and non-Hispanic patients. *Ethn Dis.* 2008;18(3):306-10.
23. Apolito RA, Greenberg MA, Menegus MA, Lowe AM, Sleeper LA, Goldberger MH, et al. Impact of the New York State Cardiac Surgery and Percutaneous Coronary Intervention Reporting System on the management of patients with acute myocardial infarction complicated by cardiogenic shock. *Am Heart J.* 2008;155(2):267-73.
24. Glance LG, Dick A, Mukamel DB, Li Y, Osler TM. Are high-quality cardiac surgeons less likely to operate on high-risk patients compared to low-quality surgeons? Evidence from New York State. *Health Serv Res.* 2008;43(1 Pt 1):300-12.
25. Egorova NN, Moskowitz A, Gelijns A, Weinberg A, Curty J, Rabin-Fastman B, et al. Managing the prevention of retained surgical instruments: what is the value of counting? *Ann Surg.* 2008;247(1):13-8.
26. Hannan EL, Wu C, Bennett EV, Carlson RE, Culliford AT, Gold JP, et al. Risk index for predicting in-hospital mortality for cardiac valve surgery. *Ann Thorac Surg.* 2007;83(3):921-9.
27. Mukamel D, Glance L, Weimer D, Pearson T, Massey T, Gold J, et al. Racial variations in the choice of on-pump versus off-pump coronary artery bypass grafting. *J Health Serv Res Policy.* 2007;12(1):31-5.
28. Glance LG, Dick A, Osler TM, Li Y, Mukamel DB. Impact of changing the statistical methodology on hospital and surgeon ranking: the case of the New York State cardiac surgery report card. *Med Care.* 2006;44(4):311-9.
29. Weeks WB, Bazos DA, Bott DM, Lombardo R, Racz MJ, Hannan EL, et al. New York's statistical model accurately predicts mortality risk for veterans who obtain private sector CABG. *Health Serv Res.* 2005;40(4):1186-96.
30. Srinivas VS, Vakili BA, Brown DL. Comparison of in-hospital outcomes following early or delayed angioplasty for acute myocardial infarction. *J Invasive Cardiol.* 2002;14(12):746-50.

31. Glance LG, Osler TM. Comparing outcomes of coronary artery bypass surgery: Is the New York Cardiac Surgery Reporting System model sensitive to changes in case mix? *Crit Care Med.* 2001;29(11):2090-6.
32. Burack JH, Impellizzeri P, Homel P, Cunningham JN, Jr. Public reporting of surgical mortality: a survey of New York State cardiothoracic surgeons. *Ann Thorac Surg.* 1999;68(4):1195-200; discussion 201-2.
33. Reich DL, Bodian CA, Krol M, Kuroda M, Osinski T, Thys DM. Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery. *Anesth Analg.* 1999;89(4):814-22.
34. Hannan EL, Racz MJ, Jollis JG, Peterson ED. Using Medicare claims data to assess provider quality for CABG surgery: does it work well enough? *Health Serv Res.* 1997;31(6):659-78.
35. Hannan EL, Kilburn H, Jr., Lindsey ML, Lewis R. Clinical versus administrative data bases for CABG surgery. Does it matter? *Med Care.* 1992;30(10):892-907.
36. Hannan EL, Kilburn H, Jr., O'Donnell JF, Lukacik G, Shields EP. Adult open heart surgery in New York State. An analysis of risk factors and hospital mortality rates. *JAMA.* 1990;264(21):2768-74.
37. Tu JV, Jaglal SB, Naylor CD. Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Steering Committee of the Provincial Adult Cardiac Care Network of Ontario. *Circulation.* 1995;91(3):677-84.
38. Hammermeister KE, Johnson R, Marshall G, Grover FL. Continuous assessment and improvement in quality of care. A model from the Department of Veterans Affairs Cardiac Surgery. *Ann Surg.* 1994;219(3):281-90.
39. Gauthier N, Reynolds L, Curran T, O'Neill J, Gauvreau K, Alexander ME. FORCE Risk Stratification Tool for Pediatric Cardiac Rehabilitation and Fitness Programs. *Pediatr Cardiol.* 2023;44(6):1302-10.
40. Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. *Ann Thorac Surg.* 1994;57(1):12-9.
41. Hattler BG, Madaia C, Johnson C, Armitage JM, Hardesty RL, Kormos RL, et al. Risk stratification using the Society of Thoracic Surgeons Program. *Ann Thorac Surg.* 1994;58(5):1348-52.
42. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). *Eur J Cardiothorac Surg.* 1999;16(1):9-13.
43. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. *Eur J Cardiothorac Surg.* 1999;15(6):816-22; discussion 22-3.
44. Nashef SA, Roques F, Michel P, Cortina J, Faichney A, Gams E, et al. Coronary surgery in Europe: comparison of the national subsets of the European system for cardiac operative risk evaluation database. *Eur J Cardiothorac Surg.* 2000;17(4):396-9.
45. Roques F, Nashef SA, Michel P, Pinna Pintor P, David M, Baudet E. Does EuroSCORE work in individual European countries? *Eur J Cardiothorac Surg.* 2000;18(1):27-30.
46. Roques F, Nashef SA, Michel P. Risk factors for early mortality after valve surgery in Europe in the 1990s: lessons from the EuroSCORE pilot program. *J Heart Valve Dis.* 2001;10(5):572-7; discussion 7-8.
47. Nashef SA, Roques F, Hammill BG, Peterson ED, Michel P, Grover FL, et al. Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. *Eur J Cardiothorac Surg.* 2002;22(1):101-5.
48. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. *Eur Heart J.* 2003;24(9):881-2.
49. Roques F, Nashef SA, Michel P. Regional differences in surgical heart valve disease in Europe: comparison between northern and southern subsets of the EuroSCORE database. *J Heart Valve Dis.* 2003;12(1):1-6.
50. Wyler von Ballmoos MC, Kaneko T, Iribarne A, Kim KM, Arghami A, Fiedler A, et al. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2023 Update on Procedure Data and Research. *Ann Thorac Surg.* 2024;117(2):260-70.
51. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. *Eur J Cardiothorac Surg.* 2012;41(4):734-44; discussion 44-5.
52. American College of Surgeons. American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP): Data and Registries overview Chicago (IL): American College of Surgeons; 2025 [Available from: <https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/>].
53. Teixeira IM, Teles AR, Castro JM, Azevedo LF, Mourao JB. Physiological and Operative Severity Score for the enumeration of Mortality and Morbidity (POSSUM) System for Outcome Prediction in Elderly Patients Undergoing Major Vascular Surgery. *J Cardiothorac Vasc Anesth.* 2018;32(2):960-7.
54. Schanzer A, Goodney PP, Li Y, Eslami M, Cronenwett J, Messina L, et al. Validation of the PIII CLI risk score for the prediction of amputation-free survival in patients undergoing infrainguinal autogenous vein bypass for critical limb ischemia. *J Vasc Surg.* 2009;50(4):769-75; discussion 75.
55. Moxey PW, Brownrigg J, Kumar SS, Crate G, Holt PJ, Thompson MM, et al. The BASIL survival prediction model in patients with peripheral arterial disease undergoing revascularization in a university hospital setting and comparison with the FINNVASC and modified PREVENT scores. *J Vasc Surg.* 2013;57(1):1-7.
56. Grant SW, Hickey GL, Carlson ED, McCollum CN. Comparison of three contemporary risk scores for mortality following elective abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 2014;48(1):38-44.
57. Ranucci M, Castelvechio S, Conte M, Megliola G, Speziale G, Fiore F, et al. The easier, the better: Age, creatinine, ejection fraction score for operative mortality risk stratification in a series of 29,659 patients undergoing elective cardiac surgery. *J Thorac Cardiovasc Surg.* 2011.
58. Akhtar M, Elliott PM. Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy. *Curr Cardiol Rep.* 2019;21(12):155.
59. Holdsworth DA, Parsons IT, Chamley R, Britton J, Pavitt C, Baksi AJ, et al. Cardiac MRI improves cardiovascular risk stratification in hazardous occupations. *J Cardiovasc Magn Reson.* 2019;21(1):48.

60. Zhou D, Zhu L, Li S, Wu W, Zhuang B, Xu J, et al. Prognosis and Risk Stratification in Dilated Cardiomyopathy With LVEF $\leq$ 35%: Cardiac MRI Insights for Better Outcomes. *Circ Cardiovasc Imaging*. 2025;18(3):e017246.
61. van der Bijl P, Bax JJ. Imaging for risk stratification of sudden cardiac death. *Herzschrittmacherther Elektrophysiol*. 2022;33(3):261-7.
62. Ozeren K, Topcu AC, Kayacioglu I. Frailty Assessment to Improve Risk Stratification in Elderly Patients Undergoing Elective Cardiac Surgery. *Braz J Cardiovasc Surg*. 2025;40(2):e20230182.
63. Afilalo J, Lauck S, Kim DH, Lefevre T, Piazza N, Lachapelle K, et al. Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study. *J Am Coll Cardiol*. 2017;70(6):689-700.
64. Akar AR, Kurtcephe M, Sener E, Alhan C, Durdu S, Kunt AG, et al. Validation of the EuroSCORE risk models in Turkish adult cardiac surgical population. *Eur J Cardiothorac Surg*. 2011;40:730-5.
65. Kunt AG, Kurtcephe M, Hidiroglu M, Cetin L, Kucuker A, Bakuy V, et al. Comparison of original EuroSCORE, EuroSCORE II and STS risk models in a Turkish cardiac surgical cohort. *Interact Cardiovasc Thorac Surg*. 2013;16(5):625-9.
66. Birinci S. A Digital Opportunity for Patients to Manage Their Health: Turkey National Personal Health Record System (The e-Nabiz). *Balkan Med J*. 2023;40(3):215-21.
67. Olesen KKW, Riis AH, Nielsen LH, Steffensen FH, Norgaard BL, Jensen JM, et al. Risk stratification by assessment of coronary artery disease using coronary computed tomography angiography in diabetes and non-diabetes patients: a study from the Western Denmark Cardiac Computed Tomography Registry. *Eur Heart J Cardiovasc Imaging*. 2019;20(11):1271-8.
68. Tsukihara H, Motomura N, Takamoto S. Audit-Based Quality Validation of the Japan Cardiovascular Surgery Database. *Circ J*. 2021;85(11):2014-8.
69. Hammermeister KE. Risk, predicting outcomes, and improving care. *Circulation*. 1995;91(3):899-900.
70. Boyle L, Seretny M, Lumley T, Campbell D. Temporal validation of a multivariable surgical mortality prediction model (NZRisk): a New Zealand national cohort study. *BMJ Open*. 2023;13(3):e069911.
71. Bourke BM, Beiles CB, Thomson IA, Grigg MJ, Fitridge R. Development of the Australasian vascular surgical audit. *J Vasc Surg*. 2012;55(1):164-9.
72. Miles TJ, Ghanta RK. Machine learning in cardiac surgery: a narrative review. *J Thorac Dis*. 2024;16(4):2644-53.
73. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56.
74. Leivaditis V, Beltsios E, Papatriantafyllou A, Grapatsas K, Mulita F, Kontodimopoulos N, et al. Artificial Intelligence in Cardiac Surgery: Transforming Outcomes and Shaping the Future. *Clin Pract*. 2025;15(1).
75. Penny-Dimri JC, Bergmeir C, Perry L, Hayes L, Bello-mo R, Smith JA. Machine learning to predict adverse outcomes after cardiac surgery: A systematic review and meta-analysis. *J Card Surg*. 2022;37(11):3838-45.
76. Hassan AM, Rajesh A, Asaad M, Nelson JA, Coert JH, Mehrara BJ, et al. Artificial Intelligence and Machine Learning in Prediction of Surgical Complications: Current State, Applications, and Implications. *Am Surg*. 2023;89(1):25-30.
77. Schouten D, Nicoletti G, Dille B, Chia C, Vendittelli P, Schuurmans M, et al. Navigating the landscape of multimodal AI in medicine: A scoping review on technical challenges and clinical applications. *Med Image Anal*. 2025;105:103621.
78. Tjoa E, Guan C. A Survey on Explainable Artificial Intelligence (XAI): Toward Medical XAI. *IEEE Trans Neural Netw Learn Syst*. 2021;32(11):4793-813.
79. Thevathasan T, Spoormans E, Akin I, Fuernau G, Tebbe U, Haeusler KG, et al. Early Risk Stratification of Patients After Successfully Resuscitated Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation-The Angiography After Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation (TOMAHAWK) Risk Score. *Crit Care Explor*. 2025;7(3):e1221.
80. Thiagarajan RR, Bird GL, Harrington K, Charpie JR, Ohye RC, Steven JM, et al. Improving safety for children with cardiac disease. *Cardiol Young*. 2007;17 Suppl 2:127-32.



İNTRAAORTİK BALON

BÖLÜM 64

Hafize YALINIZ¹
Onur BENLİ²
Tüner ULUS³

DOI: 10.37609/akya.3889.c5386

İçindekiler

- » Giriş
- » Tarihçe
- » IABP çalışma prensibi (hemodinamik ve metabolik etkileri)
- » İABP’da kullanılan malzemeler
- » IABP uygulama indikasyonları
 - » Adultlarda IABP Kullanımı
 - » Çocuklarda IABP Kullanımı
- » IABP uygulamasının kontraindikasyonları
- » IABP uygulama teknikleri
 - » II. Asendan / Arcus aort yolu ile yerleştirilmesi
 - » III. Sol subklavian / aksiller arter yolu ile “ambulator” IABP yerleştirilmesi
 - » IV. Pulmoner Artere Balon Yerleştirilmesi (PABP)
- » D. Çocuklarda balon yerleştirme tekniği
- » İntraaortik balon tetikleme ve ateşleme zamanının ayarlanması (timing)
 - » Erken Deflasyon
 - » Erken İnflasyon
 - » Geç Deflasyon
 - » Geç İnflasyon
- » IABP ayırma kriterleri
- » IABP bağımlılığı ve kriterleri
- » IABP komplikasyonları
 - » A. Vasküler komplikasyonlar
 - » B. Balonun uygunsuz yerleştirilmesi
 - » C. Girişim yerinde oluşan problemler;

¹ Prof. Dr., Çukurova Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., hafize101@yahoo.com
ORCID iD: 0000-0002-7173-8518

² Dr. Öğr. Üyesi, Çukurova Üniversite, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., dronurbanli@gmail.com,
ORCID iD:0000-0003-3623-6130

³ Prof. Dr., Emekli Öğretim Üyesi, tulus@cu.edu.tr, ORCID iD: 0000-0006-4153-7428

helyum /CO₂ salınan volümü azdır ve nonfataldır (72) Aterosklerotik plağın balonu kesmesiyle oluşur. Tedavide balon alınır ve tekrar yerleştirilir.

Ancak son yıllarda IABP'daki gelişen teknolojinin etkisi ve IABP kullanım sıklığı nedeniyle komplikasyonlardaki oranın azaldığı görülmüştür (73).

Sonuç olarak; IABP hemodinamiyi iyi olmayan hastalardaki bu etkileri gözönüne alınırsa, VAD kullanımına ihtiyacı olan hastalarda IAB'ın pre-intra-postoperatif dönemde destekleyici rolünün önemli olduğu görülmektedir (74).

KAYNAKLAR

1. Creswell LL, Rosenbloom M, Cook L. et al. Intraaortic balloon counterpulsasyon. Pattern occlusage and outcome in cardiac surgery patients. *Annals of Thoracic Surgery* 1992;54:11-20.
2. Gustensen J, Goldman BS, Scully EE, Huckell VF, Adelman AG. Evolving indications for preoperative intraaortic balloon pump assistance. *Annals of Thoracic Surgery* 1976; 22:535-43.
3. Pennington DG, Swartz M Codd E, Merjavy JP JP, Kaiser GC. Intra-aortic balloon pumping in cardiac surgical patients: a nine-year experience. *Annals of Thoracic Surgery* 1983; 36:125-31.
4. Louagie Y, Jamar J, Buche M. Operation for instable angina pectoris: Factors influencing adverse in-hospital outcome. *Annals of Thoracic Surgery* 1995; 59:1141-9.
5. Gibbon JH, Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. *Minnesota Medicine* 1954 ; 37:171.
6. Harken DE. Presented at the international Colloge of Cardiology Meeting. Brussels, Belgium 1958.
7. Cooley DA, Beall AC, Jr and Alexander JL. Acute massive pulmonary embolism: Succesful surgical treatment using temporary cardiopulmonary bypass. *JAMA* 1961;177:283-6.
8. Stuckey JH, Newman MM, Dennis C, et al. The use of the heart -lung machine in selected cases of acute myocardial infarction. *Surgery Forum* 1957;8:342-5, 1957.
9. Connolly JE, Bacaner MB, Bruns EL, et al: Mechanical support of the circulation in acute heart failure. *Surgery* 1958: 44:225-28.
10. Lee WH, JR, Krumhaar E, Fonkalsrud EW, et al: Denaturation of plasma proteins as a cause of morbidity and death after intracardiac operations. *Surgery* 1961;50:29-32, 1961.
11. Clauss RH, Birtwell WC, Albertain G, et al: Assisted circulation .I. The arteriel counterpulsator. *Journal of Thoracic and Cardivascular Surgery* 1961; 41:447-50.
12. Dennis C, Carlens E, Senning A, et al: Clinical use of a cannula for left heart bypass without thoracotomy. *Annals Surgery* 1962;156:623-26.
13. DeBakey ME. Left ventricular bypass pump for cardiac assistance. Clinical experience. *American Journal of Cardiology* 1971; 27:3-6.
14. Kontrowitz A. Eksperimental augmentation of coronary flow by retardation of the arerial pressure pulse. *Surgery* 1953;34:678-87.
15. Moulopolous SD, Topaz W, Kolff WJ. Diastolic balloon pumping (with carbon dioxide) in aorta: mechanical assistance to failling circulation. *American Heart Journal* 1962; 63:669-7.
16. Kontrowitz A, Tjonneland S, Freed PS, et al. Initial clinical experience with intraaortic baloon pumping in cardiogenic shock. *JAMA* 1968;203:135-37.
17. Talpins NL, Kripke DC, Goetz RH: Counterpulsation and intra-aortic balloon pumping in cardiogenic shock: Circulatory dynamics. *Archieve Surgery* 1968; 97:991-96.
18. Powell WJ, Daggett WM, Magro AE, et al. Effects of intra-aortic balloon counter pulsation on cardiac performance, owygen consumption and coronary blood flow in dogs. *Circulation Research* 1970; 26:753-56.
19. Bregman D, Kripke DC and Goetz RH. The effect of synchronous undirectional intra-aortic balloon pumping on hemodynamics and coronary blood flow in cardiogenic shock. *Transplantation American Society Artificial İnternal Organs* 1970 ;16:439-45.
20. Buckley MJ, Leinbach RC, Kastor JA, et al. Hemodynamic evaluation of intraaortic balloon pumping in man. *Circulation* 1970; 46 (Suppl. 2):130-36.
21. Bregman D, Casarella WJ: Percutaneous intra-aortic balloon pumping: İnitail clinical experiences. *Annals of Thorac Surgery* 1980; 29:153-56.
22. Subramanian VA, Goldstein JE, Sos TA, et al: Preliminary clinical experience with percutaneous intraaortic balloon pumping. *Circulation*1980; 62 (suppl I):1-123.
23. Kusiak V, Goldberg S. Percutaneous intra-aortic balloon counterpulsion. *Cardiovascular Clinic* 1985;15:281-302 .
24. Torchiana D, Hirsch G, Buckley M, et al. İntraaortic balloon pumping for cardiac support: trends in practice and outcome, 1968-1995. *Journal of Thoracic Cardiovascular Surgery* 1997; 113:758-69.
25. Kontrawitz A, Wasfie T, Freed P, Rubenime M, Wajszczuk W, Schork M. İntraaortic balloon pumping 1967 through 1982: Analysis of complications in 733 patients. *American Journal of Cardiology* 1986;57:976-83.
26. Creswell L, Rosenbloom M, Cox J, et al: İntra-aortic balloon counterpulsation: Patterns of usage and outcome in cardiac surgery patients. *Annals of Thoracic Surgery* 1992;54:11-20 .
27. Bolooki H. Physiology of balloon-pumping. In Bolooki H.(ed): *Clinical Application of İntra-aortic Baloon Pump*. Mount Kisco, NY, Futura,1984; pp:57-126.
28. Bavaria JE, Furukawa S, Kreiner G, et al: Effect of circulatory assist devices on stunned myocardium. *Ann Thorac. Surg* 49:123-26, 1990.
29. Veasy LG, Blalock RC, Orth JL, Boucek MM. İntraaortic balloon pumping in infants and children. *Circulation* 68:1095-100, 1983.
30. Veasy LG, Webster HF, McGough EC: İntraaortic Balloon pumping. Adaptation for pediatric use. *Critical Care Clinical* 1986;2:237-49.
31. Pantalos GM, Minich LL, Tani LY, McGough EC, Hawkins JA. Estimation of timing errors for intraaortic balloon pump use in pediatric patients. *ASAIO Journal*

- 1999; 45:166-71.
32. Booker PD. Intraaortic balloon pumping in young children. *Paediatric Anaesthesia* 1997; 7:501-7.
33. Buckley M, Craver J, Gold H, Mundth E, Dagget W, Austen W. Intraaortic balloon pump assist for cardiogenic shock after cardiopulmonary bypass. *Circulation* 1973; 67(suppl III):190-3.
34. Akomea-Agyin C, Kejriwal N, Franks R, Booker P, Pozzi M. Intraaortic balloon pumping in children. *Annals of Thoracic Surgery* 1999; 67:1415-20.
35. Pollock J, Charlton M, Williams W, Edmonds J, Trusler G. Intraaortic balloon pumping in children. *Annals of Thoracic Surgery* 1979; 29: 522-8.
36. Jaggars J, Forbess J, Shah A, et al. Extracorporeal membrane oxygenation for infant postcardiotomy support: significance of shunt management. *Annals of Thoracic Surgery* 2000; 69:1476-83.
37. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). *Journal American College Cardiology* 2001; 37:2215-39.
38. Dietl C, Berkheimer M, Woods E, Gilbert C, Pharr W, Benoit C. Efficacy and cost-effectiveness of preoperative IABP in patients with ejection fraction of 0.25 or less. *Annals of Thoracic Surgery* 1996; 62:401-9.
39. Christenson J, Badel P, Simonet F, Schuziger M. Preoperative intraaortic balloon pump enhances cardiac performance and improves the outcome of redo CABG. *Annals of Thoracic Surgery* 1997; 64:1237-44.
40. Gutfinger D, Ott R, Miller M, et al. Aggressive preoperative use of intra-aortic balloon pump in elderly patients undergoing coronary artery bypass grafting. *Annals of Thoracic Surgery* 1999; 67:610-3.
41. Cochran representative, Starkey TD, Panos AL, Kunzelman KS. Ambulatory Intraaortic Balloon Pump Use as Bridge to Heart Transplant. *Ann Thorac Surg* 74:746-52, 2002.
42. Pennington DG, Swartz MT, Codd JE, Mejavy JP, Kaiser G. Intraaortic balloon pumping in cardiac surgical patients :a nine -year experience .*Annals of Thoracic Surgery* 1983;36:125-31.
43. Pennington DG, Mejavy JP, Swartz MT, et al: The importance of biventricular failure in patients with postoperative cardiogenic shock. *Annals of Thoracic Surgery* 1985;39:16-20 .
44. Arafat O, Geiran O, Andersen K, et al. Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation. *Annals Thoracic Surgery* 2000; 70:1587-93.
45. Naunheim K, Swartz M, Pennington D, et al. Intraaortic balloon pumping in patients requiring cardiac operations. *Journal of Thoracic Surgery* 1992; 104:1654-61.
46. DeWood A.M, Notske RN, Hensley GR, et al: Intraaortic balloon counterpulsation with or without reperfusion for myocardial infarction shock. *Circulation* 1980;61 :1105-8 .
47. Weintraub RM, Voukydis PC, Aroesty JM, et al: Treatment of preinfarction angina with intraaortic balloon counterpulsation and surgery. *American Journal of Cardiology* 1974; 34:809-12 .
48. Park JK, Hsu KT, Gersony WM. Intraaortic balloon pump management of refractory congestive heart failure in children. *Pediatric Cardiology*1993; 14:19-22.
49. Del Nido PJ, Swan PR, Benson LN, et al. Successful use of intraaortic balloon pumping in a 2 - kilogram infant. *Annals of Thoracic Surgery* 1988; 46:574-6 .
50. Aknes J, Abdelnoor M, Bere V, Fjeld N. Risk factors of septicemia and perioperative myocardial infarction in a cohort of patients supported with intra-aortic balloon pump (IABP) in the course of open heart surgery. *European Journal of Cardiothoracic Surgery* 1993; 7:153-7.
51. Todd GJ, Bregman DD. Voorhees A.B.,and Reemtsma, K. vascular complications with percutaneous intraaortic balloon pumping . *Archives Surgery* 1983; 118:963-66 .
52. Viagnola PA, Swaye PS and Gosselin AJ. Guidelines for effective and safe percutaneous intraaortic balloon pump insertion and removal. *American Journal of Cardiology* 1981; 48:660-63.
53. Goldberg M, Rubenfire M, Kontrowitz A, et al. Intraaortic balloon pump insertion: A randomized study comparing percutaneous and surgical techniques. *Journal American College of Cardiology* 1987; 9:515-23 .
54. Balooki H: Methods of insertion intra-aortic balloon catheter. In Balooki H (ed):*Clinical Application of Intra-Aortic Balloon Pump*. New York, Futura, 1984; p:103.
55. Mayer JH. Subclavian artery approach for insertion of intraaortic balloon. *Journal of Thoracic Cardiovascular Surgery* 76:61-3, 1978.
56. McBride LR, Miller LW, Naunheim KS, Pennington DG. Axillary artery insertion of an intra-aortic balloon pump. *Annals of Thoracic Surgery* 1989; 48:874-5 .
57. Richard P.Cochran MD, Thomas D. Starkey MD, Antony L. Panos MD. et al. Ambulatory Intraaortic Balloon pump Use as Bridge to Heart Transplant. *Annals of Thoracic Surgery* 2002; 74:746-52, 2002.
58. Spence PA, Weisel RD and Salemo TA. Right ventricular failure: Pathophysiology and treatment. *Surgery Clinical North American* 1985; 65: 689-72, 1985.
59. Jett GK, Piocone AL and Clark RE. Circulatory support for right ventricular dysfunction. *Journal of Thoracic Cardiovascular Surgery* 1987; 94:95-98 .
60. Kerrie A. Pinkney MD, MPH, L.LuAnn Minich MD, Lloyd Y. Tani MD et al: Current results with intraaortic Balloon pumping in infants and children. *Annals of Thoracic Surgery* 2002 ; 73:887-91.
61. Minich LL, Tani LY, McGough EC, Shaddy RE, Hawkins JA. A novel approach to pediatric intraaortic intra-ortic balloon pump timing using M-mode echocardiography. *American Journal of Cardiology* 1997; 80:367-9.
62. Minich LL, Tani LY, Pantalos GM, Bolland BL, Knorr BK, Hawkins JA. Neonatal piglet model of intraaortic balloon pumping: Improved efficacy using echocardiographic timing. *Annals of Thoracic Surgery* 1988; 66:1527-32.
63. Tatar H, Çicek S, Demirkılıç U, Özel E, Suer H, Aslan M, Yüksel ÖY. Vascular complications of intraaortic balloon pumping: Unstrated versus sheated insertion. *Annals of Thoracic Surgery* 1983; 55:1518-21.
64. Kırallı K, Güler M, Erentug V., Dağlar B. ve ark. İntraaortik balon pompası:765 hastada 15 yıllık klinik deneyim. *Göğüs Kalp Damar Cerrahisi* 1999; 7:353-7.
65. Gol M, Bayazit M, Emir M, Taşdemir O, Beyazit K. Vascular complications related to percutaneous insertion

- of intraaortic balloon pumps. *Annals of Thoracic Surgery* 1994 58:1476-80.
66. Barnett M, Swartz MT, Peterson GJ, et al. Vascular complications from intraaortic balloons: risk analysis. *Journal of Vascular Surgery* 1994; 19:81-9.
67. Alle K, White G, Harris J, May J, Baird D. Iatrogenic vascular trauma associated with intra aortic balloon pumping identification of risk factors. *American Surgery* 1993; 59: 813-7.
68. Bautista-Hernandez V, Moya J, Martinell J. et al. Successful Stent-grafting for perforation of the thoracic aorta by an intraaortic balloon pump. *Annals of Thoracic Surgery* 2002; 73:956-8.
69. Sirbu H, Busch T, Aleksik I, Fredrich M, Dalichau H. Ischemic complications with intraaortic balloon counterpulsation: incidence and management. *Cardiovascular Surgery* 2000; 8:66-71.
70. Cleveland RJ: IAB graft complications. *Annals of Thoracic Surgery* 1997; 23:389-42 .
71. Jarmolowski C, Poirier R. Small bowel infarction complicating intraaortic balloon counterpulsation via the ascending aorta. *Journal of Thoracic Cardiovascular Surgery* 1980; 79:735-7.
72. Kunkler A, King H. Comparison of air, oxygen and carbondioxide embolizasyon. *Annals of Surgery* 1959 ;149:95-98 .
73. Christenson TJ, Cohen M, Ferguson III JJ et al. Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery. *Annals of Thoracic Surgery* 2002; 74:1086-91.
74. Baskett FJR, Ghali AW, Maitland A et al. The intraaortic balloon pump in cardiac surgery. *Annals of Thoracic Surgery* 2002; 74:1276-87 .



VENTRİKÜLER DESTEK SİSTEMLERİ

BÖLÜM 65

Deniz Süha KÜÇÜKAKSU ¹

DOI: 10.37609/akya.3889.c5387

İçindekiler

- » GİRİŞ VE GENEL BİLGİLER
- » TARİHİ BİLGİ VE GELİŞİMİ
- » KALP YETMEZLİĞİ TANIMLAMASI VE SINIFLANDIRILMASI
- » VENTRİKÜLER DESTEK SİSTEMLERİ VE SINIFLANDIRMA
- » AKUT KALP YETERSİZLİĞİNDE KULLANILAN SİSTEMLER
- » EKSTRAKORPORAL SİSTEMLER
- » ECPPELLA (VA ECMO + IMPELLA)
- » KRONİK KALP YETERSİZLİĞİNDE KULLANILAN SİSTEMLER
- » KLİNİK SONUÇLAR
- » HASTA SEÇİM KRİTERLERİ
- » VENTRİKÜLER DESTEK İÇİN SİSTEM VE CİHAZ SEÇİMİ
- » VENTRİKÜLER DESTEK SİSTEM UYGULAMALARINDA KLİNİK ÖZELLİKLER
- » VENTRİKÜLER DESTEK SİSTEMLERİNİN FİZYOLOJİK VE HEMODİNAMİK ETKİLERİ
- » KOMPLİKASYONLAR VE ÖZEL DURUMLAR
- » VENTRİKÜLER DESTEK SİSTEM UYGULAMALARININDA YAKIN GELECEK PLANLARI

¹ Prof. Dr., İstanbul Başkent Üniversitesi Hastanesi, Kalp Damar Cerrahisi AD., suha.kucukaksu@gmail.com, ORCID iD:0000-0003-2524-4864

Ventriküler destek sistemleri; kalp yetersizliği gibi son evresinde en malign kanserlerden bile daha hızla ölüme götüren bir hastalığa yönelik günümüzde ve yakın gelecekte de en önemli tedavi modalitelerinden birini oluşturmaktadır. Bu sistemler için kalp damar cerrahisi kliniği içinde transplantasyon ve mekanik dolaşım destekleyici sistemler bölümleri kurulmalıdır. Bu bölümün hastane içindeki diğer bölümlerle (kardiyoloji, acil v.b) yakın ilişkisinin organizasyonu oluşturulmalıdır. Kalp nakli merkezlerinde kurulacak yüksek teknoloji ve yetişmiş özel ekipli bölümlerin, bölgesel olarak diğer hastanelere hizmet vermesi (VDS merkezi) sağlanmalıdır. Bu hastaların evlerinde, işlerinde rahatça yaşamaları içinde gerekli toplumsal düzenlemelerin yapılması da gereklidir..

KAYNAKLAR

- Gallois CJJ. Experiences on the principle of life. Philadelphia: Charles C Thomas, 1813. Translation of Le-Gallois CJJ. Experience sur la principe de la vie. Paris, 1812.
- Gibbon JH. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med, 1954; 37:171.
- Spencer FC, Eiseman B, Trinkle JK, Rood NP. Assited circulation for cardiac failure following intracardiac surgery with cardiorespiratory bypass. J Thorac Cardiovasc Surg, 1959;49:56.
- Stuckey JH, Newman MM, Dennis C et al. The use of the heart-lung machine in selected cases of acute myocardial infarction. Surg From, 1957;8:342-4.
- Dennis C, Carlens E, Senning A et al. Clinical use of a cannula for left heart bypass without thoracotomy. Ann Surg, 1962;156:623.
- Liotta D, Taliani T, Giffoniello AH et al. Artificial heart in the chest: Preliminary report. Trans Ann Soc Artif Intern Organs, 1961;7:318-22.
- Liotta D, Crawford ES, Cooley DA et al. Prolonged partial left ventricular bypass by means of an intrathoracic pump implanted in the chest. Trans Ann Soc Artif Organs, 1962;8:90-9.
- DeBakey ME. Left ventricular bypass pump for cardiac assistance. Clinical experience. Am J Cardiol, 1971;27:3-11.
- Liotta D: Early clinical application of assisted circulation. Tex Heart Inst J, 2002;29:229-30.
- Mouloupoulos SD, Topaz S, Kolff WJ. Diastolic balloon pumping (with carbondioxide) in the aorta. Mechanical assistance of the failing circulation. Am Heart J, 1962;63:229.
- Kantrowitz A, Tjonneland S, Freed PS et al. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA, 1968;203:135.
- Reemstma K, Drusin R, Edie R, et al. Cardiac transplantation for patients requiring mechanical circulatory support. J Engl J Med, 1978;298:670.
- Norman JC, Brook MI, Cooley DA et al. Total support of the circulation of a patient with postcardiotomy, artificial heart (AL-VAD) for 5 days followed by heart and kidney transplantation. Lancet, 1978;1:1125.
- Portner PM, Oyer PE, McGregor CG et al. First human use of an electrically powered implantable ventricular assist system. Artif Organs, 1985;9:36.
- Frazier O, Duncan J, Radovancevic B et al. Successful bridge to heart transplantation with a new left ventricular assist device. J Heart Lung Transplant 1992;11:530.
- Dew M, Kormos D, Roth L, Life Quality in the area of bridging to cardiac transplantation: Bridge patients in an outpatient setting. ASAIO J, 1993;39:145.
- Frazier O. First use of an untethered, vented electric left ventricular assist device for long term support. Circulation 1994;89:2908.
- FDA News for immediate release, 2002;P02-48.
- McCarthy PM, Smedira NO, Vargo RL et al. One hundred patients with the HeartMate left ventricular assist device: Evolving concepts and technology. J Thorac Cardiovasc Surg, 1998;115:904-12.
- Güner S, Yaşa B, Kantaroğlu B, Küçükaksu DS et al. Postkardiyotomi kardiyojenik şok tedavisinde ventriküler destek aygıtlarının kullanımı. XIV.Ulusal Kardiyoloji Kongresi Abstr, 1998;92.
- Taşdemir O, Şener E, Küçükaksu DS ve ark. Kalp transplantasyonuna bridging amaçlı DeBakey VAD implantasyonu: Türkiye'deki ilk deneyim. XVII Ulusal Kardiyoloji Kongresi (özet kitabı), 2001;29:145.
- Küçükaksu DS, Şener E, Undar A, Tasdemir O. First Turkish experience of implantable left ventricular assist device for bridging to transplantation. I. Cleveland Clinic Foundation Heart Failure & Circulatory support Summit, Cleveland, 2002;12.
- Ozbaran M, Yagdi T, Engin C et al. Mechanical cardiac support in the adult with the Berlin Heart EXCOR pulsatile ventricular assist device: Report of the first two case. Artificial Organs, 2007;31:10.
- Kucukaksu DS, Wieselthaler G, Goksedef D et al. The first implantation of DeBakey VAD for destination therapy in Turkey. Artificial Organs, 2007;10:116.
- Eygi B, Ertugay S, Turhan S et al. Intracorporeal LVAD applications: Ege University experience. 2. TUYOD (Yapay Organlar ve Destek Sistemleri) Kongresi 2009;4:S06.
- High-Risk Left Main Coronary Artery Bypass Surgery Supported by the Impella Recover LP 2.5 Assist Device: An Alternative Insertion Technique. Kucukaksu S, Ergenoglu MU, Yildiz CE, Yerebakan H, Sayin M, Dergertekin M. The Heart Surgery Forum 2009;12:1076.
- First Turkish experiences of assisted beating-heart coronary artery bypass graft with the Impella Microaxial Ventricular Assist Device. Yildiz CE, Sayin M, Yerebakan H, Kucukaksu S. Heart Surg Forum. 2010;13:E60-2.
- Bolooki H. Clinical application of the intra-aortic balloon pump. 3rd ed. Armonk, NY:Futura publishing company, Inc, 1998.
- Bolooki H. Physiology of balloon-pumping. In Bolooki, H.(ed): Clinical application of intra-aortic balloon pump. Mount Kisco, NY Futura, 1984;57-126.
- Nunez L, Aguado MG, Iglesias A, Larrea JL. Transaortic cannulation for balloon pumping in a "crowded aorta". Ann Thoracic Surg, 1980;30:400-2.

31. Symbas PN, McKeown PP, Santora AH. Pulmonary artery balloon counterpulsation for treatment of intra-operative right ventricular failure. *Ann Thorac Surg*, 1985;39:437.
32. McCarthy PM, Golding LAR. Temporary mechanical circulatory support. In: *Cardiac Surgery in the Adult*. Edited by Edmunds LH, Jr. The McGraw-Hill Companies, Inc. USA, chapter, 1997;11:319-37.
33. Jarmolowski CR, Poirier RL. Small bowel infarction complicating intra-aortic balloon counterpulsation via the ascending aorta. *J Thorac Cardiovasc Surg*, 1980; 79:735-7.
34. Minich L, Tani L, McGough E et al. A novel approach to pediatric intraaortic balloon pump timing using M-mode echocardiography. *Am J Cardiol*, 1997;80:367-9.
35. Basket RF, Ghali WA, Maitland A et al. The intraaortic balloon in cardiac surgery. *Ann Thorac Surg*, 2002; 74:1276-87.
36. Holman W, Qing L, Kiefe C et al. Prophylactic value of preincision intra-aortic balloon pump: Analysis of a state-wide experience. *J Thorac Cardiovasc Surg*, 2000;120:1112-9.
37. Dyub AM, Whitlock RP, Abouzahr LL, Cinà CS. Preoperative intra-aortic balloon pump in patients undergoing coronary bypass surgery: A systematic review and meta-analysis. *J Card Surg*, 2008;23:79-86. Bahekar A, Singh M, Singh S et al. Cardiovascular Outcomes Using Intra-Aortic Balloon Pump in High-Risk Acute Myocardial Infarction With or Without Cardiogenic Shock: A Meta-Analysis. *J Cardiovasc Pharmacol Ther*, 2011 Feb 18.
38. Bahekar A, Singh M, Singh S et al. Cardiovascular Outcomes Using Intra-Aortic Balloon Pump in High-Risk Acute Myocardial Infarction With or Without Cardiogenic Shock: A Meta-Analysis. *J Cardiovasc Pharmacol Ther*, 2011 Feb 18.
39. Goldstein D. Invited commentary. *Ann Thorac Surg*, 2002;74:751-2.
40. Kucukaksu S, Ergenoglu MU, Yildiz CE et al. High-risk left main coronary artery bypass surgery supported by the Impella Recover LP 2.5 assist device: an alternative insertion technique. *Heart Surg Forum*. 2009; 12:E324-6.
41. Dens J, Meyns B, Hilgers RD et al. First experience with the Impella Recover(R) LP 2.5 micro axial pump in patients with cardiogenic shock or undergoing high-risk revascularisation. *EuroIntervention*. 2006; 2:84-90.
42. Yildiz CE, Sayin M, Yerebakan H, Kucukaksu S. First Turkish experiences of assisted beating-heart coronary artery bypass graft with the Impella Microaxial Ventricular Assist Device. *Heart Surg Forum*. 2010;13:E60-2.
43. Rose DM, Connolly M, Cunningham JN Jr, Spencer FC. Technique and results with a roller pump left and right heart assist device. *Ann Thorac Surg*, 1989; 47:124-9.
44. Saxton GA Jr, Andrews CB. An ideal heart pump with hydrodynamic characteristics analogous to the mammalian heart. *Trans Am Soc Artif Intern Organs*, 1960;6:288-0.
45. Golding LR, Gloves LK, Peter M et al. Initial clinical experience with a new temporary left ventricular assist device. *Ann Thorac Surg*, 1980;29:66-9.
46. Curtis JJ, Walls JT, Wagner-Mann CC et al. Centrifugal pumps: Description of devices and surgical techniques. *Ann Thorac Surg*, 1999;68:666-71.
47. Curtis JJ, Walls JT, Boley TM et al. Autopsy findings in patients on postcardiotomy centrifugal ventricular assist. *ASAIO J*, 1992;38:688-90.
48. Noon GP, Ball JW Jr, Papaconstantinou HT. Clinical experience with BioMedicus centrifugal ventricular support in 172 patients. *Artif Organs*, 1995;19:756-60.
49. Curtis JJ, Wagner-Mann C. Extracorporeal support: Centrifugal Pumps. In: Goldstein DJ, Oz MC (eds): *Cardiac Assist Devices*, Futura Publishing Company, Inc. Armonk NY, USA, 2000;215-233.
50. Mehta SM, Aufiero TX, Pea WE Jr et al. Combined registry for the clinical use of mechanical ventricular assist pumps and the total artificial heart in conjunction with heart transplantation. Sixth official report- 1994. *J Heart Lung Transplant*, 1995;14:585-93.
51. Magovern JA. Cardiac Assist Technology: The Tandem Heart. Presented at the fifty International Conference on circulatory support device for severe cardiac failure, New York, 2000;15-7.
52. Intermediate Clinical Performance of the Levitronix CentriMag Ventricular Assist Device in Supporting Cardiogenic Shock Patients. Kenneth Liao; Sara Shumway; Monica Colvin-Adams; Emil Missov; Ranjit John. *Circulation*. 2010;122:A296
53. Ozdogan ME, İriz E, Qarandaghi L ve ark. Kalp nakline köprü olarak biventriküler dolaşım destek cihazları. 2. TÜYOD Kongresi Kitapçığı 1:502.
54. Spencer FC, Eisman B, Trinke JK. Assisted circulation for cardiac failure following intracardiac surgery with cardiopulmonary bypass. *J Thorac Cardiovasc Surg*, 1965;49:56-73
55. Kaplan RJ, Smedira NG. Extracorporeal membrane oxygenator in adults. In Goldstein DJ, Oz MC (eds): *Cardiac Assist Devices*, Futura Publishing Company, Inc. Armonk NY, USA. chapter, 2000;20:263-73.
56. Delius R, Anderson H, Schumacher R et al. Venovenous compares favorably with venoarterial access for extracorporeal membrane oxygenation in neonatal respiratory failure. *J Thorac Cardiovasc Surg*, 1993; 106:329-38.
57. Smedira NG, Wudel JH, Hlozek CC et al. Venovenous extracorporeal life support for patients after cardiectomy. *ASAIO J*, 1997;43:M444-6.
58. Gazmuri RJ, Weil MH, von Planta M et al. Cardiac resuscitation by extracorporeal circulation after failure of conventional CPR. *J Lab Clin Med*, 1991;118:65-73.
59. Willms DC, Atkins PJ, Dembitsky WP, et al. Analysis of clinical trends in a program of emergent ECLS for cardiovascular collapse. *ASAIO J*, 1997;43:65-8.
60. Phillips SJ, Zeff RH, Kongtaworn C et al. Percutaneous cardiopulmonary bypass: Application and indication for use. *Ann Thorac Surg*, 1989;47:121.
61. Kurusz M, Zwiscjenberger JB. Percutaneous cardiopulmonary bypass for cardiac emergencies. *Perfusion*, 2002;17:269-77.
62. Smedira NG, Wudel CH, Hlozek CC et al. Extracorporeal life support as a bridge to left ventricular assist device. *ASAIO J*, 1997;43:33.
63. Meyer DM, Jessen ME, Ring WS. Results of ECMO in neonates with sepsis. *JTCVS*, 1995;109:419-27.
64. Ko WJ, Lin CY, Chen RJ et al. Extracorporeal membrane oxygenation support for adult postcardiotomy cardiogenic shock. *Ann Thorac Surg*, 2002;73:538-45.

65. Moazami N, Smedira NG, McCarthy PM et al. Clinical experience with 229 adults on ECMO: Survival at 5 years. Presented at the fifth international conference on circulatory support devices for severe cardiac failure, New York, 2000;15-7.
66. Wang SS, Ko WJ, Chen YS et al. Mechanical bridge with extracorporeal membrane oxygenation and ventricular assist device to heart transplantation. *Artif Organs*, 2001;25:599-602.
67. Kihara S, Kawai A, Endo M, et al. Extracorporeal membrane oxygenation and left ventricular assist device: A case of double mechanical bridge. *Heart Vessels*, 2002;16:164-6.
68. Spiwak AJ. Transport issues with patients on ECMO. Presented at the I. Cleveland Clinic Foundation Heart failure&Circulatory support summit, Cleveland, Ohio, 2002;22-5.
69. Duncan BW, Hraska V, Jonas R et al. Mechanical circulatory support in children with cardiac disease. *J Thorac Cardiovasc Surg*, 1999;117:529-42.
70. Jett GK. ABIOMED BVS 5000. Experience and potential advantages. *Ann Thorac Surg*, 1996;61:301-4.
71. Guyton RA, Schonberger JPAM, Everts PA et al. Postcardiotomy shock: Clinical evaluation of the BVS 5000 biventricular support system. *Ann Thorac Surg*, 1993;56:346-56.
72. Arabia FA, Paramesh V, Toporoff B et al. Biventricular cannulation for the Thoratec ventricular assist device. *Ann Thorac Surg*, 1998;66:2119-2120.
73. Couper G, Dekkers R, Adams DH. The logistic and cost-effectiveness of circulatory support. Advantages of the Abiomed BVS 5000. *Ann Thorac Surg*, 1999;68: 646-9.
74. Tsai FC, Marelli D, Laks H et al. Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. *Am J Transplant*, 2002;2:646-51.
75. Mehta SM, Christenson D, Sun B et al. Utilization of the ABIOMED BVS 5000 circulatory support system in the resuscitation of patients with acute heart failure. Presented at the fifth international conference on circulatory support devices for severe cardiac failure, New York, Sept 15-17,2000.
76. Morgan J, Stewart A, Lee BJ, Oz M. Role of the Abiomed BVS5000 device for short-term support and bridge to transplantation. *ASAIO* 2004;50(4):360-363.
77. T. Unoki, T. Nakayama, Y. Tsurusaki. Combined use of VA-ECMO and Impella (ECPPELLA) improves short- and long-term mortality in patients with cardiogenic shock who received VA-ECMO. *European Heart Journal* 2023; 44 (Suppl 2);
78. Pierce WS, Brighton JA, O'Bannon W et al. Complete left ventricular bypass with paracorporeal pump: Design and evaluation. *Ann Surg*, 1974;180:418-26.
79. Hill JD, Farrar DJ, Hershon JJ et al. Use of prosthetic ventricle as a bridge to cardiac transplantation for postinfarction cardiogenic shock. *N Engl J Med*, 1986;314:626-8.
80. Farrar DJ. The thoratec ventricular assist device: A paracorporeal pump for treating acute and chronic heart failure. *Seminars in Thorac and Cardiovasc surg* 12:243-250,2000.
81. Hill JD, Farrar D, Naka Y et al. Positive Displacement Ventricular Assist Devices. ISHLT Monograph Series Elsevier Inc. New York. 2006;4:53-75.
82. Frazier OH. Long-term mechanical circulatory support. In. *Cardiac surgery in the adults*. edited by Edmunds LH, Jr. The McGraw-Hill companies, Inc USA, 1997;51:1477-90.
83. Farrar DJ, Hill JD. Univentricular and biventricular Thoratec VAD support as a bridge to transplantation. *Ann Thorac Surg*, 1993;55:276-82.
84. Farrar DJ; Hill JD, Pennington DG et al. Preoperative and postoperative comparison of patients with uni- ventricular and biventricular support with the Thoratec ventricular assist device as a bridge to cardiac transplantation. *J Thorac Cardiovasc Surg*, 1997;113:202-9.
85. Mehta SM, Boehmer JP, Pae WE Jr et al. Bridge to transplant equals extended survival for patients undergoing LVAD support when compared with long-term medical management. *ASAIO J*, 1996;42:406-10.
86. Körfer R, El-Banayasy A, Posival H et al. Mechanical circulatory support: The Bad Oeynhausen experience. *Ann Thorac Surg*, 1995;59:S56-63.
87. Farrar DJ, Körfer R, El-Banayasy A et al. First clinical use of the Thoratec TLC-II portable VAD driver in ambulatory and patient discharge settings. *ASAIO J*, 1998;44:35A.
88. Hetzer R, Hennig E, Schiessler A, et al. Mechanical support and heart transplantation. *J Heart Lung Transplant*, 1992;11:175-81.
89. Hetzer R, Loebe M, Potapov EV et al. Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. *Ann Thorac Surg*, 1998; 66:1498-506.
90. Loebe M, Hennig E, Müller J et al. Long-term mechanical circulatory support as a bridge to transplantation, for recovery from cardiomyopathy and for permanent replacement. *Eur J Cardiothorac Surg*, 1997; 11:S11-S24.
91. Pasic M, Bergs S, Hennig E et al. Simplified technique for implantation of a left ventricular assist system after previous cardiac operations. *Ann Thorac Surg*, 1999; 67:562-4.
92. Loebe M, Kaufmann F, Hetzer R. The Berlin Heart. In: *Cardiac Assist Devices*. Goldstein DJ, Oz MC (eds). Futura publishing company, Inc. NY, 2000;275-87.
93. Ayik F, Oguz E, Engin C, Yagdi T, Atay Y, Ozbaran M. Surgical therapy of end-stage heart failure in pediatric patient. *Transplant Proc*, 2011;43:935-7.
94. Goldstein DJ. Intracorporeal support: Thermo Cardiosystems ventricular assist device. In: Goldstein DJ and Oz MC (eds). *Cardiac Assist Devices*, Armonk NY: Futura Publishing Co Inc, 2000;307-321.
95. Slater PJ, Rose EA, Levin HR et al. Low thromboembolic risk without anticoagulation using advanced- design left ventricular assist devices. *Ann Thorac Surg*, 1996;62:1321-7.
96. Itescu S, Ankersmit HJ, Kocher AA et al. Immunobiology of left ventricular assist devices. *Prog Cardiovasc Dis*, 2000;43:67-80.
97. Frazier OH, Rose EA, Macmanus Q et al. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. *Ann Thorac Surg*, 1992;53:1080-90.
98. Frazier OH, Rose EA, Oz MC et al. Multicentric clinical evaluation of the Heartmate vented electric left ventricular assist system in patients awaiting heart transplantation. *J Heart Lung Transplant*, 2001;20:201-2.

99. Kasirajan V, McCarthy PM, Hoercher KJ et al. Clinical experience with long-term use of implantable left ventricular assist devices: Indications, implantation and outcomes. *Semin Thorac Cardiovascular Surg*, 2000; 12:229-237.
100. Navia JL, Smedira NG, Banbury MK et al. Single center experience with implantable left ventricular assist devices. Presented at the fifth International Conference on circulatory support device for severe cardiac failure, New York, 2000;15-17.
101. Portner PM, Oyer PE, Jassawalla JS et al. An alternative in end-stage heart disease: Long-term ventricular assistance. *Heart Transplant*, 1983;III:47-59.
102. Portner PM, Oyer PE, McGregor CGA et al. First human use of an electrically powered implantable ventricular assist system. *Artif Organs*, 1985;9:36.
103. Dohmen PM, Laube H, de Jonge K et al. A reliable test to detect impending pump failure. *Tex Heart Inst J*, 2002;28:139-41.
104. El-Banayosy A, Deng M, Loisanse DY et al. The European experience of Novacor left ventricular assist therapy as a bridge to transplant: A retrospective multicentre study. *European Journal of Cardiothoracic Surg*, 1999;15:835-41.
105. Mueller J, Wallukat G, Weng YG et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. *Circulation*, 1997;96:542-9.
106. Mehta SM, Pae WE. The Pennsylvania State University totally implantable left ventricular assist device and total artificial heart. In: Goldstein DJ and Oz MC (eds). *Cardiac Assist Devices*. Armonk NY: Futura Publishing Co, Inc, 2000;403-16.
107. Mehta SM, Silber D, Boehmer JP, Christensen D, Pae WE Jr. Report of the first U.S. patient successfully supported long term with the LionHeart completely implantable left ventricular assist device system. *ASAIO J*; 2006;52:31-2.
108. Pae WE, Connell JM, Adelowo A et al. Clinical Utility Baseline Study (CUBS) Group. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. *J Heart Lung Transplant*. 2007;26:219-29.
109. Mehta SM, Pae WE, Rosenberg G et al. The LionHeart LVD-2000: A completely implanted left ventricular assist device for chronic circulatory support. *Ann Thorac Surg*, 2001;71:156-61.
110. El-Banayosy A, Arusoglu L, Kizner L et al. Preliminary experience with the LionHeart left ventricular assist device in patients with end-stage heart failure. *Ann Thorac Surg*. 2003;75:1469-75.
111. Frazier OH. Future directions of cardiac assistance. *Seminars in Thorac and cardiovasc Surg*, 2000;12: 251-8.
112. Nose Y, Yoshikawa M, Murabayashi S et al. Development of rotary blood pump technology: Past, present, and future. *Artif Organs*, 2000;20:412-20.
113. Potapov EV, Loebe M, Nasser BA et al. Pulsatile flow in patients with a novel nonpulsatile implantable ventricular assist device. *Circulation*, 2000;102(Suppl III):183-7.
114. Butler KC, Moise JC, Wampler RK. The Hemopump-a new cardiac prosthetic device. *IEEE Trans Biomed Eng*, 1990;37:193.
115. Weiselthaler G, Schima H, Hiesmayer M et al. First clinical experience with the DeBakey VAD continuous-axial flow pump for bridge to transplantation. *Circulation*, 2000;101:356-59.
116. Noon GP, Deborah LM, Irwin S et al. Clinical experience with the MicroMed DeBakey ventricular assist device. *Ann Thorac Surg*, 2001;71:133-8.
117. Rothenburger M, Wilhem MJ, Hammel D et al. Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator. *Circulation*, 2002;106(Suppl 1):189-92.
118. Jarvik R, Frazier OH, Westaby S et al. Initiation of clinical use of the Jarvik 2000 Heart. *ASAIO J*, 2000;46:156.
119. Frazier OH, Myers TJ, Jarvik RK et al. Research and development of an implantable, axial-flow left ventricular assist device: The Jarvik 2000 Heart. *Ann Thorac Surg*, 2001;71:125-32.
120. Westaby S, Banning AP, Jarvik R et al. First permanent implant of the Jarvik 2000 Heart. *The Lancet*, 2000; 356:900-3.
121. Frazier OH. The Jarvik 2000 continuous flow left ventricular assist system. Presented at the I. Cleveland Clinic Foundation Heart failure&Circulatory support summit, Cleveland, Ohio, 2002;22-5.
122. Westaby S, Frazier OH, Beyersdorf F et al. The Jarvik 2000 Heart. Clinical validation of the intraventricular position. *Eur J Cardiothorac Surg*, 2000;22:228-32.
123. Kormos RL. HeartMate II and HeartMate III. An update. Presented at the I. Cleveland Clinic Foundation Heart failure&Circulatory support summit, Cleveland, Ohio, 2002;22-25.
124. Pagani FD, Miller LW, Russell SD. Extended mechanical circulatory support with a continuous flow rotary left ventricular assist device. *Journal of the American College of Cardiology*, 2009;54:312-21.
125. Hetzer R, Weng Y, Potapov EV et al. First experiences with a novel magnetically suspended axial flow left ventricular assist device. *Eur J Cardiothorac Surg*. 2004;25:964-70.
126. Schmid C, Tjan TD, Etz C et al. First clinical experience with the Incor Left Ventricular Assist Device. Presented at the Seventh international symposium on magnetic bearings, Zurich, 2000;23-5.
127. Engin C, Ayik F, Oguz E et al. Ventricular assist device as a bridge to heart transplantation in adults. *Transplant Proc*, 2011;43:927-30.
128. Strueber M, O'Driscoll G, Jansz P, Khaghani A, Levy WC, Wieselthaler GM. Multicenter evaluation of an intrapericardial left ventricular assist system. *HeartWare Investigators. J Am Coll Cardiol*. 2011; 22:1375-82.
129. FDA: Stop Using Medtronic's Heartware Ventricular Assist Device. Bridget M. Kuehn, MS. *JAMA*. 2021;326(3):215.doi:10.1001/jama.2021.11386.
130. Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, et al. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. *J Am Coll Cardiol* 2015;66:2579-89.
131. Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. *JAMA* 2022;328:1233-42.
132. Schmitto JD, Shaw S, Garbade J, et al., ELEVATE Registry: HeartMate 3 LVAD Long-Term Outcomes.

- European Heart Journal*, Volume 45, Issue 8, 21 February 2024, Pages 613–625,
133. Allen RS, Slaughter MS, Ahmed MM, et al. COMPE-TENCE Trial: The EVAHEART 2 continuous flow left ventricular assist device. *Journal of Heart and Lung Transplantation*, 2023-01-01, Volume 42, Issue 1, Pages 33-39.
 134. Golding LA, El-Banayosy A, Kormos R et al. Emerging left ventricular assist devices. *Mechanical Circulatory Support* (eds) Frazier OH, Kirklin JK: ISHLT Monograph Series, 2006;1:205-17.
 135. Chen JM, DeRose JJ, Slater JP et al. Improved survival rates support left ventricular assist device implantation early after myocardial infarction. *J Am Coll Cardiol*, 1999;33:1903-8.
 136. Williams MR and Oz MC. Indications and patient selection for mechanical ventricular assistance. *Ann Thorac Surg*, 2001;71:86-91.
 137. Chen JM, Spanier TB, Gonzalez JJ et al. Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance. *J Heart Lung Transplant*, 1999;18:351-7.
 138. Fasseas P, Kukalek SP, Samuels FL et al. Ventricular assist device support for management of sustained ventricular arrhythmias. *Tex Heart Inst J*, 2002;29:33-6.
 139. Albes JM, Eckstein FS, Heinemann MK et al. Successful weaning of a transplanted heart from biventricular assist device. *Ann Thorac Surg*, 2000;70:277-8.
 140. Gambino A, Testolin L, Gerosa G et al. New trends in heart transplantation. *Transplantation proceedings*, 2001;33:353-356.
 141. Gronda E, Mangiavacchi M, Frigerio M et al. Determination of candidacy for mechanical circulatory support: Importance of clinical indices. *J Heart Lung Transplant*, 2000;19:83-8.
 142. Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med*, 2001;345:1435-43.
 143. Long JW. Rematch trial LVAD performance, adverse events and targets to improve outcomes. Utah Artificial Heart Program. Presented at the I.Cleveland Clinic Foundation Heart Failure&Circulatory support Summit, Cleveland, Ohio, 2002;22-5.
 144. Pennington DG, Oaks T, Lohmann DP. Permanent ventricular assist device support versus cardiac transplantation. *Ann Thorac Surg*, 1999;68:729-33.
 145. Deng MC, Weyand M, Hammel D et al. Selection and management of ventricular assist device patients: The Muenster experience. *J Heart Lung Transplant*, 2000;19:77-82.
 146. Piccione W Jr. Bridge to transplantation with the HeartMate device. *J Card Surg*, 2001;16:272-9.
 147. Lynne Warner-Stevenson. The evolving role of mechanical circulatory support in advanced heart failure. *Mechanical Circulatory Support* (eds) Frazier OH, Kirklin JK: ISHLT Monograph Series 1 2006:181-203.
 148. Sun BC. Device selection. In: Goldstein DJ and Oz MC (eds). *Cardiac Assist Devices*, Armonk NY: Futura Publishing Co, Inc, 2000;387402.
 149. Fukamachi K, McCarthy PM, Smedira NG, et al. Pre-operative risk factors for right ventricular failure after implantable left ventricular assist device insertion. *Ann Thorac Surg*, 1999;68:2181-4.
 150. Swartz M, Votapka JV, McBride LR, et al. Risk stratification in patients bridged to cardiac transplantation. *Ann Thorac Surg*, 1994;58:1142-5.
 151. Miller LW. Patient selection for permanent LVAD therapy. Presented at the I.Cleveland Clinic Foundation Heart Failure&Circulatory support Summit, Cleveland, Ohio, 2002;22-5.
 152. Gracin N, Johnson MR, Spokas D et al. The use of APACHE II scores to select candidates for left ventricular assist device placement. *J Heart Lung Transplant*, 1998;17:1017-23.
 153. Lietz K, Long JW, Kfoury AG et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. *Circulation*. 2007;116:497-505.
 154. Tittle SL, Mandapati D, Kopf GS et al. Alternative technique for implantation of left ventricular assist systems: Left thoracotomy for reoperative cases. *Ann Thorac Surg*, 2002;73:994-6.
 155. McCarthy PM, Savage RM, Fraser CD et al. Hemodynamic and physiologic changes during support with an implantable LVAD. *J Thorac Cardiovasc Surg*, 1995;109:409-18.
 156. Nakatani S, Thomas JD, Vandervoort PM et al. Left ventricular diastolic filling with an implantable ventricular assist device: Beat to beat variability with overall improvement. *J Am Coll Cardiol*, 1997;30:1288-94.
 157. Santamore WP, Gray LA Jr. Left ventricular contributions to right ventricular systolic function LVAD support. *Ann Thorac Surg*, 1996;61:351-6.
 158. Chow E, Farrar DJ. Right heart function during prosthetic left ventricular assistance in a porcine model of congestive heart failure. *J Thorac Cardiovasc Surg*, 1992;2:569-78.
 159. Farrar DJ. Ventricular interactions during mechanical circulatory support. *Semin Thorac Cardiovasc Surg*, 1994;6:163-8.
 160. Pae WE Jr, Miller CA, Matthews Y et al. Ventricular assist devices for post cardiectomy cardiogenic shock: A combined registry experience. *J Thorac Cardiovasc Surg*, 1992;104:541-53.
 161. Holman WL, Bourge RC, Kirklin JK. Case report: Circulatory support for seventy days with resolution of acute heart failure. *J Thorac Cardiovasc Surg*, 1991;102:932-3.
 162. Hetzer R, Muller J, Weng Y et al. Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. *Ann Thorac Surg*, 1999;68:742-9.
 163. Westaby S, Katsumata T, Pigott D et al. Mechanical bridge to recovery in fulminant myocarditis. *Ann Thorac Surg*, 2000;70:278-83.
 164. Moravec CS. Cell on support. Presented at the I. Cleveland Clinic Foundation Heart Failure&Circulatory support Summit, Cleveland, Ohio, 2002;22-5.
 165. Küçükaksu DS. Ventriküler destek sistemleri. *Kalp ve Damar Cerrahisi*. M. Paç, A Akçevin, SA. Aka, S. Buket, T. Sarioğlu (eds). MN Medikal&Nobel, Ankara, 2004;351-416.
 166. Vatta M, et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance device therapy. *Lancet* 2002;359:936-41.
 167. McNamara DM et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy.

- haty. *Circulation*, 2001;103:2254-9.
168. Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. *Ann Thorac Surg*, 1999;68:734-41.
169. Goldstein DJ, Seldomridge JA, Chen JM et al. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. *Ann Thorac Surg*, 1995;59:1063-8.
170. Oz M, Argenziano M, Catanese K et al. Bridge experience with long-term implantable left ventricular assist device. Are they an alternative to transplantation? *Circulation*, 1997;7:1844-52.
171. Chen JM, Rose EA. Management of perioperative right-sided circulatory failure. In: Goldstein DJ and Oz MC (eds). *Cardiac Assist Devices*, Armonk NY: Futura Publishing Co Inc, 2000;83-101.
172. Chen JM, Levin HR, Rose EA et al. Experience with right ventricular assist devices for perioperative right-sided circulatory failure. *Ann Thorac Surg*, 1996;61:305-10.
173. Kormos RL, Gasior TA, Kawai A et al. Transplant candidate's clinical status rather than right ventricular function defines need for univentricular versus biventricular support. *J Thorac Cardiovasc Surg*, 1996;111:773-83.
174. Smedira NG, Massad MG, Navia J et al. Pulmonary hypertension is not a factor for RVAD use and death after left ventricular assist system support. *ASAIO J*, 1996;42:733-5.
175. Piccione Jr. M. Left ventricular assist device implantation. Short and long-term surgical complications. *J Heart Lung Transplant*, 2000;19:89-94.
176. Prendergast TW, Todd BA, Beyer III AJ et al. Management of left ventricular assist device infection with heart transplantation. *Ann Thorac Surg*, 1997;64:142-7.
177. Ankersmit HJ, Itescu S. Immunobiology of left ventricular assist device. In: Goldstein DJ and Oz MC (eds). *Cardiac Assist Devices*, Armonk NY: Futura Publishing Co, Inc, 2000;193-211.
178. Holman WA, Teitel ER, Itescu S. Biologic barriers to mechanical circulatory support. *Mechanical Circulatory Support* (eds) Frazier OH, Kirklin JK: ISHLT Monograph Series 1 2006:9-32.
179. Bonaros N, Mueller M, Salat A, et al. Extensive coagulation monitoring in patients after implantation of the MicroMed DeBakey continuous flow axial pump. *ASAIO J*, 2004;50:424-31.
180. Mandak J, Aaronson K, Mancini D. Serial assessment of exercise capacity post cardiac transplant. *J Heart Lung Transplant*, 1995;14:468-78.
181. Frazier OH, Rose EA, McCarthy P et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. *Ann Thorac Surg*, 1995;222:327-38.
182. Dew MA, Kormos RL, Winowich S et al. Human factors in ventricular assist device recipients and their family caregivers. Presented at the American Society for Artificial Internal Organs. San Diego: 1999.
183. Hutchinson J, Scott DA, Clegg AJ et al. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure. *Expert Rev Cardiovasc Ther*, 2008;6:175-85.
184. Mahle WT, Ianucci G, Vincent RN, Kanter KR. Costs associated with ventricular assist device use in children. *Ann Thorac Surg*, 2008;86:1592-7.
185. Karl TR, Horton SB. Centrifugal pump ventricular assist device in pediatric cardiac surgery. In: Duncan BW, editor. *Mechanical support for cardiac and respiratory failure in pediatric patients*. New York: Marcel Dekker; 2001;p:21-47.
186. Blume ED, Naftel DC, Bastardi HJ et al. Outcome of children listed for transplant and bridged with ventricular assist devices. A Multi-institutional study. *J Heart Lung Transplant*, 2005;24:S75.
187. Alexi-Meskishvili V, Hetzer R, Weng Y et al. The use of Berlin Heart in Children. In: Duncan BW, editor. *Mechanical support for cardiac and respiratory failure in pediatric patients*. New York: Marcel Dekker; 2001;p:287-314.
188. Imamura M, Hale S, Johnson CE et al. The first successful DeBakey VAD child implantation as a bridge to transplant. *ASAIO J*. 2005;51:670-2.
189. Seigenthaler MP, Westaby S, Frazier OH et al. Advanced heart failure: Feasibility study of long-term continuous axial flow pump support. *Eur Heart J* 2005;26:1031-8.
190. Pamboukian SV, Tallaj JA, Brown RN et al. Improvement in 2-year survival for ventricular assist device patients after implementation of an intensive surveillance protocol. *J Heart Lung Transplant*. 2011; Apr 20.
191. Sheikh FH, Russell SD. HeartMate II continuous-flow left ventricular assist system. *Expert Rev Med Devices*. 2011;8:11-21.
192. Left ventricular device as destination therapy: are we there yet? Badiwala MV, Rao V. *Curr Opin Cardiol*. 2009;24:184-9.
193. Van Meter CH, Ordoyne SKH, Kateiva JE. Ventricular assist device programs: Design and function. *Ann Thorac Surg*, 1999;68:643-5.
194. Slaughter MS, Silver MA, Farrar DJ, et al. A new method of monitoring recovery and weaning the Thoratec left ventricular assist device. *Ann Thorac Surg*, 2001;71:215-218.
195. Dew MA, Kormos RL, Roth LH et al. Life quality in the era of bridging to cardiac transplantation. Bridge patients in an outpatient setting. *ASAIO J* 1993;39:145-52.
196. Starling RC, Naka Y, Boyle AJ et al. Results of the Post-U.S. Food and Drug Administration-Approval Study With a Continuous Flow Left Ventricular Assist Device as a Bridge to Heart Transplantation A Prospective Study Using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). *J Am Coll Cardiol*. 2011;10:1890-8.
197. Deng MC, Edwards LB, Hertz MI et al. Mechanical circulatory support device database of the international society for heart and lung transplantation: Third annual report 2005. *Journal of Heart and Lung Transplantation*, 2005;24:1182-7.
198. Alba AC, McDonald M, Rao V, Ross HJ, Delgado DH. The effect of ventricular assist devices on long-term post-transplant outcomes: A systematic review of observational studies. *Eur J Heart Fail*, 2011;6.
199. Franco KL. New devices for chronic ventricular support. *J Card Surg*, 2001;16:178-92.
200. Evans RW. Costs and insurance coverage associated with permanent mechanical cardiac assist/replace- ment devices in the United States. *J Card Surg*, 2001;16:280-93.

201. Frazier OH. Mechanical circulatory support: New advances, new pumps, new ideas. *Semin Thorac Cardiovasc Surg*, 2002;14:178-86.
202. Finocchiaro T, Heinke S, Behbahani M et al. Methods of design, simulation, and control for the development of new VAD/TAH concepts. *Biomed Tech*, 2009;54:269-81.
203. Meyns BP, Simon A, Klotz S et al. Clinical benefits of partial circulatory support in New York heart association class IIIB and early class IV patients. *Eur J Cardiothorac Surg*. 2011;39:693-8.
203. Williams ML, Trivedi JR, McCants KC et al. Heart transplant vs left ventricular assist device in heart transplant-eligible patients. *Ann Thorac Surg*, 2011; 91:1330-4.



TOTAL YAPAY KALP

BÖLÜM 66

DOI: 10.37609/akya.3889.c5388

Mehmet Cahit SARICAOĞLU¹
Serenay ERSOY²
Emre ASLANCI³
Ali Fuat KARAÇUHA⁴
Fatma AKÇA⁵
Onur BÜYÜKÇAKIR⁶
Ali İhsan HASDE⁷
Ahmet Rüçhan AKAR⁸

İçindekiler

- » GİRİŞ
- » TARİHÇE
 - » Erken Dönem Gelişmeler (1910–1950)
 - » Kardiyopulmoner Baypas ve Nakil Çağı (1950–1970)
 - » Modern TAH ve Jarvik Dönemi (1970–1990)
 - » Köprü Tedavi Dönemi ve Günümüz (1990–2025)
- » İLK UYGULAMALAR
 - » LİOTTA Total Yapay Kalbi
 - » AKUTSU III Total Yapay Kalbi
 - » JARVIK-7 Total Yapay Kalp
- » TAH İMPLANTASYONUNDA GENEL BİLGİLER
 - » TAH için Endikasyonlar
 - » TAH İmplantasyonu için Kontrendikasyonlar
 - » Güncel TAH Sınıflandırma
 - » Pozitif Yer Değiştirme Pompaları
 - » Transplantasyon
 - » Sürekli Akışlı TAH

¹ Doç. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., saricaoglu@ankara.edu.tr, ORCID iD: 0000-0002-0378-8855

² Op. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., serenayersoy@gmail.com, ORCID iD: 0000-0003-2239-4349

³ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., easlanci@ankara.edu.tr, ORCID iD: 0009-0001-7401-2253


⁴ Dr. Öğr. Üyesi, Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., alifuatkaracuha@ankara.edu.tr, ORCID iD: 0009-0000-4280-6289

⁵ Op. Dr., Kırıkkale Yüksek İhtisas Hastanesi, Kalp ve Damar Cerrahisi Kliniği, akcaafatma@gmail.com, ORCID iD: 0000-0001-5633-9933

⁶ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., obuyukcakir@ankara.edu.tr, ORCID iD: 0009-0007-9516-9229

⁷ Doç. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., hasde@ankara.edu.tr, ORCID iD: 0000-0002-2932-6704

⁸ Prof. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., akar@ankara.edu.tr, ORCID iD: 0000-0002-5191-5505



Resim 6. Tarihsel (2014-2018) ve güncel (2019-2023) dönemlere göre sınıflandırılmış TAH implantasyonu uygulanan hastalar için Kaplan-Meier sağkalım analizi.

KAYNAKLAR

- Chronic Heart Failure in Adults: Diagnosis and Management. National Institute for Health and Care Excellence: Guidelines. London 2018.
- Metra M, Teerlink JR. Heart failure. Lancet. 2017;390(10106):1981-95.
- Subramaniam AV, Weston SA, Killian JM, Schulte PJ, Roger VL, Redfield MM, et al. Development of Advanced Heart Failure: A Population-Based Study. Circ Heart Fail. 2022;15(5):e009218.
- Arabia FA, Cantor RS, Koehl DA, Kasirajan V, Gregoric I, Moriguchi JD, et al. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. J Heart Lung Transplant. 2018;37(11):1304-12.
- Yang M. Introduction to artificial hearts. In: Yang M, editor. Artificial Hearts: Elsevier; 2020. p. 1-20.
- Garascia A, Palazzini M, Tedeschi A, Sacco A, Oliva F, Gentile P. Advanced heart failure: from definitions to therapeutic options. Eur Heart J Suppl. 2023;25(Suppl C):C283-C91.
- Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5):e1-e141.
- Copeland H, Knezevic I, Baran DA, Rao V, Pham M, Gustafsson F, et al. Donor heart selection: Evidence-based guidelines for providers. J Heart Lung Transplant. 2023;42(1):7-29.
- Watt T, John R. Total Artificial Heart vs LVAD and BI-VAD. Semin Thorac Cardiovasc Surg. 2025.
- Martin AC, Cholley B. The total artificial heart: An existential transformation beyond technology. Eur J Heart Fail. 2025;27(4):628-9.
- Mehra MR, Cleveland JC, Jr., Uriel N, Cowger JA, Hall S, Horstmannshof D, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. Eur J Heart Fail. 2021;23(8):1392-400.
- Logstrup BB, Nemec P, Schoenrath F, Gummert J, Pya Y, Potapov E, et al. Heart failure etiology and risk of right heart failure in adult left ventricular assist device support: the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). Scand Cardiovasc J. 2020;54(5):306-14.
- Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC, Jr., Colombo PC, et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med. 2017;376(5):440-50.
- Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, et al. The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships. Ann Thorac Surg. 2019;107(2):341-53.
- Saeed D, Feldman D, Banayosy AE, Birks E, Blume E, Cowger J, et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10-Year Update. J Heart Lung Transplant. 2023;42(7):e1-e222.
- Arabia FA. Cardiac replacement: total artificial heart. Ann Cardiothorac Surg. 2020;9(2):68.
- Lee T, Torregrossa G. Total Artificial Heart. In: Vasan RS, Sawyer DB, editors. Encyclopedia of Cardiovascular Research and Medicine: Elsevier; 2018. p. 545-57.
- McLean J. The discovery of heparin. Circulation.

- 1959;19(1):75-8.
19. Carrel A, Lindbergh CA. The Culture of Whole Organs. *Science*. 1935;81(2112):621-3.
20. Gibbon JH. Artificial maintenance of circulation during experimental occlusion of pulmonary artery. *Archives of Surgery*. 1937;34(6):1105-31.
21. Matskeplishvili S. Vladimir Petrovich Demikhov (1916-1998): A pioneer of transplantation ahead of his time, who lived out the end of his life as an unknown and in poor circumstances. *Eur Heart J*. 2017;38(46):3406-10.
22. Glyantsev SP, Tchanchaleishvili V, Bockeria LA. Demikhov's "Mechanical Heart": The Circumstances Surrounding Creation of the World's First Implantable Total Artificial Heart in 1937. *ASAIO J*. 2016;62(1):106-9.
23. Langer RM, Vladimir P. Demikhov, a pioneer of organ transplantation. *Transplant Proc*. 2011;43(4):1221-2.
24. Shoja MM, Tubbs RS, Ardalan MR, Loukas M, Phagava H, Cohen-Gadol AA. A testimony to the history of heart and lung transplantation: English translation of Demikhov's paper, "Transplantation of the Heart, Lungs and other Organs". *Int J Cardiol*. 2010;143(3):230-4.
25. Konstantinov IE. At the cutting edge of the impossible: a tribute to Vladimir P. Demikhov. *Tex Heart Inst J*. 2009;36(5):453-8.
26. Konstantinov IE. A mystery of Vladimir P. Demikhov: the 50th anniversary of the first intrathoracic transplantation. *Ann Thorac Surg*. 1998;65(4):1171-7.
27. Cooper DK. Vladimir Demikhov. *Ann Thorac Surg*. 1995;59(6):1628.
28. Shumacker HB, Jr. A surgeon to remember: notes about Vladimir Demikhov. *Ann Thorac Surg*. 1994;58(4):1196-8.
29. Dodrill FD, Hill E, Gerisch RA. Temporary mechanical substitute for the left ventricle in man. *J Am Med Assoc*. 1952;150(7):642-4.
30. Hill JD, John H, Gibbon J. Part I. The development of the first successful heart-lung machine. *Ann Thorac Surg*. 1982;34(3):337-41.
31. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. *S Afr Med J*. 1967;41(48):1271-4.
32. Haller JD, Cerruti MM. Heart transplantation in man: compilation of cases. January 1, 1964 to October 23, 1968. *Am J Cardiol*. 1968;22(6):840-3.
33. Shumway NE, Angell WW, Wuerflein RD. Progress in transplantation of the heart. *Transplantation*. 1967;5(4):Suppl:900-3.
34. Shumway NE, Angell WW, Wuerflein RD. Recent advances in cardiac replacement. *Surgery*. 1967;62(4):794-6.
35. Cooley DA, Liotta D, Hallman GL, Bloodwell RD, Leachman RD, Milam JD. Orthotopic cardiac prosthesis for two-staged cardiac replacement. *Am J Cardiol*. 1969;24(5):723-30.
36. Cooley DA, Akutsu T, Norman JC, Serrato MA, Frazier OH. Total artificial heart in two-staged cardiac transplantation. *Cardiovasc Dis*. 1981;8(3):305-19.
37. DeVries WC, Anderson JL, Joyce LD, Anderson FL, Hammond EH, Jarvik RK, et al. Clinical use of the total artificial heart. *N Engl J Med*. 1984;310(5):273-8.
38. Altman LK. William Schroeder dies 620 days after receiving artificial heart. *N Y Times Web*. 1986:A1, A25.
39. Akalin H, Çorapçıoğlu T, Uçanok K. Ülkemizde ilk yapay kalp (Symbion J-7) uygulaması. *Türkiye Klinikleri*. 1989;9:294-6.
40. Copeland J, Langford S, Giampietro J, Arancio J, Arabia F. Total Artificial Heart Update. *Surg Technol Int*. 2021;39:243-8.
41. Copeland JG, Arabia FA, Smith RG, Sethi GK, Nolan PE, Banchy ME. Arizona experience with CardioWest Total Artificial Heart bridge to transplantation. *Ann Thorac Surg*. 1999;68(2):756-60.
42. Arabia FA, Copeland JG, Smith RG, Banchy M, Foy B, Kormos R, et al. CardioWest total artificial heart: a retrospective controlled study. *Artif Organs*. 1999;23(2):204-7.
43. Arabia FA, Copeland JG, Pavie A, Smith RG. Implantation technique for the CardioWest total artificial heart. *Ann Thorac Surg*. 1999;68(2):698-704.
44. Copeland JGI, Arabia FA, Banchy ME. The CardioWest total artificial heart bridge to transplantation: 1993 to 1996 national trial. *Annals of Thoracic Surgery*. 1998;66:1662-9.
45. Rame JE, Pagani FD, Kiernan MS, Oliveira GH, Birati EY, Atluri P, et al. Evolution of Late Right Heart Failure With Left Ventricular Assist Devices and Association With Outcomes. *J Am Coll Cardiol*. 2021;78(23):2294-308.
46. Rivas-Lasarte M, Kumar S, Derbala MH, Ferrall J, Cefalu M, Rashid SMI, et al. Prediction of right heart failure after left ventricular assist implantation: external validation of the EUROMACS right-sided heart failure risk score. *Eur Heart J Acute Cardiovasc Care*. 2021;10(7):723-32.
47. Richez U, De Castilla H, Guerin CL, Gendron N, Luraghi G, Grimme M, et al. Hemocompatibility and safety of the Carmat Total Artificial Heart hybrid membrane. *Heliyon*. 2019;5(12):e02914.
48. Netuka I, Pya Y, Bekbossynova M, Ivak P, Konarik M, Gustafsson F, et al. Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart. *J Heart Lung Transplant*. 2020;39(12):1491-3.
49. Küçükaksu D, Pektok E, Arat N, Yıldız Ö, Demirozu Z, Ece F, et al. Total artificial heart for bridge to cardiac transplantation: first patient at home in Turkey. *Türk Göğüs Kalp Damar Cerrahisi Dergisi* 2013;21(4):1032-8.
50. Buyukatalay ZC, Agha Oghali AMN, Kendirli T, Can OS, Ucar T, Akar AR, et al. First Reported Cochlear Implantation in a Child with Total Artificial Heart. *Exp Clin Transplant*. 2021;19(12):1352-5.
51. Fox CS, McKenna KL, Allaire PE, Mentzer RM, Jr., Throckmorton AL. Total Artificial Hearts-Past, Current, and Future. *J Card Surg*. 2015;30(11):856-64.
52. Cooley DA. Heart substitution: transplantation and total artificial heart. The Texas Heart Institute experience. *Artif Organs*. 1985;9(1):12-6.
53. Jarvik RK. The total artificial heart. *Sci Am*. 1981;244(1):74-80.
54. Pavie A, Leger P, Regan M. Clinical experience with a total artificial heart as a bridge for transplantation: The Pitié experience. *Journal of Cardiac Surgery*. 1995;10:552-8.
55. Razumov A, Burri M, Zittermann A, Radakovic D, Lauenroth V, Rojas SV, et al. Outcomes after SynCardia(R) temporary total artificial heart implantation: A 20-year

- single-center experience in 196 patients. *Artif Organs*. 2025;49(2):266-75.
56. Meyer DM, Nayak A, Wood KL, Blumer V, Schettler S, Salerno C, et al. The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients. *Ann Thorac Surg*. 2025;119(1):34-58.
 57. Akay MH, Gregoric ID. SynCardia Total Artificial Heart Implant Procedures and Techniques. In: Gregoric ID, Myers TJ, Mihalj M, editors. *Management of Acute and Chronic Severe Heart Failure*. Cham: Springer; 2024. p. 225-39.
 58. Goodwin ML, Mokadam NA. Total Artificial Heart Implantation: How I Teach It. *Ann Thorac Surg*. 2019;108(5):1271-6.
 59. Kato TS, Farr M, Schulze PC, Maurer M, Shahzad K, Iwata S, et al. Usefulness of two-dimensional echocardiographic parameters of the left side of the heart to predict right ventricular failure after left ventricular assist device implantation. *Am J Cardiol*. 2012;109(2):246-51.
 60. Fukamachi K, Horvath DJ, Massiello AL, Fumoto H, Horai T, Rao S, et al. An innovative, sensorless, pulsatile, continuous-flow total artificial heart: device design and initial in vitro study. *J Heart Lung Transplant*. 2010;29(1):13-20.
 61. Peng DM, Davies RR, Simpson KE, Shugh SB, Morales DLS, Jacobs JP, et al. Seventh Annual Society of Thoracic Surgeons Pedimacs Report. *Ann Thorac Surg*. 2024;117(4):690-703.
 62. Chung JS, Emerson D, Megna D, Arabia FA. Total artificial heart: surgical technique in the patient with normal cardiac anatomy. *Ann Cardiothorac Surg*. 2020;9(2):81-8.
 63. Han L, Wang W. Total Artificial Heart. In: Yang M, editor. *Artificial Hearts*. Singapore: Springer; 2020. p. 95-109.
 64. Disque AA, Meltzer J. Cardiac Tamponade in a Patient with a 50 mL SynCardia Total Artificial Heart. *J Cardiothorac Vasc Anesth*. 2015;29(6):e86-9.
 65. Slepian MJ, Alemu Y, Girdhar G, Soares JS, Smith RG, Einav S, et al. The Syncardia() total artificial heart: in vivo, in vitro, and computational modeling studies. *J Biomech*. 2013;46(2):266-75.
 66. Copeland JG. SynCardia Total Artificial Heart: update and future. *Tex Heart Inst J*. 2013;40(5):587-8.
 67. Ferng AS, Oliva I, Jokerst C, Avery R, Connell AM, Tran PL, et al. Translation of First North American 50 and 70 cc Total Artificial Heart Virtual and Clinical Implantations: Utility of 3D Computed Tomography to Test Fit Devices. *Artif Organs*. 2017;41(8):727-34.
 68. Beasley G, Vogel C, Thrush P. Successful Physical Rehabilitation After Placement of a SynCardia Total Artificial Heart. *Artif Organs*. 2019;43(3):318-9.
 69. Zwischenberger JB, Cox CS, Jr. ECMO in the management of cardiac failure. *ASAIO J*. 1992;38(4):751-3.
 70. Copeland J, Copeland H, Nolan P, Gustafson M, Slepian M, Smith R. Results with an anticoagulation protocol in 99 SynCardia total artificial heart recipients. *ASAIO J*. 2013;59(3):216-20.
 71. Federman M, Dragomer D, Grant S, Reemtsen B, Biniwale R. Use of bivalirudin for anticoagulation during implantation of total artificial heart. *J Extra Corpor Technol*. 2014;46(2):170-2.
 72. Copeland H, Copeland JG, Smith RG. Total artificial heart. In: Morgan JA, Naka Y, editors. *Surgical Treatment for Advanced Heart Failure*. New York: Springer; 2013. p. 161-77.
 73. Stulak JM, Romans T, Cowger J, Romano MA, Haft JW, Aaronson KD, et al. Delayed sternal closure does not increase late infection risk in patients undergoing left ventricular assist device implantation. *J Heart Lung Transplant*. 2012;31(10):1115-9.
 74. Shah KB, Mankad AK, Tang DG, Kasirajan V. The total artificial heart. In: Eisen H, editor. *Heart Failure*. London: Springer-Verlag; 2017. p. 691-771.
 75. Jimeno-San Martin L, Goni-Viguria R, Bengoechea L, Fernandez E, Mendiluce N, Romero C, et al. Postoperative management and nursing care after implantation of a total artificial heart: Scoping review. *Enferm Intensiva (Engl Ed)*. 2024;35(3):213-28.
 76. Zimmerman H, Coehlo-Anderson R, Slepian M, al. e. Device malfunction of the CardioWest total artificial heart secondary to catheter entrapment of the tricuspid valve. *ASAIO Journal*. 2010;56:481-2.
 77. Kusne S, Mooney M, Danziger-Isakov L, Kaan A, Lund LH, Lyster H, et al. An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. *J Heart Lung Transplant*. 2017;36(10):1137-53.
 78. Runyan C, Barone H, Huie N, Hajj J. A comparison of driveline infection: left ventricular assist device vs. total artificial heart. *ASAIO 63rd Conference* 2017.
 79. Shoham AB, Patel B, Arabia FA, Murray MJ. Mechanical ventilation and the total artificial heart: optimal ventilator trigger to avoid post-operative autocycling - a case series and literature review. *J Cardiothorac Surg*. 2010;5:39.
 80. Shah KB. Renal function after implantation of the total artificial heart. *Ann Cardiothorac Surg*. 2020;9(2):124-5.
 81. El-Banayasy A, Arusoglu L, Morshuis M, Kizner L, Tenderich G, Sarnowski P, et al. CardioWest total artificial heart: Bad Oeynhausen experience. *Ann Thorac Surg*. 2005;80(2):548-52.
 82. Copeland JG, Smith RG, Arabia FA, Nolan PE, McClellan D, Tsau PH, et al. Total artificial heart bridge to transplantation: a 9-year experience with 62 patients. *J Heart Lung Transplant*. 2004;23(7):823-31.
 83. Roussel JC, Senage T, Baron O, Perigaud C, Habash O, Rigal JC, et al. CardioWest (Jarvik) total artificial heart: a single-center experience with 42 patients. *Ann Thorac Surg*. 2009;87(1):124-9; discussion 30.
 84. Smadja DM, Ivak P, Pya Y, Latremouille C, Gustafsson F, Roussel JC, et al. Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation. *J Heart Lung Transplant*. 2022;41(9):1214-7.
 85. Monteagudo-Vela M, Bowles C, Raj B, Robinson D, Simon A. Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time? *Interact Cardiovasc Thorac Surg*. 2022;34(2):322-5.
 86. Ramirez A, Riley JB, Joyce LD. Multi-Targeted Antithrombotic Therapy for Total Artificial Heart Device Patients. *J Extra Corpor Technol*. 2016;48(1):27-34.
 87. Ensor CR, Cahoon WD, Crouch MA, Katlaps GJ, Hess ML, Cooke RH, et al. Antithrombotic therapy for the CardioWest temporary total artificial heart. *Tex Heart Inst J*. 2010;37(2):149-58.

88. Crouch MA, Kasirajan V, Cahoon W, Katlaps GJ, Gunnerson KJ. Successful use and dosing of bivalirudin after temporary total artificial heart implantation: a case series. *Pharmacotherapy*. 2008;28(11):1413-20.
89. Volod O, Arabia FA, Lam LD, Runge A, Cheng C, Czer LSC. Platelet Mapping by Thromboelastography and Whole Blood Aggregometry in Adult Patients Supported by Mechanical Circulatory Support Device on Aspirin Therapy. *J Extra Corpor Technol*. 2020;52(1):13-21.
90. Tan MC, Yeo YH, Tham JW, Tan JL, Fong HK, Tan BE, et al. Adverse Events in Total Artificial Heart for End-Stage Heart Failure: Insight From the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE). *Int J Heart Fail*. 2024;6(2):76-81.
91. Mahfood Haddad T, Saurav A, Smer A, Azzouz MS, Akinapelli A, Williams MA, et al. Cardiac Rehabilitation in Patients With Left Ventricular Assist Device: A SYSTEMATIC REVIEW AND META-ANALYSIS. *J Cardiopulm Rehabil Prev*. 2017;37(6):390-6.
92. Hildebrandt A, Willemsen D, Reiss N, Bartsch P, Schmidt T, Bjarnason-Wehrens B. Characteristics, Therapeutic Needs, and Scope of Patients With a Continuous-Flow Left Ventricular Device Entering Cardiac Rehabilitation: A RETROSPECTIVE ANALYSIS. *J Cardiopulm Rehabil Prev*. 2019;39(2):91-6.
93. Kerrigan DJ, Cowger JA, Keteyian SJ. Exercise in patients with left ventricular devices: The interaction between the device and the patient. *Prog Cardiovasc Dis*. 2022;70:33-9.
94. Alswyan AH, Liberato ACS, Dougherty CM. A Systematic Review of Exercise Training in Patients With Cardiac Implantable Devices. *J Cardiopulm Rehabil Prev*. 2018;38(2):70-84.
95. Brown KD, Adams J, Meyer DM. Exercise training with cycle ergometry in the intensive care unit after total artificial heart implantation. *Proc (Bayl Univ Med Cent)*. 2020;33(4):674-6.
96. Streur MM, Beckman JA, Dougherty CM, Li S, Mahr C. Quality of life and rehabilitation after total artificial heart. *Ann Cardiothorac Surg*. 2020;9(2):128-30.
97. Bellotto F, Compostella L, Agostoni P, Torregrossa G, Setzu T, Gambino A, et al. Peripheral adaptation mechanisms in physical training and cardiac rehabilitation: the case of a patient supported by a CardioWest total artificial heart. *J Card Fail*. 2011;17(8):670-5.
98. Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. *JAMA*. 2000;283(23):3095-101.
99. Dowling RD, Gray LA, Jr., Etoch SW, Laks H, Marelli D, Samuels L, et al. Initial experience with the AbioCor implantable replacement heart system. *J Thorac Cardiovasc Surg*. 2004;127(1):131-41.
100. Dowling RD, Etoch SW, Stevens KA, Johnson AC, Gray LA, Jr. Current status of the AbioCor implantable replacement heart. *Ann Thorac Surg*. 2001;71(3 Suppl):S147-9; discussion S83-4.
101. Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. *N Engl J Med*. 2004;351(9):859-67.
102. Leprince P, Bonnet N, Rama A, Leger P, Bors V, Levasseur JP, et al. Bridge to transplantation with the Jarvik-7 (CardioWest) total artificial heart: a single-center 15-year experience. *J Heart Lung Transplant*. 2003;22(12):1296-303.
103. Leprince P, Bonnet N, Varnous S, Rama A, Leger P, Ouattara A, et al. Patients with a body surface area less than 1.7 m² have a good outcome with the CardioWest Total Artificial Heart. *J Heart Lung Transplant*. 2005;24(10):1501-5.
104. Kohli HS, Canada J, Arena R, Tang DG, Peberdy MA, Harton S, et al. Exercise blood pressure response during assisted circulatory support: comparison of the total artificial [corrected] heart with a left ventricular assist device during rehabilitation. *J Heart Lung Transplant*. 2011;30(11):1207-13.
105. Malas J, Chen Q, Akhmerov A, Tremblay LP, Egorova N, Krishnan A, et al. Experience With SynCardia Total Artificial Heart as a Bridge to Transplantation in 100 Patients. *Ann Thorac Surg*. 2023;115(3):725-32.
106. Carpentier A, Latremouille C, Cholley B, Smadja DM, Roussel JC, Boissier E, et al. First clinical use of a bioprosthetic total artificial heart: report of two cases. *Lancet*. 2015;386(10003):1556-63.
107. Pya Y, Jansen P. Management of Patients Supported by the Aeson Bioprosthetic Total Artificial Heart. In: Gregoric ID, Myers TJ, Mihalj M, editors. *Management of Acute and Chronic Severe Heart Failure*. Cham: Springer; 2024. p. 257–67.
108. Pya Y, Bekbosynova M, Medressova A, Latremouille C, Jansen P, Tauyekelova A, et al. Precise monitoring of transpulmonic resistance in bridge-to-transplant patients supported by the Aeson total artificial heart. *J Heart Lung Transplant*. 2025;44(7):1161-4.
109. Netuka I, Pya Y, Poitier B, Ivak P, Konarik M, Perles JC, et al. First Clinical Experience With the Pressure Sensor-Based Autoregulation of Blood Flow in an Artificial Heart. *ASAIO J*. 2021;67(10):1100-8.
110. Smadja DM, Roux de Bezieux J, Peronino C, Jilet L, Ivak P, Pya Y, et al. Understanding Platelet Activation in the Aeson Bioprosthetic Total Artificial Heart: Insights From Aspirin Treatment and Outcomes. *ASAIO J*. 2025;71(9):701-10.
111. Han JJ. Aeson-The Carmat total artificial heart is approved for enrollment in the United States. *Artif Organs*. 2021;45(5):445-6.
112. Vincentelli A, Pya Y, Netuka I, Haneya A, Schmitto J, Kindo M, et al. Implantation Technique for the Aeson Total Artificial Heart. *Operative Techniques in Thoracic and Cardiovascular Surgery*. 2024;29(2):149–67.
113. CARMAT. CARMAT receives MDR CE marking for its Aeson® artificial heart (Class III, BTT) — Press release (28 Jul 2025) Vélizy-Villacoublay (FR): CARMAT; 2025 [Available from: <https://www.carmatsa.com/en/press-release/carmat-receives-mdr-ce-marking-for-its-aeson-artificial-heart/>].
114. Huenges K, Panholzer B, Cremer J, Haneya A. Case report-CARMAT: the first experience with the Aeson bioprosthetic total artificial heart as a bridge to transplantation in a case of post-infarction ventricular septal rupture. *Front Cardiovasc Med*. 2023;10:1211365.
115. Martin AC, Moussa MD, Panholzer B, Verde A, Guilhaire J, Aubin H, et al. Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support. *JACC Heart Fail*. 2025;13(6):1030-3.

116. Poitier B, Chocron R, Peronino C, Philippe A, Pya Y, Rivet N, et al. Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor. *Arterioscler Thromb Vasc Biol.* 2022;42(4):470-80.
117. Peronino C, Guerin CL, Ivak P, Guyonnet L, Chocron R, Detrich G, et al. Bioprosthetic Total Artificial Heart Implantation Does Not Induce Chronic Inflammation. *ASAIO J.* 2022;68(11):e173-e8.
118. Smadja DM, Saubamea B, Susen S, Kindo M, Bruneval P, Van Belle E, et al. Bioprosthetic Total Artificial Heart Induces a Profile of Acquired Hemocompatibility With Membranes Recellularization. *J Am Coll Cardiol.* 2017;70(3):404-6.
119. Pinney SP, Anyanwu AC, Lala A, Teuteberg JJ, Uriel N, Mehra MR. Left Ventricular Assist Devices for Lifelong Support. *J Am Coll Cardiol.* 2017;69(23):2845-61.
120. Weber BN, Kobashigawa JA, Givertz MM. Evolving Areas in Heart Transplantation. *JACC Heart Fail.* 2017;5(12):869-78.
121. Kleinheyer M, Timms DL, Greatrex NA, Masuzawa T, Frazier OH, Cohn WE. Pulsatile operation of the BiVACOR TAH - Motor design, control and hemodynamics. *Annu Int Conf IEEE Eng Med Biol Soc.* 2014;2014:5659-62.
122. Timms D, Fraser J, Thompson B, al. e. In-vitro and in-vivo testing of the BiVACOR rotary BiVAD/TAH. In: Dössel O, Schlegel W, editors. *World Congress on Medical Physics and Biomedical Engineering.* Munich, Germany: Springer; 2009. p. 624-6.
123. Fukamachi K, Shiose A, Massiello AL, Horvath DJ, Golding LA, Lee S, et al. Implantable continuous-flow right ventricular assist device: lessons learned in the development of a cleveland clinic device. *Ann Thorac Surg.* 2012;93(5):1746-52.
124. Fukamachi K, Karimov JH, Sunagawa G, Horvath DJ, Byram N, Kuban BD, et al. Generating pulsatility by pump speed modulation with continuous-flow total artificial heart in awake calves. *J Artif Organs.* 2017;20(4):381-5.
125. Fumoto H, Horvath DJ, Rao S, Massiello AL, Horai T, Takaseya T, et al. In vivo acute performance of the Cleveland Clinic self-regulating, continuous-flow total artificial heart. *J Heart Lung Transplant.* 2010;29(1):21-6.
126. Horvath D, Karimov JH, Byram N, Kuban B, Golding LA, Moazami N, et al. Sensorless Suction Recognition in the Self-Regulating Cleveland Clinic Continuous-Flow Total Artificial Heart. *ASAIO J.* 2015;61(6):726-8.
127. Horvath D, Byram N, Karimov JH, Kuban B, Sunagawa G, Golding LAR, et al. Mechanism of Self-Regulation and In Vivo Performance of the Cleveland Clinic Continuous-Flow Total Artificial Heart. *Artif Organs.* 2017;41(5):411-7.
128. Grzyb C, Du D, Nair N. Artificial Intelligence Approaches for Predicting the Risks of Durable Mechanical Circulatory Support Therapy and Cardiac Transplantation. *J Clin Med.* 2024;13(7).
129. Ali SM, Ali ZJ, Abd MM. Design and Modeling of a Soft Artificial Heart by Using the SolidWorks and ANSYS. *IOP Conference Series: Materials Science and Engineering* 2020.
130. Elmezghi MF, Mohammed AH, Tawfeeq OA. Design and performance simulation of a soft artificial heart by using the ANSYS software. *i-manager's Journal on Future Engineering and Technology.* 2024.
131. Manjunath LH, Karthick V. Design and Analysis of Artificial Heart Model by Using Finite Element Analysis. *Journal of Mines, Metals and Fuels (J Mines Met Fuels).* 2022;70(10A):13-20.
132. Ali SM, Mahmood SS. Design of a New Generation Low-Cost Advanced Soft Nano-Artificial Heart for Permanent Use. 2024.
133. Itagaki S, Toyoda N, Egorova N, Sun E, Lee T, Boateng P, et al. Total artificial heart implantation as a bridge to transplantation in the United States. *J Thorac Cardiovasc Surg.* 2024;167(1):205-14 e5.
134. Arabia FA, Murray CF. The total artificial heart: where have we been, where are we now, where are we going? *Indian J Thorac Cardiovasc Surg.* 2023;39(Suppl 1):198-205.



ECMO (EXTRAKORPOREAL MEMBRAN OKSİJENASYONU)

BÖLÜM 67

Mehmet ÇAKICI ¹
Serpil NALBANT ²

DOI: 10.37609/akya.3889.c5389

İçindekiler

- » GİRİŞ
- » Ecmo Geliştirme Süreçleri
- » Ecmo Yöntemleri
- » ENDİKASYONLAR ve KONTRENDİKASYONLAR
- » Ecmo Bileşenleri
 - » Kanüller
 - » Pompa
- » Hatlar (Devreler)
- » Membran Oksijenatörleri
- » Isı Değiştirici- Gaz Mikseri-Enerji Ünitesi
- » ECMO Kanülasyon Teknikleri
 - » Hibrid ECMO Kanülasyon Teknikleri
- » ECMO Komplikasyonları
- » Ecmotan Ayrılma (Weaning)

¹ Prof. Dr, Özel Lokman Hekim Akay Hastanesi, mcakici21@gmail.com, ORCID iD: 0000-0002-9687-1147

² Msc. ECCP Perfüzyonist, Özel Memorial Ankara Hastanesi, serpil.nalbant@gmail.com, ORCID iD: 0000-0003-0081-0348

nunun değerlendirilmesinde genel biyokimyasal tetkiklerle birlikte arter kan gazı örnekleri ve laktat değerleri kullanılabilir. Tüm bu değerlendirmelerin ışığında akım değerleri kademeli olarak azaltılarak hasta ayrılmaya hazırlanır. Literatürde yapılmış kontrollü bir çalışma olmamakla birlikte, yüksek tromboz ve emboli riski nedeniyle, erişkinlerde 1L/dk akım değerlerinin altında, dekanülasyon işlemi geciktirilmemelidir. Kalp yetmezliği nedeniyle VA-ECMO desteği alan hastaların büyük çoğunluğu bir hafta içinde ECMO desteğinden ayrılabilirler. ECMO desteğinin uzamasının, mortalite ve morbidite oranlarına, ciddi olumsuz etkisi olduğu bilinmektedir. Bu süreçte gelişebilecek, kanama ve ekstremité iskemisi gibi komplikasyonlar mortal seyredebilir. Bu nedenle koagülasyon parametreleri ve ekstremité perfüzyonunun periyodik değerlendirilmesi büyük önem taşımaktadır. Periferik ECMO uygulamalarında dekanülasyon işleminin uygun hastalarda lokal anestezi altında yapılması tercih edilebilir. Perkütan ECMO uygulamalarında, femoral eksplorasyon ile kullanılan arterin ve venin cerrahi onarımı yapılarak dekanülasyon tamamlanır. Aort, aksiller veya subklavyen arter greft aracılı VA-ECMO uygulamalarında, dekanülasyon sonrası, greftin anastomoz seviyesinin hemen üstünden bağlanması, cerrah için kolaylık sağlamasının yanı sıra onarım bölgesinde oluşabilecek damar daralmalarını da önler.

Akut, hipoksemik veya hiperkapnik solunum yetmezliği nedeniyle VV-ECMO uygulamaları uzun süreli olsa da destekten ayırma oldukça basittir ve klinisyenlerin yatak başında yapmalarına olanak tanır. Normal kardiyak fonksiyonu olan hastanın kabul edilebilir mekanik ventilasyon parametreleriyle (tepe basıncı ≤ 30 cmH₂O, PEEP ≤ 15 cmH₂O, tidal hacim ≤ 6 mL/kg tahmini ağırlık, RR ≤ 35 rpm ve FiO₂ $\leq$ %60) gaz değişimini tatmin edici şekilde sürdürebilmesi ve buna iyileştirilmiş radyografik parametreler ve pulmoner uyumun eşlik etmesi durumunda başlatılabilir (14). Kan akışını koruduktan ve gaz mikserini kapattıktan sonra, hastanın SaO₂ ve PaCO₂'si takip edilmelidir. Deneme sırasında, devrede trombüs

oluşma riskini azaltmak için < 2 L/dakika ECMO akışlarından kaçınılmalıdır (1,18). Ecmo desteği kapatıldıktan sonra 2 ile 4 saat içerisinde tidal hacim ve gaz değişimi yeterliyse (yani, tidal hacim 5 mL/kg, PaO₂ 10 kPa [75 mmHg] ve PaCO₂ 7 kPa [52 mmHg]), ECMO kesilebilir ve hasta dekanüle edilebilir. (22). Kanül çıkarılırken, hasta Trendelenburg pozisyonunda olmalı ve hava embolisi riskini azaltmak için kısa etkili paraliz yapan farmakolojik ajanlar veya Valsalva manevrası yapılmalıdır. Derin ven trombozunu tespit etmek için dekanülasyondan sonra rutin venöz Doppler ultrasonu yapılmalıdır (1).

Hibrid ECMO konfigürasyonlarında, ECMO'dan ayrılmanın temel prensibi, hastanın ihtiyacı olan komponenti koruyacak şekilde, öncelikle VV veya VA konfigürasyonuna geçmektir. Örneğin VAV-ECMO konfigürasyonunda destek verilen bir hastada, hastanın hemodinamik destek ihtiyacı kalmadıysa, öncelikle VV-ECMO konfigürasyonuna geçilir. Bundan sonra standart ayrılma prosedürleri uygulanabilir.

KAYNAKLAR

1. Mossadegh, C., & Combes, A. (Eds.). (2017). Nursing care and ECMO (No. 25017). Switzerland: Springer International Publishing.
2. Xuan, C., Gu, J., Chen, J., & Xu, H. (2025). Respiratory compliance related to prognostic of lung transplant patients with veno venous extracorporeal membrane oxygenation support. *Scientific Reports*, 15(1), 1-9.
3. Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization. *ASAIO J.* 2021.1;65 (5)485-495. doi: 10.1097/MAT.0000000000001422.)
4. Ramanathan, K., Antognini, D., Combes, A., Paden, M., Zakhary, B., Ogino, M., ... & Shekar, K. (2020). Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. *The Lancet Respiratory Medicine*, 8(5), 518-526.
5. Akpınar E., Atalan ÖN. COVID-19 Ekstrakorporeal Membran Oksijenasyonu (ECMO): Güncellenmiş 2021 ELSO Kılavuz Özeti: COVID-19 ECMO. *Journal of Health Services and Education*; 6(1): 29-38 ISSN: 2636-8285 DOI: 10.29228/JOHSE.18.
6. Amaç B, Padak M, Dikme R, Korkmaz Ersöz E, Göç Ö, Hacıoğlu Y. COVID-19'da Ekstrakorporeal Membran Oksijenasyonun Kullanımı. *Med Records. Temmuz 2020*;2(2):44-48. doi:10.37990/medr.752001
7. Çakıcı, M., Durdu, S., & Şırlak, M. (2017). Erişkinlerde Venö-Arterial ECMO Uygulamaları. *Türkiye Klinikleri Cardiovascular Surgery-Special Topics*, 9(3), 238-244.

8. Çakıcı, M., Baran, Ç., Özçınar, E., Hasde, A. İ., İnan, M. B., Durdu, S., ... & Akar, A. R. (2017). Erişkin Akut Kardiyojenik şoklu Hastalarda Veno-Arteriyel Ekstra-korporeal Membran Oksijenasyon Desteği: Retrospektif Analiz.).
9. This, I., Care, I., & Book, T. R. (2017). Extracorporeal Life Support Organization (ELSO) General Guidelines for all ECLS Cases. ELSO Guideline, 1-24.).
10. Lorusso, R., Shekar, K., MacLaren, G., Schmidt, M., Pellegrino, V., Meyns, B., ... & Whitman, G. (2021). ELSO interim guidelines for venoarterial extracorporeal membrane oxygenation in adult cardiac patients. *ASAIO journal*, 67(8), 827-844.
11. Yeo, H. J., Jeon, D., Kim, Y. S., Cho, W. H., & Kim, D. (2015). Veno-veno-arterial extracorporeal membrane oxygenation treatment in patients with severe acute respiratory distress syndrome and septic shock. *Critical Care*, 20, 1-3.
12. Yu, T. Z., Tatum, R. T., Saxena, A., Ahmad, D., Yost, C. C., Maynes, E. J., ... & Tchanchaleishvili, V. (2022). Utilization and outcomes of extracorporeal CO2 removal (ECCO2R): Systematic review and meta-analysis of arterio-venous and veno-venous ECCO2R approaches. *Artificial Organs*, 46(5), 763-774.
13. He, T., Yu, S., He, J., Chen, D., Li, J., Hu, H., ... & Cui, Z. (2022). Membranes for extracorporeal membrane oxygenator (ECMO): History, preparation, modification and mass transfer. *Chinese Journal of Chemical Engineering*, 49, 46-75.
14. Chaves, R. C. D. F., Rabello, R., Timenetsky, K. T., Moreira, F. T., Vilanova, L. C. D. S., Bravim, B. D. A., ... & Corrêa, T. D. (2019). Extracorporeal membrane oxygenation: a literature review. *Revista Brasileira de terapia intensiva*, 31, 410-424.
15. ELSO. What Is ECMO? | Extracorporeal Membrane Oxygenation (ECMO) (Online) <https://www.elseo.org/extracorporeal-membrane-oxygenation.aspx> [Accessed: 16th April 2025].
16. Leprince P, Léger P, Aubert S, Gandjbakhch I, Pavie A. Assistanes circulatoires et coeurs artificiels: techniques et évolutions. EMC (Elsevier Masson SAS, Paris), Techniques chirurgicales Thorax. 2010;42-515:1-10.
17. Fiser S, Tribble CG, Kaza AK, Long SM, Zacour RK, Kern JA, et al. When to discontinue extracorporeal membrane oxygenation for postcardiotomy support. *Ann Thorac Surg* 2001;71:210-4.
18. Tonna, J. E., Abrams, D., Brodie, D., Greenwood, J. C., Mateo-Sidron, J. A. R., Usman, A., & Fan, E. (2021). Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the extracorporeal life support organization (ELSO). *ASAIO journal*, 67(6), 601-610.
19. Bektaş, Ş. G., Turan, S. Ecmo Endikasyon Ve Kontrendikasyonları
20. Lequier L, Horton SB, McMullan DM, Bartlett RH. Extracorporeal membrane oxygenation circuitry. *Pediatr Crit Care Med*. 2013 Jun;14(5 Suppl 1):S7-12. doi: 10.1097/PCC.0b013e318292dd10. PMID: 23735989; PMCID: PMC3742331.
21. Gajkowski, Evan F.; Herrera, Guillermo; Hatton, Laura; Velia Antonini, Marta; Vercaemst, Leen; Cooley, Elaine. ELSO Guidelines for Adult and Pediatric Extracorporeal Membrane Oxygenation Circuits. *ASAIO Journal* 68(2):p 133-152, February 2022
22. Sidebotham, D., Allen, S. J., McGeorge, A., Ibbott, N., & Willcox, T. (2012). Venovenous extracorporeal membrane oxygenation in adults: practical aspects of circuits, cannulae, and procedures. *Journal of cardiothoracic and vascular anesthesia*, 26(5), 893-909.
23. Slovis J., Roberts A., Kilbaugh T. J., Tschaut R. J. (ed.) *Extracorporeal Circulation in Theory and Practice*. Netherlands: Pabst Science Publishers; 2020. p. 618-619
24. Wendel HP, Ziemer G: Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. *Eur J Cardiothorac Surg* 16:342-350, 1999,19.
25. Khoshbin E, Dux AE, Killer H, et al: A comparison of radiographic signs of pulmonary inflammation during ECMO between silicon and poly-methyl pentene oxygenators. *Perfusion* 22:15-21, 2007.
26. Betit, P. (2018). Technical advances in the field of ECMO. *Respiratory care*, 63(9),1162-1173.
27. Thiara AP, Hoel TN, Kristiansen F, et al: Evaluation of oxygenator and centrifugal pumps for long-term pediatric extracorporeal membrane oxygenation. *Perfusion* 22:323-326, 2007.
28. Yu K, Long C, Hei F, et al: Clinical evaluation of two different extracorporeal membrane oxygenation systems: A single center report. *Artif Organs* 35:733-737, 2011.
29. Condello, I. (2025). Exploring the nexus: gaseous micro-embolic activity and pressure drop on ALONE ECMO oxygenator. *Biomedical Materials & Devices*, 3(1), 1-6.
30. Cakici M, Ozcinar E, Baran C, Bermede AO, Saricaoglu MC, Inan MB, et al. A retrospective cohort analysis of percutaneous versus side-graft perfusion techniques for veno-arterial extracorporeal membrane oxygenation in patients with refractory cardiogenic shock. *Perfusion* 2017;32(5):363-71.
31. Carvalho, J. L., & Keshavamurthy, S. (2024). Femoro-femoral veno-venous extracorporeal membrane oxygenation: art and science. *Journal of Thoracic Disease*, 16(1), 816.
32. Gordon, C., Koerner, M. M., Ali, A., Zeriuoh, M., Liszka, E., El-Banayasy, A., ... & Ghodsizad, A. (2015, April). Insertion of the Avalon cannula for venovenous extracorporeal membrane oxygenation in a patient with an implanted ASD occlusion device. In *The Heart Surgery Forum* (Vol. 18, No. 1, pp. E031-E032).
33. SquiersJJ, Lima B, DiMaio JM. Contemporary extracorporeal membrane oxygenation therapy in adults: fundamental principles and systematic review of the evidence. *J Thorac Cardiovasc Surg* 2016;152:20-32.
34. Hasde, A. I., Sarıcaoğlu, M. C., Dikmen Yaman, N., Baran, Ç., Özçınar, E., Çakıcı, M., ... & Akar, A. R. (2021). Comparison of left ventricular unloading strategies on venoarterial extracorporeal life support. *Interactive CardioVascular and Thoracic Surgery*, 32(3), 467-475.
35. Napp LC, Kuhn C, Hoepfer MM, Vogel-Claussen J, Haverich A, Schafer A et al. Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults. *Clin Res Cardiol* 2016;105:283-96.
36. Lindfors M, Frenckner B, Sartipy U, Bjallmark A, Broome M. Venous cannula positioning in arterial deoxygenation during Veno-arterial extracorporeal membrane oxygenation-A simulation study and case report. *Artif Organs* 2017;41:75-81.

37. Bartlett RH. Physiology of gas exchange during ECMO for respiratory failure. *J Intensive Care Med* 2017; 32:243-8.
38. Pujara D, Sandoval E, Simpson L, Mallidi HR, Singh SK. The state of the art in extracorporeal membrane oxygenation. *Semin Thorac Cardiovasc Surg* 2015;27:17-23.
39. aaM, Hofmann B, Metz D, Bucher M et al. First experiences with a combined usage of veno-arterial and veno-venous ECMO in therapy-refractory cardiogenic shock patients with cerebral hypoxemia. *PerAjsion* 2014;29:200-9.
40. Bonacchi M, Harmelin G, Peris A, Sani G. A novel strategy to improve systemic oxygenation in venovenous extracorporeal membrane oxygenation: the "chi-configuration". *J Thorac Cardiovasc Surg* 2011;142:1197-204.
41. Biscotti M, Lee A, Basner RC, Aqerstrand C, Abrams D, Brodie D et al. Hybrid configurations via percutaneous access for extracorporeal membrane oxygenation: a single-center experience. *ASAIO J* 2014;60:635-42.
42. Choi JH, Kim SW, Kim VU, Kim YS, Kim KS, Joo SJ et al. Application of veno-arterial-venous extracorporeal membrane oxygenation in differential hypoxia. *Multidiscip Respir Med* 2014;9:55.
43. Cakici, M., Gumus, F., Ozcinar, E., Baran, C., Bermede, O., Inan, M. B., ... & Akar, A. R. (2018). Controlled flow diversion in hybrid venoarterial-venous extracorporeal membrane oxygenation. *Interactive cardiovascular and thoracic surgery*, 26(1), 112-118.
44. Balci, D., Ozcelik, M., Kirimker, E. O., Cetinkaya, A., Ustuner, E., Cakici, M., ... & Akar, A. R. (2018). Extended left hepatectomy for intrahepatic cholangiocarcinoma: hepatic vein reconstruction with in-situ hypothermic perfusion and extracorporeal membrane oxygenation. *BMC surgery*, 18, 1-5.
45. Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. *Minerva Anestesiol* 2010;76:534-40.
46. Aubron C, Cheng AC, Pilcher D, Leong T, Magrin G, Cooper DJ, et al. Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. *Crit Care* 2013;17:73.
47. Makdisi G, Wang IW. Extra Corporeal Membrane Oxygenation (ECMO) review of a life saving technology. *J Thorac Dis* 2015;7(7):166-76.
48. Avgerinos DV, DeBois W, Voelvidko L, Salemi A. Regional Variation in Arterial Saturation and Oxygen Delivery during Venoarterial Extracorporeal Membrane Oxygenation. *JECT* 2013;45:183-6.
49. Rao P, Khalpey Z, Smith R, Burkhoff D, Kociol RD. Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest. *Circ Heart Fail* 2018;11:e004905.
50. Rupperecht L, Florchinger B, Schopka S, Schmid C, Philipp A, Lunz D et al. Cardiac decompression on extracorporeal life support: a review and discussion of the literature. *ASAIO J* 2013;59:547-53.43).
51. Xie A, Forrest P, Loforte A. Left ventricular decompression in veno-arterial extracorporeal membrane oxygenation. *Ann Cardiothorac Surg* 2019;8:9-18.
52. Centofanti P, Attisani M, La Torre M, Ricci D, Boffini M, Baronetto A et al. Left Ventricular Unloading during Peripheral Extracorporeal Membrane Oxygenator Support: A Bridge To Life In Profound Cardiogenic Shock. *J Extra Corpor Technol* 2017;49:201-05,45.
53. Petroni T, Harrois A, Amour J, Lebreton G, Brechot N, Tanaka S et al. Intra-aortic balloon pump effects on macrocirculation and microcirculation in cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation. *Crit Care Med* 2014;42:2075-82.
54. Aso S, Matsui H, Fushimi K, Yasunaga H. The Effect of Intraaortic Balloon Pumping Under Venoarterial Extracorporeal Membrane Oxygenation on Mortality of Cardiogenic Patients: An Analysis Using a Nationwide Inpatient Database. *Crit Care Med* 2016;44:1974-79,47.
55. Hacking DF, Best D, d'Udekem Y, Brizard CP, Konstantinov IE, Millar J et al. Elective decompression of the left ventricle in pediatric patients may reduce the duration of venoarterial extracorporeal membrane oxygenation. *Artif Organs* 2015;39:319-26.
56. Fumagalli R, Bombino M, Borelli M, Rossi F, Colombo V, Osculati G et al. Percutaneous bridge to heart transplantation by venoarterial ECMO and transaortic left ventricular venting. *Int J Artif Organs* 2004;27:410-3.
57. Hong TH, Byun JH, Lee HM, Kim YH, Kang GH, Oh JH et al. Initial Experience of Transaortic Catheter Venting in Patients with Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock. *ASAIO J* 2016;62:117-22.
58. Yamamoto M, Oshima Y, Matsuhisa H, et al. Left Atrial Decompression by Minithoracotomy During Extracorporeal Life Support. *Ann Thorac Surg* 2019;107:e227-e28.
59. Kimura M, Kinoshita O, Fujimoto Y, et al. Central extracorporeal membrane oxygenation requiring pulmonary arterial venting after near-drowning. *Am J Emerg Med* 2014;32:197 e1-2.
60. Avalli L, Maggioni E, Sangalli F, et al. Percutaneous left-heart decompression during extracorporeal membrane oxygenation: an alternative to surgical and transeptal venting in adult patients. *ASAIO J* 2011;57:38-40,53.
61. Lorusso R, Gelsomino S, Parise O, et al. Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock in Elderly Patients: Trends in Application and Outcome From the Extracorporeal Life Support Organization (ELSO) Registry. *Ann Thorac Surg* 2017;104:62-69.
62. Hlavacek AM, Atz AM, Bradley SM, et al. Left atrial decompression by percutaneous cannula placement while on extracorporeal membrane oxygenation. *J Thorac Cardiovasc Surg* 2005;130:595-6.
63. Aiyagari RM, Rocchini AP, Remenapp RT, et al. Decompression of the left atrium during extracorporeal membrane oxygenation using a transseptal cannula incorporated into the circuit. *Crit Care Med* 2006;34:2603-6.
64. Baruteau AE, Barnette T, Morin L, et al. Percutaneous balloon atrial septostomy on top of venoarterial extracorporeal membrane oxygenation results in safe and effective left heart decompression. *Eur Heart J Acute Cardiovasc Care* 2018;7:70-79.



KALP YETMEZLİĞİNDE GEOMETRİK TEDAVİ

BÖLÜM 68

Cüneyt KONURALP ¹

DOI: 10.37609/akya.3889.c5390

İçindekiler

- » GİRİŞ VE GENEL BİLGİLER
- » KALP YETMEZLİĞİNİN MEKANİZMALARI
- » KALP YETMEZLİĞİNDE KLASİK TEDAVİ STRATEJİLERİ
 - » Kardiyo-renal Model
 - » Kardiyo-sirkülatuar (hemodinamik) Model
- » NORMAL KALBİN MİKRO VE MAKRO GEOMETRİK YAPISI
 - » Ventriküler Dinamiğin Analizi
- » YETMEZLİKLİ KALBİN MİKRO VE MAKRO GEOMETRİK YAPISI
- » APOPTOSİS VE REMODELİNG
 - » Miyositlerdeki Değişiklikler
 - » Eksitasyon-Kontraksiyon Uyumunun (coupling) Bozulması
- » GEOMETRİK TEDAVİ STRATEJİLERİ
 - » Anti Remodeling Stratejiler
 - » MEDİKAL YÖNTEMLER
 - » ELEKTRİKSEL YÖNTEMLER
 - » CERRAHİ YÖNTEMLER
 - » A- Aktif ve Passif Destek Sağlayan Sistemler
 - » B-Passif Destek Sağlayan Sistemler
 - » GENETİK VE HÜCRESEL TEDAVİ YÖNTEMLERİ
 - » A- Hücresel Tedavi
 - » DOLAŞIM SİSTEMİNİN FİLOGENETİK EVRİMİ
 - » KUTSAL GEOMETRİ (SACRED GEOMETRY) VE KALP
 - » KALBİN DIŞ GEOMETRİSİ VE GEOMETRİNİN FONKSİYONLA İLİŞKİSİ
 - » NORMAL KALP SESLERİNİN CYMASCOPE İLE ANALİZİ
 - » KALP YETMEZLİĞİ TEDAVİSİNİN GELECEĞİ

¹ Doç. Dr., Özel Muayenehane, ckonuralp@usa.net, ORCID iD: 0009-0004-8008-241X

bu anatomik manevralar da bir süre sonra yetersiz kalmakta veya kontrolden çıkmaktadır. Bu durumda, bizim o anki fiziksel koşullara göre bu pompanın en optimal geometriyi almasına yardım etmemiz gereklidir. Bunun için gerekirse Kut-sal Geometri öğretilerinden de istifade etmeliyiz. Fizik kanunları ile yarışamayız. Kalbin yükünü ne kadar azaltırsak azaltalım ve miyokardı ne kadar kamçılırsak kamçılalım, eğer bozulan geometriyi düzeltmezsek pompa/empedans sisteminin yetersiz kalmasına engel olamayız.

Geometrik yaklaşımın benimsenmesi, değişik tedavi stratejileri için hekimlerin hayal güçlerini ve gözlem yeteneklerini daha çok kullanmalarını gerektirecektir. Görüldüğü kadarıyla kalp cerrahisi, cerrahın kardiyak materyalle **bir mühendis** ve **bir sanatçı** gibi oynayacağı bir döneme girmek üzeredir.

KAYNAKLAR

- Braunwald E. Pathophysiology of heart failure. In: Braunwald E (ed.): Heart Disease. 4th ed. Vol 1. Philadelphia: WB Saunders, 1992;pp:393-418.
- Sun Y. The Renin-Angiotensin-Aldosterone system and vascular remodeling. Congest Heart Fail, 2002;8:11-6.
- Torrent Guasp F, Ballester M, Buckberg GD et al. Spatial orientation of the ventricular muscle band: Physiologic contribution and surgical implications. J Thorac Cardiovasc Surg, 2001;122:389-92.
- Bovendeerd PH, Arts T, Huyghe JM et al. Dependence of local left ventricular wall mechanics on myocardial fiber orientation. A model study. J Biomech, 1992;25:1129-40.
- Bogaert J, Maes R, Van de Werf F et al. Functional recovery of subepicardial myocardial tissue in transmural myocardial infarction after successful reperfusion: An important contribution to the improvement of regional and global left ventricular function. Circulation, 1999;99:36-43.
- Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodeling: Where are the theories and trials leading us? Heart, 2000;83:76-80.
- Fox JC, Patel VV. Apoptosis and cardiovascular system. ACC Curr J Rev, 1998;7:13-5.
- Searle J, Kerr JFR, Bishop CJ. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol Ann, 1982;17:229-59.
- James TN. Apoptosis in cardiac disease. Am J Med, 1999;107:606-20.
- Li G, Willerson JT. Molecular biologic alterations in heart failure. In: Frazier OH (ed): Support and Replacement of the Failing Heart. Philadelphia: Lippincott-Raven, 1996;pp:69-85.
- Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med, 1991;325:1468-75.
- Staudth A, Schaper F, Stangl V et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation, 2001;103:266-8.
- Ishikawa T, Kimura K, Nihei T et al. Relationship between diastolic mitral regurgitation and PQ intervals or cardiac function in patients implanted with DDD pacemakers. Pacing Clin Electrophysiol, 1991;14:1797-802.
- Garrigue S, Bordachar P, Reuter S et al. Comparison of permanent left ventricular and biventricular pacing in patients with heart failure and chronic atrial fibrillation: Prospective hemodynamic study. Heart, 2002;87:529-34.
- Toussaint JF, Lavergne T, Ollitraut J et al. Biventricular pacing in severe heart failure patients reverses electrophysiological dyssynchronization from apex to base. Pacing Clin Electrophysiol, 2000;23:1731-4.
- Kass DA. Pathophysiology of physiologic cardiac pacing. Advantages of leaving well enough alone. JAMA, 2002;288:3159-61.
- Auricchio A, Spinelli JC, Trautmann SI, Kloss M. Effect of cardiac resynchronization therapy on ventricular remodeling. J Card Fail, 2002;8(Suppl 6):549-55.
- Nishimura K, Radovancevic B, Odegaard P et al. Exercise capacity recovers slowly but fully in patients with a left ventricular assist device. ASAIO J, 1996;42:568-70.
- Burkhardt D. New heart failure therapy. The shape of things to come? J Thorac Cardiovasc Surg, 2001;122:421-3.
- Muller J, Wallakulat G, Weng YG et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation, 1997;96:542-9.
- Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg, 1999;68:734-41.
- Razeghi P, Myers TJ, Frazier OH, Taegtmeyer H. Reverse remodeling of the failing human heart with mechanical unloading. Emerging concepts and unanswered questions. Cardiology, 2002;98:167-74.
- Hetzer R, Muller J, Weng Y et al. Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy. J Thorac Cardiovasc Surg, 2000;120:843-53.
- Oz MC, Artrip JH, Burkhardt D. Direct cardiac compression devices. J Heart Lung Transplant, 2002;21:1049-55.
- Kung RT, Rosenberg M. Heart booster: A pericardial support device. Ann Thorac Surg, 1999;68:764-7.
- Carpentier A, Chachques JC. Myocardial substitution with a stimulated skeletal muscle: First successful clinical case. Lancet, 1985;1:1267.
- Furuta H, Watanabe G, Misaki G, Ueyama K. A new method of double cardiomyoplasty: "Contractile muscular sling". Ann Thorac Surg, 1999;67:1339-44.
- Helou J, Misawa Y, Stewart JA, Colson M, Chiu RCJ. Optimizing "delay period" for burst stimulation in dynamic cardiomyoplasty. Ann Thorac Surg, 1995;59:74-87.
- Mott BD, Oh JH, Misawa Y et al. Mechanisms of cardiomyoplasty: Comparative effects of adynamic versus dynamic cardiomyoplasty. Ann Thorac Surg, 1998;65:1039-44.

30. Chachques JC, Marino JP, Lajos P et al. Dynamic cardiomyoplasty: Clinical follow-up at 12 years. *Eur J Cardiothorac Surg*, 1997;12:560-7.
31. Oh JH, Badhwar V, Mott BD, Li CM, Chiu RCJ. The effects of prosthetic cardiac binding and adynamic cardiomyoplasty in a model of dilated cardiomyopathy. *J Thorac Cardiovasc Surg*, 1998;116:1481-53.
32. Vaynblat M, Chiavarelli M, Shah HR, et al. Cardiac binding in experimental heart failure. *J Thorac Cardiovasc Surg*, 1997;64:81-5.
33. Unal M, Konuralp C, Kopman E. Ventricular containment technique in ischemic cardiomyopathy. *Ann Thorac Surg*, 2001;72:1446-7.
34. Konertz WF, Shapland JE, Hotz H et al. Passive containment and reverse remodeling by a novel textile cardiac support device. *Circulation*, 2001;104(Suppl I):270-5.
35. Takagi H, Hirose H, Sasaki E et al. Effects of wrapping tightness on acute cardiac function in dynamic cardiomyoplasty. *Ann Thorac Surg*, 1997;63:1706-12.
36. Raman J, Power JM, Buxton BF et al. Ventricular containment as an adjunctive procedure in ischemic cardiomyopathy: Early results. *Ann Thorac Surg*, 2000;70:1124-6.
37. Capouya ER, Gerber RS, Drinkwater DC et al. Girdling effect of nonstimulated cardiomyoplasty on left ventricular function. *Ann Thorac Surg*, 1993;56:867-70.
38. McCharty PM, Takagaki M, Ochiai Y et al. Device-based change in left ventricular shape: A new concept for the treatment of dilated cardiomyopathy. *J Thorac Cardiovasc Surg*, 2001;122:482-90.
39. Kashem A, Santamore WP, Hassan S et al. Cardio Clasp: A new passive device to re-shape cardiac enlargement. *ASAIO J*, 2002;48:253-9.
40. Kashem A, Hassan S, Crabbe DL, Melvin DB, Santamore WP. Left ventricular reshaping. Effects on the pressure-volume relationship. *J Thorac Cardiovasc Surg*, 2003;125:391-9.
41. Kawaguchi AT, Sugimachi M, Sunagawa K et al. Pre- and postoperative left ventricular pressure-volume relationship in patients undergoing partial left ventriculectomy. In: Kawaguchi AT, Linde LM (eds): *Partial Left Ventriculectomy. Its Theory, Results and Perspectives*. Amsterdam: Elsevier Science, 1998;pp:35-47.
42. Burkhoff D, Holmes JW, Madigan J et al. Left ventricular assist devices-induced reverse ventricular remodeling. *Prog Cardiovasc Dis*, 2000;43:19-26.
43. Elefteriades J, Edwards R. Coronary bypass in left heart failure. *Sem Thorac Cardiovasc Surg*, 2002;14:123-5.
44. Rahimtoola SH. Concept and evaluation of hibernating myocardium. *Annu Rev Med*, 1999;50:75-86.
45. Elefteriades J. Coronary bypass: The bad ventricle. In: Kaiser LR, Kron IL, Spray TL (eds.): *Mastery of Cardiothoracic Surgery*. Philadelphia: Lippincott- Raven, 1998;pp:409-20.
46. Elefteriades J, Kron IL. CABG in advanced left ventricular dysfunction. *Cardiol Clin*, 1995;3:35-42.
47. Smolens IA, Pagani FD, Bolling SF. Mitral valve repair in heart failure. *Eur J Heart Fail*, 2000;2:365-71.
48. Cohn LH, Rizzo RJ, Adams DH et al. The effect of pathophysiology on the surgical treatment of ischemic mitral regurgitation: Operative and late risks or repair vs. replacement. *Eur J Cardiothorac Surg*, 1995;9:568-74.
49. Tolis G, Korkolis D, Kopf G et al. Coronary artery bypass alone suffices for patients with ischemic cardiomyopathy pathy and mitral regurgitation. 38th Annual Meeting of the Society for Thoracic Surgeons. Fort Lauderdale, FL, USA. January 2002.
50. Kherani AR, Cheema FH, Oz MC. Nontransplant surgical options for congestive heart failure. *Congest Heart Fail*, 2003;9:17-24.
51. Velazquez EJ, Lee KL, Deja MA et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med*, 2011;364:1607-16.
52. Velazquez EJ, Lee KL, Jones RH et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. *N Engl J Med*, 2016;374:1511-20.
53. Petrie MC, Jhund PS, She L, et al. Ten-year outcomes after Coronary Artery Bypass Grafting according to age in patients with Heart failure and Left Ventricular systolic dysfunction: An analysis of the extended follow-up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). *Circulation*, 2016;134:1314-24.
54. Acerbo V, Cesaro A, Scherillo G, et al. Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease. *Heart Fail Rev*, 2023; 28:1325-34.
55. Ranganathan N, Lam JH, Wigle ED et al. Morphology of the human mitral valve II. The value leaflets. *Circulation*, 1970;41:459-67.
56. Badhwar V, Bolling SF. Mitral valve surgery in the patient with left ventricular dysfunction. *Sem Thorac Cardiovasc Surg*, 2002;14:133-6.
57. Bolling SF, Pagani FD, Deeb GM, et al. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. *J Thorac Cardiovasc Surg*, 1998;115:381-8.
58. Hueb AC, Jatene FB, Moreira LPB et al. Ventricular remodeling and mitral valve modifications in dilated cardiomyopathy: New insights from anatomic study. *J Thorac Cardiovasc Surg*, 2002;124:1216-24.
59. Bogaert J, Maes A, Van de Werf F et al. Functional recovery of subepicardial myocardial tissue in transmural myocardial infarction after successful reperfusion. *Circulation*, 1999;99:36-43.
60. Gaudron P, Eilles C, Kugler I et al. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. *Circulation*, 1993;87:755-762.
61. White HD, Norris RM, Brown MA et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. *Circulation*, 1987;76:44-51.
62. Migrino RQ, Young JB, Ellis SG et al. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. *Circulation*, 1997;96:116-121.
63. Cooley D, Collins H, Morris G, Chapman D. Ventricular aneurysm after myocardial infarction: Surgical excision with the use of temporary cardiopulmonary bypass. *JAMA*, 1958;167:557-60.
64. Mickleborough LL, Carson S, Ivanov J. Repair of dysskinetic or akinetic left ventricular aneurysm: Results obtained with a modified linear closure. *J Thorac Cardiovasc Surg*, 2001;121:675-82.

65. Jatene AD. Left ventricular aneurysmectomy. Resection or reconstruction. *J Thorac Cardiovasc Surg*, 1985;89:321-31.
66. Fontan F. Transplantation of knowledge. *J Thorac Cardiovasc Surg*, 1990;99:387-95.
67. Dor V. Left ventricular aneurysms: The endoventricular patch plasty. *Sem Thorac Cardiovasc Surg*, 1998;116:50-9.
68. Cooley D. Ventricular endoaneurysmorrhaphy: A simplified repair for extensive postinfarction aneurysm. *J Cardiac Surg*, 1989;4:200-5.
69. Grossi E, Chinitz L, Galloway A et al. Endoventricular remodeling of left ventricular aneurysm: Functional, clinical and electrophysiological results. *Circulation*, 1995;92(Suppl 2):98-100.
70. Cooley D. Management of left ventricular aneurysm by intracavitary repair. *Oper Tech Thorac Cardiovasc Surg*, 1997;2:151-60.
71. Salati M, Di Biasi P, Paje A, Santoli C. Left ventricular geometry after endoventriculoplasty. *Eur J Cardiovasc Surg*, 1995;110:1291-301.
72. Dor V, Di Donato, Sabatier M et al. Left ventricular reconstruction by endoventricular circular patch plasty repair: A 17-year experience. *Sem Thorac Cardiovasc Surg*, 2001;13:435-47.
73. Athanasuleas CL, Stanley AWH Jr, Buckberg GD et al. Surgical anterior ventricular endocardial restoration (SAVER) for dilated ischemic cardiomyopathy. *Sem Thorac Cardiovasc Surg*, 2001;13:448-58.
74. Athanasuleas CL, Buckberg GD, Menicanti L, Gharib M, the RESTORE Group. Optimizing ventricular shape in anterior restoration. *Sem Thorac Cardiovasc Surg*, 2001;459-67.
75. Dickstein ML, Spotnitz HM, Rose EA et al. Heart reduction surgery: An analysis of the impact on cardiac function. *J Thorac Cardiovasc Surg*, 1997;113:1032-41.
76. Batista RJV, Verde J, Nery P et al. Partial left ventriculectomy to treat end-stage heart disease. *Ann Thorac Surg*, 1997;64:634-8.
77. McCharty PM, Starling RC, Wong J et al. Early results with partial left ventriculectomy. *J Thorac Cardiovasc Surg*, 1997;114:1-11.
78. Idiz M, Konuralp C, Unal M. How can we obtain maximal benefits from partial left ventriculectomy? *Eur J Cardiothorac Surg*, 2001;19:537-538.
79. Suma H, Isomura T, Horii T et al. Nontransplant cardiac surgery for end-stage cardiomyopathy. *J Thorac Cardiovasc Surg*, 2000;119:1233-45.
80. Matsui Y, Fukada Y, Suto Y et al. Overlapping cardiac volume reduction operation. *J Thorac Cardiovasc Surg*, 2002;124:395-7.
81. Franco-Cereceda A, McCharty PM, Blackstone EH et al. Partial left ventriculectomy for dilated cardiomyopathy: Is this an alternative to transplantation? *J Thorac Cardiovasc Surg*, 2001;121:879-93.
82. Suma H. Internal left ventricular restoration, *Oper Tech Thorac Cardiovasc Surg*, 2002;7:103-6.
83. Ratcliffe MB, Wallace AW, Teerlink JR, et al. Radio frequency heating of chronic ovine infarct leads to sustained infarct area and ventricular volume reduction. *J Thorac Cardiovasc Surg*, 2000;119:1194-204.
84. Komeda M. Nontransplant surgery for congestive heart failure. New insights in the 21st century. *International Symposium on Surgical Options in Heart Failure Management*. Singapour. February 2003.
85. Mayer NJ, Stanley PD, Rubin A. Molecular and cellular prospects for repair, augmentation, and replacement of the failing heart. *Am Heart J*, 1997;134:577-86.
86. Schumacher B, Pecher P, von Specht BU et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. *Circulation*, 1998;97:645-50.
87. Jockusch H, Fuchtbauer E, Fuchtbauer A et al. Long-term expression of isomyosins and myoendocrine function in ectopic grafts of atrial tissue. *Proc Natl Acad Sci*, 1998;83:7325-9.
88. Li RK, Jia ZQ, Weisel RD, Mickle DAG. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. *J Mol Cell Cardiol*, 1999;100:247-56.
89. Atkins BZ, Emani S, Hutcheson K et al. Transplanted autologous skeletal myoblast improve myocardial performance after coronary artery ligation. *Card Vasc Regener*, 2000;1:76-84.
90. Makino S, Fukudo K, Miyoshi S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. *J Clin Invest*, 1999;103:697-705.
91. Kalka C, Masuda H, Takahashi T et al. Transplantation of ex-vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci*, 2000;97:3422-7.
92. Li RK, Weisel RD, Mickle DAG et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. *J Thorac Cardiovasc Surg*, 2000;119:62-8.
93. Miyamoto M, del Monte F, Schmidt U et al. Adenoviral gene transfer of SRCA 2a improves left ventricular function in aortic-banded rats in transition to heart failure. *Proc Natl Acad Sci*, 2000;97:793-7.
94. Maurice JP, Hata JA, Shah AS et al. Enhanced of cardiac function adenoviral mediated in-vivo intracoronary 2-adrenergic gene delivery. *J Clin Invest*, 1999;104:21-9.
95. Konuralp C. Mikrop Teorisi mi? Ortam Teorisi mi? İkisi de yetersiz. Yeni bir Teori: Kontrat Teorisi. In: Konuralp C: Bağışıklığın arka bahçesi-2: 'Bilim'in gerçeklerinden 'İlim'in hakikatlerine ve daha derine. İstanbul:Hayygrup Yayıncılık AŞ, 2024; pp:57-88.
96. Ljungdahl LG, Adams MW, Barton LL et al (Editors). *Biochemistry and Physiology of anaerobic bacteria*. New York: Springer, 2003; pp:128-42.
97. Demirsoy A. Yaşamın temel kuralları- Cilt I, Kısım II: Genel Biyoloji/Genel Zooloji. 5. baskı. Ankara: Meteksan AŞ, 1994; pp:106-28; 129-49.
98. Demirsoy A. Yaşamın temel kuralları- Cilt III, Kısım I: Omurgalılar/Anamnıyota. 2. baskı. Ankara: Meteksan AŞ, 1993; pp:138-48; 290-3; 555-62.
99. Kuru M. Omurgalı Hayvanlar. 5. baskı. Ankara: Palme Yayıncılık, 1999; pp:161-4; 290-7; 356-8; 578-82.
100. Demirsoy A. Yaşamın temel kuralları- Cilt II, Kısım II: Entomoloji (Omurgasızlar/Böcekler). 6. baskı. Ankara: Meteksan AŞ, 1999; pp:113-6.
101. Demirsoy A. Yaşamın temel kuralları- Cilt II, Kısım I: Omurgasızlar= İntervertebrata (Böcekler dışında). 2. baskı. Ankara: Meteksan AŞ, 1998; pp:502-4; 708-11; 1007-9.
102. Furst B. *The Heart and Circulation: An integrative Model*. 2nd edition. Cham:Springer Nature Switzerland, 2020;pp:3-10; 68; 97-120.

103. Pough FH, Janis CM, Heiser JB. Omurgalı yaşamı. 9. baskı. Ankara: Nobel Akademik Yayıncılık, 2014;pp:40; 238-41; 294-6.
104. Budak A, Göçmen B. Herpetoloji. 3. baskı. İzmir: Ege Üniversitesi, Basımevi, 2014;pp:80.
105. Demirsoy A. Yaşamın temel kuralları- Cilt III, Kısım II: Omurgalılar/Amniyot (Sürüngenler, Kuşlar ve Memeliler). Ankara: Meteksan AŞ, 1992; pp:49-53; 229-31; 553-60.
106. Smith RB. Ventilation at high respiratory frequencies. High frequency positive pressure ventilation, high frequency jet ventilation and high frequency oscillation. *Anaesthesia*, 1982;37:1011-8.
107. Pettigrew JB. The Physiology of the circulation in Plants, in the lower Animals, and in Man. London: MacMillan and Co, 1874;pp:164-5.
108. Yamaguchi H. Hypothalamic control of torpor and hibernation. *Temperature*, 2024;11:187-9.
109. Ernst Haeckel. The history of creation. Vol 1. Frankfurt:Verlag GmbH, 2020;pp:1-244.
110. Schneider MS. A beginner's guide to constructing the Universe: The Mathematical archetypes of nature, Art, and Science. New York: HayperCollins, 1995;pp:1-352.
111. French KL. The hidden Geometry of Life. Singapore: I-mago, 2012;pp:1-240.
112. Rajput C. Metallic Ratios: Beyond the Golden Ratio- The Mathematical relationships between different Metallic Means. *JAM*, 2021;20:158-66.
113. Garland TM. Fascinating Fibonacci: Mystery and magic in Numbers. Parsippany: Pearson Education, Inc., 1987;pp:1-103.
114. Pettigree JB. Design in Nature. Vol 1. London: Longman, Greens and Co, 1908; pp:1-421.
115. Pettigree JB. Design in Nature. Vol 2. London: Longman, Greens and Co, 1908; pp:422-1072.
116. Pettigree JB. Design in Nature. Vol 3. London: Longman, Greens and Co, 1908; pp:1073-416.
117. Euclid: Öklid'in elemanları. Ankara: Ofset Fotomat, 2019;pp:1-691.
118. Hambidge J. Elements of Dynamic Symmetry. New York: Dover Publications, 1948;pp:1-133.
119. Caskey LD. Geometry of Greek vases: Attic vases in the Museum of Fine Arts analysed according to the principles of proportion discovered by Jay Hambidge. Boston: Museum of Fine Arts, 1922;pp:1-235.
120. Konuralp C. Plasebo, Nosebo ve Sebo etkileri ve Pandemi ile ilişkileri. In: Konuralp C: Bağışıklığın arka bahçesi: 'Bilim'in gerçeklerinden 'İlim'in hakikatlerine. İstanbul: Hayygrup Yayıncılık AŞ, 2023; pp:85-97.
121. Çelik M, Gökoğlu Y, Develi S et al. İnsan Kalbinde altın oran. *Gülhane Tıp Derg*, 2015; 57:1-4.
122. Altıntaş O, Bahtiyar A. İnsan vücudunda Matematik. Ankara: Atlas Akademik Basım, 2024;pp:1-102.
123. Holdrege C (Ed.). The dynamic Heart and circulation. Fair Oaks: The Association of Waldorf Schools of North America, 2002;pp:1-151.
124. Henein MY, Zhao Y, Nicoll R et al. The human heart: Application of the golden ratio and angle. *Int J Cardiol*, 2011;150:239-42.
125. <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2004097709>
126. Konuralp C, İdiz M, Ateş M. A novel reporting approach to coronary angiography: "Segmental Coding System". *Int J Cardiol*, 2005;98:113-21.
127. Konuralp C. Tıpta görüntüleme tekniklerinin raporlanmasında formülatif yaklaşım. *Türkiye Klinikleri J Med Sci*, 2004;24:525-33.
128. Miller ST. A new sacred geometry: The Art and Science of Frank Chester. New York: Spirit Alchemy Design, 2012;pp:1-59.
129. Goss CM. The physiology of the embryonic mammalian heart before circulation. *Am J Physiol*, 1942;137:146-52.
130. Alexander W. Branko Furst's radical alternative: Is the heart moved by blood, rather than vice versa? *P T*, 2017;42:33-9.
131. Marinelli P, Fuerst B, Zee HVD et al. The Heart is not a pump: A refutation of the pressure propulsion premise of Heart function. *Semantic Scholar.org*, 1995; Corpus ID:5361522;pp:1-10.
132. Stonebridge PA, Brophy CM. Spiral laminar flow in arteries? *Lancet*, 1991;338:1360-1.
133. Cuneo B, Hughes S, Benson D. Heart rate perturbation in the stage 17-27 chick embryo: Effect on stroke volume and aortic flow. *Am J Phys Heart Circ Phys*. 1993;264:H755-9.
134. Cowan TS. Human Heart, Cosmic Heart: A Doctor's quest to understand, treat, and prevent cardiovascular disease. White River Junction: Chelsea Green Publishing, 2016; pp:1-176.
135. Jenny H. Cymatics: A study of wave Phenomena and vibration (compilation of volume 1 and 2). New York: Macromedia, 2001;pp:1-295.
136. Emoto M. The hidden messages in water. Hillsboro: Beyond Words Publishing, Inc., 2004;pp:1-159.
137. Austin V. Living language of Water. Matakana: Veda Austin Books, 2024;pp:1-134.
138. Bentley WA, Humphreys WJ. Snow crystals. New York: Dover publications, 1991;pp:1-224.
139. Bigelsen H. Holographic Blood: A new dimension in Medicine. New York: Hemobiographic Publications, 2006;pp:1-148.
140. Konuralp C: "Bilim" ile "İlim" ve Gerçek" ile "Hakikat" arasındaki fark. In: Konuralp C: Bağışıklığın arka bahçesi-2: 'Bilim'in gerçeklerinden 'İlim'in hakikatlerine ve daha derine. İstanbul: Hayygrup Yayıncılık AŞ, 2024; pp:38-56.



KALP VE DAMAR CERRAHİSİNDE REJENERATİF TEDAVİLER

DOI: 10.37609/akya.3889.c5391

BÖLÜM 69

Günseli ÇUBUKÇUOĞLU DENİZ ¹

Fatma AKÇA ²

Ümmü Nur VAR ³

Ali ARDAKANI ⁴

Salih Anıl BOĞA ⁵

Elif Ezel KADİROĞLU ⁶

Çağdaş BARAN ⁷

Ahmet Rüçhan AKAR ⁸

İçindekiler

- » GİRİŞ
- » REJENERATİF TIBBIN TEMELLERİ
- » KALP CERRAHİSİNDE KÖK HÜCRE TEMELLİ YAKLAŞIMLAR
- » KULLANILAN KÖK HÜCRE TÜRLERİ VE İ
 - » Mezenkimal Kök Hücreler
 - » Pluripotent Kök Hücreler: iPSC ve ESC
 - » Kardiyak Progenitor Hücreler (CPC)
- » HÜCRE SİZ REJENERATİF YAKLAŞIMLAR: EKZOZOMLAR
- » MOLEKÜLER MEKANİZMALAR VE SİNYAL YOLAKLARI
- » DOKU MÜHENDİSLİĞİ VE BİYOMATERYAL YAKLAŞIMLAR
 - » Tüm-Organ Deselülerizasyon Yaklaşımı
 - » Klinik Uygulamalar İçin Zorluklar
- » KALP CERRAHİSİNDE KÖK HÜCRE TEMELLİ YAKLAŞIMLAR
 - » Akut Miyokard Enfarktüsünde Klinik Çalışmalar
 - » Kronik Kalp Yetmezliği ve Kardiyomiyopati Çalışmaları
 - » Hiberne Miyokardın Önemi
 - » Cerrahi Uygulamalarda Entegrasyon
- » DAMAR CERRAHİSİNDE REJENERATİF UYGULAMALAR
- » LENFÖDEMDE KÖK HÜCRE TEMELLİ YAKLAŞIMLAR
- » GELECEK PERSPEKTİFLERİ VE KİŞİSELLEŞTİRİLMİŞ TIP
- » SONUÇ

¹ Öğr. Gör. Dr., Ankara Üniversitesi Kök Hücre Enstitüsü, Kök Hücre ve Yenileyici Tıp AD., gdeniz@ankara.edu.tr, ORCID iD: 0000-0002-2407-2450

² Op. Dr., Kırıkkale Yüksek İhtisas Hastanesi, Kalp ve Damar Cerrahisi Kliniği, akcaafatma@gmail.com, ORCID iD: 0000-0001-5633-9933

³ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kalp ve Damar Cerrahisi AD., unvar@ankara.edu.tr, ORCID iD: 0000-0001-5993-0163

⁴ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kalp ve Damar Cerrahisi AD., aardakani@ankara.edu.tr, ORCID iD: 0009-0003-0721-3519

⁵ Op. Dr., Ankara Üniversitesi Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kalp ve Damar Cerrahisi AD., salihanil.boga@saglik.gov.tr, ORCID iD: 0000-0002-6657-0810

⁶ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kalp ve Damar Cerrahisi AD., eekadiroglu@ankara.edu.tr, ORCID iD: 0000-0002-0224-5138

⁷ Doç. Dr., Ankara Üniversitesi Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kalp ve Damar Cerrahisi AD., cbaran@ankara.edu.tr, ORCID iD: 0000-0003-4079-4442

⁸ Prof. Dr., Ankara Üniversitesi Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kalp ve Damar Cerrahisi AD., akar@ankara.edu.tr, ORCID iD: 0000-0002-5191-5505,

Sonuç olarak, rejeneratif tıp, kardiyovasküler cerrahi pratiğinde yalnızca destekleyici değil, aynı zamanda hastalığın seyrini değiştirme potansiyeline sahip yenilikçi bir tedavi paradigması olarak görülmektedir.

KAYNAKLAR

1. Collaborators GBDELE. Changing life expectancy in European countries 1990-2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021. *Lancet Public Health*. 2025;10(3):e172-e88.
2. Jagannathan R, Patel SA, Ali MK, Narayan KMV. Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors. *Curr Diab Rep*. 2019;19(7):44.
3. Zhu XY, Shi MQ, Jiang ZM, Xiao L, Tian JW, Su FF. Global, regional, and national burden of cardiovascular diseases attributable to metabolic risks across all age groups from 1990 to 2021: an analysis of the 2021 global burden of disease study data. *BMC Public Health*. 2025;25(1):1704.
4. Swift SL, O'Donnell L, Horn B, Kezios K, Elfassy T, Reagan J, et al. State adoption of paid sick leave and cardiovascular disease mortality among adults in the United States, 2008-2019. *J Public Health Policy*. 2025;46(1):53-70.
5. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022;79(17):e263-e421.
6. Mason C, Dunnill P. A brief definition of regenerative medicine. *Regen Med*. 2008;3(1):1-5.
7. Pfister O, Della Verde G, Liao R, Kuster GM. Regenerative therapy for cardiovascular disease. *Transl Res*. 2014;163(4):307-20.
8. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, et al. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med*. 2001;344(23):1750-7.
9. Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, Nadal-Ginard B, et al. Chimerism of the transplanted heart. *N Engl J Med*. 2002;346(1):5-15.
10. Wu H, Lan Q, He YX, Xue JY, Liu H, Zou Y, et al. Programmed cardiomyocyte death in myocardial infarction. *Apoptosis*. 2025;30(3-4):597-615.
11. Schachinger V, Erbs S, Elsasser A, Haberbusch W, Hambrecht R, Holschermann H, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. *Eur Heart J*. 2006;27(23):2775-83.
12. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOW transfer to enhance ST-elevation infarct regeneration) trial. *Circulation*. 2006;113(10):1287-94.
13. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. *JAMA*. 2012;308(22):2380-9.
14. Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, et al. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. *Tex Heart Inst J*. 2010;37(4):412-20.
15. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomized, double blind phase 1 trial. *Lancet*. 2012;379(9819):895-904.
16. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *JAMA*. 2012;308(22):2369-79.
17. Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. *Eur Heart J*. 2017;38(9):648-60.
18. Johnston PV, Raval AN, Henry TD, Traverse JH, Pepine CJ. Dare to dream? Cell-based therapies for heart failure after DREAM-HF: Review and roadmap for future clinical study. *Am Heart J Plus*. 2022;13:100118.
19. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. *J Am Coll Cardiol*. 2002;39(7):1151-8.
20. Ali SA, Mahmood Z, Mubarak Z, Asad M, Sarfraz Chaudhri MT, Bilal L, et al. Assessing the Potential Benefits of Stem Cell Therapy in Cardiac Regeneration for Patients With Ischemic Heart Disease. *Cureus*. 2025;17(1):e76770.
21. Poliwoda S, Noor N, Downs E, Schaaf A, Cantwell A, Ganti L, et al. Stem cells: a comprehensive review of origins and emerging clinical roles in medical practice. *Orthop Rev (Pavia)*. 2022;14(3):37498.
22. Ayavoo T, Murugesan K, Gnanasekaran A. Roles and mechanisms of stem cell in wound healing. *Stem Cell Investig*. 2021;8:4.
23. Noorabadi P, Shahabi Rabori V, Jamali S, Jafari N, Sabeiryan M. An overview on cardiac regeneration revolution: exploring the promise of stem cell therapies. *Mol Biol Rep*. 2025;52(1):511.
24. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science*. 1999;284(5411):143-7.
25. Xu M, Wani M, Dai YS, Wang J, Yan M, Ayub A, et al. Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes. *Circulation*. 2004;110(17):2658-65.
26. Xiang Q, Yi X, Zhu XH, Wei X, Jiang DS. Regulated cell death in myocardial ischemia-reperfusion injury. *Trends Endocrinol Metab*. 2024;35(3):219-34.

27. Mias C, Lairez O, Trouche E, Roncalli J, Calise D, Seguelas MH, et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. *Stem Cells*. 2009;27(11):2734-43.
28. Wen Z, Mai Z, Zhu X, Wu T, Chen Y, Geng D, et al. Mesenchymal stem cell-derived exosomes ameliorate cardiomyocyte apoptosis in hypoxic conditions through microRNA144 by targeting the PTEN/AKT pathway. *Stem Cell Res Ther*. 2020;11(1):36.
29. Song Y, Wang B, Zhu X, Hu J, Sun J, Xuan J, et al. Human umbilical cord blood-derived MSCs exosome attenuate myocardial injury by inhibiting ferroptosis in acute myocardial infarction mice. *Cell Biol Toxicol*. 2021;37(1):51-64.
30. Wang T, Li T, Niu X, Hu L, Cheng J, Guo D, et al. ADS-C-derived exosomes attenuate myocardial infarction injury by promoting miR-205-mediated cardiac angiogenesis. *Biol Direct*. 2023;18(1):6.
31. Scharf Y, Rotem I, Caller T, Lewis N, Shaihov-Teper O, Brzezinski RY, et al. CRISPR-Cas9 editing of TLR4 to improve the outcome of cardiac cell therapy. *Sci Rep*. 2023;13(1):4481.
32. Garbern JC, Lee RT. Cardiac stem cell therapy and the promise of heart regeneration. *Cell Stem Cell*. 2013;12(6):689-98.
33. Schaun MI, Eibel B, Kristocheck M, Sausen G, Machado L, Koche A, et al. Cell Therapy in Ischemic Heart Disease: Interventions That Modulate Cardiac Regeneration. *Stem Cells Int*. 2016;2016:2171035.
34. Pawani H, Bhartiya D. Pluripotent stem cells for cardiac regeneration: overview of recent advances & emerging trends. *Indian J Med Res*. 2013;137(2):270-82.
35. Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S, et al. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. *Eur Heart J*. 2016;37(23):1789-98.
36. Demurtas J, Fanelli GN, Romano SL, Solari M, Yang L, Soysal P, et al. Stem cells for treatment of cardiovascular diseases: An umbrella review of randomized controlled trials. *Ageing Res Rev*. 2021;67:101257.
37. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006;126(4):663-76.
38. Cyganek L, Tiburcy M, Sekeres K, Gerstenberg K, Bohnenberger H, Lenz C, et al. Deep phenotyping of human induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes. *JCI Insight*. 2018;3(12).
39. Denning C, Borgdorff V, Crutchley J, Firth KS, George V, Kalra S, et al. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. *Biochim Biophys Acta*. 2016;1863(7 Pt B):1728-48.
40. Theodoris CV, Zhou P, Liu L, Zhang Y, Nishino T, Huang Y, et al. Network-based screen in iPSC-derived cells reveals therapeutic candidate for heart valve disease. *Science*. 2021;371(6530).
41. Jiang L, Liang J, Huang W, Ma J, Park KH, Wu Z, et al. CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy. *Mol Ther*. 2022;30(1):54-74.
42. Inacio JM, Nunes MM, Almeida M, Cristo F, Anjos R, Belo JA. Gene-Edited Human-Induced Pluripotent Stem Cell Lines to Elucidate DAND5 Function throughout Cardiac Differentiation. *Cells*. 2023;12(4).
43. Bryl R, Kulus M, Bryja A, Domagala D, Mozdziak P, Antosik P, et al. Cardiac progenitor cell therapy: mechanisms of action. *Cell Biosci*. 2024;14(1):30.
44. Witman N, Sahara M. Cardiac Progenitor Cells in Basic Biology and Regenerative Medicine. *Stem Cells Int*. 2018;2018:8283648.
45. Kanazawa H, Tseliou E, Malliaras K, Yee K, Dawkins JF, De Couto G, et al. Cellular postconditioning: allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. *Circ Heart Fail*. 2015;8(2):322-32.
46. Abou-Saleh H, Zouein FA, El-Yazbi A, Sanoudou D, Raynaud C, Rao C, et al. The march of pluripotent stem cells in cardiovascular regenerative medicine. *Stem Cell Res Ther*. 2018;9(1):201.
47. Jiang Y, Lian XL. Heart regeneration with human pluripotent stem cells: Prospects and challenges. *Bioact Mater*. 2020;5(1):74-81.
48. Balbi C, Bollini S. Fetal and perinatal stem cells in cardiac regeneration: Moving forward to the paracrine era. *Placenta*. 2017;59:96-106.
49. Kumar R, Mishra N, Tran T, Kumar M, Vijayaraghavalu S, Gurusamy N. Emerging Strategies in Mesenchymal Stem Cell-Based Cardiovascular Therapeutics. *Cells*. 2024;13(10).
50. Shouman S, Zaher A, Abdelhameed A, Elshaboury S, Sakr S, Fouda BE, et al. Cardiac Progenitor Cells. *Adv Exp Med Biol*. 2021;1312:51-73.
51. Yan W, Xia Y, Zhao H, Xu X, Ma X, Tao L. Stem cell-based therapy in cardiac repair after myocardial infarction: Promise, challenges, and future directions. *J Mol Cell Cardiol*. 2024;188:1-14.
52. Yuan Y, Du W, Liu J, Ma W, Zhang L, Du Z, et al. Stem Cell-Derived Exosome in Cardiovascular Diseases: Macro Roles of Micro Particles. *Front Pharmacol*. 2018;9:547.
53. Lazar E, Benedek T, Korodi S, Rat N, Lo J, Benedek I. Stem cell-derived exosomes - an emerging tool for myocardial regeneration. *World J Stem Cells*. 2018;10(8):106-15.
54. Gartz M, Strande JL. Examining the Paracrine Effects of Exosomes in Cardiovascular Disease and Repair. *J Am Heart Assoc*. 2018;7(11).
55. Pan W, Zhu Y, Meng X, Zhang C, Yang Y, Bei Y. Immunomodulation by Exosomes in Myocardial Infarction. *J Cardiovasc Transl Res*. 2019;12(1):28-36.
56. Li N, Rochette L, Wu Y, Rosenblatt-Velin N. New Insights into the Role of Exosomes in the Heart After Myocardial Infarction. *J Cardiovasc Transl Res*. 2019;12(1):18-27.
57. Barile L, Moccetti T, Marban E, Vassalli G. Roles of exosomes in cardioprotection. *Eur Heart J*. 2017;38(18):1372-9.
58. Rezaie J, Rahbarghazi R, Pezeshki M, Mazhar M, Yekani F, Khaksar M, et al. Cardioprotective role of extracellular vesicles: A highlight on exosome beneficial effects in cardiovascular diseases. *J Cell Physiol*. 2019;234(12):21732-45.
59. He N, Zhang Y, Zhang S, Wang D, Ye H. Exosomes:

- Cell-Free Therapy for Cardiovascular Diseases. *J Cardiovasc Transl Res.* 2020;13(5):713-21.
60. Xin M, Olson EN, Bassel-Duby R. Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. *Nat Rev Mol Cell Biol.* 2013;14(8):529-41.
61. Guo QY, Yang JQ, Feng XX, Zhou YJ. Regeneration of the heart: from molecular mechanisms to clinical therapeutics. *Mil Med Res.* 2023;10(1):18.
62. Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, et al. Signaling pathways and targeted therapy for myocardial infarction. *Signal Transduct Target Ther.* 2022;7(1):78.
63. Rizzo P, Mele D, Caliceti C, Pannella M, Fortini C, Clementz AG, et al. The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors. *Front Oncol.* 2014;4:384.
64. Samakova A, Gazova A, Sabova N, Valaskova S, Jurikova M, Kyselovic J. The PI3k/Akt pathway is associated with angiogenesis, oxidative stress and survival of mesenchymal stem cells in pathophysiologic condition in ischemia. *Physiol Res.* 2019;68(Suppl 2):S131-S8.
65. Aisagbonhi O, Rai M, Ryzhov S, Atria N, Feoktistov I, Hatzopoulos AK. Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. *Dis Model Mech.* 2011;4(4):469-83.
66. Ozhan G, Weidinger G. Wnt/beta-catenin signaling in heart regeneration. *Cell Regen.* 2015;4(1):3.
67. Lin Z, Zhou P, von Gise A, Gu F, Ma Q, Chen J, et al. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. *Circ Res.* 2015;116(1):35-45.
68. Zhang Z, Yang Z, Wang S, Wang X, Mao J. Targeting MAPK-ERK/JNK pathway: A potential intervention mechanism of myocardial fibrosis in heart failure. *Biomed Pharmacother.* 2024;173:116413.
69. Dronkers E, Wauters MMM, Goumans MJ, Smits AM. Epicardial TGFbeta and BMP Signaling in Cardiac Regeneration: What Lesson Can We Learn from the Developing Heart? *Biomolecules.* 2020;10(3).
70. Zimmermann WH, Melnychenko I, Wasmeier G, Didie M, Naito H, Nixdorff U, et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. *Nat Med.* 2006;12(4):452-8.
71. Zimmermann WH, Cesnjevar R. Cardiac tissue engineering: implications for pediatric heart surgery. *Pediatr Cardiol.* 2009;30(5):716-23.
72. Naito Y, Williams-Fritze M, Duncan DR, Church SN, Hibino N, Madri JA, et al. Characterization of the natural history of extracellular matrix production in tissue-engineered vascular grafts during neovessel formation. *Cells Tissues Organs.* 2012;195(1-2):60-72.
73. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. *Nat Med.* 2008;14(2):213-21.
74. Wainwright JM, Czajka CA, Patel UB, Freytes DO, Tobita K, Gilbert TW, et al. Preparation of cardiac extracellular matrix from an intact porcine heart. *Tissue Eng Part C Methods.* 2010;16(3):525-32.
75. Oberwallner B, Brodarac A, Choi YH, Saric T, Anic P, Morawietz L, et al. Preparation of cardiac extracellular matrix scaffolds by decellularization of human myocardium. *J Biomed Mater Res A.* 2014;102(9):3263-72.
76. Ng SL, Narayanan K, Gao S, Wan AC. Lineage restricted progenitors for the repopulation of decellularized heart. *Biomaterials.* 2011;32(30):7571-80.
77. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med.* 1999;5(4):434-8.
78. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science.* 1997;275(5302):964-7.
79. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet.* 2002;360(9331):427-35.
80. Walter DH, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schluter M, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). *Circ Cardiovasc Interv.* 2011;4(1):26-37.
81. Idei N, Soga J, Hata T, Fujii Y, Fujimura N, Mikami S, et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. *Circ Cardiovasc Interv.* 2011;4(1):15-25.
82. Hirakawa S, Hong YK, Harvey N, Schacht V, Matsuda K, Libermann T, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. *Am J Pathol.* 2003;162(2):575-86.
83. Kataru RP, Kim H, Jang C, Choi DK, Koh BI, Kim M, et al. T lymphocytes negatively regulate lymph node lymphatic vessel formation. *Immunity.* 2011;34(1):96-107.
84. Toyserkani NM, Jensen CH, Sheikh SP, Sorensen JA. Cell-Assisted Lipotransfer Using Autologous Adipose-Derived Stromal Cells for Alleviation of Breast Cancer-Related Lymphedema. *Stem Cells Transl Med.* 2016;5(7):857-9.
85. Kang HJ, Moon SY, Kim BK, Myung Y, Lee JH, Jeong JH. Recellularized lymph node scaffolds with human adipose-derived stem cells enhance lymph node regeneration to improve lymphedema. *Sci Rep.* 2023;13(1):5397.



KALP TRANSPLANTASYONUNDA İMMÜNOLOJİ VE İMMÜNOSUPRESYON

BÖLÜM 70

Kaan KIRALI¹
Hakan HANÇER²

DOI: 10.37609/akya.3889.c5392

İçindekiler

- » GENEL BİLGİLER
- » ALLOTRANSPLANTASYONDA TEMEL İMMÜNOLOJİ
- » İMMUN CEVAP
 - » Humoral Cevap (B-Lenfositler)
 - » Hücresel Cevap (T-Lenfositler)
- » ALLOGREFT REJEKSİYONUNDA HİSTOPATOLOJİ
 - » Endomiyokardiyal Biyopsi
 - » Akut Allograft Rejeksiyonu
 - » Hiperakut Allograft Rejeksiyonu
 - » Kronik Allograft Rejeksiyonu
- » ALLOGREFT REJEKSİYONUNUN TANISI
- » İMMÜNSUPRESYON
 - » Kortikosteroidler
 - » mTOR İnhibitörleri
 - » Azatioprin
 - » Mikofenolat Mofetil
 - » Anti-Lenfosit ve Anti-Timosit Globulinler
 - » OKT3
 - » Anti-CD25
- » ALLOGREFT REJEKSİYONUN ÖNLENMESİ
 - » Greftin İmmünojenitesinin Azaltılması
 - » Alıcı İmmün Sisteminin Baskılanması
- » ALLOGREFT İMMÜNSUPRESİF TEDAVİ ALGORTİMASI
 - » İndüksiyon Dönemi (peroperatif yükleme)
 - » Erken İdame Dönemi (postoperatif ilk 15 gün)
 - » Hiperakut Rejeksiyon Tedavisi
 - » Akut Rejeksiyon Tedavisi

¹ Prof. Dr., SBÜ, İstanbul Kartal Koşuyolu Yüksek İhtisas Sağlık Uygulama ve Araştırma Merkezi, Kalp ve Damar Cerrahisi AD., imkbkiralı@yahoo.com, ORCID iD: 0000-0003-0044-4691

² Uzm. Dr., SBÜ, İstanbul Kartal Koşuyolu Yüksek İhtisas Sağlık Uygulama ve Araştırma Merkezi, Kalp ve Damar Cerrahisi AD., hhancertr@yahoo.com, ORCID iD: 0000-0002-8823-819X

eklenmesi) düşünülmelidir. Humoral rejeksiyon sonrası tekrar DSA düzeyleri ve kompleman C4d birikimi de izlenmelidir. Rejeksiyonun tamamen kontrol altına alınamaması durumunda mekanik destek tedavileri gündeme gelir.

Son yıllarda, rejeksiyon tedavisinde **biyobelirteç temelli kişiselleştirilmiş yaklaşım** önerilmektedir. Özellikle **granzyme B, perforin mRNA düzeyleri, donör-derived cell-free DNA (dd-cfDNA), troponin I ve NT-proBNP** gibi parametreler, rejeksiyonun erken tespitinde yardımcı olmakta ve tedaviye yanıtın değerlendirilmesinde kullanılmaktadır. Örneğin dd-cfDNA düzeylerinin %0.2 üzerine çıkması akut rejeksiyon göstergesi sayılabilir. Bu nedenle biyobelirteçlere dayalı algoritmalar, özellikle subklinik rejeksiyonları erken evrede tespit etmede yardımcıdır. Ayrıca rejeksiyon sırasında sistemik sitokin düzeylerinin artışı (IL-2, IFN- γ , TNF- α) da sitokin soğurma filtrelerinin destekleyici tedavi olarak kullanılmasını gündeme getirmiştir.

KAYNAKLAR

1. Ahmed T, Jain A. Heart Transplantation. 2023 May 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. PMID: 32491503.
2. Sayegh MH, Carpenter CB. Transplantation 50 years later—progress, challenges, and promises. *N Engl J Med*. 2004;351(26):2761-6. doi: 10.1056/NEJMon043418.
3. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*. 2023;42(5):e1-e141. doi: 10.1016/j.healun.2022.10.015.
4. Tolou-Ghamari Z. Tacrolimus and cyclosporin pharmacotherapy, detection methods, cytochrome P450 enzymes after heart transplantation. *Cardiovasc Hematol Agents Med Chem*. 2024;22(2):106-113. doi: 10.2174/1871525721666230726150021.
5. Dwyer, Gaelen K., and Hëth R. Turnquist. "Untangling local pro-inflammatory, reparative, and regulatory damage-associated molecular-patterns (DAMPs) pathways to improve transplant outcomes." *Frontiers in Immunology* 12 (2021): 611910.
6. Sacks SH, Chowdhury P, Zhou W. Role of the complement system in rejection. *Curr Opin Immunol*. 2003;15(5):487-92. doi: 10.1016/s0952-7915(03)00100-6.
7. Firoz A, Geier S, Yanagida R, et al. Heart transplant human leukocyte antigen matching in the modern era. *J Card Fail*. 2024;30(2):362-372. doi: 10.1016/j.cardfail.2023.06.016.
8. Starzl TE. History of clinical transplantation. *World J Surg*. 2000;24(7):759-82. doi: 10.1007/s002680010124.
9. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. *Immunol Rev*. 2003;196:125-46. doi: 10.1046/j.1600-065x.2003.00079.x.
10. Tambur AR, Claas FH. HLA epitopes as viewed by antibodies: what is it all about? *Am J Transplant*. 2015;15(5):1148-54. doi: 10.1111/ajt.13192.
11. Thurman JM, Panzer SE, Le Quintrec M. The role of complement in antibody mediated transplant rejection. *Mol Immunol*. 2019;112:240-246. doi: 10.1016/j.molimm.2019.06.002.
12. García-Villegas R, Arni S. Hemoadsorption in organ preservation and transplantation: a narrative review. *Life (Basel)*. 2023;14(1):65. doi: 10.3390/life14010065.
13. Ronco C, Bagshaw SM, Bellomo R, et al. Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 Pandemic: Expert Review and Recommendation. *Blood Purif*. 2021;50(1):17-27. doi: 10.1159/000508125.
14. Firoz A, Geier S, Yanagida R, et al. Heart transplant human leukocyte antigen matching in the modern era. *J Card Fail*. 2024;30(2):362-372. doi: 10.1016/j.cardfail.2023.06.016.
15. Ahmed T, Goyal A. Endomyocardial Biopsy. 2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. PMID: 32491529.
16. Lee DH, Usmani A, Wu R, et al. Relationship between donor-derived cell-free DNA and tissue-based rejection-related transcripts in heart transplantation. *J Heart Lung Transplant*. 2024;43(7):1118-1125. doi: 10.1016/j.healun.2024.02.011.
17. Beck-da-Silva L, Bridi LH, Matte BS, Valle FH. Endomyocardial biopsy using rigid bioprobe technique and the risk of tricuspid regurgitation after heart transplantation. *Arq Bras Cardiol*. 2024;121(10):e20240223. doi: 10.36660/abc.20240223.
18. Marrón-Liñares GM, Núñez L, Crespo-Leiro MG, et al. Polymorphisms in genes related to the complement system and antibody-mediated cardiac allograft rejection. *J Heart Lung Transplant*. 2018;37(4):477-485. doi: 10.1016/j.healun.2017.07.006.
19. Kim JV, Assadian S, Hollander Z, et al. Regulatory T cell biomarkers identify patients at risk of developing acute cellular rejection in the first year following heart transplantation. *Transplantation*. 2023;107(8):1810-1819. doi: 10.1097/TP.0000000000004607.
20. Szymanska S, Grajkowska W, Sobieszczyńska-Malek M, Zielinski T, Pyzlak M, Pronicki M. Prevalence of the Quilty effect in endomyocardial biopsy of patients after heart transplantation - from cellular rejection to antibody-mediated rejection? *Pol J Pathol*. 2016;67(3):216-220. doi: 10.5114/pjp.2016.63772.
21. Orang E, Sayyahfar S, Mahdavi M, Khanaliha K, Amiri M. Comparison of serologic status of Toxoplasma gondii infection in pre- and post-heart transplantation in a pediatric population: A preliminary study. *Transpl Infect Dis*. 2020 g;22(4):e13339. doi: 10.1111/tid.13339.
22. Sperry BW, Zein RE, Fendler TJ, et al. Stabilization of rapidly progressive cardiac allograft vasculopathy using mTOR inhibition after heart transplantation. *J Card Fail*. 2024;30(4):613-617. doi: 10.1016/j.cardfail.2023.10.483.
23. Usman AA, Taimen K, Wasielewski M, et al. Cardiac magnetic resonance T2 mapping in the monitoring and

- follow-up of acute cardiac transplant rejection: a pilot study. *Circ Cardiovasc Imaging*. 2012;5(6):782-90. doi: 10.1161/CIRCIMAGING.111.971101.
24. Randhawa MK, Sultana S, Stib MT, Nagpal P, Michel E, Hedgire S. Role of radiology in assessment of post-operative complications of heart transplantation. *Radiol Clin North Am*. 2024;62(3):453-471. doi: 10.1016/j.rcl.2023.12.002.
25. Habal M. Immunosuppression Management in Heart Transplantation. *Methodist Debakey Cardiovasc J*. 2025;21(3):40-50. doi: 10.14797/mdcvj.1596.
26. Kugathasan L, Rayner DG, Wang SM, et al. Induction therapy in heart transplantation: A systematic review and network meta-analysis for developing evidence-based recommendations. *Clin Transplant*. 2024;38(5):e15326. doi: 10.1111/ctr.15326. PMID: 38716786.
27. Söderlund C, Rådegran G. Immunosuppressive therapies after heart transplantation--The balance between under- and over-immunosuppression. *Transplant Rev (Orlando)*. 2015;29(3):181-9. doi: 10.1016/j.tre.2015.02.005.
28. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. *Circulation*. 2004;110(25):3858-65. doi: 10.1161/01.CIR.0000150332.42276.69.
29. Heegaard B, Nelson LM, Gustafsson F. Steroid withdrawal after heart transplantation in adults. *Transpl Int*. 2021;34(12):2469-2482. doi: 10.1111/tri.14142.
30. Dashti-Khavidaki S, Saidi R, Lu H. Current status of glucocorticoid usage in solid organ transplantation. *World J Transplant*. 2021 Nov 18;11(11):443-465. doi: 10.5500/wjt.v11.i11.443.
31. Bartz-Overman C, Li S, Puligandla B, Colaco N, Steiner J, Masha L. Two case reports of fulminant giant cell myocarditis treated with rabbit anti-thymocyte globulin. *Eur Heart J Case Rep*. 2024;8(4):ytac128. doi: 10.1093/ehjcr/ytac128.
32. Sivathanan C. Experience with cyclosporine in heart transplantation. *Transplant Proc*. 2004 Mar;36(2 Suppl):346S-348S. doi: 10.1016/j.transproceed.2004.01.072.
33. Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. *Transplant Proc*. 2004;36(2 Suppl):396S-403S. doi: 10.1016/j.transproceed.2004.01.013.
34. Abd-Eldayem AM, Makram SM, Messiha BAS, Abd-Elhafeez HH, Abdel-Reheim MA. Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF- α , NF- κ B, and Bax. *Sci Rep*. 2024;14(1):7434. doi: 10.1038/s41598-024-57300-x.
35. Taler SJ, Textor SC, Canzanella VJ, Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. *Drug Saf*. 1999;20(5):437-49. doi: 10.2165/00002018-199920050-00004. PMID: 10348094.
36. Sikma MA, van Maarseveen EM, van de Graaf EA, et al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation. *Am J Transplant*. 2015;15(9):2301-13. doi: 10.1111/ajt.13309.
37. Guethoff S, Meiser BM, Groetzner J, et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine in a combination with mycophenolate mofetil after heart transplantation. *Transplantation*. 2013;95(4):629-34. doi: 10.1097/TP.0b013e318277e378.
38. Tory R, Sachs-Barrable K, Goshko CB, Hill JS, Wasan KM. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. *Transplantation*. 2009;88(1):62-8. doi: 10.1097/TP.0b013e3181aa7d04.
39. Topilsky Y, Hasin T, Raichlin E, et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. *Circulation*. 2012;125(5):708-20. doi: 10.1161/CIRCULATIONA-HA.111.040360.
40. Mabasa VH, Ensom MH. The role of therapeutic monitoring of everolimus in solid organ transplantation. *Ther Drug Monit*. 2005;27(5):666-76. doi: 10.1097/01.ftd.0000175911.70172.2e.
41. Arora S, Ueland T, Wennerblom B, et al. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. *Transplantation*. 2011;92(2):235-43. doi: 10.1097/TP.0b013e31822057f1.
42. Mohammadi O, Kassim TA. Azathioprine. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
43. Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and risk of skin cancer in organ transplant recipients: Systematic Review and Meta-Analysis. *Am J Transplant*. 2016;16(12):3490-3503. doi: 10.1111/ajt.13863.
44. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Mycophenolate.
45. Al-Khouja A, Chaudhri N, Velidedeoglu E, Belen O, Bi Y, Doddapaneni S, Chen J. Approval of mycophenolate mofetil for prophylaxis of organ rejection in pediatric recipients of heart or liver transplants: A Regulatory Perspective. *Clin Pharmacol Ther*. 2024;116(3):807-813. doi: 10.1002/cpt.3288.
46. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. *Leukemia*. 2007;21(7):1387-94. doi: 10.1038/sj.leu.2404683.
47. Xia CQ, Chernatynskaya AV, Wasserfall CH, et al. Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice. *BMC Immunol*. 2012 ;13:70. doi: 10.1186/1471-2172-13-70.
48. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. *Drugs*. 1996;51(5):865-94. doi: 10.2165/00003495-199651050-00010.
49. Rudzik KN, Rivosecchi RM, Palmer BA, et al. Basiliximab induction versus no induction in adult heart transplantation. *Clin Transplant*. 2023;37(5):e14937. doi: 10.1111/ctr.14937.
50. Chen TT, Greene MM, Everitt MD, Simpson KE. Basiliximab as maintenance immunosuppression in heart transplant recipients: A single pediatric center experience. *Pediatr Transplant*. 2023 Mar;27(2):e14438. doi: 10.1111/petr.14438. Epub 2022 Nov 17. PMID: 36397270.



İNTRATORASİK ORGAN PREZERVASYONU

BÖLÜM 71

Ayhan GÜNEŞ¹
Sabit SARIKAYA²
Kaan KIRALI³

DOI: 10.37609/akya.3889.c5393

İçindekiler

- » GİRİŞ
- » Hücre Metabolizması
- » KALP PREZERVASYONU
- » MİYOKARDİYAL PREZERVASYONDA TEMEL PRENSİPLER
 - » Isı Kontrolü
 - » Enerji Metabolizmasının Desteklenmesi
 - » Oksidatif Stresin Azaltılması
 - » Reperfüzyon Hasarının Önlenmesi
- » MİYOKARD PREZERVASYONUNUN DÖNEMLERİ
 - » Donör Hazırlık Dönemi
 - » İskemi Dönemi
 - » Reperfüzyon Dönemi
 - » Donör Kalp Transfer Yöntemleri
- » KALP-AKCIĞER NAKLİNDE AKCIĞER PREZERVASYONU
 - » Akciğer Prezervasyonunun Temel Amaçları
 - » Akciğer Prezervasyon Teknikleri
 - » Akciğer Prezervasyon Solüsyonları
 - » Reperfüzyon Hasarı ve Önleme Stratejileri
 - » Gelecek Yöntemler

¹ Op. Dr., Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, dr.ayhangunes@hotmail.com, ORCID iD: 0000-0001-7055-0508

² Prof. Dr., Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, sabitsarikaya@yahoo.com, ORCID iD: 0000-0002-8921-3584

³ Prof. Dr., Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, imkbkiralı@yahoo.com, ORCID iD: 0000-0003-0044-4691

İskemi-reperfüzyon hasarının azaltılması amacıyla, genetik mühendislik ve biyoteknoloji tabanlı stratejiler umut vaat etmektedir. Özellikle antioksidan gen terapileri, inflamatuvar yanıtı baskılayan RNA bazı tedaviler ve hücresel dayanıklılığı artıran biyomühendislik yöntemleri araştırılmaktadır. Gen düzenleme teknikleri (CRISPR-Cas9 gibi), hücresel düzeyde iskemiye karşı dayanıklılığı artıran proteinleri kodlayan genleri aktive edebilir veya zararlı sinyal yollarını inaktif hale getirebilir (81).

Kalp-akciğer nakillerinde akciğer prezervasyonu, transplantasyonun başarısını belirleyen en kritik faktörlerden biridir. Uygun prezervasyon tekniklerinin seçimi, iskemi süresince doku bütünlüğünün korunmasını sağlayarak nakil sonrası komplikasyonları en aza indirir ve organın fonksiyonel kapasitesini artırır. Geleneksel statik soğuk depolama yöntemleri, akciğer saklamada yaygın olarak kullanılsa da makine perfüzyonu, sub-zero koruma stratejileri ve biyoteknolojik yaklaşımlar gibi yenilikçi yöntemler, iskemi-reperfüzyon hasarını azaltarak transplantasyon sonuçlarını iyileştirme potansiyeline sahiptir. Bu gelişmeler, bağışlanan organların daha uzun süre korunmasını sağlarken, marjinal donör akciğerlerinin kullanımını artırarak transplant bekleme listelerindeki hasta sayısının azaltılmasına katkıda bulunabilir. Gelecekte, genetik mühendislik, nanoteknoloji destekli tedaviler ve immünomodülatör yaklaşımlarla desteklenen gelişmiş prezervasyon teknikleri, akciğer transplantasyonlarının uzun vadeli başarısını artırarak hasta yaşam süresi ve kalitesinde önemli iyileşmeler sağlayacaktır.

KAYNAKLAR

1. Lepoittevin M, Giraud S, Kerforne T, et al. Preservation of Organs to Be Transplanted: An Essential Step in the Transplant Process. *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute; 2022;23(9): 4989. doi:10.3390/ijms23094989
2. Maathuis M-HJ, Leuvenink HGD, Ploeg RJ. Perspectives in Organ Preservation. *Transplantation*. 2007;83(10): 1289. doi:10.1097/01.tp.0000265586.66475.cc
3. Pradegan N, Gallo M, Fabozzo A, et al. Nonischemic Donor Heart Preservation: New Milestone in Heart Transplantation History. *ASAIO Journal*. 2023;69(8): 725. doi:10.1097/MAT.0000000000002001
4. Ughetto A, Roubille F, Molina A, et al. Heart graft preservation technics and limits: an update and perspectives. *Frontiers in Cardiovascular Medicine*. 2023;10: 1248606. doi:10.3389/fcvm.2023.1248606
5. Hess NR, Ziegler LA, Kaczorowski DJ. Heart Donation and Preservation: Historical Perspectives, Current Technologies, and Future Directions. *Journal of Clinical Medicine*. Multidisciplinary Digital Publishing Institute; 2022;11(19): 5762. doi:10.3390/jcm11195762
6. Gasmi A, Peana M, Arshad M, et al. Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis. *Archives of Toxicology*. 2021;95(4): 1161–1178. doi:10.1007/s00204-021-02974-9
7. Zheng Y, Sun J, Luo Z, et al. Emerging mechanisms of lipid peroxidation in regulated cell death and its physiological implications. *Cell Death & Disease*. Nature Publishing Group; 2024;15(11): 1–19. doi:10.1038/s41419-024-07244-x
8. Turer AT, Hill JA. Pathogenesis of Myocardial Ischemia-Reperfusion Injury and Rationale for Therapy. *The American Journal of Cardiology*. 2010;106(3): 360–368. doi:10.1016/j.amjcard.2010.03.032
9. Murphy GS, Hessel EA, Groom RC. Optimal perfusion during cardiopulmonary bypass: an evidence-based approach. *Anesthesia and Analgesia*. 2009;108(5): 1394–1417. doi:10.1213/ane.0b013e3181875e2e
10. Vrints CJM. Pathophysiology of the no-reflow phenomenon. *Acute Cardiac Care*. Taylor & Francis; 2009;11(2): 69–76. doi:10.1080/17482940902978061
11. Heusch G. The Coronary Circulation as a Target of Cardioprotection. *Circulation Research*. Lippincott Williams & Wilkins/Hagerstown, MD; 2016; doi:10.1161/CIRC-RESAHA.116.308640
12. Badoe N, Shah P. History of Heart Transplant. In: Bogar L, Stempien-Otero A (eds.) *Contemporary Heart Transplantation*. Cham: Springer International Publishing; 2020. p. 3–12. doi:10.1007/978-3-319-58054-8_1
13. Crawford TC, Magruder JT, Grimm JC, et al. The Paradoxical Relationship Between Donor Distance and Survival After Heart Transplantation. *The Annals of Thoracic Surgery*. 2017;103(5): 1384–1391. doi:10.1016/j.athoracsurg.2017.01.055
14. Gaffey AC, Chen CW, Chung JJ, et al. Extended distance cardiac allograft can successfully be utilized without impacting long-term survival. *The Journal of Heart and Lung Transplantation*. 2017;36(9): 968–972. doi:10.1016/j.healun.2017.04.002
15. Chew HC, Macdonald PS, Dhital KK. The donor heart and organ perfusion technology. *Journal of Thoracic Disease*. 2019;11(Suppl 6): S938–S945. doi:10.21037/jtd.2019.02.59
16. Que W, Hu X, Fujino M, et al. Prolonged Cold Ischemia Time in Mouse Heart Transplantation Using Supercooling Preservation. *Transplantation*. 2020;104(9): 1879. doi:10.1097/TP.0000000000003089
17. Lechiancole A, Sponga S, Benedetti G, et al. Graft preservation in heart transplantation: current approaches. *Frontiers in Cardiovascular Medicine*. 2023;10: 1253579. doi:10.3389/fcvm.2023.1253579
18. Das SN, Chauhan S, Saxena N. Myocardial preservation during cardiac surgery. *Annals of Cardiac Anaesthesia*. 2002;5(1): 25–32.
19. Barth AS, Tomaselli GF. Cardiac Metabolism and Arrhythmias. *Circulation: Arrhythmia and Electrophysiology*.

- 2009;2(3): 327–335. doi:10.1161/CIRCEP.108.817320
20. Watts RP, Thom O, Fraser JF. Inflammatory Signalling Associated with Brain Dead Organ Donation: From Brain Injury to Brain Stem Death and Posttransplant Ischaemia Reperfusion Injury. *Journal of Transplantation*. 2013;2013: 521369. doi:10.1155/2013/521369
21. McKeown DW, Bonser RS, Kellum JA. Management of the heartbeating brain-dead organ donor. *BJA: British Journal of Anaesthesia*. 2012;108(suppl_1): i96–i107. doi:10.1093/bja/aer351
22. Barklin A. Systemic inflammation in the brain-dead organ donor. *Acta Anaesthesiologica Scandinavica*. 2009;53(4): 425–435. doi:10.1111/j.1399-6576.2008.01879.x
23. Anwar ASMT, Lee J. Medical Management of Brain-Dead Organ Donors. *Acute and Critical Care*. 2019;34(1): 14–29. doi:10.4266/acc.2019.00430
24. Kutsogiannis DJ, Pagliarello G, Doig C, et al. Medical management to optimize donor organ potential: review of the literature. *Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie*. 2006;53(8): 820–830. doi:10.1007/BF03022800
25. Braithwaite SA, Kaaij NP van der. New Techniques for Optimization of Donor Lungs/Hearts. *Anesthesiology Clinics*. Elsevier; 2019;37(4): 639–660. doi:10.1016/j.ancin.2019.08.010
26. Güvenç Doğan OK. *Donör Bakımı*. [Online] Turkish Journal of Intensive Care; doi:10.4274/tybd.galenos.2023.50570
27. Blitzer D, Baran DA, Lirette S, et al. Does donor treatment with inotropes and/or vasopressors impact post-transplant outcomes? *Clinical Transplantation*. 2023;37(4): e14912. doi:10.1111/ctr.14912
28. Carter KT, Lirette ST, Baran DA, et al. The Effect of Cardiac Preservation Solutions on Heart Transplant Survival. *Journal of Surgical Research*. Elsevier; 2019;242: 157–165. doi:10.1016/j.jss.2019.04.041
29. Buckberg GD, Athanasuleas CL. Cardioplegia: solutions or strategies? *European Journal of Cardio-Thoracic Surgery*. 2016;50(5): 787–791. doi:10.1093/ejcts/ezw228
30. Cullen PP, Tsui SS, Caplice NM, et al. A state-of-the-art review of the current role of cardioprotective techniques in cardiac transplantation. *Interactive Cardiovascular and Thoracic Surgery*. 2021;32(5): 683–694. doi:10.1093/icvts/ivaa333
31. Minasian SM, Galagudza MM, Dmitriev YV, et al. Preservation of the donor heart: from basic science to clinical studies. *Interactive Cardiovascular and Thoracic Surgery*. 2015;20(4): 510–519. doi:10.1093/icvts/ivu432
32. Salvemini D, Cuzzocrea S. Superoxide, superoxide dismutase and ischemic injury. *Current Opinion in Investigational Drugs (London, England: 2000)*. 2002;3(6): 886–895.
33. Zhou K, Zhang X, Li D, et al. Myocardial Protection With Different Cardioplegia in Adult Cardiac Surgery: A Network Meta-Analysis. *Heart, Lung and Circulation*. 2022;31(3): 420–429. doi:10.1016/j.hlc.2021.09.004
34. Carvajal C, Goyal A, Tadi P. Cardioplegia. *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2025. <http://www.ncbi.nlm.nih.gov/books/NBK554463/>
35. Whittaker A, Aboughdir M, Mahub S, et al. Myocardial protection in cardiac surgery: how limited are the options? A comprehensive literature review. *Perfusion*. 2021;36(4): 338–351. doi:10.1177/0267659120942656
36. Bradić J, Andjić M, Novaković J, et al. Cardioplegia in Open Heart Surgery: Age Matters. *Journal of Clinical Medicine*. Multidisciplinary Digital Publishing Institute; 2023;12(4): 1698. doi:10.3390/jcm12041698
37. Li Y, Guo S, Liu G, et al. Three Preservation Solutions for Cold Storage of Heart Allografts: A Systematic Review and Meta-Analysis. *Artificial Organs*. 2016;40(5): 489–496. doi:10.1111/aor.12585
38. Kaliyev R, Lesbekov T, Bekbossynov S, et al. Comparison of Custodiol vs warm blood cardioplegia and conditioning of donor hearts during transportation with the organ care system. *Journal of Cardiac Surgery*. 2019;34(10): 969–975. doi:10.1111/jocs.14162
39. Lema Zuluaga GL, Serna Agudelo RE, Zuleta Tobón JJ. Preservation solutions for liver transplantation in adults: celsior versus custodiol: a systematic review and meta-analysis with an indirect comparison of randomized trials. *Transplantation Proceedings*. 2013;45(1): 25–32. doi:10.1016/j.transproceed.2012.02.031
40. Qin G, Jernryd V, Sjöberg T, et al. Machine Perfusion for Human Heart Preservation: A Systematic Review. *Transplant International: Official Journal of the European Society for Organ Transplantation*. 2022;35: 10258. doi:10.3389/ti.2022.10258
41. Bryner BS, Schroder JN, Milano CA. Heart transplant advances: Ex vivo organ-preservation systems. *JTCVS Open*. Elsevier; 2021;8: 123–127. doi:10.1016/j.xjon.2021.04.020
42. Mauerhofer C, Grumet L, Schemmer P, et al. Combating Ischemia-Reperfusion Injury with Micronutrients and Natural Compounds during Solid Organ Transplantation: Data of Clinical Trials and Lessons of Preclinical Findings. *International Journal of Molecular Sciences*. 2021;22(19): 10675. doi:10.3390/ijms221910675
43. Safaei N, Sheikhalizadeh MA, Badalzadeh R. Effect of ischemic postconditioning on myocardial protection in patients undergoing coronary artery bypass grafting surgery with cardiopulmonary bypass. *Journal of Cardiovascular and Thoracic Research*. 2016;8(2): 65–71. doi:10.15171/jcvtr.2016.13
44. Sabe SA, Harris DD, Broadwin M, et al. Cardioprotection in cardiovascular surgery. *Basic Research in Cardiology*. 2024;119(4): 545–568. doi:10.1007/s00395-024-01062-0
45. Granger DN, Kvietys PR. Reperfusion injury and reactive oxygen species: The evolution of a concept. *Redox Biology*. 2015;6: 524–551. doi:10.1016/j.redox.2015.08.020
46. Slodzinski MK, Aon AM, O'Rourke B. Glutathione Oxidation as a Trigger of Mitochondrial Depolarization and Oscillation in Intact Hearts. *Journal of molecular and cellular cardiology*. 2008;45(5): 650–660. doi:10.1016/j.yjmcc.2008.07.017
47. Zhang N, Aiyasiding X, Li W, et al. Neutrophil degranulation and myocardial infarction. *Cell Communication and Signaling*. 2022;20(1): 50. doi:10.1186/s12964-022-00824-4
48. Jiang K, Hwa J, Xiang Y. Novel strategies for targeting neutrophil against myocardial infarction. *Pharmacological Research*. 2024;205: 107256. doi:10.1016/j.phrs.2024.107256
49. Naruka V, Salmasi MY, Arjomandi Rad A, et al. Use of Cytokine Filters During Cardiopulmonary Bypass: Systematic Review and Meta-Analysis. *Heart, Lung*

- & *Circulation*. 2022;31(11): 1493–1503. doi:10.1016/j.hlc.2022.07.015
50. Ozgur OS, Namsrai B-E, Pruett TL, et al. Current practice and novel approaches in organ preservation. *Frontiers in Transplantation*. Frontiers; 2023;2. doi:10.3389/frtra.2023.1156845
 51. Kounatidis D, Brozou V, Anagnostopoulos D, et al. Donor Heart Preservation: Current Knowledge and the New Era of Machine Perfusion. *International Journal of Molecular Sciences*. 2023;24(23): 16693. doi:10.3390/ijms242316693
 52. Lerman JB, Agarwal R, Patel CB, et al. Donor Heart Recovery and Preservation Modalities in 2024. *JACC. Heart failure*. 2024;12(3): 427–437. doi:10.1016/j.jchf.2023.10.012
 53. Rega F, Lebreton G, Para M, et al. Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial. *The Lancet*. Elsevier; 2024;404(10453): 670–682. doi:10.1016/S0140-6736(24)01078-X
 54. Nilsson J, Jernryd V, Qin G, et al. A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation. *Nature Communications*. Nature Publishing Group; 2020;11(1): 2976. doi:10.1038/s41467-020-16782-9
 55. Pinnelas R, Kobashigawa JA. Ex vivo normothermic perfusion in heart transplantation: a review of the TransMedics® Organ Care System. *Future Cardiology*. 2022;18(1): 5–15. doi:10.2217/fca-2021-0030
 56. Egle M, Longnus S, Yildiz M, et al. Surgical techniques for cardiac procurement, preparation and perfusion using the Organ Care System. *Multimedia manual of cardiothoracic surgery: MMCTS*. 2024;2024. doi:10.1510/mmcts.2024.057
 57. Wan L, Powell-Palm MJ, Lee C, et al. Preservation of rat hearts in subfreezing temperature isochoric conditions to –8 °C and 78 MPa. *Biochemical and Biophysical Research Communications*. 2018;496(3): 852–857. doi:10.1016/j.bbrc.2018.01.140
 58. Faria I, Canizares S, Devos L, et al. Machine perfusion organ preservation: Highlights from the American Transplant Congress 2023. *Artificial Organs*. 2024;48(7): 794–799. doi:10.1111/aor.14765
 59. Plumblee L, Atkinson C, Jaishankar D, et al. Nanotherapeutics in transplantation: How do we get to clinical implementation? *American Journal of Transplantation*. 2022;22(5): 1293–1298. doi:10.1111/ajt.17012
 60. Chen F, Date H. Update on ischemia-reperfusion injury in lung transplantation. *Current Opinion in Organ Transplantation*. 2015;20(5): 515. doi:10.1097/MOT.0000000000000234
 61. Jungraithmayr W. Novel Strategies for Endothelial Preservation in Lung Transplant Ischemia-Reperfusion Injury. *Frontiers in Physiology*. Frontiers; 2020;11. doi:10.3389/fphys.2020.581420
 62. Hidalgo MA, Shah KA, Fuller BJ, et al. Cold ischemia-induced damage to vascular endothelium results in permeability alterations in transplanted lungs. *The Journal of Thoracic and Cardiovascular Surgery*. 1996;112(4): 1027–1035. doi:10.1016/S0022-5223(96)70104-6
 63. Gao W, Jiang T, Liu Y, et al. Endothelial progenitor cells attenuate the lung ischemia/reperfusion injury following lung transplantation via the endothelial nitric oxide synthase pathway. *The Journal of Thoracic and Cardiovascular Surgery*. 2019;157(2): 803–814. doi:10.1016/j.jtcvs.2018.08.092
 64. Ferrari RS, Andrade CF. Oxidative Stress and Lung Ischemia-Reperfusion Injury. *Oxidative Medicine and Cellular Longevity*. 2015;2015(1): 590987. doi:10.1155/2015/590987
 65. Mathis S, Putzer G, Schneeberger S, et al. The Endothelial Glycocalyx and Organ Preservation—From Physiology to Possible Clinical Implications for Solid Organ Transplantation. *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute; 2021;22(8): 4019. doi:10.3390/ijms22084019
 66. Sack F-U, Dollner R, Reidenbach B, et al. Intravital Microscopy of Pulmonary Microcirculation After Single Lung Transplantation in Pigs. *Transplantation Proceedings*. 2006;38(3): 737–740. doi:10.1016/j.transproceed.2006.01.060
 67. Niroomand A, Hirdman G, Pierre L, et al. Proteomic changes to immune and inflammatory processes underlie lung preservation using ex vivo cytokine adsorption. *Frontiers in Cardiovascular Medicine*. Frontiers; 2023;10. doi:10.3389/fcvm.2023.1274444
 68. Lindstedt S, Silverborn M, Lannemyr L, et al. Design and Rationale of Cytokine Filtration in Lung Transplantation (GLUSorb): Protocol for a Multicenter Clinical Randomized Controlled Trial. *JMIR Research Protocols*. 2023;12(1): e52553. doi:10.2196/52553
 69. Götzfried J, Smirnova NF, Morrone C, et al. Preservation with α 1-antitrypsin improves primary graft function of murine lung transplants. *The Journal of Heart and Lung Transplantation*. 2018;37(8): 1021–1028. doi:10.1016/j.healun.2018.03.015
 70. Cypel M, Rubacha M, Yeung J, et al. Normothermic Ex Vivo Perfusion Prevents Lung Injury Compared to Extended Cold Preservation for Transplantation. *American Journal of Transplantation*. 2009;9(10): 2262–2269. doi:10.1111/j.1600-6143.2009.02775.x
 71. Halpern SE, Kesseli SJ, Au S, et al. Lung transplantation after ex vivo lung perfusion versus static cold storage: An institutional cost analysis. *American Journal of Transplantation*. 2022;22(2): 552–564. doi:10.1111/ajt.16794
 72. Burlage LC, Karimian N, Westerkamp AC, et al. Oxygenated hypothermic machine perfusion after static cold storage improves endothelial function of extended criteria donor livers. *HPB*. 2017;19(6): 538–546. doi:10.1016/j.hpb.2017.02.439
 73. Hoetzenecker K, Benazzo A, Schwarz S, et al. The Advent of Semi-Selective Lung Transplantation—Prolonged Static Cold Storage at 10°C. *Transplant International*. Frontiers Publishing Partnerships; 2024;37: 12310. doi:10.3389/ti.2024.12310
 74. Wu M, Yang Q, Yim APC, et al. Cellular electrophysiologic and mechanical evidence of superior vascular protection in pulmonary microcirculation by Perfadex compared with Celsior. *The Journal of Thoracic and Cardiovascular Surgery*. 2009;137(2): 492–498. doi:10.1016/j.jtcvs.2008.08.047
 75. Medeiros IL, Pêgo-Fernandes PM, Mariani AW, et al. Comparison of lung preservation solutions in human lungs using an ex vivo lung perfusion experimental model. *Clinics*. 2012;67(9): 1101–1106. doi:10.6061/clinics/2012(09)19

76. Wittwer T, Albes JM, Fehrenbach A, et al. Experimental lung preservation with perfadex: effect of the no-donor nitroglycerin on postischemic outcome. *The Journal of Thoracic and Cardiovascular Surgery*. 2003;125(6): 1208–1216. doi:10.1016/S0022-5223(02)73244-3
77. L L, X W, Z Y. Ischemia-reperfusion Injury in the Brain: Mechanisms and Potential Therapeutic Strategies. *Bi-chemistry & pharmacology : open access*. 2016;5(4): 213. doi:10.4172/2167-0501.1000213
78. Salameh A, Dhein S. Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury. *Frontiers in Pharmacology*. Frontiers; 2015;6. doi:10.3389/fphar.2015.00296
79. Rodrigo R, Prieto JC, Castillo R. Cardioprotection against ischaemia/reperfusion by vitamins C and E plus n-3 fatty acids: molecular mechanisms and potential clinical applications. *Clinical Science*. 2012;124(1): 1–15. doi:10.1042/CS20110663
80. Yemaneberhan KH, Kang M, Jang JH, et al. Beyond the icebox: modern strategies in organ preservation for transplantation. *Clinical Transplantation and Research*. 2024;38(4): 377–403. doi:10.4285/ctr.24.0039
81. Maganti HB, Bailey AJM, Kirkham AM, et al. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies. *Stem Cells Translational Medicine*. 2021;10(7): 996–1007. doi:10.1002/sctm.20-0520



KARDİYAK DONÖR SEÇİMİ VE BAKIMI

DOI: 10.37609/akya.3889.c5394

BÖLÜM 72

Ahmet Rüçhan AKAR¹
Mehmet Cahit SARICAOĞLU²
Melisa KANDEMİR³
Ezel KADİROĞLU⁴
Deniz Ladin ÖZDEMİR⁵
Ayşegül GÜVEN⁶
Mustafa ŞIRLAK⁷
Mustafa Bahadır İNAN⁸

İçindekiler

- » GİRİŞ
 - » Kalp Yetmezliği Yüku ve Donör Eksikliği
 - » Optimal Donör Kavramı
 - » Uluslararası Modellerde Kardiyak Donörler: Avrupa ve ABD Örnekleri
 - » Kalp Naklinde Güncel Gelişmeler ve Ventrikül Destek Sistemleri
 - » Türkiye’de Kadaverik Organ Bağışının Güncel Durumu
- » KALP NAKLİNDE DONÖR DEĞERLENDİRMESİ
 - » POTANSİYEL KARDİYAK DONÖR SEÇİMİ
- » MARJİNAL DONÖR KAVRAMI
 - » Alternatif Alıcı Listeleri; “Old-for-old” Programı
- » KARDİYAK DONÖR RİSK SKORLAMA SİSTEMLERİ
- » KARDİYAK DONÖR BAKIMI
 - » Potansiyel Kardiyak Donörde Hemodinamik Bakım
 - » Potansiyel Kardiyak Donörde Sıvı Elektrolit Dengesi
 - » Potansiyel Kardiyak Donörde İnotropik Ajanların Kullanımı
 - » Potansiyel Kardiyak Donörde Respiratuar Bakım
 - » Potansiyel Kardiyak Donörde Endokrin Bakım ve Hormon Replasman Tedavileri
 - » Potansiyel Kardiyak Donörde Hematolojik Bakım
 - » Vücut Isısındaki Değişiklikler
 - » Potansiyel Kardiyak Donörde Böbrek Fonksiyonlarının Korunması
 - » Enfeksiyon Yönetimi
- » KARDİYAK DONÖR TRANSPORTU
 - » Soğuk Koruma
 - » Kardiyak Donörün Sürekli Perfüzyonu
- » GELECEK PERSPEKTİFLERİ

¹ Prof. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., akar@ankara.edu.tr, ORCID iD: 0000-0002-5191-5505
² Doç. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., saricaoglu@ankara.edu.tr, ORCID iD: 0000-0002-0378-8855
³ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., mlskandemir@ankara.edu.tr, ORCID iD: 0000-0003-2536-3820
⁴ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., eekadiroglu@ankara.edu.tr, ORCID iD: 0000-0002-0224-5138
⁵ Arş. Gör. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., dlozdemir@ankara.edu.tr, ORCID iD: 0000-0002-5644-5717
⁶ Dr. Öğr. Üyesi, Ankara Üniversitesi Tıp Fakültesi, Anesteziyoloji ve Reanimasyon AD., ayguven@ankara.edu.tr, ORCID iD: 0000-0002-7837-7655
⁷ Prof. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., sirlak@ankara.edu.tr, ORCID iD: 0000-0001-6806-7672
⁸ Prof. Dr., Ankara Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., mbinan@ankara.edu.tr, ORCID iD: 0000-0002-7766-3625

post-nakil immünsupresyonu dönüştürebilir. Donör ve alıcıya özgü immünogenetik özelliklere göre tedavi protokollerinin bireyselleştirilmesi, reddi azaltabilir, uzun dönem greft sağkalımını iyileştirebilir ve yan etkileri azaltabilir.

Çok Uluslu ve Bölgesel İş Birlikleri: Gelecekteki başarı, uluslararası veri paylaşımı, bölgesel donör ağlarının kurulması ve küresel kalite ölçütleri ile yakından bağlantılı olacaktır. Güçlü sağlık altyapısına sahip olan Türkiye, yapısal engellerin aşılmasıyla bu tür iş birliklerinden hem fayda sağlayacak hem de katkıda bulunabilecek konumdadır.

Ulusal Derneklerin Rolü: Türkiye’de Türk Kalp ve Damar Cerrahisi Derneği (TKDCD), Türk Kardiyoloji Derneği (TKD) ve organ nakli alanında faaliyet gösteren diğer ulusal dernekler, kalp nakli pratiğinin şekillendirilmesinde kritik role sahiptir. Bu kuruluşlar; ulusal donör seçimi ve bakım kılavuzlarının hazırlanması, donör koordinatörleri ve organ çıkarma ekipleri için standart eğitim programlarının geliştirilmesi, aile reddini azaltmaya yönelik kamuoyu farkındalık kampanyalarının yürütülmesi gibi çok boyutlu katkılar sağlayabilir. Ayrıca T.C. Sağlık Bakanlığı ile iş birliği içinde politika geliştirme süreçlerinde aktif rol üstlenmeleri, DCD programlarının entegrasyonu, adil organ dağıtımının sağlanması ve ex vivo perfüzyon, yapay zekâ gibi yenilikçi teknolojilerin ulusal pratiğe kazandırılması açısından büyük önem taşımaktadır.

KAYNAKLAR

1. Copeland H, Knezevic I, Baran DA, Rao V, Pham M, Gustafsson F, et al. Donor heart selection: Evidence-based guidelines for providers. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2023;42(1):7-29.
2. Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2023;42(5):e1-e141.
3. Jain R, Kransdorf EP, Cowger J, Jeevanandam V, Kobashigawa JA. Donor Selection for Heart Transplantation in 2025. JACC Heart Fail. 2025;13(3):389-401.
4. Stehlik J, Kobashigawa J, Hunt SA, Reichenspurner H, Kirklin JK. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. Circulation. 2018;137(1):71-87.
5. Aliabadi-Zuckermann AZ, Gokler J, Kaider A, Riebandt J, Moayedifar R, Osorio E, et al. Donor heart selection and outcomes: An analysis of over 2,000 cases. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2018;37(8):976-84.
6. Khush KK, Ball RL. Great variability in donor heart acceptance practices across the United States. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020;20(6):1582-96.
7. Moayed Y, Rodenas-Alesina E, Mueller B, Fan CS, Cherikh WS, Stehlik J, et al. Rethinking Donor and Recipient Risk Matching in Europe and North America: Using Heart Transplant Predictors of Donor and Recipient Risk. Circulation Heart failure. 2023;16(5):e009994.
8. Wayda B, Angleitner P, Smits JM, van Kins A, Berchtold-Herz M, De Pauw M, et al. Disparities in donor heart acceptance between the USA and Europe: clinical implications. European heart journal. 2023;44(44):4665-74.
9. Baran DA, Long A, Lansinger J, Copeland JG, Copeland H. Donor Utilization in the Recent Era: Effect of Sex, Drugs, and Increased Risk. Circulation Heart failure. 2022;15(7):e009547.
10. Khush KK, Zaroff JG, Nguyen J, Menza R, Goldstein BA. National decline in donor heart utilization with regional variability: 1995-2010. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2015;15(3):642-9.
11. Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB. Care of the potential organ donor. The New England journal of medicine. 2004;351(26):2730-9.
12. Hyun J, Lee SE, Kim JJ. Management of potential cardiac donors. Clin Transplant Res. 2024;38(1):37-45.
13. Wijdicks EF. The diagnosis of brain death. N Engl J Med. 2001;344(16):1215-21.
14. Burkle CM, Sharp RR, Wijdicks EF. Why brain death is considered death and why there should be no confusion. Neurology. 2014;83(16):1464-9.
15. Lewis A, Bernat JL, Blosser S, Bonnie RJ, Epstein LG, Hutchins J, et al. An interdisciplinary response to contemporary concerns about brain death determination. Neurology. 2018;90(9):423-6.
16. Bernat JL. Brain death is a scientific concept. Lancet. 2010;375(9714):554; author reply
17. Danovitch GM, Delmonico FL. Determination of Brain Death. The New England journal of medicine. 2022;386(16):e44.
18. Greer DM. Determination of Brain Death. The New England journal of medicine. 2021;385(27):2554-61.
19. Magnus DC, Wilfond BS, Caplan AL. Accepting brain death. The New England journal of medicine. 2014;370(10):891-4.
20. Lewis A, Kirschen MP, Greer D. The 2023 AAN/AAP/CNS/SCCM Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Practice Guideline: A Comparison With the 2010 and 2011 Guidelines.

- Neurol Clin Pract. 2023;13(6):e200189.
21. Greer DM, Kirschen MP, Lewis A, Gronseth GS, Rae-Grant A, Ashwal S, et al. Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline. *Neurology*. 2023;101(24):1112-32.
 22. Greer DM, Shemie SD, Lewis A, Torrance S, Varelas P, Goldenberg FD, et al. Determination of Brain Death/Death by Neurologic Criteria: The World Brain Death Project. *JAMA : the journal of the American Medical Association*. 2020;324(11):1078-97.
 23. Nagy A, Szecsi B, Eke C, Szabo A, Mihaly S, Fazekas L, et al. Endocrine Management and Hormone Replacement Therapy in Cardiac Donor Management: A Retrospective Observational Study. *Transplantation proceedings*. 2021;53(10):2807-15.
 24. Zimpfer D, Alexander PMA, Davies RR, Dipchand AI, Feingold B, Joong A, et al. Pediatric donor management to optimize donor heart utilization. *Pediatric transplantation*. 2020;24(3):e13679.
 25. Dhar R, Cotton C, Coleman J, Brockmeier D, Kappel D, Marklin G, et al. Comparison of high- and low-dose corticosteroid regimens for organ donor management. *J Crit Care*. 2013;28(1):111 e1-7.
 26. Cypel M, Keshavjee S. Strategies for safe donor expansion: donor management, donations after cardiac death, ex-vivo lung perfusion. *Current opinion in organ transplantation*. 2013;18(5):513-7.
 27. Ullah S, Zabala L, Watkins B, Schmitz ML. Cardiac organ donor management. *Perfusion*. 2006;21(2):93-8.
 28. Chamorro C, Silva JA, Romera MA. Cardiac donor management: another point of view. *Transplantation proceedings*. 2003;35(5):1935-7.
 29. Delgado DH, Rao V, Ross HJ. Donor management in cardiac transplantation. *The Canadian journal of cardiology*. 2002;18(11):1217-23.
 30. Rodeheffer RJ, Naftel DC, Stevenson LW, Porter CB, Young JB, Miller LW, et al. Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A multi-institutional study. *Cardiac Transplant Research Database Group. Circulation*. 1996;94(11):2883-9.
 31. Copeland JG. Only optimal donors should be accepted for heart transplantation: protagonist. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 1995;14(6 Pt 1):1038-42.
 32. Wayda B, Luikart H, Weng Y, Zhang S, Neidlinger N, Wood RP, et al. Reasons for donor heart offer refusal in the United States: Results from 14,132 transplant clinician surveys in the Donor Heart Study. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2025;44(7):1075-82.
 33. Ardehali A, Esmailian F, Deng M, Soltesz E, Hsieh E, Naka Y, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. *Lancet*. 2015;385(9987):2577-84.
 34. Tolmie SB, Gibbons RD, Anderson AS, Khush KK, Chhikara K, Churpek M, et al. Association of the 2018 U.S. Heart Allocation Policy Change and the Survival Benefit of Heart Transplantation. *JACC Heart Fail*. 2025;13(7):102480.
 35. Guenther SPW, Schramm R, Teuteberg JJ, Shudo Y, Rogge AL, Schaeper KE, et al. Which Donor and Recipient Risk Factors Matter in Heart Transplantation? Results From a Survey of 53 Centers Across Five Countries. *Clinical transplantation*. 2025;39(6):e70214.
 36. Matesanz R, Marazuela R, Dominguez-Gil B, Coll E, Mahillo B, de la Rosa G. The 40 donors per million population plan: an action plan for improvement of organ donation and transplantation in Spain. *Transplantation proceedings*. 2009;41(8):3453-6.
 37. Matesanz R, Marazuela R, Coll E, Mahillo B, Dominguez-Gil B. About the Opt-Out System, Live Transplantation, and Information to the Public on Organ Donation in Spain ... Y ole! *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2017;17(6):1695-6.
 38. Matesanz R, Dominguez-Gil B, Coll E, Mahillo B, Marazuela R. How Spain Reached 40 Deceased Organ Donors per Million Population. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2017;17(6):1447-54.
 39. Matesanz R, Dominguez-Gil B, Marazuela R, Coll E, de la Rosa G. Benchmarking in organ donation after brain death in Spain. *Lancet*. 2012;380(9842):649-50.
 40. Dominguez-Gil B, Haase-Kromwijk B, Van Leiden H, Neuberger J, Coene L, Morel P, et al. Current situation of donation after circulatory death in European countries. *Transplant international : official journal of the European Society for Organ Transplantation*. 2011;24(7):676-86.
 41. Groba Marco MDV, Cabrera Santana M, Galvan Ruiz M, Fernandez de Sanmamed M, Romero Lujan JL, Gonzalez Martin JM, et al. Expanding Horizons in Cardiac Transplant: Efficacy and Outcomes of Circulatory and Brain Death Donor Hearts in a Newly Implemented Cardiac Transplant Program with Limited Donor Accessibility and a Literature Review. *J Clin Med*. 2024;13(17).
 42. Shah KS, Kittleson MM, Kobashigawa JA. Updates on Heart Transplantation. *Curr Heart Fail Rep*. 2019;16(5):150-6.
 43. Ribeiro RVP, Alvarez JS, Yu F, Paradiso E, Adamson MB, Maria Ruggeri G, et al. Hearts Donated After Circulatory Death and Reconditioned Using Normothermic Regional Perfusion Can Be Successfully Transplanted Following an Extended Period of Static Storage. *Circulation Heart failure*. 2019;12(4):e005364.
 44. Beuth J, Falter F, Pinto Ribeiro RV, Badiwala M, Meineri M. New Strategies to Expand and Optimize Heart Donor Pool: Ex Vivo Heart Perfusion and Donation After Circulatory Death: A Review of Current Research and Future Trends. *Anesth Analg*. 2019;128(3):406-13.
 45. DePasquale EC, Schweiger M, Ross HJ. A contemporary review of adult heart transplantation: 2012 to 2013. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2014;33(8):775-84.
 46. Reyentovich A, Leacche M, Moazami N. DCD Heart Transplantation with NRP: Excellent Results and a Continued Uphill Battle. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2025.
 47. Messer S, Page A, Axell R, Berman M, Hernandez-San-

- chez J, Colah S, et al. Outcome after heart transplantation from donation after circulatory-determined death donors. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2017;36(12):1311-8.
48. Meyer DM, Nayak A, Wood KL, Blumer V, Schettler S, Salerno C, et al. The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients. *The Annals of thoracic surgery*. 2025;119(1):34-58.
 49. Yin MY, Wever-Pinzon O, Mehra MR, Selzman CH, Toll AE, Cherikh WS, et al. Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2019;38(8):858-69.
 50. Yagdi T, Oguz E, Engin C, Engin Y, Nalbantgil S, Zoghi M, et al. Changing face of heart failure surgery. *Transplant Proc*. 2012;44(6):1729-31.
 51. Tore Altun G, Corman Dincer P, Birtan D, Arslantas R, Kasap Yakin D, Ozdemir I, et al. Reasons Why Organs From Deceased Donors Were Not Accepted for Transplantation. *Transplantation proceedings*. 2019;51(7):2202-4.
 52. Yagdi T, Nalbantgil S, Ozbaran M. [Heart transplantation: preoperative evaluation, perioperative management, postoperative follow-up]. *Turk Kardiyol Dern Ars*. 2015;43(1):95-108.
 53. Erbasan O, Koksel U, Bayezid O. Kalp Transplantasyonu için Resipient ve Donör Seçimi, Donör-Resipient Uyumu. In: Bayezid O, editor. *Kalp & Akciğer Transplantasyonu*. Antalya: Akdeniz Üniversitesi; 2010. p. 99-137.
 54. Kotloff RM, Blosser S, Fulda GJ, Malinoski D, Ahya VN, Angel L, et al. Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/ American College of Chest Physicians/ Association of Organ Procurement Organizations Consensus Statement. *Critical care medicine*. 2015;43(6):1291-325.
 55. A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. *JAMA*. 1968;205(6):337-40.
 56. Diagnosis of brain death. Statement issued by the honorary secretary of the Conference of Medical Royal Colleges and their Faculties in the United Kingdom on 11 October 1976. *Br Med J*. 1976;2(6045):1187-8.
 57. Landmark article Aug 5, 1968: A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to examine the definition of brain death. *JAMA*. 1984;252(5):677-9.
 58. Stehlik J, J. L. Cardiac transplantation: Overview. In: Domanski MJ, Mehra MR, M.A. P, editors. *Oxford Textbook of Advanced Heart Failure and Cardiac Transplantation*. United Kingdom: Oxford University Press; 2016. p. 255-78.
 59. Kwon YIC, Keller M, Elhigzi K, Adibi I, Jones HC, Lai A, et al. Early Outcomes of Primary Graft Dysfunction Comparing Donation After Circulatory and Brain Death Heart Transplantation: An Analysis of the UNOS Registry. *Clinical transplantation*. 2025;39(7):e70222.
 60. Khush KK, Malinoski D, Luikart H, Wayda B, Groat T, Nguyen J, et al. Left Ventricular Dysfunction Associated With Brain Death: Results From the Donor Heart Study. *Circulation*. 2023;148(10):822-33.
 61. Cohen O, De La Zerda DJ, Beygui R, Hekmat D, Laks H. Donor brain death mechanisms and outcomes after heart transplantation. *Transplantation proceedings*. 2007;39(10):2964-9.
 62. Nguyen A, Rana A, Shafii A, Loor G, Civitello A, Reyes JEM, et al. Potential intermediate-term survival differences among heart transplant recipients from circulatory death vs brain death donors. *JHLT Open*. 2025;9:100342.
 63. Atkinson C, Floerchinger B, Qiao F, Casey S, Williamson T, Moseley E, et al. Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. *Circulation*. 2013;127(12):1290-9.
 64. Wilhelm MJ, Pratschke J, Beato F, Taal M, Kusaka M, Hancock WW, et al. Activation of the heart by donor brain death accelerates acute rejection after transplantation. *Circulation*. 2000;102(19):2426-33.
 65. Bittner HB, Chen EP, Milano CA, Kendall SW, Jennings RB, Sabiston DC, Jr., et al. Myocardial beta-adrenergic receptor function and high-energy phosphates in brain death-related cardiac dysfunction. *Circulation*. 1995;92(9 Suppl):II472-8.
 66. Galinanes M, Smolenski RT, Hearse DJ. Brain death-induced cardiac contractile dysfunction and long-term cardiac preservation. *Rat heart studies of the effects of hypophysectomy*. *Circulation*. 1993;88(5 Pt 2):II270-80.
 67. Smith M. Physiologic changes during brain stem death--lessons for management of the organ donor. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2004;23(9 Suppl):S217-22.
 68. Boone M, Deen PM. Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. *Pflügers Arch*. 2008;456(6):1005-24.
 69. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. *Transplantation*. 1995;59(1):58-62.
 70. Kinoshita Y, Okamoto K, Yahata K, Yoshioka T, Sugimoto T, Kawaguchi N, et al. Clinical and pathological changes of the heart in brain death maintained with vasopressin and epinephrine. *Pathol Res Pract*. 1990;186(1):173-9.
 71. Iwai A, Sakano T, Uenishi M, Sugimoto H, Yoshioka T, Sugimoto T. Effects of vasopressin and catecholamines on the maintenance of circulatory stability in brain-dead patients. *Transplantation*. 1989;48(4):613-7.
 72. Mascia L, Mastromauro I, Viberti S, Vincenzi M, Zanello M. Management to optimize organ procurement in brain dead donors. *Minerva Anestesiol*. 2009;75(3):125-33.
 73. Lewis A. An Update on Brain Death/Death by Neurologic Criteria since the World Brain Death Project. *Semin Neurol*. 2024;44(3):236-62.
 74. Dorent R, Gandjbakhch E, Goeminne C, Ivanov F, Sebbag L, Bauer F, et al. Assessment of potential heart donors: A statement from the French heart transplant community. *Arch Cardiovasc Dis*. 2018;111(2):126-39.
 75. Griepp RB, Stinson EB, Clark DA, Dong E, Jr., Shumway NE. The cardiac donor. *Surgery, gynecology & obstetrics*. 1971;133(5):792-8.
 76. Copeland JG, Stinson EB. Human heart transplantation

- on. *Curr Probl Cardiol*. 1979;4(8):1-5.
77. Griepp RB, Stinson EB, Bieber CP, Reitz BA, Cope-land JG, Oyer PE, et al. Human heart transplantation: current status. *The Annals of thoracic surgery*. 1976;22(2):171-5.
 78. Zaroff JG, Rosengard BR, Armstrong WF, Babcock WD, D'Alessandro A, Dec GW, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. *Circulation*. 2002;106(7):836-41.
 79. Smits JM, De Pauw M, de Vries E, Rahmel A, Meiser B, Laufer G, et al. Donor scoring system for heart transplantation and the impact on patient survival. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2012;31(4):387-97.
 80. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. *Drugs*. 2002;62 Suppl 2:1-9.
 81. Ali AA, Lim E, Thanikachalam M, Sudarshan C, White P, Parameshwar J, et al. Cardiac arrest in the organ donor does not negatively influence recipient survival after heart transplantation. *Eur J Cardiothorac Surg*. 2007;31(5):929-33.
 82. Stehlik J, Feldman DS, Brown RN, VanBakel AB, Rus-sel SD, Ewald GA, et al. Interactions among donor characteristics influence post-transplant survival: a multi-institutional analysis. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2010;29(3):291-8.
 83. Costa D, Picascia A, Grimaldi V, Amarelli C, Petraio A, Levi A, et al. Role of HLA matching and donor specific antibody development in long-term survival, acute rejection and cardiac allograft vasculopathy. *Transplant immunology*. 2024;83:102011.
 84. Thompson JS, Thacker LR, 2nd, Takemoto S. The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: an analysis from the United Network of Organ Sharing Scientific Registry. *Transplantation*. 2000;69(10):2178-86.
 85. Khaghani A, Yacoub M, McCloskey D, Awad J, Burden M, Fitzgerald M, et al. The influence of HLA matching, donor/recipient sex, and incidence of acute rejection on survival in cardiac allograft recipients receiving cyclosporin A and azathioprine. *Transplantation proceedings*. 1989;21(1 Pt 1):799-800.
 86. Festenstein H, Banner N, Smith J, Awad J, Burden M, Fitzgerald N, et al. The influence of HLA matching and lymphocytotoxic antibody status in heart-lung allograft recipients receiving cyclosporin and azathioprine. *Transplantation proceedings*. 1989;21(1 Pt 1):797-8.
 87. Lick SD, Beckles DL, Piovesana G, Vaidya S, Indriko-vs A, Barbagelata NA, et al. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. *The Annals of thoracic surgery*. 2011;92(4):1428-34.
 88. Lick SD, Vaidya S, Kollar AC, Boor PJ, Vertrees RA. Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2008;27(9):1036-9.
 89. Han J, Rushakoff J, Moayed Y, Henricksen E, Lee R, Luikart H, et al. HLA sensitization is associated with an increased risk of primary graft dysfunction after heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2024;43(3):387-93.
 90. Rao RA, Kransdorf EP, Patel JK, Kobashigawa JA, Kittleson MM. How to Approach HLA Sensitization in Heart Transplant Candidates. *JACC Heart Fail*. 2023;11(4):469-75.
 91. Colvin MM, Cook JL, Chang PP, Hsu DT, Kiernan MS, Kobashigawa JA, et al. Sensitization in Heart Transplantation: Emerging Knowledge: A Scientific Statement From the American Heart Association. *Circulation*. 2019;139(12):e553-e78.
 92. Habal MV. Current Desensitization Strategies in Heart Transplantation. *Front Immunol*. 2021;12:702186.
 93. Dronavalli VB, Banner NR, Bonser RS. Assessment of the potential heart donor: a role for biomarkers? *J Am Coll Cardiol*. 2010;56(5):352-61.
 94. Zaroff J. Echocardiographic evaluation of the potential cardiac donor. *J Heart Lung Transplant*. 2004;23(9 Suppl):S250-2.
 95. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;16(3):233-70.
 96. Dupuis S, Amiel JA, Desgroseilliers M, Williamson DR, Thiboutot Z, Serri K, et al. Corticosteroids in the management of brain-dead potential organ donors: a systematic review. *British journal of anaesthesia*. 2014;113(3):346-59.
 97. Pinsard M, Ragot S, Mertes PM, Bleichner JP, Zitouni S, Cook F, et al. Interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: the CORTICOME study. *Crit Care*. 2014;18(4):R158.
 98. Buchanan IA, Mehta VA. Thyroid hormone resuscitation after brain death in potential organ donors: A primer for neurocritical care providers and narrative review of the literature. *Clin Neurol Neurosurg*. 2018;165:96-102.
 99. Cooper LB, Milano CA, Williams M, Swafford W, Croezen D, Van Bakel AB, et al. Thyroid hormone use during cardiac transplant organ procurement. *Clinical transplantation*. 2016;30(12):1578-83.
 100. Holndonner-Kirst E, Nagy A, Czobor NR, Fazekas L, Dohan O, Kertai MD, et al. The Impact of l-Thyroxine Treatment of Donors and Recipients on Postoperative Outcomes After Heart Transplantation. *Journal of cardiothoracic and vascular anesthesia*. 2019;33(6):1629-35.
 101. Mi Z, Novitzky D, Collins JF, Cooper DK. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. *Clin Epidemiol*. 2015;7:17-27.
 102. Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis.

- Transplantation. 2014;98(10):1119-27.
103. Al-Khafaji A, Elder M, Lebovitz DJ, Murugan R, Souther M, Stuart S, et al. Protocolized fluid therapy in brain-dead donors: the multicenter randomized MOnIToR trial. *Intensive Care Med.* 2015;41(3):418-26.
 104. McKeown DW, Ball J. Treating the donor. *Current opinion in organ transplantation.* 2014;19(2):85-91.
 105. Abdelnour T, Rieke S. Relationship of hormonal resuscitation therapy and central venous pressure on increasing organs for transplant. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2009;28(5):480-5.
 106. Dimopoulou I, Tsagarakis S, Anthi A, Milou E, Ilias I, Stavrakaki K, et al. High prevalence of decreased cortisol reserve in brain-dead potential organ donors. *Critical care medicine.* 2003;31(4):1113-7.
 107. Plurad DS, Bricker S, Neville A, Bongard F, Putnam B. Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. *American journal of surgery.* 2012;204(6):856-60; discussion 60-1.
 108. Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft use and recipient outcomes after heart transplantation. *Circulation Heart failure.* 2013;6(2):300-9.
 109. Tryon D, Hasaniya NW, Jabo B, Razzouk AJ, Bailey LL, Rabkin DG. Effect of left ventricular dysfunction on utilization of donor hearts. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2018;37(3):349-57.
 110. Sibona A, Khush KK, Oyoyo UE, Martens TP, Hasaniya NW, Razzouk AJ, et al. Long-term transplant outcomes of donor hearts with left ventricular dysfunction. *The Journal of thoracic and cardiovascular surgery.* 2019;157(5):1865-75.
 111. Mohamedali B, Bhat G, Zelinger A. Frequency and pattern of left ventricular dysfunction in potential heart donors: implications regarding use of dysfunctional hearts for successful transplantation. *J Am Coll Cardiol.* 2012;60(3):235-6.
 112. Zaroff JG, Babcock WD, Shiboski SC, Solinger LL, Rosengard BR. Temporal changes in left ventricular systolic function in heart donors: results of serial echocardiography. *J Heart Lung Transplant.* 2003;22(4):383-8.
 113. Kono T, Nishina T, Morita H, Hirota Y, Kawamura K, Fujiwara A. Usefulness of low-dose dobutamine stress echocardiography for evaluating reversibility of brain death-induced myocardial dysfunction. *The American journal of cardiology.* 1999;84(5):578-82.
 114. Zaroff JG, Babcock WD, Shiboski SC. The impact of left ventricular dysfunction on cardiac donor transplant rates. *J Heart Lung Transplant.* 2003;22(3):334-7.
 115. Casartelli M, Bombardini T, Simion D, Gaspari MG, Procaccio F. Wait, treat and see: echocardiographic monitoring of brain-dead potential donors with stunned heart. *Cardiovasc Ultrasound.* 2012;10:25.
 116. Bombardini T, Arpesella G, Maccherini M, Procaccio F, Potena L, Bernazzali S, et al. Medium-term outcome of recipients of marginal donor hearts selected with new stress-echocardiographic techniques over standard criteria. *Cardiovasc Ultrasound.* 2014;12:20.
 117. Cheng A, Schumer EM, Trivedi JR, Van Berkel VH, Massey HT, Slaughter MS. Does Donor Cardiopulmonary Resuscitation Time Affect Heart Transplantation Outcomes and Survival? *The Annals of thoracic surgery.* 2016;102(3):751-8.
 118. Galeone A, Lebreton G, Leprince P. Old Europe carefully looks at a new heart: Cardiac arrest-resuscitated donors should not be turned down for heart transplant at first glance. *The Journal of thoracic and cardiovascular surgery.* 2017;154(2):540.
 119. Quader MA, Wolfe LG, Kasirajan V. Heart transplantation outcomes from cardiac arrest-resuscitated donors. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2013;32(11):1090-5.
 120. Quader M, Wolfe L, Katlaps G, Kasirajan V. Donor Heart Utilization following Cardiopulmonary Arrest and Resuscitation: Influence of Donor Characteristics and Wait Times in Transplant Regions. *Journal of transplantation.* 2014;2014:519401.
 121. Grauhan O, Patzurek J, Hummel M, Lehmkuhl H, Dandel M, Pasic M, et al. Donor-transmitted coronary atherosclerosis. *J Heart Lung Transplant.* 2003;22(5):568-73.
 122. Shemie SD, Ross H, Pagliarello J, Baker AJ, Greig PD, Brand T, et al. Organ donor management in Canada: recommendations of the forum on Medical Management to Optimize Donor Organ Potential. *CMAJ.* 2006;174(6):S13-32.
 123. Ivanov F, Cantrelle C, Genet T, Le Feuvre C, Legeai C, Jasseron C, et al. Performing diagnostic coronary angiography to evaluate high-risk cardiac donors: A French nationwide cohort study. *International journal of cardiology.* 2019;277:71-8.
 124. Schweiger M, Kluber J, Bosch A, von Levinski D, Prener G, Stiegler P, et al. Low incidence of coronary angiography in the evaluation process of the potential heart donor. *Transplantation proceedings.* 2014;46(10):3339-42.
 125. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2016;35(1):1-23.
 126. Butts RJ, Toombs L, Kirklin JK, Schumacher KR, Conway J, West SC, et al. Waitlist Outcomes for Pediatric Heart Transplantation in the Current Era: An Analysis of the Pediatric Heart Transplant Society Database. *Circulation.* 2024.
 127. Peled Y, Ducharme A, Kittleson M, Bansal N, Stehlik J, Amdani S, et al. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024. *J Heart Lung Transplant.* 2024;43(10):1529-628 e54.
 128. Copeland H, Knezevic I, Baran DA, Rao V, Pham M, Gustafsson F, et al. Donor heart selection: Evidence-based guidelines for providers. *J Heart Lung Transplant.* 2023;42(1):7-29.
 129. Brock MV, Salazar JD, Cameron DE, Baumgartner WA, Conte JV. The changing profile of the cardiac donor. *J Heart Lung Transplant.* 2001;20(9):1005-9.
 130. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation

- on: 29th official adult heart transplant report--2012. *J Heart Lung Transplant*. 2012;31(10):1052-64.
131. Young JB. Age before beauty: the use of "older" donor hearts for cardiac transplantation. *J Heart Lung Transplant*. 1999;18(5):488-91.
 132. McCarthy JF, McCarthy PM, Massad MG, Cook DJ, Smedira NG, Kasirajan V, et al. Risk factors for death after heart transplantation: does a single-center experience correlate with multicenter registries? *The Annals of thoracic surgery*. 1998;65(6):1574-8; discussion 8-9.
 133. Blanche C, Kamlot A, Blanche DA, Kearney B, Magliato KE, Czer LS, et al. Heart transplantation with donors fifty years of age and older. *J Thorac Cardiovasc Surg*. 2002;123(4):810-5.
 134. Gupta D, Piacentino V, 3rd, Macha M, Singhal AK, Goughan JP, McClurken JB, et al. Effect of older donor age on risk for mortality after heart transplantation. *The Annals of thoracic surgery*. 2004;78(3):890-9.
 135. Weber DJ, Wang IW, Gracon AS, Hellman YM, Hornmuth DA, Wozniak TC, et al. Impact of donor age on survival after heart transplantation: an analysis of the United Network for Organ Sharing (UNOS) registry. *Journal of cardiac surgery*. 2014;29(5):723-8.
 136. Roig E, Almenar L, Crespo-Leiro M, Segovia J, Mirabet S, Delgado J, et al. Heart transplantation using allografts from older donors: Multicenter study results. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2015;34(6):790-6.
 137. Wittwer T, Wahlers T. Marginal donor grafts in heart transplantation: lessons learned from 25 years of experience. *Transpl Int*. 2008;21(2):113-25.
 138. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2014;33(10):996-1008.
 139. Li H, Tanaka K, Anzai H, Oeser B, Lai D, Kobashigawa JA, et al. Influence of pre-existing donor atherosclerosis on the development of cardiac allograft vasculopathy and outcomes in heart transplant recipients. *Journal of the American College of Cardiology*. 2006;47(12):2470-6.
 140. Caforio AL, Tona F, Fortina AB, Angelini A, Piaserico S, Gambino A, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2004;4(6):962-70.
 141. Kuppahally SS, Valantine HA, Weisshaar D, Parekh H, Hung YY, Haddad F, et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2007;7(10):2388-95.
 142. Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. *J Heart Lung Transplant*. 2000;19(5):496-503.
 143. Leone O, Gherardi S, Targa L, Pasanisi E, Mikus P, Tanganeli P, et al. Stress echocardiography as a gatekeeper to donation in aged marginal donor hearts: anatomic and pathologic correlations of abnormal stress echocardiography results. *J Heart Lung Transplant*. 2009;28(11):1141-9.
 144. Dark JH. Safe and effective use of the extended donor heart. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery*. 2015;47(1):78-9.
 145. Singh N, Raees MA, Zafar F. Donor considerations in pediatric heart transplantation. *Transl Pediatr*. 2019;8(4):284-9.
 146. Westbrook TC, Morales DLS, Khan MS, Bryant R, Castleberry C, Chin C, et al. Interaction of older donor age and survival after weight-matched pediatric heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2017;36(5):554-8.
 147. Hada T, Seguchi O, Kitahata N, Komeyama S, Mochizuki H, Watanabe T, et al. Heart transplantation with super-aged donors older than 65 years. *JHLT Open*. 2024;4:100083.
 148. Bergenfeldt H, Stehlik J, Hoglund P, Andersson B, Nilsson J. Donor-recipient size matching and mortality in heart transplantation: Influence of body mass index and gender. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2017;36(9):940-7.
 149. Young JB, Naftel DC, Bourge RC, Kirklin JK, Clemson BS, Porter CB, et al. Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. *The Cardiac Transplant Research Database Group. J Heart Lung Transplant*. 1994;13(3):353-64; discussion 64-5.
 150. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*. 2010;29(8):914-56.
 151. Khush KK, Kubo JT, Desai M. Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2012;31(5):459-66.
 152. Gong TA, Joseph SM, Lima B, Gonzalez-Stawinski GV, Jamil AK, Felius J, et al. Donor predicted heart mass as predictor of primary graft dysfunction. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2018;37(7):826-35.
 153. Kransdorf EP, Kittleson MM, Benck LR, Patel JK, Chung JS, Esmailian F, et al. Predicted heart mass is the optimal metric for size match in heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2019;38(2):156-65.
 154. Miller RJH, Hedman K, Amsallem M, Tulu Z, Kent W,

- Fatehi-Hassanabad A, et al. Donor and Recipient Size Matching in Heart Transplantation With Predicted Heart and Lean Body Mass. *Semin Thorac Cardiovasc Surg.* 2021.
155. Sethi GK, Lanaue P, Rosado LJ, Huston C, McCarthy MS, Butman S, et al. Clinical significance of weight difference between donor and recipient in heart transplantation. *J Thorac Cardiovasc Surg.* 1993;106(3):444-8.
156. Hosenpud JD, Pantely GA, Morton MJ, Norman DJ, Cobanoglu AM, Starr A. Relation between recipient: donor body size match and hemodynamics three months after heart transplantation. *J Heart Transplant.* 1989;8(3):241-3.
157. Patel ND, Weiss ES, Nwakanma LU, Russell SD, Baumgartner WA, Shah AS, et al. Impact of donor-to-recipient weight ratio on survival after heart transplantation: analysis of the United Network for Organ Sharing Database. *Circulation.* 2008;118(14 Suppl):S83-8.
158. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. *Int J Obes Relat Metab Disord.* 1999;23(9):936-42.
159. Kwon MH, Wong S, Kittleson M, Ardehali A, Laks H, Shemin RJ, et al. Selecting oversized donor cardiac allografts for patients with pulmonary hypertension may be unnecessary. *Transplantation proceedings.* 2014;46(5):1497-501.
160. Reed RM, Netzer G, Hunsicker L, Mitchell BD, Rajagopal K, Scharf S, et al. Cardiac size and sex-matching in heart transplantation : size matters in matters of sex and the heart. *JACC Heart Fail.* 2014;2(1):73-83.
161. Szugye NA, Lorts A, Zafar F, Taylor M, Morales DLS, Moore RA. Can virtual heart transplantation via 3-dimensional imaging increase the maximum acceptable donor size? *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2019;38(3):331-3.
162. Plasencia JD, Kamarianakis Y, Ryan JR, Karamlou T, Park SS, Nigro JJ, et al. Alternative methods for virtual heart transplant-Size matching for pediatric heart transplantation with and without donor medical images available. *Pediatric transplantation.* 2018;22(8):e13290.
163. UNOS. Predicted Heart Mass (PHM) Match Calculator. 2019.
164. Tao R, Hess TM, Kuchnia A, Hermsen J, Raza F, Dhingra R. Association of Size Matching Using Predicted Heart Mass With Mortality in Heart Transplant Recipients With Obesity or High Pulmonary Vascular Resistance. *JAMA Netw Open.* 2023;6(6):e2319191.
165. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Jr., Hsich E, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2019;38(10):1056-66.
166. Kawabori M, Critsinelis AC, Hironaka CE, Chen FY, Zhan Y, Thayer KL, et al. Right ventricular undersizing is associated with increased 1-year mortality. *The Journal of thoracic and cardiovascular surgery.* 2021;161(3):1048-59 e3.
167. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol.* 2008;52(25):2148-55.
168. Nakamura Y, Yoshioka D, Asanoi H, Miyagawa S, Yoshikawa Y, Hata H, et al. Effect of a reduced donor heart right ventricular distensibility on post-heart transplant haemodynamics. *Interact Cardiovasc Thorac Surg.* 2021;32(1):141-9.
169. Holzhauser L, Imamura T, Bassi N, Fujino T, Nitta D, Kanelidis AJ, et al. Increasing heart transplant donor pool by liberalization of size matching. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2019;38(11):1197-205.
170. Jeevanandam V. Improving the metrics for donor heart sizing. *Journal of cardiac surgery.* 2021;36(9):3250.
171. Kaczmarek I, Meiser B, Beiras-Fernandez A, Guethoff S, Uberfuhr P, Angele M, et al. Gender does matter: gender-specific outcome analysis of 67,855 heart transplants. *The Thoracic and cardiovascular surgeon.* 2013;61(1):29-36.
172. Shugh SB, Szugye NA, Zafar F, Riggs KW, Villa C, Lorts A, et al. Expanding the donor pool for congenital heart disease transplant candidates by implementing 3D imaging-derived total cardiac volumes. *Pediatric transplantation.* 2020;24(1):e13639.
173. Aziz S, Soine LA, Lewis SL, Kruse AP, Levy WC, Wehe KM, et al. Donor left ventricular hypertrophy increases risk for early graft failure. *Transpl Int.* 1997;10(6):446-50.
174. Weiss ES, Allen JG, Kilic A, Russell SD, Baumgartner WA, Conte JV, et al. Development of a quantitative donor risk index to predict short-term mortality in orthotopic heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2012;31(3):266-73.
175. Jasseron C, Legeai C, Jacquelinet C, Nubret-Le Coniat K, Flecher E, Cantrelle C, et al. Optimization of heart allocation: The transplant risk score. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2019;19(5):1507-17.
176. Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis MA, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. *J Am Coll Cardiol.* 2008;51(12):1214-20.
177. Wever Pinzon O, Stoddard G, Drakos SG, Gilbert EM, Nativi JN, Budge D, et al. Impact of donor left ventricular hypertrophy on survival after heart transplant. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2011;11(12):2755-61.
178. Kransdorf EP, Stehlik J. Donor evaluation in heart transplantation: The end of the beginning. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2014;33(11):1105-13.
179. Fonarow GC. How old is too old for heart transplantation? *Curr Opin Cardiol.* 2000;15(2):97-103.

180. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK, 3rd, Boehmer JP, Brozena SC, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. *Cardiac Transplant Research Database. J Heart Lung Transplant.* 1998;17(8):744-53.
181. Wong CK, Yeung AC. The topography of intimal thickening and associated remodeling pattern of early transplant coronary disease: influence of pre-existent donor atherosclerosis. *J Heart Lung Transplant.* 2001;20(8):858-64.
182. Marelli D, Laks H, Bresson S, Ardehali A, Bresson J, Esmailian F, et al. Results after transplantation using donor hearts with preexisting coronary artery disease. *J Thorac Cardiovasc Surg.* 2003;126(3):821-5.
183. Tenderich G, Koerner MM, Stuetgen B, Arusoglu L, Bairaktaris A, Hornik L, et al. Extended donor criteria: hemodynamic follow-up of heart transplant recipients receiving a cardiac allograft from donors > or = 60 years of age. *Transplantation.* 1998;66(8):1109-13.
184. Grauhan O, Siniawski H, Dandel M, Lehmkuhl H, Knosalla C, Pasic M, et al. Coronary atherosclerosis of the donor heart-impact on early graft failure. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.* 2007;32(4):634-8.
185. Couto-Mallon D, Almenar-Bonet L, Barge-Caballero E, Hernandez-Perez FJ, Lopez-Azor Garcia JC, Valero-Masa MJ, et al. Prevalence, Characteristics, and Prognostic Relevance of Donor-Transmitted Coronary Artery Disease in Heart Transplant Recipients. *Journal of the American College of Cardiology.* 2023;82(9):753-67.
186. Watanabe T, Seguchi O, Yanase M, Fujita T, Murata Y, Sato T, et al. Donor-Transmitted Atherosclerosis Associated With Worsening Cardiac Allograft Vasculopathy After Heart Transplantation: Serial Volumetric Intravascular Ultrasound Analysis. *Transplantation.* 2017;101(6):1310-9.
187. Yamasaki M, Sakurai R, Hirohata A, Honda Y, Bonneau HN, Luikart H, et al. Impact of donor-transmitted atherosclerosis on early cardiac allograft vasculopathy: new findings by three-dimensional intravascular ultrasound analysis. *Transplantation.* 2011;91(12):1406-11.
188. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report--2013; focus theme: age. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.* 2013;32(10):951-64.
189. Foroutan F, Alba AC, Guyatt G, Duero Posada J, Ng Fat Hing N, Arseneau E, et al. Predictors of 1-year mortality in heart transplant recipients: a systematic review and meta-analysis. *Heart.* 2018;104(2):151-60.
190. Massad MG, Smedira NG, Hobbs RE, Hoercher K, Vandervoort P, McCarthy PM. Bench repair of donor mitral valve before heart transplantation. *Ann Thorac Surg.* 1996;61(6):1833-5.
191. Coskun KO, Coskun ST, El Arousy M, Amin Parsa M, Schulz U, Deyerling W, et al. Cardiac surgery after heart transplantation: coronary artery bypass grafting and heart valve replacement. *Heart Surg Forum.* 2007;10(2):E110-4.
192. Pawale A, Tang GH, Milla F, Pinney S, Adams DH, Anyanwu AC. Bench mitral valve repair of donor hearts before orthotopic heart transplantation. *Circ Heart Fail.* 2012;5(6):e96-7.
193. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. *N Engl J Med.* 1991;325(7):454-60.
194. Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, et al. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. *The New England journal of medicine.* 2019;380(17):1606-17.
195. Haji SA, Avery RK, Yamani MH, Tuzcu EM, Crowe TD, Cook DJ, et al. Donor or recipient hepatitis B seropositivity is associated with allograft vasculopathy. *J Heart Lung Transplant.* 2006;25(3):294-7.
196. Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. *Current opinion in organ transplantation.* 2019;24(3):351-7.
197. Kilic A, Hickey G, Mathier M, Sultan I, Gleason TG, Horn E, et al. Outcomes of Adult Heart Transplantation Using Hepatitis C-Positive Donors. *J Am Heart Assoc.* 2020;9(2):e014495.
198. Ruck JM, Zeiser LB, Zhou AL, Chidi AP, Winchester SL, Durand CM, et al. Trends in use and three-year outcomes of hepatitis C virus-viremic donor lung transplants for hepatitis C virus-seronegative recipients. *The Journal of thoracic and cardiovascular surgery.* 2023;165(4):1587-95 e2.
199. Ruck JM, Zhou AL, Zeiser LB, Alejo D, Durand CM, Massie AB, et al. Trends and three-year outcomes of hepatitis C virus-viremic donor heart transplant for hepatitis C virus-seronegative recipients. *JTCVS Open.* 2022;12:269-79.
200. Filip I. HIV-positive donor hearts - a game changer for patients with HIV and organ failure? *AIDS.* 2023;37(8):N1-N2.
201. Wolfe CR, Ison MG, Practice ASTIDCo. Donor-derived infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clinical transplantation.* 2019;33(9):e13547.
202. Tomida M, Muraki M, Uemura K, Yamasaki K. Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. *Stroke.* 1998;29(8):1584-7.
203. Tung PP, Olmsted E, Kopelnik A, Banki NM, Drew BJ, Ko N, et al. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. *Stroke.* 2005;36(7):1567-9.
204. Venkateswaran RV, Ganesh JS, Thekkudan J, Steeds R, Wilson IC, Mascaro J, et al. Donor cardiac troponin-I: a biochemical surrogate of heart function. *Eur J Cardiothorac Surg.* 2009;36(2):286-92; discussion 92.
205. Grant JW, Canter CE, Spray TL, Landt Y, Saffitz JE, Ladenson JH, et al. Elevated donor cardiac troponin I. A marker of acute graft failure in infant heart recipients. *Circulation.* 1994;90(6):2618-21.
206. Hokl J, Cerny J, Nemec P, Studenik P, Simkova M. Troponin T serum levels in donors related to troponin T levels in recipients immediately after heart transplantation. *Transplant Proc.* 1999;31(1-2):137-8.
207. Potapov EV, Ivanitskaia EA, Loebe M, Mockel M, Mul-

- ler C, Sodian R, et al. Value of cardiac troponin I and T for selection of heart donors and as predictors of early graft failure. *Transplantation*. 2001;71(10):1394-400.
208. Vijay P, Scavo VA, Morelock RJ, Sharp TG, Brown JW. Donor cardiac troponin T: a marker to predict heart transplant rejection. *The Annals of thoracic surgery*. 1998;66(6):1934-9.
209. Madan S, Saeed O, Shin J, Sims D, Goldstein D, Pina I, et al. Donor Troponin and Survival After Cardiac Transplantation: An Analysis of the United Network of Organ Sharing Registry. *Circulation Heart failure*. 2016;9(6).
210. Khush KK, Menza RL, Babcock WD, Zaroff JG. Donor cardiac troponin I levels do not predict recipient survival after cardiac transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2007;26(10):1048-53.
211. Liu Z, Perry LA, Penny-Dimri JC, Handscombe M, Overmars I, Plummer M, et al. Donor Cardiac Troponin for Prognosis of Adverse Outcomes in Cardiac Transplantation Recipients: a Systematic Review and Meta-analysis. *Transplant Direct*. 2022;8(1):e1261.
212. Tapaskar N, Wayda B, Malinoski D, Luikart H, Groat T, Nguyen J, et al. Donor Electrocardiogram Associations With Cardiac Dysfunction, Heart Transplant Use, and Survival: The Donor Heart Study. *JACC Heart Fail*. 2024;12(4):722-36.
213. Amir NL, Gerber IL, Edmond JJ, Langlands JM, Richards AM, Ruygrok PN. Plasma B-type natriuretic peptide levels in cardiac donors. *Clin Transplant*. 2009;23(2):174-7.
214. Dronavalli VB, Ranasinghe AM, Venkateswaran RJ, James SR, McCabe CJ, Wilson IC, et al. N-terminal pro-brain-type natriuretic peptide: a biochemical surrogate of cardiac function in the potential heart donor. *Eur J Cardiothorac Surg*. 2010;38(2):181-6.
215. Vorlat A, Conraads VM, Jorens PG, Aerts S, Van Gorp S, Vermeulen T, et al. Donor B-type natriuretic peptide predicts early cardiac performance after heart transplantation. *J Heart Lung Transplant*. 2012;31(6):579-84.
216. Birks EJ, Owen VJ, Burton PB, Bishop AE, Banner NR, Khaghani A, et al. Tumor necrosis factor-alpha is expressed in donor heart and predicts right ventricular failure after human heart transplantation. *Circulation*. 2000;102(3):326-31.
217. Venkateswaran RV, Dronavalli V, Lambert PA, Steeds RP, Wilson IC, Thompson RD, et al. The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. *Transplantation*. 2009;88(4):582-8.
218. Wagner FD, Jonitz B, Potapov EV, Qedra N, Wegscheider K, Abraham K, et al. Procalcitonin, a donor-specific predictor of early graft failure-related mortality after heart transplantation. *Circulation*. 2001;104(12 Suppl 1):I192-6.
219. Wagner FD, Jonitz B, Potapov E, Qedra N, Wegscheider K, Weinmann E, et al. Procalcitonin: a donor-specific predictor of early graft failure and early graft failure mortality after heart transplantation. *J Heart Lung Transplant*. 2001;20(2):206.
220. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2017;36(10):1037-46.
221. Chambers DC, Yusen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khush K, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2017;36(10):1047-59.
222. Goldfarb SB, Levvey BJ, Cherikh WS, Chambers DC, Khush K, Kucheryavaya AY, et al. Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Lung and Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2017;36(10):1070-9.
223. Rossano JW, Cherikh WS, Chambers DC, Goldfarb S, Khush K, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2017;36(10):1060-9.
224. Kirsch M, Baufretton C, Naftel DC, Benvenuti C, Loisanse DY. Pretransplantation risk factors for death after heart transplantation: the Henri Mondor experience. *J Heart Lung Transplant*. 1998;17(3):268-77.
225. Bourge RC, Naftel DC, Costanzo-Nordin MR, Kirklin JK, Young JB, Kubo SH, et al. Pretransplantation risk factors for death after heart transplantation: a multi-institutional study. *The Transplant Cardiologists Research Database Group. J Heart Lung Transplant*. 1993;12(4):549-62.
226. Fernandez J, Aranda J, Mabbot S, Weston M, Cintron G. Overseas procurement of donor hearts: ischemic time effect on postoperative outcomes. *Transplant Proc*. 2001;33(7-8):3803-4.
227. Briganti EM, Bergin PJ, Rosenfeldt FL, Esmore DS, Rabinov M. Successful long-term outcome with prolonged ischemic time cardiac allografts. *J Heart Lung Transplant*. 1995;14(5):840-5.
228. Sunjaya AF, Sunjaya AP. Combating Donor Organ Shortage: Organ Care System Prolonging Organ Storage Time and Improving the Outcome of Heart Transplantations. *Cardiovasc Ther*. 2019;2019:9482797.
229. Cantin B, Kwok BW, Chan MC, Valentine HA, Oyer PE, Robbins RC, et al. The impact of brain death on survival after heart transplantation: time is of the essence. *Transplantation*. 2003;76(9):1275-9.
230. Mehra MR, Uber PA, Ventura HO, Scott RL, Park MH. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. *Journal of the American College of Cardiology*. 2004;43(5):806-10.
231. Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation:

- Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2016;35(10):1158-69.
232. Singhal AK, Sheng X, Drakos SG, Stehlik J. Impact of donor cause of death on transplant outcomes: UNOS registry analysis. *Transplant Proc*. 2009;41(9):3539-44.
 233. Szabo G, Hackert T, Buhmann V, Sebering C, Vahl CF, Hagl S. Myocardial performance after brain death: studies in isolated hearts. *Ann Transplant*. 2000;5(4):45-50.
 234. Mohamedali B, Bhat G, Tatroles A, Zelinger A. Neurogenic stress cardiomyopathy in heart donors. *Journal of cardiac failure*. 2014;20(3):207-11.
 235. Berman M, Ali A, Ashley E, Freed D, Clarke K, Tsui S, et al. Is stress cardiomyopathy the underlying cause of ventricular dysfunction associated with brain death? *J Heart Lung Transplant*. 2010;29(9):957-65.
 236. Karamlou T, Shen I, Slater M, Crispell K, Chan B, Ravichandran P. Decreased recipient survival following orthotopic heart transplantation with use of hearts from donors with projectile brain injury. *J Heart Lung Transplant*. 2005;24(1):29-33.
 237. Tsai FC, Marelli D, Bresson J, Gjertson D, Kermani R, Patel J, et al. Use of hearts transplanted from donors with atraumatic intracranial bleeds. *J Heart Lung Transplant*. 2002;21(6):623-8.
 238. Baroldi G, Di Pasquale G, Silver MD, Pinelli G, Lusa AM, Fineschi V. Type and extent of myocardial injury related to brain damage and its significance in heart transplantation: a morphometric study. *J Heart Lung Transplant*. 1997;16(10):994-1000.
 239. Waller DA, Thompson AM, Wrightson WN, Gould FK, Corris PA, Hilton CJ, et al. Does the mode of donor death influence the early outcome of lung transplantation? A review of lung transplantation from donors involved in major trauma. *J Heart Lung Transplant*. 1995;14(2):318-21.
 240. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. *Transplantation*. 1998;65(12):1533-42.
 241. Wahlers T, Cremer J, Fieguth HG, Dammenhayn L, Albes J, Schafers HJ, et al. Donor heart-related variables and early mortality after heart transplantation. *J Heart Lung Transplant*. 1991;10(1 Pt 1):22-7.
 242. Hornik L, Tenderich G, Wlost S, Zittermann A, Minami K, Koerfer R. Organs from donors with primary brain malignancy: the fate of cardiac allograft recipients. *Transplantation proceedings*. 2004;36(10):3133-7.
 243. Warrens AN, Birch R, Collett D, Daraktchiev M, Dark JH, Galea G, et al. Advising potential recipients on the use of organs from donors with primary central nervous system tumors. *Transplantation*. 2012;93(4):348-53.
 244. Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. *The British journal of surgery*. 2014;101(7):768-74.
 245. Freimark D, Aleksic I, Trento A, Takkenberg JJ, Valenza M, Admon D, et al. Hearts from donors with chronic alcohol use: a possible risk factor for death after heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 1996;15(2):150-9.
 246. Houyel L, Petit J, Nottin R, Duffet JP, Mace L, Neveux JY. Adult heart transplantation: adverse role of chronic alcoholism in donors on early graft function. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 1992;11(6):1184-7.
 247. Shea KJ, Sopko NA, Ludrosky K, Hoercher K, Smedira NG, Taylor DO, et al. The effect of a donor's history of active substance on outcomes following orthotopic heart transplantation. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery*. 2007;31(3):452-6; discussion 6.
 248. Houser SL, MacGillivray T, Aretz HT. The impact of cocaine on the donor heart: a case report. *J Heart Lung Transplant*. 2000;19(6):609-11.
 249. Freimark D, Czer LS, Admon D, Aleksic I, Valenza M, Barath P, et al. Donors with a history of cocaine use: effect on survival and rejection frequency after heart transplantation. *J Heart Lung Transplant*. 1994;13(6):1138-44.
 250. Koerner MM, Tenderich G, Minami K, Morshuis M, Mirow N, Arusoglu L, et al. Extended donor criteria: use of cardiac allografts after carbon monoxide poisoning. *Transplantation*. 1997;63(9):1358-60.
 251. Ogawa Y, Tenderich G, Minami K, Schulz U, Kleikamp G, Hornik L, et al. Successful use of a cardiac allograft from tricyclic antidepressant intoxication. *Transplantation*. 2003;76(8):1239-40.
 252. Tenderich G, Dagge A, Schulz U, Holzinger J, Hornik L, Mirow N, et al. Successful use of cardiac allograft from serotonin antagonist intoxication. *Transplantation*. 2001;72(3):529.
 253. MacGowan GA, Dark JH, Corris PA, Nair AR. Effects of drug abuse, smoking and alcohol on donor hearts and lungs. *Transplant international : official journal of the European Society for Organ Transplantation*. 2019;32(10):1019-27.
 254. Okoh AK, Chan O, Schultheis M, Gupta M, Shah A, Gold J, et al. Association between increased-risk donor social behaviors and recipient outcomes after heart transplantation. *Clinical transplantation*. 2020;34(3):e13787.
 255. Vieira JL, Cherikh WS, Lindblad K, Stehlik J, Mehra MR. Cocaine use in organ donors and long-term outcome after heart transplantation: An International Society for Heart and Lung Transplantation registry analysis. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2020;39(12):1341-50.
 256. Hussain Z, Yu M, Wozniak A, Kim D, Krepostman N, Liebo M, et al. Impact of donor smoking history on post heart transplant outcomes: A propensity-matched analysis of ISHLT registry. *Clinical transplantation*. 2021;35(1):e14127.
 257. Loupy A, Coutance G, Bonnet G, Van Keer J, Raynaud M, Aubert O, et al. Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study. *Circulation*. 2020;141(24):1954-67.
 258. Buell JF, Trofe J, Hanaway MJ, Lo A, Rosengard B, Rilo

- H, et al. Transmission of donor cancer into cardiothoracic transplant recipients. *Surgery*. 2001;130(4):660-6; discussion 6-8.
259. Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. *Transplantation*. 2012;94(12):1200-7.
260. Garrido G, Matesanz R. The Spanish National Transplant Organization (ONT) tumor registry. *Transplantation*. 2008;85(8 Suppl):S61-3.
261. Kransdorf EP, Rushakoff JA, Han J, Benck L, Malinoski D, Emerson D, et al. Donor hyperoxia is a novel risk factor for severe cardiac primary graft dysfunction. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2023;42(5):617-26.
262. Jeevanandam V, Furukawa S, Prendergast TW, Todd BA, Eisen HJ, McClurken JB. Standard criteria for an acceptable donor heart are restricting heart transplantation. *The Annals of thoracic surgery*. 1996;62(5):1268-75.
263. Hunt SA, Baldwin J, Baumgartner W, Bricker JT, Costanzo MR, Miller L, et al. Cardiovascular management of a potential heart donor: a statement from the Transplantation Committee of the American College of Cardiology. *Crit Care Med*. 1996;24(9):1599-601.
264. Laks H, Marelli D, Fonarow GC, Hamilton MA, Ardehali A, Moriguchi JD, et al. Use of two recipient lists for adults requiring heart transplantation. *J Thorac Cardiovasc Surg*. 2003;125(1):49-59.
265. Patel J, Kobashigawa JA. Cardiac transplantation: the alternate list and expansion of the donor pool. *Curr Opin Cardiol*. 2004;19(2):162-5.
266. Chen JM, Russo MJ, Hammond KM, Mancini DM, Kherani AR, Fal JM, et al. Alternate waiting list strategies for heart transplantation maximize donor organ utilization. *The Annals of thoracic surgery*. 2005;80(1):224-8.
267. Felker GM, Milano CA, Yager JE, Hernandez AF, Blue L, Higginbotham MB, et al. Outcomes with an alternate list strategy for heart transplantation. *J Heart Lung Transplant*. 2005;24(11):1781-6.
268. Arns W, Citterio F, Campistol JM. 'Old-for-old'--new strategies for renal transplantation. *Nephrol Dial Transplant*. 2007;22(2):336-41.
269. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. *Transplantation*. 2007;83(5):539-45.
270. Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. *Transplantation*. 2009;88(2):231-6.
271. Rizzi G, Startseva X, Wolfrum M, Luscher TF, Ruschitzka F, Frohlich GM, et al. Unfavorable Donor Pretransplant APACHE II, SAPS II, and SOFA Scores Are Not Associated With Outcome: Implications for Heart Transplant Donor Selection. *Transplantation proceedings*. 2016;48(8):2582-7.
272. Fraser CD, 3rd, Grimm JC, Zhou X, Lui C, Giuliano K, Suarez-Pierre A, et al. Children's Heart Assessment Tool for Transplantation (CHAT) Score: A Novel Risk Score Predicts Survival After Pediatric Heart Transplantation. *World J Pediatr Congenit Heart Surg*. 2019;10(3):296-303.
273. Coutance G, Kransdorf E, Bonnet G, Loupy A, Kobashigawa J, Patel JK. Statistical performance of 16 posttransplant risk scores in a contemporary cohort of heart transplant recipients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2021;21(2):645-56.
274. Powner DJ, Darby JM. Management of variations in blood pressure during care of organ donors. *Prog Transplant*. 2000;10(1):25-30; quiz 1-2.
275. Powner DJ, Kellum JA. Maintaining acid-base balance in organ donors. *Prog Transplant*. 2000;10(2):98-103; quiz 4-5.
276. Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. *Transplantation*. 1987;43(6):852-4.
277. Wheeldon DR, Potter CD, Oduro A, Wallwork J, Large SR. Transforming the "unacceptable" donor: outcomes from the adoption of a standardized donor management technique. *J Heart Lung Transplant*. 1995;14(4):734-42.
278. Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. *Thyroid*. 1997;7(1):139-45.
279. Hornby K, Ross H, Keshavjee S, Rao V, Shemie SD. Non-utilization of hearts and lungs after consent for donation: a Canadian multicentre study. *Can J Anaesth*. 2006;53(8):831-7.
280. McKeown DW, Bonser RS, Kellum JA. Management of the heartbeating brain-dead organ donor. *Br J Anaesth*. 2012;108 Suppl 1:i96-107.
281. Rayburn BK, Burton TM, Wannenburg T, Pennington DG, Oaks TE. Are efforts at expanding the donor pool misdirected? *J Heart Lung Transplant*. 1998;17(10):998-1003.
282. Potter CD, Wheeldon DR, Wallwork J. Functional assessment and management of heart donors: a rationale for characterization and a guide to therapy. *J Heart Lung Transplant*. 1995;14(1 Pt 1):59-65.
283. Stoica SC, Satchithananda DK, Charman S, Sharples L, King R, Rozario C, et al. Swan-Ganz catheter assessment of donor hearts: outcome of organs with borderline hemodynamics. *J Heart Lung Transplant*. 2002;21(6):615-22.
284. Powner DJ, Crommett JW. Advanced assessment of hemodynamic parameters during donor care. *Prog Transplant*. 2003;13(4):249-57; quiz 56-7.
285. Agrawal A, Timothy J, Cincu R, Agarwal T, Waghmare LB. Bradycardia in neurosurgery. *Clin Neurol Neurosurg*. 2008;110(4):321-7.
286. Szabo G, Hackert T, Sebening C, Vahl CF, Hagl S. Modulation of coronary perfusion pressure can reverse cardiac dysfunction after brain death. *The Annals of thoracic surgery*. 1999;67(1):18-25; discussion -6.
287. Anwar A, Lee JM. Medical Management of Brain-Dead Organ Donors. *Acute Crit Care*. 2019;34(1):14-29.
288. Nygaard CE, Townsend RN, Diamond DL. Organ donor management and organ outcome: a 6-year review from a Level I trauma center. *J Trauma*. 1990;30(6):728-32.
289. Dictus C, Vienenkoetter B, Esmaeilzadeh M, Unterberg

- A, Ahmadi R. Critical care management of potential organ donors: our current standard. *Clin Transplant*. 2009;23 Suppl 21:2-9.
290. Kamarainen A, Virkkunen I, Tenhunen J. Hypothermic preconditioning of donor organs prior to harvesting and ischaemia using ice-cold intravenous fluids. *Med Hypotheses*. 2009;73(1):65-6.
 291. Bugge JF. Brain death and its implications for management of the potential organ donor. *Acta Anaesthesiol Scand*. 2009;53(10):1239-50.
 292. Pandit RA, Zirpe KG, Gurav SK, Kulkarni AP, Karnath S, Govil D, et al. Management of Potential Organ Donor: Indian Society of Critical Care Medicine: Position Statement. *Indian J Crit Care Med*. 2017;21(5):303-16.
 293. Mascia L, Pasero D, Slutsky AS, Arguis MJ, Berardino M, Grasso S, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. *JAMA*. 2010;304(23):2620-7.
 294. Powner DJ, Darby JM, Kellum JA. Proposed treatment guidelines for donor care. *Prog Transplant*. 2004;14(1):16-26; quiz 7-8.
 295. Dominguez-Roldan JM, Jimenez-Gonzalez PI, Garcia-Alfaro C, Hernandez-Hazanas F, Fernandez-Hinojosa E, Bellido-Sanchez R. Electrolytic disorders, hyperosmolar states, and lactic acidosis in brain-dead patients. *Transplant Proc*. 2005;37(5):1987-9.
 296. Yellon DM, Baxter GF. Sodium-hydrogen exchange in myocardial reperfusion injury. *Lancet*. 2000;356(9229):522-3.
 297. Kaczmarek I, Groetzner J, Mueller M, Landwehr P, Uberfuhr P, Nollert G, et al. Impact of donor serum sodium levels on outcome after heart transplantation. *J Heart Lung Transplant*. 2005;24(7):928-31.
 298. Powner DJ, Hernandez M. A review of thyroid hormone administration during adult donor care. *Prog Transplant*. 2005;15(3):202-7.
 299. Barklin A. Systemic inflammation in the brain-dead organ donor. *Acta Anaesthesiol Scand*. 2009;53(4):425-35.
 300. Gelb AW, Robertson KM. Anaesthetic management of the brain dead for organ donation. *Can J Anaesth*. 1990;37(7):806-12.
 301. Cerutti E, Stratta C, Romagnoli R, Serra R, Lepore M, Fop F, et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. *Liver Transpl*. 2006;12(8):1253-9.
 302. Meyfroidt G, Gunst J, Martin-Loeches I, Smith M, Robba C, Taccone FS, et al. Management of the brain-dead donor in the ICU: general and specific therapy to improve transplantable organ quality. *Intensive Care Med*. 2019;45(3):343-53.
 303. Len O, Garzoni C, Lumberras C, Molina I, Meije Y, Pahissa A, et al. Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections. *Clin Microbiol Infect*. 2014;20 Suppl 7:10-8.
 304. Freeman RB, Giatras I, Falagas ME, Supran S, O'Connor K, Bradley J, et al. Outcome of transplantation of organs procured from bacteremic donors. *Transplantation*. 1999;68(8):1107-11.
 305. Lumberras C, Sanz F, Gonzalez A, Perez G, Ramos MJ, Aguado JM, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. *Clin Infect Dis*. 2001;33(5):722-6.
 306. Ruiz I, Gavalda J, Monforte V, Len O, Roman A, Bravo C, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2006;6(1):178-82.
 307. Bahrami T, Vohra HA, Shaikhrezai K, Tadjkarimi S, Banner N, Amrani M, et al. Intrathoracic organ transplantation from donors with meningitis: a single-center 20-year experience. *The Annals of thoracic surgery*. 2008;86(5):1554-6.
 308. Webb WR, Howard HS, Neely WA. Practical methods of homologous cardiac transplantation. *The Journal of thoracic surgery*. 1959;37(3):361-6.
 309. Shumway NE, Lower RR, Stofer RC. Selective hypothermia of the heart in anoxic cardiac arrest. *Surgery, gynecology & obstetrics*. 1959;109:750-4.
 310. Cass MH, Brock R. Heart excision and replacement. *Guys Hosp Rep*. 1959;108:285-90.
 311. Bretschneider HJ, Hubner G, Knoll D, Lohr B, Nordbeck H, Spieckermann PG. Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. *The Journal of cardiovascular surgery*. 1975;16(3):241-60.
 312. Li Y, Guo S, Liu G, Yuan Y, Wang W, Zheng Z, et al. Three Preservation Solutions for Cold Storage of Heart Allografts: A Systematic Review and Meta-Analysis. *Artif Organs*. 2016;40(5):489-96.
 313. Wicomb WN, Cooper DK, Novitzky D, Barnard CN. Cardiac transplantation following storage of the donor heart by a portable hypothermic perfusion system. *The Annals of thoracic surgery*. 1984;37(3):243-8.
 314. Dhital KK, Iyer A, Connellan M, Chew HC, Gao L, Doyle A, et al. Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series. *Lancet*. 2015;385(9987):2585-91.
 315. Celik A, Lindstedt S, McGiffin DC, Suen JY, Fraser JF, Del Nido PJ, et al. Revitalizing donor organs: The potential of mitochondrial transplantation in heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2025;44(10):1648-58.
 316. Moskowitzova K, Shin B, Liu K, Ramirez-Barbieri G, Guariento A, Blitzer D, et al. Mitochondrial transplantation prolongs cold ischemia time in murine heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2019;38(1):92-9.
 317. Doulamis IP, Nomoto RS, Tzani A, Hong X, Duignan T, Celik A, et al. Transcriptomic and proteomic pathways of diabetic and non-diabetic mitochondrial transplantation. *Sci Rep*. 2022;12(1):22101.
 318. Guariento A, Piekarski BL, Doulamis IP, Blitzer D, Ferraro AM, Harrild DM, et al. Autologous mitochondrial transplantation for cardiogenic shock in pediatric patients following ischemia-reperfusion injury. *The Journal of thoracic and cardiovascular surgery*. 2021;162(3):992-1001.



KALP TRANSPLANTASYONU

BÖLÜM 73

Abdullah MAŞTA¹
Ömer BAYAZIT²

DOI: 10.37609/akya.3889.c5395

İçindekiler

- » GİRİŞ VE GENEL BİLGİLER
- » KALP TRANSPLANTASYONUNUN TARİHÇESİ
- » RESİPIENT SEÇİMİ
- » DONÖR SEÇİMİ VE DEĞERLENDİRİLMESİ
- » DONÖR – RESİPIENT UYUMU
- » KALP TRANSPLANTASYONUNDA CERRAHİ TEKNİK
- » ERKEN POSTOPERATİF TAKİP VE KOMPLİKASYONLAR
- » KALP TRANSPLANTASYONUNUN İMMÜNOBİYOLOJİSİ
- » AKUT REJEKSİYON TANI VE TEDAVİSİ
- » TRANSPLANTASYON SONRASINDA GELİSEN İNFEKSİYON HASTALIKLARI
- » İNFEKSİYON PROFLAKSİ
- » KARDİYAK ALLOGREFT VASKÜLOPATİ
- » KALP TRANSPLANT HASTALARINDA GEÇ DÖNEM TAKİP
- » TRANSPLANTASYON SONRASI YAŞAM SÜRESİ VE HAYAT KALİTESİ

¹ Uzm. Dr., Akdeniz Üniversitesi Hastanesi, Kalp ve Damar Cerrahisi, abduhahmasta@hotmail.com, ORCID iD: 0009-0002-7479-2840

² Prof. Dr., Akdeniz Üniversitesi Tıp Fakültesinde, bayezid@akdeniz.edu.tr

beklentisi %85'den fazla ve 10 yıllık yaşam beklentisi %50-60 arasındadır. Cleveland kliniğın kalp transplantasyonu sonuçlarında, sağ kalım oranları, ilk ay %96, 1. Yıl %89, 3. Yıl %85, 5. Yıl %78 ve 8. Yıl %69 olarak bildirilmiştir. ISHLT verilerine göre, 1982-2007 yılları arasında kalp transplantasyonu yapılmış 78050 hastada, ortalama yarı ömür 10 yıldan fazladır. 1982-1991 yılları arasında transplantasyon yapılmış hastaların ortalama yarı ömürleri 8.8 yıl iken 1992-2001 arası transplant yapılanlarda bu süre 10.5 yıla dek yükselmiştir. Sağ kalım oranları birinci yıl %82, 5. Yıl %69, 10. Yıl %51 ve 15. Yılda %34'dür. (176) İlk yıldaki mortalite nedenlerinin sonraki yıllarla karşılaştırıldığında farklı sebeplerden olduğu görülmektedir. Transplantasyon sonrası ilk 30 günde ki ölümlerin en sık sebebi primer greft yetmezliğidir. Birinci yıl içinde ki ölümlerin en sık sebepleri ise akut rejeksiyon ve enfeksiyonlardır. Birinci yıldan sonra ise maligniteler ve kardiyak allogreft vaskülopati (KAV) başlıca mortalite nedenini oluşturmaktadır.(176) Kalp transplantasyonunun başarısını tek başına sağ kalım oranı ile değerlendirmek doğru değildir, hayat kalitesi de göz önünde bulundurulmalıdır.

Hayat kalitesi: fonksiyonel yeterlilik, psiko-sosyal, kişisel ve mental durum ile değerlendirilir. Kalp transplantasyon adaylarının bir yıllık beklenen sağ kalım oranı ortalama 650 olup hayat kalitesi ciddi kalp yetmezliği semptomlarına bağlı ileri derecede kötüdür, Transplantasyon sonrası hastaların %90'dan fazlasında yetmezlik semptomları tamamen kaybolur veya çok azalır Hastaların tamamına yakınında preoperatif fonksiyonel kapasite NYHA sınıf III veya IV iken transplantasyondan sonra sınıf I veya II dir.(182) transplantasyondan 9-13 yıl sonra hastaların %91'inin sınıf I veya II olduğunu ve bunların %79'unun genel durumlarının çok iyi olduğunu bildirmişlerdir. (183) ISHLT verilerine göre 5 yıllık takipte, hastaların 96914'ü hiçbir aktivite kısıtlaması olmadan hayatlarını idame ettirebilmekte, sadece %0.4'ü tamamen dış desteğe bağımlı olarak yaşamaktadırlar.(176)

Fonksiyonel yeterlilik, günlük yaşam aktiviteleri, aile içi aktiviteler, iş hayatı, maddi durum,

cinsel fonksiyonlar, yaşama sevinci ve öz güven ile değerlendirilir. Transplantasyon öncesi hastaların çok büyük bir kısmı iş hayatında aktif olarak çalışamaz konumdadır. Transplantasyon sonrası ise hastalar normal kalp fonksiyonları ile üretken insanlar olarak işlerine dönebilirler. Transplantasyon yapılmış 25-55 yaş arası resipientlerin %39.3'ünün birinci yılda tekrar çalışmaya başladığı, 7 yılda ise %54.4'ünün part-time veya tamamen aktif olarak çalışma hayatında yer aldığı bildirilmiştir. (176)

Cinsel fonksiyonlarda transplantasyon öncesi döneme göre önemli düzeltilmeler olduğu bilinmektedir. Bir çalışmada cinsel fonksiyon bozukluğunun, transplant öncesi hastaların %84'ünde, transplant sonrası ise %29'unda görüldüğü bildirilmiştir. (184) Transplantasyonu takiben geç dönemde özellikle steroid kullanımına bağlı kas güçsüzlüğü, miyalji, osteopeni veya eklem harabiyetine bağlı günlük aktivitelerde de bozulmalar görülebilmektedir. Aravot ve arkadaşlarının, 5 yıldan fazla yaşayan kalp transplant resipientleriyle yaptıkları çalışmada günlük ortalama yürüyüş mesafesinin 6.5 km olduğunu ve hastaların %60'nın aktif olarak çalıştığını bildirmişlerdir. Hastaların %80'i cinsel fonksiyonlarının yeterli olduğu ve %80'i hayat kalitesinden yeterince tatmin olduklarını ifade etmişlerdir. (185)

KAYNAKLAR

1. American Heart Association. (2024). *Heart failure facts*. <https://www.heart.org>
2. European Society of Cardiology. (2021). *2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure*. European Heart Journal, 42(36), 3599–3726. <https://doi.org/10.1093/eurheartj/ehab368>
3. Organ Procurement and Transplantation Network (OPTN), & Scientific Registry of Transplant Recipients (SRTR). (2023). *OPTN/SRTR 2023 annual data report: Heart transplantation*. <https://optn.transplant.hrsa.gov>
4. T.C. Sağlık Bakanlığı. (2010). *Kalp nakli istatistikleri* [Heart transplant statistics]. Organ Nakli Koordinasyon Merkezi.
5. T.C. Sağlık Bakanlığı. (2024). *2024 yılı organ nakli verileri* [2024 organ transplant data]. Organ Nakli Koordinasyon Merkezi.
6. TransMedics Inc. (2023). *Clinical results from the Organ Care System (OCS) for heart transplantation*. <https://www.transmedics.com>

7. Carrel, A. (1905). The surgery of blood vessels. *Journal of the American Medical Association*, 44(5), 353-355. <https://doi.org/10.1001/jama.1905.92500180001001d>
8. Markus E, Wong SNT, Luisada AA: Homologous heart grafts: Transplantation of the heart in dogs. *Surg Forum* 2:12, 1951.
9. Demikhov VP. *Texperimental Transplantation of vital Organs*.(B. Haigh, Trans.), New York, Consultants Bureau, 1962.
10. Willman VL, Jellinek M, Cooper T, et al: Metabolism of the transplanted heart: Effect of excision and reimplantation on myocardial glycogen, hexokinase, and acetylcholine esterase. *Surgery* 56:266, 1964.
11. Kantrowitz A, Huller JD, Joos H, Cerroto MM, Carstensen HE. Transplantation of the heart in an infant and an adult. *Am J Cardiol*. 22, 782-790, 1968
12. Bayezid Ö, Balkanay M, Carin M ve ark. Türkiye’de ilk takipli ortotopik kalp transplantasyonu. *Türk Kardiyol Dern Arş*. 18: 136-141, 1990
13. Bayezid Ö, Balkanay M, Öztekin İ ve ark. The first successful heart transplantation in Turkey. *Koşuyolu Heart Journal*.1:3-10, 1990
14. Oto Ö, Açikel Ü, Hazan E ve ark. Çocukluk çağında Kalp ve akciğer transplantasyonu: Ülkemizde ilk uygulama. *Türk Kardiyol Dern Arş*. 26: 446-448, 1998.
15. <https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.109.858076>
16. Baumwol J. “I Need Help”-A mnemonic to aid timely referral in advanced heart failure. *J Heart Lung Transplant* 2017;36:593-4. <https://doi.org/10.1016/j.healun.2017.02.010>.
17. Rahimi K, Bennett D, Conrad N, et al. Risk prediction in patients with heart failure: a systematic review and analysis. *JACC Heart Fail* 2014;2:440-6. <https://doi.org/10.1016/j.jchf.2014.04.008>.
18. Khush KK, Hsich E, Potena L, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report - 2021; focus on recipient characteristics. *J Heart Lung Transplant* 2021;40:1035-49. <https://doi.org/10.1016/j.healun.2021.07.015>.
19. Weiss ES, Nwakanma LU, Patel ND, Yuh DD. Outcomes in patients older than 60 years of age undergoing orthotopic heart transplantation: an analysis of the UNOS database. *J Heart Lung Transplant* 2008;27:184-91. <https://doi.org/10.1016/j.healun.2007.11.566>.
20. Goldstein DJ, Bello R, Shin JJ, et al. Outcomes of cardiac transplantation in septuagenarians. *J Heart Lung Transplant* 2012;31:679-85. <https://doi.org/10.1016/j.healun.2012.03.019>. published correction appears in *J Heart Lung Transplant*. 2014 Mar;33(3):326.
21. Jaiswal A, Gadela NV, Baran D, et al. Clinical outcomes of older adults listed for heart transplantation in the United States. *J Am Geriatr Soc* 2021;69:2507-17. <https://doi.org/10.1111/jgs.17271>.
22. Russo MJ, Hong KN, Davies RR, et al. The effect of body mass index on survival following heart transplantation: do outcomes support consensus guidelines. *Ann Surg* 2010;251:144-52. <https://doi.org/10.1097/SLA.0b013e3181b5db3c>.
23. Batra J, DeFilippis EM, Golob S, et al. Impact of pre-transplant malignancy on heart transplantation outcomes: contemporary United Network for Organ Sharing analysis amidst evolving cancer therapies. *Circ Heart Fail* 2022;15:e008968. <https://doi.org/10.1161/CIRC-HEARTFAILURE.121.008968>.
24. Russo MJ, Chen JM, Hong KN, et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. *Circulation* 2006;114:2280-7. <https://doi.org/10.1161/CIRCULATIONAHA.106.615708>.
25. Newman JD, Schlendorf KH, Cox ZL, et al. Post-transplant diabetes mellitus following heart transplantation. *J Heart Lung Transplant* 2022;41:1537-46. <https://doi.org/10.1016/j.healun.2022.07.011>.
26. Vakil K, Duval S, Sharma A, et al. Impact of pre-transplant pulmonary hypertension on survival after heart transplantation: a UNOS registry analysis. *Int J Cardiol* 2014;176:595-9. <https://doi.org/10.1016/j.ijcard.2014.08.072>.
27. Costard-Jäckle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. *J Am Coll Cardiol* 1992;19:48-54. [https://doi.org/10.1016/0735-1097\(92\)90050-w](https://doi.org/10.1016/0735-1097(92)90050-w).
28. Zern EK, Cheng S, Wolfson AM, et al. Angiotensin receptor-neprilysin inhibitor therapy reverses pulmonary hypertension in end-stage heart failure patients awaiting transplantation. *Circ Heart Fail* 2020;13:e006696. <https://doi.org/10.1161/CIRC-HEARTFAILURE.119.006696>.
29. Kittleson MM, Sharma K, Brennan DC, et al. Dual-organ transplantation: indications, evaluation, and outcomes for heart-kidney and heart-liver transplantation: a scientific statement from the American Heart Association. *Circulation* 2023;148:622-36. <https://doi.org/10.1161/>
30. Kobashigawa J, Dadhania DM, Farr M, et al. Consensus conference on heart-kidney transplantation. *Am J Transpl* 2021;21:2459-67. <https://doi.org/10.1111/ajt.16512>.
31. Karamlou T, Welke KF, McMullan DM, et al. Combined heart-kidney transplant improves post-transplant survival compared with isolated heart transplant in recipients with reduced glomerular filtration rate: analysis of 593 combined heart-kidney transplants from the United Network Organ Sharing Database. *J Thorac Cardiovasc Surg* 2014;147:456-461.e1. <https://doi.org/10.1016/j.jtcvs.2013.09.017>.
32. Itagaki S, Toyoda N, Moss N, et al. Outcomes of simultaneous heart and kidney transplantation. *J Am Coll Cardiol* 2023;81:729-40.
33. Deo SV, Al-Kindi SG, Altarabsheh SE, et al. Model for end-stage liver disease excluding international normalized ratio (MELD-XI) score predicts heart transplant outcomes: evidence from the registry of the United Network for Organ Sharing. *J Heart Lung Transplant* 2016;35:222-7. <https://doi.org/10.1016/j.healun.2015.10.008>.
34. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. *Liver Transplant* 2008;14:159-72. <https://doi.org/10.1002/lt.21278>.
35. Duerinckx N, Burkhalter H, Engberg SJ, et al. Correlates and outcomes of post-transplant smoking in solid or-

- gan transplant recipients: a systematic literature review and meta-analysis. *Transplantation* 2016;100:2252-63. <https://doi.org/10.1097/TP.0000000000001335>.
36. Helmy R, Duerinckx N, De Geest S, et al. The international prevalence and variability of nonadherence to the nonpharmacologic treatment regimen after heart transplantation: Findings from the cross-sectional BRI-GHT study. *Clin Transplant* 2018;32:e13280. <https://doi.org/10.1111/ctr.13280>.
37. de la Rosa A, Singer-Englar T, Hamilton MA, IsHak WW, Kobashigawa JA, Kittleson MM. The impact of depression on heart transplant outcomes: a retrospective single-center cohort study. *Clin Transplant* 2021;35:e14204. <https://doi.org/10.1111/ctr.14204>.
38. Solomon NA, McGiven JR, Alison PM et al. Changing donor and recipient demographics in a heart transplantation program: Influence on early outcome. *Ann Thorac Surg*, 2004;77:2096-102.
39. Vega JD, Moore J, Murray S et al. Heart transplantation in the United States, 1998-2007. *Am J Transplant*, 2009;9:932-41.
40. Jaiswal A, Kittleson MM, Pillai A, Baran DT, Baker WL, Baker WM, et al. Usage of older donors is associated with higher mortality after heart transplantation: A UNOS observational study. *J Heart Lung Transplant*. 2024 May;43(5):806–815. doi:10.1016/j.healun.2024.01.005
41. Jaiswal A, Kittleson MM, Pillai A, Baran DT, Baker WL, Baker WM, et al. Usage of older donors is associated with higher mortality after heart transplantation: A UNOS observational study. *J Heart Lung Transplant*. 2024 May;43(5):806–815. doi:10.1016/j.healun.2024.01.005.
42. Russo MJ, Chen JM, Sorabella RA et al. The effect of ischemic time on survival after heart transplantation varies by donor age: An analysis of the United Network for Organ Sharing database. *J Thorac Cardiovasc Surg*, 2007;133:554-9.
43. Apostolakis E, Parissis H, Dougenis D. Brain death and donor heart dysfunction: Implication in cardiac transplantation. *J Card Surg*, 2010;25:98-106.
44. Cohen O, De La Zerda DJ, Beygui R, Hekmat D, Laks H. Donor brain death mechanisms and outcomes after heart transplantation. *Transplant Proc*, 2007;39:2964-9.
45. Cantin B, Kwok BW, Chan MC et al. The impact of brain death on survival after heart transplantation: Time is of the essence. *Transplantation*, 2003;76:1275-9.
46. Bentley MJ, Mullen JC, Lopushinsky SR, Modry DL. Successful cardiac transplantation with methanol or carbon monoxide-poisoned donors. *Ann Thorac Surg*, 2001;71:1194-7.
47. Tenderich G, Koerner MM, Posival Het al. Hemodynamic followup of cardiac allografts from poisoned donors. *Transplantation*, 1998;66:1163-7.
48. Wood DM, Dargan PI, Jones AL. Poisoned patients as potential organ donors: Postal survey of transplant centres and intensive care units. *Crit Care*, 2003;7:147-54.
49. Baldwin JC, Anderson JL, Boucek MM, Bristow MR, Jennings B. Task Force 2: Donor Guidelines. *J Am Coll Cardiol*, 1993;22:15-20.
50. Brown ME, Sarris GE, Oyer PE. Cardiac donor evaluation, Retrieval, and matching to recipient. Smith JA(Ed) *The Stanford manual of cardiopulmonary transplantation*, Futura publishing company, 1996, p:15-29.
51. Center for Disease Control: US Public Health Service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen. *Morb Mortal Wkly Rep*. 1996;45:1-9.
52. Avery RK, Pappas PG. Infections after heart(and heart/lung) transplantation. In Kirklin JKYoung JB, McGiffin DC(eds): *Heart Transplantation*, New York: Churchill Livingstone, 2002;521-83.
53. West LJ, Pollock-BarZiv SM, Dipchand AI et al. ABO incompatible heart transplantation in infants. *N Engl J Med*, 2001;344:793-800.
54. Dises VJ, Mull R, Daly ES, Edmunds LH, Mancini DM. Cardiac transplant donor heart allocation based on prospective tissue matching. *Ann Thorac Surg*, 1994;58:1050-342.
55. Smith, J. D., Danskin, A., & Pomerance, A. (1993). The beneficial effect of HLA-DR matching on rejection episodes following cardiac transplantation. *Journal of Heart and Lung Transplantation*, 12(S76).
56. George JF. *The Donor Heart*, Kirklin JK.(ed) *Heart Transplantation*, Churchill Livingstone, New York, Edinburg, 2002;1:293-338.
57. Golberg M, Berman EF, Akman LC. Homologous transplantation of the canine heart. *J Int Coll Surg*. 1958;3:145-51.
58. Costanzo MR. Selection and treatment of candidates for heart transplantation. *Semin Thorac Cardiovasc Surg*. 1996;8:113-25
59. Russo MJ, Chen JM, Sorabella RA et al. The effect of ischemic time on survival after heart transplantation varies by donor age: An analysis of the United Network for Organ Sharing database. *J Thorac Cardiovasc Surg*. 2007;133:554-9.
60. Xavier MM, Hendrick TT, Frank S et al, Gastrointestinal Disease following Heart Transplantation. *World J. Surg*, 1999;23:650-6.
61. James K Kirklin, James B Young. David C. McGiffin *The Heart Transplant Operation*. Heart Transplantation Churchill Livingstone Philadelphia, Pennsylvania. 2002:339-52
62. David K. Swanson and P. David Myerowitz. *Heart Preservation for Transplantation*, Heart Transplantation on P. David Myerowitz. MD. Heart Transplantation. Futura Publishing Company Inc. Mount Kisco, New York, 1987,339-55
63. P David Myerowitz. *Orthotopic Heart Transplantation: Operative Technique*. P David Myerowitz. Heart Transplantation. Futura Publishing Company. Mount Kisco. New York, 1987,141-54.
64. Dreyfus G, Jebara V, Mihaileanu S, Carpentier AF. Total orthotopic heart transplantation: An alternative to the standard technique. *Ann Thorac Surg*. 1991;52:1181-4.
65. Sarsam MA, Campbell CS, Yonan NA et al. An alternative surgical technique in orthotopic cardiac transplantation *J Card Surg*, 1993;8:344-9
66. Delezue Ph, Benvenuti C, Mszucchelli Petal *Orthotopic Cardiac Transplantation With Direct Caval Anastomosis: Is it optimal procedure?* *The Journal of Thoracic and Cardiovascular Surgery*, 1906731-7
67. Barnard CN, Loeman JG. Left ventricular bypass *S Afr Med J*.1975 49:30-12
68. G. Howard Frazier, OU John Olkerekere, et al. *Heterotopic Heart Transplantation in Three Patients at the Texas Heart Institute* *Texas Heart Institute Journal*, 1985-12-221-32

69. McCarthy, P. M., & Stinson, E. B. (1996). Routine posttransplant procedures and early postoperative problems after cardiac transplantation. In J. A. Smith (Ed.), *The Stanford manual of cardiopulmonary transplantation* (pp. 63–76). Armonk, NY: Futura Publishing Company.
70. Stobierska-Dzierzek, B., Awad, H., & Michler, R. E. (2001). The evolving management of acute right-sided heart failure in cardiac transplant recipients. *Journal of the American College of Cardiology*, 38(4), 923–931.
71. Kirklin, J. K., Young, J. B., & McGiffin, D. C. (2002). Management of the recipient during the transplant hospitalization. In *Heart Transplantation* (pp. 375–389). Philadelphia, PA: Churchill Livingstone.
72. Lima, B., Rajagopal, K., Petersen, R. P., Shah, A. S., Soule, B., & Felker, G. M. (2006). Marginal cardiac allografts are not associated with increased primary graft dysfunction in alternative listing transplantation. *Circulation*, 114(1_suppl), I-27–I-32. <https://doi.org/10.1161/CIRCULATIONAHA.105.000737>
73. McCarthy, P. M., & Stinson, E. B. (1996). Routine posttransplant procedures and early postoperative problems after cardiac transplantation. In J. A. Smith (Ed.), *The Stanford manual of cardiopulmonary transplantation* (pp. 63–76). Armonk, NY: Futura Publishing Company.
74. Blumer, V., Marbach, J., Veasey, T., & Kanwar, M. (2022). The role of medical management of cardiogenic shock in the era of mechanical circulatory support. *Current Opinion in Cardiology*, 37(3), 250–260. <https://doi.org/10.1097/HCO.0000000000000966>
75. Marasco, S. F., Vale, M., Pellegrino, V., Preovolos, A., Leet, A., & Kras, A. (2010). Extracorporeal membrane oxygenation for primary graft failure after heart transplantation. *The Annals of Thoracic Surgery*, 90(5), 1541–1546. <https://doi.org/10.1016/j.athoracsur.2010.05.066>
76. Pollock, K. A., McMillan, Z., Diederick, G., & Cronin, B. (2017). Low cardiac output after orthotopic heart transplantation due to large inferior vena cava thrombus following prothrombin complex administration: A case report. *A&A Practice*, 8(3), 43–46. <https://doi.org/10.1213/XAA.0000000000000418>
77. Drogalis-Kim, D. E., Gallotti, R. G., Blais, B. A., Perens, G., & Moore, J. P. (2018). Clinical and electrophysiological characteristics of atrial tachycardia after pediatric heart transplantation. *Pacing and Clinical Electrophysiology*, 41(9), 1093–1100. <https://doi.org/10.1111/pace.13415>
78. Taylor, M. E., McDiarmid, A. K., Matthews, I. G., Kararla, J., McComb, J. M., & Parry, G. (2021). Retrospective evaluation of catheter ablation for atrial flutter after heart transplantation. *Clinical Transplantation*, 35(10), e14429. <https://doi.org/10.1111/ctr.14429>
79. Scott, C. D., Dark, J. H., & McComb, J. M. (1992). Arrhythmias after cardiac transplantation. *American Journal of Cardiology*, 70(10), 1061–1063.
80. Potena, L., Prestinenzi, P., Bianchi, I. G., Masetti, M., Romani, P., Magnani, G., Fallani, F., Coccolo, F., Russo, A., Ponticelli, C., Rapezzi, C., Grigioni, F., & Branzi, A. (2012). Cyclosporine-sparing effect of everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized prospective study. *The Journal of Heart and Lung Transplantation*, 31(4), 373–379. <https://doi.org/10.1016/j.healun.2012.01.002>
81. Brent, L. B. (1999). The immunobiology of transplantation. *International Surgery*, 84(3), 275–278.
82. Bourge RC, Rodriguez ER, Tan CD. Cardiac allograft rejection. Kirklin JK.(ed) *Heart Transplantation*, Churchill Livingstone, New York, Edinburg 2002;1:464-520.
83. Cherry R, Nielsen H, Reed E et al. Vascular(humoral) rejection in human cardiac allograft biopsies: Relation to circulating anti-HLA antibodies. *J Heart Lung Transplant*, 1992;11:24-9.
84. Billingham ME, Cary NRB, Hammond ME et al. A working formulation for standardization of nomenclature in the diagnosis of heart and lung rejection. *J Heart Lung Transplant*, 1990;9:587-93
85. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant*, 2005;24:1710-20.
86. Fan PH, Kirklin JK, Naftel DC et al. Application of echo color flow Doppler mitral regurgitation to the diagnosis of acute cardiac transplant rejection. *Echocardiography*, 1992;8:169-74.
87. Gao SZ, Hunt SA, Wiederhold MA, Schroeder JS. Characteristics of serial electrocardiograms in heart transplant recipients. *Am Heart J*, 1991;2:771-4.
88. Jacquet L, Ziady G, Griffith B et al. Cardiac rhythm disturbances early after orthotopic heart transplantation: Prevalence and clinical importance of the observed abnormalities. *J Am Coll Cardiol*, 1990;16:832-7.
89. Fieguth HG, Haverich A, Schaeffers JH. Cytoimmunologic monitoring for the invasive diagnosis of cardiac rejection. *Transplant Proc*, 1987;19:2541-2.
90. Kobashigawa JA, Warner-Stevenson L. Noninvasive detection of acute cardiac allograft rejection. In Kapoor AS, Laks H, Schroeder Js, Yacoub MH(eds): *Cardiomyopathies and Heart-Lung Transplantation*. New York: McGraw-Hill, 1991; p:293-303.
91. Yamani MH, Taylor DO, Rodriguez ER et al. Transplant vasculopathy is associated with increased AlloMap gene expression score. *J Heart Lung Transplant*, 2007;26:403-6.
92. Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. *Am J Transplant*, 2006;6:150-60.
93. Hershberger RE, Starling RC, Eisen HJ et al. Daclizumab to prevent rejection after cardiac transplantation. *N. Engl. J. Med*, 2005;352:2705-13.
94. Mehra MR, Zucker MJ, Wagoner L et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. *J. Heart Lung Transplant*, 2005;24:1297-304.
95. Christie JD, Edwards LB, Aurora P et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth official adult heart transplant report 2009. *J Heart Lung Transplant*, 2009;28:1021-49.
96. Gammie JS, Pham SM. Tacrolimus (FK506) in thoracic organ transplantation. In Cooper DKC, Miller LW, Patterson GA(eds): *The transplantation and replacement of thoracic organs*. Boston: Kluwer publisher, 1996.
97. Taylor DO, Barr ML, Radovancevic B. Randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in car-

- diac transplanta-tion: Decreased hyperlipidemia and hypertension with tacrolimus. *J Heart Lung Transplant*,1999;18:336-45.
98. Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. *J Heart Lung Transplant*.2005;24:517-25.
99. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. *Transplantation*,2005;80:235-43.
100. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. *N. Engl. J. Med*.2003;349:847-58.
101. Delgado JF, Pombo M, Dalmau R et al. Low-dose oral prednisone in the treatment of acute cardiac allograft rejection. *Transplant Proc*,2002;34:117.
102. Heublein B, Wahlers T, Haverich A. Pulsed steroids for treatment of cardiac rejection after transplantation. What dosage is necessary? *Circulation*, 1989;80:III97-9.
103. Lindenfeld J, Miller GG, Shaker SF et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. *Circulation*,2004;110:3734-40.
104. Onsager DR, Canver CC, Jahania MS et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. *J. Heart Lung Transplant*,1999;18:448-55.
105. Costanzo-Nordin MR, Mcmanus BM, Wilson JE et al. Efficacy of photopheresis in the rescue therapy of acute cellular rejection in human heart allografts: a preliminary clinical and immunopathologic report. *Transplant. Proc*,1993;25:881-3.
106. Fishman, J. A. (2007). Infection in solid-organ transplant recipients. **New England Journal of Medicine**, 357(25), 2601–2614.
107. Kotton, C. N., Kumar, D., Caliendo, A. M., Asberg, A., Chou, S., Danziger-Isakov, L., ... & Snyderman, D. R. (2013). The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. **Transplantation**, 96(4), 333–360.
108. Singh, N., & Paterson, D. L. (2005). Infections in solid-organ transplant recipients. **Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases**, 3433–3452.
109. Razonable, R. R. (2011). Cytomegalovirus infection after liver transplantation: current concepts and challenges. **World Journal of Gastroenterology**, 17(34), 3952.
110. Snyderman, D. R. (2001). Epidemiology of infections after solid-organ transplantation. **Clinical Infectious Diseases**, 33(Supplement_1), S5–S8.
111. Rubin, R. H. (1993). Prevention and treatment of cytomegalovirus disease in heart transplant patients. **Reviews of Infectious Diseases**, 15(Supplement_1), S45–S52.
112. Danziger-Isakov, L., & Kumar, D. (2013). Vaccination in solid organ transplantation. **American Journal of Transplantation**, 13(s4), 311–317.
113. Freeman, R. B., Giatras, I., Falagas, M. E., Supran, S., & Tolkoff-Rubin, N. (2001). Meta-analysis of renal transplantation trials with anti-thymocyte globulin induction therapy. **Transplantation**, 71(7), 1060–1063.
114. Avery, R. K. (2004). Strategies for safe living after solid organ transplantation. **American Journal of Transplantation**, 4(6), 1040–1048.
115. Humar, A., & Michaels, M. (2006). American Society of Transplantation recommendations for screening, monitoring and reporting infectious complications in immunosuppression trials in recipients of organ transplantation. **American Journal of Transplantation**, 6(2), 262–274.
116. Taylor DO, Stehlik J, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. *J Heart Lung Transplant*, 2009;28:1007-22.
117. Costanzo MR, Naftel DC, Pritzker MR et al. Heart transplant coronary artery disease detected by coronary angiography: A multi-institutional study of pre-operative donor and recipient risk factors. *J Heart Lung Transplant*, 1998;17:744-53
118. Yeung AC, Davis SF, Hauptman PJ et al. Incidence and progression of transplant coronary artery disease over 1 year. Results of a multicenter trial with use of intravascular ultrasound. Multicenter intravascular Ultrasound Transplant Study Group. *J Heart Lung Transplant*, 1996;14:215-20
119. Sharples LD, Jackson CH, Parameshwar J, Wallwork J, Large SR Diagnostic accuracy of coronary angiography and risk factors for post heart-transplant cardiac allograft vasculopathy. *Transplantation*, 2003. 16:679-82
120. Kemna MS, Valentine HA, Hunt SA, Metabolic risk factors for atherosclerosis in heart transplant recipients. *Am Heart J*. 1994;128:68-72
121. Szeto WY, Krasinskas AM, Kreisel D, Krupnick AS, Popma SH, Rosengard BR. Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy. *Transplantation* 2002;73:1116-22
122. Gohra H, MacDonald TO, Verrier ED, Aziz S. Endothelial loss and regeneration in a model of transplant arteriosclerosis. *Transplantation* 1995;60:96-102.
123. Esper E, Glagov S, Karp RB et al. Role of hypercholesterolemia in accelerated transplant coronary vasculopathy: Results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation. *J Heart Lung Transplant*, 1997;16:420-35.
124. Brozena SC, Johnson MR, Ventura H et al. Effectiveness and safety of diltiazem or lisinopril in the treatment of hypertension after heart transplantation Results of a prospective, randomized multicenter trial. *Journal of American College of Cardiology*. 1996;27:1707-12
125. Depczynski B, Daly B, Campbell LV et al. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. *Diabet Med*, 2000;17:15-9.
126. Lang CC, Beniaminovitz A, Edwards N et al. Morbidity and mortality in diabetic patients following cardiac transplantation. *J Heart Lung Transplant*, 2003;22:244-9.
127. Zhang X, Li H, Jin H, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. *Am J Physiol Renal Physiol*, 2000;279:F671-8
128. Weis M, Kledal TN, Lin KY, Panchal SN et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway, Role of asymmetric dimethylarginine in transplant arteriosclerosis. *Circulation*, 2004;109: 500-5.

129. Pratschke J, Neuhaus P., Tullius SG. What can be learned from brain-death models? *Transpl Int.* 2005;18:15-21.
130. Benza RL, Tallaj J. Cardiac allograft vasculopathy (chronic rejection) In: Kirklin JK, McGiffin DC, ed. *Heart transplantation*. Philadelphia: Churchill Livingstone; 2002.pp:615-64.
131. Johnson DE, Gao 52. Schroeder JS. De Campli WM. Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. *J Heart Lung Transplant*, 1989;8:349-59.
132. Ramzy D, Rao V, Brahmi J et al. Cardiac allograft vasculopathy. A review. *Can J Surg.* 2005;48:319-27
133. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft Vasculopathy versus Atherosclerosis. *Circ Res*, 2006;99:801-15.
134. Mehra MR, Ventura HO, Stapleton DD et al. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft Vasculopathy. *J Heart Lung Transplant*, 1995;14:632-9
135. Tuzcu EM, Kapadia SR, Sachar R et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. *J Am Coll Cardiol*, 2005;45:1538-42.
136. Schoenhagen P., Nissen S. Understanding coronary artery disease: Tomographic imaging with intravascular ultrasound. *Heart*, 2002;88:91-6.
137. Tuzcu EM, Kapadia SR, Tutar E et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. *Circulation*, 2001;103:2705-10.
138. Delgado JF, Manito N, Segovia J et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. *Transplantation Reviews*, 2009;23:69-9.
139. Stork S, Behr TM, Birk M et al. Assessment of cardiac allograft vasculopathy late after heart transplantation: when is coronary angiography necessary? *J Heart Lung Transplant*, 2006;25:1103-8.
140. Zhao XM, Hu Y, Miller GG, Mitchell RN, Libby P. Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts. *Circulation*, 2001;103:525-31.
141. De Souza AL, Wait R, Mitchell AG et al. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. *Circ Res.* 2005;97:192-8.
142. Escaned J, Segovia J, Flores A et al. Assessment of coronary microcirculation in cardiac allografts: A comparison of intracoronary physiology, intravascular ultrasound and histological morphometry. *J. Heart Lung Transplant*, 2001;20:204-5.
143. Spes CH, Mudra H, Schnack SD et al. Dobutamine stress echocardiography for noninvasive diagnosis of cardiac allograft vasculopathy. A comparison with angiography and intravascular ultrasound. *Am J Cardiol*, 1996;78:168-74
144. Romeo G, Houyel L, Angel CY et al. Coronary stenosis detection by 16-slice computed tomography in heart transplant patients: Comparison with conventional angiography and impact on clinical management. *J Am Coll Cardiol*, 2006;45:1826-31
145. Iyengar S, Feldman DS, Cooke GE, Lever CV, Raman SV. Detection of coronary artery disease in orthotopic heart transplant recipients with 64-detector row computed tomography angiography. *J Heart Lung Transplant*, 2006;25:1363-6
146. Wu YW, Yen RE, Lee CM et al. Diagnostic and prognostic value of dobutamine thallium-201 singlephoton emission computed tomography after heart transplantation. *J Heart Lung Transplant*, 2005;24:544-50
147. Ciliberto GR, Ruffini L, Mangiavacchi M et al. Resting echocardiography and quantitative dipyridamole technetium-99m sestamibi tomography in the identification of cardiac allograft vasculopathy and the prediction of long-term prognosis after heart transplantation. *Eur Heart J.* 2001;22: 964-71.
148. Muehling OM, Wilke NM, Parseh P et al. Reduced myocardial perfusion reserve and transmural perfusion gradient in heart transplant arteriopathy assessed by magnetic resonance imaging. *J Am Coll Cardiol* 2003;42:1054-60
149. Schmauss D, Was M. Cardiac Allograft Vasculopathy Recent Developments. *Circulation*, 2008;117:2131-41.
150. Hognestad A, Endresen K, Wergeland R et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. *J Am Coll Cardiol*, 2003;42:477-82
151. Labarrere CA, Nelson DR, Cax C et al. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. *JAMA*, 2000;284:457-64
152. Mehra MR, Uber PA, Potluri S et al. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. *Am J Cardiol*, 2004;94:454-8.
153. Kass M, Haddad H. Cardiac allograft vasculopathy pathology, prevention and treatment. *Curr Opin Cardiol*, 2006;21:132-7.
154. Fedak PW, Rao V, Ramzy D et al. Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. *J Thorac Cardiovasc Surg.* 2006;129:407-15
155. Pinney SP, Mancini D. Cardiac allograft vasculopathy Advances in understanding its pathophysiology, prevention, and treatment. *Curr Opin Cardiol.*, 2004;19: 170-6
156. Mehra MR, Raval NY Metaanalysis of statins and survival in de novo cardiac transplantation. *Transplant Proc.* 2004;36:1539-41
157. Weis M, Pehlivanli S, von Scheidt W. Vasodilator response to nifedipine in human coronary arteries with endothelial dysfunction *J Cardiovasc Pharmacol* 2002;30:172-80
158. Bae JH, Rihal CS, Edwards BS et al Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. *Transplantation*, 2006.821108-11
159. Bonaros NE, Kocher A, Dunkler D et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. *Transplantation*, 2004;77:890-7
160. Kutschka I, Pething K, Strüder M et al. Homocysteine a treatable risk factor for allograft vascular disease

- after heart transplantation? *J Heart Lung Transplant*, 2001;20:743-6
161. Lim DS, Mooradian SJ. Goldberg CS et al. Effect of oral L-arginine on oxidant stress, endothelial dysfunction, and systemic arterial pressure in young cardiac transplant recipients. *Am J Cardiol*. 2004;94:828-31.
162. Fang JC, Kinlay S, Beltrame J et al. Effect of vitamins C and E on progression of transplant-associated atherosclerosis: A randomised trial. *Lancet*, 2002;359:1108-13.
163. Iwanaga K, Hasegawa T, Hultquist DE et al. Riboflavin mediated reduction of oxidant injury, rejection, and vasculopathy after cardiac allotransplantation. *Transplantation*, 2007;83:747-53.
164. Kobashigawa JA, Patel J, Furukawa H et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. *J Heart Lung Transplant*, 2006;25:434-9
165. Meiser BM, Groetzner J, Kaczmarek I et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? *Transplantation*, 2004;78:591-8
166. Petrakopoulou P., Anthopoulou L. Muschall M et al. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. *J Am Coll Cardiol*, 2006;47:1622-9.
167. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. *Circulation*, 2004;110:2694-700.
168. Segovia J, Alonso-Pulpon L-Ortiz P et al. Rapastat: evaluation of the role of oral sirolimus in the treatment of established graft vessel disease. A prospective, randomized intravascular ultrasound study. *J. Heart Lung Transplant*. 2004;23:51-2.
169. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. *N Engl J Med*. 2003;349:847-58.
170. Raichlin E, Edwards B, Clavell A et al. Sirolimus as primary immunosuppression prevents progression of cardiac allograft vasculopathy: A 30 IVUS study. *J Heart Lung Transplant*, 2007;26:69-70
171. Miller LW, Donohue TJ, Wolford TA. The surgical management of allograft coronary disease: A paradigm shift. *Thorac Cardiovasc Surg*. 1996; 81:338
172. Benza RL, Zoghbi GJ, Tallaj J et al. Palliation of allograft vasculopathy with transluminal angioplasty—a decade of experience. *J Am Coll Cardiol*. 2004; 43:1973-81.
173. Simpson L, Lee EK, Hott BJ, Vega DJ, Book WM. Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. *J. Heart Lung Transplant*, 2005;24:1211-7.
174. Bader FM, Kfoury AG, Gilbert EM et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. *J Heart Lung Transplant*, 2006; 25:298-301
175. Musci M, Loebe M, Wellnhofer E et al. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. *Thorac Cardiovasc Surg*. 1998;46:268-74.
176. Taylor DO, Stehlik J, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. *J Heart Lung Transplant*, 2009;28:1007-22.
177. Rayburn BK. Other long term complications. In: Kirklin JK, Young JB, McGiffin DC (eds): *Heart Transplantation*, New York: Churchill Livingstone, 2002,666-702
178. 161. John R, Rajasinghe HA, Chen JM et al. Long-term outcomes after cardiac transplantation: An experience based on different eras of immunosuppressive therapy. *Ann Thorac Surg*, 2001;72:440-9.
179. 107. Esper E, Glagov S, Karp RB et al. Role of hypercholesterolemia in accelerated transplant coronary vasculopathy: Results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation. *J Heart Lung Transplant*, 1997;16:420-35.
180. 162 Braith RW, Howard C, Fricker FJ, Mitchell M, Edwards DG. Glucocorticoid induced osteopenia in adolescent heart transplant recipients. *J Heart Lung Transplant* 2000;19:840-5
181. 163 Ying AL, Myerowitz PD, Marsh WL. post transplantation lymphoproliferative disorder in cardiac transplant allografts. *Ann Thorac Surg*. 1997;64:1822-4.
182. White-Williams C. Quality of life after heart transplantation. In: Kirklin JK, Young JB, McGiffin DC eds. *Heart Transplantation*. Philadelphia: Churchill Livingstone: 2002,p:703-13
183. Lough ME. Quality of life for heart transplant recipients. *J Cardiovasc Nurs*, 1988;2:11-22.
184. Evangelista LS, Dracup K, Moser DK et al. Two-year follow-up of quality of life in patients referred for heart transplant. *Heart Lung*, 2005;34:187-93
185. Aravot D, Berman M, Ben-Gal T, Sahar G, Vidne B. Functional status and quality of life of heart transplant recipients surviving beyond 5 years. *Transplant Proc*. 2000;32:731-2



ÇOCUKLARDA KALP TRANSPLANTASYONU

DOI: 10.37609/akya.3889.c5396

BÖLÜM 74

M. Emin ÖZDOĞAN ¹
G. Levent OKTAR ²
Hüseyin DEMİRTAŞ ³
Dilek ERER ⁴
Erkan İRİZ ⁵

İçindekiler

- » GİRİŞ VE GENEL BİLGİLER
- » TARİHSEL GELİŞİM VE GÜNÜMÜZDEKİ VERİLER
- » ENDİKASYONLAR
- » KONTRENDİKASYONLAR
- » PREOPERATİF DÖNEMDE KARŞILAŞILAN SORUNLAR VE YAPILMASI GEREKEN HAZIRLIKLAR
- » ANESTEZİ
- » CERRAHİ TEKNİK
- » İMMUNOSUPRESYON
 - » Transplant Öncesi Alıcı İmmunosupresyon Tedavisi
 - » Postoperatif İndüksiyon İmmunosupresyon Tedavisi
 - » İdame İmmunosupresyon Tedavisi
- » İNFEKSİYON PROFLAKSİSİ VE TEDAVİSİ
 - » Nystatin
 - » Co-Trimoxazole
 - » Acyclovir
- » PROGNOZ
- » MORTALİTEYİ ETKİLEYEN RİSK FAKTÖRLERİ VE MORTALİTE NEDENLERİ
- » AKUT REJEKSİYON TANI VE TEDAVİSİ
 - » Tanı
- » İMMUNOSUPRESYON İLAÇLAR
 - » Anti-Timosit Globulin (ATG)
- » HATG
 - » Yan Etkileri
- » OKT3
 - » Cyclosporine-A (Cys-A)
 - » Tacrolimus (FK 506)
 - » Azathioprine
 - » Metilprednizolon
 - » İmmunosupresyon alanında yeni ilaçlar
- » KALP TRANSPLANTASYONUNDAN SONRA HASTANIN HASTANEDEN ÇIKTIKTAN SONRAKİ TAKİBİ
- » KOMPLİKASYONLAR
- » POSTOPERATİF DÖNEMDE BÜYÜME, GELİŞME VE SOSYAL KONUM
- » SONUÇLAR

¹ Prof.Dr., Gazi Üniversitesi Tıp Fakültesi Hastanesi Kalp ve Damar Cerrahisi AD., ozdogan.mehmetemin@gmail.com
ORCID: 0000- 0002-3181-9532

² Prof.Dr., Gazi Üniversitesi Tıp Fakültesi Hastanesi Kalp ve Damar Cerrahisi AD., gloktar@gazi.edu.tr
ORCID: 0000- 0002-3223-2418

³ Doç.Dr., Gazi Üniversitesi Tıp Fakültesi Hastanesi Kalp ve Damar Cerrahisi AD. hdemirtas@gazi.edu.tr,
ORCID: 0000-0002-5710-1385

⁴ Prof.Dr., Gazi Üniversitesi Tıp Fakültesi Hastanesi Kalp ve Damar Cerrahisi AD. dilekerer@hotmail.com,
ORCID: 0000- 0003-1926-720X

⁵ Prof.Dr., Gazi Üniversitesi Tıp Fakültesi Hastanesi Kalp ve Damar Cerrahisi AD. erkaniriz@gazi.edu.tr,
ORCID: 0000- 0003-4754-733X

KAYNAKLAR

1. Dipchand, A. I. (2018). *Current state of pediatric cardiac transplantation*. Annals of Cardiothoracic Surgery, 7(1), 31-55. <https://doi.org/10.21037/acs.2018.01.07>
2. Mancini, D., Gibson, G. T., & Rangasamy, S. (2021). *Improving survival after heart transplantation despite increasing complexity*. European Heart Journal, 42(48), 4944-4946. <https://doi.org/10.1093/eurheartj/ehab517>
3. T.C. Sağlık Bakanlığı, 2022. Türkiye'de Çocuk Kalp Nakli İstatistikleri.
4. Kantrowitz A, Haller JD, Joos H et al. Transplantation of the heart in an infant and an adult. Am J Cardio, 1968;22:782-90.
5. Parisi F. Advances in pediatric transplantation: Heart and lung. Transplant Proc, 2001;33:1725-6.
6. Bailey LL, Nehlsen-Cannarella SL, Doroshow RW et al. Cardiac allotransplantation in newborns as therapy for hypoplastic left heart syndrome. N Engl J Med, 1986; 315:949-51.
7. Boucek MM, Edwards LB, Keck Bm et al. The Registry of the International Society for Heart and Lung Transplantation: Fifth Official Pediatric Report 2001 to 2002. J Heart Lung Transplant, 2002;21:827-40.
8. International Society for Heart and Lung Transplantation (ISHLT). (2023). International Thoracic Organ Transplant (TTX) Registry Data Slides. [<https://ishlt.org/research-data/registries/ttx-registry>]
9. Kindel, S. J., & Everitt, M. D. (2016). *A contemporary review of paediatric heart transplantation and mechanical circulatory support*. Cardiology in the Young, 26(5), 851-859. <https://doi.org/10.1017/S1047951116000184>
10. İğüdbashian J, Yoeli D, Everitt MD, Campbell DN, Mitchell MB, Jagers J, Stone ML. Pediatric Heart Transplant Waiting List Times in the US During the COVID-19 Pandemic. JAMA Network Open. 2022;5(10). doi:10.1001/jamanetworkopen.2022.34874.
11. Cascino TM, McCullough JS, Wu X, et al. Comparison of Evaluations for Heart Transplant Before Durable Left Ventricular Assist Device and Subsequent Receipt of Transplant at Transplant vs Nontransplant Centers. JAMA Network Open. 2022;5(11) doi:10.1001/jamanetworkopen.2022.40646.
12. Özdoğan ME, Erer D, Soncul H ve ark. Çocukluk yaş grubunda yapılan ve yaşayan ilk kalp transplantasyonu. Organ Nakli Kuruluşları Koordinasyon Derneği III. Kongresi, 17-20 Ekim 2002, Adana.
13. Özer A, Erer D, İriz E, Özdoğan ME. Kalp nakli sonrası Türkiye'de doğum yapıp ve sağlıklı bebek sahibi olan ilk vakamız. Türk Kalp ve Damar Cerrahisi Derneği 15. Kongresi; 2018. Bildiri No: SS-188. (79)
14. Özdoğan ME, İriz E, Erer D, Kula S, Aslan AT, Ünal Y, et al. Orthotopic heart transplantation in a two-year-old patient with dilated cardiomyopathy. Turkish J Thorac Cardiovasc Surg. 2012;20(4):723-6. doi:10.5606/tgkdc.dergisi.2012.173
15. Del Rio M, Bailey LL. Heart transplantation for congenital heart disease. In Baue AE (ed): Glenn's Thoracic and Cardiovascular Surgery, 6th ed. volume II. Stamford, Appleton & Lange, 1996;1475-90.
16. Ciarambino T, Menna G, Sansone G, Giordano M. Cardiomyopathies: An Overview. Int J Mol Sci. 2021;22(14):7722. doi:10.3390/ijms22147722.
17. Birla AK, Brimmer S, Short WD, et al. Current state of the art in hypoplastic left heart syndrome. Front Cardiovasc Med. 2022;9:878266. doi:10.3389/fcvm.2022.878266.
18. Kotani Y, Chetan D, Zhu J, et al. Fontan failure and death in contemporary Fontan circulation: Analysis from the last two decades. Ann Thorac Surg. 2018;105:1240-1247.
19. Wu Y, Jin X, Zhang Y, et al. Genetic and epigenetic mechanisms in the development of congenital heart diseases. World Jnl Ped Surg 2021;4:e000196. doi:10.1136/wjps-2020-000196
20. Atti V, Narayanan MA, Patel B, et al. A Comprehensive Review of Mechanical Circulatory Support Devices. Heart International. 2022;16(1):37-48. doi:10.17925/HI.2022.16.1.37.
21. Morrow WR. Cardiomyopathy and heart transplantation in children. Curr Opin Cardiol, 2000;15:216-23.
22. McNamara N, Narroway H, Williams M, et al. Contemporary outcomes of continuous-flow left ventricular assist devices—a systematic review. Ann Cardiothorac Surg. 2021;10(2):186-208. doi:10.21037/acs-2021-cfmcs-35.
23. Malinow I, Fong DC, Miyamoto M, et al. Pediatric dilated cardiomyopathy: a review of current clinical approaches and pathogenesis. Front Pediatr. 2024;12:1404942. doi:10.3389/fped.2024.1404942.
24. Huebler M, Schubert S, Lehmkühl HB, et al. Pediatric heart transplantation: 23-year single-center experience. Eur J Cardiothorac Surg. 2011;39(5) . doi:10.1016/j.ejcts.2010.12.067.
25. Parisi F, Squitieri C, Carotti A et al. Ten-year follow-up after pediatric transplantation. J Heart Lung Transplant, 1999;18:275-7.
26. Morrow WR, Naftel D, Chinnock R et al. Outcome of listing for heart transplantation in infants younger than six months: Predictors of death and interval to transplantation. J Heart Lung Transplant, 1997;16:1255-66.
27. Nessler N, Mansour A, Cholley B, et al. Perioperative Management of Heart Transplantation: A Clinical Review. Anesthesiology. 2023;139:493-510. doi:10.1097/ALN.0000000000004627.
28. Martin RD, Parisi F, Robinson TW, Bailey LL. Anesthetic management of neonatal cardiac transplantation. J Cardiothorac Anesth, 1989;3:465-9.
29. Ortega R, Connor CW. Intraoperative Management of Patients with Pulmonary Hypertension. Advances in Pulmonary Hypertension. 2013;12(1):18-23. doi:10.21693/1933-088X-12.1.18.
30. Stark J, De Leval M (ed). Surgery for Congenital Heart Defects. 2nd Edition, W.B. Saunders Company, 1994;665- 81.
31. Morris, E. A., Parvizi, R., Orzechowski, N. M., Whitfield, M. L., & Pioli, P. A. (2024). Mycophenolate mofetil directly modulates myeloid viability and pro-fibrotic activation of human macrophages. Rheumatology. <https://doi.org/10.1093/rheumatology/keae517>
32. Lobo, D. N. (2024). High-dose glucocorticoids: improving outcomes of emergency laparotomy by reducing inflammation. British Journal of Surgery, 111(7), znac153. <https://doi.org/10.1093/bjs/znac153>
33. Nourbakhsh, N., Ekberg, J., Skov, K., et al. (2021). Effects of corticosteroid treatment on mycophenolic acid exposure in renal transplant patients—Results from the SAILOR study. Frontiers in Pharmacology, 12, 742444. <https://doi.org/10.3389/fphar.2021.742444>

34. Pietra, B. A., & Boucek, M. M. (2000). Immunosuppression for pediatric cardiac transplantation in the modern era. *Progress in Pediatric Cardiology*, 11, 115-129.
35. Katz, D. T., Torres, N. S., Chatani, B., et al. (2020). Care of pediatric solid organ transplant recipients: An overview for primary care providers. *Pediatrics*, 146(6), e20200696. <https://doi.org/10.1542/peds.2020-0696>
36. Velleca, A., Shullo, M. A., Dhital, K., et al. (2022). The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. *Journal of Heart and Lung Transplantation*, 1053-2498. <https://doi.org/10.1016/j.healun.2022.10.015>
37. Liversedge, M., Wang, J., Boustany, M., Sharova, A., Downes, K. J., & Otto, W. (2024). Invasive fungal disease in pediatric heart transplant recipients. *Journal of the Pediatric Infectious Diseases Society*, 13(Suppl_4), 25-26. <https://doi.org/10.1093/jpids/piae093.070>
38. Dadwal, S. S., Papanicolaou, G. A., & Boeckh, M. (2023). How I prevent viral reactivation in high-risk patients. *Blood*, 141(17), 2062-2074. <https://doi.org/10.1182/blood.2021014676>
39. Kim, Y. H. (2021). Pediatric heart transplantation: How to manage problems affecting long-term outcomes? *Clinical and Experimental Pediatrics*, 64(2), 49-59. <https://doi.org/10.3345/cep.2019.01417>
40. Kanter KR, Tam VKH, Vincent RN et al. Current results with pediatric heart transplantation. *Ann Thorac Surg*, 1999;68:527-31.
41. Shaddy RE, Naftel DC, Kirklin JK et al. Outcome of cardiac transplantation in children. Survival in a contemporary multi-institutional experience. *Circulation*, 1996;94(Suppl II):69-73.
42. Radley-Smith RC, Yacoub MH. Long-term results of pediatric heart transplantation. *J Heart Lung Transplant*, 1992;11:277-81.
43. Hsu DT, Quaegebeur JM, Michler RE et al. Heart transplantation in children with congenital heart disease. *J Am Coll Cardiol*, 1995;26:743-9.
44. Gajarski RJ, Smith EO, Denfield SW et al. Long-term results of triple-drug-based immunosuppression in nonneonatal pediatric heart transplant recipients. *Transplantation*, 1998;65:1470-6.
45. Dellgren G, Koirala B, Sakopoulos A et al. Pediatric heart transplantation: Improving results in high-risk patients. *J Thorac Cardiovasc Surg*, 2001;121:782-91.
46. Bauer J, Thul J, Kramer U et al. Heart transplantation in children and infants: short-term outcome and long-term follow-up. *Pediatr Transplant*, 2001;5:457-62.
47. Luikart H. Pediatric cardiac transplantation: Management issues. *Pediatr Nurs*, 2001;16:320-31.
48. Kounatidis, D., Brozou, V., Anagnostopoulos, D., Pantos, C., Loubopoulos, A., & Mourouzis, I. (2023). Donor Heart Preservation: Current Knowledge and the New Era of Machine Perfusion. *International Journal of Molecular Sciences*, 24(23), 16693. <https://doi.org/10.3390/ijms242316693>.
49. Amdani, S., Kirklin, J.K., Cantor, R., et al. (2024). Prevalence and Impact of Recurrent Rejection on Pediatric Heart Transplant Recipients: A PHTS Multi-Institutional Analysis. *Journal of the American College of Cardiology (JACC)*, Published online October 02, 2024. <https://doi.org/10.1016/j.jacc.2024.08.010>.
50. Bahakel, H., Waghmare, A., & Madan, R. P. (2024). Impact of Respiratory Viral Infections in Transplant Recipients. *Journal of the Pediatric Infectious Diseases Society*, 13(Supplement_1), S39-S48. <https://doi.org/10.1093/jpids/piad094.40>
51. Sethi GK, Rosado LJ, McCarthy M, Butman SS, Copeland JG. Futility of yearly biopsies in patients undergoing heart transplantation. *J Thorac Cardiovasc Surg*, 1992;104:90-3.
52. Glanville AR, Imoto E, Baldwin JC et al. The role of right ventricular biopsy in the late management of heart- lung transplant recipients. *J Heart Transplant*, 1987;6:357-61.
53. Schultz, J., & Stehlik, J. (2022). Emergence of Donor-Derived Cell-Free DNA Monitoring For Heart Transplant: Future of Rejection Surveillance. *American College of Cardiology*, Expert Analysis, May 05, 2022. Retrieved from <https://www.acc.org>.
54. Farcas, A. O., Stoica, M. C., Maier, I. M., et al. (2024). Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling. *Biomedicine*, 12(8), 1926. <https://doi.org/10.3390/biomedicine12081926>.
55. Das, B. B., Deshpande, S., & Hussain, T. (2022). Multimodality Imaging to Detect Rejection, and Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients—An Illustrative Review. *Transplantation*, 3(3), 241-256. <https://doi.org/10.3390/transplantation3030025>.
56. de Koning, C., Prockop, S., van Roessel, I., et al. (2021). CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host disease: a dual-center validation. *Blood*, 137(6), 848-855. <https://doi.org/10.1182/blood.2020007905>.
57. Green, D. J., Duong, S. Q., Burckart, G. J., et al. (2018). Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis. *Journal of Pediatric Pharmacology and Therapeutics: JPPT*, 23(2), 131-138. <https://doi.org/10.5863/1551-6776-23.2.131>.
58. van Saet, A., Zeilmaker-Roest, G. A., Stolker, R. J., Bogers, A. J. J. C., & Tibboel, D. (2021). Methylprednisolone in Pediatric Cardiac Surgery: Is There Enough Evidence? *Frontiers in Cardiovascular Medicine*, 8, Article 730157. <https://doi.org/10.3389/fcvm.2021.730157>.
59. Spinner, J. A., & Denfield, S. W. (2022). Immunosuppressant Drugs and Their Effects on Children Undergoing Solid Organ Transplant. *Pediatrics Review*, 43(2), 71-86. <https://doi.org/10.1542/pir.2020-000620>.
60. Nguyen, C., & Shapiro, R. (2014). New immunosuppressive agents in pediatric transplantation. *Clinics*, 69(S1), 8-16. [https://doi.org/10.6061/clinics/2014\(-Sup01\)02](https://doi.org/10.6061/clinics/2014(-Sup01)02).
61. Masarone, D., Kittleson, M., Gravino, R., Valente, F., Petraio, A., & Pacileo, G. (2021). The Role of Echocardiography in the Management of Heart Transplant Recipients. *Diagnostics*, 11(12), 2338. <https://doi.org/10.3390/diagnostics11122338>.
62. Gupta, D., & Clifford, S. A. (2023). Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19. *Cardiology in the Young*, 33(3), 496-497. <https://doi.org/10.1017/S1047951122002190>.
63. Özdoğan E, Banner N, Fitzgerald M et al. Factors influencing the development of hypertension after heart transplantation. *J Heart Transplant*, 1990;9:548-53.

64. Baum ME, Chinnock RE, Ashwal S et al. Growth and neurodevelopmental outcome of infants undergoing heart transplantation. *J Heart Lung Transplant*, 1993;12:211-7.
65. Amengual, J. E., & Pro, B. (2023). How I treat posttransplant lymphoproliferative disorder. *Blood*, 142(17), 1426-1437. <https://doi.org/10.1182/blood.2023020075>.
66. Jimenez Ubieto, A., Gil Manso, R., Gil Alós, D., et al. (2023). Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital. *Blood*, 142(Supplement 1), 4490. <https://doi.org/10.1182/blood-2023-189478>.
67. Rao, P. S. (2023). Advances in the Diagnosis and Management of Congenital Heart Disease in Children. *Children*, 10(4), 753. <https://doi.org/10.3390/children10040753>.
68. Townsend, M., Khoury, M., Koehl, D., et al. (2024). Uncertain Benefit of Statins in Pediatric Heart Transplant Recipients: A PHTS Analysis. *The Journal of Heart and Lung Transplantation*, 43(5), 703-713. <https://doi.org/10.1016/j.healun.2023.11.021>.
69. Nesseler, N., Mansour, A., & Cholley, B., et al. (2023). Perioperative management of heart transplantation: A clinical review. *Anesthesiology*, 139, 493-510. <https://doi.org/10.1097/ALN.0000000000004627>
70. De Broux E, Huot CH, Chartrand S, Chartrand C. Growth after pediatric heart transplantation. *Transplant Proc*, 2001;33:1735-7.
71. Nixon PA, Morris KA. Quality of life in pediatric heart, heart-lung, and lung transplant recipients. *Int J Sports Med*, 2000;21(Suppl 2):109-12.
72. Cousino, M. K., Schumacher, K. R., & Rea, K. E., et al. (2018). Psychosocial functioning in pediatric heart transplant recipients and their families. *Pediatric Transplantation*, 22(2), e13110. <https://doi.org/10.1111/petr.13110>
73. Tadros, H. J., Gupta, D., Rawlinson, A., et al. (2020). Assessing the psychosocial impact of pediatric heart transplantation on family functioning: A cross-sectional study identifying variables associated with poor psychosocial outcomes. *Pediatrics*, 146(1_MeetingAbstract), 605-606. <https://doi.org/10.1542/peds.146.1MA7.605>
74. Stanford, N. T., McAllister, J., Gibbons, M., et al. (2022). Quality of life and lifetime achievement in adult survivors of pediatric heart transplant. *Pediatric Transplantation*, 26(7), e14370. <https://doi.org/10.1111/petr.14370>



AORT LEZYONLARINDA CERRAHİ NEDEN UYGULANMALIDIR?

DOI: 10.37609/akya.3889.c5397

BÖLÜM
75

Suat BÜKET¹
Çağatay ENGİN²
Tahir YAĞDI³


İçindekiler

» GİRİŞ VE GENEL BİLGİLER

¹ Prof. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, suat.buket59@gmail.com, ORCID iD: 0000-0002-8038-0722

² Prof. Dr., Ege Üniversitesi Tıp Fakültesi Kalp Damar Cerrahisi AD., cagatayengin@yahoo.com, ORCID iD: 0000-0003-4025-7874


³ Prof. Dr., Ege Üniversitesi Tıp Fakültesi Kalp Damar Cerrahisi AD., tahir.yagdi@gmail.com, ORCID iD: 0000-0001-6282-2489




Resim 46. Asendan ve innominat arter anevrizmalı bir olguda trakea basısı.



Resim 49. Abdominal aort anevrizmalı bir olguda izlenen trash emboli.



Resim 47. Asendan ve Innominat arter anevrizması.



Resim 48. Asendan aort ve innominat arter replasmanı.

KAYNAKLAR

1. Sterpetti AV, Cavallaro A, Cavallari N, Allegrucci P, Tamburelli A, Agosta F, Bartoli S. Factors influencing the rupture of abdominal aortic aneurysms. Surgery, Gynecology & Obstetrics.173:175, 1991.
2. Darling RC, Messina CR, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms. Circulation 56 (3 Suppl):III161-164, 1977.
3. Szilagyi D, Smith R, Derusso F, et al. Contribution of abdominal aneurysmectomy to prolongation of life. Ann Surg 164:678-99, 1966.
4. Guirguis EM, Barber CG. The natural history of abdominal aortic aneurysms. Am J Surg. 162:481-483, 1991.
5. Brown PM, Pattenden R, Vernooy C, Zelt DT, Gutelius JR. Selective management of abdominal aortic aneurysms in a prospective measurement program. J Vasc Surg 23:213-222, 1996.
6. Nevitt MP, Ballard DJ, Hallett JW. Prognosis of abdominal aortic aneurysms: A population based study. N Engl J Med 321:1009- 1014, 1989.
7. Glimaker H, Holmberg L, Elvin A, Nybacka O, Almgren B, Bjorck CG, Eriksson I. Natural history of patients with abdominal aortic aneurysm. European Journal of Vascular Surgery 5:125-130, 1991.
8. Bernstein EF, Chan EL. Abdominal aortic aneurysm in high-risk patients. Outcome of selective management based on size and expansion rate. Annals of Surgery 200:255-263, 1984.
9. Cronenwett JL, Murphy TF, Zelenock GB, Whitehouse WM, Lindenauer SM, Graham LM, Quint LE, Silver TM, Stanley JC. Actuarial analysis of variables associated with rupture of small abdominal aortic aneurysms. Surgery 98:472-483, 1985.
10. Harky A, Bashir M, Antoniou A, et al. Size and dissection: what is the relation? Indian J Thorac Cardiovasc Surg. 2019;35:72-78.
11. Saeyeldin A, Zafar MA, Velasquez CA, et al. Natural history of aortic root aneurysms in Marfan syndrome. Ann Cardiothorac Surg. 2017;6:625-632.
12. Della Corte A, Bancone C, Buonocore M, et al. Pattern

- of ascending aortic dimensions predicts the growth rate of the aorta in patients with bicuspid aortic valve. *J Am Coll Cardiol Img.* 2013;6:1301–1310.
13. Kim JB, Spotnitz M, Lindsay ME, et al. Risk of aortic dissection in the moderately dilated ascending aorta. *J Am Coll Cardiol.* 2016;68:1209–1219.
 14. Yiu RS, Cheng SW. Natural history and risk factors for rupture of thoracic arch aneurysms. *J Vasc Surg.* 2016;63:1189–1194.
 15. Zafar MA, Chen JF, Wu J, et al. Natural history of descending thoracic and thoracoabdominal aortic aneurysms. *J Thorac Cardiovasc Surg.* 2021;161:498–511.e1.
 16. Hendy K, Gunnarson R, Golledge J. Growth rates of small abdominal aortic aneurysms assessed by computerised tomography-a systematic literature review. *Atherosclerosis.* 2014;235:182–188.
 17. The UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. *Lancet.* 21; 352:1649-55, 1998.
 18. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, Barone GW, Bandyk D, Moneta GL, Makhoul RG. The aneurysm detection and management study screening program: validation cohort and final results. *Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med* 22;160(10):1425-30, 2000.
 19. RAP Scott, NM Wilson, HA Ashton, DN Kay. Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. *British Journal of Surgery* 82:1066-70, 1995.
 20. Lederle FA, Freischlag JA, Kyriakides TC, et al. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: A randomized trial. *JAMA* 2009;302:1535-42.
 21. Dimick JB, Cowan JA Jr, Stanley JC, Henke PK, Pronovost PJ, Upchurch GR Jr. Surgeon specialty and provider volumes are related to outcome of intact abdominal aortic aneurysm repair in the United States. *J Vasc Surg* 2003;38:739-44.
 22. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG; EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: Randomised controlled trial. *Lancet* 2004;364:843-8.
 23. Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. *N Engl J Med* 2004;351:1607-18.
 24. Lederle FA, Kane RL, MacDonald R, Wilt TJ. Systematic review: Repair of unruptured abdominal aortic aneurysm. *Ann Intern Med* 2007;146:735-41.
 25. Teufelsbauer H, Prusa AM, Wolff K, et al. Endovascular stent grafting versus open surgical operation in patients with infrarenal aortic aneurysms: A propensity score-adjusted analysis. *Circulation* 2002;106:782-7.
 26. Lederle FA. Abdominal aortic aneurysm – open versus endovascular repair. *N Engl J Med* 2004;351:1677-9.
 27. Lederle FA. Endovascular repair of abdominal aortic aneurysm – round two. *N Engl J Med* 2005;352:2443-5.
 28. McNamara JJ, Pressler VM. Natural history of arteriosclerotic thoracic aortic aneurysms. *Ann Thorac Surg* 26:468-73, 1978.
 29. Crawford ES, Natale RW. Thoracoabdominal aortic aneurysm: Observations regarding the natural course of the disease. *J Vasc Surg* 3:578-82, 1986.
 30. DeBakey ME, McCollum CH, Crawford ES, et al. Dissection and dissecting aneurysms of the aorta: Twenty-year follow-up of 527 patients treated surgically. *Surgery* 6:1118-34, 1982.
 31. Griepp RB, Ergin MA, Galla JD, et al. Natural history of descending thoracic and thoracoabdominal aneurysms. *Ann Thorac Surg* 67:1927-30, 1999.
 32. Shennan T. Dissecting aneurysms. Special report. Medical Research Council, London, 1934.
 33. Anagnostopoulos CE, Prabhakar MJ, Kittle CF. Aortic dissections and dissecting aneurysms. *Am J Cardiol* 30:263, 1972.
 34. Miller DC. The continuing dilemma concerning medical versus surgical management of patients with acute type B dissections. *Semin Thorac Cardiovasc Surg* 5:33, 1993.
 35. Heinemann M, Laas J, Jurmann M, et al. Surgery extended into the aortic arch in acute type A dissection. Indications, techniques and results. *Circulation* 84:III25, 1991.
 36. Glower DD, Fann FJ, Speier RH, et al. Comparison of medical and surgical therapy for uncomplicated descending aortic dissection. *Circulation* 82:IV39, 1990.
 37. Appelbaum A, Karp RB, Kirklin JW. Ascending vs descending aortic dissections. *Ann surg* 1990;264:2537, 1990.
 38. Doroghazi RM, Slater EE, De Sanctis RW, et al. Long term survival of patients with treated aortic dissection. *J Am Coll Cardiol* 3:1026, 1984.
 39. Miller DC. Acute dissection of the descending aorta: clinical dilemma and historical perspective. *Chest Surg Clin North Am* 2:347, 1992.
 40. Lindsay JJ, Hurst JW. Clinical features and prognosis in dissecting aneurysms of the aorta; a re-appraisal. *Circulation* 35:880-8, 1967.
 41. De Bakey ME, Henly W, Cooley DA, et al. Surgical management of dissecting aneurysms of the aorta. *J Thorac Cardiovasc Surg* 49:130, 1965.
 42. Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? *J Thorac Cardiovasc Surg* 113:476-91, 1997.
 43. Epperlein S, Mohr-Kahaly S, Erbel R, et al. Aorta and aortic valve morphologies predisposing to aortic dissection. An in vivo assessment with transeoesophageal echocardiography. *Eur Heart J* 15:1520-7, 1994.
 44. Prenger K, Pieters I, Cheriex E. Aortic dissection after aortic valve replacement: incidence and consequences for strategy. *J Card Surg* 9:495-8, 1994.
 45. Elefteriades JA. Thoracic Aortic Aneurysm: Reading the Enemy's Playbook. *Curr Probl Cardiol* 33:203-277, 2008.
 46. Chao CP, Walker TG, Kalva SP. Natural history and CT appearances of aortic intramural hematoma. *Radiographics.* 29(3):791-804, 2009.
 47. Schlatter T, Aurio J, Marcheix B, et al. Type B intramural hematoma of the aorta: evolution and prognostic value of intimal erosion. *J Vasc Interv Radiol.*

- 22(4):533-41,2011
48. Eggebrecht H, Plicht B, Kahlert P, Erbel R. Intramural hematoma and penetrating ulcers: indications to endovascular treatment. *Eur J Vasc Endovasc Surg*. 38(6):659-65,2009
 49. Shores J, Berger KR, Murphy EA, et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *New Engl J Med* 1994;330(19):1335-41.
 50. Sanz J, Einstein J, Fuster V. Acute aortic dissection: anti-impulse therapy. In: Elefteriades JA, editor. *Acute Aortic Disease*. New York. Informa Healthcare, 2007
 51. Hackmann AE, LeMaire SA, Thompson RW. Long term suppressive therapy: clinical reality and future prospects. In: Elefteriades J, editor. *Acute Aortic Conditions*. New York: Informa Healthcare, 2007.
 52. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse mode syndrome. *Science* 2006;312:117-21.
 53. Laas J, Jurmann M, Heinemann M, Borst HG. Management and follow-up results of proximal aortic aneurysms. *Sem Thorac Cardiovasc Surg* 3:266-9, 1991.
 54. Crawford ES, Svensson LG, Coselli JS. Surgical treatment of aneurysm and/or dissection of the ascending aorta, transvers aortic arch, and ascending aorta and transverse aortic arch. Factors influencing survival in 717 patients. *J Thorac Cardiovasc Surg* 98:659- 74, 1989.
 55. Gott VL, Pyeritz RE, Macgovern GJ, et al. Surgical treatment of aneurysms of the ascending aorta in the Marfan syndrome. Results of composite-graft repair in 50 patients. *N Engl J Med* 314:1070-4, 1986.
 56. Ergin MA, Spielvogel D, Apaydin A, et al. Surgical treatment of the dilated ascending aorta: when and how? *Ann Thorac Surg* 67: 1834-9, 1999.
 57. Crawford ES, Cohen ES: Aortic aneurysm: a multifocal disease. *Arch Surg* 117:1393-400, 1982.



DEJENERATİF AORT ANEVRİZMALARINDA ETİYOLOJİ VE DOĞAL GİDİŞ

BÖLÜM
76

Tanzer ÇALKAVUR ¹

DOI: 10.37609/akya.3889.c5398

İçindekiler

- » DEJENERATİF AORT ANEVİRİZMALARI
- » AORTUN HİSTOPATOLOJİSİ
- » DEJENERATİF AORT ANEVİRİZMALARININ ETİYOLOJİSİ
- » DEJENERATİF AORT ANEVİRİZMALARININ DOĞAL GİDİŞİ

¹ Prof. Dr., Ege Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., tanzercalkavur@gmail.com, ORCID iD: 0000-0003-1909-0031

terit, Behçet Hastalığı, tekrarlayan polikondritis, tromboanjitis obliterans, periarteritis nodoza, sistemik lupus eritematozuz, skleroderma, Kawasaki Hastalığı, romatoid artrit, juvenil romatoid artrit, Reiter Sendromu, Sjögren Sendromu, polimyaljia romatika, ankilozan spondilit, Paget Hastalığı, ülseratif kolit, Reidel stroması ve Hashimoto tiroiditi vardır.(5)

DEJENERATİF AORT ANEVRIZMALARININ DOĞAL GİDİŞİ

Anevrizmalı olgularda rüptür riskini hesaplamak ve operasyonu zamanlamak zordur. Modern aort operasyonları genellikle profilaktik, bazen terapötik, nadirinde palyatif olarak yapılmaktadır. Profilaktik operasyonlarda amaç ölüme neden olacak anevrizma rüptürünü önlemektir. Çünkü yeri ve nedeni ne olursa olsun anevrizması olan hastalar, eğer başka bir nedenle ölmezlerse, ölüm kaçınılmaz olarak anevrizma rüptüründen olacaktır.(18) Rüptür riskinden korunmak için profilaktik operasyona alınacak olgularda operasyon zamanını saptamadaki en önemli nokta, ölüme neden olacak rüptür riski ile hastada var olan yandaş patolojilerin oluşturduğu risk ve cerrahi riskin birbirine oranlanmasıdır. Eğer hasta anevrizmaya bağlı semptom ve bulgu vermekte ise, cerrahi terapatik amaca yönelik olarak yapılmaktadır. Bu hastaların rüptür riski daha yüksektir. By-pass uygulanarak anevrizmal segmentin bağlanması gibi palyatif yöntemler ise modern tıpta çok nadir endikasyon bulmaktadırlar.

Anevrizma nedeniyle operasyona karar verirken, anevrizmal segmentin yeri, çapı ve etiyojisine bağlı rüptür risklerini önceden bilmek çok önemlidir. Anevrizmaların rüptür risklerinin saptanmasında genellikle tarihsel kontrol serileri ve anevrizma operasyonunun kontrendike olduğu nadir hasta grupları ele alınmaktadır. Anevrizmalı hastalarda rüptür riskini içeren prospektif bir çalışma yapmak etik olarak mümkün değildir.

Estes ve arkadaşlarının Mayo klinikte, 1950 yılında inceledikleri 102 abdominal aort anevrizmalı hastada yaşam oranının 3 yılda %50, 5 yılda %19 ve 8 yılda %10 olduğunu bulmuşlardır.(19) Hiç bir

hasta 10 yıl yaşamamıştır ve olguların 631'ünde ölüm nedeni anevrizma rüptürüdür.

Tedavi edilmemiş infrarenal abdominal aort anevrizmalarında rüptüre bağlı ölüm oranı yapılan araştırmalarda %30 ile %63 arasında değişmektedir.(18,19) İlginç bir nokta, 4 cm ya da daha küçük anevrizması olan olgularda da rüptürün %9.5 oranında ölümden sorumlu olmasıdır. Bu durum küçük anevrizmalarında, büyük anevrizmalar kadar sık olmasada, rüptüre olabileceğini göstermektedir. Abdominal aort anevrizmalarında rüptürün büyük bir kısmı (%80-85) posterolateral olarak retroperitona olmaktadır.

Bickerstaff ve arkadaşları torakal aort anevrizmalarının %75'inde rüptür oluştuğunu ve bunlarında %94'ünün kaybedildiğini bildirmişlerdir.(20) Bu çalışmada cerrahiye giden %11 olguda mortalite %40 bulunmuştur. Elektif cerrahi uygulanmayan hastalarda ise 3 yıllık yaşam oranı %25.7 olarak tespit edilmiştir.

Yandaş hastalık, yaş, küçük anevrizma çapı veya hastanın operasyonu reddetmesi nedeniyle operasyon uygulanmayan 94 torakoabdominal aort anevrizmalı hastada Crawford ve DeNatale 2 yıllık yaşam oranını %24 olarak bulmuşlardır.(21) Bu hastalarda ölümlerin yaklaşık yarısı rüptür nedeniyle gerçekleşmiştir.

KAYNAKLAR

1. Crawford ES, Beckett WC, Greer MS. Juxtarenal infrarenal abdominal aortic aneurysm: Special diagnostic and therapeutic considerations. Ann Surg, 1986; 203:661-70.
2. Svensson LG, Crawford ES. Aortic dissection and aortic aneurysm surgery: Clinical observations, experimental investigations and statistical analyses. Part II Curr Probl Surg, 1992;29:915-1057.
3. Trotter SE, Olsen EG. Marfan's disease and Erdheim's cystic medionecrosis: A study of their pathology. Eur Heart J, 1991;12:83-7.
4. Costa M, Robbs JV. Abdominal aneurysms in a black population: Clinico-pathological study. Br J Surg, 1986; 73:554-8.
5. Svensson LG, Crawford ES. Aortic dissection and aortic aneurysm surgery: Clinical observations, experimental investigations and statistical analyses. Part III Curr Probl Surg, 1993;30:1-172.
6. Bacharach JM, Colville DS, Lie JT. Accelerated atherosclerosis, aneurysmal disease and aortitis: Possible pathogenetic association with cocaine abuse. Int Angiol, 1992;11:83-6.

7. Gadalet D, Hall M-H, Nelson RL. Cocaine-induced acute aortic dissection. *Chest*, 1989;96:1203-5.
8. Clifton MA. Familial abdominal aortic aneurysm. *Br J Surg*, 1977;64:7656.
9. Bengtsson H, Norrgard O, Angquist KA, et al. Ultrasonographic screening of the abdominal aorta among siblings of patients with abdominal aortic aneurysms. *Br J Surg*, 1989;76:589-91.
10. Majumder PP, St Jean PL, Ferrell RE, et al. On the inheritance of abdominal aortic aneurysm. *Am J Hum Genet*, 1991;48:164-70.
11. Tentolouris C, Kontozoglou T, Toutouzas P. Familial calcification of aorta and calcific aortic valve disease associated with immunologic abnormalities. *Am Heart J*, 1993;126:904-9.
12. Campa JS, Greenhalgh RM, Powell JT. Elastin degradation in abdominal aortic aneurysms. *Atherosclerosis*, 1987; 65:13-21.
13. Baxter BT, McGee GS, Shively VP, et al. Elastin content, cross-links and mRNA in normal and aneurysmal human aorta. *J Vasc Surg*, 1992;16:192-200.
14. Anidjar S, Salzmann JL, Gentric D, et al. Elastase-induced experimental aneurysms in rats. *Circulation*, 1990; 82:973-81.
15. Cohen JR, Faust G, Tenenbaum N, et al. The calcium messenger system and the kinetics of elastase release from human neutrophils in patients with abdominal aortic aneurysms. *Ann Vasc Surg*, 1990;4:5704.
16. Busuttil RW, Cardenas A. Collagenase activity of the human aorta. *Arch Surg*, 1980;115:1373-8.
17. Rizzo RJ, McCarthy WJ, Dixit SN, et al. Collagen types and matrix protein content in human abdominal aortic aneurysms. *J Vasc Surg*, 1989;10:35-73.
18. Darling RC, Messina CR, Brewster DC, et al. Autopsy study of unoperated abdominal aortic aneurysms: The case for early resection. *Circulation*, 1976;56 (Suppl 2):161.
19. Estes JR Jr. Abdominal aortic aneurysm: a study of one hundred and two cases. *Circulation*, 1950;2:258-64.
20. Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: A population based study. *Surgery*, 1982;92:1103-9.
21. Crawford ES, DeNatale RW. Thoracoabdominal aortic aneurysm: Observations regarding the natural course of the disease. *J Vasc Surg*, 1986;3:578-82.



ANEVRİZMATİK ASENDAN AORTA CERRAHİ YAKLAŞIM

BÖLÜM 77

Alizamin YUSİFLİ ¹
Arzum KALE ²
Yılmaz DENİZ ³
Ulusal COŞKUN ⁴

DOI: 10.37609/akya.3889.c5399

İçindekiler

- » GİRİŞ
- » TARİHÇE
- » ANATOMİ
- » ETİYOLOJİ VE PATOFİZYOLOJİ
 - » Dejenerasyon
 - » Konjenital
 - » Enfeksiyon
 - » Non-enfeksiyöz inflamatuvar sendromlar
 - » Ateroskleroz
 - » Travma
- » KLİNİK
- » GÖRÜNTÜLEME YÖNTEMLERİ
- » AMELİYAT ENDİKASYONLARI
- » CERRAHİ TEKNİKLER
 - » İzole Asendan Aort Replasmanı
 - » Aort kök replasmanı
 - » Kapak Koruyucu Ameliyatlar
- » POSTOPERATİF KOMPLİKASYONLAR
- » SONUÇLAR

¹ Op. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, dr.alizamin.yusifli@gmail.com, ORCID iD: 0000-0002-3686-0323
² Op. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, arzumkale@gmail.com, ORCID iD: 0000-0004-8347-7468
³ Op. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, denizyilmaz@gmail.com, ORCID iD: 0000-0003-0405-4690
⁴ Op. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, ulusalcoskun@gmail.com, ORCID iD: 0009-0009-8846-8508

sı ve sistemik antibiyoterapi verilmesi, pediküllü kas flepleri veya omentum ile greftin sarılması şeklinde yapılabilir.(50)

Omental flep, kanlanması sağ gastroepiploik arterden alacak şekilde midenin geniş kurvatüründen ayrılır ve sternuma çevrilir.

Psödoanevrizmalar

Bu anevrizmalar çoğunlukla aort üzerindeki kanülasyon, klemp ve sütür yerlerinden köken alır. Sütür hatlarındaki aşırı gerginlikle oluşan kanamaya bağlı da psödoanevrizma gelişebilir. Ayrıca, Marfan sendromu gibi kistik mediyal dejenerasyonun olduğu vakalarda postoperatif psödoanevrizma gelişme riski artmıştır.

SONUÇLAR

Erken Dönem Mortalite

Asendan aort anevrizmasının elektif onarımından sonra erken dönem hastane ölümlerinin %10'a kadar çıktığını bildiren yayınlar olsa da, cerrahi teknikteki önemli gelişmeler operatif ölüm oranını %3'ün altına düşürmüştür.(51,52) Erken ölümün yaygın nedenleri kalp yetmezliği, felç, kanama ve pulmoner yetmezliktir. Erken mortaliteye neden olan en önemli risk faktörü ise acil cerrahidir. Diğer risk faktörleri ileri yaş, uzamış kardiyopulmoner bypass süresi, kötü sol ventrikül foksasyonu, geçirilmiş aort veya koroner arter cerrahisi ve arkusun olaya katılmış olmasıdır. Marfan hastalarını inceleyen bir çalışmada ise 30 günlük ölüm oranı elektif onarım için %1,5 olarak bildirilmiş, acil cerrahi yaklaşım ise %12'lik erken ölüm oranıyla sonuçlanmıştır.(53)

Geç dönem mortalite

Geç dönem mortalite, hasta özellikleri ve cerrahi tekniğe bağlı olarak değişkendir. Sağkalım oranları 1 yılda %80 ila %95, 5 yılda %70 ila %90, 10 yılda %60 ila %75 ve 14 yılda %50 ila %60 arasında değişmektedir.⁽⁵⁴⁾ Elektif olarak aort kök replasmanı geçiren hastalarla ilgili yapılan bir çalışmada

hastaların %95'nin 10 yıllık takipte reoperasyondan kurtulduğu görüldü.(55) Uzun dönemde meydana gelen ölümlerin en yaygın nedenleri ise kardiyak ve geri kalan aortta gelişen patolojilere bağlı nedenlerdir. Arkusta ve distal aortta hastalık bulunması geç ölüm için önemli bir risk faktörüdür.(56) Geç ölüm için diğer risk faktörleri ise; ileri yaş, Marfan sendromunun bulunması, NYHA klasisinin yüksek olmasıdır.(57)

Reoperasyonlar

Reoperasyon nedenleri arasında, psödoanevrizma oluşumu, kapak trombozu, endokardit veya greft enfeksiyonu, doğal kapakta veya kalan aort segmentlerinde hastalığın ilerlemesi veya biyoprotezin dejenerasyonu sayılabilir. Özellikle kronik diseksiyonu veya Marfan sendromu olanlarda geri kalan aorttaki patoloji nedeniyle reoperasyon oranı yüksektir.(58) Ayrıca, reoperasyonların büyük çoğunluğunun ilk ameliyat sırasında yetersiz onarım nedeniyle yapıldığını gösteren çalışmalar da yayınlanmıştır.(59) 10-15 yıllık izlemlerde reoperasyon oranı %5-17 arasında değişmektedir.(57) Crawford'un serisinde tüp greft replasmanı yapılanlarda 1 yıllık reoperasyon oranı %2, kompozit greft replasmanı içinde ise %4 olarak saptanmıştır.(13)

KAYNAKLAR

1. Cooley DA, DeBakey ME. Resection of the entire ascending aorta in fusiform aneurysm using cardiac bypass. JAMA,1956;162:1158.
2. Mueller WH, Dammann FJ, Warren WD. Surgical correction of cardiovascular deformities in Marfan's Syndrome. Ann Surg,1960;152:506.
3. Starr A, Edwards ML, McCord CW et al. Aortic replacement. Circulation,1963;27:779.
4. Wheat MW Jr, Wilson JR, Bartley TD. Successful replacement of the entire ascending aorta and aortic valve. JAMA,1964;188:717.
5. Bentall H, DeBono A. A technique for complete replacement of the ascending aorta. Thorax,1968;28:338.
6. Edwards WS, Kerr AR. A safer technique for replacement of the entire ascending aorta and aortic valve. J Thorac Cardiovasc Surg,1970;59:837.
7. Inberg MV, Niinikoski J, Savunen T, Vanttinen E. Total repair of annuloaortic ectasia with composite graft and reimplantation of coronary ostia: A consecutive series of 41 patients. World J Surg,1985;9:493.
8. Kouchoyos NT, Marshall WG Jr. Eleven-year experience with composite graft replacement of the ascen-

- ding aorta and aortic valve. *J Thorac Cardiovasc Surg*, 1986; 92:691.
9. Cabrol C, Pavie A, Ganjbakch I et al. Complete replacement of the ascending aorta with reimplantation of the coronary arteries. *J Thorac Cardiovasc Surg*, 1981;81:309
10. Robert S. Dieter, Raymond A. Dieter Jr., editors. *Diseases of the Aorta*. 1st ed. Springer Nature Switzerland AG; 2019. pp.161-174
11. O'Rourke MF, Avolio AP, Nichols WW. Left ventricular- systemic arterial coupling in humans and strategies to improve coupling in disease states. In Yin FCP (ed): *Ventricular/Vascular Coupling: Clinical, Physiological and Engineering Aspects*. New York, Springer-Verlag, 1987
12. Andreotti L, Bussotti A, Cammelli D et al. Aortic connective tissue in atherosclerotic aorta-a biochemical study. *Angiology*, 1986;37:735
13. Crawford ES, Svensson LG, Coselli JS et al. Surgical treatment of aneurysm and/or dissection of the aorta, transverse aortic arch, and ascending aorta and transverse aortic arch. Factors influencing survival in 717 patients. *J Thorac Cardiovasc Surg*, 1989;98:659
14. Moreno-Cabral CE, Miller DC, et al. Degenerative and atherosclerotic aneurysms of the thoracic aorta. *J Thorac Cardiovasc Surg*, 1984;88:1020
15. Galloway AC, Covlin SB, LaMendola CL et al. Ten year experience with 165 aneurysms of the ascending aorta and aortic arch. *Circulation*, 1989;80:249
16. Ellis PR, Cooley DA, DeBakey ME. Clinical consideration and surgical treatment of annuloaortic ectasia. *J Thorac Cardiovasc Surg*, 1961;42:363
17. Cohn, Lawrence H., and David H. Adams, eds. *Cardiac Surgery in the Adult*. 5th ed. New York: McGraw-Hill Education; 2018. pp.1037-1074
18. Robbins SL, Cotran RS, Kumar V. *Pathologic Basis of Disease*, 3rd ed. Philadelphia, WB Saunders, p:503,1984
19. Fuster V, Halperin JL. Aortic dissection: A medical perspective. *J Card Surg*, 1994;9:713
20. Milewicz D. Inheritable disorders of connective tissue, in Willerson JT, Cohn JN (eds). *Cardiovascular Medicine*. 1st ed. New York, Churchill Livingstone, p:1638,1995.
21. Marselese DL, Moodie DS, Vacante M et al. Marfan's syndrome: natural history and long-term follow-up of cardiovascular involvement. *J Am Coll Cardiol*, 1989;44:422
22. Jondeau G, Detaint D, Tubach F, et al. Aortic event rate in the Marfan population: a cohort study. *Circulation*. 2012;125(2):226-32
23. Pope FM, Narcisi P, Nicholls AC et al. Clinical presentations of Ehlers Danlos syndrome type IV. *Arch Dis Child*, 1988;63:1016
24. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. *Nat Genet*. 2005;37(3):275-81.
25. MacCarrick G, Black JH 3rd, Bowdin S, et al. Loeys-Dietz syndrome: a primer for diagnosis and management. *Genet Med*. 2014;16(8):576-87
26. Kaiser LR, Kron IL, Spray TL, editors. *Mastery of cardiothoracic surgery*. 3rd ed. Philadelphia:Lippincott Williams & Wilkins; 2013. pp.590-598
27. Chan FY, Crawford ES, Coselli JS et al. In situ prosthetic graft replacement of mycotic aneurysm of the aorta. *Ann Thorac Surg*, 1989;44:193
28. Heggteit HA. Syphilitic aortitis: A clinicopathologic autopsy study of 100 cases, 1950 to 1960. *Circulation*, 1964;29:346
29. Pressler V, McNamara JJ. Thoracic aortic aneurysm. Natural history and treatment. *J Thorac Cardiovasc Surg*,1980;79:489
30. Pressler V, McNamara JJ. Aneurysm of the thoracic aorta. Review of 260 cases. *J Thorac Cardiovasc Surg*, 1985;89:50
31. Joyce JW, Fairburn JF, Kincaid OW, Juergens JL. Aneurysm of the thoracic aorta. A clinical study with a special reference to prognosis. *Circulation*, 1964;29:176
32. Schappert T, Sadony V, Schoden F et al. Diagnosis and therapeutic consequences of intramural aortic hematoma. *J Card Surg*, 1994;9:508
33. Erbel R. Role of transesophageal echocardiography in dissection of the aorta and evaluation of degenerative aortic disease. *Cardiol Clin*, 1993;11:461
34. Konstadt SN, Reich DL, Quintana C, Levy M. The ascending aorta: how much does transesophageal echocardiography see? *Anesth Analg*, 1994;78:240
35. Coady MA, Rizzo JA, Hammond GL et al. What is the appropriate size criterion for resection of the thoracic aneurysms? *J Thorac Cardiovasc Surg*, 1997;113:476-91.
36. Epperlein S, Mohr-Kahaly S, Erbel R et al. Aorta and aortic valve morphologies predisposing to aortic dissection. An in vivo assessment with transoesophageal echocardiography. *Eur Heart J*, 1994;15:1520-7
37. Child AH. Marfan syndrome-current medical and genetic knowledge: How to treat and when. *J Card Surg*, 1997;12(suppl):131-6
38. Marsalese DL, Moodie DS, Lytle BW et al. Cystic medial necrosis of the aorta in patients without Marfan syndrome: surgical outcome and long term follow up. *J Am Coll Cardiol*, 1990;16:68-73
39. Braverman AC. Bicuspid aortic valve and associated aortic wall abnormalities (editorial). *Curr Opin Cardiol*, 1996;11:501-3
40. Kouchoukos NT, Wareing TH, Daily BB, Murphy SF. Management of the severely atherosclerotic aorta during cardiac operations. *J Card Surg*, 1994;9:490-4
41. Davila-Roman VG, Philips KJ, Daily BB et al. Intraoperative transesophageal echocardiography and epiaortic ultrasound for assessment of atherosclerosis of the thoracic aorta. *J Am Coll Cardiol*, 1996;28:942-7
42. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. *Am J Cardiol*, 1989;64:507-512
43. Isselbacher EM, Preventza O, Black JH 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;146:e334-e482
44. Legget ME, Under TA, O'Sullivan CK et al. Aortic root complications in Marfan's syndrome: Identification of a lower risk group. *Heart*, 1996;75:389-95
45. Czerny M, Grabenwoger M, Berger T, et al. EACTS/STS Guidelines for Diagnosing and Treating Acute and

- Chronic Syndromes of the Aortic Organ. *Ann Thorac Surg.* 2024;118:5-115
46. Kırallı K, Mansuroğlu D, Ömeroğlu SN et al. Five-year experience in aortic root replacement with the flanged composite graft. *Ann Thorac Surg.* 2002;73:1130-7
 47. Griep RB, Ergin MA, Lansman SL et al. The physiology of hypothermic circulatory arrest. *Sem Thorac Cardiovasc Surg.* 1991;3:188
 48. Gott VL, Gillinov AM, Pyritz RE et al. Aortic root replacement. Risk factor analysis of a seventeen-year experience with 270 patients. *J Thorac Cardiovasc Surg.* 1995;109:536-44
 49. Coselli JS, Crawford ES, Williams TW Jr et al. Treatment postoperative infection of ascending aorta and transverse aortic arch, including use of viable omentum and muscle flaps. *Ann Thorac Surg.* 1990;50:868
 50. Hargrove WC 3rd, Edmunds LH Jr. Management of infection thoracic aortic prosthetic grafts. *Ann Thorac Surg.* 37,1984
 51. Achneck HE, Rizzo JA, Tranquilli M, Eleftheriades JA. Safety of thoracic aortic surgery in the present era. *Ann Thorac Surg.* 2007;84(4):1180-5; discussion 1185
 52. Fleck TM, Koinig H, Czerny M, et al. Impact of surgical era on outcomes of patients undergoing elective atherosclerotic ascending aortic aneurysm operations. *Eur J Cardiothorac Surg.* 2004;26(2):342-7
 53. Gott VL, Greene PS, Alejo DE, et al: Replacement of the aortic root in patients with Marfan's syndrome. *N Engl J Med* 1999; 340:1307
 54. Estrera AL, Miller CC 3rd, Huynh TT, Porat EE, Safi HJ. Replacement of the ascending and transverse aortic arch: determinants of long-term survival. *Ann Thorac Surg.* 2002;74(4):1058- 64; discussion 1064-1055
 55. McCarthy FH, Bavaria JE, McDermott KM, et al. At the root of the repair debate: outcomes after elective aortic root replacements for aortic insufficiency with aneurysm. *Ann Thorac Surg.* 2016;102(4):1199-205
 56. Jault F, Nataf P, Rama A et al. Chronic disease of the ascending aorta: Surgical treatment and longterm results. *J Thorac Cardiovasc Surg.* 1994;108:747
 57. Kouchoukos NT, Wareing TH, Murphy SF, Perrillo JB. Sixteen-year experience with aortic root replacement. *Ann Surg.* 1991;214:308
 58. Taniguchi K, Nakano S, Matsuda H et al. Long-term survival and complications after composite graft replacement for ascending aortic aneurysm associated with aortic regurgitation. *Circulation.* 1991;84(Suppl):III-31
 59. Luciani GB, Casali G, Faggian G, Mazzucco A: Predicting outcome after reoperative procedures on the aortic root and ascending aorta. *Eur J Cardiothorac Surg* 2000; 17:602



AORTİK ARKUS, CERRAHİ YAKLAŞIM VE SEREBRAL KORUMA

BÖLÜM 78

Alizamin YUSİFLİ ¹
Arzum KALE ²
Makbule KESİCİ ³
M. Fatih AYIK ⁴

DOI: 10.37609/akya.3889.c5400

İçindekiler

- » GİRİŞ
- » ANATOMİ
- » TARİHÇE
- » ETİYOLOJİ
- » AMELİYAT ENDİKASYONLARI
- » GÖRÜNTÜLEME YÖNTEMLERİ
- » İNTRAOPERATİF YÖNETİM
 - » Serebral Monitörizasyon
- » BEYİN KORUMA YÖNTEMLERİ
- » HİPOTERMİK SİRKÜLATUAR ARREST
 - » Antegrad Serebral Perfüzyon
 - » Retrograd Serebral Perfüzyon
- » CERRAHİ YAKLAŞIM
- » SONUÇLAR

¹ Op. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, dr.alizamin.yusifli@gmail.com, ORCID iD: 0000-0002-3686-0323

² Op. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, arzumkale@gmail.com, ORCID iD: 0000-0004-8347-7468

³ Op. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, makbule.kesici@medicana.com.tr, ORCID iD: 0009-0003-9434-2334

⁴ Op. Dr., İzmir Medicana International Hospital, Kalp Damar Cerrahisi, fayik35@gmail.com, ORCID iD: 0000-0002-0780-3047

lojik komplikasyonlar ve kanama gelmektedir. Arkus cerrahisinde başarının en iyi göstergesi ameliyat sonrası hastanın nörolojik durumudur. Nörolojik komplikasyonlar büyük ölçüde ark cerrahisi sırasında serebral kan akışının kesintiye uğramasının bir sonucudur. Serebral hipoperfüzyona ek olarak, diğer etiyolojik faktörler arasında embolik fenomenler ve kardiyopulmoner baypasa (CPB) inflamatuvar yanıt bulunur.

Geniş total arkus replasmanı serilerinde orta hipotermiyle antegrad selektif serebral perfüzyon uygulayan Bachet %17, Kazui ise %13 hastane mortalitesi bildirmiştir.(7,8) Bachet'nin serisinde genel nörolojik komplikasyon oranını %13'dür. Kazui kalıcı strok oranını %3.3, geçici nörolojik bozukluk oranını %6 olarak bildirmiş, kalıcı strok gelişiminin belirleyicilerinin geçirilmiş eski strok ve uzun pompa süresi olduğunu belirtmiştir. Ergin ve arkadaşları, HSA sonrası gelişen nörolojik hasarı; kalıcı hasar (lokalize strok, enfarkt) ve geçici nörolojik bozukluk olarak ikiye ayırmıştır.(17) Geçici nörolojik bozukluk, yetersiz akım ya da koruma sonucu global iskeminin neden olduğu bariz olmayan beyin hasarı sonucu gelişir ve klinik olarak konfüzyon, ajitasyon, uzamış küntlük, geçici parkinsonizm gibi tablolarla karakterizedir. Kalıcı hasar ise genellikle emboli sonucu gelişen lokalize iskemik enfarktılar sonucu oluşur ve klinik örneği hemiplejidir. Retrograd serebral perfüzyon uygulayan Coselli total arkus replasmanında mortalite oranını %6 olarak vermiştir.(19) Kazui, total arkus replasmanı yapılan 220 hastalık serisinde 5 yıllık hayatta kalma oranının %80 olduğunu ve bu oranın anevrizma etiyolojisine göre farklılık göstermediğini bildirmiştir.(8)

Total arkus replasmanı yapılan olgular diğer aort bölümlerinde diseksiyon veya dilatasyon içeriyorsa yıllık kontrastlı BT ile izlenmelidir. Diseksiyonu ve Marfan sendromu olan olgulara bir kontrendikasyon yoksa beta bloker verilmeli, hipertansif hastalarda kan basıncı iyi kontrol edilmelidir.

KAYNAKLAR

1. DeBakey ME, Cooley DA, Crawford ES, Morris GC Jr. Successful resection of fusiform aneurysm of aortic arch with replacement by homografts. Surg Gynecol Obstet, 1957;105:656-64.
2. Coselli JS, LeMaire SA, editors. *Aortic Arch Surgery: Principles, Strategies, and Outcomes*. 1st ed. Oxford: Wiley-Blackwell; 2008. pp.12-18.
3. Griepp RB, Stinson EB, Hollingsworth JF, Buehler D. Prosthetic replacement of the aortic arch. J Thorac Cardiovasc Surg, 1975;70:105-63.
4. Cooley DA, Livesay JJ. Technique of "open" distal anastomosis for ascending and transverse arch resection. Bull Tex Heart Inst, 1981;8:421-66.
5. Borst HG, Walterbusch G, Schaps D. Extensive aortic replacement using "elephant trunk" prosthesis. J Thorac Cardiovasc Surg, 1983;31:37-40.
6. Ueda Y, Miki S, Kusuha K et al. Surgical treatment of aneurysm or dissection involving the ascending aorta and aortic arch, using circulatory arrest and retrograde cerebral perfusion. J Cardiovasc Surg, 1990;31:553-8.
7. Bachet J, Guilmet D, Goudot B et al. Antegrade cerebral perfusion with cold blood: A 13-year experience. Ann Thorac Surg, 1999;67:1874-8.
8. Kazui T, Washiyama N, Muhammad B et al. Total arch replacement using aortic arch branched grafts with the aid of antegrade selective cerebral perfusion. Ann Thorac Surg, 2000;70:3-9.
9. Czerny M, Grabenwoger M, Berger T, et al. EACTS/STS Guidelines for Diagnosing and Treating Acute and Chronic Syndromes of the Aortic Organ. Ann Thorac Surg, 2024;118:5-115. P40
10. Isselbacher EM, Preventza O, Black JH 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146:e334-e482.
11. Petersen S, Pichlmaier M, Curtis A, Luehr M, Born F, Hagl C. Patient management in aortic arch surgery. Eur J Cardiothorac Surg, 2017;51:i4-i14.
12. Griepp Randall B et al., Hypothermia for aortic surgery. J Thorac Cardiovasc Surg, 2013;145:S56-8
13. Coselli JS, LeMaire SA, editors. *Aortic Arch Surgery: Principles, Strategies, and Outcomes*. 1st ed. Oxford: Wiley-Blackwell; 2008. pp. 135-153.
14. McCullough JN, Zhang N, Reich DL et al. Cerebral metabolic suppression during hypothermic circulatory arrest in humans. Ann Thorac Surg, 1999;67:1895-9.
15. Svensson LG, Crawford ES, Hess KR et al. Deep hypothermia with circulatory arrest: Determinants of stroke and early mortality in 656 patients. J Thorac Cardiovasc Surg, 1993;106:19-31.
16. Svensson LG. Antegrade perfusion during suspended animation? J Thorac Cardiovasc Surg, 2002;124:1068-70.
17. Ergin MA, Griepp RB, Lansman SL et al. Hypothermic circulatory arrest and other methods of cerebral protection during operations on the thoracic aorta. J Card Surg, 1994;9:525-37
18. Mills NL, Ochsner JL. Massive air embolism during cardiopulmonary bypass. J Thorac Cardiovasc Surg, 1980;80:708-17.
19. Coselli JS, Buket S, Djukanovic B. Aortic arch operation: Current treatment and results. Ann Thorac Surg, 1995;59:19-27.



DOI: 10.37609/akya.3889.c5401

ABDOMİNAL VE TORAKOABDOMİNAL AORT ANEVRİZMALARINDA CERRAHİ VE ENDOVASKÜLER GİRİŞİM

BÖLÜM 79

Kamran KAZIMOĞLU MUSAYEV ¹

İçindekiler

» GİRİŞ

- » İnfrarenal Anevrizmalar
- » Kompleks Anevrizmalar
- » Tedavi: Açık cerrahi ve endovasküler girişim
- » AAA için cerrahi endikasyonlar
- » Anevrizma çapı
- » Semptom varlığı
- » Sakküler anevrizma
- » Hızlı büyüme gösteren anevrizmalar
- » Endovasküler Aort Anevrizma Onarımı (EVAR)
- » Komplikasyonlar
- » Açık Cerrahi Onarım (OSR)
- » Açık Cerrahi Tamirde Cerrahi Yaklaşımlar
- » Açık Cerrahi ve Endovasküler Onarımın Karşılaştırılması

» TORAKOABDOMİNAL AORT ANEVRİZMALARINDA CERRAHİ VE

ENDOVASKÜLER GİRİŞİM

- » Tanısal Yöntemler
- » Doğal Seyir
- » Tedavi Alternatifleri
- » 2. Endovasküler Onarım (EVAR / TEVAR / FEVAR / BEVAR)
- » 3. Hibrit Onarım
- » Distal Perfüzyon: Parsiyel CPB ve Sol Kalp Bypass

» KOMPLEKS AORT ANERİZMALARINDA ENDOVASKÜLER TEDAVİ

- » Endovasküler Yaklaşımın Temel Prensipleri
- » Hasta Seçimi ve Görüntüleme
- » Klinik Başarı ve Komplikasyonlar

»

¹ Prof. Dr., Merkezi Klinik Hastane, Kalp ve Damar Cerrahisi, kamrancan@yahoo.com, ORCID iD: 0000-0002-0020-2118

Ancak bu tedavi stratejileri yüksek teknik uzmanlık gerektirdiği gibi, uzun vadeli başarı için düzenli takip ve tecrübeli merkezler şarttır. Hasta seçimi, cihaz planlaması ve postoperatif izlem multidisipliner ekiplerce yapılmalıdır.

KAYNAKLAR

- 1 Sakalihan N, Michel JB, Katsargyris A, Kuivaniemi H, Defraigne JO, Nchimi A, Powell JT, Yoshimura K, Hultgren R. Abdominal aortic aneurysms. *Nat Rev Dis Primers*. 2018;4:34.
- 2 Isselbacher EM, Preventza O, Hamilton Black J, 3rd, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A, Jr., Fanola CL, Girardi LN, Hicks CW, Hui DS, Schuyler Jones W, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Gyang Ross E, Schermerhorn ML, Singleton Times S, Tseng EE, Wang GJ, Woo YJ, Peer Review Committee M. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;146:e334-e482.
- 3 Sampson UK, Norman PE, Fowkes FG, Aboyans V, Song Y, Harrell FE, Jr., Forouzanfar MH, Naghavi M, Denenberg JO, McDermott MM, Criqui MH, Mensah GA, Ezzati M, Murray C. Estimation of global and regional incidence and prevalence of abdominal aortic aneurysms 1990 to 2010. *Glob Heart*. 2014;9:159-70.
- 4 Tang W, Yao L, Roetker NS, Alonso A, Lutsey PL, Steenson CC, Lederle FA, Hunter DW, Bengtson LG, Guan W, Missov E, Folsom AR. Lifetime Risk and Risk Factors for Abdominal Aortic Aneurysm in a 24-Year Prospective Study: The ARIC Study (Atherosclerosis Risk in Communities). *Arterioscler Thromb Vasc Biol*. 2016;36:2468-77.
- 5 Sakalihan N, Defraigne JO, Kersten MA, Cheramy-Bien JP, Smelser DT, Tromp G, Kuivaniemi H. Family members of patients with abdominal aortic aneurysms are at increased risk for aneurysms: analysis of 618 probands and their families from the Liege AAA Family Study. *Ann Vasc Surg*. 2014;28:787-97.
- 6 Carter JL, Morris DR, Sherliker P, Clack R, Lam KBH, Halliday A, Clarke R, Lewington S, Bulbulia R. Sex-Specific Associations of Vascular Risk Factors With Abdominal Aortic Aneurysm: Findings From 1.5 Million Women and 0.8 Million Men in the United States and United Kingdom. *J Am Heart Assoc*. 2020;9:e014748.
- 7 Lederle FA, Johnson GR, Wilson SE, Ballard DJ, Jordan WD, Jr., Blebea J, Littooy FN, Freischlag JA, Bandyk D, Rapp JH, Salam AA, Veterans Affairs Cooperative Study I. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. *JAMA*. 2002;287:2968-72.
- 8 van Beek SC, Conijn AP, Koelemay MJ, Balm R. Editor's Choice - Endovascular aneurysm repair versus open repair for patients with a ruptured abdominal aortic aneurysm: a systematic review and meta-analysis of short-term survival. *Eur J Vasc Endovasc Surg*. 2014;47:593-602.
- 9 Sweeting MJ, Thompson SG, Brown LC, Powell JT, collaborators R. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. *Br J Surg*. 2012;99:655-65.
- 10 Wanhainen A, Van Herzele I, Bastos Goncalves F, Belmunt Montoya S, Berard X, Boyle JR, D'Oria M, Prendes CF, Karkos CD, Kazimierczak A, Koelemay MJW, Kolbel T, Mani K, Melissano G, Powell JT, Trimarchi S, Tsilimparis N, Committee EG, Antoniou GA, Bjorck M, Coscas R, Dias NV, Kolh P, Lepidi S, Mees BME, Resch TA, Ricco JB, Tulamo R, Twine CP, Document R, Branzan D, Cheng SWK, Dalman RL, Dick F, Golledge J, Haulon S, van Herwaarden JA, Illic NS, Jawien A, Mastracci TM, Oderich GS, Verzini F, Yeung KK. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. *Eur J Vasc Endovasc Surg*. 2024;67:192-331.
- 11 Accarino G, Giordano AN, Falcone M, Celano A, Vassallo MG, Fornino G, Bracale UM, Vecchione C, Galasso G. Abdominal Aortic Aneurysm: Natural History, Pathophysiology and Translational Perspectives. *Transl Med UniSa*. 2022;24:30-40.
- 12 Ali Z, Kim L, Gupta K. Endovascular Abdominal Aortic Aneurysm Repair. *Interv Cardiol Clin*. 2025;14:173-90.
- 13 Czerny M, Grabenwoger M, Berger T, Aboyans V, Della Corte A, Chen EP, Desai ND, Dumfarth J, Elefteriades JA, Etz CD, Kim KM, Kreibich M, Lescan M, Di Marco L, Martens A, Mestres CA, Milojevic M, Nienaber CA, Piffaretti G, Preventza O, Quintana E, Rylski B, Schlett CL, Schoenhoff F, Trimarchi S, Tsagakis K, Group ESSD. EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. *Eur J Cardiothorac Surg*. 2024;65.
- 14 Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, Mastracci TM, Mell M, Murad MH, Nguyen LL, Oderich GS, Patel MS, Schermerhorn ML, Starnes BW. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. *J Vasc Surg*. 2018;67:2-77 e2.
- 15 Cambria RP, Brewster DC, Abbott WM, Freehan M, Megerman J, LaMuraglia G, Wilson R, Wilson D, Teplick R, Davison JK. Transperitoneal versus retroperitoneal approach for aortic reconstruction: a randomized prospective study. *J Vasc Surg*. 1990;11:314-24; discussion 24-5.
- 16 Sicard GA, Reilly JM, Rubin BG, Thompson RW, Allen BT, Flye MW, Schechtman KB, Young-Beyer P, Weiss C, Anderson CB. Transabdominal versus retroperitoneal incision for abdominal aortic surgery: report of a prospective randomized trial. *J Vasc Surg*. 1995;21:174-81; discussion 81-3.
- 17 Sieunarine K, Lawrence-Brown MM, Goodman MA. Comparison of transperitoneal and retroperitoneal approaches for infrarenal aortic surgery: early and late results. *Cardiovasc Surg*. 1997;5:71-6.
- 18 Johnston KW, Scobie TK. Multicenter prospective study of nonruptured abdominal aortic aneurysms. I. Population and operative management. *J Vasc Surg*. 1988;7:69-81.
- 19 Johnston KW. Multicenter prospective study of nonruptured abdominal aortic aneurysm. Part II. Variab-

- les predicting morbidity and mortality. *J Vasc Surg.* 1989;9:437-47.
- 20 Brewster DC, Franklin DP, Cambria RP, Darling RC, Moncure AC, Lamuraglia GM, Stone WM, Abbott WM. Intestinal ischemia complicating abdominal aortic surgery. *Surgery.* 1991;109:447-54.
 - 21 Becquemin JP, Majewski M, Fermani N, Marzelle J, Desgrandes P, Allaire E, Roudot-Thoraval F. Colon ischemia following abdominal aortic aneurysm repair in the era of endovascular abdominal aortic repair. *J Vasc Surg.* 2008;47:258-63; discussion 63.
 - 22 Mitchell KM, Valentine RJ. Inferior mesenteric artery reimplantation does not guarantee colon viability in aortic surgery. *J Am Coll Surg.* 2002;194:151-5.
 - 23 Senekowitsch C, Assadian A, Assadian O, Hartleb H, Ptakovsky H, Hagmuller GW. Replanting the inferior mesentery artery during infrarenal aortic aneurysm repair: influence on postoperative colon ischemia. *J Vasc Surg.* 2006;43:689-94.
 - 24 Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Becquemin JP, Greenhalgh RM, Evar DO, Trialists ACE. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. *Br J Surg.* 2017;104:166-78.
 - 25 Patel R, Sweeting MJ, Powell JT, Greenhalgh RM, investigators Et. Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. *Lancet.* 2016;388:2366-74.
 - 26 Lederle FA, Kyriakides TC, Stroupe KT, Freischlag JA, Padberg FT, Jr., Matsumura JS, Huo Z, Johnson GR, Group OVACS. Open versus Endovascular Repair of Abdominal Aortic Aneurysm. *N Engl J Med.* 2019;380:2126-35.
 - 27 van Schaik TG, Meekel JP, de Bruin JL, Yeung KK, Blankensteijn JD, collaborators DR-t. Identifying high risk for proximal endograft failure after endovascular aneurysm repair in patients suitable for both open and endovascular elective aneurysm repair. *J Vasc Surg.* 2022;76:1261-9.
 - 28 Sweeting MJ, Patel R, Powell JT, Greenhalgh RM, Investigators ET. Endovascular Repair of Abdominal Aortic Aneurysm in Patients Physically Ineligible for Open Repair: Very Long-term Follow-up in the EVAR-2 Randomized Controlled Trial. *Ann Surg.* 2017;266:713-9.
 - 29 Patel R, Powell JT, Sweeting MJ, Epstein DM, Barrett JK, Greenhalgh RM. The UK EndoVascular Aneurysm Repair (EVAR) randomised controlled trials: long-term follow-up and cost-effectiveness analysis. *Health Technol Assess.* 2018;22:1-132.
 - 30 Clouse WD, Hallett JW, Jr., Schaff HV, Gayari MM, Ilstrup DM, Melton LJ, 3rd. Improved prognosis of thoracic aortic aneurysms: a population-based study. *JAMA.* 1998;280:1926-9.
 - 31 Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades JA. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. *Ann Thorac Surg.* 2002;73:17-27; discussion 8.
 - 32 Juvonen T, Ergin MA, Galla JD, Lansman SL, Nguyen KH, McCullough JN, Levy D, de Asla RA, Bodian CA, Griep RB. Prospective study of the natural history of thoracic aortic aneurysms. *Ann Thorac Surg.* 1997;63:1533-45.
 - 33 Cambria RA, Gloviczki P, Stanson AW, Cherry KJ, Jr., Bower TC, Hallett JW, Jr., Pairolero PC. Outcome and expansion rate of 57 thoracoabdominal aortic aneurysms managed nonoperatively. *Am J Surg.* 1995;170:213-7.
 - 34 Coselli JS, LeMaire SA, Preventza O, de la Cruz KI, Cooley DA, Price MD, Stolz AP, Green SY, Arredondo CN, Rosengart TK. Outcomes of 3309 thoracoabdominal aortic aneurysm repairs. *J Thorac Cardiovasc Surg.* 2016;151:1323-37.
 - 35 Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, Norton HJ, Glaeser DH. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. *J Vasc Surg.* 1986;3:389-404.
 - 36 Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic Diseases. *Circ Res.* 2019;124:588-606.
 - 37 Ouzounian M, Tadros RO, Svensson LG, Lyden SP, Oderich GS, Coselli JS. Thoracoabdominal Aortic Disease and Repair: JACC Focus Seminar, Part 3. *J Am Coll Cardiol.* 2022;80:845-56.
 - 38 Rimbau V, Bockler D, Brunkwall J, Cao P, Chiesa R, Coppi G, Czerny M, Fraedrich G, Haulon S, Jacobs MJ, Lachat ML, Moll FL, Setacci C, Taylor PR, Thompson M, Trimarchi S, Verhagen HJ, Verhoeven EL, Esvs Guidelines C, Kolh P, de Borst GJ, Chakfe N, Debus ES, Hinchliffe RJ, Kakkos S, Koncar I, Lindholt JS, Vega de Ceniga M, Vermassen F, Verzini F, Document R, Kolh P, Black JH, 3rd, Busund R, Bjorck M, Dake M, Dick F, Eggebrecht H, Evangelista A, Grabenwoger M, Milner R, Naylor AR, Ricco JB, Rousseau H, Schmidli J. Editor's Choice - Management of Descending Thoracic Aorta Diseases: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg.* 2017;53:4-52.
 - 39 Conrad MF, Cambria RP. Contemporary management of descending thoracic and thoracoabdominal aortic aneurysms: endovascular versus open. *Circulation.* 2008;117:841-52.
 - 40 Safi HJ, Winnerkvist A, Miller CC, 3rd, Iliopoulos DC, Reardon MJ, Espada R, Baldwin JC. Effect of extended cross-clamp time during thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg.* 1998;66:1204-9.
 - 41 Kim JB, Kim K, Lindsay ME, MacGillivray T, Isselbacher EM, Cambria RP, Sundt TM, 3rd. Risk of rupture or dissection in descending thoracic aortic aneurysm. *Circulation.* 2015;132:1620-9.
 - 42 Zafar MA, Chen JF, Wu J, Li Y, Papanikolaou D, Abdelbaky M, Faggion Vinholo T, Rizzo JA, Ziganshin BA, Mukherjee SK, Elefteriades JA, Yale Aortic Institute Natural History I. Natural history of descending thoracic and thoracoabdominal aortic aneurysms. *J Thorac Cardiovasc Surg.* 2021;161:498-511 e1.
 - 43 Lobato AC, Puech-Leao P. Predictive factors for rupture of thoracoabdominal aortic aneurysm. *J Vasc Surg.* 1998;27:446-53.
 - 44 Gambardella I, Gaudino MFL, Rahouma M, Farrington WJ, Khan FM, Hameed I, Lau C, Iannacone E, Girardi

- LN. Impact of left ventricular ejection fraction on the outcomes of open repair of descending thoracic and thoracoabdominal aneurysms. *J Thorac Cardiovasc Surg.* 2021;161:534-41 e5.
- 45 Girardi LN, Lau C, Ohmes LB, Degner BC, Leonard JR, Abouarab A, Di Franco A, Iannacone EM, Munjal M, Gaudino M. Open repair of descending and thoracoabdominal aortic aneurysms in octogenarians. *J Vasc Surg.* 2018;68:1287-96 e3.
- 46 Etheredge SN, Yee J, Smith JV, Schonberger S, Goldman MJ. Successful resection of a large aneurysm of the upper abdominal aorta and replacement with homograft. *Surgery.* 1955;38:1071-81.
- 47 Debaquey ME, Creech O, Jr., Morris GC, Jr. Aneurysm of thoracoabdominal aorta involving the celiac, superior mesenteric, and renal arteries; report of four cases treated by resection and homograft replacement. *Ann Surg.* 1956;144:549-73.
- 48 Crawford ES. Thoraco-abdominal and abdominal aortic aneurysms involving renal, superior mesenteric, celiac arteries. *Ann Surg.* 1974;179:763-72.
- 49 Etz CD, Halstead JC, Spielvogel D, Shahani R, Lazala R, Homann TM, Weisz DJ, Plestis K, Griepp RB. Thoracic and thoracoabdominal aneurysm repair: is reimplantation of spinal cord arteries a waste of time? *Ann Thorac Surg.* 2006;82:1670-7.
- 50 Afifi RO, Sandhu HK, Zaidi ST, Trinh E, Tanaka A, Miller CC, 3rd, Safi HJ, Estrera AL. Intercostal artery management in thoracoabdominal aortic surgery: To reattach or not to reattach? *J Thorac Cardiovasc Surg.* 2018;155:1372-8 e1.
- 51 Huynh TT, van Eps RG, Miller CC, 3rd, Villa MA, Estrera AL, Azizzadeh A, Porat EE, Goodrick JS, Safi HJ. Glomerular filtration rate is superior to serum creatinine for prediction of mortality after thoracoabdominal aortic surgery. *J Vasc Surg.* 2005;42:206-12.
- 52 Tanaka A, Smith HN, Safi HJ, Estrera AL. Open Treatments for Thoracoabdominal Aortic Aneurysm Repair. *Methodist Debaquey Cardiovasc J.* 2023;19:49-58.
- 53 Sandhu HK, Evans JD, Tanaka A, Atay S, Afifi RO, Charlton-Ouw KM, Azizzadeh A, Miller CC, 3rd, Safi HJ, Estrera AL. Fluctuations in Spinal Cord Perfusion Pressure: A Harbinger of Delayed Paraplegia After Thoracoabdominal Aortic Repair. *Semin Thorac Cardiovasc Surg.* 2017;29:451-9.
- 54 Estrera AL, Miller CC, 3rd, Huynh TT, Azizzadeh A, Porat EE, Vinnerkvist A, Ignacio C, Sheinbaum R, Safi HJ. Preoperative and operative predictors of delayed neurologic deficit following repair of thoracoabdominal aortic aneurysm. *J Thorac Cardiovasc Surg.* 2003;126:1288-94.
- 55 Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Thoracoabdominal aortic aneurysms associated with celiac, superior mesenteric, and renal artery occlusive disease: methods and analysis of results in 271 patients. *J Vasc Surg.* 1992;16:378-89; discussion 89-90.
- 56 Lemaire SA, Jones MM, Conklin LD, Carter SA, Cridell MD, Wang XL, Raskin SA, Coselli JS. Randomized comparison of cold blood and cold crystalloid renal perfusion for renal protection during thoracoabdominal aortic aneurysm repair. *J Vasc Surg.* 2009;49:11-9; discussion 9.
- 57 Karaolanis GI, Antonopoulos CN, Scali S, Koutsias SG, Kotelis D, Donas KP. Systematic review with pooled data analysis reveals the need for a standardized reporting protocol including the visceral vessels during fenestrated endovascular aortic repair (FEVAR). *Vascular.* 2022;30:405-17.



AORT DİSSEKSİYONLARI VE AKUT AORTİK SENDROMLAR

DOI: 10.37609/akya.3889.c5402

BÖLÜM 80

Tahir YAĞDI ¹
Çağatay ENGİN ²
Mehmet Fatih AYIK ³
Ayşen Yaprak KAPKIN ⁴

İçindekiler

- » GİRİŞ
- » AKUT AORTİK SENDROMLARIN KLİNİK ALT TİPLERİ
- » AORT DİSSEKSİYONU
 - » Tanım ve Patofizyoloji
 - » Epidemiyoloji ve Etiyoloji
 - » Aort disseksiyonu sınıflamaları
 - » Aort disseksiyonunda klinik bulgular ve fizik muayene
 - » Tanı Yöntemleri
 - » Risk Skorlama Sistemleri
 - » Tedavi Yaklaşımı ve Aort takımı
 - » Tıbbi Tedavi (Kan basıncı kontrolü, ağrı kontrolü
 - » Aort disseksiyonlarında cerrahi tedavi
- » Tip A aort disseksiyonunda malperfüzyon
- » Tip A aort disseksiyonunda endovasküler tedavi
- » Non-A non-B aort disseksiyonunda tedavi
- » Akut Tip B aort disseksiyonunda tedavi
- » Kronik tip B aort disseksiyonun girişimsel tedavisi
- » Aortik İntramural Hematom
- » Penetran Aterosklerotik Ülserler
- » Travmatik Aort Yaralanmaları
- » Aortik Psödoanevrizma
- » İyatrojenik Aort Yaralanmaları
- » Akut Aortik Sendrom Hastalarının Takibi

¹ Prof. Dr., Ege Üniversitesi Tıp Fakültesi Kalp Damar Cerrahisi AD., tahir.yagdi@gmail.com, ORCID iD: 0000-0001-6282-2489

² Prof. Dr., Ege Üniversitesi Tıp Fakültesi Kalp Damar Cerrahisi AD., cagatayengin@yahoo.com, ORCID iD: 0000-0003-4025-7874

³ Doç. Dr., Medica International İzmir Hastanesi Kalp Damar Cerrahisi Kliniği, fayik35@gmail.com, ORCID iD: 0000-0002-0780-3047

⁴ Dr. Öğr. Üyesi, Ege Üniversitesi Tıp Fakültesi Kalp Damar Cerrahisi AD., yaprakkapkin@hotmail.com, ORCID iD: 0000-0002-0763-2719

KAYNAKLAR

1. Coselli JS, Köksoy C. Aortic Dissections. In: Franco KL, Verrier ED: Advanced Therapy in Cardiac Surgery Eds. BC Decker Inc (32), p:296-310, 1999.
2. Mészáros I, Mórocz J, Szlávi J, Schmidt J, Tornóci L, Nagy L, et al. Epidemiology and clinicopathology of aortic dissection. *Chest*. 2000 May;117(5):1271-8. doi: 10.1378/chest.117.5.1271. PMID: 10807810.
3. Clouse WD, Hallett JW Jr, Schaff HV, Spittell PC, Rowland CM, Ilstrup DM, et al. Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture. *Mayo Clin Proc*. 2004 Feb;79(2):176-80. doi: 10.4065/79.2.176. PMID: 14959911.
4. Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. *JAMA*. 2000 Feb 16;283(7):897-903. doi: 10.1001/jama.283.7.897. PMID: 10685714.
5. Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: diagnosis and management, an update. *European Heart Journal* 2018, 39(9), 739–749. <https://doi.org/10.1093/eurheartj/ehx319>.
6. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. ESC Scientific Document Group, 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM), *European Heart Journal*, Volume 45, Issue 36, 21 September 2024, Pages 3538–3700, <https://doi.org/10.1093/eurheartj/ehae179>.
7. Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes. *Nat Rev Cardiol* 2021;18:331–48. <https://doi.org/10.1038/s41569-020-00472-6>.
8. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the diagnosis and treatment of aortic diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2014;35:2873–926. <https://doi.org/10.1093/eurheartj/ehu281>.
9. Isselbacher EM, Preventza O, Hamilton Black J 3rd, Augoustides JG, Beck AW, Bolen MA, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. *Circulation* 2022;146:e334-482. <https://doi.org/10.1161/cir.0000000000001106>.
10. Aboyans V, Boukhris M. Dissecting the epidemiology of aortic dissection. *Eur Heart J Acute Cardiovasc Care* 2021;10:710–1. <https://doi.org/10.1093/ehjacc/zuab065>.
11. Tsai TT, Nienaber CA, Eagle KA. Acute aortic syndromes. *Circulation*. 2005 Dec 13;112(24):3802-13. doi: 10.1161/CIRCULATIONAHA.105.534198. PMID: 16344407.
12. Uchida K, Imoto K, Karube N, Minami T, Cho T, Goda M, et al. Intramural haematoma should be referred to as thrombosed-type aortic dissection. *Eur J Cardiothorac Surg*. 2013 Aug;44(2):366-9; discussion 369. doi: 10.1093/ejcts/ezt040. Epub 2013 Mar 20. PMID: 23515169.
13. Katzenschlager R, Ugurluoglu A, Ahmadi A, Hülsmann M, Koppensteiner R, Larch E, et al. Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. *Radiology* 1995;195:463–6. <https://doi.org/10.1148/radiology.195.2.7724767>.
14. Mulder EJ, van Bockel JH, Maas J, van den Akker PJ, Hermans J. Morbidity and mortality of reconstructive surgery of noninfected false aneurysms detected long after aortic prosthetic reconstruction. *Arch Surg* 1998;133:45–9. <https://doi.org/10.1001/archsurg.133.1.45>.
15. Chaud GJ, Mohammadi S, Cervetti MR, Guimaron S, Sebestyen A, Dagenais F, et al. Aortic pseudoaneurysm after type A aortic dissection: results of conservative management. *Semin Thorac Cardiovasc Surg* 2022;35:457–64. <https://doi.org/10.1053/j.semtcvs.2022.04.004>.
16. Richens D, Kotidis K, Neale M, Oakley C, Fails A. Rupture of the aorta following road traffic accidents in the United Kingdom 1992–1999. The results of the co-operative crash injury study. *Eur J Cardiothorac Surg* 2003;23:143–8. [https://doi.org/10.1016/s1010-7940\(02\)00720-0](https://doi.org/10.1016/s1010-7940(02)00720-0).
17. Harky A, Bleetman D, Chan JSK, Eriksen P, Chaplin G, MacCarthy-Ofosu B, et al. A systematic review and meta-analysis of endovascular versus open surgical repair for the traumatic ruptured thoracic aorta. *J Vasc Surg* 2020;71:270-82. <https://doi.org/10.1016/j.jvs.2019.05.011>.
18. Heneghan RE, Aarabi S, Quiroga E, Gunn ML, Singh N, Starnes BW. Call for a new classification system and treatment strategy in blunt aortic injury. *J Vasc Surg* 2016; 64:171–6. <https://doi.org/10.1016/j.jvs.2016.02.047>.
19. Dunning DW, Kahn JK, Hawkins ET, O'Neill W. Iatrogenic coronary artery dissections extending into and involving the aortic root. *Catheter Cardiovasc Interv* 2000;51:387–93. [https://doi.org/10.1002/1522-726x\(200012\)51:4](https://doi.org/10.1002/1522-726x(200012)51:4).
20. Januzzi JL, Sabatine MS, Eagle KA, Evangelista A, Bruckman D, Fattori R, et al. Iatrogenic aortic dissection. *Am J Cardiol* 2002;89:623–6. [https://doi.org/10.1016/s0002-9149\(01\)02312-8](https://doi.org/10.1016/s0002-9149(01)02312-8).
21. Gómez-Moreno S, Sabaté M, Jiménez-Quevedo P, Vázquez P, Alfonso F, Angiolillo DJ, et al. Iatrogenic dissection of the ascending aorta following heart catheterisation: incidence, management and outcome. *EuroIntervention* 2006;2:197–202.
22. LeMaire SA, Russell L. Epidemiology of thoracic aortic dissection. *Nat Rev Cardiol*. 2011 Feb;8(2):103-13. doi: 10.1038/nrcardio.2010.187. Epub 2010 Dec 21. PMID: 21173794.
23. Reece TB, Green GR, Kron IL. Aortic dissection. In: Cohn LH, editor. *Cardiac Surgery in the Adult*. New York, NY: McGraw-Hill, 2008;1195–222.

24. Gore I. Pathogenesis of dissecting aneurysm of the aorta. *Ame Arch Pathol* 1952;53:142-53.
25. Krukenberg E. Beiträge zur pathologischen Anatomie und zur allgemeinen Pathologie. *Beitr Pathol Anat Allg Pathol* 1920;67:329-51.
26. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. *Nat Genet.* 2005;37:275-81.
27. Mehta RH, O'Gara PT, Bossone E, Nienaber CA, Myrmet T, Cooper JV, et al. International Registry of Acute Aortic Dissection (IRAD) Investigators. Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era. *J Am Coll Cardiol.* 2002 Aug 21;40(4):685-92. doi: 10.1016/s0735-1097(02)02005-3. PMID: 12204498.
28. Januzzi JL, Isselbacher EM, Fattori R, Cooper JV, Smith DE, Fang J, et al. International Registry of Aortic Dissection (IRAD). Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). *J Am Coll Cardiol.* 2004 Feb 18;43(4):665-9. doi: 10.1016/j.jacc.2003.08.054. PMID: 14975480.
29. Cambria RP. Surgical treatment of complicated distal aortic dissection. *Sem Vasc Surg* 15:97-107, 2002.
30. Evangelista A, Isselbacher EM, Bossone E, Gleason TG, Eusanio MD, Sechtem U, Ehrlich MP, Trimarchi S, Braverman AC, Myrmet T, Harris KM, Hutchinson S, O'Gara P, Suzuki T, Nienaber CA, Eagle KA; IRAD Investigators. Insights From the International Registry of Acute Aortic Dissection: A 20-Year Experience of Collaborative Clinical Research. *Circulation.* 2018 Apr 24;137(17):1846-1860. doi: 10.1161/CIRCULATIONAHA.117.031264. PMID: 29685932.
31. Larson EW, Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 cases. *Am J Cardiol.* 1984 Mar 1;53(6):849-55. doi: 10.1016/0002-9149(84)90418-1. PMID: 6702637.
32. Spittell PC, Spittell JA Jr, Joyce JW, Tajik AJ, Edwards WD, Schaff HV, et al. Clinical features and differential diagnosis of aortic dissection: experience with 236 cases (1980 through 1990). *Mayo Clin Proc.* 1993 Jul;68(7):642-51. doi: 10.1016/s0025-6196(12)60599-0. PMID: 8350637.
33. Landenhed M, Engström G, Gottsäter A, Caulfield MP, Hedblad B, Newton-Cheh C, et al. Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study. *J Am Heart Assoc.* 2015 Jan 21;4(1):e001513. doi: 10.1161/JAHA.114.001513. PMID: 25609416; PMCID: PMC4330075.
34. Howard DP, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM; Oxford Vascular Study. Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control: 10-year results from the Oxford Vascular Study. *Circulation.* 2013 May 21;127(20):2031-7. doi: 10.1161/CIRCULATIONAHA.112.000483. Epub 2013 Apr 18. PMID: 23599348; PMCID: PMC6016737.
35. Pape LA, Awais M, Woznicki EM, Suzuki T, Trimarchi S, Evangelista A, Myrmet T, Larsen M, Harris KM, Gerson K, Di Eusanio M, Bossone E, Montgomery DG, Eagle KA, Nienaber CA, Isselbacher EM, O'Gara P. Presentation, Diagnosis, and Outcomes of Acute Aortic Dissection: 17-Year Trends From the International Registry of Acute Aortic Dissection. *J Am Coll Cardiol.* 2015 Jul 28;66(4):350-8. doi: 10.1016/j.jacc.2015.05.029. PMID: 26205591.
36. Hsue PY, Salinas CL, Bolger AF, Benowitz NL, Waters DD. Acute aortic dissection related to crack cocaine. *Circulation.* 2002 Apr 2;105(13):1592-5. doi: 10.1161/01.cir.0000012524.44897.3a. PMID: 11927528.
37. Elefteriades JA, Hatzaras I, Tranquilli MA, Elefteriades AJ, Stout R, Shaw RK, Silverman D, Barash P. Weight lifting and rupture of silent aortic aneurysms. *JAMA.* 2003 Dec 3;290(21):2803. doi: 10.1001/jama.290.21.2803. PMID: 14657063.
38. Marsalese DL, Moodie DS, Lytle BW, et al. Cystic medial necrosis of the aorta in patients without Marfan's syndrome: Surgical outcome and long-term follow-up. *J Am Coll Cardiol* 16:68-73, 1990.
39. He R, Guo DC, Estrera AL, et al. Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections. *J Thorac Cardiovasc Surg.* 2006;131: 671-8.
40. Tang PC, Coady MA, Lovoulos C, et al. Hyperplastic cellular remodeling of the media in ascending thoracic aortic aneurysms. *Circulation.* 2005;112:1098-105.
41. Segura AM, Luna RE, Horiba K, et al. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. *Circulation.* 1998;98: II331-II337.
42. Fedak PW, de Sa MP, Verma S, et al. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. *J Thorac Cardiovasc Surg.* 2003;126:797-806.
43. Lemaire SA, Wang X, Wilks JA, et al. Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves. *J Surg Res.* 2005;123:40-8.
44. Lemaire SA, Pannu H, Tran-Fadulu V, et al. Severe aortic and arterial aneurysms associated with a TGFBR2 mutation. *Nat Clin Pract Cardiovasc Med.* 2007;4:167-71.
45. Ikonomidis JS, Jones JA, Barbour JR, et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. *J Thorac Cardiovasc Surg.* 2007;133:1028-36.
46. Svensson LG, Crawford ES, Coselli JS, et al. Impact of cardiovascular operation on survival in the Marfan patient. *Circulation* 80:1233, 1989.
47. Slater DN, Grundman MJ, Mitchell L. Turner's syndrome associated with bicuspid aortic stenosis and dissecting aortic aneurysm. *Postgrad Med J* 58:436, 1982.
48. Shachter N, Perloff JK, Mulder DG. Aortic dissection in Noonan's syndrome (46 XY Turner). *Am J Cardiol* 54:464, 1984.
49. Wilson SK, Hutchins GM. Aortic dissecting aneurysms: causative factors in 204 subjects. *Arch Pathol Lab Med* 106:175, 1982.
50. Gott VL, Cameron DE, Pyeritz RE et al. Composite graft repair of Marfan aneurysm of the ascending aorta: results in 150 patients. *J Cardiac Surg* 9:482, 1994.
51. Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kD glycoprotein is a component of extracellular microfibrils. *J Cell Biol* 103:2499, 1986.

52. McKusick VA. Association of congenital bicuspid aortic valve and Erdheim's cystic medial necrosis. *Lancet* 1:1026, 1972.
53. Sakai LY, Keene DR, Glanville RW, Bachinger HP. Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. *J Biol Chem* 266:14763, 1991.
54. Prenger KB, Pieters F, Cheriex E. Aortic dissection after aortic valve replacement: incidence and consequences for strategy. *J Card Surg* 9:495, 1994.
55. de Virgilio C, Nelson RJ, Milliken J et al. Ascending aortic dissection in weight lifters with cystic medial degeneration. *Ann Thorac Surg* 49:638, 1990.
56. Lepore V, Jeppsson A, Radberg G, Mantovani V, Bugge M. Aortic surgery in patients with marfan syndrome: long-term survival, morbidity and function. *J Heart Valve Dis* 10:25-30, 2001.
57. Rosenfeld RG. Hypertension, aortic dilatation and aortic dissection in Turner syndrome: a potentially lethal triad. *Clin Endocrinol (Oxf)*. 54:155-6, 2001.
58. Dietz HC, Pyeritz RE. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. *Hum Mol Genet*. 1995;4 Spec No:1799-809.
59. Hilhorst-Hofstee Y, Rijlaarsdam ME, Scholte AJ, Swart-van den Berg M, Versteegh MI, van der Schoot-van Velzen I, et al. The clinical spectrum of missense mutations of the first aspartic acid of cbEGF-like domains in fibrillin-1 including a recessive family. *Hum Mutat*. 2010 Dec;31(12):E1915-27. doi: 10.1002/humu.21372. PMID: 20886638; PMCID: PMC3051827.
60. Smallridge RS, Whiteman P, Doering K, Handford PA, Downing AK. EGF-like domain calcium affinity modulated by N-terminal domain linkage in human fibrillin-1. *J Mol Biol*. 1999 Feb 26;286(3):661-8. doi: 10.1006/jmbi.1998.2536. PMID: 10024441.
61. Sinha S, Nevett C, Shuttleworth CA, Kielty CM. Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins. *Matrix Biol*. 1998 Dec;17(8-9):529-45. doi: 10.1016/s0945-053x(98)90106-8. PMID: 9923648.
62. Reinhardt DP, Keene DR, Corson GM, Pöschl E, Bächinger HP, Gambee JE, Sakai LY. Fibrillin-1: organization in microfibrils and structural properties. *J Mol Biol*. 1996 Apr 26;258(1):104-16. doi: 10.1006/jmbi.1996.0237. PMID: 8613981.
63. Zhang H, Hu W, Ramirez F. Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrils. *J Cell Biol*. 1995 May;129(4):1165-76. doi: 10.1083/jcb.129.4.1165. PMID: 7744963; PMCID: PMC2120487.
64. Putnam EA, Cho M, Zinn AB, Towbin JA, Byers PH, Milewicz DM. Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene. *Am J Med Genet*. 1996 Mar 29;62(3):233-42. doi: 10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U. PMID: 8882780.
65. Faivre L, Collod-Beroud G, Callewaert B, Child A, Loeys BL, Binquet C, et al. Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion. *Am J Med Genet A* 2009 May;149A(5):854-60. doi: 10.1002/ajmg.a.32809. PMID: 19353630.
66. Adams JN, Trent RJ. Aortic complications of Marfan's syndrome. *Lancet*. 1998 Nov 28;352(9142):1722-3. Doi: 10.1016/S0140-6736(05)79822-6. PMID: 9848345.
67. Jeremy RW, Huang H, Hwa J, McCarron H, Hughes CF, Richards JG. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. *Am J Cardiol*. 1994 Aug 15;74(4):369-73. Doi: 10.1016/0002-9149(94)90405-7. PMID: 8059700.
68. Adams JN, Brooks M, Redpath TW, Smith FW, Dean J, Gray J, Walton S, Trent RJ. Aortic distensibility and stiffness index measured by magnetic resonance imaging in patients with Marfan's syndrome. *Br Heart J*. 1995 Mar;73(3):265-9. Doi: 10.1136/hrt.73.3.265. PMID: 7727188; PMCID: PMC483810.
69. Roman MJ, Devereux RB, Kramer-Fox R, Spitzer MC. Comparison of cardiovascular and skeletal features of primary mitral valve prolapse and Marfan syndrome. *Am J Cardiol*. 1989 Feb 1;63(5):317-21. Doi: 10.1016/0002-9149(89)90338-x. PMID: 2913733.
70. Bruno L, Tredici S, Mangiavacchi M, Colombo V, Mazzotta GF, Sirtori CR. Cardiac, skeletal, and ocular abnormalities in patients with Marfan's syndrome and in their relatives. Comparison with the cardiac abnormalities in patients with kyphoscoliosis. *Br Heart J*. 1984 Feb;51(2):220-30. Doi: 10.1136/hrt.51.2.220. PMID: 6691872; PMCID: PMC481487.
71. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology of the Marfan syndrome. *J Med Genet*. 2010 Jul;47(7):476-85. Doi: 10.1136/jmg.2009.072785. PMID: 20591885.
72. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. *Am J Cardiol*. 1989 Sep 1;64(8):507-12. Doi: 10.1016/0002-9149(89)90430-x. PMID: 2773795.
73. Rybczynski M, Mir TS, Sheikhzadeh S, Bernhardt AM, Schach C, Treede H, et al. Frequency of the related course of mitral valve dysfunction in the Marfan syndrome. *Am J Cardiol*. 2010 Oct 1;106(7):1048-53. Doi: 10.1016/j.amjcard.2010.05.038. PMID: 20854973.
74. Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C, Gautier E, et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. *Am J Hum Genet*. 2007 Sep;81(3):454-66. Doi: 10.1086/520125. Epub 2007 Jul 25. PMID: 17701892; PMCID: PMC1950837.
75. Alpendurada F, Wong J, Kiotsekoglou A, Banya W, Child A, Prasad SK, et al. Evidence for Marfan cardiomyopathy. *Eur J Heart Fail*. 2010 Oct;12(10):1085-91. Doi: 10.1093/eurjhf/hfq127. PMID: 20861133.
76. Erkula G, Jones KB, Sponseller PD, Dietz HC, Pyeritz RE. Growth and maturation in Marfan syndrome. *Am J Med Genet*. 2002 Apr 22;109(2):100-15. Doi: 10.1002/ajmg.10312. PMID: 11977157.
77. Speed TJ, Mathur VA, Hand M, Christensen B, Sponseller PD, Williams KA, et al. Characterization of pain, disability, and psychological burden in Marfan syndrome. *Am J Med Genet A*. 2017 Feb;173(2):315-323. Doi: 10.1002/ajmg.a.38051. Epub 2016 Nov 14. PMID: 27862906; PMCID: PMC6059361.
78. Tsiouras P, Del Mastro R, Sarfarazi M, Lee B, Vitale E, Child AH, et al. Genetic linkage of the Marfan sy-

- ndrome, ectopia lentis, and congenital contractural arachnodactyly to the fibrillin genes on chromosomes 15 and 5. The International Marfan Syndrome Collaborative Study. *N Engl J Med*. 1992 Apr 2;326(14):905-9. Doi: 10.1056/NEJM199204023261401. PMID: 1542340.
79. Dyhdalo K, Farver C. Pulmonary histologic changes in Marfan syndrome: a case series and ort heon review. *Am J Clin Pathol*. 2011 Dec;136(6):857-63. Doi: 10.1309/AJCP79SNDHKGQFIN. PMID: 22095370.
 80. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. *Nat Genet*. 2004;36:855-60.
 81. Singh KK, Rommel K, Mishra A, et al. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. *Hum Mutat*. 2006;27:770-7.
 82. Williams JA, Loeys BL, Nwakanma LU, et al. Early surgical experience with Loeys-Dietz: a new syndrome of aggressive thoracic aortic aneurysm disease. *Ann Thorac Surg*. 2007;83:S757-63.
 83. Pepin M, Schwarze U, Superti-Furga A, et al. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. *N Engl J Med*. 2000;342:673-80.
 84. Ascione R, Gomes WJ, Bates M, et al. Emergency repair of type A aortic dissection in type IV Ehlers-Danlos syndrome. *Cardiovasc Surg*. 2000;8:75-8.
 85. Gravholt CH, Landin-Wilhelmsen K, Stochholm K, et al. Clinical and epidemiological description of aortic dissection in Turner's syndrome. *Cardiol Young*. 2006;16:430-6.
 86. Lee CC, Chang WT, Fang CC, et al. Sudden death caused by dissecting thoracic aortic aneurysm in a patient with autosomal dominant polycystic kidney disease. *Resuscitation*. 2004;63:93-6.
 87. Purnell R, Williams I, Von Oppell U, et al. Giant aneurysms of the sinuses of Valsalva and aortic regurgitation in a patient with Noonan's syndrome. *Eur J Cardiothorac Surg*. 2005;28:346-8.
 88. Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissections: incidence, modes of inheritance, and phenotypic patterns. *Ann Thorac Surg*. 2006;82:1400-5.
 89. Meszaros I, Morocz J, Szilavi J, et al. Epidemiology and clinicopathology of aortic dissection. *Chest*. 2000;117:1271-8.
 90. Braverman AC, Guven H, Beardslee MA, et al. The bicuspid aortic valve. *Curr Probl Cardiol*. 2005;30:470-522.
 91. Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. *J Am Coll Cardiol*. 1997;30:1809-12.
 92. Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ, et al. International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes. *J Thorac Cardiovasc Surg*. 2021 Sep;162(3):e383-e414. Doi: 10.1016/j.jtcvs.2021.06.019. Epub 2021 Jul 22. PMID: 34304896.
 93. Kouchoukos NT, Masetti P. Aberrant subclavian artery and Kommerell aneurysm: surgical treatment with a standard approach. *J Thorac Cardiovasc Surg*. 2007;133:888-92.
 94. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/ SCA/SCAI/ SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine (developed in collaboration with the American College of Emergency Physicians). *J Am Coll Cardiol*. 2010;55:e27-129.
 95. Harris KM, Braverman AC, Eagle KA, Woznicki EM, Pyeritz RE, Myrmel T, Peterson MD, Voehringer M, Fattori R, Januzzi JL, Gilon D, Montgomery DG, Nienaber CA, Trimarchi S, Isselbacher EM, Evangelista A. Acute aortic intramural hematoma: an analysis from the International Registry of Acute Aortic Dissection. *Circulation*. 2012 Sep 11;126(11 Suppl 1):S91-6. doi: 10.1161/CIRCULATIONAHA.111.084541. PMID: 22965999.
 96. Tittle SL, Lynch RJ, Cole PE, Singh HS, Rizzo JA, Kopf GS, Elefteriades JA. Midterm follow-up of penetrating ulcer and intramural hematoma of the aorta. *J Thorac Cardiovasc Surg*. 2002 Jun;123(6):1051-9. doi: 10.1067/mtc.2002.121681. PMID: 12063450.
 97. Evangelista A, Mukherjee D, Mehta RH, O'Gara PT, Fattori R, Cooper JV, Smith DE, Oh JK, Hutchison S, Sechtem U, Isselbacher EM, Nienaber CA, Pape LA, Eagle KA; International Registry of Aortic Dissection (IRAD) Investigators. Acute intramural hematoma of the aorta: a mystery in evolution. *Circulation*. 2005 Mar 1;111(8):1063-70. doi: 10.1161/01.CIR.0000156444.26393.80. Epub 2005 Feb 14. PMID: 15710757.
 98. Hirst AE, Gore I. The etiology and pathology of aortic dissection. P. 13. In Doroghazi RM, Slater EE (eds): *Aortic Dissection*. McGraw-Hill, New York, 1983.
 99. Svenson LG, Crawford ES. Aortic dissection and aortic aneurysm surgery: clinical observations experimental investigations and statistical analyses. Part II *Curr Probl Surg* 29:913, 1992.
 100. Harris M. Dissecting aneurysm of the aorta due to giant cell arteritis. *Br Heart J* 30:840, 1968.
 101. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. *Arthritis Rheum*. 2003; 48:3522-31.
 102. Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. *Semin Arthritis Rheum*. 1995;24:422-31.
 103. Cooley DA, Wakasch DC, Hallman GL. Acute dissecting ascending aortic aneurysm resulting from coronary arteriography: successful surgical treatment. *Chest* 61:317, 1972.
 104. Holm J, Schersten T. Subintimal dissection secondary to the use of the Fogarty catheter. *J Cardiovasc Surg (Torino)* 15:684, 1974.

105. DeSanctis RW, Doroghazi RM, Austen WG, Buckley MJ. Aortic dissection. *N Engl J Med* 317:1060, 1987.
106. Cambria RP, Brewster DC, Gertler J et al. Vascular complications associated with spontaneous aortic dissection. *J Vasc Surg* 7:199, 1988.
107. Templeton JY, Johnson RG, Griffith JR. Dissecting aneurysm of the thoracic aorta as a complication of catheter aortography. *J Thorac Cardiovasc Surg* 40:209, 1960.
108. Derkac W, Laks H, Cohn LH, Collins JJJ. Dissecting aneurysm after aortic valve replacement. *Arch Surg* 109:388, 1974.
109. Fukuda T, Tadavarthy SM, Edwards JE. Dissecting aneurysm of aorta complicating aortic valvular stenosis. *Circulation* 53:169, 1976.
110. Benedict JS, Buhl TL, Henney RP. Acute aortic dissection during cardiopulmonary bypass. Successful treatment of three patients. *Arch Surg* 108:810, 1974.
111. Murphy DA, Craver JM, Jones EL et al. Recognition and management of ascending aortic dissection complicating cardiac surgical operations. *J Thorac Cardiovasc Surg* 85:247, 1983.
112. Williams GM, Gott VL, Brawley RK, et al. Aortic disease associated with pregnancy. *J Vasc Surg* 8:470-75, 1988.
113. Fabricius AM, Autschbach AM, Doll N, Mohr W. Acute aortic dissection during pregnancy. *Thorac Cardiovasc Surg*. 49:56-7, 2001.
114. Pacini L, Digne F, Boumendil A, et al. Maternal complication of pregnancy in Marfan syndrome. *Int J Cardiol*. 2009;136:156-61. 535.
115. Strickland RA, Oliver WC Jr., Chantigian RC, et al. Anesthesia, cardiopulmonary bypass, and the pregnant patient. *Mayo Clin Proc*. 1991;66:411-29.
116. Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. *Eur Heart J*. 2001;22:1642- 81.
117. Hirst AE Jr, Johns VJ Jr, Kime SW Jr. Dissecting aneurysm of the aorta: a review of 505 cases. *Medicine (Baltimore)* 1958;37:217-79.
118. Peterss S, Mansour AM, Ross JA, Vaitkeviciute I, Charilaou P, Dumfarth J, et al. Changing pathology of the thoracic aorta from acute to chronic dissection: literature review and insights. *J Am Coll Cardiol* 2016;68:1054-65.
119. Booher AM, Isselbacher EM, Nienaber CA, Trimarchi S, Evangelista A, Montgomery DG, et al. The IRAD classification system for characterizing survival after aortic dissection. *Am J Med* 2013;126:730.e19-24.
120. Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC, Kundt G, et al. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. *Circ Cardiovasc Interv* 2013;6:407-16. <https://doi.org/10.1161/circinterventions.113.000463>.
121. Rodriguez JA, Olsen DM, Lucas L, Wheatley G, Ramiah V, Diethrich EB. Aortic remodeling after endografting of thoracoabdominal aortic dissection. *J Vasc Surg* 2008;47:1188-94.
122. Clough RE, Nienaber CA. Management of acute aortic syndrome. *Nat Rev Cardiol* 2015;12:103-14. <https://doi.org/10.1038/nrcardio.2014.203>.
123. Mitchell RS, Ishimaru S, Ehrlich MP, Iwase T, Lauterjung L, Shimono T, et al. First International Summit on Thoracic Aortic Endografting: roundtable on thoracic aortic dissection as an indication for endograft- ing. *J Endovasc Ther* 2002;9(suppl 2):II98-105.
124. Fillinger MF, Greenberg RK, McKinsey JF, Chaikof EL; Society for Vascular Surgery Ad Hoc Committee on TEVAR Reporting Standards. Reporting standards for thoracic endovascular aortic repair (TEVAR). *J Vasc Surg*. 2010 Oct;52(4):1022-33, 1033.e15. doi: 10.1016/j.jvs.2010.07.008. PMID: 20888533.
125. Augoustides JG, Szeto WY, Desai ND, Pochettino A, Cheung AT, Savino JS et al. Classification of acute type A dissection: focus on clinical presentation and extent. *Eur J Cardiothorac Surg* 2011;39:519-22.
126. Dake MD, Thompson M, van Sambeek M, Vermassen F, Morales JP; DEFINE Investigators. DISSECT: a new mnemonic-based approach to the categorization of aortic dissection. *Eur J Vasc Endovasc Surg* 2013;46:175-90.
127. Lombardi JV, Hughes GC, Appoo JJ, Bavaria JE, Beck AW, Cambria RP, et al. Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) reporting standards for type B aortic dissections. *J Vasc Surg*. 2020 Mar;71(3):723-747. doi: 10.1016/j.jvs.2019.11.013. Epub 2020 Jan 27. PMID: 32001058.
128. Sievers HH, Rylski B, Czerny M, Baier ALM, Kreibich M, Siepe M et al. Aortic dissection reconsidered: type, entry site, malperfusion classification adding clarity and enabling outcome prediction. *Interact CardioVasc Thorac Surg* 2020;30:451-7.
129. Rylski B, Perez M, Beyersdorf F, Reser D, Kari FA, Siepe M et al. Acute non-A non-B aortic dissection: incidence, treatment and outcome. *Eur J Cardiothorac Surg* 2017;52:1111-7.
130. Kosiorowska M, Berezowski M, Widenka K, Kreibich M, Beyersdorf F, Czerny M et al. Non-A non-B acute aortic dissection with entry tear in the aortic arch. *Interact CardioVasc Thorac Surg* 2022;34:878-84.
131. Czerny M, Grabenwöger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al; EACTS/STS Scientific Document Group. EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. *Eur J Cardiothorac Surg*. 2024 Feb 1;65(2):ezad426. doi: 10.1093/ejcts/ezad426. Erratum in: *Eur J Cardiothorac Surg*. 2024 Jun 3;65(6):ezae235. doi: 10.1093/ejcts/ezae235. PMID: 38408364.
132. Svensson LG, Labib SB, Eisenhauser AC, Butterfly JR. Intimal tear without haematoma. *Circulation* 99:1331-6,1999.
133. Nienaber CA, Fattori R, Mehta RH, et al. Gender-related differences in acute aortic dissection. *Circulation*. 2004;109:3014 -21.
134. Baydin A, Nargis C, Nural MS, et al. Painless, acute aortic dissection presenting as an acute stroke. *Mt Sinai J Med*. 2006;73:1129 -31.
135. Ayrik C, Cece H, Aslan O, et al. Seeing the invisible: painless aortic dissection in the emergency setting. *Emerg Med J*. 2006;23:e24.
136. Nallamothu BK, Mehta RH, Saint S, et al. Syncope in acute aortic dissection: diagnostic, prognostic, and clinical implications. *Am J Med*. 2002;113:468 -71.
137. Klompas M. Does this patient have an acute thoracic aortic dissection? *JAMA*. 2002;287:2262-72.
138. Lee SI, Pyun SB, Jang DH. Dysphagia and hoarseness associated with painless aortic dissection: a rare case of

- cardiovascular syndrome. *Dysphagia*. 2006;21:129–32.
139. Gaul C, Dietrich W, Friedrich I, et al. Neurological symptoms in type A aortic dissections. *Stroke*. 2007;38:292–7.
 140. Syed MA, Fiad TM. Transient paraplegia as a presenting feature of aortic dissection in a young man. *Emerg Med J*. 2002;19:174–5.
 141. Fessler AJ, Alberts MJ. Stroke treatment with tissue plasminogen activator in the setting of aortic dissection. *Neurology*. 2000;54:1010.
 142. Morita S, Shibata M, Nakagawa Y, et al. Painless acute aortic dissection with a left hemiparesis. *Neurocrit Care*. 2006;4:234–6.
 143. Zaidat OO, Ubogu EE, Lerner AJ. Recurrent transient ischemic attacks as the initial presenting manifestation of type A aortic dissection. *Ann Vasc Surg*. 2002;16:676–8.
 144. John LC. Fluctuating neurological deficit with acute aortic dissection: the omega sign. *Int J Cardiol*. 2006;106:130–1.
 145. von Kodolitsch Y, Schwartz AG, Nienaber CA. Clinical prediction of acute aortic dissection. *Arch Intern Med*. 2000;160:2977–82.
 146. Young J, Herd AM. Painless acute aortic dissection and rupture presenting as syncope. *J Emerg Med*. 2002;22:171–4.
 147. Kawarabuki K, Sakakibara T, Hirai M, et al. Acute aortic dissection presenting as a neurologic disorder. *J Stroke Cerebrovasc Dis*. 2006;15:26–9.
 148. Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and management: Part I: from etiology to diagnostic strategies. *Circulation*. 2003;108:628–35.
 149. Huynh TTT, Porat EE, Miller CC III, Estrera AL, Smith JJ, Safi HJ. The effect of aortic dissection on outcome in descending thoracic and thoracoabdominal aortic aneurysm repair. *Sem Vasc Surg* 15:108–15, 2002.
 150. Williams DM, Lee DY, Hamilton BH, et al. The dissected aorta: part III. Anatomy and radiologic diagnosis of branch-vessel compromise. *Radiology*. 1997;203:37–44.
 151. Khan IA, Nair CK. Clinical, diagnostic, and management perspectives of aortic dissection. *Chest*. 2002;122:311–28.
 152. Yagdi T, Atay Y, Engin C, et al. Impact of organ malperfusion on mortality and morbidity in acute type A aortic dissections. *J Card Surg*. 2006;21:363–9.
 153. Jamieson WR, Munro AI, Miyagishima RT, et al. Aortic dissection: early diagnosis and surgical management are the keys to survival. *Can J Surg* 25:145, 1982.
 154. Borst HG, Laas J, Heinemann M. Type A aortic dissection: diagnosis and management of malperfusion phenomena. *Semin Thorac Cardiovasc Surg* 3:238, 1991.
 155. Henke PK, Williams DM, Upchurch GR, Jr., et al. Acute limb ischemia associated with type B aortic dissection: clinical relevance and therapy. *Surgery*. 2006;140:532–9.
 156. Armstrong WF, Bach DS, Carey LM, et al. Clinical and echocardiographic findings in patients with suspected acute aortic dissection. *Am Heart J*. 1998;136:1051–60.
 157. Gilon D, Mehta RH, Oh JK, et al. Characteristics and in-hospital outcomes of patients with cardiac tamponade complicating type A acute aortic dissection. *Am J Cardiol*. 2009;103:1029–31.
 158. Prisant LM, Nalamolu VR. Aortic dissection. *J Clin Hypertens (Greenwich)*. 2005;7:367–71.
 159. Suzuki T, Mehta RH, Ince H, et al. Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International Registry of Aortic Dissection (IRAD). *Circulation*. 2003;108 Suppl 1:II312–7.
 160. Trimarchi S, Nienaber CA, Rampoldi V, et al. Role and results of surgery in acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). *Circulation*. 2006;114:1357–64.
 161. Tsai TT, Fattori R, Trimarchi S, et al. Long-term survival in patients presenting with type B acute aortic dissection: insights from the International Registry of Acute Aortic Dissection. *Circulation*. 2006;114:2226–31.
 162. Januzzi JL, Eagle KA, Cooper JV, et al. Acute aortic dissection presenting with congestive heart failure: results from the International Registry of Acute Aortic Dissection. *J Am Coll Cardiol*. 2005;46:733–5.
 163. Tsai TT, Bossone E, Isselbacher EM, et al. Clinical characteristics of hypotension in patients with acute aortic dissection. *Am J Cardiol*. 2005;95:48–52.
 164. Hata N, Tanaka K, Imaizumi T, et al. Clinical significance of pleural effusion in acute aortic dissection. *Chest*. 2002;121:825–30.
 165. Gandelman G, Barzilay N, Krupsky M, et al. Left pleural hemorrhagic effusion. A presenting sign of thoracic aortic dissecting aneurysm. *Chest*. 1994;106:636–8.
 166. Tristano AG, Tairouz Y. Painless right hemorrhagic pleural effusions as presentation sign of aortic dissecting aneurysm. *Am J Med*. 2005;118: 794–5.
 167. Masuo M, Takano H, Takamoto S, et al. Pulmonary artery obstruction caused by thoracic aortic dissection: a case with unique pathological findings. *Circ J*. 2004;68:392–5.
 168. Guidetti AS, Pik A, Peer A, et al. Haemoptysis as the sole presenting symptom of dissection of the aorta. *Thorax*. 1989;44:444–5.
 169. Miller DC, Stinson EB, Oyer PE, et al. Operative treatment of aortic dissections. Experience with 125 patients over a sixteen-year period. *J Thorac Cardiovasc Surg*. 1979;78:365–82.
 170. Born C, Forster A, Rock C, et al. A case of an upper gastrointestinal bleeding due to a ruptured dissection of a right aortic arch. *Cardiovasc Intervent Radiol*. 2003;26:506–9.
 171. Nath HP, Jaques PF, Soto B, et al. Aortic dissection masquerading as gastrointestinal disease. *Cardiovasc Intervent Radiol*. 1986;9:37–41.
 172. Svensson LG, Crawford ES, Hess KR, et al. Dissection of the aorta and dissecting aortic aneurysms: improving early and long-term surgical results. *Circulation* 82(Suppl):IV 24–38, 1990.
 173. Kunzelmann KS, Grande KJ, David TE, et al. Aortic root and valve relationships: impact on surgical repair. *J Thorac Cardiovasc Surg* 107:162, 1994.
 174. Von Segesser LK, Lorenzetti E, Lachat M, et al. Aortic valve preservation in acute type A dissection: is it sound? *J Thorac Cardiovasc Surg*. 1996;111:381–90.
 175. Massimo CG, Presenti LF, Marranci P, et al. Extended and total aortic resection in the surgical treatment of acute type A aortic dissection: experience with 54 patients. *Ann Thorac Surg*. 1998;46:420–4.

176. Borst HG, Heinemann MK, Stone CD. Alternative procedures. In: Borst HG, Heinemann MK, Stone CD, Eds. *Surgical Treatment of Aortic Dissection*. New York: Churchill Livingstone; 285-93, 1996.
177. Pego Fernandes PM, Stolf NA, Moreira LF, et al. Management of aortic insufficiency in chronic aortic dissection. *Ann Thorac Surg* 51:438, 1991.
178. Miller DC. Surgical management of acute aortic dissection: new data. *Semin Thorac Cardiovasc Surg* 3:225, 1991.
179. David TE, Feindel CM. An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. *J Thorac Cardiovasc Surg* 103:617, 1992.
180. Posacıoğlu H, Atay Y, Okur F, Çetindağ B, Alat İ, Can L, Alayunt A, Yüksel M, Büket S, Bilkay Ö. Proksimal disseksiyonlarda aort kapağına yaklaşım. *Türk Kardiyol Dern Arş* 25:39-44, 1997.
181. Movsowitz HD, Levine RA, Hilgenberg AD, et al. Transesophageal echocardiographic description of the mechanisms of aortic regurgitation in acute type A aortic dissection: implications for aortic valve repair. *J Am Coll Cardiol*. 2000;36:884-90.
182. Coselli JS, Crawford ES. Composite aortic valve replacement and graft replacement of the ascending aorta plus coronary ostial reimplantation: how to do it. *Semin Thorac Cardiovasc Surg* 5:55, 1993.
183. Gertz ZM, Levitt SA, Epps KC, Bavaria JE, Moser GW, Kolansky DM. Cardiac catheterization in patients with ascending aortic aneurysms: safety, success, and prevalence of coronary artery disease. *J Invasive Cardiol* 2014;26:241-4.
184. Schlett CL, Hendel T, Hirsch J, Weckbach S, Caspers S, Schulz-Menger J et al. Quantitative, organ-specific interscanner and intrascanner variability for 3 T whole-body magnetic resonance imaging in a multicenter, multivendor study. *Invest Radiol* 2016;51:255-65.
185. Rajendran K, Petersilka M, Henning A, Shanblatt ER, Schmidt B, Flohr TG et al. First clinical photon-counting detector CT system: technical evaluation. *Radiology* 2022;303:130-8.
186. Yoshida S, Akiba H, Tamakawa M, Yama N, Hareyama M, Morishita K et al. Thoracic involvement of type A aortic dissection and intramural hematoma: diagnostic accuracy—comparison of emergency helical CT and surgical findings. *Radiology* 2003;228:430-5.
187. Thoongsuwan N, Stern EJ. Chest CT scanning for clinical suspected thoracic aortic dissection: beware the alternate diagnosis. *Emerg Radiol* 2002;9:257-61.
188. Catalan P, Leta R, Hidalgo A, Montiel J, Alomar X, Vilade´s D et al. Ruling out coronary artery disease with noninvasive coronary multidetector CT angiography before noncoronary cardiovascular surgery. *Radiology* 2011;258:426-34.
189. Wenzel JP, Nikorowitsch J, Bei der Kellen R, Dohm L, Girdauskas E, Lund G et al. Comparison of cine cardiac magnetic resonance and echocardiography derived diameters of the aortic root in a large population-based cohort. *Sci Rep* 2022;12:15307.
190. Gorla R, Erbel R, Kahlert P, Tsagakis K, Jakob H, Mahabadi AA, et al. Accuracy of a diagnostic strategy combining aortic dissection detection risk score and D-dimer levels in patients with suspected acute aortic syndrome. *Eur Heart J Acute Cardiovasc Care* 2017;6:371-8. <https://doi.org/10.1177/2048872615594497>.
191. Strayer RJ, Shearer PL, Hermann LK. Screening, evaluation, and early management of acute aortic dissection in the ED. *Curr Cardiol Rev* 2012;8:152-7. <https://doi.org/10.2174/157340312801784970>.
192. Nazerian P, Mueller C, Soeiro AM, Leidel BA, Salvadeo SAT, Giachino F, et al. Diagnostic accuracy of the aortic dissection detection risk score plus D-dimer for acute aortic syndromes: the ADvISED prospective multicenter study. *Circulation* 2018;137:250-8. <https://doi.org/10.1161/circulationaha.117.029457>.
193. Bima P, Pivetta E, Nazerian P, Toyofuku M, Gorla R, Bossone E, et al. Systematic review of aortic dissection detection risk score plus d-dimer for diagnostic rule-out of suspected acute aortic syndromes. *Acad Emerg Med* 2020;27:1013-27. <https://doi.org/10.1111/acem.13969>.
194. Rogers AM, Hermann LK, Booher AM, Nienaber CA, Williams DM, Kazerooni EA, et al. Sensitivity of the aortic dissection detection risk score, a novel guideline-based tool for identification of acute aortic dissection at initial presentation: results from the international registry of acute aortic dissection. *Circulation* 2011;123:2213-8. <https://doi.org/10.1161/CIRCULATIONAHA.110.988568>.
195. Suzuki T, Distant A, Zizza A, Trimarchi S, Villani M, Salerno Uriarte JA, et al. Diagnosis of acute aortic dissection by D-dimer: the international registry of acute aortic dissection substudy on biomarkers (IRAD-bio) experience. *Circulation* 2009;119:2702-7. <https://doi.org/10.1161/circulationaha.108.833004>.
196. Baliga RR, Nienaber CA, Bossone E, Oh JK, Isselbacher EM, Sechtem U, et al. The role of imaging in aortic dissection and related syndromes. *JACC Cardiovasc Imaging* 2014;7:406-24. <https://doi.org/10.1016/j.jcmg.2013.10.015>.
197. Nazerian P, Mueller C, Vanni S, Soeiro AM, Leidel BA, Cerini G, et al. Integration of transthoracic focused cardiac ultrasound in the diagnostic algorithm for suspected acute aortic syndromes. *Eur Heart J* 2019;40:1952-60. <https://doi.org/10.1093/eurheartj/ehz207>.
198. Bhavne NM, Nienaber CA, Clough RE, Eagle KA. Multimodality imaging of thoracic aortic diseases in adults. *JACC Cardiovasc Imaging* 2018;11:902-19. <https://doi.org/10.1016/j.jcmg.2018.03.009>.
199. Nienaber CA, Clough RE, Sakalihasan N, Suzuki T, Gibbs R, Mussa F, et al. Aortic dissection. *Nat Rev Dis Primers* 2016;2:16053. <https://doi.org/10.1038/nrdp.2016.53>.
200. Andersen ND, Ganapathi AM, Hanna JM, Williams JB, Gaca JG, Hughes GC. Outcomes of acute type A dissection repair before and after implementation of a multidisciplinary thoracic aortic surgery program. *J Am Coll Cardiol* 2014;63:1796-803.
201. Miyata H, Motomura N, Ueda Y, Tsukihara H, Tabayashi K, Takamoto S. Toward quality improvement of thoracic aortic surgery: estimating volume-outcome effect from nationwide survey. *Eur J Cardiothorac Surg* 2009;36:517-21.
202. Henebiens M, van den Broek TAA, Vahl AC, Koelemay MJW. Relation between hospital volume and outcome of elective surgery for abdominal aortic aneurysm: a systematic review. *Eur J Vasc Endovasc Surg* 2007;33:285-92.

203. Cowan JA, Dimick JB, Henke PK, Huber TS, Stanley JC, Upchurch GR. Surgical treatment of intact thoracoabdominal aortic aneurysms in the United States: hospital and surgeon volume-related outcomes. *J Vasc Surg* 2003;37:1169–74.
204. Schaffer JM, Lingala B, Miller DC, Woo YJ, Mitchell RS, Dake MD. Midterm survival after thoracic endovascular aortic repair in more than 10,000 Medicare patients. *J Thorac Cardiovasc Surg* 2015;149:808–20;discussion 820–3.
205. Badheka AO, Patel NJ, Panaich SS, Patel SV, Jhamnani S, Singh V et al. Effect of hospital volume on outcomes of transcatheter aortic valve implantation. *Am J Cardiol* 2015;116:587–94.
206. Tadros RO, Tang GHL, Barnes HJ, Mousavi I, Kovacic JC, Faries P, et al. Optimal treatment of uncomplicated type B aortic dissection: JACC review topic of the week. *J Am Coll Cardiol* 2019;74:1494–504. <https://doi.org/10.1016/j.jacc.2019.07.063>.
207. Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: diagnosis and management, an update. *Eur Heart J* 2018;39:739–49d. <https://doi.org/10.1093/eurheartj/ehx319>.
208. Kodama K, Nishigami K, Sakamoto T, Sawamura T, Hirayama T, Misumi H, et al. Tight heart rate control reduces secondary adverse events in patients with type B acute aortic dissection. *Circulation* 2008;118:S167–70. <https://doi.org/10.1161/circulationaha.107.755801>.
209. Estrera AL, Miller CC, III, Safi HJ, Goodrick JS, Keyhani A, Porat EE, et al. Outcomes of medical management of acute type B aortic dissection. *Circulation* 2006;114:I384–389. <https://doi.org/10.1161/circulationaha.105.001479>.
210. Nejim B, Mathlouthi A, Naazie I, Malas MB. The effect of intravenous and oral beta-blocker use in patients with type B thoracic aortic dissection. *Ann Vasc Surg* 2022;80:170–9. <https://doi.org/10.1016/j.avsg.2021.07.056>.
211. Vilacosta I, San Román JA, di Bartolomeo R, Eagle K, Estrera AL, Ferrera C, et al. Acute aortic syndrome revisited: JACC state-of-the-art review. *J Am Coll Cardiol* 2021;78:2106–25. <https://doi.org/10.1016/j.jacc.2021.09.022>.
212. Alviar CL, Gutierrez A, Cho L, Krishnaswamy A, Saleh A, Lincoff MA et al. Clevidipine as a therapeutic and cost-effective alternative to sodium nitroprusside in patients with acute aortic syndromes. *Eur Heart J Acute Cardiovasc Care* 2020;9:S5–12.
213. Nienaber CA, Clough RE. Management of acute aortic dissection. *Lancet* 2015;385:800–11. [https://doi.org/10.1016/s0140-6736\(14\)61005-9](https://doi.org/10.1016/s0140-6736(14)61005-9).
214. Hameed I, Cifu AS, Vallabhajosyula P. Management of thoracic aortic dissection. *JAMA* 2023;329:756–7. <https://doi.org/10.1001/jama.2023.0265>.
215. Fukui T. Management of acute aortic dissection and thoracic aortic rupture. *J Intensive Care* 2018;6:15. <https://doi.org/10.1186/s40560-018-0287-7>.
216. Czerny M, Schoenhoff F, Etz C, Englberger L, Khaladj N, Zierer A et al. The impact of pre-operative malperfusion on outcome in acute type A aortic dissection: results from the GERAADA Registry. *J Am Coll Cardiol* 2015;65:2628–35.
217. Hirst AE, Jr, Johns VJ, Jr, Kime SW, Jr. Dissecting aneurysm of the aorta: a review of 505 cases. *Medicine* 1958;37:217–79. <https://doi.org/10.1097/00005792-195809000-00003>.
218. Harris KM, Nienaber CA, Peterson MD, Woznicki EM, Braverman AC, Trimarchi S, et al. Early mortality in type A acute aortic dissection: insights from the international registry of acute aortic dissection. *JAMA Cardiol* 2022;7:1009–15. <https://doi.org/10.1001/jamacardio.2022.2718>.
219. Berretta P, Trimarchi S, Patel HJ, Gleason TG, Eagle KA, Di Eusanio M. Malperfusion syndromes in type A aortic dissection: what we have learned from IRAD. *J Vis Surg* 2018;4:65. <https://doi.org/10.21037/jovs.2018.03.13>.
220. Perko MJ, Nørgaard M, Herzog TM, Olsen PS, Schroeder TV, Pettersson G. Unoperated aortic aneurysm: a survey of 170 patients. *Ann Thorac Surg* 1995;59:1204–9. [https://doi.org/10.1016/0003-4975\(95\)00132-5](https://doi.org/10.1016/0003-4975(95)00132-5).
221. Trimarchi S, Eagle KA, Nienaber CA, Rampoldi V, Jonker FHW, De Vincentiis C, et al. Role of age in acute type A aortic dissection outcome: report from the international registry of acute aortic dissection (IRAD). *J Thorac Cardiovasc Surg* 2010;140:784–9. <https://doi.org/10.1016/j.jtcvs.2009.11.014>.
222. Czerny M, Siepe M, Beyersdorf F, Feisst M, Gabel M, Pilz M, et al. Prediction of mortality rate in acute type A dissection: the German registry for acute type A aortic dissection score. *Eur J Cardiothorac Surg* 2020;58:700–6. <https://doi.org/10.1093/ejcts/ezaa156>.
223. Wolfe SB, Sundt TM 3rd, Isselbacher EM, Cameron DE, Trimarchi S, Bekeredjian R, et al; IRAD researchers. Survival after operative repair of acute type A aortic dissection varies according to the presence and type of preoperative malperfusion. *J Thorac Cardiovasc Surg*. 2024 Jul;168(1):37-49.e6. doi: 10.1016/j.jtcvs.2022.09.034. Epub 2022 Sep 29. PMID: 36333247.
224. Rampoldi V, Trimarchi S, Eagle KA, Nienaber CA, Oh JK, Bossone E et al. International Registry of Acute Aortic Dissection (IRAD) Investigators. Simple risk models to predict surgical mortality in acute type A aortic dissection: the International Registry of Acute Aortic Dissection score. *Ann Thorac Surg* 2007;83:55–61.
225. Long SM, Tribble CG, Raymond DP, Fiser SM, Kaza AK, Kern JA et al. Preoperative shock determines outcome for acute type A aortic dissection. *Ann Thorac Surg* 2003;75:520–4.
226. Cruz I, Stuart B, Caldeira D, Morgado G, Gomes AC, Almeida AR, et al. Controlled pericardiocentesis in patients with cardiac tamponade complicating aortic dissection: experience of a centre without cardiothoracic surgery. *Eur Heart J Acute Cardiovasc Care* 2015;4:124–8. <https://doi.org/10.1177/2048872614549737>.
227. Hayashi T, Tsukube T, Yamashita T, Haraguchi T, Matsukawa R, Kozawa S, et al. Impact of controlled pericardial drainage on critical cardiac tamponade with acute type A aortic dissection. *Circulation* 2012;126:S97–101. <https://doi.org/10.1161/CIRCULATIONAHA.111.082685>.
228. Olsson C, Ahlsson A, Fuglsang S, Geirsson A, Gunn J, Hansson EC et al. Medium-term survival after surgery for acute type A aortic dissection is improving. *Eur J Cardiothorac Surg* 2017;52:852–7.
229. Kawahito K, Aizawa K, Kimura N, Yamaguchi A, Adachi H. Influence of residual primary entry following

- the tear-oriented strategy for acute type A aortic dissection. *Eur J Cardiothorac Surg* 2022;61:1077–84.
230. Ghoreishi M, Sundt TM, Cameron DE, Holmes SD, Rosselli EE, Pasirja C et al. Factors associated with acute stroke after type A aortic dissection repair: an analysis of the Society of Thoracic Surgeons National Adult Cardiac Surgery Database. *J Thorac Cardiovasc Surg* 2020;159:2143–54.e3.
231. Geirsson A, Shioda K, Olsson C, Ahlsson A, Gunn J, Hansson EC et al. Differential outcomes of open and clamp-on distal anastomosis techniques in acute type A aortic dissection. *J Thorac Cardiovasc Surg* 2019;157:1750–8.
232. Malvindi PG, Modi A, Miskolczi S, Kaarne M, Velisaris T, Barlow C et al. Open and closed distal anastomosis for acute type A aortic dissection repair. *Interact CardioVasc Thorac Surg* 2016;22:776–83.
233. Inoue Y, Minatoya K, Oda T, Itonaga T, Seike Y, Tanaka H et al. Surgical outcomes for acute type A aortic dissection with aggressive primary entry resection. *Eur J Cardiothorac Surg* 2016;50:567–73.
234. Heo W, Song SW, Lee KH, Kim TH, Baek MY, Yoo KJ et al. Residual arch tears and major adverse events after acute DeBakey type I aortic dissection repair. *Ann Thorac Surg* 2018;106:1079–86.
235. Bonser RS, Ranasinghe AM, Loubani M, Evans JD, Thalji NMA, Bachet JE, et al. Evidence, lack of evidence, controversy, and debate in the provision and performance of the surgery of acute type A aortic dissection. *J Am Coll Cardiol* 2011;58:2455–74. <https://doi.org/10.1016/j.jacc.2011.06.067>.
236. Subramanian S, Leontyev S, Borger MA, Trommer C, Misfeld M, Mohr FW. Valve-sparing root reconstruction does not compromise survival in acute type A aortic dissection. *Ann Thorac Surg* 2012;94:1230–4. <https://doi.org/10.1016/j.athoracsur.2012.04.094>.
237. Urbanski PP, Hijazi H, Dinstak W, Diegeler A. Valve-sparing aortic root repair in acute type A dissection: how many sinuses have to be repaired for curative surgery? *Eur J Cardiothorac Surg* 2013;44:439–43; discussion 443–4. <https://doi.org/10.1093/ejcts/ezt042>.
238. Apaydin AZ, Posacioglu H, Yagdi T, Islamoglu F, Calkavur T, Buket S. Arch-first technique used with commercial T-graft to treat subacute type-A aortic dissection in patient with Marfan syndrome. *Tex Heart Inst J*. 2002;29(1):26–9.
239. Apaydin AZ, Islamoglu F, Posacioglu H, Yagdi T, Atay Y, Calkavur T, Oguz E. Clinical outcomes in “complex” thoracic aortic surgery. *Tex Heart Inst J*. 2007;34(3):301–4.
240. Tsagakis K, Pacini D, Grabenwöger M, Borger MA, Goebel N, Hemmer W, et al. Results of frozen elephant trunk from the international E-vita Open registry. *Ann Cardiothorac Surg* 2020;9:178–88. <https://doi.org/10.21037/acs-2020-fet-25>.
241. Beckmann E, Martens A, Kaufeld T, Natanov R, Krueger H, Rudolph L, et al. Frozen elephant trunk in acute aortic type a dissection: risk analysis of concomitant root replacement. *Eur J Cardiothorac Surg* 2022;62:ezac051. <https://doi.org/10.1093/ejcts/ezac051>.
242. Weiss G, Tsagakis K, Jakob H, Di Bartolomeo R, Pacini D, Barberio G, et al. The frozen elephant trunk technique for the treatment of complicated type B aortic dissection with involvement of the aortic arch: multicentre early experience. *Eur J Cardiothorac Surg* 2015;47:106–14; discussion 114. <https://doi.org/10.1093/ejcts/ezu067>.
243. Iafrancesco M, Goebel N, Mascaro J, Franke UFW, Pacini D, Di Bartolomeo R, et al. Aortic diameter remodelling after the frozen elephant trunk technique in aortic dissection: results from an international multicentre registry. *Eur J Cardiothorac Surg* 2017;52:310–8. <https://doi.org/10.1093/ejcts/ezx131>.
244. Tsagakis K, Wendt D, Dimitriou AM, Thielmann M, Shehada SD, El Gabry M, et al. The frozen elephant trunk treatment is the operation of choice for all kinds of arch disease. *J Cardiovasc Surg (Torino)* 2018;59:540–6. <https://doi.org/10.23736/s0021-9509.18.10597-0>.
245. Jakob H, Pacini D, Hemmer W, Grabenwoeger M, et al. Early and midterm results of frozen elephant trunk operation with Evita open stent-graft in patients with Marfan syndrome: results of a multicentre study. *BMC Cardiovasc Disord* 2022;22:333. <https://doi.org/10.1186/s12872-022-02777-5>.
246. Jakob H, Shehada SE, Dohle D, Wendt D, El Gabry M, Schlosser T, et al. New 3-zone hybrid graft: first-in-man experience in acute type I dissection. *J Thorac Cardiovasc Surg* 2022;163:568–74.e1. <https://doi.org/10.1016/j.jtcvs.2020.04.113>.
247. Tsagakis K, Osswald A, Weymann A, Demircioglu A, Schmack B, Wendt D, et al. The frozen elephant trunk technique: impact of proximalization and the four-sites perfusion technique. *Eur J Cardiothorac Surg* 2021;61:195–203. <https://doi.org/10.1093/ejcts/ezab295>.
248. Acharya M, Sherzad H, Bashir M, Mariscalco G. The frozen elephant trunk procedure: indications, outcomes and future directions. *Cardiovasc Diagn Ther*. 2022 Oct;12(5):708–721. <https://creativecommons.org/licenses/by-nc-nd/4.0>.
249. Czerny M, Schmidli J, Adler S, van den Berg JC, Bertoglio L, Carrel T et al. EACTS/ESVS scientific document group. Current options and recommendations for the treatment of thoracic aortic pathologies involving the aortic arch: an expert consensus document of the European Association for Cardio-Thoracic surgery (EACTS) and the European Society for Vascular Surgery (ESVS). *Eur J Cardiothorac Surg* 2019;55:133–62.
250. Geirsson A, Szeto WY, Pochettino A, McGarvey ML, Keane MG, Woo YJ, et al. Significance of malperfusion syndromes prior to contemporary surgical repair for acute type A dissection: outcomes and need for additional revascularizations. *Eur J Cardiothorac Surg* 2007;32:255–62. <https://doi.org/10.1016/j.ejcts.2007.04.012>.
251. Apaydin AZ, Buket S, Posacioglu H, Islamoglu F, Calkavur T, Yagdi T, Ozbaran M, Yuksel M. Perioperative risk factors for mortality in patients with acute type A aortic dissection. *Ann Thorac Surg*. 2002 Dec;74(6):2034–9.
252. Yang B, Norton EL, Rosati CM, Wu X, Kim KM, Khaja MS et al. Managing patients with acute type A aortic dissection and mesenteric malperfusion syndrome: a 20-year experience. *J Thorac Cardiovasc Surg* 2019;158:675–87.e4.
253. Yang B, Rosati CM, Norton EL, Kim KM, Khaja MS, Dasika N, et al. Endovascular fenestration/stenting first

- followed by delayed open aortic repair for acute type A aortic dissection with malperfusion syndrome. *Circulation* 2018;138:2091–103. <https://doi.org/10.1161/circulationaha.118.036328>.
254. Leshnower BG, Keeling WB, Duwayri YM, Jordan WD, Jr, Chen EP. The “thoracic endovascular aortic repair-first” strategy for acute type A dissection with mesenteric malperfusion: initial results compared with conventional algorithms. *J Thorac Cardiovasc Surg* 2019;158:1516–24. <https://doi.org/10.1016/j.jtcvs.2019.01.116>.
 255. Xu X, Wu Y, Wu Z. Revascularization-first strategy versus central repair-first strategy for acute type A aortic dissection complicated with mesenteric malperfusion syndrome: a meta-analysis. *J Card Surg* 2022;37:4427–33.
 256. Hashimoto O, Saito Y, Sasaki H, Yumoto K, Oshima S, Tobaru T et al. Angina Pectoris-Myocardial Infarction Multicenter Investigators. Treatment strategies and in-hospital mortality in patients with type A acute aortic dissection and coronary artery involvement. *J Thorac Cardiovasc Surg* 2024;167:596–601.e3.
 257. Neri E, Toscano T, Papalia U, Frati G, Massetti M, Capanzini G et al. Proximal aortic dissection with coronary malperfusion: presentation, management, and outcome. *J Thorac Cardiovasc Surg* 2001;121:552–60.
 258. Tong G, Wu J, Chen Z, Zhuang D, Zhao S, Liu Y et al. Coronary malperfusion secondary to acute type A aortic dissection: surgical management based on a modified Neri classification. *J Clin Med* 2022;11:1693.
 259. Kreibich M, Bavaria JE, Branchetti E, Brown CR, Chen Z, Khurshan F, et al. Management of patients with coronary artery malperfusion secondary to type A aortic dissection. *Ann Thorac Surg* 2019;107:1174–80.
 260. Morimoto N, Okada K, Okita Y. Lack of neurologic improvement after aortic repair for acute type A aortic dissection complicated by cerebral malperfusion: predictors and association with survival. *J Thorac Cardiovasc Surg* 2011;142:1540–4.
 261. Qiu J, Wu J, Xie E, Luo X, Chen JF, Gao W, et al. Surgical management and outcomes of the aortic root in acute type A aortic dissection. *Ann Thorac Surg* 2020;110:136–43. <https://doi.org/10.1016/j.athoracsurg.2019.10.014>.
 262. Benedetto U, Mohamed H, Vitulli P, Petrou M. Axillary versus femoral arterial cannulation in type A acute aortic dissection: evidence from a meta-analysis of comparative studies and adjusted risk estimates. *Eur J Cardiothorac Surg* 2015;48:953–9. <https://doi.org/10.1093/ejcts/ezv035>.
 263. Kreibich M, Desai ND, Bavaria JE, Szeto WY, Vallabhajosyula P, Itagaki R, et al. Preoperative neurological deficit in acute type A aortic dissection. *Interact CardioVasc Thorac Surg* 2020;30:613–9.
 264. Most H, Reinhard B, Gahl B, Englberger L, Kadner A, Weber A et al. Is surgery in acute aortic dissection type A still contraindicated in the presence of preoperative neurological symptoms? *Eur J Cardiothorac Surg* 2015;48:945–50.
 265. Dumfarth J, Kofler M, Stastny L, Gasser S, Plaikner M, Semsroth S et al. Immediate surgery in acute type A dissection and neurologic dysfunction: fighting the inevitable? *Ann Thorac Surg* 2020;110:5–12.
 266. Chiu P, Rotto TJ, Goldstone AB, Whisenant JB, Woo YJ, Fischbein MP. Time-to-operation does not predict outcome in acute type A aortic dissection complicated by neurologic injury at presentation. *J Thorac Cardiovasc Surg* 2019;158:665–72.
 267. Felipe Gaia D, Bernal O, Castilho E, Baeta Neves Duarte Ferreira C, Dvir D, Simonato M, et al. First-in-Human Endo-Bentall Procedure for Simultaneous Treatment of the Ascending Aorta and Aortic Valve. *JACC Case Rep*. 2020 Feb 12;2(3):480–485. doi: 10.1016/j.jaccas.2019.11.071. PMID: 34317269; PMCID: PMC8311619.
 268. Rylski B, Szeto WY, Bavaria JE, Branchetti E, Moser W, Milewski RK. Development of a single endovascular device for aortic valve replacement and ascending aortic repair. *J Card Surg* 2014;29:371–6. <https://doi.org/10.1111/jocs.12348>.
 269. Kreibich M, Rylski B, Kondov S, Morlock J, Scheumann J, Kari FA, et al. Endovascular treatment of acute type A aortic dissection-the Endo Bentall approach. *J Vis Surg* 2018;4:69. <https://doi.org/10.21037/jovs.2018.03.14>.
 270. Urbanski PP, Wagner M. Acute non-A-non-B aortic dissection: surgical or conservative approach? *Eur J Cardiothorac Surg* 2016;49:1249–54.
 271. Trimarchi S, de Beaufort HWL, Tolenaar JL, Bavaria JE, Desai ND, Di Eusanio M et al. Acute aortic dissections with entry tear in the arch: a report from the International Registry of Acute Aortic Dissection. *J Thorac Cardiovasc Surg* 2019;157:66–73.
 272. Luo C, Qi R, Zhong Y, Chen S, Liu H, Guo R et al. Early and long-term follow-up for chronic type B and type non-A non-B aortic dissection using the frozen elephant trunk technique. *Front Cardiovasc Med* 2021;8:714638.
 273. Wang W, Piao H, Wang Y, Li B, Zhu Z, Wang T et al. Early outcomes with a hybrid technique for repair of a non-A non-B aortic dissection. *J Thorac Cardiovasc Surg* 2022;163:1766–74.
 274. Liu J, Yang F, Chen L, Xie E, Su S, Liu Y et al. Management and outcomes of non-A non-B aortic dissection. *Eur J Vasc Endovasc Surg* 2022;64:497–506.
 275. Li Q, Wu Q, Wu W, Dai X, Fang G, Xie X et al. Triple-branched stent graft implantation for acute non-A-non-B aortic dissection. *Ann Thorac Surg* 2023;115:583–9.
 276. Kreibich M, Siepe M, Berger T, Kondov S, Morlock J, Pingpoh C et al. The frozen elephant trunk technique for the treatment of type B and type non-A non-B aortic dissection. *Eur J Vasc Endovasc Surg* 2021;61:107–13.
 277. Hauck SR, Kupferthaler A, Kern M, Rousseau H, Ferrer C, Iwakoshi S et al. Branched versus fenestrated thoracic endovascular aortic repair in the aortic arch: a multicenter comparison. *J Thorac Cardiovasc Surg* 2022;164:1379–89.e1.
 278. Carino D, Singh M, Molardi A, Agostinelli A, Goldoni M, Pacini D, et al. Non-A non-B aortic dissection: a systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2019;55:653–9. <https://doi.org/10.1093/ejcts/ezy337>.
 279. Brown CR, Chen Z, Khurshan F, Kreibich M, Bavaria J, Groeneveld P, et al. Outcomes after thoracic endovascular aortic repair in patients with chronic kidney disease in the Medicare population. *J Thorac Cardiovasc Surg* 2020;159:402–13. <https://doi.org/10.1016/j.jtcvs.2019.01.118>.

280. Evangelista Masip A, Lopez-Sainz A, Barros Membri-
rilla AJ, Calvo Iglesias F, Lopez Ayerbe J, Azqueta
Molluna M et al. Spanish Registry of Acute Aortic Syn-
drome (RESA). Changes in therapeutic management
and lower mortality in acute aortic syndrome. *Rev Esp
Cardiol (Engl Ed)* 2022;75:816–24.
281. Obel LM, Lindholt JS, Lasota AN, Jensen HK, Benhas-
sen LL, Kristensen AL et al. Aortic dissections in the
population-based Danish National Patient Registry
from 1996-2016: a validation study. *Clin Epidemiol*
2022;14:51–8.
282. Weiss G, Wolner I, Folkmann S, Sodeck G, Schmidli
J, Grabenwoiger M et al. The location of the primary
entry tear in acute type B aortic dissection affects early
outcome. *Eur J Cardiothorac Surg* 2012;42:571–6.
283. Trimarchi S, Jonker FH, van Bogerijen GH, Tolenaar JL,
Moll FL, Czerny M et al. Predicting aortic enlargement
in type B aortic dissection. *Ann Cardiothorac Surg*
2014;3:285–91.
284. Evangelista A, Salas A, Ribera A, Ferreira-Gonzalez I,
Cuellar H, Pineda V et al. Long-term outcome of aortic
dissection with patent false lumen: predictive role of
entry tear size and location. *Circulation* 2012;125:3133–
41.
285. Codner JA, Lou X, Duwayri YM, Chen EP, Binongo JN,
Moon R et al. The distance of the primary intimal tear
from the left subclavian artery predicts aortic growth
in uncomplicated type B aortic dissection. *J Vasc Surg*
2019;69:692–700.
286. Evangelista A, Pineda V, Guala A, Bijmens B, Cuellar
H, Rudenick P et al. False lumen flow assessment by
magnetic resonance imaging and long-term outcomes
in uncomplicated aortic dissection. *J Am Coll Cardiol*
2022;79:2415–27.
287. Ante M, Mylonas S, Skrypnik D, Bischoff MS, Ren-
gier F, Brunkwall J et al. Prevalence of the computed
tomographic morphological DISSECT predictors in
uncomplicated Stanford type B aortic dissection. *Eur J
Vasc Endovasc Surg* 2018;56:525–33.
288. Song JM, Kim SD, Kim JH, Kim MJ, Kang DH, Seo JB et
al. Long-term predictors of descending aorta aneurys-
mal change in patients with aortic dissection. *J Am Coll
Cardiol* 2007;50:799–804.
289. Estrera AL, Miller CC 3rd, Safi HJ, Goodrick JS, Key-
hani A, Porat EE, Achouh PE, Meada R, Azizzadeh A,
Dhareshwar J, Allaham A. Outcomes of medical man-
agement of acute type B aortic dissection. *Circulation*.
2006 Jul 4;114(1 Suppl):I384-9. doi: 10.1161/CIRCULA-
TIONAHA.105.001479. PMID: 16820605.
290. Muller M, Yau P, Pham A, Lipsitz EC, DeRose JJ, Cho
JS et al. A comparison of endovascular repair to medi-
cal management for acute vs subacute uncomplicated
type B aortic dissections. *J Vasc Surg* 2023;78:53–60.
291. Schwartz SI, Durham C, Clouse WD, Patel VI, Lan-
caster RT, Cambria RP, et al. Predictors of late aortic
intervention in patients with medically treated type B
aortic dissection. *J Vasc Surg* 2018;67:78–84. <https://doi.org/10.1016/j.jvs.2017.05.128>.
292. Onitsuka S, Akashi H, Tayama K, Okazaki T, Ishihara
K, Hiromatsu S, et al. Long-term outcome and prog-
nostic predictors of medically treated acute type B
aortic dissections. *Ann Thorac Surg* 2004;78:1268–73.
<https://doi.org/10.1016/j.athoracsur.2004.02.031>.
293. Hughes GC, Ganapathi AM, Keenan JE, Englum BR,
Hanna JM, Schechter MA, et al. Thoracic endovascular
aortic repair for chronic DeBakey IIIb aortic dissection.
Ann Thorac Surg 2014;98:2092–7; discussion 2098. <https://doi.org/10.1016/j.athoracsur.2014.06.066>.
294. Jánosi RA, Tsagakakis K, Bettin M, Kahlert P, Horacek M,
Al-Rashid F, et al. Thoracic aortic aneurysm expansion
due to late distal stent graft-induced new entry. *Cat-
heter Cardiovasc Interv* 2015;85:E43–53. <https://doi.org/10.1002/ccd.25614>.
295. Cheng L, Xiang D, Zhang S, Zheng C, Wu X. Reinter-
vention after thoracic endovascular aortic repair of
uncomplicated type B aortic dissection. *J Clin Med*
2023;12:1418. <https://doi.org/10.3390/jcm12041418>.
296. Akutsu K, Nejima J, Kiuchi K, Sasaki K, Ochi M, Ta-
naka K, et al. Effects of the patent false lumen on the
long-term outcome of type B acute aortic dissection.
Eur J Cardiothorac Surg 2004;26:359–66. <https://doi.org/10.1016/j.ejcts.2004.03.026>.
297. Tsai TT, Evangelista A, Nienaber CA, Myrmel T, Mein-
hardt G, Cooper JV, et al. Partial thrombosis of the false
lumen in patients with acute type B aortic dissection. *N
Engl J Med* 2007;357:349–59. <https://doi.org/10.1056/NEJMoa063232>.
298. Brunkwall J, Kasprzak P, Verhoeven E, Heijmen R,
Taylor P, Alric P, et al. Endovascular repair of acute
uncomplicated aortic type B dissection promotes aortic
remodelling: 1 year results of the ADSORB trial. *Eur
J Vasc Endovasc Surg* 2014;48:285–91. <https://doi.org/10.1016/j.ejvs.2014.05.012>.
299. Weissler EH, Osazuwa-Peters OL, Greiner MA, Hardy
NC, Kougas P, O'Brien SM et al. Initial thoracic en-
dovascular aortic repair vs medical therapy for acute
uncomplicated type B aortic dissection. *JAMA Cardiol*
2023;8:44–53.
300. Hossack M, Patel S, Gambardella I, Neequaye S, An-
toniou GA, Torella F. Endovascular vs. medical man-
agement for uncomplicated acute and sub-acute type
B aortic dissection: a meta-analysis. *Eur J Vasc Endo-
vasc Surg* 2020;59:794–807. <https://doi.org/10.1016/j.ejvs.2019.08.003>.
301. Sa MP, Jacquemyn X, Van den Eynde J, Chu D, Ser-
na-Gallegos D, Singh MJ, et al. Midterm outcomes of en-
dovascular vs. medical therapy for uncomplicated type
B aortic dissection: meta-analysis of reconstructed time
to event data. *Eur J Vasc Endovasc Surg* 2023;66:609–
19. <https://doi.org/10.1016/j.ejvs.2023.07.004>.
302. Sa MP, Jacquemyn X, Brown JA, Ahmad D, Ser-
na-Gallegos D, Arnaoutakis GJ, et al. Thoracic en-
dovascular aortic repair for hyperacute, acute, subacute
and chronic type B aortic dissection: meta-analysis of
reconstructed time-to-event data. *Trends Cardiovasc
Med* 2023;S1050-1738(23)00113-5. <https://doi.org/10.1016/j.tcm.2023.12.005>.
303. Wang J, Jin T, Chen B, Pan Y, Shao C. Systematic re-
view and meta-analysis of current evidence in endog-
raft therapy vs medical treatment for uncomplicated
type B aortic dissection. *J Vasc Surg* 2022;76:1099–108.
e3. <https://doi.org/10.1016/j.jvs.2022.03.876>.
304. Jubouri M, Al-Tawil M, Yip HCA, Bashir A, Tan SZCP,
Bashir M, et al. Mid- and long-term outcomes of tho-
racic endovascular aortic repair in acute and subacute
uncomplicated type B aortic dissection. *J Card Surg*
2022;37:1328–39. <https://doi.org/10.1111/jocs.16349>.

305. Torrent DJ, McFarland GE, Wang G, Malas M, Pearce BJ, Aucoin V, et al. Timing of thoracic endovascular aortic repair for uncomplicated acute type B aortic dissection and the association with complications. *J Vasc Surg* 2021;73:826–35. <https://doi.org/10.1016/j.jvs.2020.05.073>.
306. MacGillivray TE, Gleason TG, Patel HJ, Aldea GS, Bavaria JE, Beaver TM, et al. The Society of Thoracic Surgeons/American Association for Thoracic Surgery clinical practice guidelines on the management of type B aortic dissection. *J Thorac Cardiovasc Surg* 2022;163:1231–49. <https://doi.org/10.1016/j.jtcvs.2021.11.091>.
307. Martin G, Patel N, Grant Y, Jenkins M, Gibbs R, Bicknell C. Antihypertensive medication adherence in chronic type B aortic dissection is an important consideration in the management debate. *J Vasc Surg* 2018;68:693–9. e2. <https://doi.org/10.1016/j.jvs.2017.12.063>.
308. Brooke BS, Griffin CL, Glotzbach JP, Horns JJ, Patel S, Kraiss LW, et al. Predictors of adherence to anti-impulse therapy among patients treated for acute type-B aortic dissections. *Ann Vasc Surg* 2021;76:95–103. <https://doi.org/10.1016/j.avsg.2021.04.011>.
309. Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection: perspectives from the international registry of acute aortic dissection (IRAD). *Eur J Vasc Endovasc Surg* 2009;37:149–59. <https://doi.org/10.1016/j.ejvs.2008.11.032>.
310. Trimarchi S, Nienaber CA, Rampoldi V, Myrmet T, Suzuki T, Bossone E, et al. Role and results of surgery in acute type B aortic dissection: insights from the international registry of acute aortic dissection (IRAD). *Circulation* 2006;114:I357–64. <https://doi.org/10.1161/circulationaha.105.000620>.
311. Tolenaar JL, Froehlich W, Jonker FH, Upchurch GR, Rampoldi V, Tsai TT, et al. Predicting in-hospital mortality in acute type B aortic dissection: evidence from international registry of acute aortic dissection. *Circulation* 2014;130:S45–50. <https://doi.org/10.1161/circulationaha.113.007117>.
312. Zeeshan A, Woo EY, Bavaria JE, Fairman RM, Desai ND, Pochettino A, et al. Thoracic endovascular aortic repair for acute complicated type B aortic dissection: superiority relative to conventional open surgical and medical therapy. *J Thorac Cardiovasc Surg* 2010;140:S109–115; discussion S142–S146. <https://doi.org/10.1016/j.jtcvs.2010.06.024>.
313. Steuer J, Eriksson MO, Nyman R, Björck M, Wanhainen A. Early and long-term outcome after thoracic endovascular aortic repair (TEVAR) for acute complicated type B aortic dissection. *Eur J Vasc Endovasc Surg* 2011;41:318–23. <https://doi.org/10.1016/j.ejvs.2010.11.024>.
314. Zipfel B, Czerny M, Funovics M, Coppi G, Ferro C, Rousseau H, et al. Endovascular treatment of patients with types A and B thoracic aortic dissection using Relay thoracic stent-grafts: results from the RESTORE patient registry. *J Endovasc Ther* 2011;18:131–43. <https://doi.org/10.1583/10-3233mr.1>.
315. Hanna JM, Andersen ND, Ganapathi AM, McCann RL, Hughes GC. Five-year results for endovascular repair of acute complicated type B aortic dissection. *J Vasc Surg* 2014;59:96–106. <https://doi.org/10.1016/j.jvs.2013.07.001>.
316. Stelzmueller ME, Nolz R, Mahr S, Beitzke D, Wolf F, Funovics M, et al. Thoracic endovascular repair for acute complicated type B aortic dissections. *J Vasc Surg* 2019;69:318–26. <https://doi.org/10.1016/j.jvs.2018.05.234>.
317. Wilson-Smith AR, Muston B, Kamalanathan H, Yung A, Chen C-HJ, Sahai P, et al. Endovascular repair of acute complicated type B aortic dissection-systematic review and meta-analysis of long-term survival and reintervention. *Ann Cardiothorac Surg* 2021;10:723–30. <https://doi.org/10.21037/acs-2021-taes-17>.
318. Liu D, Luo H, Lin S, Zhao L, Qiao C. Comparison of the efficacy and safety of thoracic endovascular aortic repair with open surgical repair and optimal medical therapy for acute type B aortic dissection: a systematic review and meta-analysis. *Int J Surg* 2020;83:53–61.
319. Li FR, Wu X, Yuan J, Wang J, Mao C, Wu X. Comparison of thoracic endovascular aortic repair, open surgery and best medical treatment for type B aortic dissection: a meta-analysis. *Int J Cardiol* 2018;250:240–6.
320. Lombardi JV, Gleason TG, Panneton JM, Starnes BW, Dake MD, Haulon S, et al. STABLE II investigators. Five-year results of the STABLE II study for the endovascular treatment of complicated, acute type B aortic dissection with a composite device design. *J Vasc Surg* 2022;76:1189–97.e3.
321. The VIRTUE Registry Investigators. Mid-term outcomes and aortic remodelling after thoracic endovascular repair for acute, subacute, and chronic aortic dissection: the VIRTUE Registry. *Eur J Vasc Endovasc Surg* 2014;48:363–71.
322. Chia MC, Khorfan R, Eskandari MK. Adjunctive branch interventions during thoracic endovascular aortic repair for acute complicated type B dissection are not associated with inferior outcomes. *J Vasc Surg* 2021;74:895–901.
323. Liu Y, Jiang X, Chen B, Jiang J, Ma T, Dong Z, et al. Risk factors and treatment outcomes for type B aortic dissection with malperfusion requiring adjunctive procedures after thoracic endovascular aortic repair. *J Vasc Surg* 2022;75:1192–200.e2.
324. Reutersberg B, Gleason T, Desai N, Ehrlich M, Evangelista A, Braverman A, et al. Neurological event rates and associated risk factors in acute type B aortic dissections treated by thoracic aortic endovascular repair. *J Thorac Cardiovasc Surg* 2022;167:52–62.e5.
325. Lortz J, Leinburger F, Tsagakis K, Rammos C, Lind A, Schlosser T, et al. Distal stent graft induced new entry: risk factors in acute and chronic type B aortic dissections. *Eur J Vasc Endovasc Surg* 2019;58:822–30.
326. Spinelli D, Weaver FA, Azizzadeh A, Magee GA, Piffaretti G, Benedetto F et al. Endovascular treatment of complicated versus uncomplicated acute type B aortic dissection. *J Thorac Cardiovasc Surg* 2023;165:4–13.e1.
327. Teraa M, Hazenberg CE, Houben IB, Trimarchi S, van Herwaarden JA. Important issues regarding planning and sizing for emergent TEVAR. *J Cardiovasc Surg (Torino)* 2020;61:708–12. <https://doi.org/10.23736/S0021-9509.20.11571-4>.
328. Kreibich M, Berger T, Morlock J, Kondov S, Scheumann J, Kari FA et al. The frozen elephant trunk technique for the treatment of acute complicated type B aortic dissection. *Eur J Cardiothorac Surg* 2018;53:525–30.

329. Di Marco L, Pantaleo A, Leone A, Murana G, Di Bartolomeo R, Pacini D. The frozen elephant trunk technique: European Association for Cardio-Thoracic Surgery Position and Bologna Experience. *Korean J Thorac Cardiovasc Surg* 2017;50:1-7.
330. Lau C, Soletti GJ, Lawrence KM, Rahouma M, Iannaccone E, Gambardella I et al. Contemporary outcomes of open repair of acute complicated type B aortic dissection. *J Vasc Surg* 2023;78:593-601.e4.
331. Marui A, Mochizuki T, Mitsui N, Koyama T, Kimura F, Horibe M. Toward the best treatment for uncomplicated patients with type B acute aortic dissection: a consideration for sound surgical indication. *Circulation* 1999;100:II275-80. https://doi.org/10.1161/01.cir.100.suppl_2.ii-275.
332. Crawford ES. The diagnosis and management of aortic dissection. *JAMA* 1990;264:2537-41.
333. Hata M, Shiono M, Inoue T, Sezai A, Niino T, Negishi N, et al. Optimal treatment of type B acute aortic dissection: long-term medical follow-up results. *Ann Thorac Surg* 2003;75:1781-4. [https://doi.org/10.1016/s0003-4975\(03\)00113-9](https://doi.org/10.1016/s0003-4975(03)00113-9).
334. Oda T, Minatoya K, Sasaki H, Tanaka H, Seike Y, Itonaga T, et al. Surgical indication for chronic aortic dissection in descending thoracic and thoracoabdominal aorta. *Circ Cardiovasc Interv* 2017;10:e004292. <https://doi.org/10.1161/circinterventions.116.004292>.
335. Conrad MF, Chung TK, Cambria MR, Paruchuri V, Brady TJ, Cambria RP. Effect of chronic dissection on early and late outcomes after descending thoracic and thoracoabdominal aneurysm repair. *J Vasc Surg* 2011;53:600-7; discussion 607. <https://doi.org/10.1016/j.jvs.2010.09.053>.
336. Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, et al. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. *J Vasc Surg* 1986;3:389-404. <https://doi.org/10.1067/mva.1986.avs0030389>.
337. Zoli S, Etz CD, Roder F, Mueller CS, Brenner RM, Bodian CA, et al. Long-term survival after open repair of chronic distal aortic dissection. *Ann Thorac Surg* 2010;89:1458-66. <https://doi.org/10.1016/j.athoracsurg.2010.02.014>.
338. Etz CD, Zoli S, Mueller CS, Bodian CA, Di Luozzo G, Lazala R, et al. Staged repair significantly reduces paraplegia rate after extensive thoracoabdominal aortic aneurysm repair. *J Thorac Cardiovasc Surg* 2010;139:1464-72. <https://doi.org/10.1016/j.jtcvs.2010.02.037>.
339. Conrad MF, Ergul EA, Patel VI, Paruchuri V, Kwolek CJ, Cambria RP. Management of diseases of the descending thoracic aorta in the endovascular era: a Medicare population study. *Ann Surg* 2010;252:603-10. <https://doi.org/10.1097/SLA.0b013e3181f4eaf>.
340. Sobocinski J, Dias NV, Berger L, Midulla M, Hertault A, Sonesson B, et al. Endograft repair of complicated acute type B aortic dissections. *Eur J Vasc Endovasc Surg* 2013; 45:468-74. <https://doi.org/10.1016/j.ejvs.2013.01.031>.
341. Conrad MF, Carvalho S, Ergul E, Kwolek CJ, Lancaster RT, Patel VI, et al. Late aortic remodeling persists in the stented segment after endovascular repair of acute complicated type B aortic dissection. *J Vasc Surg* 2015;62:600-5. <https://doi.org/10.1016/j.jvs.2015.03.064>.
342. Thrumurthy SG, Karthikesalingam A, Patterson BO, Holt PJE, Hinchliffe RJ, Loftus IM, et al. A systematic review of mid-term outcomes of thoracic endovascular repair (TEVAR) of chronic type B aortic dissection. *Eur J Vasc Endovasc Surg* 2011;42:632-47. <https://doi.org/10.1016/j.ejvs.2011.08.009>.
343. Boufi M, Patterson BO, Loundou AD, Boyer L, Grima MJ, Loftus IM, et al. Endovascular versus open repair for chronic type B dissection treatment: a meta-analysis. *Ann Thorac Surg* 2019;107:1559-70. <https://doi.org/10.1016/j.athoracsurg.2018.10.045>.
344. Conway AM, Qato K, Mondry LR, Stoffels GJ, Giangola G, Carroccio A. Outcomes of thoracic endovascular aortic repair for chronic aortic dissections. *J Vasc Surg* 2018;67:1345-52. <https://doi.org/10.1016/j.jvs.2017.08.098>.
345. Ouzounian M, Tadros RO, Svensson LG, Lyden SP, Oderich GS, Coselli JS. Thoracoabdominal aortic disease and repair: JACC focus seminar, part 3. *J Am Coll Cardiol* 2022;80:845-56. <https://doi.org/10.1016/j.jacc.2021.05.056>.
346. Tenorio ER, Oderich GS, Farber MA, Schneider DB, Timaran CH, Schanzer A, et al. Outcomes of endovascular repair of chronic postdissection compared with degenerative thoracoabdominal aortic aneurysms using fenestrated-branched stent grafts. *J Vasc Surg* 2020;72:822-36.e9. <https://doi.org/10.1016/j.jvs.2019.10.091>.
347. Marques De Marino P, Ibraheem A, Gafur N, Verhoeven EL, Katsargyris A. Outcomes of fenestrated and branched endovascular aortic repair for chronic post-dissection thoracoabdominal aortic aneurysms. *J Cardiovasc Surg* 2020;61:427-34. <https://doi.org/10.23736/s0021-9509.20.11367-3>.
348. Gallitto E, Faggioli G, Melissano G, Fargion A, Isernia G, Bertoglio L, et al. Fenestrated and branched endografts for post-dissection thoraco-abdominal aneurysms: results of a national multicentre study and literature review. *Eur J Vasc Endovasc Surg* 2022;64:630-8. <https://doi.org/10.1016/j.ejvs.2022.06.019>.
349. Geisbüsch S, Kuehn A, Salvermoser M, Reutersberg B, Trenner M, Eckstein H-H. Editor's choice—hospital incidence, treatment, and in hospital mortality following open and endovascular surgery for thoraco-abdominal aortic aneurysms in Germany from 2005 to 2014: secondary data analysis of the Nationwide German DRG microdata. *Eur J Vasc Endovasc Surg* 2019;57:488-98. <https://doi.org/10.1016/j.ejvs.2018.10.030>.
350. Yen HT, Wu CC, Lee YW, Lo CM, Chen YY. CT characteristics and clinical implications of acute type A aortic intramural hematoma. *Front Cardiovasc Med* 2022;9:1041796.
351. Kim MS, Kim TH, Lee H, Song SW, Heo W, Sim SA et al. Note the descending aorta: predictors of postoperative major adverse aortic event in pure acute type A intramural hematoma. *J Thorac Dis* 2021;13:4935-46.
352. Moral S, Cuellar H, Avegliano G, Ballesteros E, Salcedo MT, Ferreira-Gonzalez I et al. Clinical implications of focal intimal disruption in patients with type B intramural hematoma. *J Am Coll Cardiol* 2017;69:28-39.
353. Evangelista A, Moral S, Ballesteros E, Castillo-Gandia A. Beyond the term penetrating aortic ulcer: a

- morphologic descriptor covering a constellation of entities with different prognoses. *Prog Cardiovasc Dis* 2020;63:488–95.
354. Mussa FF, Horton JD, Moridzadeh R, Nicholson J, Trimarchi S, Eagle KA. Acute aortic dissection and intramural hematoma: a systematic review. *JAMA* 2016;316:754–63. <https://doi.org/10.1001/jama.2016.10026>.
 355. DeMartino RR, Sen I, Huang Y, Bower TC, Oderich GS, Pochettino A, et al. Population-based assessment of the incidence of aortic dissection, intramural hematoma, and penetrating ulcer, and its associated mortality from 1995 to 2015. *Circ Cardiovasc Qual Outcomes* 2018;11:e004689. <https://doi.org/10.1161/circoutcomes.118.004689>.
 356. Goldstein SA, Evangelista A, Abbata S, Arai A, Asch FM, Badano LP, et al. Multimodality imaging of diseases of the thoracic aorta in adults: from the American Society of Echocardiography and the European Association of Cardiovascular Imaging: endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr* 2015;28:119–82. <https://doi.org/10.1016/j.echo.2014.11.015>.
 357. Estrera A, Miller C, Lee T-Y, De Rango P, Abdullah S, Walkes J-C et al. Acute type A intramural hematoma: analysis of current management strategy. *Circulation* 2009;120:S287–91.
 358. Chou AS, Ziganshin BA, Charilaou P, Tranquilli M, Rizzo JA, Eleftheriades JA. Long-term behavior of aortic intramural hematomas and penetrating ulcers. *J Thorac Cardiovasc Surg* 2016;151:361–72, 373.e1.
 359. Wee I, Varughese RS, Syn N, Choong A. Non-operative management of type A acute aortic syndromes: a systematic review and meta-analysis. *Eur J Vasc Endovasc Surg* 2019;58:41–51.
 360. Chow SCY, Wong RHL, Lakhani I, Wong MV, Tse G, Yu PSY et al. Management of acute type A intramural hematoma: upfront surgery or individualized approach? A retrospective analysis and meta-analysis. *J Thorac Dis* 2020;12:680–9.
 361. Ganaha F, Miller DC, Sugimoto K, et al. Prognosis of aortic intramural hematoma with and without penetrating atherosclerotic ulcer: a clinical and radiological analysis. *Circulation*. 2002;106:342–348.
 362. Li Z, Chen Y, Guo J, et al. Prediction of adverse events in patients with initially medically treated type A intramural hematoma. *Int J Cardiol*. 2020;313:114–120.
 363. Li Z, Lu B, Chen Y, et al. Acute type B aortic intramural hematoma: the added prognostic value of a follow-up CT. *Eur Radiol*. 2019;29:6571–6580.
 364. Kageyama S, Mitake H, Nakajima A, et al. A novel risk score on admission for predicting death or need for surgery in patients with acute type A intramural hematoma receiving medical therapy. *Heart Vessels*. 2020;35:1164–1170.
 365. Evangelista A, Dominguez R, Sebastia C, et al. Prognostic value of clinical and morphologic findings in short-term evolution of aortic intramural haematoma. Therapeutic implications. *Eur Heart J*. 2004;25:81–87.
 366. Hata M, Hata H, Sezai A, et al. Optimal treatment strategy for type A acute aortic dissection with intramural hematoma. *J Thorac Cardiovasc Surg*. 2014;147:307–311.
 367. Wang Y, Song S, Zhou C, Zhu W, Liu J, Shi Q, et al. Thoracic endovascular aortic repair for retrograde type A intramural hematoma with intimal disruption in the descending aorta. *J Endovasc Ther* 2022;29:724–30.
 368. Chen D, Luo M, Fang K, Shu C. Endovascular repair of acute zone 0 intramural hematoma with most proximal tear or ulcer-like projection in the descending aorta. *J Vasc Surg* 2022;75:1561–9.
 369. Evangelista A, Czerny M, Nienaber C, Schepens M, Rousseau H, Cao P, et al. Interdisciplinary expert consensus on management of type B intramural haematoma and penetrating aortic ulcer. *Eur J Cardiothorac Surg* 2015;47:209–17.
 370. Mesar T, Lin MJ, Kabir I, Dexter DJ, Rathore A, Panneton JM. Medical therapy in type B aortic intramural hematoma is associated with a high failure rate. *J Vasc Surg* 2020;71:1088–96.
 371. Brown JA, Arnaoutakis GJ, Kilic A, Gleason TG, Aranda-Michel E, Sultan I. Medical and surgical management of acute type B aortic intramural hematoma. *J Card Surg* 2020;35:2324–30.
 372. Chakos A, Twindyawardhani T, Evangelista A, Maldonado G, Piffaretti G, Yan TD et al. Endovascular versus medical management of type B intramural hematoma: a meta-analysis. *Ann Cardiothorac Surg* 2019;8:447–55.
 373. Mesar T, Alie-Cusson FS, Lin MJ, Dexter DJ, Rathore A, Stokes GK, et al. Impact of thoracic endovascular aortic repair timing on aortic remodeling in acute type B aortic intramural hematoma. *J Vasc Surg* 2022;75:464–72.e2.
 374. Czerny M, Funovics M, Sodeck G, Dumfarth J, Schoder M, Juraszek A, et al. Results after thoracic endovascular aortic repair in penetrating atherosclerotic ulcers. *Ann Thorac Surg* 2011;92:562–6.
 375. Oderich GS, Karkkainen JM, Reed NR, Tenorio ER, Sandri GA. Penetrating aortic ulcer and intramural hematoma. *Cardiovasc Intervent Radiol* 2019;42:321–34.
 376. Nathan DP, Boonn W, Lai E, et al. Presentation, complications, and natural history of penetrating atherosclerotic ulcer disease. *J Vasc Surg*. 2012;55:10–15.
 377. Kreibich M, Kremer J, Votsch A, Berger T, Farag M, Winkler A, et al. Multicentre experience with the frozen elephant trunk technique to treat penetrating aortic ulcers involving the aortic arch. *Eur J Cardiothorac Surg* 2021;59:1238–44.
 378. Czerny M, Berger T, Kondov S, Siepe M, Saint Lebes B, Mokrane F, et al. Results of endovascular aortic arch repair using the Relay Branch system. *Eur J Cardiothorac Surg* 2021;60:662–8.
 379. Isernia G, Simonte G, Orrico M, Silingardi R, Gaggiano A, Covic T, et al. Italian Najuta Registry study group. Preliminary results from an Italian National Registry on the outcomes of the Najuta fenestrated aortic arch endograft. *J Vasc Surg* 2023;77:1330–8.e2.
 380. Kupferthaler A, Hauck SR, Schwarz M, Kern M, Deinsberger J, Dachs TM, et al. Endovascular repair of penetrating thoracic aortic ulcers using tubular stent grafts versus stent grafts with a proximal scallop. *J Endovasc Ther* 2023;15266028221149919.
 381. Neschis DG, Scalea TM, Flinn WR, Griffith BP. Blunt aortic injury. *N Engl J Med* 2008;359:1708–16.
 382. Azizzadeh A, Keyhani K, Miller CC 3rd, Coogan SM, Safi HJ, Estrera AL. Blunt traumatic aortic injury: initial experience with endovascular repair. *J Vasc Surg* 2009;49:1403–8.

383. Lee WA, Matsumura JS, Mitchell RS, Farber MA, Greenberg RK, Azizzadeh A, et al. Endovascular repair of traumatic thoracic aortic injury: clinical practice guidelines of the Society for Vascular Surgery. *J Vasc Surg* 2011;53:187–92.
384. Riambau V, Bockler D, Brunkwall J, Cao P, Chiesa R, Coppi G, et al. Editor's choice—Management of descending thoracic aorta diseases: clinical practice guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg* 2017;53:4–52. <https://doi.org/10.1016/j.ejvs.2016.06.005>.
385. Mandigers TJ, Bissacco D, Domanin M, D'Alessio I, Tolva VS, Piffaretti G, et al. Cardiac and aortic modifications after endovascular repair for blunt thoracic aortic injury: a systematic review. *Eur J Vasc Endovasc Surg* 2022;64:176–87.
386. Mohapatra A, Liang NL, Makaroun MS, Schermerhorn ML, Farber A, Eslami MH. Improved outcomes of endovascular repair of thoracic aortic injuries at higher volume institutions. *J Vasc Surg* 2021;73:1314–9.
387. Rabin J, DuBose J, Sliker CW, O'Connor JV, Scalea TM, Griffith BP. Parameters for successful nonoperative management of traumatic aortic injury. *J Thorac Cardiovasc Surg* 2014;147:143–9.
388. Starnes BW, Lundgren RS, Gunn M, Quade S, Hatsukami TS, Tran NT, et al. A new classification scheme for treating blunt aortic injury. *J Vasc Surg* 2012;55:47–54.
389. Harris DG, Rabin J, Starnes BW, Khoynezhad A, Conway RG, Taylor BS et al. Evolution of lesion-specific management of blunt thoracic aortic injury. *J Vasc Surg* 2016;64:500–5.
390. Gavant ML. Helical CT grading of traumatic aortic injuries. Impact on clinical guidelines for medical and surgical management. *Radiol Clin North Am* 1999;37:553–74.
391. DuBose JJ, Leake SS, Brenner M, Pasley J, O'Callaghan T, Luo-Owen X, et al. Aortic Trauma Foundation. Contemporary management and outcomes of blunt thoracic aortic injury: a multicenter retrospective study. *J Trauma Acute Care Surg* 2015;78:360–9.
392. Fortuna GR Jr, Perlick A, DuBose JJ, Leake SS, Charlton-Ouw KM, Miller CC 3rd, et al. Injury grade is a predictor of aortic-related death among patients with blunt thoracic aortic injury. *J Vasc Surg* 2016;63:1225–31.
393. Demetriades D, Velmahos GC, Scalea TM, Jurkovich GJ, Karmy-Jones R, Teixeira PG, et al. Operative repair or endovascular stent graft in blunt traumatic thoracic aortic injuries: results of an American Association for the Surgery of Trauma Multicenter Study. *J Trauma* 2008;64:561–70; discussion 570–1. <https://doi.org/10.1097/TA.0b013e3181641bb3>.
394. Rylski B, Hoffmann I, Beyersdorf F, Suedkamp M, Siepe M, Nitsch B, et al. Iatrogenic acute aortic dissection on type A: insight from the German registry for acute aortic dissection type A (GERAADA). *Eur J Cardiothorac Surg* 2013;44:353–9; discussion 359. <https://doi.org/10.1093/ejcts/ezt055>.
395. Riambau V, Bockler D, Brunkwall J, Cao P, Chiesa R, Coppi G, et al. Editor's choice—management of descending thoracic aorta diseases: clinical practice guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg* 2017;53:4–52. <https://doi.org/10.1016/j.ejvs.2016.06.005>.
396. Bekkers JA, te Riele RJ, Takkenberg JJ, Bol Raap G, Hofland J, Roos-Hesselink JW, et al. Thoracic aortic surgery: an overview of 40 years clinical practice. *J Thorac Cardiovasc Surg* 2014;147:332–43. <https://doi.org/10.1016/j.jtcvs.2012.11.036>.
397. Meena RA, Benarroch-Gampel J, Leshnower BG, Escobar GA, Duwayri Y, Jordan WD, et al. Surveillance recommendations after thoracic endovascular aortic repair should be based on initial indication for repair. *Ann Vasc Surg* 2019;57:51–9. <https://doi.org/10.1016/j.avsg.2018.11.001>.
398. Giles KA, Beck AW, Lala S, Patterson S, Back M, Fatima J, et al. Implications of secondary aortic intervention after thoracic endovascular aortic repair for acute and chronic type B dissection. *J Vasc Surg* 2019;69:1367–78. <https://doi.org/10.1016/j.jvs.2018.07.080>.
399. Iribarne A, Keenan J, Benrashid E, Wang H, Meza JM, Ganapathi A, et al. Imaging surveillance after proximal aortic operations: is it necessary? *Ann Thorac Surg* 2017;103:734–41. <https://doi.org/10.1016/j.athoracsur.2016.06.085>.
400. Ameli-Renani S, Das R, Morgan RA. Thoracic endovascular aortic repair for the treatment of aortic dissection: post-operative imaging, complications and secondary interventions. *Cardiovasc Intervent Radiol* 2015;38:1391–404. <https://doi.org/10.1007/s00270-015-1072-9>.
401. Smedberg C, Hultgren R, Leander K, Steuer J. Pharmacological treatment in patients with aortic dissection. *Open Heart* 2022;9:e002082. <https://doi.org/10.1136/openhrt-2022-002082>.
402. Fleischmann D, Afifi RO, Casanegra AI, Elefteriades JA, Gleason TG, Hanneman K, et al. Imaging and surveillance of chronic aortic dissection: a scientific statement from the American Heart Association. *Circ Cardiovasc Imaging* 2022;15:e000075. <https://doi.org/10.1161/hci.0000000000000075>.
403. Colacchio EC, Squizzato F, Piazza M, Menegolo M, Grego F, Antonello M. Clinical and imaging predictors of disease progression in type B aortic intramural hematomas and penetrating aortic ulcers: a systematic review. *Diagnostics (Basel)* 2022;12:2727. <https://doi.org/10.3390/diagnostics12112727>.



TORASİK AORT HASTALIKLARINDA ENDOVASKÜLER TEDAVİ

BÖLÜM 81

Fatih İSLAMOĞLU ¹

DOI: 10.37609/akya.3889.c5403

İçindekiler

- » GİRİŞ
- » TORASİK AORT ANEVİZMALARINDA ENDOVASKÜLER TEDAVİ
- » HASTA SEÇİMİ
- » ENDOVASKÜLER GREFT TİPLERİ
- » OPERATİF HAZIRLIK VE İŞLEM
- » ENDOGREFT SEÇİMİ
- » ÖZEL DURUMLAR
- » KOMPLİKASYONLAR
- » SONUÇLAR
- » AORT DİSEKSİYONLARINDA ENDOVASKÜLER TEDAVİ
- » Tip A Aort Diseksiyonunda Endovasküler Tedavi
- » Tip B Aort Diseksiyonunda Endovasküler Tedavi
- » Yeni Çalışmalar
- » Genel Olarak TEVAR Sonrası Komplikasyonların Değerlendirilmesi ve Tedavi
- » Spinal İskemi (SCI)
- » Endoleak – Sızma
- » Endograft Kollapsı - Çökmesi
- » Vasküler Erişim ve Yerleştirme Yaralanmaları
- » Böbrek Yetmezliği
- » Açık Cerrahi Onarıma Geçiş

¹ Prof. Dr., Ege Üniversitesi Tıp Fakültesi Kalp-Damar Cerrahisi AD., fatih.islamoglu@ege.edu.tr, ORCID iD: 0000-0001-9406-2189

talıkları veya stent greftlerin retrograd yerleştirilmesini engelleyen diğer faktörleri olan hastalar için antegrad yaklaşım uygulanabilir. Antegrad yol olarak aksiller arter, asendan aort veya doğrudan yerleştirme kullanılabilir. Antegrad erişimdeki başlıca komplikasyonlar felç, omurilik yaralanması, solunum yetmezliği ve böbrek yetmezliğidir (86).

Böbrek Yetmezliği

TEVAR aortik kros klemp veya kardiyopulmoner baypası önlese de, akut böbrek hasarı (ABH) hala yaygın bir komplikasyondur ve %1 ile %34 arasında değişmektedir (85). Geniş değişkenlik aralığı, böbrek yetmezliği için standart birtanım eksikliğinden kaynaklanmaktadır. Preoperatif hipertansiyon ve kronik böbrek yetmezliği gibi ABH riskini artıran hasta faktörlerinin yanı sıra, iyotlu kontrast kullanımının ABH'ye katkıda bulunan bir faktör olarak yaygın olarak kabul edilmektedir. Ameliyat öncesi hidrasyon ve N-asetilsistein uygulanması gibi önleyici stratejiler yaygın olarak kullanılmış ancak farklı sonuçlar elde edilmiştir (87).

Açık Cerrahi Onarıma Geçiş

TEVAR'dan açık torasik aort anevrizması onarımına geçiş gerektiren hastaların insidansının deneyimli merkezlerde %2,2 ila %7,2 olduğu bildirilmiştir (88). Retrograd Tip A diseksiyon, sekonder aortobronşiyal fistül, stent-greft enfeksiyonu, aortoözofageal fistül, anevrizma genişlemesi açık cerrahi onarıma geçilmesine yol açan temel nedenlerdir (77, 88). TEVAR'ın artan kullanımına rağmen klinisyenlerin açık onarıma hızlı dönüşüm gerektiren bu olaylar için dikkat ve hızlı karar verilmesi çok önemlidir.

Genel olarak özetlenecek olursa torasik aort hastalıklarında endovasküler tedavi, TEVAR, elektif torasik aort anevrizması onarımları için kısa işlem süresi, düşük parapleji oranı, hızlı iyileşme, kısa hospitalizasyon, cerrahi riski yüksek acil diseksiyon olgularında düşük morbidite ve mortalite oranları ile altın standart haline gelme-

sine ve belirgin avatajlara sahip olmasına rağmen maliyet konusu henüz tartışmalıdır. Önümüzdeki yıllarda TEVAR'dan uzun vadeli takip verileriyle, klinisyenler ve mühendisler endovasküler teknolojiyi geliştirmeye devam edebilecek ve endovasküler teknikler için uygulamaları yeniden tanımlayabileceklerdir. Gelecekte, gelişmiş teknoloji ile sağlanacak daha iyi sonuçlar yanında olgu sayısı, gerçek anatomik özelliklerin kavranması, buna uygun greft tiplerinin çeşitlendirilmesi ve endikasyonlardaki kısıtlılıkların aşılması ile endovasküler tedavinin tüm akut diseksiyonlar, travmatik aort rüptürleri, anevrizma rüptürleri, arkus ve torakoabdominal anevrizmalar gibi kompleks patolojilerde de yaygın kullanımı mümkün olabilecektir.

KAYNAKLAR

1. Yoshida H, Yasuda K, Tanabe T. New approach to aortic dissection: Development of an insertable aortic prosthesis. *Ann Thorac Surg* 1994;56:806-10.
2. Dotter CT. Transluminally-placed coilspring endarterial tube grafts. Long-term patency in canine popliteal artery. *Invest Radiol*. 1969;4(5):329-32.
3. Balko A, Piasecki GJ, Shah DM, et al. Transfemoral placement of intraluminal polyurethane prosthesis for abdominal aortic aneurysm. *J Surg Res* 1986;40:305-9.
4. Lawrence DD, Charnsangavej C, Wright KC, et al. Percutaneous endovascular graft: Experimental evaluation. *Radiology* 1987;163:357-60.
5. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysm. *Ann Vasc Surg* 1991;5:491-9.
6. Dake MD, Miller DC, Semba CP, et al. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms. *N Engl J Med* 1994;331:1729-34.
7. Coady MA, Rizzo JA, Hammond GL, Kopf GS. Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications. *Ann Thor Surg* 1999;67:1639-47.
8. McNamara JJ, Pressler VM. Natural history of arteriosclerotic thoracic aortic aneurysms. *Ann thorac surg* 1978;26:468-73.
9. Moreno-Cabral CE, Miller DC, Mitchell RS, et al. Degenerative and atherosclerotic aneurysms of the thoracic aorta. *J Thorac Cardiovasc Surg* 1984;88:1020-32.
10. Crawford ES, Walker HSJ, Saleh SA, et al. Graft replacement of aneurysm in descending thoracic aorta: Results without bypass or shunting. *Surgery* 1981;89:73-85.
11. DeBakey ME, McCollum CH, Graham JM. Surgical treatment of aneurysms of the descending thoracic aorta. *J Cardiovasc Surg* 1978;19:571-6.
12. Hamerlijnck RP, Rutsaert RR, DeGeest R, et al. Surgical correction of descending thoracic aortic aneurys-

- ms under simple aortic cross-clamping. *J Vasc Surg* 1989;9:568-73.
13. Livesay JJ, Cooley DA, Ventemiglia RA, et al. Surgical experience in descending thoracic aneurysmectomy with and without adjuncts to avoid ischemia. *Ann Thorac Surg* 1985;39:37-46.
 14. Najafi H, Javid H, Hunter J, et al. Descending thoracic aneurysmectomy without adjuncts to avoid ischemia. *Ann Thorac Surg*. 1980;30:326-35.
 15. Von Segesser LK, Killer I, Jenni R, et al. Improved distal circulatory support for repair of descending thoracic aortic aneurysms. *Ann Thorac Surg* 1993;56:1373-80.
 16. Dake MD, Miller DC, Mitchell RS, et al. The first generation of endovascular stent-grafts for patients with descending thoracic aortic aneurysms. *J Thorac Cardiovasc Surg* 1998;116:689-704.
 17. Marin ML, Veith FJ, Panetta TF, et al. Percutaneous transfemoral insertion of a stented graft to repair a traumatic arteriovenous fistula. *J Vasc Surg* 1993;18:299-302.
 18. Sze DY, Slonim SM, Dake MD. Endovascular stent-graft treatment of thoracic aortic aneurysms. In: Franco KL, Verrier ED, eds. *Advanced Therapy in Cardiac Surgery*. Hamilton-Ontario: B. C. Decker Inc., 1999:319-25.
 19. Dieter RS. Transluminal endovascular stent grafting of aortic dissections and aneurysms: a concise review of the major trials. *Clin Cardiol* 2001;24:358-63.
 20. Mitchell RS. Endovascular stent graft repair of thoracic aortic aneurysms. *Semin Thorac Cardiovasc Surg* 1997;9:257-68.
 21. Buth J, Penn O, Tielbeek A, Mersman M. Combined approach to stent-graft treatment of an aortic arch aneurysm. *J Endovasc Surg* 1998;5:329-32.
 22. Mitchell RS, Miller DC, Dake MD, Semba CP, Moore KA, Sakai T. Thoracic aortic aneurysm repair with an endovascular stentgraft: the first generation. *Ann Thorac Surg* 1999;67:1971-4.
 23. Heijmen RH, Deblieck IG, Moll FL, Dossche KM, van den Berg JC, Overtom TT, Ernst SM, Schepens MA. Endovascular stent-grafting for descending thoracic aortic aneurysms. *Eur J Cardiothorac Surg* 2002;21:5-9.
 24. Resch T, Koul B, Dias N, Lindblad B, Ivancev K. Changes in aneurysm morphology and stent-graft configuration after endovascular repair of aneurysms of the descending thoracic aorta. *J Thorac Cardiovasc Surg* 2001;122:47-52.
 25. Thurnher SA, Grabenwöger M. Endovascular treatment of thoracic aortic aneurysms: a review. *Eur Radiol* 2002;12:1370-87.
 26. Moon MR, Mitchell RS, Dake MD, Zarins CK, Fann JL, Miller DC. Simultaneous abdominal aortic replacement and thoracic stent-graft placement for multilevel aortic disease. *J Vasc Surg* 1997;25 :332-40.
 27. Mita T, Arita T, Matsunaga N, et al. Complications of endovascular repair for thoracic and abdominal aortic aneurysm: an imaging spectrum. *Radiographics* 2000;20:1263-78.
 28. Malina M, Brunkwall J, Ivancev K, et al. Late aortic-arch perforation by graft-anchoring stent : complication of endovascular thoracic aneurysm exclusion. *J Endovasc Surg* 1998;5:274-7.
 29. VonFricken K, Karamanoukian HL, Ricci M, Taheri A, Bergsland J, Salerno TA. Aortobrochial fistula after endovascular stent graft repair of the thoracic aorta. *Ann Thorac Surg* 2000;70:1407-9.
 30. Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms. *J Thorac Cardiovasc Surg* 1997;113:476-91.
 31. Tetik Ö, İslamoğlu F, Yağdı T, Atay Y, Çalkavur T, Özbek C, Canpolat L, Büket S. An intraaortic solution trial to prevent spinal cord injury in a rabbit model. *European Journal of Vascular and Endovascular Surgery*. 2001;22:175-9.
 32. Tetik Ö, Yağdı T, İslamoğlu F, Çalkavur T, Posacioğlu H, Atay Y, Ayık F, Canpolat L. The effects of L-Carnitin on spinal cord ischemia/reperfusion injury in rabbits. *Thorac Cardiovasc Surg* 2002;50:11-5.
 33. Coselli JS, LeMaire SA, Schmittling SC, Koksoy C. Cerebrospinal fluid drainage in thoracoabdominal aortic surgery. *Semin Vasc Surg* 2000;13:308-14.
 34. Safi HJ, Subramaniam MH, Miller CC, et al. Progress in the management of type I thoracoabdominal and descending aortic aneurysms. *Ann Vasc Surg* 1999;13:457-62.
 35. Midorikawa H, Hoshino S, Iwaya F, Igari T, Satou K, Ishikawa K. Prevention of paraplegia in transluminally placed endoluminal prosthetic grafts for descending thoracic aortic aneurysms. *Jpn J Thorac Cardiovasc Surg* 2000;48:761-8.
 36. Yamada N, Okita Y, Minatoya K, et al. Preoperative demonstration of the Adamkiewics artery by magnetic resonance angiography in patients with descending or thoracoabdominal aortic aneurysms. *Eur J Cardiothorac Surg* 2000;18:104-11.
 37. McArthur C, Teodorescu V, Eisen L, et al. Histopathologic analysis of endovascular stent grafts from patients with aortic aneurysms: does healing occur? *J Vasc Surg* 2001;33:733-8.
 38. Ishimaru S, Kawaguchi S, Kouzumi N, Obitsu Y, Ishikawa M. Preliminary report on prediction of spinal cord ischemia in endovascular stent-graft repair of thoracic aortic aneurysm by retrievable stent-graft. *J Thorac Cardiovasc Surg* 1998;115:811-8.
 39. Inoue K, Hosokawa H, Iwase T, et al. Aortic arch reconstruction by transluminally placed endovascular branched stent graft. *Circulation* 1999;100:316-21.
 40. Swenson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Dissection of the aorta and dissecting aortic aneurysms: improving early and long-term surgical results. *Circulation* 1990;suppl IV:24-38.
 41. Williams DM, Do Yun L, Hamilton BH, et al. The dissected aorta. *Radiology* 1997;203:37-44.
 42. Kato N, Shimono T, Hirano T, Ishida M, Yada I, Takeida K. Transluminal placement of endovascular stent-grafts for the treatment of type A aortic dissection with an entry tear in the descending thoracic aorta. *J Vasc Surg* 2001;34:1023-8.
 43. Yano H, Ishimaru S, Kawaguchi S, Obitsu Y. Endovascular stent grafting of the descending thoracic aorta after arch repair in acute type A dissection. *Ann Thorac Surg* 2002;73:288-91.
 44. Sueda T, Watari M, Orihashi K, Shikata H, Matsuura Y. Open stent-graft repair for acute type A aortic dissection with an intimal tear in the descending aorta. *Ann Thorac Cardiovasc Surg* 1999;5:273-5.

45. Shigemura N, Kato M, Kuratani T, Funakoshi Y, Kaneko M.J. New operative method for acute type B dissection: left carotid artery-left subclavian artery bypass combined with endovascular stent-graft implantation. *Thorac Cardiovasc Surg.* 2000;120:406-8.
46. Kato M, Matsuda T, Kaneko M *et al.*, Outcomes of stent-graft treatment of false lumen in aortic dissection. *Circulation* 1998;98:305-312.
47. Nienaber CA, Fattori R, Lund G, Dieckmann C, Wolf W, von Kodolitsch Y, Nicolas V, Pierangeli A. Non-surgical reconstruction of thoracic aortic dissection by stent-graft placement. *N Engl J Med* 1999;340:1539-45.
48. Dake MD, Kato N, Mitchell RS, Semba CP, et al. Endovascular stent-graft replacement for the treatment of acute aortic dissection. *N Engl J Med* 1999;340:1546-52.
49. Glower DD, Fann JJ, Speier RH, et al. Comparison of medical and surgical therapy for uncomplicated descending aortic dissection. *Circulation* 1990;82:39-46.
50. Greenberg R. Treatment of aortic dissections with endovascular stent grafts. *Semin Vasc Surg* 2002;15:122-7.
51. Sailer J, Peloschek P, Rand T, Grabenwoger M, Thurnher S, Lammner J. Endovascular treatment of aortic type B dissection and penetrating ulcer using commercially available stent-grafts. *AJR Am J Roentgenol* 2001;177:1365-9.
52. Ochi M, Tabata M, Sakamoto S, et al. Surgical endovascular stent grafting for a ruptured penetrating atherosclerotic ulcer of the aortic arch. *J Nippon Med Sch* 2002 ;69 :49-52.
53. Czermak BV, Waldenberger P, Fraedrich G, et al. Treatment of Stanford Type B Aortic Dissection with Stent-Grafts: Preliminary Results. *Radiology* 2000;217:544-550.
54. Lundblom J, Wesche J, Hatlinghus S, et al. Endovascular treatment of type B aortic dissections. *Cardiovasc Surg* 2001;9:266-71.
55. Buth J, Penn O, Tielbeek A, Mersman M. Combined approach to stent-graft treatment of an aortic arch aneurysm. *J Endovasc Surg* 1998;5:329-32.
56. Hausegger KA, Oberwalder P, Tiesenhausen K, et al. Intentional left subclavian artery occlusion by thoracic aortic stent-grafts without surgical transposition. *J Endovasc Ther* 2001;8:472-6.
57. Slonim SM, Miller DC, Mitchell RS, Semba CP, Razavi MK, Dake MD. Percutaneous balloon fenestration and stenting for life threatening ischemic complications in patients with acute aortic dissection. *J Thorac Cardiovasc Surg* 1999;117:1118-27.
58. Kawaharada N, Kurimoto Y, Ito T, Koyanagi T, Yamauchi A, Nakamura M, Takagi N, Higami T. Hybrid treatment for aortic arch and proximal descending thoracic aneurysm: experience with stent grafting for second-stage elephant trunk repair. *Eur J Cardiothorac Surg.* 2009 ;36(6):956-61.
59. Fattori R, Russo V, Lovato L, Buttazzi K, Rinaldi G. Endovascular Management of Thoracic Aortic Aneurysms. *Cardiovasc Intervent Radiol.* 2011 Feb 3. [Epub ahead of print].
60. Riesenman PJ, Reeves JG, Kasirajan K. Endovascular management of a ruptured thoracoabdominal aneurysm-damage control with superior mesenteric artery snorkel and thoracic stent-graft exclusion. *Ann Vasc Surg.* 2011 ;25(4):555.e5-9
61. Handa N, Nishina T, Kato M, Nishio I, Asano M, Noda K, Suzuki T, Ueno Y. Multiple aneurysm repair: hybrid approach to chronic dissection around visceral branches. *Gen Thorac Cardiovasc Surg.* 2011;59(4):288-92.
62. Rabellino M, Garcia-Nielsen L, Maynar M. Endovascular repair of a complex thoracoabdominal aneurysm covering the descending thoracic and abdominal aortic artery with a four fenestrated stent graft. *J Invasive Cardiol.* 2010;22(12):615-6
63. Rimbaut V, Zipfel B, Coppi G, Czerny M, Tealdi DG, Ferro C, Chiesa R, Sassi C, Rousseau H, Berti S; RELAY Endovascular Registry for Thoracic Disease RESTORE Investigators. Final operative and midterm results of the European experience in the RELAY Endovascular Registry for Thoracic Disease (RESTORE) study. *J Vasc Surg.* 2011;53(3):565-73.
64. Mangialardi N, Costa P, Bergeron P, Serrao E, Ronchey S . Staged hybrid repair of thoracoabdominal aortic aneurysm after chronic type B aortic dissection. *Vascular.* 2010 ;18(6):336-43.
65. Inoue Y, Yozu R. Echo-endoscope biplane navigation system for endovascular aneurysm repair. *Ann Thorac Surg.* 2010;90(2):622-6.
66. Rynio P, Kazimierzczak A, Jedrzejczak T, Gutowski P. A 3-dimensional printed aortic arch template to facilitate the creation of physician-modified stent-grafts. *J Endovasc Ther* 2018;25(05): 554-8.
67. Awad H, Ramadan ME, El Sayed HF, Tolpin DA, Tili E, Collard CD. Spinal cord injury after thoracic endovascular aortic aneurysm repair. *Can J Anaesth* 2017;64(12):1218-35.
68. Khan NR, Smalley Z, Nesvick CL, Lee SL, Michael LM II. The use of lumbar drains in preventing spinal cord injury following thoracoabdominal aortic aneurysm repair: an updated systematic review and meta-analysis. *J Neurosurg Spine* 2016;25(03): 383-39.
69. Maurel B, Mastracci ITM. Thoracic and thoraco-abdominal aneurysms: aortic stent grafts and techniques of thoracic endovascular aortic repair. In: Sidawy AN, Perler AB, eds. *Rutherford's Vascular Surgery and Endovascular Therapy.* 9th ed. Elsevier; 2019: 1025-35.
70. Ullery BW, Cheung AT, Fairman RM, et al. Risk factors, outcomes, and clinical manifestations of spinal cord ischemia following thoracic endovascular aortic repair. *J Vasc Surg* 2011;54(03): 677-68.
71. Khan NR, Smalley Z, Nesvick CL, Lee SL, Michael LM II. The use of lumbar drains in preventing spinal cord injury following thoracoabdominal aortic aneurysm repair: an updated systematic review and meta-analysis. *J Neurosurg Spine* 2016;25(03): 383-93.
72. Uchida N. How to prevent spinal cord injury during endovascular repair of thoracic aortic disease. *Gen Thorac Cardiovasc Surg* 2014;62(07):391-7.
73. Etz CD, Debus ES, Mohr FW, Kölbel T. First-in-man endovascular preconditioning of the paraspinal collateral network by segmental artery coil embolization to prevent ischemic spinal cord injury. *J Thorac Cardiovasc Surg* 2015;149(04):1074-9.
74. Kasprzak PM, Gallis K, Cucuruz B, Pfister K, Janotta M, Kopp R. Editor's choice-Temporary aneurysm sac perfusion as an adjunct for prevention of spinal cord ischemia after branched endovascular repair of thoracoabdominal aneurysms. *Eur J Vasc Endovasc Surg* 2014;48(03):258-65.

75. Awad H, Ramadan ME, El Sayed HF, Tolpin DA, Tili E, Collard CD. Spinal cord injury after thoracic endovascular aortic aneurysm repair. *Can J Anaesth* 2017;64(12):1218–35.
76. Lima B, Nowicki ER, Blackstone EH, et al. Spinal cord protective strategies during descending and thoraco-abdominal aortic aneurysm repair in the modern era: the role of intrathecal papaverine. *J Thorac Cardiovasc Surg* 2012;143(04):945–52.
77. Chen SW, Lee KB, Napolitano MA, et al. Complications and management of the thoracic endovascular aortic repair. *Aorta* 2020;8:49–58.
78. Hajibandeh S, Hajibandeh S, Antoniou SA, Torella F, Antoniou GA. Meta-analysis of left subclavian artery coverage with and without revascularization in thoracic endovascular aortic repair. *J Endovasc Ther* 2016;23(04):634–641.
79. Voskresensky I, Scali ST, Feezor RJ, et al. Outcomes of thoracic endovascular aortic repair using aortic arch chimney stents in high-risk patients. *J Vasc Surg* 2017;66(01):9–20.
80. Chen J, Stavropoulos SW. Management of Endoleaks. *Semin Intervent Radiol* 2015;32(03):259–264.
81. Biasi L, Ali T, Hinchliffe R, Morgan R, Loftus I, Thompson M. Intraoperative DynaCT detection and immediate correction of a type Ia endoleak following endovascular repair of abdominal aortic aneurysm. *Cardiovasc Intervent Radiol* 2009;32(03):535–538.
82. Thomas BG, Sanchez LA, Geraghty PJ, Rubin BG, Money SR, Sicard GA. A comparative analysis of the outcomes of aortic cuffs and converters for endovascular graft migration. *J Vasc Surg* 2010;51 (06):1373–1380.
83. Kougias P, Lin PH, Dardik A, Lee WA, El Sayed HF, Zhou W. Successful treatment of endotension and aneurysm sac enlargement with endovascular stent graft reinforcement. *J Vasc Surg* 2007;46(01):124–127.
84. Jordan WD Jr, Mehta M, Varnagy D, et al; Aneurysm Treatment using the Heli-FX Aortic Securement System Global Registry (ANCHOR) Workgroup Members. Results of the ANCHOR prospective, multicenter registry of EndoAnchors for type Ia endoleaks and endograft migration in patients with challenging anatomy. *J Vasc Surg* 2014;60(04):885–92.
85. Sattah AP, Secrist MH, Sarin S. Complications and perioperative management of patients undergoing thoracic endovascular aortic repair. *J Intensive Care Med* 2018;33(07):394–406.
86. van Bogerijen GHW, Williams DM, Eliason JL, Dasika NL, Deeb GM, Patel HJ. Alternative access techniques with thoracic endovascular aortic repair, open iliac conduit versus endoconduit technique. *J Vasc Surg* 2014;60(05):1168–1176.
87. Azzalini L, Spagnoli V, Ly HQ. Contrast-induced nephropathy: from pathophysiology to preventive strategies. *Can J Cardiol* 2016;32(02):247–255.
88. Canaud L, Alric P, Gandet T, Ozdemir BA, Albat B, Marty-Ane C. Open surgical secondary procedures after thoracic endovascular aortic repair. *Eur J Vasc Endovasc Surg* 2013;46(06):667–674.



ATEROSKLEROTİK PERİFER ARTER HASTALIĞINDA MEDİKAL TEDAVİ

BÖLÜM 82

Adil POLAT ¹

DOI: 10.37609/akya.3889.c5404

İçindekiler

- » TANIMLAR
 - » Kanama
 - » İşlem Başarı ve Komplikasyonları
- » ATEROSKLEROTİK PAH RİSK FAKTÖRLERİ & KORUNMA (BİRİNCİL VE İKİNCİL)
 - » Yaşam Şekli Değişiklikleri
 - » Sigara Kullanımı
 - » Diyabet
 - » Dislipidemi ve Farmakoterapi
 - » Hipertansiyon
- » TEDAVİ YAKLAŞIMI
 - » En İyi Medikal Tedavi (EMT)
 - » Egzersiz Tedavisi
 - » PAH Tedavisinde Antitrombotik İlaçlar
 - » Diğer İlaçlar
- » KETİ HASTALARINDA TIBBİ TEDAVİNİN DÜZENLENMESİ
 - » KETİ Tedavisinde Antiagregan/Antikoagülan Kullanımı
 - » KETİ Tedavisinde Kardiyovasküler Risk Faktörlerinin Tedavisi
 - » KETİ Tedavisinde Prostanoidler


¹ Prof. Dr., Sağlık Bilimleri Üniversitesi, Hamidiye Tıp Fakültesi, İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, adil.polat@sbu.edu.tr, ORCID iD: 0000-0002-4043-7421

KAYNAKLAR

- 1 Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. *Nat Rev Cardiol.* 2022;19(7):456-74. doi: 10.1038/s41569-021-00663-9.
- 2 Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. *Circ Res.* 2021;128(12):1868-84. doi: 10.1161/CIRC-RESAHA.121.318258
- 3 Dittman JM, Amendola MF, Lavingia KS. Medical optimization of the peripheral artery disease patient. *Semin Vasc Surg.* 2022;35(2):113-23. doi: 10.1053/j.semvascsurg.2022.04.003
- 4 Sullivan AE, Beckman JA. Medical Management of Peripheral Artery Disease. *Semin Intervent Radiol.* 2023;40(2):119-28. doi: 10.1055/s-0043-57257
- 5 Iida O, Takahara M, Mano T. Evidence-Experience Gap and Future Perspective on the Treatment of Peripheral Artery Disease. *J Atheroscler Thromb.* 2021;28(12):1251-1259. doi: 10.5551/jat.RV17058
- 6 Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011;123:2736-47
- 7 Polat A. Bölüm A. Periferik Arter Hastalığı. Şu kitapta: Periferik Arter ve Ven Hastalıkları: Ulusal Tedavi Kılavuzu 2021. Ed: Bozkurt AK, pp:1-99, Türk Kalp ve Damar Cerrahisi Derneği, Ulusal Vasküler ve Endovasküler Cerrahi Derneği, Fleboloji Derneği, 2021, Bayçınar Yayınevi, İstanbul.
- 8 Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. *J Vasc Surg* 2009;50:1462-73.e1-3
- 9 López-Laguna N, Martínez-González MA, Toledo E, Babio N, Sorlí JV, Ros E, et al. Risk of peripheral artery disease according to a healthy lifestyle score: The PRE-DIMED study. *Atherosclerosis* 2018;275:133-40
- 10 Sánchez-Quesada C, Toledo E, González-Mata G, Ramos-Ballesta MI, Peis JI, Martínez-González MÁ, et al. Relationship between olive oil consumption and ankle-brachial pressure index in a population at high cardiovascular risk. *Atherosclerosis* 2020;314:48-57.
- 11 Patel KK, Jones PG, Ellerbeck EF, Buchanan DM, Chan PS, Pacheco CM, et al. Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: Insights from the International PORTRAIT Registry. *J Am Heart Assoc* 2018;7:e010076
- 12 Allagbé I, Servier C, Le Faou AL. Factors associated with smoking cessation in patients with peripheral arterial disease consulting French cessation services. *J Vasc Surg.* 2025;S0741-5214(25)00361-1. doi: 10.1016/j.jvs.2025.03.002. Epub ahead of print
- 13 Nordanstig J, Behrendt CA, Baumgartner I, Belch J, Bäck M, Fitridge R, Hinchliffe R, Lejay A, Mills JL, Rother U, Sigvart B, Spanos K, Szeberin Z, van de Water W; ESVS Guidelines Committee; Antoniou GA, Björck M, Gonçalves FB, Coscas R, Dias NV, Van Herzele I, Lepidi S, Mees BME, Resch TA, Ricco JB, Trimarchi S, Twine CP, Tulamo R, Wanhainen A; Document Reviewers; Boyle JR, Brodmann M, Dardik A, Dick F, Goëffic Y, Holden A, Kakkos SK, Kolh P, McDermott MM. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. *Eur J Vasc Endovasc Surg.* 2024;67(1):9-96. doi: 10.1016/j.ejvs.2023.08.067
- 14 Chen SL, Whealon MD, Kabutay NK, Kuo JJ, Sgroi MD, Fujitani RM. Outcomes of open and endovascular lower extremity revascularization in active smokers with advanced peripheral arterial disease. *J Vasc Surg* 2017;65:1680-9
- 15 Yıldızhan İ, Mert B, Özkaynak B, Kük ZG, Polat A. Directional atherectomy in femoropopliteal occlusive diseases: Our midterm results. *Turk J Vasc Surg* 2019;28:1-8.
- 16 Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Büller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: A meta-analysis. *J Vasc Surg* 2005;42:67-74
- 17 Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral artery disease: Past, present, and future. *Am J Med* 2019;132:1133-41
- 18 Neupane S, Edla S, Maidona E, Sweet MC, Szpunar S, Davis T, et al. Long-term outcomes of patients with diabetes mellitus undergoing percutaneous intervention for popliteal and infrapopliteal peripheral arterial disease. *Catheter Cardiovasc Interv* 2018;92:117-23
- 19 Patel KK, Alturkmani H, Gosch K, Mena-Hurtado C, Shishehbor MH, Peri-Okonny PA, et al. Association of diabetes mellitus with health status outcomes in patients with peripheral artery disease: Insights from the PORTRAIT Registry. *J Am Heart Assoc* 2020;9:e017103
- 20 Nativel M, Potier L, Alexandre L, Baillet-Blanco L, Ducasse E, Velho G, et al. Lower extremity arterial disease in patients with diabetes: A contemporary narrative review. *Cardiovasc Diabetol* 2018;17:138.
- 21 Mohammadi K, Woodward M, Hirakawa Y, Zoungas S, Colagiuri S, Hamet P, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: Results from the ADVANCE-ON study. *Cardiovasc Diabetol* 2016;15:129
- 22 American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. *Diabetes Care.* 2025 Jan 1;48(1 Suppl 1):S128-S145. doi: 10.2337/dc25-S006
- 23 Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, et al. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. *Cardiovasc Diabetol* 2020;19:160
- 24 Huang CY, Lee JK. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals. *Diabetes Obes Metab* 2020;22:2348-55
- 25 Tsai S, Vega GL. Coronary and peripheral artery plaques: do differences in plaque characteristics translate to differences in lipid management? *J Investig Med* 2020;68:1141-51
- 26 Peters F, Kuchenbecker J, Kreutzburg T, Marschall U, Debus ES, Behrendt CA. Long-term effectiveness and

- safety of initiating statin therapy after index revascularization in patients with peripheral arterial occlusive disease. *J Am Heart Assoc* 2020;9:e018338
- 27 Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are independently associated with reduced mortality in patients undergoing infringuinal bypass graft surgery for critical limb ischemia. *J Vasc Surg* 2008;47:774-81.
- 28 Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S, Katsaros I, Jawaid O, Jonnalagadda AK, et al. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: A systematic review and meta-analysis. *Vasc Med* 2020;25:106-17
- 29 Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). *Circulation* 2018;137:338-50
- 30 Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: Role of lipoprotein(a) and modification by alirocumab: Prespecified analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. *Circulation* 2020;141:1608-17
- 31 Yadav A, Sawant V, Singh Bedi V, Yadav K. Dyslipidemia and peripheral arterial disease. *Indian Heart J*. 2024;76 Suppl 1(Suppl 1):S86-S89. doi: 10.1016/j.ihj.2024.01.010
- 32 Ya'qoub L, Peri-Okonny P, Wang J, Patel KK, Stone N, Smolderen K. Blood pressure management in patients with symptomatic peripheral artery disease: Insights from the PORTRAIT Registry. *Eur Heart J Qual Care Clin Outcomes* 2019;5:79-81
- 33 Authors/Task Force Members, Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur J Prev Cardiol* 2016;23:NP1-NP96.
- 34 Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: The European Stroke Organization (ESO) The task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J* 2018;39:763-816
- 35 Vlachopoulos C, Terentes-Printzios D, Aboyans V, Brodmann M, De Carlo M, Tousoulis D. Angiotensin converting enzyme inhibitors and walking distance: Have we walked the whole distance? *Atherosclerosis* 2016;252:199-200.
- 36 Shahin Y, Barnes R, Barakat H, Chetter IC. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication. *Atherosclerosis* 2013;231:283-90.
- 37 Khan SZ, Montross B, Rivero M, Cherr GS, Harris LM, Dryjski ML, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers (ACEI/ARB) are associated with improved limb salvage after infrapopliteal interventions for critical limb ischemia. *Ann Vasc Surg* 2020;63:275-86
- 38 Vrsalovic M. Blood pressure goals in hypertensive patients with peripheral arterial disease. *Eur Heart J Qual Care Clin Outcomes* 2019;5:183
- 39 Itoga NK, Tawfik DS, Lee CK, Maruyama S, Leeper NJ, Chang TI. Association of blood pressure measurements with peripheral artery disease events. *Circulation* 2018;138:1805-14
- 40 Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: Findings from the International Verapamil-SR/Trandolapril Study. *Hypertension* 2010;55:48-53
- 41 Thomas Manapurathe D, Moxon JV, Krishna SM, Rowbotham S, Quigley F, Jenkins J, et al. Cohort study examining the association between blood pressure and cardiovascular events in patients with peripheral artery disease. *J Am Heart Assoc* 2019;8:e010748
- 42 Saxon JT, Safley DM, Mena-Hurtado C, Heyligers J, Fitridge R, Shishehbor M, et al. Adherence to guideline-recommended therapy-including supervised exercise therapy referral-across peripheral artery disease specialty clinics: Insights from the International PORTRAIT Registry. *J Am Heart Assoc* 2020;9:e012541
- 43 Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER 3rd, Cohen DJ, Reynolds MR, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: The CLEVER study. *J Am Coll Cardiol* 2015;65:999-1009
- 44 Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. *Cochrane Database Syst Rev* 2017;12:CD000990
- 45 Kobayashi T, Hamamoto M, Okazaki T, Honma T, Iba K, Takakuwa T, et al. Effectiveness of continuous unsupervised exercise therapy after above-knee femoropopliteal bypass. *Vascular* 2020;1708538120957488
- 46 Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. *Res Pract Thromb Haemost* 2018;2:188-98
- 47 Bonaca MP, Barnes GD, Bauersachs R, Bessada Y, Conte MS, Dua A, Hess CN, Serhal M, Mena-Hurtado C, Weitz JI, Beckman JA. Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement. *J Am Coll Cardiol*. 2024;84(10):936-952. doi: 10.1016/j.jacc.2024.06.027
- 48 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet* 1996;348:1329-39.
- 49 Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, et al. Ticagrelor versus clopidogrel in patients with symptomatic peripheral ar-

- tery disease and prior coronary artery disease: Insights from the EUCLID trial. *Vasc Med* 2018;23:523-30
- 50 Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA* 2006;295:180-9
 - 51 Weitz JI, Angiolillo DJ, Geisler T, Heitmeier S. Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: Rationale and review of the evidence. *Thromb Haemost* 2020;120:1147-58
 - 52 Franzone A, Piccolo R, Gargiulo G, Ariotti S, Marino M, Santucci A, et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: A subgroup analysis of the PRODIGY Randomized Clinical Trial. *JAMA Cardiol* 2016;1:795-803
 - 53 Bauersachs R, Wu O, Briere JB, Bowrin K, Borkowska K, Jakubowska A, et al. Antithrombotic treatments in patients with chronic coronary artery disease or peripheral artery disease: A systematic review of randomised controlled trials. *Cardiovasc Ther* 2020;2020:3057168
 - 54 Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med* 2012;366:9-19
 - 55 Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, et al. Major adverse limb events and mortality in patients with peripheral artery disease: The COMPASS Trial. *J Am Coll Cardiol* 2018;71:2306-15
 - 56 Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abo-la MT, Verhamme P, et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: A subanalysis of the COMPASS Randomized Clinical Trial. *JAMA Cardiol* 2021;6:21-9
 - 57 Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. *N Engl J Med* 2020;382:1994-2004
 - 58 Lee HF, See LC, Li PR, Liu JR, Chao TF, Chang SH, et al. Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. *Eur Heart J Cardiovasc Pharmacother* 2021;7:50-8
 - 59 Magnani G, Denegri A, Gurgoglione FL, Barocelli F, Indrigo E, Catellani D, Signoretta G, Bettella A, Tutto-lomondo D, Solinas E, Nicolini F, Niccoli G, Ardissino D. Dual Antiplatelet Therapy or Antiplatelet Plus Anti-coagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review. *J Clin Med*. 2023;12(16):5284. doi: 10.3390/jcm12165284
 - 60 Ajmal M, Friedman J, Sipra QUAR, Lassar T. Riva-roxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review. *Cardiovasc Ther*. 2021;2021:8886210. doi: 10.1155/2021/8886210
 - 61 Gupta R, Majumdar M, Imran R, Yi J. A comprehen-sive review on antithrombotic therapy for peripheral artery disease. *Semin Vasc Surg*. 2022;35(2):124-31. doi: 10.1053/j.semvascsurg.2022.04.004
 - 62 Zavgorodnyaya D, Knight TB, Daley MJ, Teixeira PG. Antithrombotic therapy for postinterventional man-agement of peripheral arterial disease. *Am J Health Syst Pharm* 2020;77:269-76
 - 63 Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, et al. Twelve-month results of a rando-mized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with perip-heral artery disease. *J Endovasc Ther* 2013;20:699-706
 - 64 Belch JJ, Dormandy J; CASPAR Writing Committee, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al. Results of the randomized, placebo-controlled clopi-dogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. *J Vasc Surg* 2010;52:825-33
 - 65 Belch JJ, Dormandy J; CASPAR Writing Committee, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al. Results of the randomized, placebo-controlled clopi-dogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. *J Vasc Surg* 2010;52:825-33
 - 66 Abaraogu UO, Abaraogu OD, Dall PM, Tew G, Stuart W, Brittenden J, et al. Exercise therapy in routine man-agement of peripheral arterial disease and intermittent claudication: a scoping review. *Ther Adv Cardiovasc Dis* 2020;14:1753944720924270
 - 67 Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. *Cochrane Database Syst Rev* 2020;10:CD005262
 - 68 Wübbcke LF, Naves CCLM, Daemen JHC, Jacobs MJ, Mees BME. Editor's choice - mortality and major am-putation after revascularisation in octogenarians ver-sus non-octogenarians with chronic limb threatening ischaemia: A systematic review and meta-analysis. *Eur J Vasc Endovasc Surg* 2020;60:231-41
 - 69 Baubeta Fridh E, Andersson M, Thuresson M, Sigvant B, Kragsterman B, Johansson S, et al. Editor's choice - impact of comorbidity, medication, and gender on am-putation rate following revascularisation for chronic limb threatening ischaemia. *Eur J Vasc Endovasc Surg* 2018;56:681-8
 - 70 Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fit-ridge R, et al. Global vascular guidelines on the man-agement of chronic limb-threatening ischemia. *Eur J Vasc Endovasc Surg* 2019;58:S1-S109.e33
 - 70 Vietto V, Franco JV, Saenz V, Cytryn D, Chas J, Ciappo-ni A. Prostanoids for critical limb ischaemia. *Cochrane Database Syst Rev* 2018;1:CD006544
 - 72 Meini S, Dentali F, Melillo E, de Donato G, Mumoli N, Mazzone A. Prostanoids for critical limb ischemia: A clinical review and consideration of current guideline recommendations. *Angiology* 2020;71:226-34
 - 73 Treatment of limb threatening ischaemia with intra-venous iloprost: A randomised double-blind placebo controlled study. U.K. Severe Limb Ischaemia Study Group. *Eur J Vasc Surg* 1991;5:511-6



DOI: 10.37609/akya.3889.c5405

ATEROSKLEROTİK PERİFER ARTER HASTALIĞI CERRAHİ VE ENDOVASKÜLER TEDAVİSİ

BÖLÜM 83

Adil POLAT ¹

İçindekiler

- » VASKÜLER CERRAHİ AMELİYATHANE HAZIRLIĞI
 - » Vasküler Cerrahi Setin Hazırlanması
 - » Greftler
- » TEMEL CERRAHİ TEKNİKLER
 - » Damarın ortaya konması ve diseksiyonu
 - » Temel vasküler kontrol yöntemleri
 - » Pıhtının çıkarılması
 - » Endarterektomi
 - » İnterpozisyon
 - » Baypas işlemleri
- » FARKLI YERLEŞİMLERDE ATEROSKLEROTİK TIKANIKLIKLARIN CERRAHİ TEDAVİSİ
 - » Alt Ekstremitte Girim Tikanıklıklarının Tedavisi
 - » İnfringuinal Tikanıklıklarının Tedavisi
 - » Üst Ekstremitte Tikanıklıklarının Tedavisi
- » LAPAROSKOPİ VE ROBOTİK CERRAHİ TEDAVİ
- » ENDOVASKÜLER TEDAVİ
 - » Balon Anjiyoplasti
 - » Stentleme
 - » Subintimal Anjiyoplasti
 - » Aterektomi diğer damar hazırlama teknikleri
 - » İlaç Teknolojisi
- » ENDİKASYONLAR
 - » KETİ Olgularında Revaskülarizasyon
 - » AK Olgularında Revaskülarizasyon
 - » Üst Ekstremitenin Revaskülarizasyonu

¹ Prof. Dr., Sağlık Bilimleri Üniversitesi, Hamidiye Tıp Fakültesi, İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, adil.polat@sbu.edu.tr, ORCID iD: 0000-0002-4043-7421

yon sonuçları hakkında çok değerli sonuçlar vermiştir (68). Amerika Birleşik Devletleri ve Kanada'da 600'den fazla merkezde, 2003-2018 yılları arasında AK endikasyonu ile yapılan 34.944 işlem ve takip sonuçları analiz edilmiştir. Femoropopliteal (FP), infrapopliteal (İP) ve kombine işlemlerin bir yıllık yeniden girişim olmadan sağkalım oranları sırasıyla %89.2, %91.3 ve %85.3 olmuştur. Aşağıdaki grafikte, majör ve minör amputasyon olmadan sağkalımın dizaltı işlemlerde belirgin olarak düşük olduğu görülmektedir (68).

Üst Ekstremitenin Revaskülarizasyonu

Toplam yedi klinik çalışmada yer alan 731 hastada uygulanan 760 girişimi inceleyen ayrıntılı bir metaanaliz subklaviyen arter darlığı için uygulanan açık cerrahi ve endovasküler tedavileri karşılaştırmıştır (69). Endovasküler işlem uygulanan grupta stentleme oranı %87 olurken cerrahi yapılan grupta şu işlemler uygulanmıştır: Baypas cerrahisi (karotis-subklaviyen, aksillo-aksiller, subklaviyo-subklaviyen) veya karotis-subklaviyen transpozisyon. Erken dönem sonuçları benzer olmakla beraber açık cerrahi grupta nöral komplikasyon oranı daha yüksek (%5.4'e karşın %0.2) bulunmuştur. Bir (%95'e karşın %89), üç (%91'e karşın %83) ve beş yıllık (%87'ye karşın %75) açıklık oranları değerlendirildiğinde açık cerrahi tedavinin endovasküler tedaviden çok üstün olduğu görülmüştür (69). İlginç bir şekilde, uzun dönem sağkalım ve şikâyetlerin yeniden ortaya çıkması açısından iki tedavi arasında fark bulunamamıştır. Literatürde benzer sonuçlar bildirildiği gibi endovasküler tedaviyle daha yüksek veya belirgin fark olmayan açıklık oranları bildiren çalışmalar mevcuttur (26).

KAYNAKLAR

- Hoballah JJ. Chapter-1. Vascular Instruments. Şu Kitapta: Vascular Reconstructions. 2nd Ed. Hoballah JJ, Bechara CF Ed. pp:3-16; 2021, Springer, New York, NY, USA
- Hoballah JJ, Wehbe MR. Chapter-2. Vascular Grafts, Patches and Sutures. Şu kitapta: Vascular Reconstructions. 2nd Ed. Hoballah JJ, Bechara CF Ed. pp:17-28; 2021, Springer, New York, NY, USA
- Reilly BP, Dryjski ML. Chapter-65. Autogenous Grafts (Including Vein Harvest, Surgical and Endoscopic). Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:838-48; 2023, Elsevier, Philadelphia PA, USA
- Gasper WJ, Owens CD, Kim JM, Hills N, Belkin M, Creager MA, Conte MS. Thirty-day vein remodeling is predictive of midterm graft patency after lower extremity bypass. J Vasc Surg. 2013;57(1):9-18. doi: 10.1016/j.jvs.2012.06.098
- Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS; PREVENT III Investigators. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43(4):742-751; discussion 751. doi: 10.1016/j.jvs.2005.12.058
- Nierlich P, Enzmann F, Dabernig W, Martin J, Akhavan F, Linn K, Hölzenbein T. Small Saphenous Vein and Arm Vein as Bypass Grafts for Upper Extremity Ischemia. Annals of vascular surgery. 2019;60:264-9 https://doi.org/10.1016/j.avsg.2019.02.015
- Hamouda M, Zarrintan S, Vootukuru N, Thandra S, Quatromoni JG, Malas MB, Gaffey AC. Outcomes of prosthetic and biological grafts compared to arm vein grafts in patients with chronic limb-threatening ischemia. J Vasc Surg. 2025;81(3):682-92. doi: 10.1016/j.jvs.2024.10.069
- Kalish J, Farber A. Chapter-67. Biologic Grafts. Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:864-73; 2023, Elsevier, Philadelphia PA, USA
- Sanin GD, Negmadjanov U, Patterson JW, Hamid RN, Torosian T, Stafford JM, Sheehan MK, Goldman MP, Hurie J, Edwards MS, Velazquez G. Contemporary outcomes for arterial reconstruction with non-saphenous vein cryo-preserved conduits. J Vasc Surg. 2024;79(6):1457-1465. doi: 10.1016/j.jvs.2024.01.201
- Neville RF. Chapter-66. Prosthetic Grafts. Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:849-62; 2023, Elsevier, Philadelphia PA, USA
- Dexter DJ, O'Neill F, Neville RF. Systematic literature review comparing clinical utility of heparin-bonded expanded polytetrafluoroethylene graft with autologous saphenous vein graft for the management of below-the-knee peripheral arterial disease. J Vasc Surg. 2024 Dec;80(6):1863-1870.e6. doi: 10.1016/j.jvs.2024.07.023
- Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, Hamza TH, Assmann SF, Creager MA, Cziraky MJ, Dake MD, Jaff MR, Reid D, Siami FS, Sopko G, White CJ, van Over M, Strong MB, Villarreal MF, McKean M, Azene E, Azarbal A, Barleben A, Chew DK, Clavijo LC, Douville Y, Findeiss L, Garg N, Gasper W, Giles KA, Goodney PP, Hawkins BM, Herman CR, Kalish JA, Koopmann MC, Laskowski IA, Mena-Hurtado C, Motaganahalli R, Rowe VL, Schanzer A, Schneider PA, Siracuse JJ, Venermo M, Rosenfield K; BEST-CLI Investigators. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. N Engl J Med. 2022 Dec 22;387(25):2305-2316. doi: 10.1056/NEJMoa2207899

13. Neville RF, Sam II AD, Sidawy AN. Chapter-61 Open Surgical Technique. Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:771-89; 2023, Elsevier, Philadelphia PA, USA
14. Menard MT, Sharma G, Belkin M. Chapter-109 Aortoiliac Disease: Direct Reconstruction. Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:1434-51; 2023, Elsevier, Philadelphia PA, USA
15. Szilagyi DE, Elliott JP Jr, Smith RF, Reddy DJ, McPharlin M. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. J Vasc Surg. 1986;3(3):421-36. doi: 10.1067/mva.1986.avs0030421
16. Tanaka A, Sandhu HK, Perlick A, Miller CC 3rd, Saqib NU, Safi HJ, Charlton-Ouw KM. Superficial Femoral Artery Occlusion Reduces Aortofemoral Bypass Graft Patency. Eur J Vasc Endovasc Surg. 2019;57(5):650-657. doi: 10.1016/j.ejvs.2018.10.031
17. Squizzato F, D'Oria M, Bozza R, Porcellato L, Grego F, Lepidi S. Propensity-Matched Comparison of Endovascular versus Open Reconstruction for TASC-II C/D Aortoiliac Occlusive Disease. A Ten-Year Single-Center Experience with Self-Expanding Covered Stents. Ann Vasc Surg. 2021 Feb;71:84-95. doi: 10.1016/j.avsg.2020.08.139
18. Smith AH, Beach JM, Dash S, Rowse J, Parodi FE, Kirksey L, Caputo FJ, Lyden SP, Smolock CJ. Comparison of Aortobifemoral Bypass to Aortoiliac Stenting with Bifurcation Reconstruction for TASC II D Aortoiliac Occlusive Disease. Ann Vasc Surg. 2022 May;82:120-130. doi: 10.1016/j.avsg.2021.10.040
19. Schneider J. Chapter-111 Aortoiliac Disease: Open Extra-Anatomic Bypass. Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:1434-51; 2023, Elsevier, Philadelphia PA, USA
20. Mills Sr JL. Chapter-112 Infrainguinal Disease: Surgical Treatment. Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:1476-501; 2023, Elsevier, Philadelphia PA, USA
21. Raptis S, Miller JH. Influence of a vein cuff on polytetrafluoroethylene grafts for primary femoropopliteal bypass. Br J Surg. 1995;82(4):487-91. doi: 10.1002/bjs.1800820419
22. Khalil AA, Boyd A, Griffiths G. Interposition vein cuff for infragenicular prosthetic bypass graft. Cochrane Database Syst Rev. 2012;2012(9):CD007921. doi: 10.1002/14651858.CD007921.pub2
23. Yeung KK, Mills JL Sr, Hughes JD, Berman SS, Gentile AT, Westerband A. Improved patency of infrainguinal polytetrafluoroethylene bypass grafts using a distal Taylor vein patch. Am J Surg. 2001;182(6):578-83. doi: 10.1016/s0002-9610(01)00791-7
24. Kluckner M, Gruber L, Wippel D, Lobenwein D, Westreicher W, Pilz M, Enzmann FK. Long-Term Outcome of Bypass Surgery versus Endovascular Revascularization in Long Femoropopliteal Lesions. J Clin Med. 2023;12(10):3507. doi: 10.3390/jcm12103507
25. Betz T, Ingolf T, Markus S, Florian Z, Christian U. Evaluation of Long-Term Outcomes of Femoropopliteal Bypass Surgery in Patients With Chronic Limb-Threatening Ischemia in an Endovascular Era. Ann Vasc Surg. 2022;79:191-200. doi: 10.1016/j.avsg.2021.06.046
26. Polat A. Bölüm A. Periferik Arter Hastalığı. Şu kitapta: Periferik Arter ve Ven Hastalıkları: Ulusal Tedavi Kılavuzu 2021. Ed: Bozkurt AK, 2021; pp:1-99, Türk Kalp ve Damar Cerrahisi Derneği, Ulusal Vasküler ve Endovasküler Cerrahi Derneği, Fleboloji Derneği, 2021, Baycınar Yayınevi, İstanbul.
27. Botelho FE, Cacione DG, Leite JO, Baptista-Silva JC. Endoluminal interventions versus surgical interventions for stenosis in vein grafts following infrainguinal bypass. Cochrane Database Syst Rev. 2021 28;4(4):CD013702. doi: 10.1002/14651858.CD013702.pub2
28. Yeh CC, Roddy SP, Daling III RC. Chapter-121 Upper Extremity Disease: Medical, Endovascular and Open Surgical Management. Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:1602-10; 2023, Elsevier, Philadelphia PA, USA
29. Lengyel BC, Chinnadurai P, Corr SJ, Lumsden AB, Bavare CS. Robot-assisted vascular surgery: literature review, clinical applications, and future perspectives. J Robot Surg. 2024;18(1):328. doi: 10.1007/s11701-024-02087-2
30. Lecot F, Sabbe T, Houthoofd S, Daenens K, Fourneau I. Long-term Results of Totally Laparoscopic Aortobifemoral Bypass. Eur J Vasc Endovasc Surg. 2016;52(5):581-587. doi: 10.1016/j.ejvs.2016.05.006
31. Ricco JB, Thaveau F. Chapter-64. Laparoscopic and Robotic Aortic Surgery. Şu kitapta: Rutherford's Vascular Surgery and Endovascular Therapy. 10th Ed. Sidawy AN, Perler BA Ed. pp:826-37; 2023, Elsevier, Philadelphia PA, USA
32. Sutter W, Alsac JM, Ben Abdallah I, Michel C, Julia P, Empana JP, El Batti S. Treatment of Aortoiliac Occlusive Lesions by Aortic Robotic Surgery: Learning Curve and Midterm Outcome. Ann Vasc Surg. 2024;104:258-267. doi: 10.1016/j.avsg.2024.02.018
33. Polat A. Femoropopliteal Arter Hastalıklarında Endovasküler Tedavi. Şu kitapta: Endovasküler. Eds.; Kavala AA, İnce İ, Bozkurt AK. 2024; pp:121-38, Kare Tanıtım Hizmetleri, İstanbul
34. Voûte MT, Stathis A, Schneider P. Ark. Delphi Consensus Study Toward a Comprehensive Classification System for Angioplasty-Induced Femoropopliteal Dissection: The DISFORM Study. JACC Cardiovasc Interv. 2021;14(21):2391-401. doi: 10.1016/j.jcin.2021.07.056
35. Polat A. Bölüm-12. Stentler. Şu kitapta: Endovasküler Cerrahiye Giriş: Temel Tel ve Kateter Teknikleri. Ed. Polat A, pp:117-26; 2016, Türk Kalp ve Damar Cerrahisi Derneği, İstanbul, Türkiye
36. Kavala AA, Toz H. Aortiliyak Periferik Arter Hastalığında Endovasküler Girişimler. Şu kitapta: Endovasküler. Eds.; Kavala AA, İnce İ, Bozkurt AK. 2024; pp:105-120, Kare Tanıtım Hizmetleri, İstanbul
37. Polat A. Bölüm-14. İleri Teknik Uygulamalar ve Yeni Malzemeler. Şu kitapta: Endovasküler Cerrahiye Giriş: Temel Tel ve Kateter Teknikleri. Ed. Polat A, pp:147-53; 2016, Türk Kalp ve Damar Cerrahisi Derneği, İstanbul, Türkiye

38. Ormiston W, Dyer-Hartnett S, Fernando R, Holden A. An update on vessel preparation in lower limb arterial intervention. *CVIR Endovasc*. 2020;3(1):86. doi: 10.1186/s42155-020-00175-6
39. Tepe G, Brodmann M, Werner M, ve ark; Disrupt PAD III Investigators. Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial. *JACC Cardiovasc Interv*. 2021 Jun 28;14(12):1352-1361. doi: 10.1016/j.jcin.2021.04.010
40. Nordanstig J, Behrendt CA, Baumgartner I, ve ark. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. *Eur J Vasc Endovasc Surg*. 2024;67(1):9-96. doi: 10.1016/j.ejvs.2023.08.067
41. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR; IN. PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. *Circulation*. 2015;131(5):495-502. doi: 10.1161/CIRCULATIONAHA.114.011004
42. Laird JA, Schneider PA, Jaff MR, Brodmann M, Zeller T, Metzger DC, Krishnan P, Scheinert D, Micari A, Wang H, Masters M, Tepe G. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. *Circ Cardiovasc Interv*. 2019;12(6):e007702. doi: 10.1161/CIRCINTERVENTIONS.118.007702
43. Gouëffic Y, Torsello G, Zeller T, Esposito G, Vermassen F, Hausegger KA, Tepe G, Thieme M, Gschwandtner M, Kahlberg A, Schindewolf M, Sapoval M, Diaz-Cartelle J, Stavroulakis K; EMINENT Investigators. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial. *Circulation*. 2022;146(21):1564-1576. doi: 10.1161/CIRCULATIONAHA.122.059606
44. Real-world registry shows sustained efficacy for Eluvia DES in the SFA. Şu internet sitesinde: <https://interventionalnews.com/real-world-registry-shows-sustained-efficacy-for-eluvia-des-in-the-sfa/> (son ziyaret tarihi: 11 Haziran 2025)
45. Behrendt CA, Sigvant B, Kuchenbecker J, Grima MJ, Schermerhorn M, Thomson IA, et al. Editor's choice-international variations and sex disparities in the treatment of peripheral arterial occlusive disease: A report from VASCUNET and the International Consortium of Vascular Registries. *Eur J Vasc Endovasc Surg*. 2020;60:873-80.
46. Klapshak S, Buettner S, Ultee KH, van Rijn MJ, Hoeks SE, Verhagen HJ. Combination of endovascular revascularization and supervised exercise therapy for intermittent claudication: A systematic review and meta-analysis. *J Cardiovasc Surg (Torino)* 2018;59:150-7.
47. Rocha-Singh KJ, Beckman JA, Ansel G, Lyden SP, Schneider P, Mehta M, et al. Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation. *Catheter Cardiovasc Interv* 2017;89:1250-6
48. Küçükler ŞA. Revaskularizasyon yöntemleri. In: Bozkurt AK, editor. *Periferik Arter ve Ven Hastalıkları: Ulusal Tedavi Kılavuzu* 2016. Bölüm I.5.E. İstanbul: Baycınar Tıbbi Yayınevi; 2016. s. 63-84
49. Anantha-Narayanan M, Sheikh AB, Nagpal S, Jelani QU, Smolderen KG, Regan C, et al. Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease. *J Vasc Surg* 2021;73:331-40.e4.
50. Dayama A, Tsilimparis N, Kolakowski S, Matolo NM, Humphries MD. Clinical outcomes of bypass-first versus endovascular-first strategy in patients with chronic limb-threatening ischemia due to infrageniculate arterial disease. *J Vasc Surg* 2019;69:156-63.e1.
51. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fittidge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. *Eur J Vasc Endovasc Surg* 2019;58:S1-S109.e33
52. Darling JD, Bodewes TCF, Deery SE, Guzman RJ, Wyers MC, Hamdan AD, et al. Outcomes after first-time lower extremity revascularization for chronic limb-threatening ischemia between patients with and without diabetes. *J Vasc Surg* 2018;67:1159-69.
53. Hsu CC, Kwan GN, Singh D, Rophael JA, Anthony C, van Driel ML. Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischemia. *Cochrane Database Syst Rev* 2018;12:CD009195
54. Lavingia KS, Tran K, Dua A, Itoga N, Deslarzes-Dubuis C, Mell M, et al. Multivessel tibial revascularization does not improve outcomes in patients with critical limb ischemia. *J Vasc Surg* 2020;71:2083-8
55. Giannopoulos S, Jeon-Slaughter H, Kahlon RS, Tejani I, Baskar A, Banerjee S, et al. Comparative 12-month outcomes of drug-coated balloon versus non-drug-coated balloon revascularization strategy in chronic limb-threatening ischemia: Results from the XLPAD Registry. *Cardiovasc Revasc Med* 2020;21:1276-84
56. Giannopoulos S, Ghanian S, Parikh SA, Secemsky EA, Schneider PA, Armstrong EJ. Safety and efficacy of drug-coated balloon angioplasty for the treatment of chronic limb-threatening ischemia: A systematic review and meta-analysis. *J Endovasc Ther* 2020;27:647-57.
57. Bradbury AW, Hall JA, Popplewell MA, Meecham L, Bate GR, Kelly L, Deeks JJ, Moakes CA; BASIL-3 Investigators. Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial. *BMJ*. 2025;388:e080881. doi: 10.1136/bmj-2024-080881
58. McGinagle KL, Zhou CW, Freeman NLB, Conte MS, Strong MB, Barshes N, Bonaca M, Farber A, Rosenfield K, Menard MT. Anatomic Profile of Arterial Occlusive Disease in the BEST-CLI Trial. *J Vasc Surg*. 2025 Jun 18:S0741-5214(25)01360-6. doi: 10.1016/j.jvs.2025.06.019. Epub ahead of print
59. Mufarrih SH, Khan MS, Qureshi NQ, Akbar MS, Kazimuddin M, Goldsweig AM, Goodney PP, Aronow HD. An Endovascular- Versus a Surgery-First Revascularization Strategy for Chronic Limb-Threatening Ischemia: A Meta-Analysis of Randomized Controlled Trials. *Am J Cardiol*. 2024;214:149-156. doi: 10.1016/j.amjcard.2024.01.007

- 60 Reijnen MMPJ, van Wijck I, Zeller T, Micari A, Veroux P, Keirse K, et al. Outcomes after drug-coated balloon treatment of femoropopliteal lesions in patients with critical limb ischemia: A post hoc analysis from the IN. PACT Global Study. *J Endovasc Ther* 2019;26:305-15
- 61 Conte MS. Appropriate use of revascularization for claudication. *J Vasc Surg* 2020;71:131.
- 62 Sorber R, Alshaikh HN, Nejim B, Abularrage CJ, Black JH 3rd, Malas MB, et al. Quantifying the riskadjusted hospital costs of postoperative complications after lower extremity bypass in patients with claudication. *J Vasc Surg* 2020;S0741-5214(20)32016-4
- 63 Dakhel A, Zarrouk M, Ekelund J, Acosta S, Nilsson P, Miftaraj M, et al. Worse cardiovascular prognosis after endovascular surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes. *Ther Adv Endocrinol Metab* 2020;11:2042018820960294
- 64 Fakhry F, Fokkenrood HJ, Spronk S, Teijink JA, Rouwet EV, Hunink MGM. Endovascular revascularisation versus conservative management for intermittent claudication. *Cochrane Database Syst Rev* 2018;3:CD010512
- 65 Jansen SCP, van Nistelrooij LPJ, Scheltinga MRM, Rouwet EV, Teijink JAW, Vahl AC. Successful implementation of the exercise first approach for intermittent claudication in the Netherlands is associated with few lower limb revascularisations. *Eur J Vasc Endovasc Surg* 2020;60:881-7.
- 66 Hicks CW, Holscher CM, Wang P, Black JH 3rd, Abularrage CJ, Makary MA. Overuse of early peripheral vascular interventions for claudication. *J Vasc Surg* 2020;71:121-30.e1.
- 67 Raja A, Song Y, Li S, Parikh SA, Saab F, Yeh RW, Secemsky EA. Variations in Revascularization Strategies for Chronic Limb-Threatening Ischemia: A Nationwide Analysis of Medicare Beneficiaries. *JACC Cardiovasc Interv.* 2025 Feb 10;18(3):352-363. doi: 10.1016/j.jcin.2024.09.024
- 68 Mullins CH, Novak Z, Axley JC, Sutzko DC, Spangler EL, Pearce BJ, et al. Prevalence and outcomes of endovascular infrapopliteal interventions for intermittent claudication. *Ann Vasc Surg* 2021;70:79-86
- 69 Galyfos GC, Kakisis I, Maltezos C, Geroulakos G. Open versus endovascular treatment of subclavian artery atherosclerotic disease. *J Vasc Surg* 2019;69:269-79.e7.



KAROTİD ARTER HASTALIKLARI VE CERRAHİ TEDAVİSİ

BÖLÜM 84

Sadettin DERNEK ¹
Aykut ŞAHİN ²


DOI: 10.37609/akya.3889.c5406

İçindekiler


- » GİRİŞ
- » TARİHÇE
- » ANATOMİ
- » EPİDEMİYOLOJİ VE RİSK FAKTÖRLERİ
 - » Patofizyoloji
- » BULGULAR
- » TANI YÖNTEMLERİ
- » CERRAHİ TEDAVİ ENDİKASYONLARI
 - » Semptomatik Hastalar
 - » Asemptomatik Hastalar
- » CERRAHİ TEDAVİ SEÇENEKLERİ
- » CERRAHİ TEDAVİ
 - » İntraoperatif Monitorizasyon ve Değerlendirme
- » POSTOPERATİF KOMPLİKASYONLAR
 - » Karotid Arter Stentleme (KAS)
- » KAS İÇİN KONTRAENDİKASYONLAR
- » KAS RİSK DEĞERLENDİRMESİ
- » ENDOVASKÜLER TEKNİK
- » KOMPLİKASYONLAR

¹ Prof. Dr., Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., sdernek26@gmail.com, ORCID iD: 0000-0002-0865-7694

² Doç. Dr., Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi AD., draykutsahin@gmail.com, ORCID iD: 0000-0003-3731-6327



Şekil 2 64 yaşında erkek hasta. 1 hafta önce sağ tarafta güçsüzlük ve konuşma bozukluğu. Şuanki muayenesi normal. A. Sol İKA bulbus distalinde %90 darlık. B. Predilatasyon anjioplasti. C. Stent yerleştirildikten sonra gelişen vazospazm için intraarteriyel vazodilatattör tedavi verildi. Ve ardından balon anjioplasti yapıldı. D. Lezyonda tama yakın açıklık sağlandı.*(Doç.Dr. Özlem Aykaç tarafından hazırlanmıştır)



Şekil 3. 65 yaşında asemptomatik erkek hasta. A. Sağ İKA 'da bulbus seviyesinde %70, ülseratif plak B. Sol İKA oklüde izleniyor C. Sağ KKA'dan enjeksiyonla sol MCA kısmen dolum gösteriyor E. Sağ İKA darlığına stent ve balon anjioplasti ile endovasküler müdahale yapıldı.* (Doç.Dr. Özlem Aykaç tarafından hazırlanmıştır)

nadir bir komplikasyonudur. %0,67 intraserebral kanamaya neden olabilir. İlk semptom genellikle baş ağrısıdır. Fokal nöbetler, intraserebral kanama izlenebilir. İşlem sırasında hipertansiyon sendromunun önemli bir prediktörüdür. Bu nedenle, işlem sırasında yakın kan basıncı takibi önemlidir.

Vazospazm özellikle stentin açılması sonrası veya distal koruma cihazına bağlı gelişebilir. Nitrogliserin gibi intraarteriyel vazodilatörlerle tedavi edilebilir.

Diğer komplikasyonlar arasında myokard infarktüsü, böbrek yetmezliği, erişimle ilgili problemler (kanama, psödoanevrizma, distal ateroembolizasyon), stentin restenozu ve karotis stent kırığı yer almaktadır.

KAYNAKLAR

1. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, vd. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation. 26 Temmuz 2011;124(4):489-532.
2. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, vd. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American

- Stroke Association. *Stroke*. Şubat 2011;42(2):517-84.
3. Karami M, Eriksen E, Ouweneel DM, Claessen BE, Vis MM, Baan J, vd. Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. *Eur Heart J Acute Cardiovasc Care*. 06 Aralık 2021;10(9):1009-15.
 4. Ferguson GG, Eliasziw M, Barr HW, Clagett GP, Barnes RW, Wallace MC, vd. The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients. *Stroke*. Eylül 1999;30(9):1751-8.
 5. Gaca JG, Sheng S, Daneshmand M, Rankin JS, Williams ML, O'Brien SM, vd. Current outcomes for tricuspid valve infective endocarditis surgery in North America. *Ann Thorac Surg*. 2013;96(4):1374-81.
 6. Warlow C. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. *The Lancet*. 25 Mayıs 1991;337(8752):1235-43.
 7. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, vd. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation*. 05 Mart 2019;139(10):e56-528.
 8. Long-term outcomes of eversion and conventional carotid endarterectomy: A multicenter clinical trial - Yuri V Belov, Anton N Kazantsev, Roman A Vinogradov, Alexander V Korotkikh, 2023 [Internet]. [a.yer 02 Haziran 2025]. Erişim adresi: <https://journals.sagepub.com/doi/abs/10.1177/17085381221084803>
 9. Kumar V, Ramachandran S, Sylaja P, Pitchai S. Conventional carotid endarterectomy with shunt versus eversion carotid endarterectomy without shunt does the technique influence the outcome in symptomatic critical carotid stenosis. *Asian J Neurosurg*. 16 Ağustos 2022;16:321-5.
 10. AbuRahma AF, Darling RC. Literature review of primary versus patching versus eversion as carotid endarterectomy closure*. *J Vasc Surg*. 01 Ağustos 2021;74(2):666-75.
 11. Wang Y, Li L, Wang T, Zhao L, Feng H, Wang Q, vd. The Efficacy of Near-Infrared Spectroscopy Monitoring in Carotid Endarterectomy: A Prospective, Single-Center, Observational Study. *Cell Transplant*. Şubat 2019;28(2):170-5.
 12. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet Lond Engl*. 09 Mayıs 1998;351(9113):1379-87.
 13. Henry M, Gopalakrishnan L, Rajagopal S, Rath PC, Henry I, Hugel M. Bilateral carotid angioplasty and stenting. *Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv*. Mart 2005;64(3):275-82.
 14. The risks and benefits of carotid endarterectomy in patients with near occlusion of the carotid artery | *Neurology* [Internet]. [a.yer 10 Haziran 2025]. Erişim adresi: <https://www.neurology.org/doi/abs/10.1212/WNL.48.4.911>
 15. McCrory DC, Goldstein LB, Samsa GP, Oddone EZ, Landsman PB, Moore WS, vd. Predicting complications of carotid endarterectomy. *Stroke*. Eylül 1993;24(9):1285-91.
 16. León Jorba A, Velescu A, Álvarez López-Herrero N, Mases Fernández A, Romero Montana L, Clarà Velasco A. Early detection of cranial nerve dysfunction during carotid endarterectomy through intraoperative neurophysiological monitoring. *Clin Neurophysiol*. 01 Nisan 2025;172:10-6.
 17. White CJ, Ramee SR, Collins TJ, Jenkins JS, Silva JA, Chan AW, vd. Carotid stents to prevent stroke: a non-surgical option. *Ochsner J*. 2003;5(1):18-23.
 18. Bijuklic K, Wandler A, Varnakov Y, Tuebler T, Schofer J. Risk factors for cerebral embolization after carotid artery stenting with embolic protection: a diffusion-weighted magnetic resonance imaging study in 837 consecutive patients. *Circ Cardiovasc Interv*. Haziran 2013;6(3):311-6.
 19. Mathur A, Roubin GS, Iyer SS, Piamsonboon C, Liu MW, Gomez CR, vd. Predictors of stroke complicating carotid artery stenting. *Circulation*. 07 Nisan 1998;97(13):1239-45.
 20. Moulakakis KG, Mylonas SN, Lazaris A, Tsvigoulis G, Kakisis J, Sfyroeras GS, vd. Acute Carotid Stent Thrombosis: A Comprehensive Review. *Vasc Endovascular Surg*. Ekim 2016;50(7):511-21.
 21. Lin PH, Zhou W, Koungias P, El Sayed HF, Barshes NR, Huynh TT. Factors associated with hypotension and bradycardia after carotid angioplasty and stenting. *J Vasc Surg*. Kasım 2007;46(5):846-53; discussion 853-854.



KRONİK VENÖZ YETMEZLİK

BÖLÜM 85

Suat DOĞANCI ¹
Tuna DEMİRKIRAN ²
Emre KUBAT ³

DOI: 10.37609/akya.3889.c5407

İçindekiler

- » GİRİŞ
- » EPİDEMİYOLOJİ VE RİSK FAKTÖRLERİ
- » KLİNİK
 - » Semptom ve Bulgular
 - » Hastalığın Doğal Seyri
- » TANI
 - » Venöz Doppler Ultrasonografi
 - » Kesitsel görüntüleme yöntemleri
 - » Endovenöz görüntüleme yöntemleri
- » TEDAVİ
 - » Medikal Tedavi
 - » Kompresyon tedavisi
 - » Aralıklı Pnömotik Kompresyon
 - » Endovasküler ve Cerrahi Tedavi
- » TERMAL ABLASYON TEKNİKLERİ
 - » Endovenöz Lazer Ablasyonu
 - » Radyofrekans Ablasyon
 - » Diğer Termal Yöntemler
 - » Komplikasyonlar
- » NON-TERMAL YÖNTEMLER
 - » Siyanoakrilat ile Kapama
 - » Mekanokimyasal Ablasyon
 - » Ultrason Eşliğinde Köpük Skleroterapi
- » YÜKSEK LİGASYON VE STRIPPING
- » ESTETİK FLEBOLOJİK YÖNTEMLER
 - » Skleroterapi
 - » Transkütan Lazer Tedavisi
 - » Kriyo-lazer Kriyo-skleroterapi (KLAKS)

¹ Prof. Dr., Prof. Dr. Suat Doğancı Muayenehanesi, suat_doganci@yahoo.com, ORCID iD: 0000-0001-7088-7151

² Uzm. Dr., Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, drtunademirkiran@gmail.com, ORCID iD: 0000-0001-5254-3339

³ Doç. Dr., Özel İskenderun Gelişim Hastanesi, ekubat@gmail.com, ORCID iD: 0000-0002-9884-8565

düşük doz enerji uygulanır. Lazer enerjisi damar duvarında selektif fototermoliz yoluyla ısı üretir ve damar kasılmasını, kısmi kapanmayı tetikler. Bu, tedavi etkinliğini artırır ve damar yapısının bozulmasını sağlar.

4. **Skleroterapi (Ks):** Soğuk uygulama altındayken sklerozan madde enjekte edilir. Soğuk sayesinde enjeksiyon sırasında ağrı azalır ve damar spazmı desteklenerek skleroterapinin etkisi artırılır. Sklerozan madde damar endotelinde hasar oluşturarak damar kapanmasını sağlar.

Perforan ven yetersizliği

Perforan ven yetmezliği, bazı olgularda primer reflü odağı olarak rol oynayabilirken, birçok durumda derin venöz sistemdeki bozulmalar ve genel venöz fonksiyon kaybının sekonder sonucu olarak gelişmektedir. Perforan ven yetmezliği, reflü süresi 350 milisaniyenin üzerinde olan geniş perforan damarları tanımlamak için kullanılmaktadır. Klinik C3-C6 evresindeki hastalarda öncelikle yüzeysel venöz sistemdeki patolojiler ile varsa eşlik eden derin venöz yetmezlik değerlendirilip tedavi edilmelidir. Bu sistemlerin başarılı bir şekilde tedavi edilmesini takiben, perforan venlerdeki patolojik reflü sıklıkla gerileyebilir. Ancak, belirli hasta gruplarında şikayetlerin devam etmesi ya da venöz ülserlerin yeterli iyileşme göstermemesi durumunda, perforan venlere yönelik girişimsel tedavilerin planlanması uygun bir yaklaşımdır. American Venous Forum'un 2020 yılında yayımladığı kılavuza göre, C4-C6 evresindeki hastalarda yüksek reflü hızına sahip ve çapı artmış perforan venlerin varlığı durumunda, girişimsel tedavi önerilmektedir. C3 evresinde ise, ödemin diğer olası nedenleri dışlandıktan sonra perforanlara yönelik müdahale planlanmalıdır. Ancak semptomu olmayan bireylerde, genişlemiş perforan ven varlığı tek başına ablasyon endikasyonu oluşturmamaktadır (57).

Perforan Ven Ligasyonu: Açık cerrahi ile yapılan PV ligasyonu, endovenöz seçeneklerin bulunmadığı durumlarda tercih edilebilir. Cerrahi öncesinde ultrason ile perforan venlerin işaretlenmesi önemlidir. Alternatif olarak, subkutanöz tortiyöz perforan ven dallarına yönelik flebektomi uygula-

nabilir. Ancak bu yöntemin başarı oranlarına dair veriler sınırlıdır.

Perforan Ven Ablasyonu: Endovenöz yöntemler arasında EVLA, RFA, MOCA, CAC ve UGFS yer alır. Perforan venlerin tortiyöz yapısı ve üzerindeki ciltte ülser varlığı, direkt girişimi zorlaştırabilir. Bu nedenle, komşu varisli damarlar üzerinden dolaylı giriş tercih edilebilir. RFA ve EVLA ile sağlanan kapatma oranları PV'lerde %60-80 arasında değişirken, bu oran trunkal venlerde genellikle >%90'dır. Perforan venlerde zamanla rekürrens görülebileceğinden, erken dönemde DUS takibi ve gerekirse yeniden müdahale önerilmektedir (94).

Diğer Teknikler: Subfasial endoskopik perforan ven cerrahisi, açık ligasyona minimal invaziv bir alternatiftir. Genel veya spinal anestezi gerektiren bu yöntemde, perforan venler subfasial olarak diatermi veya klipsle kesilir. Kapatma oranı endovenöz yöntemlere göre daha yüksek bildirilmiştir, ancak doğrudan karşılaştırma yapan bir çalışma bulunmamaktadır. Komplikasyonlar genellikle minör olup; hematoma, ağrı ve geçici sinir hasarı şeklindedir. Ciddi komplikasyonlar nadirdir (95).

KAYNAKLAR

1. Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P, American Venous Forum et al. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. *J Vasc Surg.* 2009;49(2):498-501.
2. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. *Circulation.* 2014;130(4):333-346.
3. Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. *Ann Surg.* 2021;274(6):971-976.
4. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quésada F, VCP Coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. *Int Angiol.* 2012;31(2):105-115.
5. Bozkurt AK. Kronik Venöz Hastalık Epidemiyolojisi. In: Bozkurt AK, ed. *Kronik Venöz Hastalıklar: Tanı ve Tedavi*. 1. baskı. İstanbul: Nobel Tıp Kitabevleri; 2016. p. 3-10.
6. Robertson LA, Evans CJ, Lee AJ, Allan PL, Ruckley CV, Fowkes FG. Incidence and risk factors for venous reflux in the general population: Edinburgh Vein Study. *Eur J Vasc Endovasc Surg.* 2014;48(2):208-214.
7. Allison MA, Cushman M, Callas PW, Denenberg JO, Jansky NE, Criqui MH. Adipokines are associated with lower extremity venous disease: the San Diego popula-

- tion study. *J Thromb Haemost.* 2010;8(9):1912–1918.
8. Fowkes FG, Lee AJ, Evans CJ, Allan PL, Bradbury AW, Ruckley CV. Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study. *Int J Epidemiol.* 2001;30(4):846–852.
 9. Fukaya E, Flores AM, Lindholm D, Gustafsson S, Zanetti D, Ingelsson E, et al. Clinical and genetic determinants of varicose veins. *Circulation.* 2018;138(25):2869–2880.
 10. Davies HO, Popplewell M, Singhal R, Smith N, Bradbury AW. Obesity and lower limb venous disease – The epidemic of phlebesity. *Phlebology.* 2017;32(4):227–233.
 11. Munger SJ, Geng X, Srinivasan RS, Witte MH, Paul DL, Simon AM. Segregated Foxc2, NFATc1 and Connexin expression at normal developing venous valves, and Connexin-specific differences in the valve phenotypes of Cx37, Cx43, and Cx47 knockout mice. *Dev Biol.* 2016;412(2):173–190.
 12. Kienzl P, Deinsberger J, Weber B. Chronic venous disease: pathophysiological aspects, risk factors, and diagnosis. *Hamostaseologie.* 2024;44(4):277–286.
 13. Fraile-Martinez O, García-Montero C, Gomez-Lahoz AM, Sainz F, Bujan J, Barrena-Blázquez S, et al. Evidence of inflammatory network disruption in chronic venous disease: an analysis of circulating cytokines and chemokines. *Biomedicines.* 2025;13(1):150.
 14. Meissner MH, Moneta G, Burnand K, Gloviczki P, Lohr JM, Lurie F, et al. The hemodynamics and diagnosis of venous disease. *J Vasc Surg.* 2007;46 Suppl S:4S–24S.
 15. Chiesa R, Marone EM, Limoni C, Volontè M, Petrini O. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. *J Vasc Surg.* 2007;46(2):322–330.
 16. Perrin M, Eklof B, van Rij A, Labropoulos N, Vasquez M, Nicolaides A, et al. Venous symptoms: the SYM Vein Consensus statement developed under the auspices of the European Venous Forum. *Int Angiol.* 2016;35(4):374–398.
 17. O'Donnell TF Jr, Passman MA. Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum—Management of venous leg ulcers. *J Vasc Surg.* 2014;60(2 Suppl):1S–2S.
 18. Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H, et al. The 2020 update of the CEAP classification system and reporting standards. *J Vasc Surg Venous Lymphat Disord.* 2020;8(3):342–352.
 19. Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA, Gillespie D, et al. Revision of the venous clinical severity score: venous outcomes consensus statement. *J Vasc Surg.* 2010;52(5):1387–1396.
 20. Kahn SR. Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome. *J Thromb Haemost.* 2009;7(5):884–888.
 21. Karahan O, Yavuz C, Kankilic N, Demirtas S, Tezcan O, Caliskan A, et al. Simple blood tests as predictive markers of disease severity and clinical condition in patients with venous insufficiency. *Blood Coagul Fibrinolysis.* 2016;27(6):684–690.
 22. Coleridge-Smith P, Labropoulos N, Partsch H, Myers K, Nicolaides A, Cavezzi A. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs—UIP consensus document. Part I. Basic principles. *Eur J Vasc Endovasc Surg.* 2006;31(1):83–92.
 23. De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. *Eur J Vasc Endovasc Surg.* 2022;63(2):184–267.
 24. Labropoulos N, Tiongson J, Pryor L, Tassiopoulos AK, Kang SS, Ashraf Mansour M, et al. Definition of venous reflux in lower-extremity veins. *J Vasc Surg.* 2003;38(4):793–798.
 25. Bach AM, Hann LE. When the common femoral vein is revealed as flattened on spectral Doppler sonography: is it a reliable sign for diagnosis of proximal venous obstruction? *AJR Am J Roentgenol.* 1997;168(3):733–736.
 26. Coelho A, O'Sullivan G. Usefulness of direct computed tomography venography in predicting inflow for venous reconstruction in chronic post-thrombotic syndrome. *Cardiovasc Intervent Radiol.* 2019;42(5):677–684.
 27. Lau I, Png CYM, Eswarappa M, Miller M, Kumar S, Tadros R, et al. Defining the utility of anteroposterior venography in the diagnosis of venous iliofemoral obstruction. *J Vasc Surg Venous Lymphat Disord.* 2019;7(4):514–521.e4.
 28. Gagne PJ, Tahara RW, Fastabend CP, Dzieciuchowicz L, Marston W, Vedantham S, et al. Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction. *J Vasc Surg Venous Lymphat Disord.* 2017;5(5):678–687.
 29. Christopoulos DG, Nicolaides AN, Szendro G, Irvine AT, Bull ML, Eastcott HH. Air-plethysmography and the effect of elastic compression on venous hemodynamics of the leg. *J Vasc Surg.* 1987;5(1):148–159.
 30. Gürdal Karakelle S, Ipek Y, Tulin O, Alpagut İÜ. The efficiency of exercise training in patients with venous insufficiency: a double blinded, randomized controlled trial. *Phlebology.* 2021;36(6):440–449.
 31. Silva KLS, Figueiredo EAB, Lopes CP, Vianna MVA, Lima VP, Figueiredo PHS, et al. The impact of exercise training on calf pump function, muscle strength, ankle range of motion, and health-related quality of life in patients with chronic venous insufficiency at different stages of severity: a systematic review. *J Vasc Bras.* 2021;20:e20200125.
 32. Padberg FT Jr, Johnston MV, Sisto SA. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. *J Vasc Surg.* 2004;39(1):79–87.
 33. Meulendijks AM, Franssen WMA, Schoonhoven L, Neumann HAM. A scoping review on chronic venous disease and the development of a venous leg ulcer: the role of obesity and mobility. *J Tissue Viability.* 2020;29(3):190–196.
 34. Alguire PC, Mathes BM. Chronic venous insufficiency and venous ulceration. *J Gen Intern Med.* 1997;12(6):374–383.
 35. Protz K, Dissemond J, Seifert M, Hintner M, Temme B, Verheyen-Cronau I, et al. Education in people with venous leg ulcers based on a brochure about compression therapy: a quasi-randomised controlled trial. *Int Wound J.* 2019;16(6):1252–1262.
 36. Žulec M, Rotar Pavlič D, Žulec A. The effect of an educational intervention on self-care in patients with venous leg ulcers: a randomized controlled trial. *Int J Environ Res Public Health.* 2022;19(8):4657.

37. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, De Maeseneer M, Eklof B, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. *Int Angiol.* 2018;37(3):181–254.
38. Blair SD, Wright DD, Backhouse CM, Riddle E, McColm CN. Sustained compression and healing of chronic venous ulcers. *BMJ.* 1988;297(6657):1159–1161.
39. Bergan JJ, Schmid-Schönbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. *N Engl J Med.* 2006;355(5):488–498.
40. Mosti G, Mattaliano V, Partsch H. Inelastic compression increases venous ejection fraction more than elastic bandages in patients with superficial venous reflux. *Phlebology.* 2008;23(6):287–294.
41. Nelson EA, Bell-Syer SE. Compression for preventing recurrence of venous ulcers. *Cochrane Database Syst Rev.* 2014;(9):CD002303.
42. Mayrovitz HN, Aoki KC, Colon J. Chronic venous insufficiency with emphasis on the geriatric population. *Cureus.* 2023;15(6):e40687.
43. Stevenson EM, Coda A, Bourke MDJ. Investigating low rates of compliance to graduated compression therapy for chronic venous insufficiency: a systematic review. *Int Wound J.* 2024;21(4):e14833.
44. Rabe E, Partsch H, Morrison N, Meissner MH, Mosti G, Lattimer CR, et al. Risks and contraindications of medical compression treatment—a critical reappraisal. An international consensus statement. *Phlebology.* 2020;35(7):447–460.
45. Stücker M, Rabe E. Medizinische Kompressionsstrümpfe bei chronischen venösen Erkrankungen und Lymphödem: wissenschaftliche Evidenz und Ergebnisse einer Patient*innen-Befragung zur Versorgungsqualität. *Dermatologie (Heidelb).* 2022;73(9):708–717.
46. Azirar S, Appelen D, Prins MH, Neumann MH, de Feiter AN, Kolbach DN. Compression therapy for treating post-thrombotic syndrome. *Cochrane Database Syst Rev.* 2019;9(9):CD004177.
47. Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, et al. Phlebotonics for venous insufficiency. *Cochrane Database Syst Rev.* 2020;11(11):CD003229.
48. Chen L, Gao Y, Liu M, Li Q, Han C, Zhao Y, et al. Efficacy and safety of pentoxifylline for chronic venous leg ulcers: study protocol for a multicenter randomized controlled trial in China (ESPECT study). *Trials.* 2023;24(1):491.
49. Urbanek T, Krasinski Z, Sumińska-Jasińska K, Baum E, Borej-Nowicka G, Begier-Krasińska B, et al. Sulodexide reduces the inflammatory reaction and senescence of endothelial cells in conditions involving chronic venous disease. *Int Angiol.* 2016;35(2):140–147.
50. Siddiqui F, Hoppensteadt D, Bontekoe E, Farooqui A, Jeske W, Fareed J. Comparative anticoagulant and thrombin generation inhibitory profile of heparin, sulodexide and its components. *Clin Appl Thromb Hemost.* 2020;26:1076029620954913.
51. Wu B, Lu J, Yang M, Xu T. Sulodexide for treating venous leg ulcers. *Cochrane Database Syst Rev.* 2016;(6):CD010694.
52. Jull A, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. *Cochrane Database Syst Rev.* 2007;(3):CD001733.
53. Helen T, Liz C, Laura C, Illary S, Martin B, Hannah B, et al. Aspirin versus placebo for the treatment of venous leg ulcers—a phase II, pilot, randomised trial (AVURT). *Trials.* 2019;20(1):459.
54. Carradice D, Wallace T, Gohil R, Chetter I. A comparison of the effectiveness of treating those with and without the complications of superficial venous insufficiency. *Ann Surg.* 2014;260(2):396–401.
55. Michaels JA, Brazier JE, Campbell WB, MacIntyre JB, Palfreyman SJ, Ratcliffe J. Randomized clinical trial comparing surgery with conservative treatment for uncomplicated varicose veins. *Br J Surg.* 2006;93(2):175–181.
56. Marsden G, Perry M, Bradbury A, Hickey N, Kelley K, Trender H, et al. A cost-effectiveness analysis of surgery, endothermal ablation, ultrasound-guided foam sclerotherapy and compression stockings for symptomatic varicose veins. *Eur J Vasc Endovasc Surg.* 2015;50(6):794–801.
57. Masuda E, Ozsvath K, Vossler J, Woo K, Kistner R, Lurie F, et al. The 2020 appropriate use criteria for chronic lower extremity venous disease of the American Venous Forum, the Society for Vascular Surgery, the American Vein and Lymphatic Society, and the Society of Interventional Radiology. *J Vasc Surg Venous Lymphat Disord.* 2020;8(4):505–525.e4.
58. Doganci S, Demirkilic U. Comparison of 980 nm laser and bare-tip fibre with 1470 nm laser and radial fibre in the treatment of great saphenous vein varicosities: a prospective randomised clinical trial. *Eur J Vasc Endovasc Surg.* 2010;40(2):254–259.
59. Shutze WP, Kane K, Fisher T, Doud Y, Lassiter G, Leuking R, et al. The effect of wavelength on endothermal heat-induced thrombosis incidence after endovenous laser ablation. *J Vasc Surg Venous Lymphat Disord.* 2016;4(1):36–43.
60. Teter KA, Kabnick LS, Sadek M. Endovenous laser ablation: a comprehensive review. *Phlebology.* 2020;35(9):656–662.
61. Malskat WSJ, Engels LK, Hollestein LM, Nijsten T, van den Bos RR. Commonly used endovenous laser ablation (EVLA) parameters do not influence efficacy: results of a systematic review and meta-analysis. *Eur J Vasc Endovasc Surg.* 2019;58(2):230–242.
62. Proebstle TM, Alm BJ, Göckeritz O, Wenzel C, Noppene T, Lebard C, et al. Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. *Br J Surg.* 2015;102(3):212–218.
63. Wright TF, Brunetti GF, Kennedy P. Lidocaine safety after saphenous vein tumescent anesthesia. *Phlebology.* 2019;34(10):683–689.
64. Milleret R, Huot L, Nicolini P, Creton D, Roux AS, Decullier E, et al. Great saphenous vein ablation with steam injection: results of a multicentre study. *Eur J Vasc Endovasc Surg.* 2013;45(4):391–396.
65. Yang L, Wang XP, Su WJ, Zhang Y, Wang Y. Randomized clinical trial of endovenous microwave ablation combined with high ligation versus conventional surgery for varicose veins. *Eur J Vasc Endovasc Surg.* 2013;46(4):473–479.
66. Healy DA, Kimura S, Power D, Elhaj A, Abdeldaim Y, Cross KS, et al. A systematic review and meta-analysis of thrombotic events following endovenous thermal ablation of the great saphenous vein. *Eur J Vasc Endovasc Surg.* 2018;56(3):410–424.

67. Kubat E, Ünal CS, Geldi O, Çetin E, Keskin A. What is the optimal treatment technique for great saphenous vein diameter of ≥ 10 mm? Comparison of five different approaches. *Acta Chir Belg.* 2021;121(2):94–101.
68. Chan YC, Law Y, Cheung GC, Ting AC, Cheng SW. Cyanoacrylate glue used to treat great saphenous reflux: measures of outcome. *Phlebology.* 2017;32(2):99–106.
69. Gibson K, Ferris B. Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: initial outcomes of a post-market evaluation of the VenaSeal System (the WAVES Study). *Vascular.* 2017;25(2):149–156.
70. Proebstle TM, Alm J, Dimitri S, Rasmussen L, Whiteley M, Lawson J, et al. The European multicenter cohort study on cyanoacrylate embolization of refluxing great saphenous veins. *J Vasc Surg Venous Lymphat Disord.* 2015;3(1):2–7.
71. Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. *J Vasc Surg Venous Lymphat Disord.* 2020;8(6):978–989.
72. Bozkurt AK. Cyanoacrylate glue is an effective alternative in chronic venous insufficiency. *Phlebology.* 2024;39(7):498–499.
73. Bozkurt AK, Balkanay OO, Dinc R. Comparative analysis of VenaBlock and VenaSeal systems for catheter-guided endovenous cyanoacrylate closure in treating chronic venous insufficiency of the lower extremity: effectiveness and feasibility. *Int Angiol.* 2024;43(3):331–341.
74. Kubat E, Kadan M, Akyol FB, Doğanç S. Large diameter is associated with high recanalization rate during cyanoacrylate closure treatment of great saphenous vein insufficiency. *Dermatol Surg.* 2022;48(2):263.
75. Gibson K, Minjarez R, Rinehardt E, Ferris B. Frequency and severity of hypersensitivity reactions in patients after VenaSeal cyanoacrylate treatment of superficial venous insufficiency. *Phlebology.* 2020;35(5):337–344.
76. Cho S, Gibson K, Lee SH, Kim SY, Joh JH. Incidence, classification, and risk factors of endovenous glue-induced thrombosis after cyanoacrylate closure of the incompetent saphenous vein. *J Vasc Surg Venous Lymphat Disord.* 2020;8(6):991–998.
77. Vos CG, Ünlü Ç, Bosma J, van Vlijmen CJ, de Nie AJ, Schreve MA. A systematic review and meta-analysis of two novel techniques of nonthermal endovenous ablation of the great saphenous vein. *J Vasc Surg Venous Lymphat Disord.* 2017;5(6):880–896.
78. Pappas JN, Pappas PJ, Lakhanpal S, Kennedy R, Soto T. Natural history and role of anticoagulation in the management of endovenous glue-induced thrombus. *J Vasc Surg Venous Lymphat Disord.* 2023;11(5):938–945.
79. AlHamzah M. Surgical treatment of persistent glue extension into common femoral vein following endovenous glue ablation. *Cureus.* 2024;16(3):e56364.
80. Lam YL, Toonder IM, Wittens CH. Clarivein mechano-chemical ablation: an interim analysis of a randomized controlled trial dose-finding study. *Phlebology.* 2016;31(3):170–176.
81. hierens N, Holewijn S, Vissers WH, Werson DA, de Vries JPPM, Reijnen MM. Five-year outcomes of mechano-chemical ablation of primary great saphenous vein incompetence. *Phlebology.* 2020;35(4):255–261.
82. Darvall KA, Bate GR, Bradbury AW. Patient-reported outcomes 5–8 years after ultrasound-guided foam sclerotherapy for varicose veins. *Br J Surg.* 2014;101(9):1098–1104.
83. Lim SY, Tan JX, D'Cruz RT, Syn N, Chong TT, Tang TY. Catheter-directed foam sclerotherapy, an alternative to ultrasound-guided foam sclerotherapy for varicose vein treatment: a systematic review and meta-analysis. *Phlebology.* 2020;35(6):369–383.
84. Rasmussen L, Lawaetz M, Bjoern L, Blemings A, Eklof B. Randomized clinical trial comparing endovenous laser ablation and stripping of the great saphenous vein with clinical and duplex outcome after 5 years. *J Vasc Surg.* 2013;58(2):421–426.
85. Whing J, Nandhra S, Nesbitt C, Stansby G. Interventions for great saphenous vein incompetence. *Cochrane Database Syst Rev.* 2021;8(8):CD005624.
86. Pan Y, Zhao J, Mei J, Shao M, Zhang J. Comparison of endovenous laser ablation and high ligation and stripping for varicose vein treatment: a meta-analysis. *Phlebology.* 2014;29(2):109–119.
87. van Rij AM, Chai J, Hill GB, Christie RA. Incidence of deep vein thrombosis after varicose vein surgery. *Br J Surg.* 2004;91(12):1582–1585.
88. Olivencia JA. Complications of ambulatory phlebectomy: review of 1000 consecutive cases. *Dermatol Surg.* 1997;23(1):51–54.
89. Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy: etiology, prevention, and treatment. *Dermatol Surg.* 1995;21(1):19–32.
90. Zhang J, Jing Z, Schliephake DE, Otto J, Malouf GM, Gu YQ. Efficacy and safety of Aethoxysklerol (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). *Phlebology.* 2012;27(4):184–190.
91. Rabe E, Breu FX, Cavezzi A, Coleridge Smith P, Frullini A, Gillet JL, et al. European guidelines for sclerotherapy in chronic venous disorders. *Phlebology.* 2014;29(6):338–354.
92. Adamić M, Pavlović MD, Troilius Rubin A, Palmertun-Ekback M, Boixeda P. Guidelines of care for vascular lasers and intense pulse light sources from the European Society for Laser Dermatology. *J Eur Acad Dermatol Venereol.* 2015;29(9):1661–1678.
93. Miyake RK, Chi YW, Franklin IJ, Ganesini S. State of the art on cryo-laser cryo-sclerotherapy in lower limb venous aesthetic treatment. *J Vasc Surg Venous Lymphat Disord.* 2020;8(5):893–895.
94. Nelzén O, Fransson I. Varicose vein recurrence and patient satisfaction 10–14 years following combined superficial and perforator vein surgery: a prospective case study. *Eur J Vasc Endovasc Surg.* 2013;46(3):372–377.
95. Lin ZC, Loveland PM, Johnston RV, Bruce M, Weller CD. Subfascial endoscopic perforator surgery (SEPS) for treating venous leg ulcers. *Cochrane Database Syst Rev.* 2019;3(3):CD012164.



POST-TROMBOTİK SENDROM

BÖLÜM 86

Suat DOĞANCI ¹
Alperen Kutay YILDIRIM ²
Emre KUBAT ³

DOI: 10.37609/akya.3889.c5408

İçindekiler

- » GİRİŞ
- » PATOFİZYOLOJİ
- » EPİDEMİYOLOJİ
 - » Post-trombotik Sendrom için Risk Faktörleri
- » TANI
 - » Semptom ve Bulgular
 - » Skarlama Sistemleri
 - » Görüntüleme Yöntemleri
- » TEDAVİ
 - » Yaşam Tarzı Değişiklikleri
 - » Kompresyon Tedavisi
 - » Farmakolojik Tedavi
 - » Girişimsel Tedavi
- » POST-TROMBOTİK SENDROMDA HASTA TAKİBİ
- » PTS'NİN AZ GÖRÜLDÜĞÜ DİĞER DURUMLAR
 - » Pediyatrik Yaş Grubunda Post-Trombotik Sendrom
 - » Üst Ekstremitte Post-Trombotik Sendrom

¹ Prof. Dr., Prof. Dr. Suat Doğancı Muayenehanesi, suat_doganci@yahoo.com, ORCID iD: 0000-0001-7088-7151

² Uzm. Dr., Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, drayildirim@yahoo.com, ORCID iD: 0000-0002-2282-0291

³ Doç. Dr., Özel İskenderun Gelişim Hastanesi, ekubat@gmail.com, ORCID iD: 0000-0002-9884-8565

kullanımında yorgunluk, ağrı ve fonksiyonel kısıtlılık ile üç klinik bulgu (çap farkıyla ölçülen şişlik, renk değişikliği, kollateral venler) içeren yeni bir skor önerilmiştir. Bu bulguların her biri 0–3 arası puanlanarak toplam skor belirlenmekte, ayrıca işlevsel yeti kaybını ölçen bir değerlendirme ile birlikte kullanılmaktadır. Bununla birlikte, UE-PTS tanısı esasen klinik bulgulara dayanmakta olup, görüntüleme yöntemlerinin (dupleks ultrasonografi, BT venografi) tanısallık değeri konusunda fikir birliği bulunmamaktadır. Bu nedenle UE-PTS'nin tanısında standardize edilmiş görüntüleme kullanımına dair net öneriler geliştirilmemiştir (191).

Tedavi konusunda da belirsizlikler sürmektedir. Alt ekstremitte PTS için önerilen kompresyon tedavisinin üst ekstremitteye uygulanabilirliği konusunda yeterli veri bulunmamaktadır. ÜED-VT sonrası PTS gelişimini önlemek amacıyla bazı kliniklerde mezoklaviküler bölgede balon anjiyoplasti veya stentleme uygulanmaktadır. Ancak, klavikula altı yerleşimli stentlerin kırılma riski, bu bölgede stent kullanımını sınırlamaktadır. Özellikle ilk kosta rezeksiyonu ile birlikte yapılan cerrahi girişimlerde başarı oranlarının yüksek olduğu bildirilmektedir (194). Bu nedenle, kronik ÜEDVT tedavisinde öncelikle balon anjiyoplasti tercih edilmeli, ancak dirençli lezyonlarda dikkatli seçilmiş vakalarda stentleme düşünülmelidir.

KAYNAKLAR

- Kahn SR. How I treat postthrombotic syndrome. *Blood*. 2009;114(21): 4624–4631. doi: 10.1182/blood-2009-07-199174
- Kahn SR. The post-thrombotic syndrome. *Hematology*. 2016;2016(1): 413–418. doi: 10.1182/asheducation-2016.1.413
- Vedantham S. Valvular dysfunction and venous obstruction in the post-thrombotic syndrome. *Thrombosis Research*. 2009;123(SUPPL. 4): S62–S65. doi: 10.1016/s0049-3848(09)70146-x
- Bergan JJ, Schmid-Schönbein GW, Smith PDC, et al. Chronic Venous Disease. *New England Journal of Medicine*. 2006;355(5): 488–498. doi: 10.1056/NEJMra055289
- Takase S, Pascarella L, Lerond L, et al. Venous Hypertension, Inflammation and Valve Remodeling. *European Journal of Vascular and Endovascular Surgery*. 2004;28(5): 484–493. doi: 10.1016/j.ejvs.2004.05.012
- Tarbell JM, Cancel LM. The glycocalyx and its significance in human medicine. *Journal of Internal Medicine*. 2016;280(1): 97–113. doi: 10.1111/joim.12465
- Castro-Ferreira R, Cardoso R, Leite-Moreira A, et al. The Role of Endothelial Dysfunction and Inflammation in Chronic Venous Disease. *Annals of Vascular Surgery*. 2018;46: 380–393. doi: 10.1016/j.avsg.2017.06.131
- Chandrasekar A, Garry J, Gasparis A, et al. Vein wall remodeling in patients with acute deep vein thrombosis and chronic postthrombotic changes. *Journal of Thrombosis and Haemostasis*. 2017;15(10): 1989–1993. doi: 10.1111/jth.13793
- Deatrick KB, Elflin M, Baker N, et al. Postthrombotic vein wall remodeling: Preliminary observations. *Journal of Vascular Surgery*. 2011;53(1): 139–146. doi: 10.1016/j.jvs.2010.07.043
- Rabinovich A, Cohen JM, Kahn SR. The predictive value of markers of fibrinolysis and endothelial dysfunction in the post thrombotic syndrome. *Thrombosis and Haemostasis*. 2014;111(06): 1031–1040. doi: 10.1160/th13-11-0931
- Henke PK, Varga A, De S, et al. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2004;24(6): 1130–1137. doi: 10.1161/01.atv.0000129537.72553.73
- Baker SK, Strickland S. A critical role for plasminogen in inflammation. *Journal of Experimental Medicine*. 2020;217(4). doi: 10.1084/JEM.20191865
- Deatrick KB, Eliason JL, Lynch EM, et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. *Journal of Vascular Surgery*. 2005;42(1): 140–148. doi: 10.1016/j.jvs.2005.04.014
- Wakefield TW, Myers DD, Henke PK. Mechanisms of Venous Thrombosis and Resolution. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2008;28(3): 387–391. doi: 10.1161/atvbaha.108.162289
- Nguyen KP, McGilvray KC, Puttlitz CM, et al. Matrix Metalloproteinase 9 (MMP-9) Regulates Vein Wall Biomechanics in Murine Thrombus Resolution. Sen U, editor. *PLOS ONE*. 2015;10(9): e0139145. doi: 10.1371/journal.pone.0139145
- Deatrick KB, Obi A, Luke CE, et al. Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT. *Thrombosis Research*. 2013;132(3): 360–366. doi: 10.1016/j.thromres.2013.06.027
- Obi AT, Diaz JA, Ballard-Lipka NL, et al. Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitro-nectin-dependent mechanism. *J Thromb Haemost*. 2014;12(8):1353–63. doi: 10.1111/jth.12644. Epub 2014 Jul 23.
- Henke PK, Comerota AJ. An update on etiology, prevention, and therapy of postthrombotic syndrome. *Journal of Vascular Surgery*. 2011;53(2): 500–509. doi: 10.1016/j.jvs.2010.08.050
- Myers DD, Henke PK, Wroblewski SK, et al. P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. *Journal of Vascular Surgery*. 2002;36(5): 928–938. doi: 10.1067/mva.2002.128636
- Wittens C, Davies AH, Bækgaard N, et al. Editor's Choice – Management of Chronic Venous Disease. *European Journal of Vascular and Endovascular Surgery*. 2015;49(6): 678–737. doi: 10.1016/j.ejvs.2015.02.007

21. Galanaud JP, Monreal M, Kahn SR. Epidemiology of the post-thrombotic syndrome. *Thrombosis Research*. 2018;164: 100–109. doi: 10.1016/j.thromres.2017.07.026
22. Galanaud JP, Righini M, Le Collen L, et al. Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study. *Journal of Thrombosis and Haemostasis*. 2020;18(4): 857–864. doi: 10.1111/jth.14728
23. Meissner MH, Zierler BK, Bergelin RO, et al. Coagulation, fibrinolysis, and recanalization after acute deep venous thrombosis. *Journal of Vascular Surgery*. 2002;35(2): 278–285. doi: 10.1067/mva.2002.121066
24. Snow V, Qaseem A, Barry P, et al. Management of Venous Thromboembolism: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. *The Annals of Family Medicine*. 2007;5(1): 74–80. doi: 10.1370/afm.668
25. Galanaud JP, Kahn SR, Khau Van Kien A, et al. Thromboses veineuses profondes distales isolées des membres inférieurs : Épidémiologie et prise en charge. *Revue de Medecine Interne*. 2012;33(12): 678–685. doi: 10.1016/j.revmed.2012.05.012
26. Galanaud JP, Kahn SR. The post-thrombotic syndrome: A 2012 therapeutic update. *Current Treatment Options in Cardiovascular Medicine*. 2013;15(2): 153–163. doi: 10.1007/S11936-012-0224-3
27. Kahn SR, Partsch H, Vedantham S, et al. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. *Journal of Thrombosis and Haemostasis*. 2009;7(5): 879–883. doi: 10.1111/j.1538-7836.2009.03294.x
28. Kolbach DN, Neumann HAM, Prins MH. Definition of the post-thrombotic syndrome, differences between existing classifications. *European Journal of Vascular and Endovascular Surgery*. 2005;30(4): 404–414. doi: 10.1016/j.ejvs.2005.06.006
29. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: A randomised placebo-controlled trial. *The Lancet*. 2014;383(9920): 880–888. doi: 10.1016/s0140-6736(13)61902-9,
30. Kahn SR. Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome. *Journal of Thrombosis and Haemostasis*. 2009;7(5): 884–888. doi: 10.1111/j.1538-7836.2009.03339.x
31. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. *Canadian Medical Association Journal*. 2008;179(5): 417–426. doi: 10.1503/cmaj.080493
32. ten Cate-Hoek AJ, ten Cate H, Tordoir J, Hamulyák K, Prins MH. Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome. *Journal of Vascular Surgery*. 2010;52(1): 132–138. doi: 10.1016/j.jvs.2010.01.089
33. Galanaud JP, Holcroft CA, Rodger MA, et al. Comparison of the Villalta post-thrombotic syndrome score in the ipsilateral vs. Contralateral leg after a first unprovoked deep vein thrombosis. *Journal of Thrombosis and Haemostasis*. 2012;10(6): 1036–1042. doi: 10.1111/j.1538-7836.2012.04713.x
34. Galanaud JP, Ducruet T, Kahn SR. Accuracy of contralateral Villalta score to assess for pre-existing chronic venous insufficiency in patients with unilateral deep vein thrombosis. *Journal of Thrombosis and Haemostasis*. 2020;18(12): 3309–3315. doi: 10.1111/jth.15091
35. Haig Y, Enden T, Grøtta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. *The Lancet Haematology*. 2016;3(2): e64–e71. doi: 10.1016/S2352-3026(15)00248-3
36. Cheung YW, Middeldorp S, Prins MH, et al. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis: A post-hoc analysis. *Thrombosis and Haemostasis*. 2016;116(4): 733–738. doi: 10.1160/th16-01-0041
37. Palareti G. How I treat isolated distal deep vein thrombosis (IDVT). *Blood*. 2014;123(12): 1802–1809. doi: 10.1182/blood-2013-10-512616
38. Masuda EM, Kistner RL, Musikasinthorn C, et al. The controversy of managing calf vein thrombosis. *Journal of Vascular Surgery*. 2012;55(2): 550–561. doi: 10.1016/J.JVS.2011.05.092
39. Kahn SR, Kearon C, Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. *Journal of Thrombosis and Haemostasis*. 2005;3(4): 718–723. doi: 10.1111/j.1538-7836.2005.01216.x
40. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. *Annals of Internal Medicine*. 2008;149(10): 698–707. doi: 10.7326/0003-4819-149-10-200811180-00004
41. Mol GC, Van De Ree MA, Klok FA, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): Randomised controlled trial. *BMJ (Online)*. 2016;353. doi: 10.1136/bmj.i2691
42. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): A randomised controlled trial. *The Lancet*. 2012;379(9810): 31–38. doi: 10.1016/s0140-6736(11)61753-4,
43. Kahn SR, Galanaud JP, Vedantham S, et al. Guidance for the prevention and treatment of the post-thrombotic syndrome. *Journal of Thrombosis and Thrombolysis*. 2016;41(1): 144–153. doi: 10.1007/s11239-015-1312-5
44. Rabinovich A, Kahn SR. The postthrombotic syndrome: current evidence and future challenges. *Journal of Thrombosis and Haemostasis*. 2017;15(2): 230–241. doi: 10.1111/jth.13569
45. Stain M, Schönauer V, Minar E, et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. *Journal of Thrombosis and Haemostasis*. 2005;3(12): 2671–2676. doi: 10.1111/j.1538-7836.2005.01648.x
46. Cowell GW, King SC, Reid JH, et al. Long-term adverse effects associated with isolated below-knee deep-vein thrombosis: a 10-year follow-up study. *Clinical Radiology*. 2016;71(4): 369–374. doi: 10.1016/j.crad.2015.12.014
47. Tick LW, Kramer MHH, Rosendaal FR, et al. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. *Journal of Thrombosis and*

- Haemostasis*. 2008;6(12): 2075–2081. doi: 10.1111/j.1538-7836.2008.03180.x
48. Asbeutah AM, Riha AZ, Cameron JD, et al. Five-year outcome study of deep vein thrombosis in the lower limbs. *Journal of Vascular Surgery*. 2004;40(6): 1184–1189. doi: 10.1016/j.jvs.2004.10.025
 49. Labropoulos N, Waggoner T, Sammis W, et al. The effect of venous thrombus location and extent on the development of post-thrombotic signs and symptoms. *Journal of Vascular Surgery*. 2008;48(2): 407–412. doi: 10.1016/j.jvs.2008.03.016
 50. Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation*. 2014;130(18): 1636–1661. doi: 10.1161/cir.0000000000000130
 51. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest*. 2016;149(2): 315–352. doi: 10.1016/j.chest.2015.11.026
 52. Bouman AC, Cheung YW, Spronk HM, et al. Biomarkers for post thrombotic syndrome: A case-control study. *Thrombosis Research*. 2014;134(2): 369–375. doi: 10.1016/j.thromres.2014.06.010
 53. Strijkers RH, de Wolf MA, Wittens CH. Risk factors of postthrombotic syndrome before and after deep venous thrombosis treatment. *Phlebology: The Journal of Venous Disease*. 2017;32(6): 384–389. doi: 10.1177/0268355516652010
 54. Galanaud JP, Holcroft CA, Rodger MA, et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. *Journal of Thrombosis and Haemostasis*. 2013;11(3): 474–480. doi: 10.1111/jth.12106
 55. Lee JJ, Al-Jubouri M, Acino R, et al. Role of coexisting contralateral primary venous disease in development of post-thrombotic syndrome following catheter-based treatment of iliofemoral deep venous thrombosis Presented at the Twenty-sixth Annual Meeting of the American Venous Forum, New Orleans, La, February 19–21, 2014. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2015;3(4): 354–357. doi: 10.1016/j.jvsv.2015.05.004
 56. Prandoni P, Lensing AWA, Prins MH, et al. Below-Knee Elastic Compression Stockings To Prevent the Post-Thrombotic Syndrome. *Annals of Internal Medicine*. 2004;141(4): 249–256. doi: 10.7326/0003-4819-141-4-200408170-00004
 57. Wik HS, Jacobsen AF, Sandvik L, et al. Long-term impact of pregnancy-related venous thrombosis on quality-of-life, general health and functioning: results of a cross-sectional, case-control study. *BMJ Open*. 2012;2(6): e002048. doi: 10.1136/bmjopen-2012-002048
 58. Prandoni P, Lensing AWA, Prins MH, et al. Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism. *Annals of Internal Medicine*. 2002;137(12): 955–960. doi: 10.7326/0003-4819-137-12-200212170-00008
 59. Comerota AJ, Grewal N, Martinez JT, et al. Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. *Journal of Vascular Surgery*. 2012;55(3): 768–773. doi: 10.1016/j.jvs.2011.10.032
 60. Vedovetto V, Valle FD, Milan M, et al. Residual vein thrombosis and trans-popliteal reflux in patients with and without the postthrombotic syndrome. *Thrombosis and Haemostasis*. 2013;110(10): 854–855. doi: 10.1160/th13-06-0442
 61. Prandoni P, Lensing A, Prins M, et al. The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation. *Seminars in Thrombosis and Hemostasis*. 2015;41(02): 133–140. doi: 10.1055/s-0035-1544161
 62. Incalcaterra E, Meli F, Muratori I, et al. Residual vein thrombosis and onset of post-thrombotic syndrome: Influence of the 4G/5G polymorphism of plasminogen activator inhibitor-1 gene. *Thrombosis Research*. 2014;133(3): 371–374. doi: 10.1016/j.thromres.2013.12.032
 63. Tick LW, Doggen CJ, Rosendaal FR, et al. Predictors of the post-thrombotic syndrome with non-invasive venous examinations in patients 6 weeks after a first episode of deep vein thrombosis. *J Thromb Haemost*. 2010;8(12):2685-92. doi: 10.1111/j.1538-7836.2010.04065.x
 64. Galanaud JP, Monreal M, Kahn SR. Predictors of the post-thrombotic syndrome and their effect on the therapeutic management of deep vein thrombosis. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2016;4(4): 531–534. doi: 10.1016/j.jvsv.2015.08.005
 65. Khider L, Planquette B, Smadja DM, et al. Acute phase determinant of post-thrombotic syndrome: A review of the literature. *Thrombosis Research*. 2024;238: 11–18. doi: 10.1016/j.thromres.2024.04.004
 66. Chitsike RS, Rodger MA, Kovacs MJ, et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: Results from the REVERSE study. *Journal of Thrombosis and Haemostasis*. 2012;10(10): 2039–2044. doi: 10.1111/j.1538-7836.2012.04872.x
 67. Galanaud JP, Bertolotti L, Amitrano M, et al. Predictors of Post-Thrombotic Ulcer after Acute DVT: The RIETE Registry. *Thrombosis and Haemostasis*. 2018;118(2): 320–328. doi: 10.1160/th17-08-0598
 68. Wang J, Smeath E, Lim HY, et al. Current challenges in the prevention and management of post-thrombotic syndrome—towards improved prevention. *International Journal of Hematology*. 2023;118(5): 547–567. doi: 10.1007/s12185-023-03651-6
 69. Henke P, Sharma S, Wakefield T, et al. Insights from experimental post-thrombotic syndrome and potential for novel therapies. *Translational Research*. 2020;225: 95–104. doi: 10.1016/j.trsl.2020.05.005
 70. Villalta S, Bagatella P, Piccioli A, et al. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. *Haemostasis*. 1994;24(suppl 1): 158a
 71. Ginsberg JS, Hirsh J, Julian J, et al. Prevention and treatment of postphlebotic syndrome: Results of a 3-part study. *Archives of Internal Medicine*. 2001;161(17): 2105–2109. doi: 10.1001/archinte.161.17.2105
 72. Wik HS, Enden TR, Ghanima W, et al. Diagnostic scales for the post-thrombotic syndrome. *Thrombosis Research*. 2018;164: 110–115. doi: 10.1016/j.thromres.2017.10.022
 73. Eklöf B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: Con-

- sensus statement. *Journal of Vascular Surgery*. 2004;40(6): 1248–1252. doi: 10.1016/j.jvs.2004.09.027
74. Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2020;8(3): 342–352. doi: 10.1016/j.jvsv.2019.12.075
75. Lattimer CR, Kalodiki E, Azzam M, et al. Validation of the Villalta scale in assessing post-thrombotic syndrome using clinical, duplex, and hemodynamic comparators. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2014;2(1): 8–14. doi: 10.1016/j.jvsv.2013.06.003
76. Meissner MH, Khilnani NM, Labropoulos N, et al. The Symptoms-Varices-Pathophysiology classification of pelvic venous disorders: A report of the American Vein & Lymphatic Society International Working Group on Pelvic Venous Disorders. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2021;9(3): 568–584. doi: 10.1016/j.jvsv.2020.12.084
77. Çırak Y, Savcı S, Karahan Z, et al. Quality of life following acute deep vein thrombosis: the cultural adaptation, reliability and validity of the VEINES-QOL/Sym scale: a Turkish version study. *Turkish Journal of Thoracic and Cardiovascular Surgery*. 2013;21(3): 659–668. doi: 10.5606/tgkdc.dergisi.2013.7463
78. Lamping DL, Schroter S, Kurz X, et al. Evaluation of outcomes in chronic venous disorders of the leg: Development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. *Journal of Vascular Surgery*. 2003;37(2): 410–419. doi: 10.1067/mva.2003.152
79. Kahn SR, Lamping DL, Ducruet T, et al. VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis. *Journal of Clinical Epidemiology*. 2006;59(10): 1056.e1–1056.e4. doi: 10.1016/j.jclinepi.2005.10.016
80. Catarinella FS, Nieman FHM, de Wolf MAF, et al. Quality-of-life in interventional treated patients with post-thrombotic syndrome. *Phlebology*. 2015;30(1 Suppl): 89–94. doi: 10.1177/0268355515569431
81. Lee A, Gu CS, Vedantham S, et al. Performance of two clinical scales to assess quality of life in patients with post-thrombotic syndrome. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2021;9(5): 1257–1265.e2. doi: 10.1016/j.jvsv.2021.01.017
82. Wik H, Ghanima W, Sandset P, et al. Scoring Systems for Postthrombotic Syndrome. *Seminars in Thrombosis and Hemostasis*. 2017;43(05): 500–504. doi: 10.1055/s-0037-1599142
83. Farrell JJ, Sutter C, Tavri S, et al. Incidence and interventions for post-thrombotic syndrome. *Cardiovascular Diagnosis and Therapy*. 2016;6(6): 623–631. doi: 10.21037/cdt.2016.11.22
84. Malgor RD, Labropoulos N. Diagnosis of venous disease with duplex ultrasound. *Phlebology*. 2013;28 Suppl 1: 158–161. doi: 10.1177/0268355513476653
85. Garcia R, Labropoulos N. Duplex Ultrasound for the Diagnosis of Acute and Chronic Venous Diseases. *Surgical Clinics of North America*. 2018;98(2): 201–218. doi: 10.1016/j.suc.2017.11.007
86. Dronkers CEA, Mol GC, Maraziti G, et al. Predicting Post-Thrombotic Syndrome with Ultrasonographic Follow-Up after Deep Vein Thrombosis: A Systematic Review and Meta-Analysis. *Thrombosis and Haemostasis*. 2018;118(8): 1428–1438. doi: 10.1055/s-0038-1666859
87. Haenen JH, van Langen H, Janssen MC, et al. Venous duplex scanning of the leg: range, variability and reproducibility. *Clinical science (London, England : 1979)*. 1999;96(3): 271–277.
88. Labropoulos N, Tiongsong J, Pryor L, et al. Definition of venous reflux in lower-extremity veins. *Journal of Vascular Surgery*. 2003;38(4): 793–798. doi: 10.1016/S0741-5214(03)00424-5
89. Lin C, Martin KA, Wang M, Stein BL, et al. Long-term antithrombotic therapy after venous stent placement. *Phlebology*. 2020;35(6): 402–408. doi: 10.1177/0268355519893819
90. Vrtiska TJ, Glockner JF. Computed tomography and magnetic resonance imaging in venous disease. In: *Handbook of Venous and Lymphatic Disorders*. CRC Press; 2017. p. 177–202
91. Arnoldussen CWKP, Strijkers RHW, Lambregts DMJ, et al. Feasibility of identifying deep vein thrombosis characteristics with contrast enhanced MR-Venography. *Phlebology*. 2014;29(S1): 119–124. doi: 10.1177/0268355514529697
92. Arnoldussen CWKP, De Graaf R, Wittens CHA, et al. Value of magnetic resonance venography and computed tomographic venography in lower extremity chronic venous disease. *Phlebology*. 2013;28(1_suppl): 169–175. doi: 10.1177/0268355513477785
93. Abdalla G, Fawzi Matuk R, Venugopal V, et al. The diagnostic accuracy of magnetic resonance venography in the detection of deep venous thrombosis: A systematic review and meta-analysis. *Clinical Radiology*. 2015;70(8): 858–871. doi: 10.1016/j.crad.2015.04.007
94. Schleimer K, Barbati ME, Grommes J, et al. Update on diagnosis and treatment strategies in patients with post-thrombotic syndrome due to chronic venous obstruction and role of endovenous recanalization. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2019;7(4): 592–600. doi: 10.1016/j.jvsv.2019.01.062
95. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. *International Angiology*. 2018;37(3): 181–254. doi: 10.23736/s0392-9590.18.03999-8
96. Barbati ME, Gombert A, Schleimer K, et al. Assessing radiation exposure to patients during endovascular treatment of chronic venous obstruction. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2019;7(3): 392–398. doi: 10.1016/j.jvsv.2018.10.015
97. Lidstone JSM, Eells LJ, Finn P, et al. Independent associations between weight status and disability in adults: Results from the health survey for England. *Public Health*. 2006;120(5): 412–417. doi: 10.1016/j.puhe.2005.12.003
98. Xia ZD, Hu D, Wilson JM, et al. How echographic image analysis of venous oedema reveals the benefits of leg elevation. *Journal of Wound Care*. 2004;13(4): 125–128. doi: 10.12968/jowc.2004.13.4.26601
99. Orr L, Klement KA, McCrossin L, et al. A Systematic Review and Meta-analysis of Exercise Intervention for the Treatment of Calf Muscle Pump Impairment in Individuals with Chronic Venous Insufficiency. *Ostomy Wound Management*. 2017;63(8): 30–43. doi: 10.25270/owm.2017.08.3043

100. Padberg FT, Johnston M V, Sisto SA. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. *Journal of Vascular Surgery*. 2004;39(1): 79–87. doi: 10.1016/j.jvs.2003.09.036
101. Kahn SR, Shrier I, Shapiro S, et al. Six-month exercise training program to treat post-thrombotic syndrome: A randomized controlled two-centre trial. *CMAJ Canadian Medical Association Journal*. 2011;183(1): 37–44. doi: 10.1503/cmaj.100248
102. Golbidi S, Edvinsson L, Laher I. Smoking and Endothelial Dysfunction. *Current Vascular Pharmacology*. 2018;18(1): 1–11. doi: 10.2174/1573403X14666180913120015
103. Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity: Risk factors for venous thromboembolism among middle-aged men: "The study of men born in 1913." *Archives of Internal Medicine*. 1999;159(16): 1886–1890. doi: 10.1001/archinte.159.16.1886
104. Ibegbuna V, Delis KT, Nicolaides AN, et al. Effect of elastic compression stockings on venous hemodynamics during walking. *Journal of Vascular Surgery*. 2003;37(2): 420–425. doi: 10.1067/mva.2003.104
105. Murphy MA, Joyce WP, Condrón C, et al. A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. *European Journal of Vascular and Endovascular Surgery*. 2002;23(4): 349–352. doi: 10.1053/ejvs.2002.1597
106. Partsch B, Partsch H. Calf compression pressure required to achieve venous closure from supine to standing positions. *Journal of Vascular Surgery*. 2005;42(4): 734–738. doi: 10.1016/j.jvs.2005.06.030
107. Attaran RR, Ochoa Chara CI. Compression therapy for venous disease. *Phlebology*. 2017;32(2): 81–88. doi: 10.1177/0268355516633382
108. Rabe E, Partsch H, Morrison N, et al. Risks and contraindications of medical compression treatment – A critical reappraisal. An international consensus statement. *Phlebology: The Journal of Venous Disease*. 2020;35(7): 447–460. doi: 10.1177/0268355520909066
109. Palacios F, Rathbun S. Medical Treatment for Postthrombotic Syndrome. *Seminars in Interventional Radiology*. 2017;34(01): 61–67. doi: 10.1055/s-0036-1597765
110. Mauck KF, Asi N, Elraiyah TA, et al. Comparative systematic review and meta-analysis of compression modalities for the promotion of venous ulcer healing and reducing ulcer recurrence. *Journal of Vascular Surgery*. 2014;60(2): 71S–90S.e2. doi: 10.1016/j.jvs.2014.04.060
111. Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. *Blood*. 2012;119(6): 1561–1565. doi: 10.1182/blood-2011-11-391961
112. Azirar S, Appelen D, Prins MH, et al. Compression therapy for treating post-thrombotic syndrome. *The Cochrane database of systematic reviews*. 2019;9(9). doi: 10.1002/14651858.cd004177.pub2
113. Coccheri S, Andreozzi GM, D'addato M, et al. Effects of defibrotide in patients with chronic deep insufficiency. The PROVEDIS study. *International angiology: a journal of the International Union of Angiology*. 2004;23(2): 100–107
114. Prandoni P. Elastic stockings, hydroxyethylrutosides or both for the treatment of post-thrombotic syndrome. *Thrombosis and haemostasis*. 2005;93(1): 183–185
115. Li KX, Diendéré G, Galanaud JP, et al. Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review. *Research and Practice in Thrombosis and Haemostasis*. 2021;5(4). doi: 10.1002/rth2.12527
116. Głowiczki ML, Stoughton J, Puggioni A, et al. Utility of venoactive compounds in post-thrombotic syndrome: A systematic review. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2025;13(4). doi: 10.1016/j.jvsv.2025.102228
117. Bauer G. Thrombosis; early diagnosis and abortive treatment with heparin. *The Lancet*. 1946;247(6396): 447–454. doi: 10.1016/s0140-6736(46)91429-8
118. Galanaud JP, Righini M, Quéré I. Compression stockings to prevent post-thrombotic syndrome. *The Lancet*. 2014;384(9938): 129. doi: 10.1016/s0140-6736(14)61158-2
119. Van Dongen CJJ, Prandoni P, Frulla M, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. *Journal of Thrombosis and Haemostasis*. 2005;3(5): 939–942. doi: 10.1111/j.1538-7836.2005.01333.x
120. Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: A systematic review. *American Journal of Medicine*. 2011;124(8): 756–765. doi: 10.1016/j.amjmed.2011.02.033
121. Romera A, Cairols MA, Vila-Coll R, et al. A Randomised Open-Label Trial Comparing Long-term Sub-Cutaneous Low-Molecular-weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis. *European Journal of Vascular and Endovascular Surgery*. 2009;37(3): 349–356. doi: 10.1016/j.ejvs.2008.11.030
122. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. *Journal of Vascular Surgery*. 1999;30(2): 283–292. doi: 10.1016/s0741-5214(99)70139-4
123. Rabinovich A, Cohen JM, Cushman M, et al. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of postthrombotic syndrome. *Journal of Thrombosis and Haemostasis*. 2015;13(3): 398–408. doi: 10.1111/jth.12814
124. Makedonov I, Kahn SR, Galanaud JP. Prevention and management of the post-thrombotic syndrome. *Journal of Clinical Medicine*. 2020;9(4). doi: 10.3390/jcm9040923
125. Kubat E, Gulpinar OA, Karasoy D, et al. A link between cytotoxicity in cell culture and gastrointestinal side effects of oral anticoagulants: Bench-to-bedside. *Bratislava Medical Journal*. 2018;119(11): 706–712. doi: 10.4149/BLL_2018_126
126. Rathbun SW, Kirkpatrick AC. Treatment of chronic venous insufficiency. *Current Treatment Options in Cardiovascular Medicine*. 2007;9(2): 115–126. doi: 10.1007/s11936-007-0005-6
127. Raju S, Darcey R, Neglén P. Unexpected major role for venous stenting in deep reflux disease. *Journal of Vascular Surgery*. 2010;51(2): 401–408. doi: 10.1016/j.jvs.2009.08.032

128. Masuda E, Ozsvath K, Vossler J, et al. The 2020 appropriate use criteria for chronic lower extremity venous disease of the American Venous Forum, the Society for Vascular Surgery, the American Vein and Lymphatic Society, and the Society of Interventional Radiology. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2020;8(4): 505-525.e4. doi: 10.1016/J.JVSV.2020.02.001
129. Dalsing MC, Raju S, Wakefield TW, et al. A multicenter, phase I evaluation of cryopreserved venous valve allografts for the treatment of chronic deep venous insufficiency. *Journal of Vascular Surgery*. 1999;30(5): 854-866. doi: 10.1016/S0741-5214(99)70010-8
130. Shortell CK, AbuRahma AF, Robinson PA. Clinical, hemodynamic, and anatomic predictors of long-term outcome of lower extremity venovenous bypasses. *Journal of Vascular Surgery*. 1991;14(5): a32346. doi: 10.1067/mva.1991.32346
131. Coleman DM, Rectenwald JE, Vandy FC, et al. Contemporary results after sapheno-popliteal bypass for chronic femoral vein occlusion. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2013;1(1): 45-51. doi: 10.1016/j.jvsv.2012.10.055
132. Husni EA. Reconstruction of veins: the need for objectivity. *The Journal of cardiovascular surgery*. 1983;24(5): 525-528
133. Garg N, Gloviczki P, Karimi KM, et al. Factors affecting outcome of open and hybrid reconstructions for nonmalignant obstruction of iliofemoral veins and inferior vena cava. *Journal of Vascular Surgery*. 2011;53(2): 383-393. doi: 10.1016/j.jvs.2010.08.086
134. Jost CJ, Gloviczki P, Cherry KJ, et al. Surgical reconstruction of iliofemoral veins and the inferior vena cava for nonmalignant occlusive disease. *Journal of Vascular Surgery*. 2001;33(2): 320-328. doi: 10.1067/mva.2001.112805
135. Berger A, Jaffe JW, York TN. Iliac compression syndrome treated with stent placement. *Journal of Vascular Surgery*. 1995;21(3): 510-514. doi: 10.1016/s0741-5214(95)70295-4
136. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part II. *International Angiology*. 2020;39(3): 175-230. doi: 10.23736/s0392-9590.20.04388-6
137. Taha MA, Busuttill A, Bootun R, et al. A systematic review on the use of deep venous stenting for acute venous thrombosis of the lower limb. *Phlebology: The Journal of Venous Disease*. 2019;34(2): 115-127. doi: 10.1177/0268355518772760
138. Engeseth M, Enden T, Sandset PM, et al. Predictors of long-term post-thrombotic syndrome following high proximal deep vein thrombosis: a cross-sectional study. *Thrombosis Journal*. 2021;19(1): 3. doi: 10.1186/S12959-020-00253-8
139. Elfeky M, Barbati ME, Schleimer K, et al. Factors associated with difficulty in stenting the chronic iliofemoral venous obstruction. *International Angiology*. 2023;42(4): 337-343. doi: 10.23736/s0392-9590.23.05001-0
140. Parikh RA, Williams DM. *Managing Chronic Iliac Venous Occlusions That Extend Below the Inguinal Ligament*. Vol 1. (Kahn SL, Arslan B, Masrani A, editors). New York: Oxford University Press; 2018. doi: 10.1093/med/9780199986071.003.0034
141. Zaldivar-Jolissaint JF, de Schlichting E, Haller C, et al. Foot Drop After Iliocaval Vein Stenting: Radicular Syndrome from Stent Misplacement in Spinal Canal. *World Neurosurgery*. 2020;137: 43-45. doi: 10.1016/j.wneu.2020.01.055
142. Lichaa H, Lakhter V, Mohan J, et al. Intravascular Ultrasound Use for Iliac Vein Interventions. *Current Cardiovascular Imaging Reports*. 2021;14(8): 1-18. doi: 10.1007/S12410-021-09558-2
143. Sayed MH, Salem M, Desai KR, et al. A review of the incidence, outcome, and management of venous stent migration. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2022;10(2): 482-490. doi: 10.1016/j.jvsv.2021.07.015
144. Razavi M, Ouriel K, Marston W, et al. Early Vein Straightening and Tenting After Iliofemoral Venous Stent Deployment: Anatomic Assessment and Clinical Implications. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2017;5(1): 163-164. doi: 10.1016/j.jvsv.2016.10.049
145. Dumantepe M, Aydin S, Ökten M, et al. Endophlebectomy of the common femoral vein and endovascular iliac vein recanalization for chronic iliofemoral venous occlusion. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2020;8(4): 572-582. doi: 10.1016/j.jvsv.2019.11.008
146. de Wolf MAF, Jalaie H, van Laanen JHH, et al. Endophlebectomy of the common femoral vein and arteriovenous fistula creation as adjuncts to venous stenting for post-thrombotic syndrome. *British Journal of Surgery*. 2017;104(6): 718-725. doi: 10.1002/bjs.10461
147. de Wolf MAF, Arnoldussen CWKP, Wittens CHA. Indications for endophlebectomy and/or arteriovenous fistula after stenting. *Phlebology*. 2013;28(1_suppl): 123-128. doi: 10.1177/0268355513477063
148. Hartung O, Vecchini F, Ejargue M, et al. Treatment by Endophlebectomy and Stenting of Severe Post-thrombotic Femoro-iliac Obstructive Lesions Extending to the Femoral Junction. *Annals of Vascular Surgery*. 2018;53: 24-25. doi: 10.1016/j.avsg.2018.08.047
149. Puggioni A, Kistner RL, Eklof B, Lurie F. Surgical disobliteration of postthrombotic deep veins—endophlebectomy—is feasible. *Journal of Vascular Surgery*. 2004;39(5): 1048-1052. doi: 10.1016/j.jvs.2003.12.036
150. Rinfret F, Gu C, Vedantham S, et al. New and known predictors of the postthrombotic syndrome: A subanalysis of the ATTRACT trial. *Research and Practice in Thrombosis and Haemostasis*. 2022;6(6): e12796. doi: 10.1002/rth2.12796
151. Barbati ME, Aygerinos ED, Baccellieri D, et al. Interventional treatment for post-thrombotic chronic venous obstruction: Progress and challenges. *Journal of vascular surgery Venous and lymphatic disorders*. 2024;12(5): 101910. doi: 10.1016/j.jvsv.2024.101910
152. Neglén P, Darcey R, Olivier J, et al. Bilateral stenting at the iliocaval confluence. *Journal of Vascular Surgery*. 2010;51(6): 1457-1466. doi: 10.1016/j.jvs.2010.01.056
153. de Graaf R, de Wolf M, Sailer AM, et al. Iliocaval Confluence Stenting for Chronic Venous Obstructions. *Cardiovascular and interventional radiology*. 2015;38(5): 1198-1204. doi: 10.1007/s00270-015-1068-5
154. Barbati ME, Gombert A, Toonder IM, et al. Iliocaval Skip Stent Reconstruction Technique for Chronic Bilateral Iliocaval Venous Occlusion. *Journal of vascular and*

- interventional radiology: JVIR*. 2020;31(12): 2060–2065. doi: 10.1016/j.jvir.2020.08.021
155. Sze DY, Razavi MK, Mitri RK, et al. The “Y” Stent: A Technique Using Nitinol Stents to Treat Bifurcations. *Journal of Endovascular Therapy*. 2003;10(4): 780–787. doi: 10.1177/152660280301000415
 156. Neglén P, Hollis KC, Olivier J, et al. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. *Journal of vascular surgery*. 2007;46(5): 979–990. doi: 10.1016/j.jvs.2007.06.046
 157. Raju S, Neglén P. Percutaneous recanalization of total occlusions of the iliac vein. *Journal of Vascular Surgery*. 2009;50(2): 360–368. doi: 10.1016/j.jvs.2009.01.061
 158. Wen-da W, Yu Z, Yue-xin C. Stenting for chronic obstructive venous disease: A current comprehensive meta-analysis and systematic review. *Phlebology: The Journal of Venous Disease*. 2016;31(6): 376–389. doi: 10.1177/0268355515596474
 159. Qiu P, Zha B, Xu A, et al. Systematic Review and Meta-Analysis of Iliofemoral Stenting for Post-thrombotic Syndrome. *European Journal of Vascular and Endovascular Surgery*. 2019;57(3): 407–416. doi: 10.1016/j.ejvs.2018.09.022
 160. Seager MJ, Busuttill A, Dharmarajah B, et al. Editor’s Choice – A Systematic Review of Endovenous Stenting in Chronic Venous Disease Secondary to Iliac Vein Obstruction. *European Journal of Vascular and Endovascular Surgery*. 2016;51(1): 100–120. doi: 10.1016/j.ejvs.2015.09.002
 161. de Wolf MAF, de Graaf R, Kurstjens RLM, et al. Short-Term Clinical Experience with a Dedicated Venous Nitinol Stent: Initial Results with the Sinus-Venous Stent. *European Journal of Vascular and Endovascular Surgery*. 2015;50(4): 518–526. doi: 10.1016/j.ejvs.2015.05.011
 162. Stuck AK, Kunz S, Baumgartner I, et al. Patency and Clinical Outcomes of a Dedicated, Self-Expanding, Hybrid Oblique Stent Used in the Treatment of Common Iliac Vein Compression. *Journal of Endovascular Therapy*. 2017;24(1): 159–166. doi: 10.1177/1526602816676803
 163. van Vuuren TMAJ, Doganci S, Witten CHA. Patency rates and clinical outcomes in a cohort of 200 patients treated with a dedicated venous stent. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2018;6(3): 321–329. doi: 10.1016/j.jvsv.2017.09.013
 164. Sebastian T, Hakki LO, Spirk D, et al. Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis. *Thrombosis Research*. 2018;172: 86–93. doi: 10.1016/j.thromres.2018.10.027
 165. Neglén P, Berry MA, Raju S. Endovascular Surgery in the Treatment of Chronic Primary and Post-thrombotic Iliac Vein Obstruction. *European Journal of Vascular and Endovascular Surgery*. 2000;20(6): 560–571. doi: 10.1053/ejvs.2000.1251
 166. Gagne PJ, Tahara RW, Fastabend CP, et al. Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2017;5(5): 678–687. doi: 10.1016/j.jvsv.2017.04.007
 167. Rossi FH, Kambara AM, Rodrigues TO, et al. Comparison of computed tomography venography and intravascular ultrasound in screening and classification of iliac vein obstruction in patients with chronic venous disease. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. 2020;8(3): 413–422. doi: 10.1016/j.jvsv.2019.09.015
 168. Kurstjens RLM, de Wolf MAF, Kleijnen J, et al. The predictive value of haemodynamic parameters for outcome of deep venous reconstructions in patients with chronic deep vein obstruction – A systematic review. *Phlebology*. 2017;32(8): 532–542. doi: 10.1177/0268355516671464
 169. Neglén P, Tackett TP, Raju S. Venous stenting across the inguinal ligament. *Journal of Vascular Surgery*. 2008;48(5): 1255–1261. doi: 10.1016/j.jvs.2008.06.035
 170. Notten P, Ten Cate H, Ten Cate-Hoek AJ. Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review. *Journal of thrombosis and haemostasis: JTH*. 2021;19(3): 753–796. doi: 10.1111/jth.15197
 171. Vogel D, Comerota AJ, Al-Jabouri M, Assi ZI. Common femoral endovenectomy with ilio caval endoluminal recanalization improves symptoms and quality of life in patients with postthrombotic iliofemoral obstruction. *Journal of Vascular Surgery*. 2012;55(1): 129–135. doi: 10.1016/j.jvs.2011.05.017
 172. Doğanç S, Erol G, Yıldırım AK. Tıkayıcı Venöz Lezyonların Girişimsel Tedavisi. In: Polat A, Tankut HA, Köksal C, Bozkurt AK (eds) *Damar*. İstanbul: Baycınar Tıbbi Yayıncılık; 2019. p. 619–649
 173. Jalaie H, Barbati ME, Piao L, et al. Prognostic Value of a Classification System for Iliofemoral Stenting in Patients with Chronic Venous Obstruction. *European Journal of Vascular and Endovascular Surgery*. 2025;69(2): 315–322. doi: 10.1016/j.ejvs.2024.10.002
 174. Comerota AJ, Grewal NK, Thakur S, et al. Endovenectomy of the common femoral vein and intraoperative iliac vein recanalization for chronic iliofemoral venous occlusion. *Journal of Vascular Surgery*. 2010;52(1): 243–247. doi: 10.1016/j.jvs.2010.02.260
 175. Kurstjens RLM, de Graaf R, Barbati ME, et al. Arteriovenous fistula geometry in hybrid recanalisation of post-thrombotic venous obstruction. *Phlebology*. 2015;30: 42–49. doi: 10.1177/0268355514568270
 176. Jalaie H, Schleimer K, Barbati ME, et al. Interventionelle Therapie des postthrombotischen Syndroms. *Gefäßchirurgie*. 2016;21(Suppl 2): 37–44. doi: 10.1007/s00772-016-0156-4
 177. Doğanç S. Posttrombotik sendrom. In: Kürşat AB (eds) *Periferik Arter ve Ven Hastalıkları Ulusal Tedavi Kılavuzu*. İstanbul: Baycınar Tıbbi Yayıncılık; 2021. p. 329–343
 178. van Vuuren TMAJ, de Wolf MAF, Arnoldussen CWKP, et al. Editor’s Choice – Reconstruction of the femoro-ilio-caval outflow by percutaneous and hybrid interventions in symptomatic deep venous obstruction. *European Journal of Vascular and Endovascular Surgery*. 2017;54(4): 495–503. doi: 10.1016/j.ejvs.2017.06.023
 179. De Maeseneer MG, Kakkos SK, Aherne T, et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. *European Journal of Vascular and Endovascular Surgery*. 2022;63(2): 184–267. doi: 10.1016/j.ejvs.2021.12.024
 180. Prandoni P, Haas S, Fluharty ME, et al. Incidence and predictors of post-thrombotic syndrome in patients with proximal DVT in a real-world setting: findings

- from the GARFIELD-VTE registry. *Journal of Thrombosis and Thrombolysis*. 2023;57(2): 312–321. doi: 10.1007/s11239-023-02895-7
181. Endo M, Jahangiri Y, Horikawa M, et al. Antiplatelet Therapy is Associated with Stent Patency After Iliocaval Venous Stenting. *CardioVascular and Interventional Radiology*. 2018;41(11): 1691–1698. doi: 10.1007/s00270-018-2062-5
182. Langwieser N, Bernlochner I, Wustrow I, et al. Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral post-thrombotic venous obstruction. *Phlebology*. 2016;31(6): 430–437. doi: 10.1177/0268355515596289
183. Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus. *European Journal of Vascular and Endovascular Surgery*. 2018;55(4): 537–544. doi: 10.1016/j.ejvs.2018.01.007
184. Goldenberg NA, Donadini MP, Kahn SR, et al. Post-thrombotic syndrome in children: A systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. *Haematologica*. 2010;95(11): 1952–1959. doi: 10.3324/haematol.2010.026989
185. Vosicka K, Qureshi MI, Shapiro SE, et al. Post thrombotic syndrome following deep vein thrombosis in paediatric patients. *Phlebology: The Journal of Venous Disease*. 2018;33(3): 185–194. doi: 10.1177/0268355516686597
186. Betensky M, Goldenberg NA. Post-thrombotic syndrome in children. *Thrombosis Research*. 2018;164: 129–135. doi: 10.1016/j.thromres.2017.07.024
187. Kumar R, Rodriguez V, Matsumoto JMS, et al. Health-related quality of life in children and young adults with post-thrombotic syndrome: Results from a cross-sectional study. *Pediatric Blood and Cancer*. 2014;61(3): 546–551. doi: 10.1002/PBC.24840
188. Smith J, Thornhill D, Goldenberg NA, et al. Validation of Outcome Instruments for Pediatric Postthrombotic Syndrome: Introducing the Peds-VEINES-QOL, a New Health-Related Quality of Life Instrument. *Thrombosis and Haemostasis*. 2021;121(10): 1367–1375. doi: 10.1055/s-0041-1725199
189. Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: A systematic review. *Thrombosis Research*. 2006;117(6): 609–614. doi: 10.1016/j.thromres.2005.05.029
190. Cote LP, Greenberg S, Caprini JA, et al. Comparisons between Upper and Lower Extremity Deep Vein Thrombosis: A Review of the RIETE Registry. *Clinical and Applied Thrombosis/Hemostasis*. 2017;23(7): 748–754. doi: 10.1177/1076029616663847
191. de Kleijn RJCME, Schropp L, van Hattum ES, et al. Post-thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study. *Journal of Thrombosis and Haemostasis*. 2022;20(8): 1880–1886. doi: 10.1111/jth.15767
192. Prandoni P, Bernardi E, Marchiori A, et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. *BMJ*. 2004;329(7464): 484–485. doi: 10.1136/bmj.38167.684444.3a
193. Kahn SR, Elman EA, Bornais C, et al. Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults. *Thrombosis and Haemostasis*. 2005;93(3): 499–502. doi: 10.1160/th04-10-0640
194. Naeem M, Soares G, Ahn S, et al. Paget-Schroetter syndrome: A review and Algorithm (WASPS-IR). *Phlebology*. 2015;30(10): 675–686. doi: 10.1177/0268355514568534



DERİN VEN TROMBOZU

BÖLÜM 87

Suat DOĞANCI ¹
Işıl TAŞÖZ ÖZDAŞ ²
Emre KUBAT ³

DOI: 10.37609/akya.3889.c5409

İçindekiler

- » TANIM VE EPİDEMİYOLOJİ
- » DVT PATOFİZYOLOJİSİ VE RİSK FAKTÖRLERİ
- » TANI
 - » Wells Skorlaması
 - » D-Dimer
 - » Görüntüleme Yöntemleri
- » TEDAVİ
 - » Antikoagülan İlaçlar
 - » Derin Ven Trombozunda Kompresyon Tedavisi
 - » Derin Ven Trombozunda Girişimsel Yöntemler
- » DERİN VEN TROMBOZU İLE İLGİLİ DİĞER KLİNİK DURUMLAR
 - » Üst Ekstremitte Derin Ven Trombozu
 - » Atipik Lokalizasyonda Derin Ven Trombozu
 - » Katater ilişkili Derin Ven Trombozu
 - » Özel Hasta Gruplarında Derin Ven Trombozu
 - » Pediatrik Hastalarda Derin Ven Trombozu

¹ Prof. Dr., Prof. Dr. Suat Doğancı Muayenehanesi, suat_doganci@yahoo.com, ORCID iD: 0000-0001-7088-7151

² Uzm. Dr., Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, dr.isiltasoz@gmail.com, ORCID iD: 0000-0002-0281-6754

³ Doç. Dr., Özel İskenderun Gelişim Hastanesi, ekubat@gmail.com, ORCID iD: 0000-0002-9884-8565

ve sayısında da artış göstermektedir. Pediatrik yaş grubundaki çocuklarda venöz tromboemboli gelişiminden sıklıkla SVK sorumlu tutulmaktadır (120). Yetişkinlerden farklı olarak antikoagülasyonun aPTT, anti-Xa düzeyleri gibi tetkiklerle pediatrik grupta takibi daha da önem kazanmaktadır. Pediatrik grupta rivaroksaban yapılan bazı çalışmalarda etkin bulunsu da NOAK'lar için pediatrik popülasyonda yeterli çalışma bulunmamaktadır. Aynı şekilde tromboliz tedavisi için de yüz güldürücü sonuçlar izlenmiştir ancak çalışma sayısı bu tedavi seçeneği için de yetersizdir. Derin ven trombozuna sahip çocuklarda tedavi planlaması ve takibi bu konuda uzmanlaşmış klinisyenlerce yönetilmelidir.


KAYNAKLAR

1. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest*. 2016;149:315-352.
2. Bell EJ, Lutsey PL, Basu S, Cushman M, Heckbert SR, Lloyd-Jones DM, Folsom AR. Lifetime Risk of Venous Thromboembolism in Two Cohort Studies. *Am J Med*. 2016;129:339.e19-26.
3. Sogaard KK, Schmidt M, Pedersen L, Horvath-Puho E, Sorensen HT. 30-year mortality after venous thromboembolism: a population-based cohort study. *Circulation*. 2014;130:829-836.
4. Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. *Nat Rev Cardiol*. 2023;20:248-262.
5. Muñoz FJ, Mismetti P, Poggio R, Valle R, Barrón M, Guil M, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. *Chest*. 2008;133:143-8.
6. Dronkers CE, Klok FA, Huisman MV. Current and future perspectives in imaging of venous thromboembolism. *J Thromb Haemost*. 2016;14:1696-710.
7. Kearon C, Kahn SR. Long-term treatment of venous thromboembolism. *Blood*. 2020;135:317-325.
8. Albertsen IE, Piazza G, Goldhaber SZ. Let's stop dichotomizing venous thromboembolism as provoked or unprovoked. *Circulation*. 2018;138:2591-2593.
9. Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. *BMJ*. 2019;24:366:l4363.
10. Cushman M. Epidemiology and risk factors for venous thrombosis. *Semin Hematol*. 2007;44:62-9.
11. White RH. The epidemiology of venous thromboembolism. *Circulation*. 2003;107:14-8.
12. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis*. 2016;41:3-14.
13. Roach RE, Cannegieter SC, Lijfering WM. Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment. *J Thromb Haemost*. 2014;12:1593-1600.
14. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. *Thromb Res*. 2009;123:11-7.
15. Dentali F, Ageno W, Rancan E, Donati AV, Galli L, Squizzato A, et al. Seasonal and monthly variability in the incidence of venous thromboembolism. A systematic review and a meta-analysis of the literature. *Thromb Haemost*. 2011;106:439-47.
16. Cohen AT, Agnelli G, Anderson FA, Arcelus JJ, Bergqvist D, Brecht JG, et al (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost*. 2007;98:756-64.
17. Panova-Noeva M, Wagner B, Nagler M, Koeck T, Ten Cate V, Prochaska JH, et al. Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observation studies. *EBioMedicine*. 2020;60:102978.
18. Virchow RLK. *Gesammelte Abhandlungen zur wissenschaftlichen Medizin*. Frankfurt: Meidinger Sohn & Co, 1856:219-732.
19. Mackman N. *New insights into the mechanisms of venous thrombosis*. *J Clin Invest*. 2012;122:2331-6.
20. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Köllnberger M, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. *Blood*. 2011;117:1400-7.
21. von Brühl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. *J Exp Med*. 2012;209:819-35.
22. Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. *J Clin Invest*. 1996;97:493-500.
23. Sparkenbaugh EM, Chantrathammachart P, Wang S, Jonas W, Kirchhofer D, Gailani D, et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice. *Haematologica*. 2015;100:308-14.
24. Huang Y, Ge H, Wang X, Zhang X. Association Between Blood Lipid Levels and Lower Extremity Deep Venous Thrombosis: A Population-Based Cohort Study. *Clin Appl Thromb Hemost*. 2022;28:10760296221121282.
25. Baylis RA, Smith NL, Klarin D, Fukaya E. Epidemiology and Genetics of Venous Thromboembolism and Chronic Venous Disease. *Circ Res*. 2021;128:1988-2002.
26. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation*. 2003;107:19-16.
27. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. *EClinicalMedicine*. 2020;29:100639.
28. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. *J Thromb Haemost*. 2008;6:632-7.
29. Devis P, Knuttinen MG. Deep venous thrombosis in

- pregnancy: incidence, pathogenesis and endovascular management. *Cardiovasc Diagn Ther.* 2017;7:309-319.
30. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. *Am J Obstet Gynecol.* 2006;194:1311-5.
 31. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. *Arch Intern Med.* 2004;164:1965-76.
 32. van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. *J Thromb Haemost.* 2016;14:1393-1403.
 33. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Combined oral contraceptives: venous thrombosis. *Cochrane Database Syst Rev.* 2014;CD010813.
 34. Branchford BR, Carpenter SL. The Role of Inflammation in Venous Thromboembolism. *Front Pediatr.* 2018;6:142.
 35. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. *Eur J Vasc Endovasc Surg.* 2021;61:9-82.
 36. Meissner MH. The clinical presentation and natural history of acute deep venous thrombosis. In: *Gloviczki P, editor. Handbook of venous and lymphatic disorders. 4th edn. Boca Raton, FL: CRC Press; 2017. p. 205e19.*
 37. Mukhopadhyay P, Sinha U, Ghosh J, Philips CA. Predictive value of bedside clinical signs and symptoms in early diagnosis of deep vein thrombosis in acutely ill medical patients with special reference to deep vein thrombosis prophylaxis. *J Indian Med Assoc.* 2012;110:218-23.
 38. Kearon C. Natural history of venous thromboembolism. *Circulation.* 2003;107:122-130.
 39. Gupta R, Stouffer GA. Deep venous thrombosis: a review of the pathophysiology, clinical features, and diagnostic modalities. *Am J Med Sci.* 2001;322:358-64.
 40. Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. *Ann Intern Med.* 2004;140:589-602.
 41. Canas A, Epstein J, Chen T, Dunn AS. Diagnosis of Venous Thromboembolism. *Med Clin North Am.* 2025;109:787-801.
 42. Righini M, Le Gal G, Bounameaux H. Venous thromboembolism diagnosis: unresolved issues. *Thromb Haemost.* 2015;113:1184-92.
 43. Su LY, Guo FJ, Xu G, Han XJ, Sun CK, Zhang Z, et al. Differential diagnosis of isolated calf muscle vein thrombosis and gastrocnemius hematoma by high-frequency ultrasound. *Chin Med J (Engl).* 2013;126:4448-52.
 44. Alonso-Gómez N, Pérez-Piqueras A, Martínez-Izquierdo A, Sáinz-González F. Giant baker' cyst. Differential diagnosis of deep vein thrombosis. *Reumatol Clin.* 2015;11:179-81.
 45. Geersing GJ, Zuithoff NP, Kearon C, Anderson DR, Ten Cate-Hoek AJ, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. *BMJ.* 2014;348:g1340.
 46. Wells PS, Owen C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis? *JAMA.* 2006 Jan 11;295(2):199-207.
 47. Kelly J, Hunt BJ. The utility of pretest probability assessment in patients with clinically suspected venous thromboembolism. *J Thromb Haemost.* 2003;1:1888-96.
 48. Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. *Health Technol Assess.* 2006;10:1-168.
 49. Bernardi E, Camporese G. Diagnosis of deep-vein thrombosis. *Thromb Res.* 2018;163:201-206.
 50. Sartori M, Cosmi B, Legnani C, Favaretto E, Valdré L, Guazzaloca G, et al. The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis. *J Thromb Haemost.* 2012;10:2264-9.
 51. Engelberger RP, Aujesky D, Calanca L, Staeger P, Hugli O, Mazzolai L. Comparison of the diagnostic performance of the original and modified Wells score in inpatients and outpatients with suspected deep vein thrombosis. *Thromb Res.* 2011;127:535-9.
 52. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med.* 2003;349:1227-35.
 53. Haase C, Joergensen M, Ellervik C, Joergensen MK, Bathum L. Age- and sex-dependent reference intervals for D-dimer: evidence for a marked increase by age. *Thromb Res.* 2013;132:676-80.
 54. Parry BA, Chang AM, Schellong SM, House SL, Fermann GJ, Deadmon EK, et al. International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs. *Thromb Res.* 2018;166:63-70.
 55. Stubbs MJ, Mouyis M, Thomas M. Deep vein thrombosis. *BMJ.* 2018;360:k351.
 56. Perrier A, Nendaz MR, Sarasin FP, Howarth N, Bounameaux H. Cost-effectiveness analysis of diagnostic strategies for suspected pulmonary embolism including helical computed tomography. *Am J Respir Crit Care Med.* 2003; 167: 39-44.
 57. Runyon MS, Richman PB, Kline JA. Emergency medicine practitioner knowledge and use of decision rules for the evaluation of patients with suspected pulmonary embolism: variations by practice setting and training level. *Acad Emerg Med.* 2007; 14: 53-57.
 58. Needleman L, Cronan JJ, Lilly MP, Merli GJ, Adhikari S, Hertzberg BS, et al. Ultrasound for Lower Extremity Deep Venous Thrombosis: Multidisciplinary Recommendations From the Society of Radiologists in Ultrasound Consensus Conference. *Circulation.* 2018;137:1505-1515.
 59. Cogo A, Lensing AW, Koopman MM, Piovella F, Siragusa S, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. *BMJ.* 1998;316:17-20.
 60. Schellong SM, Schwarz T, Halbritter K, Beyer J, Siegert G, Oettler W, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. *Thromb Haemost.* 2003;89:228-34.

61. Bhatt M, Braun C, Patel P, Patel P, Begum H, Wiercioch W, et al. Diagnosis of deep vein thrombosis of the lower extremity: a systematic review and meta-analysis of test accuracy. *Blood Adv.* 2020;4:1250-1264
62. Ageno W, Camporese G, Riva N, Iotti M, Bucherini E, et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. *Lancet Haematol.* 2015;2:e474-80.
63. Barutca H, Kantarcı F, Şahin S, Mihmanlı İ. A comparison of multidetector computed tomography direct venography with color Doppler ultrasound in the diagnosis of lower limb and inferior vena cava deep venous thrombosis. *Türk Gogus Kalp Damar Cerrahisi Derg.* 2012;20:780-787
64. Karande GY, Hedgire SS, Sanchez Y, Baliyan V, Mishra V, Ganguli S, et al. Advanced imaging in acute and chronic deep vein thrombosis. *Cardiovasc Diagn Ther.* 2016;6:493-507.
65. Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. *Eur Radiol.* 2007;17:175-81.
66. Mendichovszky IA, Priest AN, Bowden DJ, Hunter S, Joubert I, Hilborne S, et al. Combined MR direct thrombus imaging and non-contrast magnetic resonance venography reveal the evolution of deep vein thrombosis: a feasibility study. *Eur Radiol.* 2017;27:2326-2332.
67. van Dam LF, Dronkers CEA, Gautam G, Eckerbom Å, Ghanima W, et al. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. *Blood.* 2020;135:1377-1385.
68. Min SK, Kim YH, Joh JH, Kang JM, Park UJ, Kim HK, et al. Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines. *Vasc Specialist Int.* 2016;32:77-104.
69. Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141:53-70.
70. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141:e351S-e418S.
71. Limone BL, Hernandez AV, Michalak D, Bookhart BK, Coleman CI. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. *Thromb Res.* 2013; 132: 420-426
72. Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation.* 2014;130:1636-61.
73. Abramowitz S, Shaikh A, Mojibian H, Mouawad NJ, Bunte MC, Skripochnik E, et al. Comparison of anticoagulation vs mechanical thrombectomy for the treatment of iliofemoral deep vein thrombosis. *J Vasc Surg Venous Lymphat Disord.* 2024;12:101825.
74. Comerota AJ, Gravett MH. Iliofemoral venous thrombosis. *J Vasc Surg.* 2007;46:1065-1076.
75. Tritschler T, Kraaijpoel N, Le Gal G, Wells PS. Venous Thromboembolism: Advances in Diagnosis and Treatment. *JAMA.* 2018;320:1583-1594.
76. Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. *Blood Adv.* 2020;4:4693-4738.
77. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133:141S-159S.
78. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. *JAMA.* 2014;312:1122-35
79. Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsr AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. *J Thromb Thrombolysis.* 2016;41:165-86.
80. Mulder FI, Bosch FTM, Young AM, Marshall A, McBanne RD, Zemla TJ, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. *Blood.* 2020;136:1433-1441.
81. Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, et al. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. *J Thromb Haemost.* 2021;19:2801-2813.
82. Wang KL, van Es N, Cameron C, Castellucci LA, Büller HR, Carrier M. Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. *Heart.* 2019;105:545-552
83. Kyrle PA. How I treat recurrent deep-vein thrombosis. *Blood.* 2016;127:696-702.
84. Labropoulos N, Jen J, Jen H, Gasparis AP, Tassiopoulos AK. Recurrent deep vein thrombosis: long-term incidence and natural history. *Ann Surg.* 2010;251:749-53
85. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. *Arch Intern Med.* 2010;170:1710-6.
86. Farzamnia H, Rabiei K, Sadeghi M, Roghani F. The predictive factors of recurrent deep vein thrombosis. *ARYA Atheroscler.* 2011;7:123-8
87. Amin E, Joore MA, ten Cate-Hoek AJ. Compression to prevent PTS: a controversy? *Phlebology.* 2016;3:41-47..
88. Appelen D, van Loo E, Prins MH, Neumann MH, Kolbach DN. Compression therapy for prevention of post-thrombotic syndrome. *Cochrane Database Syst Rev.* 2017;9:CD004174.
89. Thieme D, Linnemann B, Mühlberg K, Noppeney T, Kreutz M, Thieme M. Compression Therapy in Acute Deep Venous Thrombosis of the Lower Limb and for the Prevention of Post-Thrombotic Syndrome—a Re-

- view Based on a Structured Literature Search. *Dtsch Arztebl Int.* 2024;121:188-194.
90. Hupperetz R, Ten Cate-Hoek A. The Postthrombotic syndrome, where are we now? *Vasa.* 2025;54:7-19.
 91. Plate G, Eklöf B, Norgren L, Ohlin P, Dahlström JA. Venous thrombectomy for iliofemoral vein thrombosis--10-year results of a prospective randomised study. *Eur J Vasc Endovasc Surg.* 1997;14:367-74.
 92. Rodríguez LE, Aboukheir-Aboukheir A, Figueroa-Vicente R, Soler-Bernardini H, Bolanos-Avila G, Torruella-Bartolomei LJ, et al. Hybrid operative thrombectomy is noninferior to percutaneous techniques for the treatment of acute iliofemoral deep venous thrombosis. *J Vasc Surg Venous Lymphat Disord.* 2017;5:177-184.
 93. vFoegh P, Jensen LP, Klitfod L, Broholm R, Bækgaard N. Editor's Choice - Factors Associated with Long-Term Outcome in 191 Patients with Ilio-Femoral DVT Treated With Catheter-Directed Thrombolysis. *Eur J Vasc Endovasc Surg.* 2017;53:419-424.
 94. Engelberger RP, Stuck A, Spirk D, Willenberg T, Haine A, Périard D, et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: 1-year follow-up data of a randomized-controlled trial. *J Thromb Haemost.* 2017;15:1351-1360.
 95. Garcia MJ, Lookstein R, Malhotra R, Amin A, Blitz LR, Leung DA, et al. Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) Registry. *J Vasc Interv Radiol.* 2015;26:777-85.
 96. Enden T, Haig Y, Klow NE, et al. Longterm outcome after additional catheterdirected thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. *Lancet* 2012; 379: 31-38.
 97. Haig Y, Enden T, Grøtta O, Kløw NE, Slagsvold CE, Ghanima W, Set al Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. *Lancet Haematol.* 2016;3:64-71.
 98. Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al; ATTRACT Trial Investigators. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. *N Engl J Med.* 2017;377:2240-2252.
 99. Comerota AJ, Kearon C, Gu CS, Julian JA, Goldhaber SZ, Kahn SR, et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. *Circulation* 2019;139:1162e73
 100. Notten P, Ten Cate-Hoek AJ, Arnoldussen CWKP, Strijkers RHW, de Smet AAEEA, Tick LW, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. *Lancet Haematol.* 2020;7:40-49.
 101. Greenfield LJ, Zocco J, Wilk J, Schroeder TM, Elkins RC. Clinical experience with the Kim-Ray Greenfield vena caval filter. *Ann Surg.* 1977;185:692-698.
 102. Turner TE, Saeed MJ, Novak E, Brown DL. Association of Inferior Vena Cava Filter Placement for Venous Thromboembolic Disease and a Contraindication to Anticoagulation With 30-Day Mortality. *JAMA Netw Open.* 2018;1:e180452.
 103. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. *Circulation.* 2005;112:416-422.
 104. van den Houten MM, van Grinsven R, Pouwels S, Yo LS, van Sambeek MR, Teijink JA. Treatment of upper-extremity outflow thrombosis. *Phlebology.* 2016;31:28-33.
 105. Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, et al. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. *Thromb Haemost.* 2019;119:1365-1372.
 106. Thiagarajah K, Ellingwood L, Endres K, Hegazi A, Radford J, Iansavitchene A, et al. Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis. *Thromb Res.* 2019;174:34-39.
 107. Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. *N Engl J Med.* 2011;364:861-869.
 108. Povlsen S, Povlsen B. Diagnosing Thoracic Outlet Syndrome: Current Approaches and Future Directions. *Diagnostics (Basel).* 2018;8:21.
 109. Montiel FS, Ghazvinian R, Gottsäter A, Elf J. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. *Thromb J.* 2017;15:26.
 110. Barco S, Atema JJ, Coppens M, Serlie MJ, Middeldorp S. Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal. *Blood Transfus.* 2017;15:369-377.
 111. Engelberger RP, Kucher N. Management of deep vein thrombosis of the upper extremity. *Circulation.* 2012;126:768-773
 112. Grant JD, Stevens SM, Woller SC, Lee EW, Kee ST, Liu DM, et al. Diagnosis and management of upper extremity deep-vein thrombosis in adults. *Thromb Haemost.* 2012;108:1097-108.
 113. Akl EA, Ramly EP, Kahale LA, Yosucio VE, Barba M, Sperati F, et al Anticoagulation for people with cancer and central venous catheters. *Cochrane Database Syst Rev.* 2014;10:CD006468.
 114. Howley MM, Fisher SC, Van Zutphen AR, Papadopoulos EA, Patel J, Lin AE, et al. Maternal exposure to heparin products and risk of birth defects in the National Birth Defects Prevention Study. *Birth Defects Res.* 2023;115:133-144.
 115. Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. *Blood Adv.* 2018;2:3317-3359
 116. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. *Cancer.* 2007;110:2339-2346.



DOI: 10.37609/akya.3889.c5410

HEMODİYALİZ AMAÇLI DAMAR ERİŞİM YOLU OLARAK ARTERİOVENÖZ FİSTÜL CERRAHİSİ

BÖLÜM 88

Tamer KEHLİBAR ¹
Berat HASBAL ²

İçindekiler

- » GİRİŞ
- » SON DÖNEM BÖBREK YETMEZLİĞİ YAŞAM PLANI VE AVF TERCİHİ
- » PREOPERATİF HAZIRLIK
- » ARTERİOVENÖZ ERİŞİM YOLU LOKASYONLARI
- » ÖZELLİKLİ HASTALARA YAKLAŞIM
- » ARTERİOVENÖZ FİSTÜL CERRAHİSİNDE TEMEL YAKLAŞIMLAR
- » ÖN KOL ARTERİOVENÖZ FİSTÜLLERİ
- » ANTEKÜBİTAL FOSSA VE ÜST KOL ARTERİOVENÖZ FİSTÜLLERİ
- » SONUÇLAR
- » ARTERİOVENÖZ FİSTÜL KOMPLİKASYONLARI VE TEDAVİSİ

¹ Op.Dr., Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi, tamerkehlbar@gmail.com, ORCID iD: 0000-0002-5274-7654

² Op.Dr., Artvin Devlet Hastanesi, berathasbal@gmail.com, ORCID iD: 0009-0002-6999-304X

antekübitalde ulnar sinirin bası altında kaldığı kübital tünel sendromu veya el bileğinde median sinirin bası altında kaldığı karpal tünel sendromudur. Tuzak nöropatisi mononöropatidir. AVF oluşumu ve iskemiyle ilişkisi yoktur. Üremik veya diyabetik nöropati bilateral tutulum gösterir.

İskemik monomelik nöropati unilateral (monomelik), üç önkol sinirinin tutulumu ile karakterizedir. AVF girişiminden hemen sonra ortaya çıkar, nadiren gecikmiş şekilde görülür. Belirgin iskemi bulgusu görülmez. Ağrı, parestezi, hissizlik ve motor kayıp görülebilir. Selektif olarak vasa nervorum akımının azalması sorumlu tutulmaktadır. EEG ile ayırıcı tanı yapılır. AV fistülün iptali veya çalma sendromundaki gibi arteriyel inflow değiştirme teknikleri ve banding uygulanabilir. Ancak en kesin tedavi AV fistülün acil olarak kapatılmasıdır. AVF kapama ile hızlı düzelme görülür. Geç kalınan olgularda ve acil AVF kapama uygulanan bazı olgularda kalıcı hasar ve ekstremit malfonksiyonu raporlanmıştır (79-81).

KAYNAKLAR

- Johansen KL, Gilbertson DT, Li S, et al. US Renal Data System 2024 Annual Data Report: Epidemiology of Kidney Disease in the United States. *American Journal of Kidney Diseases*. 2025;85(6S1): A8-A11. doi: 10.1053/j.ajkd.2025.02.602.
- Ateş K, Seyahi N, Koçyiğit İ, et al. *Türkiye'de Nefroloji, Diyaliz ve Transplantasyon – Registry 2023*. Ankara: BAYT Bilimsel Arş. Basın Yayın Tanıtım Ltd. Şti. 2024.
- Voorzaat BM, Janmaat CJ, van der Bogt KEA, et al. Patency outcomes of arteriovenous fistulas and grafts for hemodialysis access: A trade-off between nonmaturation and long-term complications. *Kidney 360*. 2020;1(9): 916-924. doi: 10.34067/KID.0000462020.
- Collins AJ, Foley RN, Herzog C, et al. U.S. Renal Data System 2012 Annual Data Report. *American Journal of Kidney Diseases*. 2013;61(1 Suppl 1): A7, e1-476. doi: 10.1053/j.ajkd.2012.11.031.
- Tonnissen BH, Money SR: Embracing the fistula first national vascular access improvement initiative. *Journal of Vascular Surgery*. 2005;42(3): 585-586. doi: 10.1016/j.jvs.2005.05.030.
- Vascular Access 2006 Work Group: Clinical practice guidelines for vascular access. *American Journal of Kidney Diseases*. 2006;48(Suppl 1): S176-247. doi: 10.1053/j.ajkd.2006.04.029.
- Lok CE, Allon M, Moist LM, et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). *Journal of American Society of Nephrology*. 2006;17(11): 3204-3212. doi: 10.1681/ASN.2006030190.
- Richardson AI, Leake A, Schmieder GC. Should fistulas really be first in the elderly patient? *Journal of Vascular Access*. 2009;10(3): 199-202. doi: 10.1177/112972980901000311.
- Peterson WJ, Barker J, Allon M. Disparities in fistula maturation persist despite preoperative vascular mapping. *Clinical Journal of the American Society of Nephrology*. 2008;3(2): 437-441. doi: 10.2215/CJN.03480807
- Woodside K, Bell S, Mukhopadhyay. Arteriovenous fistula maturation in prevalent hemodialysis patients in the United States: a national study. *American Journal of Kidney Diseases*. 2018;71(6): 793-801. doi: 10.1053/j.ajkd.2017.11.020
- Lok CE, Huber TS, Lee T, et al; National Kidney Foundation. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. *American Journal of Kidney Diseases*. 2020;75(4 Suppl 2): S1-S164. doi: 10.1053/j.ajkd.2019.12.001.
- Zaccardi MJ, Mokadam NA. Radial artery evaluation before coronary artery bypass grafts. In Zierler RE, editor. 2010. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 385-398.
- Mudoni A, Caccetta F, Caroppo M, et al. Echo color Doppler ultrasound: a valuable diagnostic tool in the assessment of arteriovenous fistula in hemodialysis patients. *Journal of Vascular Access*. 2016;17: 446-452. doi: 10.5301/jva.5000588.
- Chlorogiannis DD, Bousi SE, Zachiotis M, et al. Preoperative ultrasound mapping before arteriovenous fistula formation: an updated systematic review and meta-analysis. *Journal of Nephrology*. 2024;37: 281-292. doi: 10.1007/s40620-023-01814-6.
- Heye S, Maleux G, Marchal GJ. Upper-extremity venography: CO2 versus iodinated contrast material. *Radiology*. 2006;241(1): 291-297. doi: 10.1148/radiol.2411050714.
- Sullivan KL, Bonn J, Shapiro MJ. Venography with carbon dioxide as a contrast agent. *Cardiovascular and Interventional Radiology*. 1995;18(3): 141-145. doi: 10.1007/BF00204138.
- Caridi JG, Hawkins IF, Jr. CO2 digital subtraction angiography: potential complications and their prevention. *Journal of Vascular and Interventional Radiology*. 1997;8(3): 383-391. doi: 10.1016/s1051-0443(97)70577-3.
- Brown PW. Preoperative radiological assessment for vascular access. *European Journal of Vascular and Endovascular Surgery*. 2006;31(1): 64-69. doi: 10.1016/j.ejvs.2005.10.002.
- Mc Grogan DG, Field MA, Maxwell AP, et al. Patient survival following arteriovenous fistula formation. *Journal of Vascular Access* 2015;16(3): 195-9. doi: 10.5301/jva.5000343.
- Letourneau I, Ouimet D, Dumont M, Pichette V, Leblanc M. Renal replacement in end-stage renal disease patients over 75 years old. *American Journal of Nephrology*. 2003;23(2): 71-7. doi: 10.1159/000068040.
- Roca-Tey R. Permanent arteriovenous fistula or catheter dialysis for heart failure patients. *Journal of Vascular Access*. 2016;17(Suppl 1): S23-9. doi: 10.5301/jva.5000511.
- Scholz H. *Arteriovenous access surgery: Ensuring adequate vascular access for hemodialysis*. Berlin, Heidelberg: Springer; 2015.
- Darcy M, Vachharajani N, Zhang T, et al. Long-term outcome of upper extremity arteriovenous fistula using pSLOT: single-center longitudinal follow-up using a protocol-based approach. *Journal of Vascular Access*. 2017;18(6): 515-521. doi: 10.5301/jva.5000764.

24. Brescia MJ, Cimino JE, Appel K, et al. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. *New England Journal of Medicine*. 1966;275: 1089-1092. doi: 10.1056/NEJM196611172752002.
25. Yamine K, Mirela E. Patterns of the superficial veins of the cubital fossa: A meta-analysis. *Phlebology*. 2017;32(6): 403-414. doi: 10.1177/0268355516655670.
26. Anaya-Ayala JE, Younes HK, Kaiser CL, et al. Prevalence of variant brachial-basilic vein anatomy and implications for vascular access planning. *Journal of Vascular Surgery*. 2011;53(3): 720-724. doi: 10.1016/j.jvs.2010.09.072.
27. Rodriguez-Niedenführ M, Vazquez T, Nearn L, et al. Variations of the arterial pattern in the upper limb revisited: a morphological and statistical study, with a review of the literature. *Journal of Anatomy*. 2001;199(Pt5): 547-566. doi: 10.1046/j.1469-7580.2001.19950547.x.
28. Baktıroğlu S. Üst kolda AV fistül operasyonları. In: Kösem M (ed.) *Hemodiyaliz İçin Damaryolu Multidisipliner Yaklaşım*. İstanbul: Nobel Tıp Kitabevleri; 2021. p. 207-215.
29. Robbin ML, Chamberlain NE, Lockhart ME, et al. Hemodialysis arteriovenous fistula maturity: US evaluation. *Radiology*. 2002;225(1): 59-64. doi: 10.1148/radiol.2251011367.
30. Malovrh M. Native arteriovenous fistula: preoperative evaluation. *American Journal of Kidney Diseases*. 2002;39(6): 1218-1225. doi: 10.1053/ajkd.2002.33394.
31. Ferring M, Henderson J, Wilms T. Accuracy of early postoperative clinical and ultrasound examination of arteriovenous fistulae to predict dialysis use. *Journal of Vascular Access*. 2014;15(4): 291-297. doi: 10.5301/jva.5000210.
32. Wong V, Ward R, Taylor J, et al. Factors associated with early failure of arteriovenous fistulae for haemodialysis access. *European Journal of Vascular and Endovascular Surgery*. 1996;12(2): 207-213. doi: 10.1016/s1078-5884(96)80108-0.
33. Zhu YL, Ding H, Fan PL, et al. Predicting the maturity of haemodialysis arteriovenous fistulas with colour Doppler ultrasound: a single-centre study from China. *Clinical Radiology*. 2016;71(6): 576-582. doi:10.1016/j.crad.2016.02.025.
34. Voormolen EH, Jahrome AK, Bartels LW, et al. Non-maturation of arm arteriovenous fistulas for hemodialysis access: A systematic review of risk factors and results of early treatment. *Journal of Vascular Surgery*. 2009;49(5): 1325-36. doi: 10.1016/j.jvs.2008.11.059.
35. Rooijens PP, Tordoir JH, Stijnen T, et al. Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. *European Journal of Vascular and Endovascular Surgery*. 2004;28: 583-589. doi: 10.1016/j.ejvs.2004.08.014.
36. Golledge J, Smith CJ, Emery J, et al. Outcome of primary radiocephalic fistula for haemodialysis. *British Journal of Surgery*. 1999;86: 211-216. doi: 10.1046/j.1365-2168.1999.01007.x.
37. Smith GE, Gohil R, Chetter IC. Factors affecting the patency of arteriovenous fistulas for dialysis access. *Journal of Vascular Surgery*. 2012;55: 849-855. doi: 10.1016/j.jvs.2011.07.095.
38. Dixon BS, Novak L, Fangman J. Hemodialysis vascular access survival: upper arm native arteriovenous fistula. *American Journal of Kidney Diseases* 2002;39: 92-101. doi: 10.1053/ajkd.2002.29886.
39. Lok CE, Oliver MJ, Su J, et al. Arteriovenous fistula outcomes in the era of the elderly dialysis population. *Kidney International*. 2005;67(6): 2462-2469. doi: 10.1111/j.1523-1755.2005.00355.x.
40. Zeebgeerts CJ, Tiellu IF, Hulsebos RG, et al. Determinants of failure of brachiocephalic elbow fistulas for hemodialysis. *European Journal of Vascular and Endovascular Surgery*. 2005;30(2): 209-214. doi: 10.1016/j.ejvs.2005.04.009.
41. Koksoy C, Demirci RK, Balci D, et al. Brachiocephalic versus brachiocephalic arteriovenous fistula: a prospective randomized study. *Journal of Vascular Surgery*. 2009;49: 171-177.e5. doi: 10.1016/j.jvs.2008.08.002.
42. Karaca OG, Basal AN, Ecevit AN, et al. Radiobasilic versus brachiocephalic transposition on the upper arm to avoid steal syndrome. *Medical Science Monitor*. 2015;21: 4090-4095. doi: 10.12659/msm.896642.
43. Korkut AK, Kosem M. Superficialization of the basilic vein technique in brachiocephalic arteriovenous fistula: surgical experience of 350 cases during 4 years period. *Annals of Vascular Surgery*. 2010;24(6): 762-767. doi: 10.1016/j.avsg.2010.02.013.
44. Ozcan S, Gür AK, Yener AU, et al. Comparison of one- and two-stage basilic vein transposition for arteriovenous fistula formation in haemodialysis patients: preliminary results. *The Cardiovascular Journal of Africa*. 2013;24(9-10): 364-368. doi: 10.5830/CVJA-2013-077.
45. Kakkos SK, Lampropoulos GC, Nikolakopoulos KM, et al. A systematic review and meta-analysis of randomized trials comparing two-stage with one-stage brachiocephalic vein fistulas. *Vascular Specialist International*. 2018;34(3): 51-60. doi: 10.5758/vsi.2018.34.3.51.
46. Quencer KB, Friedman T. Declothing the thrombosed access. *Techniques in Vascular and Interventional Radiology*. 2017;20(1): 38-47. doi: 10.1053/j.tvir.2016.11.007.
47. Thalhammer C, Pfammatter T, Segerer S. Vascular access for haemodialysis-an update. *Vasa European Journal of Vascular Medicine*. 2013;42: 252-263. doi: 10.1024/0301-1526/a000286.
48. Sidawy AN, Mc Cann M, Einarsson H, et al. Vascular access management II: AVF/AVG cannulation techniques and complications. *Journal of Renal Care*. 2009;35: 90-8. doi: 10.1111/j.1755-6686.2009.00095.x.
49. Schmidli J, Widmer MK, Basile C, et al. Editor's Choice-Vascular Access: 2018 Clinical practice guidelines of the European Society for Vascular Surgery (ESVS). *European Journal of Vascular and Endovascular Surgery*. 2018;55(6): 757-818. doi: 10.1016/j.ejvs.2018.02.001.
50. Pulathan Z. Arteriovenöz fistül komplikasyonları ve cerrahi tedavileri. In: Kösem M (ed.) *Hemodiyaliz İçin Damaryolu Multidisipliner Yaklaşım*. İstanbul: Nobel Tıp Kitabevleri; 2021. p. 223-249.
51. Sadaghianloo N, Jean-Baptiste E, Gaid H, et al. Early surgical thrombectomy improves salvage of thrombosed vascular accesses. *Journal of Vascular Surgery*. 2014;59(5): 1377-1384.e1-2. doi: 10.1016/j.jvs.2013.11.092.
52. Schon D, Mishler R. Pharmacomechanical thrombolysis of natural vein fistulas: reduced dose of TPA and long-term follow-up. *Seminars in Dialysis*. 2003;16(3): 272-275. doi: 10.1046/j.1525-139x.2003.16052.x.
53. Tordoir JH, Bode AS, Peppelenbosch N, et al. Surgical or endovascular repair of thrombosed dialysis vascular access: is there any evidence? *Journal of Vascular Surgery*. 2009;50(4): 953-956. doi: 10.1016/j.jvs.2009.06.058.

54. Romann A, Beaulieu MC, Rhéaume P, et al. Risk factors associated with arteriovenous fistula failure after first radiologic intervention. *Journal of Vascular Access*. 2016;17(2): 167-174 doi: 10.5301/jva.5000459.
55. Al-Jaishi AA, Liu AR, Lok CE, Zhang JC, Moist LM. Complications of the arteriovenous fistula: a systematic review. *Journal of the American Society of Nephrology*. 2017;28(6): 1839-1850. doi: 10.1681/ASN.2016040412.
56. Zhang J, Burr RA, Sheth HS, Piraino B. Organism-specific bacteremia by hemodialysis access. *Clinical Nephrology*. 2016;86(9): 141-146. doi: 10.5414/CN108633.
57. Balaz P, Bjorck M. True aneurysm in autologous hemodialysis: definitions, classification and indications for treatment. *Journal of Vascular Access*. 2015;16(6): 446-453. doi: 10.5301/jva.5000391.
58. Inston N, Mistry H, Gilbert J, et al. Aneurysms in vascular access: state of the art and future developments. *Journal of Vascular Access*. 2017;18(6): 464-472. doi: 10.5301/jva.5000828.
59. Valenti D, Mistry H, Stephenson M. A novel classification system for autogenous arteriovenous fistula aneurysms in renal access patients. *Vascular and Endovascular Surgery*. 2014;48(7-8): 491-496. doi: 10.1177/1538574414561229.
60. Balaz P, Rokosny S, Bafrnec J, et al. Repair of aneurysmal arteriovenous fistulae: a systematic review and meta-analysis. *Eur J Vasc Endovasc Surg*. 2020;59(4):614-623. doi: 10.1016/j.ejvs.2019.07.033.
61. Duijm LE, Liem YS, van der Rijt RH, Nobrega FJ, van den Bosch HC, Douwes-Draaijer P, et al. Inflow stenoses in dysfunctional hemodialysis access fistulae and grafts. *American Journal of Kidney Diseases*. 2006;48: 98-105. doi: 10.1053/j.ajkd.2006.03.076.
62. Shemesh D, Goldin I, Zaghal I, Berlowitz D, Raveh D, Olsha O. Angioplasty with stent graft versus bare stent for recurrent cephalic arch stenosis in autogenous arteriovenous access for hemodialysis: a prospective randomized clinical trial. *Journal of Vascular Surgery*. 2008;48: 1524-31. doi: 10.1016/j.jvs.2008.07.071.
63. Basile C, Lomonte C, Vernaglione L, Casucci F, Antonelli M, Losurdo N. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. *Nephrology Dialysis Transplantation*. 2008;23: 282-287. doi: 10.1093/ndt/gfm549.
64. Wijnen E, Keuter XH, Planken NR, van der Sande FM, Tordoir JH, Leunissen KM, et al. The relation between vascular access flow and different types of vascular access with systemic hemodynamics in hemodialysis patients. *Artificial Organs*. 2005;29: 960-964. doi: 10.1111/j.1525-1594.2005.00165.x.
65. MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM. Arteriovenous fistula associated high output cardiac failure: a review of mechanisms. *American Journal of Kidney Diseases*. 2004;43: e17-22. doi: 10.1053/ajkd.2004.01.016.
66. Suding PN, Wilson SE. Strategies for management of ischemic steal syndrome. *Seminars in Vascular Surgery*. 2007;20(3): 184-188. doi: 10.1053/j.semvasc-surg.2007.07.009.
67. Malik J, Tuka V, Kasalova Z, et al. Understanding the dialysis access steal syndrome. A review of the etiologies, diagnosis, prevention and treatment strategies. *Journal of Vascular Access*. 2008;9: 155-166.
68. Guerra A, Raynaud A, Beyssen B, et al. Arterial percutaneous angioplasty in upper limbs with vascular access devices for haemodialysis. *Nephrology Dialysis Transplantation*. 2002;17: 843-851. doi: 10.1093/ndt/17.5.843.
69. Callaghan CJ, Mallik M, Sivaprakasam R, et al. Treatment of dialysis access-associated steal syndrome with the "revision using distal inflow" technique. *Journal of Vascular Access*. 2011;12: 52-56. doi: 10.5301/jva.2010.5985.
70. Loh TM, Bennett ME, Peden EK. Revision using distal inflow is a safe and effective treatment for ischemic steal syndrome and pathologic high flow after access creation. *Journal of Vascular Surgery*. 2016;63: 441-444. doi: 10.1016/j.jvs.2015.08.098.
71. Chemla E, Raynaud A, Carreres T, et al. Preoperative assessment of the efficacy of distal radial artery ligation in treatment of steal syndrome complicating access for hemodialysis. *Annals of Vascular Surgery*. 1999;13: 618-621. doi: 10.1007/s100169900309.
72. Mickley V. Steal syndrome strategies to preserve vascular access and extremity. *Nephrology Dialysis Transplantation*. 2008;23: 19-24. doi: 10.1093/ndt/gfm673.
73. Schanzer H, Schwartz M, Harrington E, et al. Treatment of ischemia due to "steal" by arteriovenous fistula with distal artery ligation and revascularization. *Journal of Vascular Surgery*. 1988;7: 770-773. doi: 10.1067/mva.1988.av0070770.
74. Knox RC, Berman SS, Hughes JD, et al. Distal revascularization-interval ligation: a durable and effective treatment for ischemic steal syndrome after hemodialysis access. *Journal of Vascular Surgery*. 2002;36: 250-255. doi: 10.1067/mva.2002.125025.
75. Anaya-Ayala JE, Pettigrew CD, Ismail N, et al. Management of dialysis access associated "steal" syndrome with DRIL procedure: challenges and clinical outcomes. *Journal of Vascular Access*. 2012;13: 299-304. doi: 10.5301/jva.5000041.
76. Misskey J, Yang C, MacDonald S, Baxter K, Hsiang Y. A comparison of revision using distal inflow and distal revascularization-interval ligation for the management of severe access-related hand ischemia. *Journal of Vascular Surgery*. 2016;63: 1574-1581. doi: 10.1016/j.jvs.2015.10.100.
77. Al Shakarchi J, Stolba J, Houston JG, et al. Surgical techniques for haemodialysis access-induced distal ischaemia. *Journal of Vascular Access*. 2016;17(1): 40-46. doi: 10.5301/jva.5000467.
78. Zanow J, Kruger U, Scholz H. Proximalization of the arterial inflow: a new technique to treat access-related ischemia. *J Vasc Surg*. 2006;43: 1216-21. discussion 1221. doi: 10.1016/j.jvs.2006.01.025.
79. Wilson SE. Complications of vascular access: thrombosis, venous hypertension, congestive heart failure, neuropathy, and aneurysm. *Vascular access principles and practice* (5th ed.). Philadelphia. Lippincott Williams and Wilkins 2010.p. 168-178.
80. Thermann F, Kornhuber M. Ischemic monomelic neuropathy: rare but important complication after hemodialysis access placement- a review. *Journal of Vascular Access*. 2011;12(2): 113-119. doi: 10.5301/JVA.2011.6365.
81. Thimmisetty RK, Pedavally S, Rossi NF, et al. Ischemic monomelic neuropathy: Diagnosis, pathophysiology, and management. *Kidney International Reports*. 2016;27(2(1): 76-79. doi: 10.1016/j.ekir.2016.08.013.